title,url,time_published,summary,ticker,relevance_score,ticker_sentiment_score,ticker_sentiment_label
AbbVie  ( ABBV )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2037579/abbvie-abbv-stock-sinks-as-market-gains-what-you-should-know,2023-01-10 22:45:20,"AbbVie (ABBV) closed the most recent trading day at $159.64, moving -1.25% from the previous trading session.",ABBV,0.64962,0.343208,Somewhat-Bullish
Halozyme Provides 2023 Financial Guidance and Outlook,https://www.prnewswire.com/news-releases/halozyme-provides-2023-financial-guidance-and-outlook-301717757.html,2023-01-10 22:15:00,2023 Total Revenue Guidance of $815 to $845 Million Representing >20% Growth Over Expected 2022 Revenue 2023 Recurring Revenues from Royalties Projected to Grow by >20% to $445 to $455 Million 2023 EBITDA Projected to Grow by >30% Year-Over-Year to $415 to $440 Million,ABBV,0.02668,0.079527,Neutral
3 Passive Income Stocks That Are Screaming Buys in January,https://www.fool.com/investing/2023/01/10/3-passive-income-stocks-are-screaming-buys-january/,2023-01-10 14:45:00,All three could make investors a little bit richer every quarter.,ABBV,0.196212,0.106556,Neutral
Abbvie raises sales outlook of two new drugs to more than $17.5 bln in 2025,https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-raises-sales-outlook-two-new-drugs-more-than-175-bln-2025-2023-01-10/,2023-01-10 14:13:00,Abbvie raises sales outlook of two new drugs to more than $17.5 bln ... ...,ABBV,0.588876,0.199712,Somewhat-Bullish
AbbVie Inc.  ( ABBV )  is Attracting Investor Attention: Here is What You Should Know,https://www.zacks.com/stock/news/2037230/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know,2023-01-10 14:00:12,"Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",ABBV,0.485711,0.134461,Neutral
AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets,https://investingnews.com/abbvie-and-anima-biotech-announce-collaboration-for-the-discovery-and-development-of-mrna-biology-modulators-against-oncology-and-immunology-targets/,2023-01-10 13:29:29,- Collaboration leverages Anima's mRNA Lightning technology platform and AbbVie's extensive expertise in Oncology and Immunology - Anima will receive an upfront payment of $42 million with potential for further milestones and royalties,ABBV,0.489549,0.207687,Somewhat-Bullish
How This Mutual Fund Soared Last Year,https://www.investors.com/etfs-and-funds/mutual-funds/how-to-invest-in-stocks-this-fund-thrived-last-year/,2023-01-10 12:00:00,How To Invest In Stocks: This Fund Thrived Last Year | Investor's ... Investor's Business Daily ...,ABBV,0.129284,0.285839,Somewhat-Bullish
3 Top Dividend Kings to Buy for the Long Haul,https://www.fool.com/investing/2023/01/10/3-top-dividend-kings-to-buy-for-the-long-haul/,2023-01-10 10:52:00,It's the underlying businesses that fund their dividends that make these stocks especially attractive.,ABBV,0.290262,0.291452,Somewhat-Bullish
Should Investors Worry About AbbVie's Dividend?,https://www.fool.com/investing/2023/01/10/should-investors-worry-about-abbvie-dividend/,2023-01-10 10:31:00,"The risks are real, but they're decreasing over time.",ABBV,0.277748,0.023485,Neutral
"If You Invested $100 In This Stock 10 Years Ago, You Would Have $500 Today - AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/news/earnings/23/01/30338802/if-you-invested-100-in-this-stock-10-years-ago-you-would-have-500-today,2023-01-09 19:01:14,"AbbVie ABBV has outperformed the market over the past 10 years by 6.47% on an annualized basis producing an average annual return of 16.73%. Currently, AbbVie has a market capitalization of $287.33 billion.",ABBV,0.983605,0.387251,Bullish
These 15 Dividend Aristocrat stocks have been the best income builders,https://www.marketwatch.com/story/these-15-dividend-aristocrat-stocks-have-been-the-best-income-builders-11673286478,2023-01-09 17:48:00,Most stocks on a new screen have outperformed the S&P 500 in the long term.,ABBV,0.09495,0.108042,Neutral
Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2023/01/09/2585376/0/en/Royalty-Pharma-Highlights-Accomplishments-and-Provides-Business-Update-at-41st-Annual-J-P-Morgan-Healthcare-Conference.html,2023-01-09 14:25:00,"NEW YORK, Jan. 09, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today provided an update on its business performance, including recent key accomplishments and the full year 2022 outlook for Net cash provided by operating activities ( GAAP financial measure ) and Adjusted Cash ...",ABBV,0.016118,0.068037,Neutral
Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference - Royalty Pharma  ( NASDAQ:RPRX ) ,https://www.benzinga.com/pressreleases/23/01/g30333489/royalty-pharma-highlights-accomplishments-and-provides-business-update-at-41st-annual-j-p-morgan-h,2023-01-09 14:25:00,"2022 Net cash provided by operating activities ( GAAP ) expected to be approximately $2,140 million to $2,150 million; 2022 Adjusted Cash Receipts ( 1 ) ( non-GAAP ) expected to be approximately $2,785 million to $2,790 million, towards the upper end of guidance range",ABBV,0.016031,0.067992,Neutral
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis' Genetic Medicines and Commercial Readiness,https://www.globenewswire.com/news-release/2023/01/09/2585361/0/en/Royalty-Pharma-and-Ionis-Enter-Into-Royalty-Agreement-for-Up-to-1-1-Billion-to-Further-Advance-Ionis-Genetic-Medicines-and-Commercial-Readiness.html,2023-01-09 14:15:00,"NEW YORK and CARLSBAD, Calif., Jan. 09, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) and Ionis Pharmaceuticals, Inc. ( Nasdaq: IONS ) today announced that Royalty Pharma has acquired an interest in Ionis' royalty in Biogen's SPINRAZA® ( nusinersen ) and Novartis' pelacarsen for ...",ABBV,0.020439,0.070167,Neutral
Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness,https://www.prnewswire.com/news-releases/ionis-and-royalty-pharma-enter-into-royalty-agreement-for-up-to-1-1-billion-to-further-advance-ionis-genetic-medicines-and-commercial-readiness-301716470.html,2023-01-09 14:05:00,Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 ... PR ...,ABBV,0.020579,0.069332,Neutral
QULIPTA Now Approved by Health Canada for the Preventive Treatment of Episodic Migraine in Adults,https://investingnews.com/qulipta-now-approved-by-health-canada-for-the-preventive-treatment-of-episodic-migraine-in-adults/,2023-01-09 12:35:31,ABBVie ( NYSE: ABBV ) announced today that Health Canada has approved QULIPTA ( atogepant ) for the prevention of episodic migraine ( ABBVie's migraine portfolio to support Canadians impacted by migraine.,ABBV,0.511256,0.40505,Bullish
Top Dividend Stocks To Invest In 2023? 3 For Your List,https://stockmarket.com/featured/top-dividend-stocks-to-invest-in-2023-3-for-your-list-2023-01-09,2023-01-09 12:00:00,A dividend stock is a type of stock that pays out a portion of the company's profits to shareholders in the form of dividends. These payments are generally paid on a regular basis. This can include quarterly or annually. While dividends are typically paid in cash.,ABBV,0.313484,0.070701,Neutral
This Stock Could Be a Surprise Growth Pick for 2023,https://www.fool.com/investing/2023/01/09/this-stock-may-be-a-surprise-growth-pick-for-2023/,2023-01-09 10:30:00,Pfizer is about to enter a whole new era of growth.,ABBV,0.059049,0.112098,Neutral
3 No-Brainer Dividend Stocks to Buy in 2023,https://www.fool.com/investing/2023/01/07/3-no-brainer-dividend-stocks-to-buy-in-2023/,2023-01-07 11:10:00,These stocks have what it takes to win over the long run.,ABBV,0.401331,0.07875,Neutral
AbbVie cuts earnings forecast due to milestone payments,https://www.marketwatch.com/story/abbvie-cuts-earnings-forecast-due-to-milestone-payments-11673048665,2023-01-06 23:52:00,AbbVie Inc. lowered its outlook for the quarter and year late Friday for research and development expenses and milestone payments to partners.,ABBV,0.817578,0.216647,Somewhat-Bullish
ABBV: 3 Blue-Chip Stocks to Make Sure You Own in 2023,https://stocknews.com/news/abbv-avgo-vz-3-blue-chip-stocks-to-make-sure-you-own-in-2023/,2023-01-06 20:37:14,ABBV: 3 Blue-Chip Stocks to Make Sure You Own in ...,ABBV,0.24316,0.164112,Somewhat-Bullish
"Dow Jumps 700 Points; S&P 500 Rises Over 2% - Aehr Test Systems  ( NASDAQ:AEHR ) , ATAI Life Sciences  ( NASDAQ:ATAI ) ",https://www.benzinga.com/news/earnings/23/01/30316154/dow-jumps-700-points-s-p-500-rises-over-2,2023-01-06 19:43:24,"U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 700 points on Friday. The Dow traded up 2.14% to 33,634.19 while the NASDAQ rose 2.54% to 10,566.63. The S&P 500 also rose, gaining, 2.30% to 3,895.60.",ABBV,0.05257,0.071651,Neutral
CytomX  ( CTMX )  Up 55% on Strategic Partnership With Moderna,https://www.zacks.com/stock/news/2036409/cytomx-ctmx-up-55-on-strategic-partnership-with-moderna,2023-01-06 18:46:00,CytomX (CTMX) inks an agreement with Moderna to develop therapeutics for oncology and non-oncology conditions. The company also provides its business outlook for 2023.,ABBV,0.381755,0.074788,Neutral
The Deal Worth Millions That Helped AbbVie Stock Briefly Break Out,https://www.investors.com/news/technology/abbvie-stock-briefly-breaks-out-on-a-new-cancer-deal/,2023-01-06 18:45:00,AbbVie Stock Briefly Breaks Out On A New $30 Million Cancer Deal ... Investor's Business Daily ...,ABBV,0.718485,-0.096058,Neutral
"AbbVie, Goldman Sachs And This Electric Vehicle Manufacturer On CNBC's 'Final Trades' - AbbVie  ( NYSE:ABBV ) , Goldman Sachs Group  ( NYSE:GS ) ",https://www.benzinga.com/trading-ideas/long-ideas/23/01/30306562/abbvie-goldman-sachs-and-this-electric-vehicle-manufacturer-on-cnbcs-final-trades,2023-01-06 16:06:37,"On CNBC's ""Halftime Report Final Trades,"" Stephen Weiss of Short Hills Capital Partners said he was shorting Rivian Automotive Inc. RIVN despite the stock recording losses on Thursday. ""They are going to lose money,"" he added. Jason Snipe of Odyssey Capital Advisors said he liked Goldman Sachs ...",ABBV,0.769861,0.41219,Bullish
Immunome Stock Jumps On Discovery Pact With AbbVie - Immunome  ( NASDAQ:IMNM ) ,https://www.benzinga.com/general/biotech/23/01/30311076/immunome-stock-jumps-on-discovery-pact-with-abbvie,2023-01-06 15:35:01,AbbVie Inc ABBV and Immunome Inc IMNM announced a worldwide collaboration and option agreement to discover up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome's Discovery Engine. Immunome will receive an upfront payment of $30 million.,ABBV,0.59972,0.393493,Bullish
"Dow Rises Over 300 Points; US Adds 223,000 Jobs In December - Aehr Test Systems  ( NASDAQ:AEHR ) , ATAI Life Sciences  ( NASDAQ:ATAI ) ",https://www.benzinga.com/news/earnings/23/01/30312063/dow-rises-over-300-points-us-adds-223-000-jobs-in-december,2023-01-06 15:27:14,"U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Friday. Following the market opening Friday, the Dow traded up 1.02% to 33,265.17 while the NASDAQ rose 0.72% to 10,379.71. The S&P 500 also rose, gaining, 1.03% to 3,847.29.",ABBV,0.054857,0.164862,Somewhat-Bullish
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets,https://investingnews.com/abbvie-and-immunome-announce-strategic-collaboration-to-discover-multiple-novel-oncology-targets/,2023-01-06 13:31:54,"- Multi-year collaboration to identify up to 10 novel target-antibody pairs leveraging Immunome's Discovery Engine - Immunome to receive $30M upfront payment with potential for further platform access and option payments as well as development, commercial, and sales-based milestones, and tiered ...",ABBV,0.307731,0.222552,Somewhat-Bullish
3 Top U.S. Stocks to Watch in January,https://www.fool.com/investing/2023/01/06/3-top-us-stocks-to-watch-in-january/,2023-01-06 13:30:00,"Considering their potential, all three stocks look like good opportunities today.",ABBV,0.298264,0.133541,Neutral
"AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets - Immunome  ( NASDAQ:IMNM ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/pressreleases/23/01/n30309000/abbvie-and-immunome-announce-strategic-collaboration-to-discover-multiple-novel-oncology-targets,2023-01-06 13:00:00,"- Multi-year collaboration to identify up to 10 novel target-antibody pairs leveraging Immunome's Discovery Engine- Immunome to receive $30M upfront payment with potential for further platform access and option payments as well as development, commercial, and sales-based milestones, and tiered ...",ABBV,0.307731,0.220237,Somewhat-Bullish
"CRISPR, Genetics And AI - Why 2023 Could Be Biotech's Year",https://www.investors.com/news/technology/biotech-stocks-how-crispr-genetics-and-ai-could-drive-a-2023-inflection/,2023-01-06 13:00:00,"Biotech Stocks: How CRISPR, Genetics And AI Could Drive A 2023 ... Investor's Business Daily ...",ABBV,0.028155,0.01046,Neutral
FDA grants priority review to Roche's bispecific antibody glofitamab for people with relapsed or refractory large B-cell lymphoma,https://www.globenewswire.com/news-release/2023/01/06/2584191/0/en/FDA-grants-priority-review-to-Roche-s-bispecific-antibody-glofitamab-for-people-with-relapsed-or-refractory-large-B-cell-lymphoma.html,2023-01-06 06:00:00,"Basel, 6 January 2023 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) today announced that the U.S. Food and Drug Administration ( FDA ) has accepted the company's Biologics License Application ( BLA ) and granted priority review for glofitamab, an investigational CD20xCD3 T-cell engaging bispecific ...",ABBV,0.024248,0.064382,Neutral
"CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics - CytomX Therapeutics  ( NASDAQ:CTMX ) , Moderna  ( NASDAQ:MRNA ) ",https://www.benzinga.com/pressreleases/23/01/g30301606/cytomx-and-moderna-announce-strategic-research-collaboration-for-mrna-based-conditionally-activate,2023-01-05 21:05:00,"Collaboration will combine Moderna's mRNA technology with CytomX's Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditions CytomX to receive $35 million upfront payment with the potential for additional research, milestone, and royalty payments",ABBV,0.04476,-0.026954,Neutral
ABBV: 3 High-Quality Stocks That Can Help Take Your Portfolio to the Next Level,https://stocknews.com/news/abbv-it-dbx-3-high-quality-stocks-that-can-help-take-your-portfolio-to/,2023-01-05 19:52:22,ABBV: 3 High-Quality Stocks That Can Help Take Your Portfolio to ... ...,ABBV,0.306538,0.192482,Somewhat-Bullish
"Insights on the Allergic Conjunctivitis Global Market to 2031 - by Drug Class, Disease Type, Distribution Channel and Region",https://www.prnewswire.com/news-releases/insights-on-the-allergic-conjunctivitis-global-market-to-2031---by-drug-class-disease-type-distribution-channel-and-region-301714458.html,2023-01-05 19:15:00,Insights on the Allergic Conjunctivitis Global Market to 2031 - by ... PR ...,ABBV,0.032871,0.020154,Neutral
Inventiva To Change Clinical Development of Its Lead NASH Candidate - Inventiva  ( NASDAQ:IVA ) ,https://www.benzinga.com/general/biotech/23/01/30295169/inventiva-to-change-clinical-development-of-its-lead-nash-candidate,2023-01-05 15:41:52,"Inventiva IVA has decided to modify the clinical development plan of lanifibranor for non-alcoholic steatohepatitis ( NASH ) . The changes follow a consultation with the FDA, Inventiva said.*",ABBV,0.205807,0.0,Neutral
AbbVie to Host Fourth-Quarter 2022 Earnings Conference Call - Investing News Network,https://investingnews.com/abbvie-to-host-fourth-quarter-2022-earnings-conference-call/,2023-01-05 13:36:01,AbbVie to Host Fourth-Quarter 2022 Earnings Conference Call Investing News Network ...,ABBV,0.95919,0.464432,Bullish
Sosei Heptares Notes its Partner Tempero Bio has Received FDA Clearance to Advance Clinical Development of TMP-301 for Treatment of Alcohol and Substance Use Disorders,https://www.globenewswire.com/news-release/2023/01/05/2583369/0/en/Sosei-Heptares-Notes-its-Partner-Tempero-Bio-has-Received-FDA-Clearance-to-Advance-Clinical-Development-of-TMP-301-for-Treatment-of-Alcohol-and-Substance-Use-Disorders.html,2023-01-05 07:37:00,"TOKYO and CAMBRIDGE, United Kingdom, Jan. 05, 2023 ( GLOBE NEWSWIRE ) -- Sosei Group Corporation ( ""the Company"". TSE: 4565 ) , the world leader in G protein-coupled receptor ( GPCR ) focused structure-based drug design ( SBDD ) and development, notes its partner Tempero Bio has announced FDA ...",ABBV,0.046273,0.04222,Neutral
Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 9,https://www.globenewswire.com/news-release/2023/01/04/2583284/0/en/Royalty-Pharma-to-Present-at-the-J-P-Morgan-Healthcare-Conference-on-January-9.html,2023-01-04 21:15:00,"NEW YORK, Jan. 04, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 11:15 a.m. ET / 8:15 a.m. PT.",ABBV,0.159569,0.105381,Neutral
Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 9 - Royalty Pharma  ( NASDAQ:RPRX ) ,https://www.benzinga.com/pressreleases/23/01/g30282957/royalty-pharma-to-present-at-the-j-p-morgan-healthcare-conference-on-january-9,2023-01-04 21:15:00,"NEW YORK, Jan. 04, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 11:15 a.m. ET / 8:15 a.m. PT.",ABBV,0.151539,0.10204,Neutral
These 2 Cheap Dividend Stocks Yield More Than 3% -- and They Beat the Market Last Year,https://www.fool.com/investing/2023/01/04/2-cheap-dividend-stocks-yield-more-than-3-percent/,2023-01-04 15:23:00,Buy these stocks for both dividends and growth potential.,ABBV,0.464393,0.557467,Bullish
1 Smart Trick That'll Make You a Better Investor Instantly,https://www.fool.com/investing/2023/01/04/1-smart-trick-thatll-make-you-a-better-investor-in/,2023-01-04 14:15:00,"Think about value, not price.",ABBV,0.181137,0.148226,Neutral
Which Stocks Show Thick Skin As Bears Sink Fangs Into New Year?,https://www.investors.com/research/breakout-stocks-technical-analysis/bear-market-takes-swipe-at-bulls-but-elf-stock-box-azn-cat-show-thick-hides/,2023-01-04 13:05:00,"The hoped-for Santa Claus rally failed to materialize in last year's bear market. Now it is the bulls, not the hungry bears, that remain in hibernation as the new year begins. Action in the IBD Breakout Stocks Index ( updated weekly ) highlights that point.",ABBV,0.103778,0.08775,Neutral
Which Stocks Show Thick Skin As Bears Sink Fangs Into New Year?,https://www.investors.com/research/breakout-stocks-technical-analysis/bear-market-takes-swipe-at-bulls-but-elf-stock-box-azn-cat-show-thick-hides/,2023-01-04 13:05:00,"The hoped-for Santa Claus rally failed to materialize in last year's bear market. Now it is the bulls, not the hungry bears, that remain in hibernation as the new year begins. Action in the IBD Breakout Stocks Index ( updated weekly ) highlights that point.",ABBV,0.102013,0.087251,Neutral
"Where to Invest $100,000 in 2023",https://www.fool.com/investing/2023/01/04/where-to-invest-100000-in-2023/,2023-01-04 10:30:00,The holidays are over. Let's put our money to work.,ABBV,0.100729,0.134376,Neutral
3 Outstanding Dividend Growth Stocks to Buy for 2023,https://www.fool.com/investing/2023/01/04/3-dividend-growth-stocks-to-buy-for-2023/,2023-01-04 10:11:00,Steadily growing dividend payments from these stocks could do wonders for your passive income portfolio down the road.,ABBV,0.267413,0.205585,Somewhat-Bullish
AbbVie  ( ABBV )  Gains As Market Dips: What You Should Know,https://www.zacks.com/stock/news/2034814/abbvie-abbv-gains-as-market-dips-what-you-should-know,2023-01-03 22:45:25,"In the latest trading session, AbbVie (ABBV) closed at $162.38, marking a +0.48% move from the previous day.",ABBV,0.672712,0.220131,Somewhat-Bullish
Beat the Dow Jones With This Unstoppable Dividend Stock,https://www.fool.com/investing/2023/01/03/beat-the-dow-jones-with-this-unstoppable-dividend/,2023-01-03 15:23:00,This drugmaker is accustomed to outperforming the broader market.,ABBV,0.699089,0.378298,Bullish
AbbVie to Present at the 41st Annual J.P. Morgan Healthcare Conference,https://investingnews.com/abbvie-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference/,2023-01-03 13:32:18,"ABBVie ( NYSE: ABBV ) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 . Richard A. Gonzalez chairman and chief executive officer, will present at 5:00 p.m. CT .",ABBV,0.889454,0.42873,Bullish
ABBV: 2 Health Care Stocks You Can't Go Wrong with Buying Right Now,https://stocknews.com/news/abbv-cah-2-health-care-stocks-you-cant-go-wrong-with-buying/,2023-01-03 13:11:44,ABBV: 2 Health Care Stocks You Can't Go Wrong with Buying Right ... ...,ABBV,0.33884,0.186312,Somewhat-Bullish
Samsung Bioepis Announces Health Canada Approval of Citrate-Free High-Concentration of HUMIRA®¹ Biosimilar  ( adalimumab; SB5 ) ,https://www.benzinga.com/pressreleases/23/01/g30254195/samsung-bioepis-announces-health-canada-approval-of-citrate-free-high-concentration-of-humira-bios,2023-01-03 12:00:00,"With the approval, Samsung Bioepis has both low ( 40mg/0.8mL ) and high ( 40 mg/0.4mL ) concentration of adalimumab biosimilar approved in Canada Reaffirms its commitment to increasing accessibility by bringing more alternative therapeutic options that meet patients' needs",ABBV,0.089462,0.0,Neutral
CollPlant Enriches Portfolio of rhCollagen-Based Bioinks with Launch of Collink.3DTM 50L in Powder Form,https://www.prnewswire.com/news-releases/collplant-enriches-portfolio-of-rhcollagen-based-bioinks-with-launch-of-collink3dtm-50l-in-powder-form-301712219.html,2023-01-03 12:00:00,CollPlant Enriches Portfolio of rhCollagen-Based Bioinks with ... PR ...,ABBV,0.037387,0.124505,Neutral
23 Top Dividend Stocks to Buy and Hold in 2023,https://www.fool.com/investing/2023/01/03/23-top-dividend-stocks-to-buy-and-hold-in-2023/,2023-01-03 10:55:00,These dividend stocks could reward investors in the new year and beyond.,ABBV,0.134968,0.068285,Neutral
Propulsion of Pancreatic Cancer Pipeline as Novel and Extensive 170+ Therapies Likely to Enter in the Treatment Domain | DelveInsight,https://www.prnewswire.com/news-releases/propulsion-of-pancreatic-cancer-pipeline-as-novel-and-extensive-170-therapies-likely-to-enter-in-the-treatment-domain--delveinsight-301711743.html,2023-01-02 15:30:00,Propulsion of Pancreatic Cancer Pipeline as Novel and Extensive ... PR ...,ABBV,0.066644,-0.023152,Neutral
"Global Joint Pain Injections Market Forecast & Share Worth USD 10.75 Billion, By 2030 at 7.9% CAGR | Joint Pain Injections Industry Trends, Demand, Growth, Value, Analysis & Size Report by Zion Market Research",https://www.prnewswire.com/news-releases/global-joint-pain-injections-market-forecast--share-worth-usd-10-75-billion-by-2030-at-7-9-cagr--joint-pain-injections-industry-trends-demand-growth-value-analysis--size-report-by-zion-market-research-301711867.html,2023-01-02 14:30:00,Global Joint Pain Injections Market Forecast & Share Worth USD ... PR ...,ABBV,0.022222,-0.045526,Neutral
Why Evolus Shares Jumped This Week,https://www.fool.com/investing/2023/01/20/why-evolus-shares-jumped-this-week/,2023-01-20 18:54:32,The company said it expects to turn a profit in the fourth quarter.,ABBV,0.148731,0.001282,Neutral
"Pharma Stock Roundup: LLY's Donanemab Gets FDA's CRL, MRNA RSV Jab Study Succeeds",https://www.zacks.com/stock/news/2041935/pharma-stock-roundup-llys-donanemab-gets-fdas-crl-mrna-rsv-jab-study-succeeds,2023-01-20 14:23:00,"FDA gives CRL to Lilly's (LLY) Alzheimer's candidate, donanemab. Moderna's (MRNA) phase III study on its mRNA-based RSV vaccine candidate in older adults meets primary efficacy endpoints ...",ABBV,0.068306,-0.125435,Neutral
Futures Fall Ahead Of Housing Data,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-rise-ahead-of-housing-data-netflix-surges-on-subscriber-growth/,2023-01-20 13:56:00,"Dow Jones futures fell modestly Friday morning ahead of housing data, threatening to extend a three-day losing streak. China's markets rallied heading into their Lunar New Year break, giving a boost to global markets. Netflix ( NFLX ) stock surged more than 6% after the company's ...",ABBV,0.050359,0.036867,Neutral
Stocks Lower After Jobless Claims; Netflix Earnings Due,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fall-ahead-of-jobless-claims-netflix-earnings-due/,2023-01-19 15:00:00,Dow Jones Falls 225 Points After Jobless Claims. Netflix Earnings Due Investor's Business Daily ...,ABBV,0.055816,0.036997,Neutral
3 Unstoppable Stocks to Keep Buying in 2023,https://www.fool.com/investing/2023/01/19/3-unstoppable-stocks-to-keep-buying-in-2023/,2023-01-19 10:30:00,These companies have what it takes to drive long-term share performance.,ABBV,0.3007,0.303837,Somewhat-Bullish
IBD Stock Of The Day Vertex Stacks Up Billions In Sales Potential,https://www.investors.com/research/ibd-stock-of-the-day/vrtx-stock-finds-support-as-billions-in-potential-sales-stack-up/,2023-01-18 17:50:00,VRTX Stock Finds Support As Billions In Potential Sales Stack Up Investor's Business Daily ...,ABBV,0.104228,0.041326,Neutral
2 Cheap Growth Stocks That Can Set You Up for Life,https://www.fool.com/investing/2023/01/18/2-cheap-growth-stocks-that-can-set-you-up-for-life/,2023-01-18 14:53:05,"Over the past 10 years, these stocks have each risen by more than 340%.",ABBV,0.439243,0.384879,Bullish
ABBV: 3 Safe High-Dividend Stocks to Buy Right Now,https://stocknews.com/news/abbv-gild-mpx-3-safe-high-dividend-stocks-to-buy-right-now/,2023-01-18 14:19:50,"The December CPI marked the sixth-straight monthly decline, as prices rose 6.5% annually, down from 7.1% in November 2022. However, Simona Mocuta, Chief economist at State Street Global Advisors, said, ""We know that we won't get the same kind of support from gasoline prices, so don't expect the ...",ABBV,0.290033,0.113432,Neutral
One of the greatest cancer drugs ever has suddenly lost its edge. This is why it was vulnerable.,https://www.marketwatch.com/story/one-of-the-greatest-cancer-drugs-ever-has-suddenly-lost-its-edge-this-is-why-it-was-vulnerable-11674050773,2023-01-18 14:06:00,"Imbruvica seemed invincible in the marketplace. But a new book, ""For Blood and Money,"" shows how the drug's creators left a trap door that led to its undoing.",ABBV,0.143202,-0.043646,Neutral
JUVÉDERM® VOLUX XC FOR IMPROVEMENT OF JAWLINE DEFINITION NOW AVAILABLE NATIONWIDE,https://investingnews.com/juvederm-r-volux-xc-for-improvement-of-jawline-definition-now-available-nationwide/,2023-01-18 13:34:08,"With JUVÉDERM ® VOLUX™ XC, You Can Receive Non-Surgical Jawline Augmentation in Your Aesthetic Provider's Office",ABBV,0.228533,0.201787,Somewhat-Bullish
"Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023",https://www.globenewswire.com/news-release/2023/01/18/2590907/0/en/Royalty-Pharma-To-Announce-Fourth-Quarter-And-Full-Year-2022-Financial-Results-On-February-15-2023.html,2023-01-18 13:25:00,"NEW YORK, Jan. 18, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will report its fourth quarter and full year 2022 financial results on Wednesday, February 15, 2023 before the U.S. financial markets open.",ABBV,0.138464,0.094471,Neutral
"Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023",https://www.benzinga.com/pressreleases/23/01/g30460541/royalty-pharma-to-announce-fourth-quarter-and-full-year-2022-financial-results-on-february-15-2023,2023-01-18 13:25:00,"NEW YORK, Jan. 18, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it will report its fourth quarter and full year 2022 financial results on Wednesday, February 15, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous ...",ABBV,0.132368,0.092288,Neutral
Capsida Biotherapeutics Announces Appointment of Julie Hakim as Chief Financial Officer,https://www.prnewswire.com/news-releases/capsida-biotherapeutics-announces-appointment-of-julie-hakim-as-chief-financial-officer-301723905.html,2023-01-18 12:45:00,Capsida Biotherapeutics Announces Appointment of Julie Hakim as ... PR ...,ABBV,0.064973,0.068269,Neutral
AbbVie  ( ABBV )  Dips More Than Broader Markets: What You Should Know,https://www.zacks.com/stock/news/2040388/abbvie-abbv-dips-more-than-broader-markets-what-you-should-know,2023-01-17 22:45:22,"In the latest trading session, AbbVie (ABBV) closed at $152.83, marking a -0.5% move from the previous day.",ABBV,0.699089,0.318268,Somewhat-Bullish
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference,https://www.benzinga.com/pressreleases/23/01/g30450762/cytomx-therapeutics-to-present-at-the-b-riley-securities-virtual-annual-oncology-investor-conferen,2023-01-17 21:05:00,"SOUTH SAN FRANCISCO, Calif., Jan. 17, 2023 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. CTMX, a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present at the B.",ABBV,0.157483,-0.053591,Neutral
ELEVAI LABS RETURNS TO INDUSTRY-LEADING OCTANE AESTHETICS TECH FORUM,https://www.prnewswire.com/news-releases/elevai-labs-returns-to-industry-leading-octane-aesthetics-tech-forum-301723876.html,2023-01-17 20:45:00,ELEVAI LABS RETURNS TO INDUSTRY-LEADING OCTANE ... PR ...,ABBV,0.092569,0.004281,Neutral
ELEVAI LABS RETURNS TO INDUSTRY-LEADING OCTANE AESTHETICS TECH FORUM,https://www.newswire.ca/news-releases/elevai-labs-returns-to-industry-leading-octane-aesthetics-tech-forum-843405503.html,2023-01-17 20:45:00,ELEVAI LABS RETURNS TO INDUSTRY-LEADING OCTANE ... Canada ...,ABBV,0.092569,0.004281,Neutral
Could This FDA Approval Boost AbbVie's Stock?,https://www.fool.com/investing/2023/01/17/could-this-fda-approval-boost-abbvies-stock/,2023-01-17 15:07:00,"Last month, one of its anti-psychotic drugs received approval from the Food and Drug Administration for another indication.",ABBV,0.266246,0.08622,Neutral
SkinMedica® Launches Even & Correct - Investing News Network,https://investingnews.com/skinmedica-r-launches-even-correct/,2023-01-17 13:36:58,SkinMedica® Launches Even & Correct Investing News Network ...,ABBV,0.252612,0.247162,Somewhat-Bullish
"With Competition on the Rise, Is AbbVie's Dividend Safe?",https://www.fool.com/investing/2023/01/17/with-competition-on-rise-is-abbvie-dividend-safe/,2023-01-17 12:45:00,This year isn't starting on the best of notes for the drugmaker.,ABBV,0.645268,0.280736,Somewhat-Bullish
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF  ( PJP ) ?,https://www.zacks.com/stock/news/2039886/should-you-invest-in-the-invesco-dynamic-pharmaceuticals-etf-pjp,2023-01-17 11:20:08,Sector ETF report for ...,ABBV,0.130926,0.063433,Neutral
"AbbVie, Eli Lilly Leave UK's Voluntary Medicines Pricing Agreement Over Increasing Prices",https://www.benzinga.com/general/biotech/23/01/30434677/abbvie-eli-lilly-leave-uks-voluntary-medicines-pricing-agreement-over-increasing-prices,2023-01-17 11:03:20,The Association of the British Pharmaceutical Industry ( ABPI ) said pharmaceutical giants AbbVie Inc ABBV and Eli Lilly And Co LLY have withdrawn from Britain's voluntary medicines pricing agreement.,ABBV,0.451494,0.359035,Bullish
This Monumental Breakthrough Could Turn the World Upside Down -- and Make Some Investors Filthy Rich,https://www.fool.com/investing/2023/01/17/monumental-breakthrough-turn-the-world-upside-down/,2023-01-17 10:55:00,The fountain of youth might not be a myth in the future.,ABBV,0.136113,0.040668,Neutral
Is AbbVie a Good Dividend Stock to Buy on the Dip?,https://www.fool.com/investing/2023/01/17/is-abbvie-a-good-dividend-stock-to-buy-on-the-dip/,2023-01-17 10:47:00,"The stock offers an attractive yield, but investors need to brace for declining revenue this year.",ABBV,0.376194,0.192707,Somewhat-Bullish
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income,https://www.zacks.com/stock/news/2039608/3-top-ranked-dividend-stocks-a-smarter-way-to-boost-your-retirement-income,2023-01-16 14:10:02,"The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",ABBV,0.210274,0.120453,Neutral
Sirona Biochem Announces the Termination of Supply Agreement with Rodan + Fields,https://www.globenewswire.com/news-release/2023/01/16/2589229/0/en/Sirona-Biochem-Announces-the-Termination-of-Supply-Agreement-with-Rodan-Fields.html,2023-01-16 14:00:00,"VANCOUVER, British Columbia, Jan. 16, 2023 ( GLOBE NEWSWIRE ) -- Sirona Biochem Corp. ( TSX-V: SBM ) ( FSE: ZSB ) ( OTC: SRBCF ) ( ""Sirona"" ) announces the termination of the Rodan + Fields ( R+F ) agreement for supply and use of TFC-1067 in commercial formulations.",ABBV,0.18967,0.188631,Somewhat-Bullish
5 Dividend Kings I Bought for My Portfolio,https://www.fool.com/investing/2023/01/16/5-dividend-kings-i-bought-for-my-portfolio/,2023-01-16 13:45:00,Rely upon income-generating stocks to see your portfolio through times of upheaval.,ABBV,0.211652,0.167831,Somewhat-Bullish
ABBV: The #1 Pharma Stock to Buy in January 2023,https://stocknews.com/news/abbv-jnj-pfe-bmy-the-no-1-pharma-stock-to-buy-in-january-2023/,2023-01-16 13:20:02,ABBV: The No. 1 Pharma Stock to Buy in January ...,ABBV,0.650496,0.212808,Somewhat-Bullish
Should First Trust Morningstar Dividend Leaders ETF  ( FDL )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2039434/should-first-trust-morningstar-dividend-leaders-etf-fdl-be-on-your-investing-radar,2023-01-16 11:20:09,Style Box ETF report for ...,ABBV,0.121037,0.068013,Neutral
"AbbVie, Eli Lilly exit UK drug pricing agreement",https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-eli-lilly-exit-uk-drug-pricing-agreement-2023-01-16/,2023-01-16 08:58:00,"[1/2] Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/Files Jan 16 ( Reuters ) - Pharmaceutical companies AbbVie ( ABBV.N ) and Eli Lilly have withdrawn from Britain's voluntary medicines pricing agreement, an industry ...",ABBV,0.366061,0.29896,Somewhat-Bullish
Bipolar Disorder Market will worth USD 7.6 billion by 2030 : GreyViews,https://www.benzinga.com/pressreleases/23/01/g30422354/bipolar-disorder-market-will-worth-usd-7-6-billion-by-2030-greyviews,2023-01-14 19:00:00,"Pune India, Jan. 14, 2023 ( GLOBE NEWSWIRE ) -- The market has been studied for the below mentioned-segmentation and regional analysis for North America, Europe, Asia, South America, and the Middle East and Africa. These are the key regions where the bipolar disorder market is operating and is ...",ABBV,0.025734,-0.024026,Neutral
"Prostate Cancer Therapeutics Market will worth to USD 19,619 million by 2030 : GreyViews",https://www.benzinga.com/pressreleases/23/01/g30416679/prostate-cancer-therapeutics-market-will-worth-to-usd-19-619-million-by-2030-greyviews,2023-01-13 20:00:00,"Pune India, Jan. 13, 2023 ( GLOBE NEWSWIRE ) -- The market has been studied for the below mentioned-segmentation and regional analysis for North America, Europe, Asia, South America, and the Middle East and Africa.",ABBV,0.024273,-0.007536,Neutral
ABBV: 3 Safe Dividend Stocks to Buy Today and Hold Forever,https://stocknews.com/news/abbv-mpx-bset-3-safe-dividend-stocks-to-buy-today-and-hold-forever/,2023-01-13 18:44:38,"The Consumer Price Index ( CPI ) for December 2022 declined further, marking the sixth consecutive month of cooling inflation. CPI rose 6.5% from a year ago, the smallest annual increase since October 2021. This is raising the possibility of slower rate hikes ahead.",ABBV,0.344074,0.073466,Neutral
ABBV: 3 Stocks to Buy Right Now for the Long Term,https://stocknews.com/news/abbv-ko-cnc-3-stocks-to-buy-right-now-for-the-long-term/,2023-01-13 17:12:30,"Last year, the Federal Reserve's seven interest rate hikes finally showed results, as the Consumer Price Index ( CPI ) for December came on par with analyst estimates, rising 6.5% year-over-year and declining 0.1% over the prior month.",ABBV,0.223718,0.11976,Neutral
Want to Get Richer? 3 Best Stocks to Buy Now and Hold Forever,https://www.fool.com/investing/2023/01/13/want-to-get-richer-3-best-stocks-to-buy-now-and-ho/,2023-01-13 14:45:00,Steady growth and dividends in an evergreen industry like healthcare can be a winning investment strategy.,ABBV,0.295155,0.221555,Somewhat-Bullish
"Autoimmune Patient Perspective on the Corporate Reputation of Pharma Companies, 2021-2022: The Views of 293 Patient Groups - Pfizer Ranked 1st, AbbVie Ranked 2nd, Novartis Ranked 3rd",https://www.prnewswire.com/news-releases/autoimmune-patient-perspective-on-the-corporate-reputation-of-pharma-companies-2021-2022-the-views-of-293-patient-groups---pfizer-ranked-1st-abbvie-ranked-2nd-novartis-ranked-3rd-301721006.html,2023-01-13 11:15:00,Autoimmune Patient Perspective on the Corporate Reputation of ... PR ...,ABBV,0.124325,0.167157,Somewhat-Bullish
Peering Into AbbVie's Recent Short Interest - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/short-sellers/23/01/30397090/peering-into-abbvies-recent-short-interest,2023-01-12 19:10:31,"AbbVie's ABBV short percent of float has fallen 5.19% since its last report. The company recently reported that it has 12.93 million shares sold short, which is 0.73% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.5 days to cover their ...",ABBV,0.224903,0.085754,Neutral
"Zacks Market Edge Highlights: EXAS, ZM, TSLA, ABBV, ZOM",https://www.zacks.com/stock/news/2038249/zacks-market-edge-highlights-exas-zm-tsla-abbv-zom,2023-01-12 10:00:00,"EXAS, ZM, TSLA, ABBV, ZOM have been highlighted in this Market Edge article.",ABBV,0.166169,0.11855,Neutral
Michael Kommonen has been appointed as the new CFO of SSH Communications Security Plc,https://www.globenewswire.com/news-release/2023/01/12/2587593/0/en/Michael-Kommonen-has-been-appointed-as-the-new-CFO-of-SSH-Communications-Security-Plc.html,2023-01-12 07:00:00,"SSH Communications Security Corporation - Stock Exchange Release - January 12, 2023, at ...",ABBV,0.114137,0.0,Neutral
The Stocks Behind 2022's Popular ETFs,https://www.zacks.com/stock/news/2038099/the-stocks-behind-2022s-popular-etfs,2023-01-11 21:01:00,What stocks do popular ETF managers like Cathie Wood own in their portfolios?,ABBV,0.189175,0.129982,Neutral
Nasdaq Leads Stock Market Gains; Real Estate Stocks Boom As Mortgage Rates Fall; Tesla Climbs,https://www.investors.com/market-trend/stock-market-today/nasdaq-leads-stock-market-gains-real-estate-stocks-boom-as-mortgage-rates-fall-tesla-climbs/,2023-01-11 18:55:00,Nasdaq Leads Stock Market Gains. Real Estate Stocks Boom As ... Investor's Business Daily ...,ABBV,0.102013,-0.171542,Somewhat-Bearish
"Stocks making the biggest moves midday: Bed Bath & Beyond, Tesla, Expedia and more",https://www.cnbc.com/2023/01/11/stocks-making-the-biggest-moves-midday-bed-bath-beyond-tesla-expedia-and-more.html,2023-01-11 17:43:42,These are the stocks posting the largest moves in midday trading.,ABBV,0.187463,0.055737,Neutral
Dow Jones Rises Ahead Of Inflation Data; Tesla Jumps On Texas Plans; Warren Buffet Stock Reports Tomorrow,https://www.investors.com/market-trend/stock-market-today/dow-jones-rises-ahead-of-inflation-data-tesla-soars-on-texas-plans-warren-buffett-stock-on-tap/,2023-01-11 15:39:00,Dow Jones Rises Ahead Of Inflation Data. Tesla Jumps On Texas ... Investor's Business Daily ...,ABBV,0.121959,-0.193377,Somewhat-Bearish
"HALOZYME THERAPEUTICS, INC. ANNOUNCES REDEMPTION OF 1.25% CONVERTIBLE SENIOR NOTES DUE 2024",https://www.prnewswire.com/news-releases/halozyme-therapeutics-inc-announces-redemption-of-1-25-convertible-senior-notes-due-2024--301718785.html,2023-01-11 13:30:00,"HALOZYME THERAPEUTICS, INC. ANNOUNCES REDEMPTION ... PR ...",ABBV,0.055236,0.084034,Neutral
3 Supercharged Dividend Stocks to Buy If There's a Stock Market Sell-Off,https://www.fool.com/investing/2023/01/11/3-supercharged-dividend-stocks-to-buy-if-theres-a/,2023-01-11 12:50:00,"These three healthcare stocks all deliver dependable dividends, with yields of 3% or more.",ABBV,0.349153,0.081689,Neutral
"If You Like Dividends, You Should Love These 3 Stocks",https://www.fool.com/investing/2023/01/11/if-you-like-dividends-you-should-love-these-3-stoc/,2023-01-11 12:10:00,"From growth to value, these companies reward shareholders handsomely.",ABBV,0.341587,0.226602,Somewhat-Bullish
"1 Hot Growth Stock to Buy Now, and 1 to Avoid",https://www.fool.com/investing/2023/01/11/1-hot-growth-stock-to-buy-now-and-1-to-avoid/,2023-01-11 10:30:00,One company is gearing up for further growth while the other stumbles over itself.,ABBV,0.163909,0.05047,Neutral
AbbVie  ( ABBV )  Stock Moves -0.43%: What You Should Know,https://www.zacks.com/stock/news/2046564/abbvie-abbv-stock-moves--043-what-you-should-know,2023-01-30 22:45:19,"AbbVie (ABBV) closed at $145.65 in the latest trading session, marking a -0.43% move from the prior day.",ABBV,0.651499,0.220281,Somewhat-Bullish
"Down 14.5%, Is Pfizer Stock a Screaming Buy?",https://www.fool.com/investing/2023/01/30/down-145-is-pfizer-stock-a-screaming-buy/,2023-01-30 21:00:00,Pfizer's declining COVID-19 franchise and upcoming patent expirations have weighed heavily on its stock.,ABBV,0.130926,0.0,Neutral
Eli Lilly  ( LLY )  Lymphoma Candidate Pirtobrutinib Gets FDA Nod,https://www.zacks.com/stock/news/2046350/eli-lilly-lly-lymphoma-candidate-pirtobrutinib-gets-fda-nod,2023-01-30 15:11:00,The FDA approves Eli Lilly's Jaypirca (pirtobrutinib) under an accelerated approval pathway as a treatment for mantle cell lymphoma (MCL).,ABBV,0.132368,0.0,Neutral
"Global Pharmaceutical Drug Delivery Market worth $2,206.5 billion by 2026 - Exclusive Report by MarketsandMarkets™",https://www.benzinga.com/pressreleases/23/01/g30622827/global-pharmaceutical-drug-delivery-market-worth-2-206-5-billion-by-2026-exclusive-report-by-marke,2023-01-30 14:30:00,"Chicago, Jan. 30, 2023 ( GLOBE NEWSWIRE ) -- According to the new market research report ""Pharmaceutical Drug Delivery Market Size, Growth by Route of Administration ( Oral, Injectors, Implantable, Syrups, Gels, Pulmonary, Solutions, Tablets, Syringes ) , Application ( Cancer, Diabetes ) , ...",ABBV,0.087503,0.021576,Neutral
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks,https://www.zacks.com/stock/news/2046227/how-to-maximize-your-retirement-portfolio-with-these-top-ranked-dividend-stocks,2023-01-30 14:10:04,"The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",ABBV,0.207127,0.119051,Neutral
"S&P Global, AbbVie, And This Big 3 Automaker On CNBC's 'Final Trades'",https://www.benzinga.com/news/23/01/30617473/s-p-global-abbvie-and-this-big-3-automaker-on-cnbcs-final-trades,2023-01-30 13:24:31,"On CNBC's ""Halftime Report Final Trades,"" Karen Firestone of Aureus Asset Management said S&P Global Inc. SPGI went through a lot during the past few years. It was a ""very hot stock"" moving into the Covid-19 pandemic, but it dropped when interest rates started moving higher.",ABBV,0.578355,0.422655,Bullish
Tech Futures Sell Off With Fed Meeting In Sight,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fall-with-fed-meeting-in-sight-tesla-stock-upgraded-to-buy/,2023-01-30 13:15:00,Dow Jones Futures Fall With Fed Meeting In Sight. Tesla Stock ... Investor's Business Daily ...,ABBV,0.05387,0.037972,Neutral
Sandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilar,https://www.globenewswire.com/news-release/2023/01/30/2597240/0/en/Sandoz-receives-positive-CHMP-opinion-for-citrate-free-high-concentration-formulation-of-adalimumab-biosimilar.html,2023-01-30 06:15:00,"Basel, January 30, 2023 - Sandoz, a global leader in off-patent ( generic and biosimilar ) medicines, today announced that the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) , has adopted a positive opinion for marketing authorization for a ...",ABBV,0.041039,0.0,Neutral
"From Jeff Bezos to Jack Dorsey, here are 14 the world's wealthiest entrepreneurs trying to crack the code of living forever",https://markets.businessinsider.com/news/stocks/list-wealthiest-entrepreneurs-searching-for-the-secret-to-longevity-2023-1,2023-01-29 12:20:00,"Oracle co-founder Larry Ellison, with a net worth of $101 billion according to the Bloomberg Billionaires Index, has donated millions to anti-aging research since 1997. Insider's Cadie Thompson reported that in 2003, Oracle founder Larry Ellison told his biographer, ""Death has never made any ...",ABBV,0.021699,0.026809,Neutral
2 of the Best Dividend Stocks to Own in 2023,https://www.fool.com/investing/2023/01/28/2-of-the-best-dividend-stocks-to-own-in-2023/,2023-01-28 10:30:00,You can count on them for passive income and growth over time.,ABBV,0.437082,0.482526,Bullish
13 Best Dividend ETFs To Outperform In 2023,https://www.forbes.com/sites/investor-hub/article/13-best-dividend-etfs-to-outperform/,2023-01-27 22:05:09,Ready to ramp up your income in 2023? The right dividend exchange-traded funds (ETFs) can make it happen.,ABBV,0.023169,0.229276,Somewhat-Bullish
ABBV: 3 High-Quality Stocks to Buy Hand Over Fist These Days,https://stocknews.com/news/abbv-csco-bossy-3-high-quality-stocks-to-buy-hand-over-fist-these-days/,2023-01-27 17:45:52,"Despite being marred by the macroeconomic headwinds and heavy losses last year, the stock market has embarked on a recovery so far in 2023. In the past three months, equities have cheered the early signs of disinflation, leading investors to hope for an end to the Fed's aggressive interest ...",ABBV,0.247208,0.170217,Somewhat-Bullish
Futures Fall After Inflation Data: Intel Plunges On Earnings,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-dip-after-inflation-data-intel-plunges-on-earnings/,2023-01-27 14:24:00,"Dow Jones futures fell slightly Friday after key inflation data, with the early release of the Personal Consumption Expenditures price index. Meanwhile, Dow Jones chipmaker Intel ( INTC ) was down nearly 10% on an earnings miss.",ABBV,0.052397,0.037938,Neutral
5 Cheapest Health Care Stocks You Should Think About,https://www.benzinga.com/trading-ideas/long-ideas/23/01/30602080/5-cheapest-health-care-stocks-you-should-think-about,2023-01-27 13:48:05,"The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.",ABBV,0.367865,-0.26568,Somewhat-Bearish
"Pharma Stock Roundup: JNJ Q4 Results Mixed, MRK Keytruda Prostate Cancer Study Ends",https://www.zacks.com/stock/news/2045345/pharma-stock-roundup-jnj-q4-results-mixed-mrk-keytruda-prostate-cancer-study-ends,2023-01-27 13:14:00,J&J (JNJ) reports mixed fourth-quarter results. Merck (MRK) discontinues an advanced prostate cancer study on blockbuster drug Keytruda for futility.,ABBV,0.04583,-0.123346,Neutral
3 Reasons Wall Street Thinks InMode Can Rocket 47% Higher in 2023,https://www.fool.com/investing/2023/01/27/3-reasons-wall-street-thinks-inmode-can-rocket-47/,2023-01-27 10:37:00,Analysts' price targets for this stock suggest it could soon put up some big gains.,ABBV,0.068112,0.071407,Neutral
"Tech Futures Rally After GDP, Jobless Claims",https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fall-ahead-of-key-economic-data-tesla-stock-surges-on-earnings-musk-comments/,2023-01-26 13:58:00,Dow Jones Futures Rise After Key Economic Data. Tesla Surges On ... Investor's Business Daily ...,ABBV,0.046452,0.037652,Neutral
CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific  ( TCB )  Collaboration with Astellas,https://www.globenewswire.com/news-release/2023/01/26/2595893/37704/en/CytomX-Therapeutics-Announces-Milestone-Achievement-in-Probody-T-Cell-Engaging-Bispecific-TCB-Collaboration-with-Astellas.html,2023-01-26 12:00:00,-Achievement of clinical candidate is the first in the multi-target collaboration and triggers a $5 million milestone payment to ...,ABBV,0.068209,-0.02641,Neutral
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years,https://www.benzinga.com/news/earnings/23/01/30574491/heres-how-much-you-would-have-made-owning-abbvie-stock-in-the-last-10-years,2023-01-25 19:30:57,"AbbVie ABBV has outperformed the market over the past 10 years by 4.47% on an annualized basis producing an average annual return of 14.72%. Currently, AbbVie has a market capitalization of $260.51 billion.",ABBV,0.983605,0.387251,Bullish
PFE: 3 Top Pharma Stocks to Buy for the Long Haul,https://stocknews.com/news/pfe-abbv-jnj-3-top-pharma-stocks-to-buy-for-the-long-haul/,2023-01-25 17:52:16,"The pharmaceutical sector played a critical role during the pandemic. Moreover, the industry is predicted to grow with an ageing population and the rise of chronic diseases. According to Statista, global pharmaceutical revenue is expected to expand at a 5.4% CAGR to $1.44 trillion by 2027.",ABBV,0.312599,0.206907,Somewhat-Bullish
Allergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023,https://investingnews.com/allergan-aesthetics-takes-a-3600approach-to-non-surgical-aesthetic-treatments-to-improve-patient-outcomes-with-expert-led-medical-education-symposium-at-imcas-2023/,2023-01-25 17:03:25,"Allergan Aesthetics, an ABBVie company ( NYSE: ABBV ) , today unveiled at the 24 th International Master Course on Aging Science ( IMCAS ) World Congress its immersive experience 'Discover your 360 °' .",ABBV,0.288214,0.345075,Somewhat-Bullish
"St. Jude Children's Research Hospital unveils 45,000-square-foot Family Commons [updated]",https://www.benzinga.com/pressreleases/23/01/g30568175/st-jude-childrens-research-hospital-unveils-45-000-square-foot-family-commons-updated,2023-01-25 14:31:00,"MEMPHIS, Tenn. and NORTH CHICAGO, Ill., Jan. 25, 2023 ( GLOBE NEWSWIRE ) -- St. Jude Children's Research Hospital® and AbbVie, a research-based global biopharmaceutical company, today unveiled the multimillion-dollar Family Commons, the first-ever treatment-and-clinical-staff-free floor at the ...",ABBV,0.251124,0.312502,Somewhat-Bullish
"Futures Fall As Boeing, Microsoft Report Earnings",https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fall-200-points-as-boeing-microsoft-drop-on-earnings-tesla-earnings-due/,2023-01-25 13:57:00,"Dow Jones Futures Fall 280 Points As Boeing, Microsoft Drop On ... Investor's Business Daily ...",ABBV,0.050786,0.037883,Neutral
3 Reasons to Buy AbbVie and 2 Reasons Not to Buy,https://www.fool.com/investing/2023/01/25/3-reasons-to-buy-abbvie-and-2-reasons-not-to-buy/,2023-01-25 12:05:00,"The pharmaceutical specialist is facing a pivotal year in 2023, thanks to growing competition.",ABBV,0.403264,0.119492,Neutral
Want Safety and Growth in 2023? Try These Dividend Stocks.,https://www.fool.com/investing/2023/01/25/want-safety-growth-in-2023-try-dividend-stocks/,2023-01-25 11:00:00,Passive income is particularly welcome during tough market times.,ABBV,0.441698,0.2807,Somewhat-Bullish
Sosei Heptares Webinar Presentation for FY2022 Financial Results,https://www.globenewswire.com/news-release/2023/01/25/2594847/0/en/Sosei-Heptares-Webinar-Presentation-for-FY2022-Financial-Results.html,2023-01-25 06:30:00,"TOKYO and CAMBRIDGE, United Kingdom, Jan. 25, 2023 ( GLOBE NEWSWIRE ) -- Sosei Group Corporation ( ""the Company"". TSE: 4565 ) , the world leader in G protein-coupled receptor ( GPCR ) focused structure-based drug design ( SBDD ) and development, will announce its earnings results and present ...",ABBV,0.072655,0.043246,Neutral
Pharma Market Forecast: 3 Top Trends That Will Affect Pharma in 2023,https://investingnews.com/pharma-forecast/,2023-01-24 21:15:00,"Pharma investments have disappointed investors in the recent past, but some experts believe the market will regain confidence from investors in 2023. Read on to learn about the trends that will drive the industry.",ABBV,0.056808,0.0,Neutral
Futures Down: Economic Data Due; 6 Earnings Reporters,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fall-as-6-key-earnings-movers-report-microsoft-earnings-due/,2023-01-24 13:27:00,Dow Jones Futures Fall As 6 Key Earnings Movers Report. Microsoft ... Investor's Business Daily ...,ABBV,0.043421,0.037417,Neutral
Alvotech and Bioventure Announce Approval of AVT02  ( adalimumab )  as Simlandi in Saudi Arabia,https://www.globenewswire.com/news-release/2023/01/24/2593871/0/en/Alvotech-and-Bioventure-Announce-Approval-of-AVT02-adalimumab-as-Simlandi-in-Saudi-Arabia.html,2023-01-24 09:00:00,"Alvotech ( NASDAQ: ALVO ) and Bioventure, a wholly owned subsidiary of GlobalOne Healthcare Holding LLC ( ""GHH"" ) , the healthcare division of Yas Holding LLC, today announced that the Saudi Food & Drug Authority ( ""SFDA"" ) has approved the manufacturing and distribution of AVT02, a biosimilar ...",ABBV,0.021562,0.0,Neutral
Alvotech and Bioventure Announce Approval of AVT02  ( adalimumab )  as Simlandi in Saudi Arabia,https://www.globenewswire.com/news-release/2023/01/24/2593869/0/en/Alvotech-and-Bioventure-Announce-Approval-of-AVT02-adalimumab-as-Simlandi-in-Saudi-Arabia.html,2023-01-24 09:00:00,"REYKJAVIK, Iceland and DUBAI, United Arab Emirates, Jan. 24, 2023 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) and Bioventure, a wholly owned subsidiary of GlobalOne Healthcare Holding LLC ( ""GHH"" ) , the healthcare division of Yas Holding LLC, today announced that the Saudi Food & Drug ...",ABBV,0.021388,0.0,Neutral
Biotech Market Forecast: 3 Top Trends That Will Affect Biotech in 2023,https://investingnews.com/biotech-forecast/,2023-01-24 02:40:50,"Pull quotes were provided by Investing News Network clients Avricore Health and Sirona Biochem. This article is not paid-for content. As investors look ahead into 2023, what trends could set the standard for the new year in the world of biotech?",ABBV,0.050679,0.108352,Neutral
AbbVie  ( ABBV )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2042882/abbvie-abbv-stock-sinks-as-market-gains-what-you-should-know,2023-01-23 22:45:21,"In the latest trading session, AbbVie (ABBV) closed at $148.55, marking a -0.7% move from the previous day.",ABBV,0.642187,0.395083,Bullish
"St. Jude Children's Research Hospital unveils 45,000-square-foot Family Commons",https://www.benzinga.com/pressreleases/23/01/g30529587/st-jude-childrens-research-hospital-unveils-45-000-square-foot-family-commons,2023-01-23 18:03:11,"MEMPHIS, Tenn. and NORTH CHICAGO, Ill., Jan. 23, 2023 ( GLOBE NEWSWIRE ) -- St. Jude Children's Research Hospital® and AbbVie, a research-based global biopharmaceutical company, today unveiled the multimillion-dollar Family Commons, the first-ever treatment-and-clinical-staff-free floor at the ...",ABBV,0.257183,0.318136,Somewhat-Bullish
Hair Transplant Market is expected to grow from USD 5 billion in 2022 to USD 24.53 billion by 2030 : GreyViews,https://www.benzinga.com/pressreleases/23/01/g30529445/hair-transplant-market-is-expected-to-grow-from-usd-5-billion-in-2022-to-usd-24-53-billion-by-2030,2023-01-23 18:00:00,"Pune India, Jan. 23, 2023 ( GLOBE NEWSWIRE ) -- The market has been studied for the below mentioned-segmentation and regional analysis for North America, Europe, Asia, South America, and the Middle East and Africa. These are the key regions where the hair transplant market is operating and is ...",ABBV,0.023418,0.018241,Neutral
JNJ: 1 Stable Stock to Put on Your Buy List Now,https://stocknews.com/news/jnj-mrk-abbv-pfe-1-stable-stock-to-put-on-your-buy-list-now/,2023-01-23 17:11:26,The market's promising start to the year is at the risk of fizzling out amid underwhelming earnings releases and other indicators of an economy weighed down by increased borrowing costs due to the Federal Reserve's perpetual interest rate hikes.,ABBV,0.104228,0.082727,Neutral
AbbVie Inc.  ( ABBV )  is Attracting Investor Attention: Here is What You Should Know,https://www.zacks.com/stock/news/2042605/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know,2023-01-23 14:00:10,"AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",ABBV,0.484798,0.095306,Neutral
"Charles River Laboratories, AbbVie, Star Bulk Carriers And This Big Bank Are CNBC's 'Final Trades'",https://www.benzinga.com/news/23/01/30517421/charles-river-laboratories-abbvie-star-bulk-carriers-and-this-big-bank-are-cnbcs-final-trades,2023-01-23 13:40:47,"On CNBC's ""Halftime Report Final Trades,"" Jason Snipe of Odyssey Capital Advisors said Charles River Laboratories International, Inc. CRL is trading at 20 time earnings and has a strong free cash flow. Stephen Weiss of Short Hills Capital Partners named The Goldman Sachs Group, Inc.",ABBV,0.495015,0.590392,Bullish
"Futures Rise Ahead Of Key Economic Data, Earnings Reports",https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-rise-ahead-of-key-economic-data-earnings-reports-amd-jumps-on-upgrade/,2023-01-23 13:28:00,"Dow Jones futures rose Monday ahead of a busy week of key economic data and as the dollar dropped to an eight-month low. A big week of earnings news includes results from Tesla, due out Wednesday. Advanced Micro Devices ( AMD ) jumped more than 2% after a Barclays upgrade to overweight.",ABBV,0.049526,0.037829,Neutral
2 Top Passive-Income Stocks to Own in 2023,https://www.fool.com/investing/2023/01/22/2-top-passive-income-stocks-to-own-in-2023/,2023-01-23 00:05:00,These dividend stocks can deliver both downside protection and capital appreciation.,ABBV,0.338582,0.247503,Somewhat-Bullish
AbbVie Is Set to Lose on Its Biggest Blockbuster. Here's Why You Shouldn't Worry.,https://www.fool.com/investing/2023/01/22/abbvie-to-lose-on-blockbuster-but-can-still-grow/,2023-01-22 10:30:00,Two newer immunology drugs look like big tickets to growth.,ABBV,0.519165,0.313578,Somewhat-Bullish
AbbVie  ( ABBV )  Q4 2022 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/02/09/abbvie-abbv-q4-2022-earnings-call-transcript/,2023-02-09 23:00:27,"ABBV earnings call for the period ending December 31, 2022.",ABBV,0.045504,0.09758,Neutral
Royalty Pharma to Present at Upcoming Investor Conferences,https://www.globenewswire.com/news-release/2023/02/09/2605520/0/en/Royalty-Pharma-to-Present-at-Upcoming-Investor-Conferences.html,2023-02-09 21:15:00,"NEW YORK, Feb. 09, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will participate in the following upcoming investor conferences during the months of February and March: ...",ABBV,0.143415,0.096318,Neutral
Royalty Pharma to Present at Upcoming Investor Conferences - Royalty Pharma  ( NASDAQ:RPRX ) ,https://www.benzinga.com/pressreleases/23/02/g30844605/royalty-pharma-to-present-at-upcoming-investor-conferences,2023-02-09 21:15:00,"NEW YORK, Feb. 09, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it will participate in the following upcoming investor conferences during the months of February and March: SVB Securities Global Biopharma Conference on Thursday, February 16 at 10:40 a.m. ET",ABBV,0.136888,0.093897,Neutral
"Diabetes Giant Easily Tops Quarterly Expectations, Keeps Outlook",https://www.investors.com/news/technology/dexcom-stock-dexcom-earnings-q4-2022/,2023-02-09 21:13:00,"Dexcom Stock Rises On Fourth-Quarter Beat, Reiterates Sales ... Investor's Business Daily ...",ABBV,0.207571,-0.184626,Somewhat-Bearish
The End of AbbVie's $200 Billion Monopoly Won't Sink the Stock,https://www.wsj.com/articles/the-end-of-abbvies-200-billion-monopoly-wont-sink-the-stock-11675965537,2023-02-09 17:58:00,The drugmaker is offering steep discounts on its immune-disease therapy Humira to protect market share this year.,ABBV,0.827318,0.215926,Somewhat-Bullish
What Stocks to Buy Today? 3 Dividend Stocks To Watch After Earnings,https://stockmarket.com/featured/what-stocks-to-buy-today-3-dividend-stocks-to-watch-after-earnings-2023-02-09,2023-02-09 17:53:50,"Dividends are payments made by a corporation to its shareholders. They are typically in the form of cash or additional shares of stock. They are a way for companies to reward their investors for holding their stock. As such, they can provide a steady source of income for investors.",ABBV,0.250386,0.154735,Somewhat-Bullish
"AbbVie  ( ABBV )  Beats Q4 Earnings Estimates, Misses on Sales",https://www.zacks.com/stock/news/2052457/abbvie-abbv-beats-q4-earnings-estimates-misses-on-sales,2023-02-09 16:37:00,"AbbVie's Q4 earnings (ABBV) beat estimates, while sales miss the same. Full-year 2023 EPS falls short of estimates.",ABBV,0.319933,0.184872,Somewhat-Bullish
AbbVie Kicks Off Humira Battle Year With Light Profit Guidance,https://www.investors.com/news/technology/abbvie-stock-abbvie-earnings-q4-2022/,2023-02-09 15:53:00,AbbVie Stock: Profit Outlook Widely Misses As U.S. Humira Battle ... Investor's Business Daily ...,ABBV,0.332658,0.258572,Somewhat-Bullish
Why AbbVie  ( ABBV )  Shares Are Trading Higher Today - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/general/biotech/23/02/30833773/abbvie-beats-on-q4-earnings-skyrizi-sales-grows-76-annual-guidance-lags-consensus,2023-02-09 15:10:47,"AbbVie Inc ABBV has reported Q4 adjusted EPS of $3.60, up 16.9% Y/Y and beating the consensus of $3.56. Overall sales increased 1.6% Y/Y ( 3.8% on an operational basis ) to $15.12 billion, missing the consensus of $15.31 billion.",ABBV,0.823417,0.202175,Somewhat-Bullish
Do Humira Biosimilars Threaten AbbVie's Dividend?,https://www.fool.com/investing/2023/02/09/do-humira-biosimilars-threaten-abbvies-dividend/,2023-02-09 14:10:00,Generic competition will eat at Humira's roughly $20 billion in annual sales.,ABBV,0.435074,0.254277,Somewhat-Bullish
AbbVie  ( ABBV )  Q4 Earnings Beat Estimates,https://www.zacks.com/stock/news/2052237/abbvie-abbv-q4-earnings-beat-estimates,2023-02-09 14:05:05,"AbbVie (ABBV) delivered earnings and revenue surprises of 1.69% and 1.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?",ABBV,0.401331,0.119612,Neutral
AbbVie Posts an Earnings Beat but Forecast Misses as Competition Intensifies,https://www.barrons.com/articles/abbvie-earnings-humira-sales-51675950222,2023-02-09 13:47:00,AbbVie reported quarterly earnings that beat analysts' estimates but revenue below consensus as sales for many of its drugs declined from the prior year. The company's full-year earnings forecast also missed estimates.,ABBV,0.933751,0.165523,Somewhat-Bullish
Futures Rise Ahead Of Jobless Claims; Disney Soars On Earnings,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-rise-ahead-of-jobless-claims-disney-surges-on-earnings/,2023-02-09 13:21:00,Futures Rise Ahead Of Jobless Claims. Disney Soars On Earnings Investor's Business Daily ...,ABBV,0.032961,0.133181,Neutral
AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results - Investing News Network,https://investingnews.com/abbvie-reports-full-year-and-fourth-quarter-2022-financial-results/,2023-02-09 13:06:14,AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results Investing News Network ...,ABBV,0.360055,0.164419,Somewhat-Bullish
AbbVie's 2023 profit forecast misses as Humira faces heat from rivals,https://www.reuters.com/business/healthcare-pharmaceuticals/abbvies-2023-profit-forecast-misses-humira-faces-heat-rivals-2023-02-09/,2023-02-09 12:51:00,"Feb 9 ( Reuters ) - AbbVie Inc ( ABBV.N ) on Thursday forecast 2023 profit below Wall Street expectations, in the first outlook since its blockbuster arthritis drug Humira faced competition from cheaper biosimilars in the United States early this year.",ABBV,0.231332,0.340654,Somewhat-Bullish
"US Stocks On Recovery Course As Earnings Lend Support: Fed's Hawkish Stance May Unwind Rally In High-Value Names, Says Analyst - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",https://www.benzinga.com/news/earnings/23/02/30829528/us-stocks-on-recovery-course-as-earnings-lend-support-feds-hawkish-stance-may-unwind-rally-in-high-,2023-02-09 11:45:21,"The see-sawing mood in the market continues as Fed's data dependency creates volatility. The index futures point to a solidly higher opening on Thursday, signaling a reversal in the sentiment seen in the previous session.",ABBV,0.110209,0.0,Neutral
"Futures rise on earnings optimism, Disney climbs on revamp plan",https://www.reuters.com/markets/us/futures-rise-earnings-optimism-disney-climbs-revamp-plan-2023-02-09/,2023-02-09 11:26:15,Feb 9 ( Reuters ) - U.S. stock index futures rose on Thursday as a slew of strong quarterly earnings lifted sentiment after worries that the Federal Reserve will keep interest rates higher for longer had fueled losses on Wall Street a day earlier.,ABBV,0.083833,0.0,Neutral
10 Highest Paying Dividend Aristocrats To Outperform In 2023,https://www.forbes.com/sites/investor-hub/article/10-highest-paying-dividend-aristocrats/,2023-02-08 22:51:43,"If you're on the hunt for reliable dividend stocks, you've likely heard of the Dividend Aristocrats.",ABBV,0.062597,0.165126,Somewhat-Bullish
Teva Pharmaceutical Industries  ( TEVA )  Q4 2022 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/02/08/teva-pharmaceutical-industries-teva-q4-2022-earnin/,2023-02-08 21:30:32,"TEVA earnings call for the period ending December 31, 2022.",ABBV,0.008961,0.094722,Neutral
Still Parsing Powell: Market Dips as Investors Ponder Latest Musings from Fed Chairman,https://www.benzinga.com/federal-reserve/23/02/30821095/still-parsing-powell-market-dips-as-investors-ponder-latest-musings-from-fed-chairman,2023-02-08 19:34:04,"( Wednesday Market Open ) Wall Street's seesaw ride continued early Wednesday as investors continued to parse Federal Reserve Chairman Jerome Powell's statements, which could be taken as hawkish or dovish depending on how you read them.",ABBV,0.037358,-0.138248,Neutral
What Are Dividend Aristocrats And Are They Good Investments?,https://www.forbes.com/sites/investor-hub/article/what-are-dividend-aristocrats-and-are-they-good-investments/,2023-02-08 18:22:58,"If you're on the hunt for reliable dividend stocks, you've likely heard of the Dividend Aristocrats.",ABBV,0.062597,0.165126,Somewhat-Bullish
Is Invesco Dynamic Pharmaceuticals ETF  ( PJP )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2051397/is-invesco-dynamic-pharmaceuticals-etf-pjp-a-strong-etf-right-now,2023-02-08 11:20:08,Smart Beta ETF report for ...,ABBV,0.11894,0.055094,Neutral
Will AbbVie's  ( ABBV )  New Drugs Continue to Drive Q4 Earnings?,https://www.zacks.com/stock/news/2051155/will-abbvies-abbv-new-drugs-continue-to-drive-q4-earnings,2023-02-07 17:17:00,AbbVie's (ABBV) fourth-quarter performance is expected to reflect the impact of strong demand for immunology and neuroscience products.,ABBV,0.3038,0.134093,Neutral
Will a More Dovish or Hawkish Powell Show Up Today After Friday's Hot Jobs Report?,https://www.benzinga.com/federal-reserve/23/02/30771524/will-a-more-dovish-or-hawkish-powell-show-up-today-after-fridays-hot-jobs-report,2023-02-07 17:13:59,"( Tuesday Market Open ) Last week, Federal Reserve Chairman Jerome Powell let loose the doves. Now, following Friday's dramatically bullish January jobs data, today's scheduled comments from the Fed chief and other central bank speakers could indicate whether the hawks are back in charge.",ABBV,0.035582,-0.137427,Neutral
ABBV: 3 Income Stocks to Buy Now if You're Starving for Cash,https://stocknews.com/news/abbv-vlo-kt-3-income-stocks-to-buy-now-if-youre-starving-for/,2023-02-07 15:10:51,"Since last year, the stock market has faced many macroeconomic challenges. The Federal Reserve has raised the interest rates several times since last year to bring down inflation which had climbed to a 40-year high.",ABBV,0.242165,0.118175,Neutral
3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income,https://www.fool.com/investing/2023/02/07/3-high-yield-healthcare-stocks-to-buy-now-for-a-li/,2023-02-07 10:41:00,These highly reliable healthcare stocks offer investors above-average dividend yields right now.,ABBV,0.275867,0.105545,Neutral
"On Tap: Earnings from Disney, Powell Speech as Market Digests Blockbuster Jobs Data - Apple  ( NASDAQ:AAPL ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/news/earnings/23/02/30733494/on-tap-earnings-from-disney-powell-speech-as-market-digests-blockbuster-jobs-data,2023-02-06 16:05:39,"( Monday Market Open ) Friday's jobs report really put the Federal Reserve in a tough place. While recession fears haven't vanished, it's tough to forecast an economic downturn with half a million people hired, upward revisions for the two prior months, and confirmation of wide breadth of jobs ...",ABBV,0.078935,-0.067231,Neutral
AbbVie  ( ABBV )  to Report Q4 Earnings: What's in the Cards?,https://www.zacks.com/stock/news/2050446/abbvie-abbv-to-report-q4-earnings-whats-in-the-cards,2023-02-06 16:01:00,AbbVie's (ABBV) Q4 performance will likely reflect strong drug demand from its immunology and neuroscience franchises. Investors will also enquire about ABBV's plans to counter Humira LOE.,ABBV,0.306416,0.171564,Somewhat-Bullish
Blue Water Vaccines Appoints Seasoned Commercial Operations Leader Frank Jaeger as Senior Vice President of Marketing and Business Development,https://www.globenewswire.com/news-release/2023/02/06/2602267/0/en/Blue-Water-Vaccines-Appoints-Seasoned-Commercial-Operations-Leader-Frank-Jaeger-as-Senior-Vice-President-of-Marketing-and-Business-Development.html,2023-02-06 15:15:00,"CINCINNATI, Feb. 06, 2023 ( GLOBE NEWSWIRE ) -- Blue Water Vaccines Inc. ( ""BWV"" or ""Blue Water Vaccines"" or the ""Company"" ) , today announced the appointment of Frank Jaeger, seasoned commercial operations and business development executive, as Senior Vice President of Marketing and Business ...",ABBV,0.072987,0.146628,Neutral
The Pulmonary Edema Therapeutics market is expected to display a steady growth of 3% due to the increase in road accidents leading to severe injury to the chest | UnivDatos Market Insights,https://www.prnewswire.com/news-releases/the-pulmonary-edema-therapeutics-market-is-expected-to-display-a-steady-growth-of-3-due-to-the-increase-in-road-accidents-leading-to-severe-injury-to-the-chest--univdatos-market-insights-301739192.html,2023-02-06 14:30:00,The Pulmonary Edema Therapeutics market is expected to display a ... PR ...,ABBV,0.038717,0.0,Neutral
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income,https://www.zacks.com/stock/news/2050321/3-top-ranked-dividend-stocks-a-smarter-way-to-boost-your-retirement-income,2023-02-06 14:10:05,"The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",ABBV,0.215894,0.122965,Neutral
The bear market could make a comeback | Business,https://www.cnn.com/2023/02/06/investing/premarket-stocks-trading,2023-02-06 12:58:00,The bear market could make a comeback ...,ABBV,0.084871,0.132447,Neutral
The bear market could make a comeback | Business,https://www.cnn.com/2023/02/06/investing/premarket-stocks-trading/index.html,2023-02-06 12:58:00,The bear market could make a comeback ...,ABBV,0.084871,0.132447,Neutral
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023,https://markets.businessinsider.com/news/stocks/neurocrine-biosciences-reports-fourth-quarter-and-fiscal-2022-financial-results-and-provides-financial-expectations-for-2023-1032070104,2023-02-06 12:30:00,Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for ...,ABBV,0.025034,0.026422,Neutral
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023,https://www.prnewswire.com/news-releases/neurocrine-biosciences-reports-fourth-quarter-and-fiscal-2022-financial-results-and-provides-financial-expectations-for-2023-301739079.html,2023-02-06 12:30:00,Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 ... PR ...,ABBV,0.020439,0.025802,Neutral
Abbvie plans to lift $2 billion cap on deals - WSJ,https://www.reuters.com/markets/deals/abbvie-plans-lift-2-billion-cap-deals-wsj-2023-02-06/,2023-02-06 11:35:00,Abbvie plans to lift $2 billion cap on deals ...,ABBV,0.485711,-0.151161,Somewhat-Bearish
News Exclusive | AbbVie Aims for New Drugs to Boost Sales as Competitors Target Humira,https://www.wsj.com/articles/abbvie-aims-for-new-drugs-to-boost-sales-as-competitors-target-humira-11675638126,2023-02-06 10:30:00,"Drugmaker is turning to next-generation successors to Humira to replenish billions of dollars in sales that will be lost, and lifting a self-imposed $2 billion limit on the size of deals it would do to add products.",ABBV,0.885652,0.351254,Bullish
Did investors learn nothing from last year's market meltdown? | Business,https://www.cnn.com/2023/02/05/investing/stocks-week-ahead/index.html,2023-02-05 12:25:00,Did investors learn nothing from last year's market meltdown? ...,ABBV,0.070725,-0.06428,Neutral
"Disney, Pepsi, Uber Set to Report During Lackluster Earnings Season",https://www.wsj.com/articles/disney-pepsi-uber-earnings-week-preview-11675467250,2023-02-04 16:00:00,"The results will shed light on the evolving state of the economy as companies face a streak of layoffs, consumers slow their spending, and the Fed works to quell inflation.",ABBV,0.366061,0.134709,Neutral
3 No-Brainer Stocks to Buy Right Now for Less Than $25,https://www.fool.com/investing/2023/02/04/3-no-brainer-stocks-to-buy-right-now-for-less-than/,2023-02-04 14:40:00,All three healthcare stocks are showing solid long-term potential.,ABBV,0.043186,0.061321,Neutral
Will These 3 Potential Blockbuster Drugs Lift Bristol Myers Squibb?,https://www.fool.com/investing/2023/02/04/will-these-3-potential-blockbuster-drugs-lift-bris/,2023-02-04 14:26:00,Bristol Myers Squibb has solid replacements for its blockbusters that are facing a patent cliff.,ABBV,0.052455,0.048975,Neutral
2 Stocks Down More Than 6% to Buy Right Now,https://www.fool.com/investing/2023/02/04/2-stocks-down-more-than-6-to-buy-right-now/,2023-02-04 13:30:00,These companies outperformed the market last year.,ABBV,0.459624,0.2965,Somewhat-Bullish
3 Unstoppable Dividend Stocks to Buy in February,https://www.fool.com/investing/2023/02/04/3-unstoppable-dividend-stocks-to-buy-in-february/,2023-02-04 12:45:00,All three belong to the elite group of stocks known as Dividend Kings.,ABBV,0.567574,0.269488,Somewhat-Bullish
Stock Market Investing Action Plan: Nasdaq's Best January in 22 Years,https://www.investors.com/research/investing-action-plan/stock-market-investing-action-plan-nasdaq-best-january-in-22-years/,2023-02-03 23:28:00,"January provided a hospitable start to 2023, giving investors a reminder of what upward stock market momentum feels like. Friday's jobs report rattled hopes for a dovish Fed, and Jerome Powell may further that message on Tuesday.",ABBV,0.038592,0.231165,Somewhat-Bullish
Stock Market Investing Action Plan: Nasdaq's Best January in 22 Years,https://www.investors.com:443/research/investing-action-plan/stock-market-investing-action-plan-nasdaq-best-january-in-22-years/,2023-02-03 23:28:00,"January provided a hospitable start to 2023, giving investors a reminder of what upward stock market momentum feels like. Friday's jobs report rattled hopes for a dovish Fed, and Jerome Powell may further that message on Tuesday.",ABBV,0.038592,0.231165,Somewhat-Bullish
AbbVie Q4 Preview: What's in Store?,https://www.zacks.com/stock/news/2049808/abbvie-q4-preview-whats-in-store,2023-02-03 22:31:00,"AbbVie has put in a mixed earnings performance, exceeding bottom line estimates in five consecutive quarters but falling short of sales expectations in each instance.",ABBV,0.44074,0.242526,Somewhat-Bullish
Cigna  ( CI )  Q4 2022 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/02/03/cigna-ci-q4-2022-earnings-call-transcript/,2023-02-03 20:00:26,"CI earnings call for the period ending December 31, 2022.",ABBV,0.004331,0.104863,Neutral
PFE: The Safest Stock to Buy on Wall Street Right Now,https://stocknews.com/news/pfe-jnj-abbv-bmy-the-safest-stock-to-buy-on-wall-street-right-now/,2023-02-03 16:59:24,"While a 25-bps interest-rate hike announced on Wednesday by the Federal Reserve Chair Jerome Powell hardly came as a surprise, market participants seem to have gone overboard over a simple acknowledgment that inflation ""has eased somewhat"" and ""the disinflationary process"" had started.",ABBV,0.080188,0.0,Neutral
"Hot, Hot, Hot: Yields Jump, Stocks Take a Dive as January Unemployment Lowest in 54 Years - Apple  ( NASDAQ:AAPL ) , Amazon.com  ( NASDAQ:AMZN ) ",https://www.benzinga.com/markets/23/02/30708851/hot-hot-hot-yields-jump-stocks-take-a-dive-as-january-unemployment-lowest-in-54-years,2023-02-03 15:44:16,"( Friday Market Open ) January jobs growth blew Wall Street's estimates completely out of the water as the government reported 517,000 new positions created. That compared with analysts' consensus for less than 200,000 and suggests the labor market is still nowhere near a slowdown.",ABBV,0.035794,-0.137529,Neutral
"If You Want Tons of Passive Income in the Future , Buy These 2 Stocks",https://www.fool.com/investing/2023/02/03/if-you-want-passive-income-buy-these-two-stocks/,2023-02-03 15:07:00,Good cash flows come to those who pick intelligently and wait.,ABBV,0.305437,0.139279,Neutral
High Adoption Rate Of A New Treatment Against Cancer is likely to proliferate the Neuroendocrine Tumor Treatment CAGR: 10%|UnivDatos Market Insights,https://www.prnewswire.com/news-releases/high-adoption-rate-of-a-new-treatment-against-cancer-is-likely-to-proliferate-the-neuroendocrine-tumor-treatment-cagr-10univdatos-market-insights-301738150.html,2023-02-03 14:30:00,High Adoption Rate Of A New Treatment Against Cancer is likely to ... PR ...,ABBV,0.039878,0.15811,Somewhat-Bullish
"Pharma Stock Roundup: MRK, LLY, PFE Q4 Results, J&J's Loss in Talc Lawsuits",https://www.zacks.com/stock/news/2049538/pharma-stock-roundup-mrk-lly-pfe-q4-results-jjs-loss-in-talc-lawsuits,2023-02-03 14:19:00,"Pfizer (PFE), Merck (MRK), Eli Lilly (LLY) and others report fourth-quarter results. An appeals court dismisses J&J's (JNJ) bankruptcy filing related to its talc lawsuits.",ABBV,0.036812,0.0,Neutral
"ABBV: The 5 Best Stocks to Invest $1,000 in Right Now",https://stocknews.com/news/abbv-vrtx-musa-mcft-pnrg-the-5-best-stocks-to-invest-1000-in-right-now/,2023-02-03 14:16:57,"The cooling inflation, historically tight labor market, China's move to reopen its economy, and signs of easing energy market stress have all contributed significantly to the improvement in investors' sentiment in recent weeks. The S&P 500 index's 8.9% rise in 2023 shows optimism in the stock ...",ABBV,0.178083,0.171383,Somewhat-Bullish
Investors Heavily Search AbbVie Inc.  ( ABBV ) : Here is What You Need to Know,https://www.zacks.com/stock/news/2049505/investors-heavily-search-abbvie-inc-abbv-here-is-what-you-need-to-know,2023-02-03 14:00:11,"Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",ABBV,0.490323,0.083626,Neutral
2 Steady Stocks to Buy in a Recession,https://www.fool.com/investing/2023/02/03/2-steady-stocks-to-buy-in-a-recession/,2023-02-03 14:00:00,Both companies are performing better than the broader market over the past year.,ABBV,0.369456,0.172125,Somewhat-Bullish
Top Fund Manager Found A Way To Make Money While Others Lose,https://www.investors.com/etfs-and-funds/mutual-funds/best-mutual-funds-manager-found-a-way-to-make-money-while-others-lose/,2023-02-03 12:00:00,"Making money in an up market is easy. But showering investors with gains when stocks are in a protracted downdraft is far more challenging, even for the best mutual funds. But that's exactly what the Integrity Dividend Harvest Fund ( IDIVX ) did in the bear market.",ABBV,0.104228,0.093773,Neutral
Biohaven Nabbed A Nearly $12 Billion Buyout - What's Next?,https://www.investors.com/news/technology/bhvn-stock-what-is-next-for-biohaven-after-a-buyout/,2023-02-02 17:52:00,BHVN Stock: What's Next For Biohaven After A $12 Billion Buyout ... Investor's Business Daily ...,ABBV,0.085022,0.055737,Neutral
"Dollar, Yields Retreat as Investors Pile into Stocks Following Fed Rate Hike - Apple  ( NASDAQ:AAPL ) , Amazon.com  ( NASDAQ:AMZN ) ",https://www.benzinga.com/news/small-cap/23/02/30692075/dollar-yields-retreat-as-investors-pile-into-stocks-following-fed-rate-hike,2023-02-02 16:33:54,"( Thursday Market Open ) Caution is napping for the moment. Yesterday's Federal Reserve meeting and press conference seemed to fuel sweet dreams for investors hoping for a so-called ""soft landing,"" and sent major indexes to five-month highs.",ABBV,0.029149,-0.133934,Neutral
ABBV: These 3 Dividend Stocks Are Worth Investing In,https://stocknews.com/news/abbv-gild-sire-these-3-dividend-stocks-are-worth-investing-in/,2023-02-02 16:19:05,"The U.S. Gross Domestic Product ( GDP ) increased at a 2.9% annualized rate in the fourth quarter of 2022, exceeding the Dow Jones forecast of 2.8%. Increases in consumer spending, government spending, private inventory investment, and nonresidential fixed investment drove the fourth-quarter ...",ABBV,0.374568,0.169804,Somewhat-Bullish
AbbVie  ( ABBV )  Earnings Expected to Grow: Should You Buy?,https://www.zacks.com/stock/news/2048437/abbvie-abbv-earnings-expected-to-grow-should-you-buy,2023-02-02 15:01:04,AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,ABBV,0.301933,0.066147,Neutral
2 Surefire Stocks to Buy in 2023 and Hold for at Least the Next Decade,https://www.fool.com/investing/2023/02/02/2-surefire-stocks-to-buy-in-2023-and-hold-at-least/,2023-02-02 14:53:00,These stocks are growing steadily and have a solid history of enriching shareholders.,ABBV,0.179788,0.131149,Neutral
3 Ultra-Profitable Businesses to Invest in for the Long Haul,https://www.fool.com/investing/2023/02/02/3-ultra-profitable-businesses-to-invest-in-for-the/,2023-02-02 14:00:00,These companies all have profit margins of at least 20%.,ABBV,0.259037,0.27601,Somewhat-Bullish
Rate Hike? No Problem: Markets Reverse Losses After Fed's Move Despite Promise of Rate Increases to Come,https://www.benzinga.com/markets/23/02/30687322/rate-hike-no-problem-markets-reverse-losses-after-feds-move-despite-promise-of-rate-increases-to-com,2023-02-02 13:31:15,"( Wednesday Post-Fed ) The Federal Reserve is taking the stairs down one step at a time. Today's 25-basis-point rate hike was half of December's, which was down from the record-setting four 75-basis-point increases from June through November. Stocks overcame an initial stumble and moved higher by ...",ABBV,0.043186,-0.140485,Neutral
Merck  ( MRK )  Beats Q4 Earnings and Revenue Estimates,https://www.zacks.com/stock/news/2048207/merck-mrk-beats-q4-earnings-and-revenue-estimates,2023-02-02 12:55:03,"Merck (MRK) delivered earnings and revenue surprises of 3.85% and 0.65%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?",ABBV,0.140076,0.0,Neutral
UK pharma body urges govt to scrap hike in repayment rate for drugmakers,https://www.reuters.com/business/healthcare-pharmaceuticals/uk-pharma-body-urges-govt-scrap-hike-repayment-rate-drugmakers-2023-02-02/,2023-02-02 00:13:00,UK pharma body urges govt to scrap hike in repayment rate for ... ...,ABBV,0.173333,0.170035,Somewhat-Bullish
"Powell Talk: It's All About the Fed Chair's Comments Today, as 0.25% Rate Hike Baked In",https://www.benzinga.com/news/23/02/30675086/powell-talk-its-all-about-the-fed-chairs-comments-today-as-0-25-rate-hike-baked-in,2023-02-01 19:52:59,"( Wednesday Market Open ) Today's Federal Reserve rate decision comes just ahead of Groundhog Day. If the groundhog sees its shadow, it means another six weeks of winter, tradition tells us. If the Fed sees an inflation shadow still overhanging the economy, it could mean many, many more weeks of ...",ABBV,0.029839,-0.134347,Neutral
"Amgen  ( AMGN )  Beats on Q4 Earnings, 2023 Sales View Disappoints",https://www.zacks.com/stock/news/2047780/amgen-amgn-beats-on-q4-earnings-2023-sales-view-disappoints,2023-02-01 15:31:00,"Amgen (AMGN) beats Q4 estimates for earnings and sales. It launches Amjevita in the United States, which is the first biosimilar of Humira to be launched in the country.",ABBV,0.054732,0.096006,Neutral
Amgen Records Slight Fall In Quarterly Earnings; Lower COVID-19 Manufacturing Pacts Impact Bottomline,https://www.benzinga.com/general/biotech/23/02/30662304/amgen-records-slight-fall-in-quarterly-earnings-lower-covid-19-manufacturing-pacts-impact-bottoml,2023-02-01 12:42:41,"Amgen Inc's AMGN fourth-quarter revenues were $6.84 billion, beating the consensus of $6.76 billion, largely unchanged from Q4 2021, and benefited from a 4% increase in product sales, offset by lower COVID-19 manufacturing collaboration revenues.",ABBV,0.282234,0.351866,Bullish
3 Juicy Dividend Stocks in Warren Buffett's Secret Portfolio to Buy in February,https://www.fool.com/investing/2023/02/01/juicy-dividend-stocks-warren-buffett-buy-february/,2023-02-01 10:55:00,"These stocks aren't in Berkshire Hathaway's SEC filings, but Buffett owns them.",ABBV,0.326643,0.313752,Somewhat-Bullish
European Commission approves label expansion of Roche's Hemlibra to include people with moderate haemophilia A in the EU,https://www.globenewswire.com/news-release/2023/02/01/2599083/0/en/European-Commission-approves-label-expansion-of-Roche-s-Hemlibra-to-include-people-with-moderate-haemophilia-A-in-the-EU.html,2023-02-01 06:00:00,"Basel, 01 February 2023 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) today announced that the European Commission approved the expansion of the Hemlibra® ( emicizumab ) European Union ( EU ) marketing authorisation. The label will now include the routine prophylaxis of bleeding episodes in people with ...",ABBV,0.023395,0.064079,Neutral
Pfizer  ( PFE )  Q4 2022 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/01/31/pfizer-pfe-q4-2022-earnings-call-transcript/,2023-02-01 00:00:18,"PFE earnings call for the period ending December 31, 2022.",ABBV,0.003578,0.050751,Neutral
Amgen revenue falls slightly as Lilly COVID deal contributes less,https://www.reuters.com/business/healthcare-pharmaceuticals/amgen-revenue-falls-slightly-lilly-covid-deal-contributes-less-2023-01-31/,2023-01-31 21:38:00,Jan 31 ( Reuters ) - Amgen Inc ( AMGN.O ) on Tuesday said its fourth-quarter revenue fell slightly as a 4% increase in sales of its own drugs was offset by lower revenue from its deal to manufacture COVID-19 antibody treatments for Eli Lilly and Co.,ABBV,0.092569,-0.015812,Neutral
First Humira Biosimilar Price Highlights Cost-Saving Challenges,https://www.barrons.com/articles/humira-amgen-abbvie-drug-generic-51675188334,2023-01-31 18:07:00,"AbbVie 's anti-inflammatory drug Humira, one of the top-selling prescription drugs in history, is facing generic-style competition for the first time this week since its introduction 20 years ago.",ABBV,0.459624,0.0,Neutral
"AbbVIe's Two-Decade Humira Monopoly Ends; So, What's Next?",https://www.investors.com/news/technology/abbvie-stock-the-20-year-humira-monopoly-ends-so-what-is-next/,2023-01-31 17:12:00,"AbbVie Stock: The 20-Year Humira Monopoly Ends. So, What's Next ... Investor's Business Daily ...",ABBV,0.688591,-0.120307,Neutral
"Waiting for Powell: As Fed Meeting Starts, Investors Parse Mixed Q4 Earnings and Consider What's Next for Rates",https://www.benzinga.com/news/earnings/23/01/30647013/waiting-for-powell-as-fed-meeting-starts-investors-parse-mixed-q4-earnings-and-consider-whats-next-,2023-01-31 16:33:28,"( Tuesday Market Open ) With three major central banks releasing rate decisions starting tomorrow, investors might be wise to expect subdued trading Tuesday following a sell-off to start the week.",ABBV,0.03319,-0.136223,Neutral
Pfizer  ( PFE )  Q4 Earnings and Revenues Beat Estimates,https://www.zacks.com/stock/news/2046833/pfizer-pfe-q4-earnings-and-revenues-beat-estimates,2023-01-31 13:15:09,"Pfizer (PFE) delivered earnings and revenue surprises of 10.68% and 0.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?",ABBV,0.140485,0.0,Neutral
Working With Cancer: from Davos to the Super Bowl,https://www.globenewswire.com/news-release/2023/01/31/2598419/0/en/Working-With-Cancer-from-Davos-to-the-Super-Bowl.html,2023-01-31 13:04:00,"Working With Cancer: from Davos to the Super Bowl After launching with the world's most influential companies at Davos, Working with Cancer issues a wake-up call to all",ABBV,0.057628,-0.052213,Neutral
KemPharm Enhances Senior Management Team,https://www.globenewswire.com/news-release/2023/01/31/2598307/16626/en/KemPharm-Enhances-Senior-Management-Team.html,2023-01-31 12:30:00,"Daniel Gallo, Ph.D., Appointed Senior Vice President of Medical Affairs and Advocacy ...",ABBV,0.051111,0.066741,Neutral
KemPharm Enhances Senior Management Team,https://www.benzinga.com/pressreleases/23/01/g30639493/kempharm-enhances-senior-management-team,2023-01-31 12:30:00,"Daniel Gallo, Ph.D., Appointed Senior Vice President of Medical Affairs and Advocacy Abbi Maher, J.D., Named Vice President of Legal Affairs CELEBRATION, Fla., Jan. 31, 2023 ( GLOBE NEWSWIRE ) -- KemPharm, Inc.",ABBV,0.047559,0.065405,Neutral
"AMJEVITA , FIRST BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES",https://investingnews.com/amjevita-first-biosimilar-to-humira-r-now-available-in-the-united-states/,2023-01-31 11:45:43,"Amgen ( NASDAQ:AMGN ) today announced AMJEVITA™ ( adalimumab-atto ) , a biosimilar to Humira ®* ( adalimumab ) , is now available in the United States . AMJEVITA was the first biosimilar to Humira approved by the U.S. Food and Drug Administration ( FDA ) , in 2016. 2,3",ABBV,0.01769,0.0,Neutral
Amgen launches biosimilar version of AbbVie's Humira,https://www.reuters.com/business/healthcare-pharmaceuticals/amgen-launches-biosimilar-version-abbvies-humira-2023-01-31/,2023-01-31 11:19:00,Amgen launches biosimilar version of ...,ABBV,0.472338,0.154125,Somewhat-Bullish
"AbbVie's Humira gets a U.S. rival, but costs could stay high",https://www.reuters.com/business/healthcare-pharmaceuticals/abbvies-humira-gets-us-rival-costs-could-stay-high-2023-01-31/,2023-01-31 11:18:00,"Jan 31 ( Reuters ) - U.S. patients will finally get access to cheaper versions of AbbVie Inc's ( ABBV.N ) blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited.",ABBV,0.123951,0.091678,Neutral
Blockbuster Arthritis Drug Humira Faces Competition From First Lower-Price Copycat in U.S.,https://www.wsj.com/articles/blockbuster-arthritis-drug-humira-faces-competition-from-first-lower-price-copycat-in-u-s-11675146649,2023-01-31 11:00:00,"The arthritis therapy is coming up against its first so-called biosimilar, after more than $135 billion in sales and fights over how long its patents last.",ABBV,0.407844,0.116213,Neutral
Why Botox and other cosmetic injections may be resilient against economic uncertainty,https://www.marketwatch.com/story/a-botox-index-why-sales-of-cosmetic-injections-arent-disappearing-amid-economic-uncertainty-3e5ab651,2023-02-19 19:34:00,They have a kind of staying power that's more akin to a staple than a discretionary purchase for many of their users.,ABBV,0.186738,0.023928,Neutral
"Copa  ( NYSE:CPA )  Cut to ""Hold"" at StockNews.com",https://www.defenseworld.net/2023/02/19/copa-nysecpa-cut-to-hold-at-stocknews-com.html,2023-02-19 09:54:45,StockNews.com downgraded shares of Copa ( NYSE:CPA - Get Rating ) from a buy rating to a hold rating in a research report released on Thursday morning. CPA has been the subject of several other reports.,ABBV,0.063594,0.11809,Neutral
GigaMedia  ( NASDAQ:GIGM )  Now Covered by StockNews.com,https://www.defenseworld.net/2023/02/19/gigamedia-nasdaqgigm-now-covered-by-stocknews-com.html,2023-02-19 08:58:41,"Stock analysts at StockNews.com started coverage on shares of GigaMedia ( NASDAQ:GIGM - Get Rating ) in a research report issued to clients and investors on Friday. The brokerage set a ""sell"" rating on the technology company's stock. Shares of GigaMedia stock opened at $1.43 on Friday.",ABBV,0.131643,0.20865,Somewhat-Bullish
StockNews.com Initiates Coverage on United States Antimony  ( NYSE:UAMY ) ,https://www.defenseworld.net/2023/02/19/stocknews-com-initiates-coverage-on-united-states-antimony-nyseuamy-2.html,2023-02-19 08:12:44,StockNews.com Initiates Coverage on United States Antimony ... Defense World ...,ABBV,0.175859,0.162658,Somewhat-Bullish
Azure Power Global  ( NYSE:AZRE )  Coverage Initiated at StockNews.com,https://www.defenseworld.net/2023/02/19/azure-power-global-nyseazre-coverage-initiated-at-stocknews-com.html,2023-02-19 08:12:43,Azure Power Global ( NYSE:AZRE ) Coverage Initiated at StockNews ... Defense World ...,ABBV,0.098659,0.149623,Neutral
Sify Technologies  ( NASDAQ:SIFY )  Now Covered by StockNews.com,https://www.etfdailynews.com/2023/02/19/sify-technologies-nasdaqsify-now-covered-by-stocknews-com-2/,2023-02-19 08:12:43,"Investment analysts at StockNews.com began coverage on shares of Sify Technologies ( NASDAQ:SIFY - Get Rating ) in a research report issued on Sunday. The firm set a ""hold"" rating on the technology company's stock. Shares of SIFY opened at $1.62 on Friday.",ABBV,0.097854,0.156761,Somewhat-Bullish
Sify Technologies  ( NASDAQ:SIFY )  Now Covered by StockNews.com,https://www.defenseworld.net/2023/02/19/sify-technologies-nasdaqsify-now-covered-by-stocknews-com.html,2023-02-19 08:12:43,"StockNews.com began coverage on shares of Sify Technologies ( NASDAQ:SIFY - Get Rating ) in a research note issued to investors on Sunday. The firm set a ""hold"" rating on the technology company's stock. NASDAQ:SIFY opened at $1.62 on Friday. Sify Technologies has a 52-week low of $1.05 and a ...",ABBV,0.095138,0.155649,Somewhat-Bullish
StockNews.com Begins Coverage on Eastern  ( NASDAQ:EML ) ,https://www.defenseworld.net/2023/02/19/stocknews-com-begins-coverage-on-eastern-nasdaqeml.html,2023-02-19 08:12:43,"Equities researchers at StockNews.com began coverage on shares of Eastern ( NASDAQ:EML - Get Rating ) in a report issued on Sunday. The firm set a ""buy"" rating on the industrial products company's stock. Shares of Eastern stock opened at $21.29 on Friday.",ABBV,0.091509,0.198384,Somewhat-Bullish
Advaxis  ( NASDAQ:ADXS )  Coverage Initiated at StockNews.com,https://www.defenseworld.net/2023/02/19/advaxis-nasdaqadxs-coverage-initiated-at-stocknews-com-2.html,2023-02-19 08:12:43,"StockNews.com started coverage on shares of Advaxis ( NASDAQ:ADXS - Get Rating ) in a research report issued to clients and investors on Sunday. The firm set a ""sell"" rating on the stock. Advaxis, Inc is a biotechnology company, which engages in the discovery, development and commercialization ...",ABBV,0.222838,0.031944,Neutral
Cemtrex  ( NASDAQ:CETX )  Earns Hold Rating from Analysts at StockNews.com,https://www.defenseworld.net/2023/02/19/cemtrex-nasdaqcetx-earns-hold-rating-from-analysts-at-stocknews-com-2.html,2023-02-19 08:12:43,Cemtrex ( NASDAQ:CETX ) Earns Hold Rating from Analysts at ... Defense World ...,ABBV,0.113062,0.20547,Somewhat-Bullish
U.S. Global Investors  ( NASDAQ:GROW )  Earns Hold Rating from Analysts at StockNews.com,https://www.defenseworld.net/2023/02/19/u-s-global-investors-nasdaqgrow-earns-hold-rating-from-analysts-at-stocknews-com-2.html,2023-02-19 08:12:42,U.S. Global Investors ( NASDAQ:GROW ) Earns Hold Rating from ... Defense World ...,ABBV,0.08687,0.126765,Neutral
Monro  ( NASDAQ:MNRO )  Stock Rating Lowered by StockNews.com,https://www.defenseworld.net/2023/02/19/monro-nasdaqmnro-stock-rating-lowered-by-stocknews-com-2.html,2023-02-19 08:12:42,"Monro ( NASDAQ:MNRO - Get Rating ) was downgraded by stock analysts at StockNews.com from a ""buy"" rating to a ""hold"" rating in a report issued on Sunday. Shares of NASDAQ MNRO opened at $54.40 on Friday. Monro has a 1 year low of $37.49 and a 1 year high of $55.70.",ABBV,0.074926,0.092238,Neutral
QuickLogic  ( NASDAQ:QUIK )  Coverage Initiated at StockNews.com,https://www.defenseworld.net/2023/02/19/quicklogic-nasdaqquik-coverage-initiated-at-stocknews-com.html,2023-02-19 08:12:42,"Equities research analysts at StockNews.com initiated coverage on shares of QuickLogic ( NASDAQ:QUIK - Get Rating ) in a research report issued to clients and investors on Sunday. The firm set a ""hold"" rating on the semiconductor company's stock. Shares of QUIK stock opened at $5.78 on Friday.",ABBV,0.063091,0.11317,Neutral
"Northfield Bancorp, Inc.  ( Staten Island, NY )   ( NASDAQ:NFBK )  Downgraded by StockNews.com",https://www.defenseworld.net/2023/02/19/northfield-bancorp-inc-staten-island-ny-nasdaqnfbk-downgraded-by-stocknews-com.html,2023-02-19 08:12:42,"Northfield Bancorp, Inc. ( Staten Island, NY ) ( NASDAQ:NFBK ... Defense World ...",ABBV,0.052685,0.153625,Somewhat-Bullish
Avinger  ( NASDAQ:AVGR )  Coverage Initiated by Analysts at StockNews.com,https://www.defenseworld.net/2023/02/19/avinger-nasdaqavgr-coverage-initiated-by-analysts-at-stocknews-com.html,2023-02-19 08:12:42,Avinger ( NASDAQ:AVGR ) Coverage Initiated by Analysts at ... Defense World ...,ABBV,0.136113,0.196442,Somewhat-Bullish
Blucora  ( NASDAQ:BCOR )  Coverage Initiated at StockNews.com,https://www.defenseworld.net/2023/02/19/blucora-nasdaqbcor-coverage-initiated-at-stocknews-com.html,2023-02-19 08:12:41,"Analysts at StockNews.com started coverage on shares of Blucora ( NASDAQ:BCOR - Get Rating ) in a research report issued to clients and investors on Sunday. The brokerage set a ""hold"" rating on the information services provider's stock.",ABBV,0.080188,0.269897,Somewhat-Bullish
Park City Group  ( NASDAQ:PCYG )  Research Coverage Started at StockNews.com,https://www.defenseworld.net/2023/02/19/park-city-group-nasdaqpcyg-research-coverage-started-at-stocknews-com.html,2023-02-19 08:12:41,Park City Group ( NASDAQ:PCYG ) Research Coverage Started at ... Defense World ...,ABBV,0.077343,0.168278,Somewhat-Bullish
Eaton  ( NYSE:ETN )  Cut to Buy at StockNews.com,https://www.defenseworld.net/2023/02/19/eaton-nyseetn-cut-to-buy-at-stocknews-com.html,2023-02-19 08:12:41,"Eaton ( NYSE:ETN - Get Rating ) was downgraded by stock analysts at StockNews.com from a ""strong-buy"" rating to a ""buy"" rating in a report issued on Sunday. Other equities analysts also recently issued reports about the company.",ABBV,0.053749,0.150745,Somewhat-Bullish
StockNews.com Begins Coverage on Ampio Pharmaceuticals  ( NYSE:AMPE ) ,https://www.defenseworld.net/2023/02/19/stocknews-com-begins-coverage-on-ampio-pharmaceuticals-nyseampe.html,2023-02-19 08:12:41,StockNews.com Begins Coverage on Ampio Pharmaceuticals ... Defense World ...,ABBV,0.181137,0.103514,Neutral
Evoke Pharma  ( NASDAQ:EVOK )  Earns Sell Rating from Analysts at StockNews.com,https://www.defenseworld.net/2023/02/19/evoke-pharma-nasdaqevok-earns-sell-rating-from-analysts-at-stocknews-com-2.html,2023-02-19 08:12:41,Evoke Pharma ( NASDAQ:EVOK ) Earns Sell Rating from Analysts at ... Defense World ...,ABBV,0.17715,0.102964,Neutral
Community Health Systems  ( NYSE:CYH )  Upgraded by StockNews.com to Hold,https://www.etfdailynews.com/2023/02/19/community-health-systems-nysecyh-upgraded-by-stocknews-com-to-hold/,2023-02-19 08:06:42,Community Health Systems ( NYSE:CYH ) Upgraded by StockNews ... ETF Daily News ...,ABBV,0.071145,0.173193,Somewhat-Bullish
Community Health Systems  ( NYSE:CYH )  Rating Increased to Hold at StockNews.com,https://www.defenseworld.net/2023/02/19/community-health-systems-nysecyh-rating-increased-to-hold-at-stocknews-com.html,2023-02-19 08:06:41,Community Health Systems ( NYSE:CYH ) Rating Increased to Hold ... Defense World ...,ABBV,0.06623,0.172465,Somewhat-Bullish
Canadian Imperial Bank of Commerce  ( NYSE:CM )  Rating Lowered to Sell at StockNews.com,https://www.defenseworld.net/2023/02/19/canadian-imperial-bank-of-commerce-nysecm-rating-lowered-to-sell-at-stocknews-com.html,2023-02-19 08:06:41,Canadian Imperial Bank of Commerce ( NYSE:CM ) Rating Lowered ... Defense World ...,ABBV,0.054732,0.219919,Somewhat-Bullish
Host Hotels & Resorts  ( NYSE:HST )  Upgraded to Hold by StockNews.com,https://www.etfdailynews.com/2023/02/19/host-hotels-resorts-nysehst-upgraded-to-hold-by-stocknews-com/,2023-02-19 07:36:53,Host Hotels & Resorts ( NYSE:HST ) Upgraded to Hold by StockNews ... ETF Daily News ...,ABBV,0.213048,0.175878,Somewhat-Bullish
PolyMet Mining  ( NYSE:PLM )  Coverage Initiated at StockNews.com,https://www.etfdailynews.com/2023/02/19/polymet-mining-nyseplm-coverage-initiated-at-stocknews-com/,2023-02-19 07:36:53,"Research analysts at StockNews.com started coverage on shares of PolyMet Mining ( NYSE:PLM - Get Rating ) in a research report issued on Friday. The firm set a ""sell"" rating on the stock. PLM stock opened at $2.53 on Friday.",ABBV,0.197413,0.110321,Neutral
CF Industries  ( NYSE:CF )  Downgraded by StockNews.com,https://www.etfdailynews.com/2023/02/19/cf-industries-nysecf-downgraded-by-stocknews-com/,2023-02-19 07:36:52,"CF Industries ( NYSE:CF - Get Rating ) was downgraded by StockNews.com from a ""buy"" rating to a ""hold"" rating in a report released on Friday.",ABBV,0.069697,0.13464,Neutral
"First Commonwealth Financial  ( NYSE:FCF )  Downgraded by StockNews.com to ""Sell""",https://www.etfdailynews.com/2023/02/19/first-commonwealth-financial-nysefcf-downgraded-by-stocknews-com-to-sell/,2023-02-19 07:36:52,First Commonwealth Financial ( NYSE:FCF ) Downgraded by ... ETF Daily News ...,ABBV,0.069495,0.207225,Somewhat-Bullish
"International Flavors & Fragrances  ( NYSE:IFF )  Cut to ""Sell"" at StockNews.com",https://www.etfdailynews.com/2023/02/19/international-flavors-fragrances-nyseiff-cut-to-sell-at-stocknews-com/,2023-02-19 07:36:52,"International Flavors & Fragrances ( NYSE:IFF ) Cut to ""Sell"" at ... ETF Daily News ...",ABBV,0.056808,0.198992,Somewhat-Bullish
Granite Construction  ( NYSE:GVA )  Stock Rating Upgraded by StockNews.com,https://www.etfdailynews.com/2023/02/19/granite-construction-nysegva-stock-rating-upgraded-by-stocknews-com/,2023-02-19 07:36:51,Granite Construction ( NYSE:GVA ) Stock Rating Upgraded by ... ETF Daily News ...,ABBV,0.073321,0.092978,Neutral
"Ally Financial  ( NYSE:ALLY )  Upgraded by StockNews.com to ""Hold""",https://www.etfdailynews.com/2023/02/19/ally-financial-nyseally-upgraded-by-stocknews-com-to-hold/,2023-02-19 07:36:51,"Ally Financial ( NYSE:ALLY - Get Rating ) was upgraded by stock analysts at StockNews.com from a ""sell"" rating to a ""hold"" rating in a research note issued on Friday. A number of other equities analysts have also issued reports on ALLY. S&P Equity Research set a $29.50 price target on Ally ...",ABBV,0.06179,0.115027,Neutral
Arista Networks  ( NYSE:ANET )  Downgraded by StockNews.com,https://www.etfdailynews.com/2023/02/19/arista-networks-nyseanet-downgraded-by-stocknews-com/,2023-02-19 07:36:51,"Arista Networks ( NYSE:ANET - Get Rating ) was downgraded by analysts at StockNews.com from a ""buy"" rating to a ""hold"" rating in a research note issued on Friday. Other equities research analysts have also recently issued research reports about the stock.",ABBV,0.051886,0.101947,Neutral
Badger Meter  ( NYSE:BMI )  Upgraded at StockNews.com,https://www.etfdailynews.com/2023/02/19/badger-meter-nysebmi-upgraded-at-stocknews-com/,2023-02-19 07:36:51,"Badger Meter ( NYSE:BMI - Get Rating ) was upgraded by investment analysts at StockNews.com from a ""hold"" rating to a ""buy"" rating in a research report issued on Friday. Badger Meter stock opened at $120.29 on Friday.",ABBV,0.122269,0.156716,Somewhat-Bullish
International Flavors & Fragrances  ( NYSE:IFF )  Rating Lowered to Sell at StockNews.com,https://www.defenseworld.net/2023/02/19/international-flavors-fragrances-nyseiff-rating-lowered-to-sell-at-stocknews-com.html,2023-02-19 07:36:46,International Flavors & Fragrances ( NYSE:IFF ) Rating Lowered to ... Defense World ...,ABBV,0.058903,0.199014,Somewhat-Bullish
StockNews.com Downgrades Cenovus Energy  ( NYSE:CVE )  to Hold,https://www.defenseworld.net/2023/02/19/stocknews-com-downgrades-cenovus-energy-nysecve-to-hold.html,2023-02-19 07:36:45,"Cenovus Energy ( NYSE:CVE - Get Rating ) ( TSE:CVE ) was downgraded by research analysts at StockNews.com from a ""buy"" rating to a ""hold"" rating in a report issued on Friday.",ABBV,0.071145,0.157086,Somewhat-Bullish
StockNews.com Upgrades Badger Meter  ( NYSE:BMI )  to Buy,https://www.defenseworld.net/2023/02/19/stocknews-com-upgrades-badger-meter-nysebmi-to-buy.html,2023-02-19 07:36:44,"Badger Meter ( NYSE:BMI - Get Rating ) was upgraded by investment analysts at StockNews.com from a ""hold"" rating to a ""buy"" rating in a research report issued on Friday. Shares of Badger Meter stock opened at $120.29 on Friday. The company has a market cap of $3.52 billion, a PE ratio of 52.99 ...",ABBV,0.077593,0.138954,Neutral
"StockNews.com Upgrades Host Hotels & Resorts  ( NYSE:HST )  to ""Hold""",https://www.defenseworld.net/2023/02/19/stocknews-com-upgrades-host-hotels-resorts-nysehst-to-hold.html,2023-02-19 07:36:44,StockNews.com Upgrades Host Hotels & Resorts ( NYSE:HST ) to ... Defense World ...,ABBV,0.207571,0.172406,Somewhat-Bullish
PolyMet Mining  ( NYSE:PLM )  Coverage Initiated at StockNews.com,https://www.defenseworld.net/2023/02/19/polymet-mining-nyseplm-coverage-initiated-at-stocknews-com.html,2023-02-19 07:36:44,"Equities research analysts at StockNews.com began coverage on shares of PolyMet Mining ( NYSE:PLM - Get Rating ) in a report released on Friday. The firm set a ""sell"" rating on the stock. NYSE:PLM opened at $2.53 on Friday. PolyMet Mining has a one year low of $2.46 and a one year high of $4.79.",ABBV,0.194242,0.108981,Neutral
StockNews.com Downgrades CF Industries  ( NYSE:CF )  to Hold,https://www.defenseworld.net/2023/02/19/stocknews-com-downgrades-cf-industries-nysecf-to-hold.html,2023-02-19 07:36:43,"CF Industries ( NYSE:CF - Get Rating ) was downgraded by stock analysts at StockNews.com from a ""buy"" rating to a ""hold"" rating in a research report issued to clients and investors on Friday. Several other equities research analysts have also recently issued reports on the stock.",ABBV,0.062597,0.134073,Neutral
StockNews.com Downgrades Arista Networks  ( NYSE:ANET )  to Hold,https://www.defenseworld.net/2023/02/19/stocknews-com-downgrades-arista-networks-nyseanet-to-hold.html,2023-02-19 07:36:43,"Arista Networks ( NYSE:ANET - Get Rating ) was downgraded by analysts at StockNews.com from a ""buy"" rating to a ""hold"" rating in a report released on Friday. Other analysts have also issued research reports about the stock.",ABBV,0.049221,0.101782,Neutral
Ally Financial  ( NYSE:ALLY )  Rating Increased to Hold at StockNews.com,https://www.defenseworld.net/2023/02/19/ally-financial-nyseally-rating-increased-to-hold-at-stocknews-com.html,2023-02-19 07:36:41,Ally Financial ( NYSE:ALLY ) Rating Increased to Hold at StockNews ... Defense World ...,ABBV,0.070105,0.11555,Neutral
NOW  ( NYSE:DNOW )  Stock Rating Lowered by StockNews.com,https://www.defenseworld.net/2023/02/19/now-nysednow-stock-rating-lowered-by-stocknews-com.html,2023-02-19 07:36:41,"NOW ( NYSE:DNOW - Get Rating ) was downgraded by research analysts at StockNews.com from a ""strong-buy"" rating to a ""buy"" rating in a report issued on Friday. Separately, TheStreet upgraded NOW from a ""c+"" rating to a ""b-"" rating in a research note on Monday, December 12th.",ABBV,0.11983,0.263957,Somewhat-Bullish
Eagle Bancorp Montana  ( NASDAQ:EBMT )  Now Covered by StockNews.com,https://reporter.am/2023/02/19/eagle-bancorp-montana-nasdaqebmt-now-covered-by-stocknews-com.html,2023-02-19 07:28:44,Eagle Bancorp Montana ( NASDAQ:EBMT ) Now Covered by ... Armenian Reporter ...,ABBV,0.066598,0.113243,Neutral
NexTier Oilfield Solutions  ( NYSE:NEX )  Rating Increased to Strong-Buy at StockNews.com,https://www.defenseworld.net/2023/02/19/nextier-oilfield-solutions-nysenex-rating-increased-to-strong-buy-at-stocknews-com.html,2023-02-19 07:02:47,NexTier Oilfield Solutions ( NYSE:NEX ) Rating Increased to Strong ... Defense World ...,ABBV,0.061473,0.203314,Somewhat-Bullish
Transocean  ( NYSE:RIG )  Stock Rating Lowered by StockNews.com,https://www.defenseworld.net/2023/02/19/transocean-nyserig-stock-rating-lowered-by-stocknews-com.html,2023-02-19 06:56:45,"Transocean ( NYSE:RIG - Get Rating ) was downgraded by equities researchers at StockNews.com from a ""hold"" rating to a ""sell"" rating in a report released on Friday. RIG has been the subject of several other reports. Benchmark began coverage on Transocean in a report on Thursday, January 19th.",ABBV,0.049835,0.111755,Neutral
"StockNews.com Upgrades Sunrun  ( NASDAQ:RUN )  to ""Sell""",https://www.etfdailynews.com/2023/02/19/stocknews-com-upgrades-sunrun-nasdaqrun-to-sell/,2023-02-19 06:22:48,"Sunrun ( NASDAQ:RUN - Get Rating ) was upgraded by analysts at StockNews.com to a ""sell"" rating in a report issued on Friday. RUN has been the subject of several other research reports.",ABBV,0.049526,0.175123,Somewhat-Bullish
"StockNews.com Upgrades Sunrun  ( NASDAQ:RUN )  to ""Sell""",https://www.defenseworld.net/2023/02/19/stocknews-com-upgrades-sunrun-nasdaqrun-to-sell.html,2023-02-19 06:22:47,"Sunrun ( NASDAQ:RUN - Get Rating ) was upgraded by analysts at StockNews.com to a ""sell"" rating in a report issued on Friday. RUN has been the subject of several other research reports.",ABBV,0.049526,0.175123,Somewhat-Bullish
"StockNews.com Upgrades Ribbon Communications  ( NASDAQ:RBBN )  to ""Buy""",https://www.defenseworld.net/2023/02/19/stocknews-com-upgrades-ribbon-communications-nasdaqrbbn-to-buy.html,2023-02-19 06:22:46,StockNews.com Upgrades Ribbon Communications ( NASDAQ ... Defense World ...,ABBV,0.07446,0.116741,Neutral
Pan American Silver  ( NASDAQ:PAAS )  Rating Lowered to Sell at StockNews.com,https://www.defenseworld.net/2023/02/19/pan-american-silver-nasdaqpaas-rating-lowered-to-sell-at-stocknews-com.html,2023-02-19 06:22:46,Pan American Silver ( NASDAQ:PAAS ) Rating Lowered to Sell at ... Defense World ...,ABBV,0.066047,0.1835,Somewhat-Bullish
Tower Semiconductor  ( NASDAQ:TSEM )  Cut to Buy at StockNews.com,https://reporter.am/2023/02/19/tower-semiconductor-nasdaqtsem-cut-to-buy-at-stocknews-com.html,2023-02-19 06:22:45,"Tower Semiconductor ( NASDAQ:TSEM - Get Rating ) was downgraded by stock analysts at StockNews.com from a ""strong-buy"" rating to a ""buy"" rating in a note issued to investors on Friday. Shares of TSEM stock opened at $40.85 on Friday.",ABBV,0.087824,0.161312,Somewhat-Bullish
"StockNews.com Upgrades Twilio  ( NYSE:TWLO )  to ""Hold""",https://reporter.am/2023/02/19/stocknews-com-upgrades-twilio-nysetwlo-to-hold.html,2023-02-19 06:22:45,"Twilio ( NYSE:TWLO - Get Rating ) was upgraded by research analysts at StockNews.com from a ""sell"" rating to a ""hold"" rating in a research note issued on Friday.",ABBV,0.069294,0.115471,Neutral
StockNews.com Upgrades Aptevo Therapeutics  ( NASDAQ:APVO )  to Hold,https://reporter.am/2023/02/19/stocknews-com-upgrades-aptevo-therapeutics-nasdaqapvo-to-hold.html,2023-02-19 06:22:45,StockNews.com Upgrades Aptevo Therapeutics ( NASDAQ:APVO ) to ... Armenian Reporter ...,ABBV,0.102888,0.080954,Neutral
StockNews.com Initiates Coverage on First Community  ( NASDAQ:FCCO ) ,https://www.etfdailynews.com/2023/02/19/stocknews-com-initiates-coverage-on-first-community-nasdaqfcco/,2023-02-19 06:22:44,StockNews.com Initiates Coverage on First Community ( NASDAQ ... ETF Daily News ...,ABBV,0.088472,0.140715,Neutral
BancFirst  ( NASDAQ:BANF )  Rating Increased to Hold at StockNews.com,https://www.defenseworld.net/2023/02/19/bancfirst-nasdaqbanf-rating-increased-to-hold-at-stocknews-com.html,2023-02-19 06:22:44,BancFirst ( NASDAQ:BANF ) Rating Increased to Hold at StockNews ... Defense World ...,ABBV,0.087824,0.133248,Neutral
Pegasystems  ( NASDAQ:PEGA )  Stock Rating Upgraded by StockNews.com,https://reporter.am/2023/02/19/pegasystems-nasdaqpega-stock-rating-upgraded-by-stocknews-com.html,2023-02-19 06:22:44,Pegasystems ( NASDAQ:PEGA ) Stock Rating Upgraded by ... Armenian Reporter ...,ABBV,0.078611,0.185132,Somewhat-Bullish
Ribbon Communications  ( NASDAQ:RBBN )  Stock Rating Upgraded by StockNews.com,https://reporter.am/2023/02/19/ribbon-communications-nasdaqrbbn-stock-rating-upgraded-by-stocknews-com.html,2023-02-19 06:22:44,Ribbon Communications ( NASDAQ:RBBN ) Stock Rating Upgraded ... Armenian Reporter ...,ABBV,0.073321,0.116543,Neutral
Pan American Silver  ( NASDAQ:PAAS )  Lowered to Sell at StockNews.com,https://reporter.am/2023/02/19/pan-american-silver-nasdaqpaas-lowered-to-sell-at-stocknews-com.html,2023-02-19 06:22:44,Pan American Silver ( NASDAQ:PAAS ) Lowered to Sell at ... Armenian Reporter ...,ABBV,0.06515,0.183396,Somewhat-Bullish
StockNews.com Downgrades Nu Skin Enterprises  ( NYSE:NUS )  to Hold,https://www.defenseworld.net/2023/02/19/stocknews-com-downgrades-nu-skin-enterprises-nysenus-to-hold.html,2023-02-19 06:22:44,StockNews.com Downgrades Nu Skin Enterprises ( NYSE:NUS ) to ... Defense World ...,ABBV,0.050572,0.157309,Somewhat-Bullish
StockNews.com Initiates Coverage on First Community  ( NASDAQ:FCCO ) ,https://www.defenseworld.net/2023/02/19/stocknews-com-initiates-coverage-on-first-community-nasdaqfcco.html,2023-02-19 06:22:43,StockNews.com Initiates Coverage on First Community ( NASDAQ ... Defense World ...,ABBV,0.088472,0.140715,Neutral
Martin Midstream Partners  ( NASDAQ:MMLP )  Stock Rating Upgraded by StockNews.com,https://reporter.am/2023/02/19/martin-midstream-partners-nasdaqmmlp-stock-rating-upgraded-by-stocknews-com.html,2023-02-19 06:22:43,Martin Midstream Partners ( NASDAQ:MMLP ) Stock Rating ... Armenian Reporter ...,ABBV,0.082393,0.149405,Neutral
"Independent Bank  ( NASDAQ:INDB )  Lifted to ""Hold"" at StockNews.com",https://reporter.am/2023/02/19/independent-bank-nasdaqindb-lifted-to-hold-at-stocknews-com.html,2023-02-19 06:22:43,"Independent Bank ( NASDAQ:INDB - Get Rating ) was upgraded by equities researchers at StockNews.com from a ""sell"" rating to a ""hold"" rating in a research report issued to clients and investors on Friday. Other equities analysts have also recently issued research reports about the stock.",ABBV,0.078354,0.188771,Somewhat-Bullish
"OGE Energy  ( NYSE:OGE )  Upgraded to ""Buy"" by StockNews.com",https://reporter.am/2023/02/19/oge-energy-nyseoge-upgraded-to-buy-by-stocknews-com.html,2023-02-19 06:22:43,"OGE Energy ( NYSE:OGE - Get Rating ) was upgraded by stock analysts at StockNews.com from a ""hold"" rating to a ""buy"" rating in a note issued to investors on Friday. Several other research analysts also recently commented on the company.",ABBV,0.072,0.145976,Neutral
"Hasbro  ( NASDAQ:HAS )  Downgraded to ""Sell"" at StockNews.com",https://reporter.am/2023/02/19/hasbro-nasdaqhas-downgraded-to-sell-at-stocknews-com.html,2023-02-19 06:22:43,"Hasbro ( NASDAQ:HAS - Get Rating ) was downgraded by research analysts at StockNews.com from a ""hold"" rating to a ""sell"" rating in a research report issued on Friday. A number of other research analysts also recently commented on the stock.",ABBV,0.067727,0.172652,Somewhat-Bullish
Xylem  ( NYSE:XYL )  Rating Lowered to Hold at StockNews.com,https://www.etfdailynews.com/2023/02/19/xylem-nysexyl-rating-lowered-to-hold-at-stocknews-com/,2023-02-19 06:22:43,"Xylem ( NYSE:XYL - Get Rating ) was downgraded by StockNews.com from a ""buy"" rating to a ""hold"" rating in a note issued to investors on Friday. A number of other equities analysts have also weighed in on the stock.",ABBV,0.066784,0.145391,Neutral
Hasbro  ( NASDAQ:HAS )  Rating Lowered to Sell at StockNews.com,https://www.defenseworld.net/2023/02/19/hasbro-nasdaqhas-rating-lowered-to-sell-at-stocknews-com.html,2023-02-19 06:22:43,"Hasbro ( NASDAQ:HAS - Get Rating ) was downgraded by stock analysts at StockNews.com from a ""hold"" rating to a ""sell"" rating in a research report issued on Friday. Other analysts have also issued research reports about the company.",ABBV,0.064623,0.172298,Somewhat-Bullish
Iridium Communications  ( NASDAQ:IRDM )  Cut to Hold at StockNews.com,https://reporter.am/2023/02/19/iridium-communications-nasdaqirdm-cut-to-hold-at-stocknews-com.html,2023-02-19 06:22:43,Iridium Communications ( NASDAQ:IRDM ) Cut to Hold at StockNews ... Armenian Reporter ...,ABBV,0.05833,0.144998,Neutral
Criteo  ( NASDAQ:CRTO )  Stock Rating Lowered by StockNews.com,https://www.defenseworld.net/2023/02/19/criteo-nasdaqcrto-stock-rating-lowered-by-stocknews-com.html,2023-02-19 06:22:43,"Criteo ( NASDAQ:CRTO - Get Rating ) was downgraded by stock analysts at StockNews.com from a ""buy"" rating to a ""hold"" rating in a note issued to investors on Friday.",ABBV,0.047465,0.167033,Somewhat-Bullish
"StockNews.com Upgrades Accelerate Diagnostics  ( NASDAQ:AXDX )  to ""Hold""",https://www.defenseworld.net/2023/02/19/stocknews-com-upgrades-accelerate-diagnostics-nasdaqaxdx-to-hold.html,2023-02-19 06:22:43,StockNews.com Upgrades Accelerate Diagnostics ( NASDAQ:AXDX ... Defense World ...,ABBV,0.111488,0.209996,Somewhat-Bullish
Ultrapar Participações  ( NYSE:UGP )  Stock Rating Upgraded by StockNews.com,https://www.etfdailynews.com/2023/02/19/ultrapar-participacoes-nyseugp-stock-rating-upgraded-by-stocknews-com/,2023-02-19 06:22:42,Ultrapar Participações ( NYSE:UGP ) Stock Rating Upgraded by ... ETF Daily News ...,ABBV,0.097062,0.145793,Neutral
Materion  ( NYSE:MTRN )  Stock Rating Upgraded by StockNews.com,https://www.defenseworld.net/2023/02/19/materion-nysemtrn-stock-rating-upgraded-by-stocknews-com.html,2023-02-19 06:22:42,"Materion ( NYSE:MTRN - Get Rating ) was upgraded by research analysts at StockNews.com from a ""hold"" rating to a ""buy"" rating in a research report issued on Friday.",ABBV,0.078354,0.134015,Neutral
StockNews.com Upgrades Telephone and Data Systems  ( NYSE:TDS )  to Hold,https://www.defenseworld.net/2023/02/19/stocknews-com-upgrades-telephone-and-data-systems-nysetds-to-hold.html,2023-02-19 06:22:42,StockNews.com Upgrades Telephone and Data Systems ( NYSE ... Defense World ...,ABBV,0.062434,0.15009,Somewhat-Bullish
StockNews.com Upgrades Tenaris  ( NYSE:TS )  to Strong-Buy,https://www.defenseworld.net/2023/02/19/stocknews-com-upgrades-tenaris-nysets-to-strong-buy.html,2023-02-19 06:22:42,"Tenaris ( NYSE:TS - Get Rating ) was upgraded by StockNews.com from a ""buy"" rating to a ""strong-buy"" rating in a note issued to investors on Friday. Several other equities analysts have also recently issued reports on TS. Cowen upped their price target on shares of Tenaris from $45.00 to $49.00 ...",ABBV,0.061949,0.097019,Neutral
"StockNews.com Upgrades United States Cellular  ( NYSE:USM )  to ""Hold""",https://www.etfdailynews.com/2023/02/19/stocknews-com-upgrades-united-states-cellular-nyseusm-to-hold/,2023-02-19 06:22:42,StockNews.com Upgrades United States Cellular ( NYSE:USM ) to ... ETF Daily News ...,ABBV,0.055621,0.124882,Neutral
Johnson Controls International  ( NYSE:JCI )  Rating Lowered to Hold at StockNews.com,https://www.etfdailynews.com/2023/02/19/johnson-controls-international-nysejci-rating-lowered-to-hold-at-stocknews-com/,2023-02-19 06:22:42,Johnson Controls International ( NYSE:JCI ) Rating Lowered to Hold ... ETF Daily News ...,ABBV,0.048919,0.175594,Somewhat-Bullish
Johnson Controls International  ( NYSE:JCI )  Rating Lowered to Hold at StockNews.com,https://www.defenseworld.net/2023/02/19/johnson-controls-international-nysejci-rating-lowered-to-hold-at-stocknews-com.html,2023-02-19 06:22:42,Johnson Controls International ( NYSE:JCI ) Rating Lowered to Hold ... Defense World ...,ABBV,0.048919,0.175594,Somewhat-Bullish
"StockNews.com Upgrades Accelerate Diagnostics  ( NASDAQ:AXDX )  to ""Hold""",https://www.etfdailynews.com/2023/02/19/stocknews-com-upgrades-accelerate-diagnostics-nasdaqaxdx-to-hold/,2023-02-19 06:22:42,StockNews.com Upgrades Accelerate Diagnostics ( NASDAQ:AXDX ... ETF Daily News ...,ABBV,0.111488,0.209996,Somewhat-Bullish
Ultrapar Participações  ( NYSE:UGP )  Stock Rating Upgraded by StockNews.com,https://www.defenseworld.net/2023/02/19/ultrapar-participacoes-nyseugp-stock-rating-upgraded-by-stocknews-com.html,2023-02-19 06:22:41,Ultrapar Participações ( NYSE:UGP ) Stock Rating Upgraded by ... Defense World ...,ABBV,0.097062,0.145793,Neutral
BancFirst  ( NASDAQ:BANF )  Rating Increased to Hold at StockNews.com,https://reporter.am/2023/02/19/bancfirst-nasdaqbanf-rating-increased-to-hold-at-stocknews-com.html,2023-02-19 06:22:41,BancFirst ( NASDAQ:BANF ) Rating Increased to Hold at StockNews ... Armenian Reporter ...,ABBV,0.091509,0.134352,Neutral
Mizuho Financial Group  ( NYSE:MFG )  Downgraded to Hold at StockNews.com,https://reporter.am/2023/02/19/mizuho-financial-group-nysemfg-downgraded-to-hold-at-stocknews-com.html,2023-02-19 06:22:41,Mizuho Financial Group ( NYSE:MFG ) Downgraded to Hold at ... Armenian Reporter ...,ABBV,0.07887,0.241566,Somewhat-Bullish
Materion  ( NYSE:MTRN )  Stock Rating Upgraded by StockNews.com,https://www.etfdailynews.com/2023/02/19/materion-nysemtrn-stock-rating-upgraded-by-stocknews-com/,2023-02-19 06:22:41,"Materion ( NYSE:MTRN - Get Rating ) was upgraded by research analysts at StockNews.com from a ""hold"" rating to a ""buy"" rating in a research report issued on Friday.",ABBV,0.078354,0.134015,Neutral
StockNews.com Begins Coverage on BIOLASE  ( NASDAQ:BIOL ) ,https://reporter.am/2023/02/19/stocknews-com-begins-coverage-on-biolase-nasdaqbiol.html,2023-02-19 06:22:41,"Research analysts at StockNews.com initiated coverage on shares of BIOLASE ( NASDAQ:BIOL - Get Rating ) in a research report issued to clients and investors on Friday. The brokerage set a ""sell"" rating on the medical technology company's stock.",ABBV,0.076602,0.113988,Neutral
Bassett Furniture Industries  ( NASDAQ:BSET )  Upgraded at StockNews.com,https://reporter.am/2023/02/19/bassett-furniture-industries-nasdaqbset-upgraded-at-stocknews-com.html,2023-02-19 06:22:41,Bassett Furniture Industries ( NASDAQ:BSET ) Upgraded at ... Armenian Reporter ...,ABBV,0.072,0.117778,Neutral
Tenaris  ( NYSE:TS )  Upgraded to Strong-Buy at StockNews.com,https://reporter.am/2023/02/19/tenaris-nysets-upgraded-to-strong-buy-at-stocknews-com.html,2023-02-19 06:22:41,"Tenaris ( NYSE:TS - Get Rating ) was upgraded by analysts at StockNews.com from a ""buy"" rating to a ""strong-buy"" rating in a note issued to investors on Friday. A number of other equities analysts have also recently commented on the stock.",ABBV,0.070517,0.097467,Neutral
StockNews.com Upgrades Telefónica  ( NYSE:TEF )  to Buy,https://www.defenseworld.net/2023/02/19/stocknews-com-upgrades-telefonica-nysetef-to-buy.html,2023-02-19 06:22:41,"Telefónica ( NYSE:TEF - Get Rating ) was upgraded by research analysts at StockNews.com from a ""hold"" rating to a ""buy"" rating in a research report issued to clients and investors on Friday.",ABBV,0.067919,0.190806,Somewhat-Bullish
StockNews.com Upgrades Telefónica  ( NYSE:TEF )  to Buy,https://www.etfdailynews.com/2023/02/19/stocknews-com-upgrades-telefonica-nysetef-to-buy/,2023-02-19 06:22:41,"Telefónica ( NYSE:TEF - Get Rating ) was upgraded by research analysts at StockNews.com from a ""hold"" rating to a ""buy"" rating in a research report issued to clients and investors on Friday.",ABBV,0.067919,0.190806,Somewhat-Bullish
Xylem  ( NYSE:XYL )  Rating Lowered to Hold at StockNews.com,https://www.defenseworld.net/2023/02/19/xylem-nysexyl-rating-lowered-to-hold-at-stocknews-com.html,2023-02-19 06:22:41,"Xylem ( NYSE:XYL - Get Rating ) was downgraded by StockNews.com from a ""buy"" rating to a ""hold"" rating in a note issued to investors on Friday. A number of other equities analysts have also weighed in on the stock.",ABBV,0.066784,0.145391,Neutral
Amedisys  ( NASDAQ:AMED )  Rating Increased to Buy at StockNews.com,https://www.defenseworld.net/2023/02/19/amedisys-nasdaqamed-rating-increased-to-buy-at-stocknews-com.html,2023-02-19 06:22:41,Amedisys ( NASDAQ:AMED ) Rating Increased to Buy at StockNews ... Defense World ...,ABBV,0.066784,0.149295,Neutral
OGE Energy  ( NYSE:OGE )  Stock Rating Upgraded by StockNews.com,https://www.defenseworld.net/2023/02/19/oge-energy-nyseoge-stock-rating-upgraded-by-stocknews-com.html,2023-02-19 06:22:41,"OGE Energy ( NYSE:OGE - Get Rating ) was upgraded by investment analysts at StockNews.com from a ""hold"" rating to a ""buy"" rating in a note issued to investors on Friday. OGE has been the topic of a number of other reports.",ABBV,0.06623,0.144929,Neutral
Telephone and Data Systems  ( NYSE:TDS )  Upgraded to Hold by StockNews.com,https://reporter.am/2023/02/19/telephone-and-data-systems-nysetds-upgraded-to-hold-by-stocknews-com.html,2023-02-19 06:22:41,Telephone and Data Systems ( NYSE:TDS ) Upgraded to Hold by ... Armenian Reporter ...,ABBV,0.063594,0.150154,Somewhat-Bullish
"Amedisys  ( NASDAQ:AMED )  Upgraded by StockNews.com to ""Buy""",https://reporter.am/2023/02/19/amedisys-nasdaqamed-upgraded-by-stocknews-com-to-buy.html,2023-02-19 06:22:41,"Amedisys ( NASDAQ:AMED - Get Rating ) was upgraded by StockNews.com from a ""hold"" rating to a ""buy"" rating in a research report issued on Friday. A number of other brokerages also recently commented on AMED. Cowen decreased their price objective on shares of Amedisys to $103.00 in a research ...",ABBV,0.063091,0.14872,Neutral
"Nabors Industries  ( NYSE:NBR )  Upgraded by StockNews.com to ""Buy""",https://reporter.am/2023/02/19/nabors-industries-nysenbr-upgraded-by-stocknews-com-to-buy.html,2023-02-19 06:22:41,"Nabors Industries ( NYSE:NBR - Get Rating ) was upgraded by StockNews.com from a ""hold"" rating to a ""buy"" rating in a research note issued to investors on Friday.",ABBV,0.06211,0.132364,Neutral
"StockNews.com Upgrades United States Cellular  ( NYSE:USM )  to ""Hold""",https://www.defenseworld.net/2023/02/19/stocknews-com-upgrades-united-states-cellular-nyseusm-to-hold.html,2023-02-19 06:22:41,StockNews.com Upgrades United States Cellular ( NYSE:USM ) to ... Defense World ...,ABBV,0.055621,0.124882,Neutral
Paramount Group  ( NYSE:PGRE )  Lowered to Sell at StockNews.com,https://reporter.am/2023/02/19/paramount-group-nysepgre-lowered-to-sell-at-stocknews-com.html,2023-02-19 06:22:41,"Paramount Group ( NYSE:PGRE - Get Rating ) was downgraded by equities research analysts at StockNews.com from a ""hold"" rating to a ""sell"" rating in a note issued to investors on Friday.",ABBV,0.053992,0.101746,Neutral
"Nu Skin Enterprises  ( NYSE:NUS )  Cut to ""Hold"" at StockNews.com",https://reporter.am/2023/02/19/nu-skin-enterprises-nysenus-cut-to-hold-at-stocknews-com.html,2023-02-19 06:22:41,"Nu Skin Enterprises ( NYSE:NUS - Get Rating ) was downgraded by StockNews.com from a ""buy"" rating to a ""hold"" rating in a research report issued to clients and investors on Friday. Other equities analysts have also issued research reports about the company.",ABBV,0.049526,0.157113,Somewhat-Bullish
"Shake Shack  ( NYSE:SHAK )  Lifted to ""Hold"" at StockNews.com",https://reporter.am/2023/02/19/shake-shack-nyseshak-lifted-to-hold-at-stocknews-com.html,2023-02-19 06:22:41,"Shake Shack ( NYSE:SHAK - Get Rating ) was upgraded by analysts at StockNews.com from a ""sell"" rating to a ""hold"" rating in a research note issued on Friday. Other analysts have also recently issued reports about the stock.",ABBV,0.048133,0.087703,Neutral
3 Dividend Stocks That Should Pay You the Rest of Your Life,https://www.fool.com/investing/2023/02/18/3-dividend-stocks-that-should-pay-you-the-rest-of/,2023-02-18 14:00:00,"Each of these companies can provide income investors with growing, market-beating passive income.",ABBV,0.249106,0.246652,Somewhat-Bullish
SemiLEDs  ( NASDAQ:LEDS )  Research Coverage Started at StockNews.com,https://www.etfdailynews.com/2023/02/18/semileds-nasdaqleds-research-coverage-started-at-stocknews-com/,2023-02-18 08:48:41,SemiLEDs ( NASDAQ:LEDS ) Research Coverage Started at ... ETF Daily News ...,ABBV,0.133841,0.271484,Somewhat-Bullish
Philip Morris International  ( NYSE:PM )  Downgraded by StockNews.com,https://www.etfdailynews.com/2023/02/18/philip-morris-international-nysepm-downgraded-by-stocknews-com/,2023-02-18 08:16:47,Philip Morris International ( NYSE:PM ) Downgraded by StockNews ... ETF Daily News ...,ABBV,0.052455,0.124581,Neutral
StockNews.com Begins Coverage on LifeVantage  ( NASDAQ:LFVN ) ,https://www.etfdailynews.com/2023/02/18/stocknews-com-begins-coverage-on-lifevantage-nasdaqlfvn-5/,2023-02-18 08:16:47,"Equities research analysts at StockNews.com assumed coverage on shares of LifeVantage ( NASDAQ:LFVN - Get Rating ) in a report released on Saturday. The firm set a ""strong-buy"" rating on the stock. LFVN opened at $3.99 on Friday. The firm has a market cap of $50.75 million, a P/E ratio of ...",ABBV,0.143415,0.195803,Somewhat-Bullish
Rave Restaurant Group  ( NASDAQ:RAVE )  Now Covered by Analysts at StockNews.com,https://www.etfdailynews.com/2023/02/18/rave-restaurant-group-nasdaqrave-now-covered-by-analysts-at-stocknews-com/,2023-02-18 08:16:46,Rave Restaurant Group ( NASDAQ:RAVE ) Now Covered by Analysts ... ETF Daily News ...,ABBV,0.091509,0.122835,Neutral
First Horizon  ( NYSE:FHN )  Downgraded by StockNews.com,https://www.etfdailynews.com/2023/02/18/first-horizon-nysefhn-downgraded-by-stocknews-com/,2023-02-18 08:16:46,"First Horizon ( NYSE:FHN - Get Rating ) was downgraded by StockNews.com from a ""hold"" rating to a ""sell"" rating in a research note issued to investors on Saturday. Shares of NYSE FHN opened at $24.84 on Friday.",ABBV,0.053509,0.156726,Somewhat-Bullish
Kite Realty Group Trust  ( NYSE:KRG )  Upgraded at StockNews.com,https://www.etfdailynews.com/2023/02/18/kite-realty-group-trust-nysekrg-upgraded-at-stocknews-com/,2023-02-18 08:16:46,"Kite Realty Group Trust ( NYSE:KRG - Get Rating ) was upgraded by equities research analysts at StockNews.com from a ""sell"" rating to a ""hold"" rating in a report released on Saturday. Several other equities analysts have also issued reports on the stock.",ABBV,0.044141,0.184644,Somewhat-Bullish
StockNews.com Initiates Coverage on Orion Energy Systems  ( NASDAQ:OESX ) ,https://www.etfdailynews.com/2023/02/18/stocknews-com-initiates-coverage-on-orion-energy-systems-nasdaqoesx/,2023-02-18 08:16:46,StockNews.com Initiates Coverage on Orion Energy Systems ... ETF Daily News ...,ABBV,0.156461,0.198218,Somewhat-Bullish
Tuniu  ( NASDAQ:TOUR )  Stock Rating Lowered by StockNews.com,https://www.defenseworld.net/2023/02/18/tuniu-nasdaqtour-stock-rating-lowered-by-stocknews-com.html,2023-02-18 08:16:45,"Tuniu ( NASDAQ:TOUR - Get Rating ) was downgraded by equities researchers at StockNews.com from a ""hold"" rating to a ""sell"" rating in a report released on Saturday. Shares of NASDAQ TOUR opened at $2.21 on Friday. Tuniu has a fifty-two week low of $0.46 and a fifty-two week high of $2.90.",ABBV,0.092927,0.107507,Neutral
DBV Technologies  ( NASDAQ:DBVT )  Now Covered by StockNews.com,https://www.etfdailynews.com/2023/02/18/dbv-technologies-nasdaqdbvt-now-covered-by-stocknews-com/,2023-02-18 08:16:45,"Research analysts at StockNews.com initiated coverage on shares of DBV Technologies ( NASDAQ:DBVT - Get Rating ) in a report issued on Saturday. The firm set a ""sell"" rating on the stock. Other research analysts have also recently issued reports about the company.",ABBV,0.085022,0.140745,Neutral
StockNews.com Upgrades Barnes Group  ( NYSE:B )  to Buy,https://www.defenseworld.net/2023/02/18/stocknews-com-upgrades-barnes-group-nyseb-to-buy.html,2023-02-18 08:16:45,"Barnes Group ( NYSE:B - Get Rating ) was upgraded by investment analysts at StockNews.com from a ""hold"" rating to a ""buy"" rating in a research report issued to clients and investors on Saturday. Several other research firms have also recently commented on B.",ABBV,0.079656,0.1793,Somewhat-Bullish
StockNews.com Begins Coverage on South Jersey Industries  ( NYSE:SJI ) ,https://www.defenseworld.net/2023/02/18/stocknews-com-begins-coverage-on-south-jersey-industries-nysesji.html,2023-02-18 08:16:45,StockNews.com Begins Coverage on South Jersey Industries ... Defense World ...,ABBV,0.078611,0.12693,Neutral
"AXIS Capital  ( NYSE:AXS )  Upgraded by StockNews.com to ""Buy""",https://www.defenseworld.net/2023/02/18/axis-capital-nyseaxs-upgraded-by-stocknews-com-to-buy-2.html,2023-02-18 08:16:45,"AXIS Capital ( NYSE:AXS - Get Rating ) was upgraded by equities researchers at StockNews.com from a ""hold"" rating to a ""buy"" rating in a note issued to investors on Saturday.",ABBV,0.069697,-0.010245,Neutral
Nabriva Therapeutics  ( NASDAQ:NBRV )  Coverage Initiated at StockNews.com,https://www.defenseworld.net/2023/02/18/nabriva-therapeutics-nasdaqnbrv-coverage-initiated-at-stocknews-com.html,2023-02-18 08:16:45,Nabriva Therapeutics ( NASDAQ:NBRV ) Coverage Initiated at ... Defense World ...,ABBV,0.154455,0.154306,Somewhat-Bullish
StockNews.com Lowers Minerva Neurosciences  ( NASDAQ:NERV )  to Sell,https://www.defenseworld.net/2023/02/18/stocknews-com-lowers-minerva-neurosciences-nasdaqnerv-to-sell.html,2023-02-18 08:16:44,StockNews.com Lowers Minerva Neurosciences ( NASDAQ:NERV ... Defense World ...,ABBV,0.095899,0.058363,Neutral
Rave Restaurant Group  ( NASDAQ:RAVE )  Earns Strong-Buy Rating from Analysts at StockNews.com,https://www.defenseworld.net/2023/02/18/rave-restaurant-group-nasdaqrave-earns-strong-buy-rating-from-analysts-at-stocknews-com.html,2023-02-18 08:16:44,Rave Restaurant Group ( NASDAQ:RAVE ) Earns Strong-Buy Rating ... Defense World ...,ABBV,0.091509,0.122835,Neutral
Rave Restaurant Group  ( NASDAQ:RAVE )  Earns Strong-Buy Rating from Analysts at StockNews.com,https://reporter.am/2023/02/18/rave-restaurant-group-nasdaqrave-earns-strong-buy-rating-from-analysts-at-stocknews-com.html,2023-02-18 08:16:44,Rave Restaurant Group ( NASDAQ:RAVE ) Earns Strong-Buy Rating ... Armenian Reporter ...,ABBV,0.091509,0.122835,Neutral
StockNews.com Initiates Coverage on Otonomy  ( NASDAQ:OTIC ) ,https://www.defenseworld.net/2023/02/18/stocknews-com-initiates-coverage-on-otonomy-nasdaqotic.html,2023-02-18 08:16:44,"Analysts at StockNews.com initiated coverage on shares of Otonomy ( NASDAQ:OTIC - Get Rating ) in a research report issued to clients and investors on Saturday. The firm set a ""hold"" rating on the biopharmaceutical company's stock. Shares of Otonomy stock opened at $0.11 on Friday.",ABBV,0.090134,0.075882,Neutral
Shinhan Financial Group  ( NYSE:SHG )  Stock Rating Upgraded by StockNews.com,https://www.defenseworld.net/2023/02/18/shinhan-financial-group-nyseshg-stock-rating-upgraded-by-stocknews-com.html,2023-02-18 08:16:44,Shinhan Financial Group ( NYSE:SHG ) Stock Rating Upgraded by ... Defense World ...,ABBV,0.087824,0.181091,Somewhat-Bullish
StockNews.com Upgrades Ormat Technologies  ( NYSE:ORA )  to Hold,https://www.defenseworld.net/2023/02/18/stocknews-com-upgrades-ormat-technologies-nyseora-to-hold.html,2023-02-18 08:16:44,"Ormat Technologies ( NYSE:ORA - Get Rating ) was upgraded by investment analysts at StockNews.com from a ""sell"" rating to a ""hold"" rating in a research note issued on Saturday. Several other research analysts also recently issued reports on the company.",ABBV,0.072,0.149085,Neutral
First Horizon  ( NYSE:FHN )  Downgraded by StockNews.com,https://www.defenseworld.net/2023/02/18/first-horizon-nysefhn-downgraded-by-stocknews-com.html,2023-02-18 08:16:44,"First Horizon ( NYSE:FHN - Get Rating ) was downgraded by equities researchers at StockNews.com from a ""hold"" rating to a ""sell"" rating in a report issued on Saturday. FHN stock opened at $24.84 on Friday. First Horizon has a 1-year low of $16.78 and a 1-year high of $24.92.",ABBV,0.062434,0.157102,Somewhat-Bullish
Equinix  ( NASDAQ:EQIX )  Downgraded to Hold at StockNews.com,https://www.defenseworld.net/2023/02/18/equinix-nasdaqeqix-downgraded-to-hold-at-stocknews-com.html,2023-02-18 08:16:44,"Equinix ( NASDAQ:EQIX - Get Rating ) was downgraded by stock analysts at StockNews.com from a ""buy"" rating to a ""hold"" rating in a report issued on Saturday. Several other equities analysts also recently issued reports on the company.",ABBV,0.049221,0.201094,Somewhat-Bullish
Mexco Energy  ( NYSE:MXC )  Receives New Coverage from Analysts at StockNews.com,https://www.defenseworld.net/2023/02/18/mexco-energy-nysemxc-receives-new-coverage-from-analysts-at-stocknews-com.html,2023-02-18 08:16:44,Mexco Energy ( NYSE:MXC ) Receives New Coverage from Analysts ... Defense World ...,ABBV,0.155451,0.15512,Somewhat-Bullish
DBV Technologies  ( NASDAQ:DBVT )  Now Covered by StockNews.com,https://www.defenseworld.net/2023/02/18/dbv-technologies-nasdaqdbvt-now-covered-by-stocknews-com.html,2023-02-18 08:16:43,"Research analysts at StockNews.com began coverage on shares of DBV Technologies ( NASDAQ:DBVT - Get Rating ) in a research report issued to clients and investors on Saturday. The brokerage set a ""sell"" rating on the stock. Several other equities research analysts also recently commented on the ...",ABBV,0.086245,0.141091,Neutral
Cidara Therapeutics  ( NASDAQ:CDTX )  Lifted to Strong-Buy at StockNews.com,https://www.defenseworld.net/2023/02/18/cidara-therapeutics-nasdaqcdtx-lifted-to-strong-buy-at-stocknews-com.html,2023-02-18 08:16:43,Cidara Therapeutics ( NASDAQ:CDTX ) Lifted to Strong-Buy at ... Defense World ...,ABBV,0.085324,0.132565,Neutral
RBC Bearings  ( NASDAQ:ROLL )  Earns Hold Rating from Analysts at StockNews.com,https://www.defenseworld.net/2023/02/18/rbc-bearings-nasdaqroll-earns-hold-rating-from-analysts-at-stocknews-com.html,2023-02-18 08:16:43,RBC Bearings ( NASDAQ:ROLL ) Earns Hold Rating from Analysts at ... Defense World ...,ABBV,0.082111,0.023736,Neutral
Expedia Group  ( NASDAQ:EXPE )  Upgraded at StockNews.com,https://www.defenseworld.net/2023/02/18/expedia-group-nasdaqexpe-upgraded-at-stocknews-com.html,2023-02-18 08:16:43,"Expedia Group ( NASDAQ:EXPE - Get Rating ) was upgraded by equities researchers at StockNews.com from a ""hold"" rating to a ""buy"" rating in a research report issued on Saturday. EXPE has been the topic of a number of other research reports.",ABBV,0.058759,0.115996,Neutral
Equinix  ( NASDAQ:EQIX )  Downgraded to Hold at StockNews.com,https://reporter.am/2023/02/18/equinix-nasdaqeqix-downgraded-to-hold-at-stocknews-com-2.html,2023-02-18 08:16:43,"Equinix ( NASDAQ:EQIX - Get Rating ) was downgraded by stock analysts at StockNews.com from a ""buy"" rating to a ""hold"" rating in a report issued on Saturday. Several other equities analysts also recently issued reports on the company.",ABBV,0.049221,0.201094,Somewhat-Bullish
"PTC Therapeutics  ( NASDAQ:PTCT )  Lifted to ""Buy"" at StockNews.com",https://www.defenseworld.net/2023/02/18/ptc-therapeutics-nasdaqptct-lifted-to-buy-at-stocknews-com.html,2023-02-18 08:16:43,"PTC Therapeutics ( NASDAQ:PTCT - Get Rating ) was upgraded by research analysts at StockNews.com from a ""hold"" rating to a ""buy"" rating in a note issued to investors on Saturday. Several other research analysts have also recently weighed in on the stock.",ABBV,0.048133,0.111908,Neutral
"Sasol  ( NYSE:SSL )  Upgraded to ""Buy"" at StockNews.com",https://www.defenseworld.net/2023/02/18/sasol-nysessl-upgraded-to-buy-at-stocknews-com.html,2023-02-18 08:16:43,"Sasol ( NYSE:SSL - Get Rating ) was upgraded by research analysts at StockNews.com from a ""hold"" rating to a ""buy"" rating in a report released on Saturday. SSL stock opened at $16.35 on Friday. The company has a 50 day moving average price of $16.61 and a 200 day moving average price of $17.51.",ABBV,0.101154,0.201308,Somewhat-Bullish
StockNews.com Initiates Coverage on Invacare  ( NYSE:IVC ) ,https://www.defenseworld.net/2023/02/18/stocknews-com-initiates-coverage-on-invacare-nyseivc.html,2023-02-18 08:16:42,"Stock analysts at StockNews.com initiated coverage on shares of Invacare ( NYSE:IVC - Get Rating ) in a note issued to investors on Saturday. The brokerage set a ""hold"" rating on the health services provider's stock.",ABBV,0.095899,0.149591,Neutral
StockNews.com Initiates Coverage on Orion Energy Systems  ( NASDAQ:OESX ) ,https://www.defenseworld.net/2023/02/18/stocknews-com-initiates-coverage-on-orion-energy-systems-nasdaqoesx.html,2023-02-18 08:16:42,StockNews.com Initiates Coverage on Orion Energy Systems ... Defense World ...,ABBV,0.092213,0.158729,Somewhat-Bullish
StockNews.com Downgrades IQVIA  ( NYSE:IQV )  to Hold,https://www.defenseworld.net/2023/02/18/stocknews-com-downgrades-iqvia-nyseiqv-to-hold.html,2023-02-18 08:16:42,"IQVIA ( NYSE:IQV - Get Rating ) was downgraded by investment analysts at StockNews.com from a ""buy"" rating to a ""hold"" rating in a report released on Saturday. Several other research firms also recently issued reports on IQV. SVB Leerink restated an ""outperform"" rating on shares of IQVIA in a ...",ABBV,0.049526,0.170549,Somewhat-Bullish
Kite Realty Group Trust  ( NYSE:KRG )  Upgraded at StockNews.com,https://www.defenseworld.net/2023/02/18/kite-realty-group-trust-nysekrg-upgraded-at-stocknews-com.html,2023-02-18 08:16:42,"Kite Realty Group Trust ( NYSE:KRG - Get Rating ) was upgraded by equities researchers at StockNews.com from a ""sell"" rating to a ""hold"" rating in a research note issued on Saturday. Several other analysts also recently commented on the stock.",ABBV,0.048327,0.165857,Somewhat-Bullish
StockNews.com Initiates Coverage on Otonomy  ( NASDAQ:OTIC ) ,https://reporter.am/2023/02/18/stocknews-com-initiates-coverage-on-otonomy-nasdaqotic-2.html,2023-02-18 08:16:41,"Analysts at StockNews.com initiated coverage on shares of Otonomy ( NASDAQ:OTIC - Get Rating ) in a research report issued to clients and investors on Saturday. The firm set a ""hold"" rating on the biopharmaceutical company's stock. Shares of Otonomy stock opened at $0.11 on Friday.",ABBV,0.090134,0.075882,Neutral
Benefitfocus  ( NASDAQ:BNFT )  Now Covered by Analysts at StockNews.com,https://www.defenseworld.net/2023/02/18/benefitfocus-nasdaqbnft-now-covered-by-analysts-at-stocknews-com-3.html,2023-02-18 08:16:41,Benefitfocus ( NASDAQ:BNFT ) Now Covered by Analysts at ... Defense World ...,ABBV,0.078354,0.222917,Somewhat-Bullish
"AtriCure  ( NASDAQ:ATRC )  Upgraded by StockNews.com to ""Hold""",https://www.defenseworld.net/2023/02/18/atricure-nasdaqatrc-upgraded-by-stocknews-com-to-hold.html,2023-02-18 08:16:41,"AtriCure ( NASDAQ:ATRC - Get Rating ) was upgraded by equities researchers at StockNews.com from a ""sell"" rating to a ""hold"" rating in a research report issued to clients and investors on Saturday. A number of other equities research analysts also recently issued reports on the stock.",ABBV,0.066598,0.098376,Neutral
StockNews.com Downgrades Gentex  ( NASDAQ:GNTX )  to Hold,https://www.defenseworld.net/2023/02/18/stocknews-com-downgrades-gentex-nasdaqgntx-to-hold.html,2023-02-18 08:16:41,"Gentex ( NASDAQ:GNTX - Get Rating ) was downgraded by analysts at StockNews.com from a ""buy"" rating to a ""hold"" rating in a report issued on Saturday. Several other brokerages also recently weighed in on GNTX. Guggenheim lowered their price target on shares of Gentex to $29.00 in a report on ...",ABBV,0.055751,0.136,Neutral
Philip Morris International  ( NYSE:PM )  Cut to Hold at StockNews.com,https://www.defenseworld.net/2023/02/18/philip-morris-international-nysepm-cut-to-hold-at-stocknews-com.html,2023-02-18 08:16:41,"Philip Morris International ( NYSE:PM - Get Rating ) was downgraded by investment analysts at StockNews.com from a ""buy"" rating to a ""hold"" rating in a research report issued to clients and investors on Saturday.",ABBV,0.054483,0.124795,Neutral
Advaxis  ( NASDAQ:ADXS )  Coverage Initiated at StockNews.com,https://www.defenseworld.net/2023/02/18/advaxis-nasdaqadxs-coverage-initiated-at-stocknews-com.html,2023-02-18 08:16:41,"Stock analysts at StockNews.com began coverage on shares of Advaxis ( NASDAQ:ADXS - Get Rating ) in a research report issued on Saturday. The firm set a ""sell"" rating on the stock. Advaxis, Inc is a biotechnology company, which engages in the discovery, development and commercialization of ...",ABBV,0.213048,0.027263,Neutral
New Concept Energy  ( NYSE:GBR )  Research Coverage Started at StockNews.com,https://www.defenseworld.net/2023/02/18/new-concept-energy-nysegbr-research-coverage-started-at-stocknews-com-2.html,2023-02-18 08:16:41,New Concept Energy ( NYSE:GBR ) Research Coverage Started at ... Defense World ...,ABBV,0.183895,0.138256,Neutral
StockNews.com Downgrades Copa  ( NYSE:CPA )  to Hold,https://www.defenseworld.net/2023/02/18/stocknews-com-downgrades-copa-nysecpa-to-hold.html,2023-02-18 08:06:42,"Copa ( NYSE:CPA - Get Rating ) was downgraded by analysts at StockNews.com from a ""buy"" rating to a ""hold"" rating in a research note issued on Thursday. A number of other equities analysts have also commented on the company.",ABBV,0.064623,0.10511,Neutral
StockNews.com Upgrades Allison Transmission  ( NYSE:ALSN )  to Strong-Buy,https://www.defenseworld.net/2023/02/18/stocknews-com-upgrades-allison-transmission-nysealsn-to-strong-buy.html,2023-02-18 08:06:41,StockNews.com Upgrades Allison Transmission ( NYSE:ALSN ) to ... Defense World ...,ABBV,0.049629,0.18115,Somewhat-Bullish
StockNews.com Downgrades USANA Health Sciences  ( NYSE:USNA )  to Buy,https://reporter.am/2023/02/18/stocknews-com-downgrades-usana-health-sciences-nyseusna-to-buy.html,2023-02-18 07:44:41,StockNews.com Downgrades USANA Health Sciences ( NYSE ... Armenian Reporter ...,ABBV,0.057628,0.155991,Somewhat-Bullish
CEMEX  ( NYSE:CX )  Rating Lowered to Buy at StockNews.com,https://www.etfdailynews.com/2023/02/18/cemex-nysecx-rating-lowered-to-buy-at-stocknews-com/,2023-02-18 07:36:47,"CEMEX ( NYSE:CX - Get Rating ) was downgraded by research analysts at StockNews.com from a ""strong-buy"" rating to a ""buy"" rating in a research report issued on Thursday. Separately, Redburn Partners began coverage on CEMEX in a research report on Thursday, December 8th.",ABBV,0.085629,0.136779,Neutral
Seaboard  ( NYSE:SEB )  Stock Rating Upgraded by StockNews.com,https://www.defenseworld.net/2023/02/18/seaboard-nyseseb-stock-rating-upgraded-by-stocknews-com.html,2023-02-18 07:36:45,"Seaboard ( NYSE:SEB - Get Rating ) was upgraded by stock analysts at StockNews.com from a ""buy"" rating to a ""strong-buy"" rating in a report released on Thursday. Shares of SEB opened at $3,995.50 on Thursday. Seaboard has a one year low of $3,295.00 and a one year high of $4,394.25.",ABBV,0.181137,0.097223,Neutral
Radiant Logistics  ( NYSE:RLGT )  Rating Lowered to Buy at StockNews.com,https://reporter.am/2023/02/18/radiant-logistics-nyserlgt-rating-lowered-to-buy-at-stocknews-com.html,2023-02-18 07:36:44,Radiant Logistics ( NYSE:RLGT ) Rating Lowered to Buy at ... Armenian Reporter ...,ABBV,0.148731,0.15098,Somewhat-Bullish
"StockNews.com Upgrades Avino Silver & Gold Mines  ( NYSE:ASM )  to ""Hold""",https://reporter.am/2023/02/18/stocknews-com-upgrades-avino-silver-gold-mines-nyseasm-to-hold.html,2023-02-18 07:36:41,StockNews.com Upgrades Avino Silver & Gold Mines ( NYSE:ASM ... Armenian Reporter ...,ABBV,0.172097,0.116302,Neutral
VAALCO Energy  ( NYSE:EGY )  Rating Lowered to Hold at StockNews.com,https://www.defenseworld.net/2023/02/18/vaalco-energy-nyseegy-rating-lowered-to-hold-at-stocknews-com.html,2023-02-18 07:36:41,VAALCO Energy ( NYSE:EGY ) Rating Lowered to Hold at ... Defense World ...,ABBV,0.100729,0.087764,Neutral
Ryder System  ( NYSE:R )  Stock Rating Upgraded by StockNews.com,https://www.etfdailynews.com/2023/02/18/ryder-system-nyser-stock-rating-upgraded-by-stocknews-com/,2023-02-18 07:26:48,"Ryder System ( NYSE:R - Get Rating ) was upgraded by analysts at StockNews.com from a ""buy"" rating to a ""strong-buy"" rating in a report issued on Thursday. R has been the topic of several other reports.",ABBV,0.045139,0.208984,Somewhat-Bullish
Ryder System  ( NYSE:R )  Raised to Strong-Buy at StockNews.com,https://www.defenseworld.net/2023/02/18/ryder-system-nyser-raised-to-strong-buy-at-stocknews-com.html,2023-02-18 07:26:41,"Ryder System ( NYSE:R - Get Rating ) was upgraded by research analysts at StockNews.com from a ""buy"" rating to a ""strong-buy"" rating in a research report issued to clients and investors on Thursday. A number of other research analysts have also recently issued reports on the company.",ABBV,0.045054,0.208956,Somewhat-Bullish
Computer Programs and Systems  ( NASDAQ:CPSI )  Lowered to Hold at StockNews.com,https://www.defenseworld.net/2023/02/18/computer-programs-and-systems-nasdaqcpsi-lowered-to-hold-at-stocknews-com.html,2023-02-18 06:54:41,Computer Programs and Systems ( NASDAQ:CPSI ) Lowered to Hold ... Defense World ...,ABBV,0.079392,0.260272,Somewhat-Bullish
Scorpio Tankers  ( NYSE:STNG )  Rating Lowered to Hold at StockNews.com,https://www.etfdailynews.com/2023/02/18/scorpio-tankers-nysestng-rating-lowered-to-hold-at-stocknews-com/,2023-02-18 06:54:41,Scorpio Tankers ( NYSE:STNG ) Rating Lowered to Hold at ... ETF Daily News ...,ABBV,0.072435,0.105718,Neutral
Scorpio Tankers  ( NYSE:STNG )  Stock Rating Lowered by StockNews.com,https://www.defenseworld.net/2023/02/18/scorpio-tankers-nysestng-stock-rating-lowered-by-stocknews-com.html,2023-02-18 06:54:41,Scorpio Tankers ( NYSE:STNG ) Stock Rating Lowered by ... Defense World ...,ABBV,0.061473,0.105015,Neutral
Westamerica Bancorporation  ( NASDAQ:WABC )  Rating Increased to Hold at StockNews.com,https://www.etfdailynews.com/2023/02/18/westamerica-bancorporation-nasdaqwabc-rating-increased-to-hold-at-stocknews-com/,2023-02-18 06:22:50,Westamerica Bancorporation ( NASDAQ:WABC ) Rating Increased to ... ETF Daily News ...,ABBV,0.082111,0.179536,Somewhat-Bullish
Mastercard  ( NYSE:MA )  Stock Rating Upgraded by StockNews.com,https://www.etfdailynews.com/2023/02/18/mastercard-nysema-stock-rating-upgraded-by-stocknews-com/,2023-02-18 06:22:50,"Mastercard ( NYSE:MA - Get Rating ) was upgraded by equities researchers at StockNews.com from a ""hold"" rating to a ""buy"" rating in a research report issued on Thursday. MA has been the subject of several other reports.",ABBV,0.048523,0.159901,Somewhat-Bullish
Olympic Steel  ( NASDAQ:ZEUS )  Stock Rating Upgraded by StockNews.com,https://www.etfdailynews.com/2023/02/18/olympic-steel-nasdaqzeus-stock-rating-upgraded-by-stocknews-com/,2023-02-18 06:22:49,Olympic Steel ( NASDAQ:ZEUS ) Stock Rating Upgraded by ... ETF Daily News ...,ABBV,0.095138,0.12287,Neutral
CRA International  ( NASDAQ:CRAI )  Stock Rating Lowered by StockNews.com,https://www.etfdailynews.com/2023/02/18/cra-international-nasdaqcrai-stock-rating-lowered-by-stocknews-com/,2023-02-18 06:22:49,CRA International ( NASDAQ:CRAI ) Stock Rating Lowered by ... ETF Daily News ...,ABBV,0.088472,0.112385,Neutral
Vector Group  ( NYSE:VGR )  Stock Rating Upgraded by StockNews.com,https://www.defenseworld.net/2023/02/18/vector-group-nysevgr-stock-rating-upgraded-by-stocknews-com.html,2023-02-18 06:22:49,"Vector Group ( NYSE:VGR - Get Rating ) was upgraded by StockNews.com from a ""hold"" rating to a ""buy"" rating in a report issued on Thursday. Shares of NYSE:VGR opened at $14.39 on Thursday. The firm has a market capitalization of $2.23 billion, a PE ratio of 14.25 and a beta of 1.06.",ABBV,0.080188,0.117029,Neutral
Enel Chile  ( NYSE:ENIC )  Rating Lowered to Hold at StockNews.com,https://www.etfdailynews.com/2023/02/18/enel-chile-nyseenic-rating-lowered-to-hold-at-stocknews-com/,2023-02-18 06:22:49,"Enel Chile ( NYSE:ENIC - Get Rating ) was downgraded by equities research analysts at StockNews.com from a ""buy"" rating to a ""hold"" rating in a research note issued to investors on Thursday. NYSE ENIC opened at $2.19 on Thursday. Enel Chile has a 52 week low of $0.98 and a 52 week high of $2.35.",ABBV,0.100729,0.12472,Neutral
Olympic Steel  ( NASDAQ:ZEUS )  Stock Rating Upgraded by StockNews.com,https://reporter.am/2023/02/18/olympic-steel-nasdaqzeus-stock-rating-upgraded-by-stocknews-com.html,2023-02-18 06:22:48,Olympic Steel ( NASDAQ:ZEUS ) Stock Rating Upgraded by ... Armenian Reporter ...,ABBV,0.095138,0.12287,Neutral
StockNews.com Downgrades Chefs' Warehouse  ( NASDAQ:CHEF )  to Sell,https://www.etfdailynews.com/2023/02/18/stocknews-com-downgrades-chefs-warehouse-nasdaqchef-to-sell/,2023-02-18 06:22:48,StockNews.com Downgrades Chefs' Warehouse ( NASDAQ:CHEF ... ETF Daily News ...,ABBV,0.077343,0.125675,Neutral
StockNews.com Downgrades Chefs' Warehouse  ( NASDAQ:CHEF )  to Sell,https://reporter.am/2023/02/18/stocknews-com-downgrades-chefs-warehouse-nasdaqchef-to-sell.html,2023-02-18 06:22:48,StockNews.com Downgrades Chefs' Warehouse ( NASDAQ:CHEF ... Armenian Reporter ...,ABBV,0.077343,0.125675,Neutral
"StockNews.com Upgrades CEVA  ( NASDAQ:CEVA )  to ""Buy""",https://www.defenseworld.net/2023/02/18/stocknews-com-upgrades-ceva-nasdaqceva-to-buy.html,2023-02-18 06:22:48,"CEVA ( NASDAQ:CEVA - Get Rating ) was upgraded by research analysts at StockNews.com from a ""hold"" rating to a ""buy"" rating in a research note issued to investors on Thursday. Other analysts also recently issued reports about the company.",ABBV,0.074001,0.213369,Somewhat-Bullish
RCI Hospitality  ( NASDAQ:RICK )  Rating Lowered to Hold at StockNews.com,https://www.defenseworld.net/2023/02/18/rci-hospitality-nasdaqrick-rating-lowered-to-hold-at-stocknews-com.html,2023-02-18 06:22:48,RCI Hospitality ( NASDAQ:RICK ) Rating Lowered to Hold at ... Defense World ...,ABBV,0.070725,0.148889,Neutral
MKS Instruments  ( NASDAQ:MKSI )  Upgraded at StockNews.com,https://www.defenseworld.net/2023/02/18/mks-instruments-nasdaqmksi-upgraded-at-stocknews-com.html,2023-02-18 06:22:48,"MKS Instruments ( NASDAQ:MKSI - Get Rating ) was upgraded by StockNews.com from a ""sell"" rating to a ""hold"" rating in a research report issued on Thursday.",ABBV,0.064276,0.152205,Somewhat-Bullish
Royalty Pharma  ( NASDAQ:RPRX )  Stock Rating Upgraded by StockNews.com,https://www.etfdailynews.com/2023/02/18/royalty-pharma-nasdaqrprx-stock-rating-upgraded-by-stocknews-com/,2023-02-18 06:22:48,Royalty Pharma ( NASDAQ:RPRX ) Stock Rating Upgraded by ... ETF Daily News ...,ABBV,0.057767,0.113976,Neutral
Inter Parfums  ( NASDAQ:IPAR )  Rating Lowered to Hold at StockNews.com,https://www.defenseworld.net/2023/02/18/inter-parfums-nasdaqipar-rating-lowered-to-hold-at-stocknews-com.html,2023-02-18 06:22:48,Inter Parfums ( NASDAQ:IPAR ) Rating Lowered to Hold at ... Defense World ...,ABBV,0.05133,0.193482,Somewhat-Bullish
Northwest Pipe  ( NASDAQ:NWPX )  Stock Rating Upgraded by StockNews.com,https://reporter.am/2023/02/18/northwest-pipe-nasdaqnwpx-stock-rating-upgraded-by-stocknews-com.html,2023-02-18 06:22:47,Northwest Pipe ( NASDAQ:NWPX ) Stock Rating Upgraded by ... Armenian Reporter ...,ABBV,0.07913,0.057286,Neutral
"Sunoco  ( NYSE:SUN )  Lowered to ""Hold"" at StockNews.com",https://www.defenseworld.net/2023/02/18/sunoco-nysesun-lowered-to-hold-at-stocknews-com.html,2023-02-18 06:22:47,"Sunoco ( NYSE:SUN - Get Rating ) was downgraded by stock analysts at StockNews.com from a ""buy"" rating to a ""hold"" rating in a report issued on Thursday. SUN has been the subject of several other reports.",ABBV,0.069094,0.11344,Neutral
"StockNews.com Upgrades SBA Communications  ( NASDAQ:SBAC )  to ""Buy""",https://www.etfdailynews.com/2023/02/18/stocknews-com-upgrades-sba-communications-nasdaqsbac-to-buy-2/,2023-02-18 06:22:47,StockNews.com Upgrades SBA Communications ( NASDAQ:SBAC ... ETF Daily News ...,ABBV,0.063425,0.143128,Neutral
US Foods  ( NYSE:USFD )  Downgraded to Buy at StockNews.com,https://www.defenseworld.net/2023/02/18/us-foods-nyseusfd-downgraded-to-buy-at-stocknews-com.html,2023-02-18 06:22:47,"US Foods ( NYSE:USFD - Get Rating ) was downgraded by investment analysts at StockNews.com from a ""strong-buy"" rating to a ""buy"" rating in a note issued to investors on Thursday.",ABBV,0.06179,0.047076,Neutral
The PNC Financial Services Group  ( NYSE:PNC )  Upgraded to Hold at StockNews.com,https://www.defenseworld.net/2023/02/18/the-pnc-financial-services-group-nysepnc-upgraded-to-hold-at-stocknews-com.html,2023-02-18 06:22:47,The PNC Financial Services Group ( NYSE:PNC ) Upgraded to Hold ... Defense World ...,ABBV,0.056808,0.114941,Neutral
StockNews.com Upgrades Marriott International  ( NASDAQ:MAR )  to Buy,https://www.etfdailynews.com/2023/02/18/stocknews-com-upgrades-marriott-international-nasdaqmar-to-buy/,2023-02-18 06:22:47,StockNews.com Upgrades Marriott International ( NASDAQ:MAR ) to ... ETF Daily News ...,ABBV,0.045224,0.113257,Neutral
Seanergy Maritime  ( NASDAQ:SHIP )  Stock Rating Lowered by StockNews.com,https://www.etfdailynews.com/2023/02/18/seanergy-maritime-nasdaqship-stock-rating-lowered-by-stocknews-com/,2023-02-18 06:22:47,Seanergy Maritime ( NASDAQ:SHIP ) Stock Rating Lowered by ... ETF Daily News ...,ABBV,0.15347,0.1623,Somewhat-Bullish
Enel Chile  ( NYSE:ENIC )  Rating Lowered to Hold at StockNews.com,https://reporter.am/2023/02/18/enel-chile-nyseenic-rating-lowered-to-hold-at-stocknews-com.html,2023-02-18 06:22:47,"Enel Chile ( NYSE:ENIC - Get Rating ) was downgraded by equities research analysts at StockNews.com from a ""buy"" rating to a ""hold"" rating in a research note issued to investors on Thursday. NYSE ENIC opened at $2.19 on Thursday. Enel Chile has a 52 week low of $0.98 and a 52 week high of $2.35.",ABBV,0.100729,0.12472,Neutral
"Wendy's  ( NASDAQ:WEN )  Downgraded to ""Hold"" at StockNews.com",https://www.defenseworld.net/2023/02/18/wendys-nasdaqwen-downgraded-to-hold-at-stocknews-com-2.html,2023-02-18 06:22:46,"Wendy's ( NASDAQ:WEN - Get Rating ) was downgraded by investment analysts at StockNews.com from a ""buy"" rating to a ""hold"" rating in a report released on Thursday.",ABBV,0.072435,0.15219,Somewhat-Bullish
RCI Hospitality  ( NASDAQ:RICK )  Rating Lowered to Hold at StockNews.com,https://www.etfdailynews.com/2023/02/18/rci-hospitality-nasdaqrick-rating-lowered-to-hold-at-stocknews-com/,2023-02-18 06:22:46,RCI Hospitality ( NASDAQ:RICK ) Rating Lowered to Hold at ... ETF Daily News ...,ABBV,0.072217,0.14912,Neutral
Sunoco  ( NYSE:SUN )  Stock Rating Lowered by StockNews.com,https://reporter.am/2023/02/18/sunoco-nysesun-stock-rating-lowered-by-stocknews-com.html,2023-02-18 06:22:46,"Sunoco ( NYSE:SUN - Get Rating ) was downgraded by stock analysts at StockNews.com from a ""buy"" rating to a ""hold"" rating in a research report issued to clients and investors on Thursday. Several other analysts also recently weighed in on the company.",ABBV,0.067919,0.101286,Neutral
Mastercard  ( NYSE:MA )  Lifted to Buy at StockNews.com,https://www.defenseworld.net/2023/02/18/mastercard-nysema-lifted-to-buy-at-stocknews-com.html,2023-02-18 06:22:46,"Mastercard ( NYSE:MA - Get Rating ) was upgraded by equities researchers at StockNews.com from a ""hold"" rating to a ""buy"" rating in a note issued to investors on Thursday.",ABBV,0.049424,0.160093,Somewhat-Bullish
StockNews.com Downgrades Kellogg  ( NYSE:K )  to Hold,https://www.defenseworld.net/2023/02/18/stocknews-com-downgrades-kellogg-nysek-to-hold.html,2023-02-18 06:22:46,"Kellogg ( NYSE:K - Get Rating ) was downgraded by investment analysts at StockNews.com from a ""buy"" rating to a ""hold"" rating in a research note issued to investors on Thursday. Several other equities analysts have also weighed in on K.",ABBV,0.049424,0.134104,Neutral
Marriott International  ( NASDAQ:MAR )  Upgraded at StockNews.com,https://www.defenseworld.net/2023/02/18/marriott-international-nasdaqmar-upgraded-at-stocknews-com.html,2023-02-18 06:22:46,"Marriott International ( NASDAQ:MAR - Get Rating ) was upgraded by equities research analysts at StockNews.com from a ""hold"" rating to a ""buy"" rating in a research report issued on Thursday. MAR has been the subject of several other reports.",ABBV,0.04583,0.101487,Neutral
StockNews.com Lowers Enel Chile  ( NYSE:ENIC )  to Hold,https://www.defenseworld.net/2023/02/18/stocknews-com-lowers-enel-chile-nyseenic-to-hold.html,2023-02-18 06:22:46,"Enel Chile ( NYSE:ENIC - Get Rating ) was downgraded by equities researchers at StockNews.com from a ""buy"" rating to a ""hold"" rating in a research report issued to clients and investors on Thursday. Shares of NYSE ENIC opened at $2.19 on Thursday.",ABBV,0.109455,0.128025,Neutral
Gray Television  ( NYSE:GTN )  Cut to Sell at StockNews.com,https://www.defenseworld.net/2023/02/18/gray-television-nysegtn-cut-to-sell-at-stocknews-com.html,2023-02-18 06:22:45,"Gray Television ( NYSE:GTN - Get Rating ) was downgraded by research analysts at StockNews.com from a ""hold"" rating to a ""sell"" rating in a research note issued to investors on Thursday. Other equities research analysts have also issued research reports about the stock.",ABBV,0.063091,0.19624,Somewhat-Bullish
"SBA Communications  ( NASDAQ:SBAC )  Upgraded to ""Buy"" at StockNews.com",https://www.defenseworld.net/2023/02/18/sba-communications-nasdaqsbac-upgraded-to-buy-at-stocknews-com.html,2023-02-18 06:22:45,"SBA Communications ( NASDAQ:SBAC ) Upgraded to ""Buy"" at ... Defense World ...",ABBV,0.062597,0.143086,Neutral
Donegal Group  ( NASDAQ:DGICA )  Upgraded at StockNews.com,https://www.defenseworld.net/2023/02/18/donegal-group-nasdaqdgica-upgraded-at-stocknews-com.html,2023-02-18 06:22:45,"Donegal Group ( NASDAQ:DGICA - Get Rating ) was upgraded by investment analysts at StockNews.com from a ""hold"" rating to a ""buy"" rating in a research report issued to clients and investors on Thursday. Separately, TheStreet cut Donegal Group from a ""b-"" rating to a ""c+"" rating in a research ...",ABBV,0.061631,0.07411,Neutral
StockNews.com Upgrades The PNC Financial Services Group  ( NYSE:PNC )  to Hold,https://www.etfdailynews.com/2023/02/18/stocknews-com-upgrades-the-pnc-financial-services-group-nysepnc-to-hold/,2023-02-18 06:22:45,StockNews.com Upgrades The PNC Financial Services Group ... ETF Daily News ...,ABBV,0.048621,0.113994,Neutral
Northwest Pipe  ( NASDAQ:NWPX )  Stock Rating Upgraded by StockNews.com,https://www.etfdailynews.com/2023/02/18/northwest-pipe-nasdaqnwpx-stock-rating-upgraded-by-stocknews-com-2/,2023-02-18 06:22:45,Northwest Pipe ( NASDAQ:NWPX ) Stock Rating Upgraded by ... ETF Daily News ...,ABBV,0.124164,0.065587,Neutral
"Cinedigm  ( NASDAQ:CIDM )  Upgraded by StockNews.com to ""Hold""",https://www.defenseworld.net/2023/02/18/cinedigm-nasdaqcidm-upgraded-by-stocknews-com-to-hold.html,2023-02-18 06:22:44,"Cinedigm ( NASDAQ:CIDM - Get Rating ) was upgraded by equities research analysts at StockNews.com from a ""sell"" rating to a ""hold"" rating in a research report issued on Thursday. Separately, Benchmark reaffirmed a ""speculative buy"" rating and issued a $5.00 price target on shares of Cinedigm in ...",ABBV,0.097062,0.177727,Somewhat-Bullish
StockNews.com Initiates Coverage on U.S. Energy  ( NASDAQ:USEG ) ,https://www.defenseworld.net/2023/02/18/stocknews-com-initiates-coverage-on-u-s-energy-nasdaquseg.html,2023-02-18 06:22:44,"StockNews.com started coverage on shares of U.S. Energy ( NASDAQ:USEG - Get Rating ) in a research note issued to investors on Thursday. The firm set a ""hold"" rating on the energy company's stock.",ABBV,0.092569,0.165309,Somewhat-Bullish
StockNews.com Lowers CRA International  ( NASDAQ:CRAI )  to Buy,https://www.defenseworld.net/2023/02/18/stocknews-com-lowers-cra-international-nasdaqcrai-to-buy.html,2023-02-18 06:22:44,"CRA International ( NASDAQ:CRAI - Get Rating ) was downgraded by StockNews.com from a ""strong-buy"" rating to a ""buy"" rating in a note issued to investors on Thursday.",ABBV,0.07913,0.096868,Neutral
Silicon Laboratories  ( NASDAQ:SLAB )  Cut to Hold at StockNews.com,https://www.defenseworld.net/2023/02/18/silicon-laboratories-nasdaqslab-cut-to-hold-at-stocknews-com.html,2023-02-18 06:22:44,"Silicon Laboratories ( NASDAQ:SLAB - Get Rating ) was downgraded by equities research analysts at StockNews.com from a ""buy"" rating to a ""hold"" rating in a research note issued on Thursday.",ABBV,0.066598,0.151401,Somewhat-Bullish
Royalty Pharma  ( NASDAQ:RPRX )  Stock Rating Upgraded by StockNews.com,https://reporter.am/2023/02/18/royalty-pharma-nasdaqrprx-stock-rating-upgraded-by-stocknews-com.html,2023-02-18 06:22:44,Royalty Pharma ( NASDAQ:RPRX ) Stock Rating Upgraded by ... Armenian Reporter ...,ABBV,0.057767,0.113976,Neutral
"ICL Group  ( NYSE:ICL )  Cut to ""Buy"" at StockNews.com",https://www.defenseworld.net/2023/02/18/icl-group-nyseicl-cut-to-buy-at-stocknews-com.html,2023-02-18 06:22:43,"ICL Group ( NYSE:ICL - Get Rating ) was downgraded by investment analysts at StockNews.com from a ""strong-buy"" rating to a ""buy"" rating in a research report issued to clients and investors on Thursday. A number of other research analysts have also commented on the company.",ABBV,0.069697,0.125577,Neutral
StockNews.com Upgrades MKS Instruments  ( NASDAQ:MKSI )  to Hold,https://www.etfdailynews.com/2023/02/18/stocknews-com-upgrades-mks-instruments-nasdaqmksi-to-hold/,2023-02-18 06:22:43,"MKS Instruments ( NASDAQ:MKSI - Get Rating ) was upgraded by research analysts at StockNews.com from a ""sell"" rating to a ""hold"" rating in a research note issued on Thursday. Other equities analysts have also issued research reports about the company.",ABBV,0.062597,0.135074,Neutral
"Ironwood  ( IRWD )  Q4 Earnings Miss, Linzess Volume Increases",https://www.zacks.com/stock/news/2055970/ironwood-irwd-q4-earnings-miss-linzess-volume-increases,2023-02-17 16:11:00,"Though Ironwood (IRWD) missed both Q4 earnings and sales estimates, the total prescription demand for the sole-marketed drug Linzess rose 9% year over year.",ABBV,0.360752,0.135509,Neutral
3 Stocks At An Inflection Point - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/23/02/30961786/3-stocks-at-an-inflection-point,2023-02-17 15:42:58,"With consumer and producer prices surprising to the upside, multiple research outlets are starting to call for more aggressive Fed against. We talk about the implications of higher than expected producer and consumer prices this week and what it means for monetary policy going forward.",ABBV,0.233556,0.060077,Neutral
2 Exceptional Growth Stocks to Buy Before the Next Bull Market,https://www.fool.com/investing/2023/02/17/2-exceptional-growth-stocks-to-buy-before-the-next/,2023-02-17 13:30:00,Both of these companies have long runways for growth and catalysts on the way.,ABBV,0.241684,0.319327,Somewhat-Bullish
JNJ: The 3 Best Pharma Stocks to Buy for Big Gains in 2023,https://stocknews.com/news/jnj-abbv-nvs-the-3-best-pharma-stocks-to-buy-for-big-gains/,2023-02-17 13:29:28,JNJ: The 3 Best Pharma Stocks to Buy for Big Gains in ...,ABBV,0.304847,0.166928,Somewhat-Bullish
3 New Stocks Added to Warren Buffett's Secret Portfolio: Here's the Best of the Bunch,https://www.fool.com/investing/2023/02/17/3-new-stocks-added-to-warren-buffetts-secret-portf/,2023-02-17 10:52:00,Buffett could now profit in a greater way from the AI revolution.,ABBV,0.057215,0.054944,Neutral
3 Exceptional Dividend Stocks to Buy Right Now,https://www.fool.com/investing/2023/02/17/3-exceptional-dividend-stocks-to-buy-right-now/,2023-02-17 10:30:00,These stocks can add to your returns -- no matter what the stock itself or the general market is doing.,ABBV,0.407019,0.26044,Somewhat-Bullish
Ophthalmic Disease Therapeutics Market Exhibits 6.4% CAGR and to Hit USD 54.87 billion by 2030,https://www.benzinga.com/pressreleases/23/02/g30956403/ophthalmic-disease-therapeutics-market-exhibits-6-4-cagr-and-to-hit-usd-54-87-billion-by-2030,2023-02-17 09:02:28,"Pune, India, Feb. 17, 2023 ( GLOBE NEWSWIRE ) -- The global Ophthalmic Disease Therapeutics Market size was valued at USD 33.56 billion in 2022 and is projected to reach a valuation of USD 35.57 billion in 2023. The market is expected to reach USD 54.87 billion by 2030 with a CAGR of 6.4% during ...",ABBV,0.033328,0.0,Neutral
'Biosimilars' Were Supposed to Tame Costs for Drugs Like Humira. It Isn't Working.,https://www.barrons.com/articles/biosimilar-drug-costs-humira-a5f42f37,2023-02-17 06:45:00,"This was expected to be the year that Humira, AbbVie 's blockbuster $90,000-a-year arthritis treatment and the best-selling biopharmaceutical in history, loses its chokehold on the healthcare system. After more than 20 years, the patents protecting AbbVie 's ( ticker: ABBV ) cash cow expired at ...",ABBV,0.891977,0.088052,Neutral
These 2 Growth Stocks Are Easily Defying the Bear Market,https://www.fool.com/investing/2023/02/16/these-2-growth-stocks-are-defying-bear-market/,2023-02-16 15:07:00,"Impressively, neither company is predicting rapid growth.",ABBV,0.209365,0.122733,Neutral
Is This the Start of a Nightmare for AbbVie Stock?,https://www.fool.com/investing/2023/02/16/is-this-the-start-of-a-nightmare-for-abbvie-stock/,2023-02-16 14:10:00,"With a competitor set to devour market share, stormy waters might be ahead.",ABBV,0.232439,0.039955,Neutral
Biora Therapeutics Announces Improved Bioavailability Results for its Systemic Delivery Platform,https://www.globenewswire.com/news-release/2023/02/16/2609843/0/en/Biora-Therapeutics-Announces-Improved-Bioavailability-Results-for-its-Systemic-Delivery-Platform.html,2023-02-16 14:00:00,Average bioavailability greater than 50% with high consistency observed in animal study Average bioavailability greater than 50% with high consistency observed in animal study ...,ABBV,0.036756,0.0,Neutral
AbbVie Declares Quarterly Dividend - Investing News Network,https://investingnews.com/abbvie-declares-quarterly-dividend-2659429039/,2023-02-16 13:41:15,AbbVie Declares Quarterly Dividend Investing News Network ...,ABBV,0.89699,0.446472,Bullish
3 Top-Ranked Healthcare Mutual Funds for Solid Returns,https://www.zacks.com/stock/news/2055106/3-top-ranked-healthcare-mutual-funds-for-solid-returns,2023-02-16 13:00:00,"Below, we are discussing three healthcare mutual funds, namely BIPSX, FSPHX and PRHSX. Each has earned a Zacks Mutual Fund Rank #1.",ABBV,0.081552,-0.010306,Neutral
"After IPO, Bausch + Lomb turns to an industry favorite to run the company",https://www.marketwatch.com/story/after-ipo-bausch-lomb-turns-to-an-industry-favorite-to-run-the-company-773e6a4f,2023-02-15 19:03:00,Bausch + Lomb's decision to bring back Brent Saunders as CEO hints at the company's broader ambitions in the global eye-care market.,ABBV,0.16171,0.008283,Neutral
"Drug/Biotech Stocks Q4 Earnings Due on Feb 16: ALKS, RARE & Others",https://www.zacks.com/stock/news/2054764/drugbiotech-stocks-q4-earnings-due-on-feb-16-alks-rare-others,2023-02-15 16:09:00,Let's look at the four biotech/drug companies slated to release quarterly results on Feb 16.,ABBV,0.047185,-0.145572,Neutral
"Got $10,000? Buy These 2 Market-Beating ETFs for the Long Haul",https://www.fool.com/investing/2023/02/15/got-10000-buy-these-2-market-beating-etfs-for-the/,2023-02-15 14:37:00,These exchange-traded funds have soundly beaten the S&P 500 over the past 10 years.,ABBV,0.063258,0.139111,Neutral
"Top 10 things the Club is watching in the stock market Wednesday: Retail sales up, stocks dip, Airbnb soars",https://www.cnbc.com/2023/02/15/top-10-things-to-watch-wednesday-retail-sales-up-stocks-dip-airbnb-soars.html,2023-02-15 14:24:01,"The Dow, the S&P 500 and the Nasdaq are set to open lower as investors digest the implications of Wednesday's stronger retail sales.",ABBV,0.115509,0.14384,Neutral
Bausch + Lomb to name Brent Saunders as CEO - WSJ,https://www.reuters.com/business/bausch-lomb-name-brent-saunders-ceo-wsj-2023-02-15/,2023-02-15 10:50:00,Bausch + Lomb to name Brent Saunders as CEO ...,ABBV,0.247838,0.0,Neutral
4 Healthcare Mutual Funds to Buy in the Post-Pandemic Period,https://www.zacks.com/stock/news/2054428/4-healthcare-mutual-funds-to-buy-in-the-post-pandemic-period,2023-02-15 10:34:00,"FBTIX, PHSYX, JNGLX and VGHCX are four healthcare mutual funds that can lend solidity to one's portfolio today and provide big returns in the foreseeable future.",ABBV,0.100941,0.069131,Neutral
AbbVie  ( NYSE:ABBV )  Lowered to Buy at StockNews.com,https://www.defenseworld.net/2023/02/15/abbvie-nyseabbv-lowered-to-buy-at-stocknews-com.html,2023-02-15 09:50:49,StockNews.com lowered shares of AbbVie ( NYSE:ABBV - Get Rating ) from a strong-buy rating to a buy rating in a research note released on Tuesday morning. Other analysts have also issued reports about the stock.,ABBV,0.866386,0.31262,Somewhat-Bullish
AbbVie  ( NYSE:ABBV )  Lowered to Buy at StockNews.com,https://reporter.am/2023/02/15/abbvie-nyseabbv-lowered-to-buy-at-stocknews-com.html,2023-02-15 09:50:41,StockNews.com lowered shares of AbbVie ( NYSE:ABBV - Get Rating ) from a strong-buy rating to a buy rating in a research note released on Tuesday morning. Other analysts have also issued reports about the stock.,ABBV,0.866386,0.31262,Somewhat-Bullish
Correction: Inventiva reports preliminary financial results for Full-Year 2022¹,https://www.globenewswire.com/news-release/2023/02/14/2608196/0/en/Correction-Inventiva-reports-preliminary-financial-results-for-Full-Year-2022.html,2023-02-14 22:00:00,"Daix ( France ) , Long Island City ( New York, United States ) , February 14, 2023 - Inventiva ( Euronext Paris and Nasdaq: IVA ) ( the ""Company"" ) , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with ...",ABBV,0.051588,0.010946,Neutral
2 High-Yielding Dividend Stocks Trading Near 52-Week Lows,https://www.fool.com/investing/2023/02/14/2-high-yielding-dividend-stocks-trading-near-lows/,2023-02-14 16:14:22,These stocks both yield more than 3% right now.,ABBV,0.386875,-0.008049,Neutral
3 of the BEST Dividend Growth Stocks,https://www.fool.com/investing/2023/02/14/3-of-the-best-dividend-growth-stocks/,2023-02-14 14:07:00,All three of these companies have consistently increased their dividends at a fast pace.,ABBV,0.779232,0.756527,Bullish
AbbVie Inc.  ( ABBV )  Is a Trending Stock: Facts to Know Before Betting on It,https://www.zacks.com/stock/news/2053961/abbvie-inc-abbv-is-a-trending-stock-facts-to-know-before-betting-on-it,2023-02-14 14:00:11,"AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",ABBV,0.483888,0.098016,Neutral
Better Buy: Johnson & Johnson or AbbVie?,https://www.fool.com/investing/2023/02/14/better-buy-johnson-johnson-or-abbvie/,2023-02-14 13:26:00,The healthcare giants are favored by income-oriented investors but have a potentially disruptive year ahead.,ABBV,0.385137,0.237492,Somewhat-Bullish
Ironwood  ( IRWD )  Gets FDA Priority Tag for Linzess sNDA,https://www.zacks.com/stock/news/2053847/ironwood-irwd-gets-fda-priority-tag-for-linzess-snda,2023-02-14 12:20:00,"With the FDA granting priority review to Ironwood Pharmaceuticals' (IRWD) sNDA seeking label expansion of Linzess for functional constipation in kids, a decision is expected in the second quarter of 2023.",ABBV,0.436009,0.105212,Neutral
Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2022,https://www.globenewswire.com/news-release/2023/02/14/2607240/0/en/Sosei-Heptares-Operational-Highlights-and-Consolidated-Results-for-12-Months-ended-31-December-2022.html,2023-02-14 06:30:00,"Tokyo, Japan and Cambridge, UK, 14 February 2023 - Sosei Group Corporation ( ""the Company"". TSE: 4565 ) , the world leader in G protein-coupled receptor ( GPCR ) focused structure-based drug design ( SBDD ) and development, provides an update on operational activities and reports its consolidated ...",ABBV,0.082535,0.105937,Neutral
Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2022,https://www.benzinga.com/pressreleases/23/02/g30892512/sosei-heptares-operational-highlights-and-consolidated-results-for-12-months-ended-31-december-202,2023-02-14 06:30:00,"Tokyo, Japan and Cambridge, UK, 14 February 2023 - Sosei Group Corporation ( ""the Company"". TSE: 4565 ) , the world leader in G protein-coupled receptor ( GPCR ) focused structure-based drug design ( SBDD ) and development, provides an update on operational activities and reports its consolidated ...",ABBV,0.081622,0.052055,Neutral
"Regenerative Medicine Market to Surpass USD 153.05 Billion by 2029, With 26.3% CAGR",https://www.benzinga.com/pressreleases/23/02/g30874563/regenerative-medicine-market-to-surpass-usd-153-05-billion-by-2029-with-26-3-cagr,2023-02-13 12:45:47,"Pune, India, Feb. 13, 2023 ( GLOBE NEWSWIRE ) -- The regenerative medicine market size was valued at USD 23.65 billion in 2021. The market is expected to grow from USD 29.86 billion in 2022 to USD 153.05 billion by 2029 with a CAGR of 26.3% during the forecast period.",ABBV,0.039548,0.0,Neutral
"Anesthesia Drugs Market to Grow by USD 1.38 Bn, AbbVie Inc. and Baxter International Inc. Among Key Vendors - Technavio",https://www.prnewswire.com/news-releases/anesthesia-drugs-market-to-grow-by-usd-1-38-bn-abbvie-inc-and-baxter-international-inc-among-key-vendors---technavio-301744229.html,2023-02-13 00:15:00,"Anesthesia Drugs Market to Grow by USD 1.38 Bn, AbbVie Inc. and ... PR ...",ABBV,0.038717,0.037358,Neutral
REGENXBIO Presents Interim Data from Phase II Bridging Study Evaluating the Clinical Performance of RGX-314 Using the NAVXpress™ Manufacturing Platform Process,https://www.prnewswire.com/news-releases/regenxbio-presents-interim-data-from-phase-ii-bridging-study-evaluating-the-clinical-performance-of-rgx-314-using-the-navxpress-manufacturing-platform-process-301744570.html,2023-02-11 13:40:00,REGENXBIO Presents Interim Data from Phase II Bridging Study ... PR ...,ABBV,0.021237,-0.087152,Neutral
Here's Exactly How AbbVie Stock Can Beat the Market In 2023,https://www.fool.com/investing/2023/02/11/heres-exactly-how-abbvie-stock-can-beat-the-market/,2023-02-11 11:00:00,Don't think the challenges for Humira doom AbbVie to a sub-par stock performance this year.,ABBV,0.893889,0.299586,Somewhat-Bullish
"If You Invested $100 In This Stock 10 Years Ago, You Would Have $400 Today - AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/news/earnings/23/02/30857105/if-you-invested-100-in-this-stock-10-years-ago-you-would-have-400-today,2023-02-10 16:01:03,"AbbVie ABBV has outperformed the market over the past 10 years by 4.94% on an annualized basis producing an average annual return of 15.26%. Currently, AbbVie has a market capitalization of $267.71 billion.",ABBV,0.983605,0.387251,Bullish
AbbVie Sidesteps 'Draconian' Expectations For Humira Downfall,https://www.investors.com/news/technology/abbvie-stock-sidesteps-draconian-expectations-for-humira-dropoff/,2023-02-10 15:52:00,AbbVie Stock Sidesteps 'Draconian' Expectations For Humira ... Investor's Business Daily ...,ABBV,0.615462,-0.058124,Neutral
Stocks Pull Back; Google Dives On AI Flop: Weekly Review,https://www.investors.com/news/stock-market-pulls-back-treasury-yields-jump-google-dives-on-ai-flop/,2023-02-10 15:20:00,Stocks Pull Back. Google Dives On AI Flop: Weekly Review Investor's Business Daily ...,ABBV,0.050786,0.047109,Neutral
"Pharma Stock Roundup: AZN, ABBV Mixed Q4 Results, BAYRY's New CEO",https://www.zacks.com/stock/news/2052858/pharma-stock-roundup-azn-abbv-mixed-q4-results-bayrys-new-ceo,2023-02-10 14:05:00,AstraZeneca (AZN) and AbbVie (ABBV) report fourth-quarter results. Roche (RHHBY) and J&J (JNJ) announce positive data from studies on pipeline candidates for rare diseases.,ABBV,0.181137,-0.047461,Neutral
"Compared to Estimates, AbbVie  ( ABBV )  Q4 Earnings: A Look at Key Metrics",https://www.zacks.com/stock/news/2052843/compared-to-estimates-abbvie-abbv-q4-earnings-a-look-at-key-metrics,2023-02-10 13:55:00,"While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",ABBV,0.306007,0.097767,Neutral
"Danaher, NextEra Energy, Paramount Global, AbbVie And This Mid-Cap ETF On CNBC's 'Final Trades' - AbbVie  ( NYSE:ABBV ) , Danaher  ( NYSE:DHR ) ",https://www.benzinga.com/trading-ideas/long-ideas/23/02/30850656/danaher-nextera-energy-paramount-global-abbvie-and-this-mid-cap-etf-on-cnbcs-final-trade,2023-02-10 13:35:31,"On CNBC's ""Halftime Report Final Trades,"" Shannon Saccocia of Boston Private named Danaher Corporation DHR as her final trade. Joshua Brown of of Ritholtz Wealth Management said NextEra Energy, Inc. NEE has a nice dividend. Don't forget to check out our premarket coverage here.",ABBV,0.524949,0.0,Neutral
Wall Street dips as Treasury yields rise after auction,https://www.moneycontrol.com/news/business/markets/wall-street-dips-as-treasury-yields-rise-after-auction-10046541.html,2023-02-10 00:33:45,"Yields on the U.S. 30-year note rose after the Treasury Department saw weak demand for a $21 billion sale, the final sale of $96 billion in coupon-bearing supply this week. In a note to clients, Jefferies said ""the buyside bid failed to come together."" ...",ABBV,0.067727,0.217772,Somewhat-Bullish
"AbbVie Can Write Diversified Growth Story Without Humira, Rest Of The Business Has Strength, Analyst Says - AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/03/31136041/abbvie-can-write-diversified-growth-story-without-humira-rest-of-the-business-has-s,2023-03-01 19:57:45,"Guggenheim initiated coverage on AbbVie Inc ABBV with a Buy and a price target of $172 on diversified growth. Investors have ""naturally"" been focused on Humira's erosion curve as it loses U.S. market exclusivity, but the analyst believes that has led to people overlooking the strength of the rest ...",ABBV,0.689185,0.678882,Bullish
3 Value Stocks You'll Regret Not Buying on the Dip,https://www.fool.com/investing/2023/03/01/3-value-stocks-youll-regret-not-buying-on-the-dip/,2023-03-01 13:45:00,These three undervalued healthcare stocks are solid picks for patient investors.,ABBV,0.343619,0.340068,Somewhat-Bullish
"Royalty Pharma Appoints Ashwin Pai as Executive Vice President, Investments",https://www.globenewswire.com/news-release/2023/03/01/2618184/0/en/Royalty-Pharma-Appoints-Ashwin-Pai-as-Executive-Vice-President-Investments.html,2023-03-01 13:15:00,"NEW YORK, March 01, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced the appointment of Ashwin Pai, M.D. as Executive Vice President, Investments. Ashwin will join Royalty Pharma in April 2023, and will report to Chris Hite, Executive Vice President and Vice Chairman.",ABBV,0.03916,0.077192,Neutral
"Royalty Pharma Appoints Ashwin Pai as Executive Vice President, Investments - Royalty Pharma  ( NASDAQ:RPRX ) ",https://www.benzinga.com/pressreleases/23/03/g31121783/royalty-pharma-appoints-ashwin-pai-as-executive-vice-president-investments,2023-03-01 13:15:00,"NEW YORK, March 01, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced the appointment of Ashwin Pai, M.D. as Executive Vice President, Investments. Ashwin will join Royalty Pharma in April 2023, and will report to Chris Hite, Executive Vice President and Vice Chairman.",ABBV,0.038655,0.077055,Neutral
Get a Dividend Every Month With These 3 Healthcare Stocks,https://www.fool.com/investing/2023/03/01/get-a-dividend-every-month-with-these-3-healthcare/,2023-03-01 12:59:00,"With a little planning, you can receive a dependable dividend payout every month.",ABBV,0.372139,0.171914,Somewhat-Bullish
DiMe Launches Free Resources for Medical Product Developers to Better Navigate U.S. Regulations,https://www.prnewswire.com/news-releases/dime-launches-free-resources-for-medical-product-developers-to-better-navigate-us-regulations-301758908.html,2023-03-01 11:00:00,DiMe Launches Free Resources for Medical Product Developers to ... PR ...,ABBV,0.053509,0.0,Neutral
CytomX Therapeutics to Present at Upcoming March Investor Conferences - CytomX Therapeutics  ( NASDAQ:CTMX ) ,https://www.benzinga.com/pressreleases/23/02/g31103016/cytomx-therapeutics-to-present-at-upcoming-march-investor-conferences,2023-02-28 21:05:00,"SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. CTMX, a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in the following investor ...",ABBV,0.165031,-0.037087,Neutral
What Does AbbVie's Debt Look Like? - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/news/23/02/31097037/what-does-abbvies-debt-look-like,2023-02-28 17:56:02,"Over the past three months, shares of AbbVie Inc. ABBV moved lower by 6.39%. Before having a look at the importance of debt, let's look at how much debt AbbVie has.",ABBV,0.382925,-0.010967,Neutral
Peering Into AbbVie's Recent Short Interest - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/short-sellers/23/02/31095185/peering-into-abbvies-recent-short-interest,2023-02-28 16:30:46,"AbbVie's ABBV short percent of float has risen 13.79% since its last report. The company recently reported that it has 11.71 million shares sold short, which is 0.66% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.1 days to cover their ...",ABBV,0.224903,0.158881,Somewhat-Bullish
ABBV: 3 Large-Cap Stocks Ready for a Bull Run,https://stocknews.com/news/abbv-ko-orcl-mfg-3-large-cap-stocks-ready-for-a-bull-run/,2023-02-28 15:55:12,"As inflation is still far from the Fed's target, interest rates are expected to remain elevated this year. The interest rate hikes are expected to keep the stock market under pressure.",ABBV,0.334008,0.056265,Neutral
AbbVie to Present at the Cowen 43rd Annual Health Care Conference,https://investingnews.com/abbvie-to-present-at-the-cowen-43rd-annual-health-care-conference/,2023-02-28 14:29:29,"ABBVie ( NYSE: ABBV ) will participate in the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023 . Robert A. Michael vice chairman and president, Scott Reents executive vice president, chief financial officer, Jeffrey R.",ABBV,0.699089,0.073462,Neutral
Dermal Fillers Market Exhibits 7.4% CAGR to Hit USD 8.74 Billion by 2029 | Report by Fortune Business Insights,https://www.benzinga.com/pressreleases/23/02/g31084009/dermal-fillers-market-exhibits-7-4-cagr-to-hit-usd-8-74-billion-by-2029-report-by-fortune-business,2023-02-28 09:58:50,"Pune, India, Feb. 28, 2023 ( GLOBE NEWSWIRE ) -- The global dermal fillers market size was valued at USD 5.05 billion in 2021 and is projected to grow from USD 5.31 billion in 2022 to USD 8.74 billion by 2029, exhibiting a CAGR of 7.4% during the forecast period.",ABBV,0.077972,0.098539,Neutral
AbbVie Inc.  ( ABBV )  is Attracting Investor Attention: Here is What You Should Know,https://www.zacks.com/stock/news/2059247/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know,2023-02-27 14:00:13,"Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",ABBV,0.493128,0.09633,Neutral
AbbVie Highlights Robust Gastroenterology Portfolio with New Analyses and Data in Inflammatory Bowel Diseases at the 18th Congress of European Crohn's and Colitis Organisation,https://investingnews.com/abbvie-highlights-robust-gastroenterology-portfolio-with-new-analyses-and-data-in-inflammatory-bowel-diseases-at-the-18th-congress-of-european-crohn-s-and-colitis-organisation/,2023-02-27 11:19:43,ABBVie ( NYSE: ABBV ) will present further analyses on SKYRIZI ® ( risankizumab ) in Crohn's disease ( CD ) and RINVOQ ® ( upadacitinib ) in ulcerative colitis ( UC ) as well as the investigational use of upadacitinib in CD at the 18th Congress of European Crohn's and Colitis Organisation ( ECCO ...,ABBV,0.180595,0.110657,Neutral
"With 6.3% CAGR, Europe Dermal Fillers Market Size to Surpass USD 2.25 Billion by 2029 | Report by Fortune Business Insights",https://www.benzinga.com/pressreleases/23/02/g31065076/with-6-3-cagr-europe-dermal-fillers-market-size-to-surpass-usd-2-25-billion-by-2029-report-by-fort,2023-02-27 11:09:07,"Pune, India, Feb. 27, 2023 ( GLOBE NEWSWIRE ) -- The Europe dermal fillers market size hit USD 1.41 billion in 2021. The market valuation is projected to rise from USD 1.46 billion in 2022 to USD 2.25 billion by 2029 at 6.3% CAGR during the forecast period.",ABBV,0.145804,0.0,Neutral
AbbVie Receives Positive CHMP Opinion for Upadacitinib for the Treatment of Adults with Moderate to Severe Crohn's Disease,https://investingnews.com/abbvie-receives-positive-chmp-opinion-for-upadacitinib-for-the-treatment-of-adults-with-moderate-to-severe-crohn-s-disease/,2023-02-27 07:20:15,ABBVie ( NYSE: ABBV ) today announced the European Medicines Agency's ( EMA ) Committee for Medicinal Products for Human Use ( CHMP ) recommended the approval of upadacitinib ( RINVOQ ® 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses] ) for the treatment of adult patients with ...,ABBV,0.197559,0.089532,Neutral
AbbVie Receives Positive CHMP Opinion for Upadacitinib  ( RINVOQ® )  for the Treatment of Adults with Moderate to Severe Crohn's Disease,https://www.prnewswire.com/news-releases/abbvie-receives-positive-chmp-opinion-for-upadacitinib-rinvoq-for-the-treatment-of-adults-with-moderate-to-severe-crohns-disease-301756139.html,2023-02-27 07:00:00,AbbVie Receives Positive CHMP Opinion for Upadacitinib ( RINVOQ ... PR ...,ABBV,0.173582,0.081399,Neutral
This Pharmaceuticals Company Looks To Be A Better Pick Over Procter & Gamble Stock,https://www.forbes.com/sites/greatspeculations/2023/02/27/this-pharmaceuticals-company-looks-to-be-a-better-pick-over-procter--gamble-stock/,2023-02-27 06:26:08,"There is more to the comparison, and in the sections below, we discuss the possible returns for P&G and AbbVie in the next three years.",ABBV,0.570743,0.287743,Somewhat-Bullish
3 Biotech Stocks To Watch Ahead Of March 2023,https://stockmarket.com/featured/3-biotech-stocks-to-watch-ahead-of-march-2023-2023-02-25,2023-02-25 20:44:12,"Biotech stocks represent shares of companies that specialize in the development and commercialization of drugs, therapies, and other medical products based on biological and chemical research. Biotech companies often focus on treating diseases that currently have no cure.",ABBV,0.366961,0.212918,Somewhat-Bullish
3 Stocks to Buy Right Now That Are Cash Cows,https://www.fool.com/investing/2023/02/25/3-stocks-to-buy-right-now-that-are-cash-cows/,2023-02-25 11:25:00,"If cash is king, these three stocks should wear crowns.",ABBV,0.429956,0.290415,Somewhat-Bullish
Nearing retirement? Here's how to transition your portfolio from growth to income.,https://www.marketwatch.com/story/are-you-nearing-retirement-heres-how-to-transition-your-portfolio-from-growth-to-income-af7f081a,2023-02-24 12:37:00,"After decades of saving and investing, it's time to start taking income from your retirement account. Here are a few things to keep in mind.",ABBV,0.014497,-0.025806,Neutral
"Infinity Pharmaceuticals Announce Merger Agreement With MEI Pharma, Share Plunge - Infinity Pharmaceuticals  ( NASDAQ:INFI ) , MEI Pharma  ( NASDAQ:MEIP ) ",https://www.benzinga.com/general/biotech/23/02/31028696/infinity-pharmaceuticals-announce-merger-agreement-with-mei-pharma-share-plunge,2023-02-23 15:14:02,MEI Pharma Inc MEIP and Infinity Pharmaceuticals Inc INFI have entered into a definitive merger agreement for an all-stock transaction forming a company focusing on three clinical-stage oncology drug candidates.,ABBV,0.303175,0.0,Neutral
"Wall Street's Most Accurate Analysts Say Hold These 3 Healthcare Stocks Delivering High-Dividend Yields - AbbVie  ( NYSE:ABBV ) , GSK  ( NYSE:GSK ) ",https://www.benzinga.com/news/23/02/31027525/wall-streets-most-accurate-analysts-say-hold-these-3-healthcare-stocks-delivering-high-dividend-yiel,2023-02-23 13:49:45,"During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.",ABBV,0.109455,-0.164415,Somewhat-Bearish
WMT: 3 Safe Haven Stocks to Buy in a Bear Market,https://stocknews.com/news/wmt-abbv-cvs-3-safe-haven-stocks-to-buy-in-a-bear-market/,2023-02-23 12:51:56,"Macroeconomic volatilities have dashed investor sentiments, and the likelihood of a continued bear market stands high. Therefore, we take a look at some of the ""safe-haven"" stocks Walmart Inc. ( WMT ) , AbbVie Inc. ( ABBV ) , and CVS Health Corporation ( CVS ) , which could help survive a market ...",ABBV,0.344644,0.16034,Somewhat-Bullish
AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need,https://investingnews.com/abbvie-and-capsida-biotherapeutics-expand-strategic-collaboration-to-develop-targeted-genetic-medicines-for-eye-diseases-with-high-unmet-need/,2023-02-23 10:29:36,"ABBVie ( NYSE: ABBV ) and Capsida Biotherapeutics Inc. ( ""Capsida"" ) today announced an expanded strategic collaboration to develop genetic medicines for eye diseases with high unmet need.",ABBV,0.67831,0.392641,Bullish
AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/pressreleases/23/02/n31022862/abbvie-and-capsida-biotherapeutics-expand-strategic-collaboration-to-develop-targeted-genetic-medi,2023-02-23 10:01:00,Partnership Combines AbbVie's extensive capabilities with Capsida's novel adeno-associated virus ( AAV ) engineering platform Builds upon the neurodegenerative disease partnership announced in 2021,ABBV,0.59016,0.365636,Bullish
AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/pressreleases/23/02/n31022845/abbvie-and-capsida-biotherapeutics-expand-strategic-collaboration-to-develop-targeted-genetic-medi,2023-02-23 09:59:00,- Partnership Combines AbbVie's extensive capabilities with Capsida's novel adeno-associated virus ( AAV ) engineering platform - Builds upon the neurodegenerative disease partnership announced in 2021,ABBV,0.546745,0.34587,Somewhat-Bullish
Genmab Publishes 2022 Annual Report,https://www.globenewswire.com/news-release/2023/02/22/2613531/0/en/Genmab-Publishes-2022-Annual-Report.html,2023-02-22 16:01:00,Company Announcement ...,ABBV,0.13975,0.061028,Neutral
Want to Get to $1 Million by Retirement? Here's How Much You Should Invest Today.,https://www.fool.com/investing/2023/02/22/want-to-get-to-1-million-by-retirement-heres-how-m/,2023-02-22 14:39:00,"If you want to be a millionaire more quickly, you can always invest more along the way.",ABBV,0.334008,0.321258,Somewhat-Bullish
Want More Reliable Dividend Income? Buy This Dividend King.,https://www.fool.com/investing/2023/02/22/want-more-reliable-dividend-income-buy-abbv-stock/,2023-02-22 12:30:00,This big pharma company possesses a deep drug portfolio and pipeline.,ABBV,0.484697,0.276454,Somewhat-Bullish
This Recession-Proof Company Has a Best-in-Class Dividend,https://www.fool.com/investing/2023/02/22/this-recession-proof-company-has-a-best-in-class-d/,2023-02-22 12:30:00,"Pfizer's highly attractive valuation, rock-solid dividend program, and enormous yield put it at the top of its big pharma peer group.",ABBV,0.207571,0.126829,Neutral
AbbVie  ( NYSE:ABBV )  Rating Increased to Strong-Buy at StockNews.com,https://www.defenseworld.net/2023/02/22/abbvie-nyseabbv-rating-increased-to-strong-buy-at-stocknews-com.html,2023-02-22 08:16:41,AbbVie ( NYSE:ABBV ) Rating Increased to Strong-Buy at StockNews ... Defense World ...,ABBV,0.757834,0.377603,Bullish
AbCellera Biologics  ( ABCL )  Q4 2022 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/02/21/abcellera-biologics-abcl-q4-2022-earnings-call-tra/,2023-02-22 03:30:39,"ABCL earnings call for the period ending December 31, 2022.",ABBV,0.021171,0.134122,Neutral
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS,https://www.prnewswire.com/news-releases/halozyme-reports-fourth-quarter-and-full-year-2022-financial-and-operating-results-301752201.html,2023-02-21 21:01:00,HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 ... PR ...,ABBV,0.01394,0.074119,Neutral
3 Top Dividend Kings to Buy for the Long Haul,https://www.fool.com/investing/2023/02/20/3-top-dividend-kings-to-buy-for-the-long-haul/,2023-02-20 12:25:00,These companies have more than 150 years of dividend growth between them.,ABBV,0.209004,0.162745,Somewhat-Bullish
"Buy these 16 dividend stocks to collect consistent cash payments while inflation stays high, according to a fund manager who outperformed 95% of his peers last year",https://www.businessinsider.com/investing-dividend-stocks-to-buy-inflation-outlook-federal-reserve-rates-2023-2,2023-02-20 10:30:00,16 Dividend Stocks to Buy As Inflation Persists: Top 5% Fund Manager - Business Insider ...,ABBV,0.081001,0.050851,Neutral
Evoke Pharma  ( NASDAQ:EVOK )  Coverage Initiated by Analysts at StockNews.com,https://www.defenseworld.net/2023/02/20/evoke-pharma-nasdaqevok-coverage-initiated-by-analysts-at-stocknews-com.html,2023-02-20 10:02:41,Evoke Pharma ( NASDAQ:EVOK ) Coverage Initiated by Analysts at ... Defense World ...,ABBV,0.183895,0.083715,Neutral
StockNews.com Downgrades Seanergy Maritime  ( NASDAQ:SHIP )  to Sell,https://www.etfdailynews.com/2023/02/20/stocknews-com-downgrades-seanergy-maritime-nasdaqship-to-sell/,2023-02-20 09:24:48,StockNews.com Downgrades Seanergy Maritime ( NASDAQ:SHIP ... ETF Daily News ...,ABBV,0.086245,0.129706,Neutral
vTv Therapeutics  ( NASDAQ:VTVT )  Now Covered by Analysts at StockNews.com,https://www.etfdailynews.com/2023/02/20/vtv-therapeutics-nasdaqvtvt-now-covered-by-analysts-at-stocknews-com/,2023-02-20 08:58:43,vTv Therapeutics ( NASDAQ:VTVT ) Now Covered by Analysts at ... ETF Daily News ...,ABBV,0.102888,0.102277,Neutral
StockNews.com Initiates Coverage on RedHill Biopharma  ( NASDAQ:RDHL ) ,https://reporter.am/2023/02/20/stocknews-com-initiates-coverage-on-redhill-biopharma-nasdaqrdhl-3.html,2023-02-20 08:58:41,StockNews.com Initiates Coverage on RedHill Biopharma ( NASDAQ ... Armenian Reporter ...,ABBV,0.082677,0.030297,Neutral
StockNews.com Begins Coverage on Oxbridge Re  ( NASDAQ:OXBR ) ,https://reporter.am/2023/02/20/stocknews-com-begins-coverage-on-oxbridge-re-nasdaqoxbr.html,2023-02-20 08:58:41,"StockNews.com started coverage on shares of Oxbridge Re ( NASDAQ:OXBR - Get Rating ) in a research note issued on Monday. The firm set a ""hold"" rating on the insurance provider's stock. Separately, TheStreet lowered Oxbridge Re from a ""c"" rating to a ""d"" rating in a report on Thursday, December ...",ABBV,0.179788,0.111827,Neutral
Tarena International  ( NASDAQ:TEDU )  Coverage Initiated at StockNews.com,https://www.defenseworld.net/2023/02/20/tarena-international-nasdaqtedu-coverage-initiated-at-stocknews-com.html,2023-02-20 08:58:41,Tarena International ( NASDAQ:TEDU ) Coverage Initiated at ... Defense World ...,ABBV,0.146916,0.116548,Neutral
Innodata  ( NASDAQ:INOD )  Earns Hold Rating from Analysts at StockNews.com,https://www.etfdailynews.com/2023/02/20/innodata-nasdaqinod-earns-hold-rating-from-analysts-at-stocknews-com/,2023-02-20 08:58:41,Innodata ( NASDAQ:INOD ) Earns Hold Rating from Analysts at ... ETF Daily News ...,ABBV,0.100308,0.167488,Somewhat-Bullish
"Air Products and Chemicals  ( NYSE:APD )  Cut to ""Hold"" at StockNews.com",https://www.defenseworld.net/2023/02/20/air-products-and-chemicals-nyseapd-cut-to-hold-at-stocknews-com-2.html,2023-02-20 08:54:41,"Air Products and Chemicals ( NYSE:APD ) Cut to ""Hold"" at ... Defense World ...",ABBV,0.056275,0.085904,Neutral
Donegal Group  ( NASDAQ:DGICA )  Upgraded at StockNews.com,https://www.defenseworld.net/2023/02/20/donegal-group-nasdaqdgica-upgraded-at-stocknews-com-2.html,2023-02-20 08:26:43,"StockNews.com upgraded shares of Donegal Group ( NASDAQ:DGICA - Get Rating ) from a hold rating to a buy rating in a research note released on Thursday morning. Separately, TheStreet downgraded shares of Donegal Group from a b- rating to a c+ rating in a research report on Wednesday, December ...",ABBV,0.059194,0.084064,Neutral
Ultralife  ( NASDAQ:ULBI )  Earns Buy Rating from Analysts at StockNews.com,https://www.defenseworld.net/2023/02/20/ultralife-nasdaqulbi-earns-buy-rating-from-analysts-at-stocknews-com.html,2023-02-20 08:22:53,Ultralife ( NASDAQ:ULBI ) Earns Buy Rating from Analysts at ... Defense World ...,ABBV,0.089129,0.1576,Somewhat-Bullish
StockNews.com Begins Coverage on Tarena International  ( NASDAQ:TEDU ) ,https://www.etfdailynews.com/2023/02/20/stocknews-com-begins-coverage-on-tarena-international-nasdaqtedu/,2023-02-20 08:22:53,StockNews.com Begins Coverage on Tarena International ... ETF Daily News ...,ABBV,0.145145,0.115734,Neutral
NortonLifeLock  ( NASDAQ:NLOK )  Coverage Initiated at StockNews.com,https://www.etfdailynews.com/2023/02/20/nortonlifelock-nasdaqnlok-coverage-initiated-at-stocknews-com/,2023-02-20 08:22:52,NortonLifeLock ( NASDAQ:NLOK ) Coverage Initiated at StockNews ... ETF Daily News ...,ABBV,0.085936,0.190929,Somewhat-Bullish
StockNews.com Initiates Coverage on RedHill Biopharma  ( NASDAQ:RDHL ) ,https://www.defenseworld.net/2023/02/20/stocknews-com-initiates-coverage-on-redhill-biopharma-nasdaqrdhl.html,2023-02-20 08:22:52,StockNews.com Initiates Coverage on RedHill Biopharma ( NASDAQ ... Defense World ...,ABBV,0.082677,0.030297,Neutral
StockNews.com Begins Coverage on Oxbridge Re  ( NASDAQ:OXBR ) ,https://www.etfdailynews.com/2023/02/20/stocknews-com-begins-coverage-on-oxbridge-re-nasdaqoxbr/,2023-02-20 08:22:52,"Equities research analysts at StockNews.com started coverage on shares of Oxbridge Re ( NASDAQ:OXBR - Get Rating ) in a report issued on Monday. The firm set a ""hold"" rating on the insurance provider's stock.",ABBV,0.169676,0.107353,Neutral
StockNews.com Initiates Coverage on RedHill Biopharma  ( NASDAQ:RDHL ) ,https://www.etfdailynews.com/2023/02/20/stocknews-com-initiates-coverage-on-redhill-biopharma-nasdaqrdhl/,2023-02-20 08:22:52,StockNews.com Initiates Coverage on RedHill Biopharma ( NASDAQ ... ETF Daily News ...,ABBV,0.137671,0.036857,Neutral
Corbus Pharmaceuticals  ( NASDAQ:CRBP )  Coverage Initiated by Analysts at StockNews.com,https://www.defenseworld.net/2023/02/20/corbus-pharmaceuticals-nasdaqcrbp-coverage-initiated-by-analysts-at-stocknews-com-2.html,2023-02-20 08:22:51,Corbus Pharmaceuticals ( NASDAQ:CRBP ) Coverage Initiated by ... Defense World ...,ABBV,0.085022,0.0777,Neutral
Marine Petroleum Trust  ( NASDAQ:MARPS )  Receives New Coverage from Analysts at StockNews.com,https://www.etfdailynews.com/2023/02/20/marine-petroleum-trust-nasdaqmarps-receives-new-coverage-from-analysts-at-stocknews-com/,2023-02-20 08:22:51,Marine Petroleum Trust ( NASDAQ:MARPS ) Receives New ... ETF Daily News ...,ABBV,0.143415,0.260331,Somewhat-Bullish
Lannett  ( NYSE:LCI )  Research Coverage Started at StockNews.com,https://www.etfdailynews.com/2023/02/20/lannett-nyselci-research-coverage-started-at-stocknews-com-2/,2023-02-20 08:22:50,"Research analysts at StockNews.com started coverage on shares of Lannett ( NYSE:LCI - Get Rating ) in a research note issued to investors on Monday. The firm set a ""hold"" rating on the stock. Shares of Lannett stock opened at $2.48 on Monday.",ABBV,0.097854,0.140774,Neutral
"Air Products and Chemicals  ( NYSE:APD )  Cut to ""Hold"" at StockNews.com",https://www.etfdailynews.com/2023/02/20/air-products-and-chemicals-nyseapd-cut-to-hold-at-stocknews-com-2/,2023-02-20 08:22:50,"Air Products and Chemicals ( NYSE:APD ) Cut to ""Hold"" at ... ETF Daily News ...",ABBV,0.051441,0.085501,Neutral
Advaxis  ( NASDAQ:ADXS )  Research Coverage Started at StockNews.com,https://www.etfdailynews.com/2023/02/20/advaxis-nasdaqadxs-research-coverage-started-at-stocknews-com/,2023-02-20 08:22:50,Advaxis ( NASDAQ:ADXS ) Research Coverage Started at ... ETF Daily News ...,ABBV,0.202366,0.170786,Somewhat-Bullish
Retractable Technologies  ( NYSE:RVP )  Receives New Coverage from Analysts at StockNews.com,https://www.defenseworld.net/2023/02/20/retractable-technologies-nyservp-receives-new-coverage-from-analysts-at-stocknews-com.html,2023-02-20 08:22:50,Retractable Technologies ( NYSE:RVP ) Receives New Coverage ... Defense World ...,ABBV,0.186738,0.160607,Somewhat-Bullish
NanoViricides  ( NYSE:NNVC )  Earns Sell Rating from Analysts at StockNews.com,https://www.defenseworld.net/2023/02/20/nanoviricides-nysennvc-earns-sell-rating-from-analysts-at-stocknews-com.html,2023-02-20 08:22:49,NanoViricides ( NYSE:NNVC ) Earns Sell Rating from Analysts at ... Defense World ...,ABBV,0.205807,0.139438,Neutral
Empire State Realty OP  ( NYSE:ESBA )  Coverage Initiated by Analysts at StockNews.com,https://www.defenseworld.net/2023/02/20/empire-state-realty-op-nyseesba-coverage-initiated-by-analysts-at-stocknews-com.html,2023-02-20 08:22:49,Empire State Realty OP ( NYSE:ESBA ) Coverage Initiated by ... Defense World ...,ABBV,0.186738,0.119536,Neutral
vTv Therapeutics  ( NASDAQ:VTVT )  Now Covered by Analysts at StockNews.com,https://reporter.am/2023/02/20/vtv-therapeutics-nasdaqvtvt-now-covered-by-analysts-at-stocknews-com.html,2023-02-20 08:22:49,vTv Therapeutics ( NASDAQ:VTVT ) Now Covered by Analysts at ... Armenian Reporter ...,ABBV,0.105604,0.103213,Neutral
NortonLifeLock  ( NASDAQ:NLOK )  Coverage Initiated at StockNews.com,https://reporter.am/2023/02/20/nortonlifelock-nasdaqnlok-coverage-initiated-at-stocknews-com.html,2023-02-20 08:22:48,NortonLifeLock ( NASDAQ:NLOK ) Coverage Initiated at StockNews ... Armenian Reporter ...,ABBV,0.079656,0.188469,Somewhat-Bullish
Almaden Minerals  ( NYSE:AAU )  Earns Sell Rating from Analysts at StockNews.com,https://www.defenseworld.net/2023/02/20/almaden-minerals-nyseaau-earns-sell-rating-from-analysts-at-stocknews-com-3.html,2023-02-20 08:22:48,Almaden Minerals ( NYSE:AAU ) Earns Sell Rating from Analysts at ... Defense World ...,ABBV,0.231332,0.227268,Somewhat-Bullish
StockNews.com Initiates Coverage on Ashford  ( NYSE:AINC ) ,https://www.etfdailynews.com/2023/02/20/stocknews-com-initiates-coverage-on-ashford-nyseainc/,2023-02-20 08:22:48,"Stock analysts at StockNews.com initiated coverage on shares of Ashford ( NYSE:AINC - Get Rating ) in a report issued on Monday. The firm set a ""buy"" rating on the stock. Shares of Ashford stock opened at $13.60 on Monday.",ABBV,0.218817,0.222807,Somewhat-Bullish
Ashford  ( NYSE:AINC )  Now Covered by StockNews.com,https://www.defenseworld.net/2023/02/20/ashford-nyseainc-now-covered-by-stocknews-com.html,2023-02-20 08:22:48,"Equities research analysts at StockNews.com started coverage on shares of Ashford ( NYSE:AINC - Get Rating ) in a report issued on Monday. The firm set a ""buy"" rating on the stock. NYSE:AINC opened at $13.60 on Monday.",ABBV,0.21686,0.178298,Somewhat-Bullish
StockNews.com Begins Coverage on Golden Minerals  ( NYSE:AUMN ) ,https://www.etfdailynews.com/2023/02/20/stocknews-com-begins-coverage-on-golden-minerals-nyseaumn/,2023-02-20 08:22:48,"Stock analysts at StockNews.com initiated coverage on shares of Golden Minerals ( NYSE:AUMN - Get Rating ) in a report released on Monday. The firm set a ""hold"" rating on the stock. NYSE AUMN opened at $0.25 on Monday. Golden Minerals has a twelve month low of $0.22 and a twelve month high of ...",ABBV,0.166169,0.138618,Neutral
StockNews.com Initiates Coverage on Golden Minerals  ( NYSE:AUMN ) ,https://www.defenseworld.net/2023/02/20/stocknews-com-initiates-coverage-on-golden-minerals-nyseaumn.html,2023-02-20 08:22:48,"Research analysts at StockNews.com began coverage on shares of Golden Minerals ( NYSE:AUMN - Get Rating ) in a report issued on Monday. The brokerage set a ""hold"" rating on the stock. Golden Minerals stock opened at $0.25 on Monday. Golden Minerals has a fifty-two week low of $0.22 and a ...",ABBV,0.166169,0.16197,Somewhat-Bullish
Tarena International  ( NASDAQ:TEDU )  Coverage Initiated at StockNews.com,https://reporter.am/2023/02/20/tarena-international-nasdaqtedu-coverage-initiated-at-stocknews-com.html,2023-02-20 08:22:48,Tarena International ( NASDAQ:TEDU ) Coverage Initiated at ... Armenian Reporter ...,ABBV,0.146916,0.116548,Neutral
Innodata  ( NASDAQ:INOD )  Earns Hold Rating from Analysts at StockNews.com,https://reporter.am/2023/02/20/innodata-nasdaqinod-earns-hold-rating-from-analysts-at-stocknews-com.html,2023-02-20 08:22:47,Innodata ( NASDAQ:INOD ) Earns Hold Rating from Analysts at ... Armenian Reporter ...,ABBV,0.09186,0.163847,Somewhat-Bullish
"Air Products and Chemicals  ( NYSE:APD )  Cut to ""Hold"" at StockNews.com",https://reporter.am/2023/02/20/air-products-and-chemicals-nyseapd-cut-to-hold-at-stocknews-com-2.html,2023-02-20 08:22:47,"Air Products and Chemicals ( NYSE:APD ) Cut to ""Hold"" at ... Armenian Reporter ...",ABBV,0.056275,0.085904,Neutral
Advaxis  ( NASDAQ:ADXS )  Research Coverage Started at StockNews.com,https://reporter.am/2023/02/20/advaxis-nasdaqadxs-research-coverage-started-at-stocknews-com-2.html,2023-02-20 08:22:47,Advaxis ( NASDAQ:ADXS ) Research Coverage Started at ... Armenian Reporter ...,ABBV,0.200688,0.163272,Somewhat-Bullish
Marine Petroleum Trust  ( NASDAQ:MARPS )  Now Covered by Analysts at StockNews.com,https://reporter.am/2023/02/20/marine-petroleum-trust-nasdaqmarps-now-covered-by-analysts-at-stocknews-com-2.html,2023-02-20 08:22:47,Marine Petroleum Trust ( NASDAQ:MARPS ) Now Covered by ... Armenian Reporter ...,ABBV,0.131643,0.249113,Somewhat-Bullish
StockNews.com Initiates Coverage on Golden Minerals  ( NYSE:AUMN ) ,https://reporter.am/2023/02/20/stocknews-com-initiates-coverage-on-golden-minerals-nyseaumn.html,2023-02-20 08:22:46,"Research analysts at StockNews.com began coverage on shares of Golden Minerals ( NYSE:AUMN - Get Rating ) in a report issued on Monday. The brokerage set a ""hold"" rating on the stock. Golden Minerals stock opened at $0.25 on Monday. Golden Minerals has a fifty-two week low of $0.22 and a ...",ABBV,0.166169,0.16197,Somewhat-Bullish
NexTier Oilfield Solutions  ( NYSE:NEX )  Upgraded at StockNews.com,https://www.defenseworld.net/2023/02/20/nextier-oilfield-solutions-nysenex-upgraded-at-stocknews-com.html,2023-02-20 07:14:42,StockNews.com upgraded shares of NexTier Oilfield Solutions ( NYSE:NEX - Get Rating ) from a buy rating to a strong-buy rating in a research note published on Friday morning.,ABBV,0.068112,0.204357,Somewhat-Bullish
3 No-Brainer Dividend Stocks to Buy in March,https://www.fool.com/investing/2023/03/11/3-no-brainer-dividend-stocks-to-buy-in-march/,2023-03-11 11:14:00,Going with these great dividend stocks is an easy choice.,ABBV,0.342093,0.269966,Somewhat-Bullish
"Diffuse large B-cell lymphoma  ( DLBCL )  therapeutics market size to increase by USD 2,061.88 million between 2022 and 2027; Growth driven by increasing approval of therapeutics - Technavio",https://www.prnewswire.com/news-releases/diffuse-large-b-cell-lymphoma-dlbcl-therapeutics-market-size-to-increase-by-usd-2-061-88-million-between-2022-and-2027-growth-driven-by-increasing-approval-of-therapeutics---technavio-301768024.html,2023-03-10 22:30:00,Diffuse large B-cell lymphoma ( DLBCL ) therapeutics market size to ... PR ...,ABBV,0.0378,0.00862,Neutral
Investors Heavily Search AbbVie Inc.  ( ABBV ) : Here is What You Need to Know,https://www.zacks.com/stock/news/2064126/investors-heavily-search-abbvie-inc-abbv-here-is-what-you-need-to-know,2023-03-10 14:00:11,"AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",ABBV,0.486627,0.095299,Neutral
U.S. FDA approves Pfizer's nasal spray for migraine,https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-pfizers-nasal-spray-migraine-2023-03-10/,2023-03-10 11:59:00,"March 10 ( Reuters ) - The U.S. Food and Drug Administration ( FDA ) on Friday approved Pfizer Inc's ( PFE.N ) nasal spray for migraine, giving patients access to a potentially fast-acting option to treat their headaches.",ABBV,0.199037,-0.09541,Neutral
"Zacks Investment Ideas feature highlights: Coca-Cola Company, AbbVie and Exxon Mobil",https://www.zacks.com/stock/news/2063913/zacks-investment-ideas-feature-highlights-coca-cola-company-abbvie-and-exxon-mobil,2023-03-10 10:00:00,"Coca-Cola Company, AbbVie and Exxon Mobil have been highlighted in this Investment Ideas article.",ABBV,0.568651,0.396399,Bullish
FDA Advisory Committee votes in favour of the clinical benefit of Roche's Polivy combination for people with previously untreated diffuse large B-cell lymphoma,https://www.globenewswire.com/news-release/2023/03/09/2624686/0/en/FDA-Advisory-Committee-votes-in-favour-of-the-clinical-benefit-of-Roche-s-Polivy-combination-for-people-with-previously-untreated-diffuse-large-B-cell-lymphoma.html,2023-03-09 23:45:00,"Basel, 10 March 2023 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today that the U.S. Food and Drug Administration ( FDA ) Oncologic Drugs Advisory Committee ( ODAC ) voted 11 to 2 in favour of Polivy® ( polatuzumab vedotin-piiq ) in combination with Rituxan® ( rituximab ) plus ...",ABBV,0.028023,0.065636,Neutral
Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/03/09/2624653/0/en/Caribou-Biosciences-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-Business-Update.html,2023-03-09 22:09:00,-- CB-010 ANTLER Phase 1 trial in r/r B-NHL ongoing with update planned for H2 2023 -- -- CB-011 CaMMouflage Phase 1 trial in r/r MM recruiting patients at dose level ...,ABBV,0.022326,0.116252,Neutral
Reap Monthly Income With This Combination of 3 Stocks,https://www.zacks.com/commentary/2063771/reap-monthly-income-with-this-combination-of-3-stocks,2023-03-09 19:29:00,"While most stocks pay quarterly dividends, investors can still construct a portfolio that allows them to get paid monthly if they position themselves carefully. Who doesn't like payday?",ABBV,0.576289,0.393232,Bullish
New drugs are coming to market at sky-high prices,https://www.foxbusiness.com/healthcare/new-drugs-coming-market-sky-high-prices,2023-03-09 19:08:03,"A new Amgen Inc. lung-cancer treatment, Lumakras, carried a hefty price tag when it came out in 2021: $17,900 per patient monthly. Just over a year later, in December 2022, a second drug for the same type of cancer, Krazati from Mirati Therapeutics Inc., had an even higher price: $19,750 a month ...",ABBV,0.033052,0.120597,Neutral
ABBV: Want Passive Income? Buy These 4 Stocks,https://stocknews.com/news/abbv-csco-wlkp-spok-sdy-want-passive-income-buy-these-4-stocks/,2023-03-09 17:59:57,"The market lapsed after Fed Chair Jerome Powell expressed concerns over the pace of interest-rate increases, and a new streak of volatility might have set in. With uncertainties still hanging around, investors could opt for dividend stocks that conventionally provide consistent returns.",ABBV,0.197574,0.228772,Somewhat-Bullish
Anti-Viral Therapies Market Growth  ( $82.92 Billion by 2028 )  Driven by Branded Drugs Segment during  ( 2022-2028 )  - Global Report by The Insight Partners,https://www.benzinga.com/pressreleases/23/03/g31276388/anti-viral-therapies-market-growth-82-92-billion-by-2028-driven-by-branded-drugs-segment-during-20,2023-03-09 13:46:17,"New York, March 09, 2023 ( GLOBE NEWSWIRE ) -- According to The Insight Partners, ""Anti-Viral Therapies Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global Analysis by Type ( Generic Drugs and Branded Drugs ) , Mechanism of Action ( Nucleotide Polymerase ...",ABBV,0.02493,0.067196,Neutral
Is WisdomTree U.S. High Dividend ETF  ( DHS )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2063350/is-wisdomtree-us-high-dividend-etf-dhs-a-strong-etf-right-now,2023-03-09 11:20:07,Smart Beta ETF report for ...,ABBV,0.115787,0.066792,Neutral
3 Surefire Stocks That Are Screaming Buys in March,https://www.fool.com/investing/2023/03/09/3-surefire-stocks-that-are-screaming-buys-in-march/,2023-03-09 11:07:00,"High-growth industries are risky, but they also have tremendous potential.",ABBV,0.28648,0.191268,Somewhat-Bullish
3 High-Yield Dividend Stocks to Buy Before the Next Bull Rally,https://www.fool.com/investing/2023/03/09/3-high-yield-dividend-stocks-to-buy-before-the-nex/,2023-03-09 10:41:00,Here's why you'll want to hurry up and buy these stocks before the next big market rally pushes them out of reach.,ABBV,0.325924,0.078587,Neutral
Is It Too Late to Buy AbbVie Stock?,https://www.fool.com/investing/2023/03/09/is-it-too-late-to-buy-abbvie-stock/,2023-03-09 10:30:00,AbbVie stock and earnings have increased over time.,ABBV,0.536866,0.47352,Bullish
"Women's Health Devices Market Size Expected to Hit USD 62.61 Billion by 2028, exhibiting 8.4% CAGR",https://www.benzinga.com/pressreleases/23/03/g31262045/womens-health-devices-market-size-expected-to-hit-usd-62-61-billion-by-2028-exhibiting-8-4-cagr,2023-03-08 17:14:50,"Pune, India, March 08, 2023 ( GLOBE NEWSWIRE ) -- The global Women's Health Devices Market size was valued at USD 34.23 billion in 2020. The market is projected to grow from USD 35.63 billion in 2021 to USD 62.61 billion in 2028, exhibiting a CAGR of 8.4% during the forecast period.",ABBV,0.035397,0.0,Neutral
BOTOX® Cosmetic Partners with IFundWomen to Help Close the Confidence Gap for Women Entrepreneurs,https://investingnews.com/botox-r-cosmetic-partners-with-ifundwomen-to-help-close-the-confidence-gap-for-women-entrepreneurs/,2023-03-08 14:34:13,"NEW PARTNERSHIP PROVIDES TRANSFORMATIVE GRANTS TO EMPOWER CONFIDENCE In honor of International Women's Day, Allergan Aesthetics, an ABBVie company ( NYSE: ABBV ) today announced that BOTOX ® Cosmetic is partnering with IFundWomen, the go-to funding marketplace for women-owned businesses, on a ...",ABBV,0.176779,0.353018,Bullish
BOTOX® Cosmetic  ( onabotulinumtoxinA )  Partners with IFundWomen to Help Close the Confidence Gap for Women Entrepreneurs,https://www.prnewswire.com/news-releases/botox-cosmetic-onabotulinumtoxina-partners-with-ifundwomen-to-help-close-the-confidence-gap-for-women-entrepreneurs-301765382.html,2023-03-08 13:45:00,BOTOX® Cosmetic ( onabotulinumtoxinA ) Partners with ... PR ...,ABBV,0.135729,0.304146,Somewhat-Bullish
AbbVie to Present at the Barclays Global Healthcare Conference,https://investingnews.com/abbvie-to-present-at-the-barclays-global-healthcare-conference/,2023-03-08 13:26:13,"ABBVie ( NYSE: ABBV ) will participate in the Barclays Global Healthcare Conference on Wednesday, March 15, 2023 . Robert A. Michael vice chairman and president, Scott Reents executive vice president, chief financial officer, Jeffrey R.",ABBV,0.70749,-0.003891,Neutral
"2 Exceptional Growth Stocks That Could Jump 37.6% to 40.2% Higher, According to Wall Street",https://www.fool.com/investing/2023/03/08/2-exceptional-growth-stocks-that-could-soar-to-acc/,2023-03-08 10:17:00,"These businesses are at the top of their respective industries, but you wouldn't know it by looking at their stock prices.",ABBV,0.061315,0.003018,Neutral
Sosei Heptares Receives Approval for Change of Market Listing Segment to the Tokyo Stock Exchange Prime Market,https://www.globenewswire.com/news-release/2023/03/08/2622696/0/en/Sosei-Heptares-Receives-Approval-for-Change-of-Market-Listing-Segment-to-the-Tokyo-Stock-Exchange-Prime-Market.html,2023-03-08 08:00:00,"Tokyo, Japan and Cambridge, UK, 8 March 2023 - Sosei Group Corporation ( ""the Company"". TSE: 4565 ) , the world leader in G protein-coupled receptor ( GPCR ) focused structure-based drug design ( SBDD ) and development, is pleased to announce it has received approval from the Tokyo Stock ...",ABBV,0.067347,0.043074,Neutral
Sosei Heptares Receives Approval for Change of Market Listing Segment to the Tokyo Stock Exchange Prime Market,https://www.benzinga.com/pressreleases/23/03/g31252344/sosei-heptares-receives-approval-for-change-of-market-listing-segment-to-the-tokyo-stock-exchange-,2023-03-08 08:00:00,"Tokyo, Japan and Cambridge, UK, 8 March 2023 - Sosei Group Corporation ( ""the Company"".",ABBV,0.064104,0.040016,Neutral
"Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason - SPDR Select Sector Fund - Health Care  ( ARCA:XLV ) , iShares Biotechnology ETF  ( NASDAQ:IBB ) ",https://www.benzinga.com/general/biotech/23/03/31223747/health-care-etfs-have-lost-in-the-last-month-these-top-pharma-stocks-are-the-reason,2023-03-08 00:34:06,"The Health Care Select Sector SPDR Fund XLV, heavily tilted towards mega-caps, lost around 5.25% over the last month, with substantial companies reporting annual earnings. Shares of Health Care Select Sector SPDR Fund opened at $129.26 on Monday, with a twelve-month low of $118.75 and a ...",ABBV,0.414559,-0.040294,Neutral
Carisma Therapeutics Closes Merger with Sesen Bio,https://www.prnewswire.com/news-releases/carisma-therapeutics-closes-merger-with-sesen-bio-301765135.html,2023-03-07 22:28:00,"Shares of Carisma to commence trading on Nasdaq under new ticker symbol ""CARM"" on March 8, 2023 Resulting cash position of approximately $140 million provides runway through 2024; expected to enable multiple clinical readouts across Carisma programs",ABBV,0.030838,0.0,Neutral
Should WisdomTree U.S. High Dividend ETF  ( DHS )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2062446/should-wisdomtree-us-high-dividend-etf-dhs-be-on-your-investing-radar,2023-03-07 11:20:07,Style Box ETF report for ...,ABBV,0.122581,0.068387,Neutral
Best And Worst S&P Sectors Over The Last 12 Months,https://www.forbes.com/sites/johndorfman/2023/03/06/best-and-worst-sp-sectors-over-the-last-12-months/,2023-03-06 18:02:30,In investing the 11 sectors identified by Standard & Poor's influence investors' thinking. Here's a look at some sectors that have been hot or cold lately.,ABBV,0.055236,0.156882,Somewhat-Bullish
2 Top Dividend Kings to Buy for the Long Haul,https://www.fool.com/investing/2023/03/04/2-top-dividend-kings-to-buy-for-the-long-haul/,2023-03-04 14:53:00,"These aren't just dividend plays, either.",ABBV,0.408672,0.053284,Neutral
2 High-Yield Dividend Stocks to Buy in March,https://www.fool.com/investing/2023/03/04/2-high-yield-dividend-stocks-to-buy-in-march/,2023-03-04 11:27:00,Putting some shares of these stocks in your portfolio now could lead to heaps of passive income in your retirement years.,ABBV,0.280294,0.174243,Somewhat-Bullish
Tissue Expanders Market is Expected to Generate $1.18 Billion by 2031: Allied Market Research,https://www.benzinga.com/pressreleases/23/03/g31194227/tissue-expanders-market-is-expected-to-generate-1-18-billion-by-2031-allied-market-research,2023-03-03 15:30:00,"Portland, OR, March 03, 2023 ( GLOBE NEWSWIRE ) -- According to the report published by Allied Market Research, the global Tissue Expanders Market garnered $671.5 million in 2021, and is estimated to generate $1.18 billion by 2031, manifesting a CAGR of 5.8% from 2022 to 2031.",ABBV,0.03798,0.048799,Neutral
Could This Humira Biosimilar Be a Winner for Amgen?,https://www.fool.com/investing/2023/03/03/could-this-humira-biosimilar-be-a-winner-for-amgen/,2023-03-03 11:00:00,This Humira biosimilar just launched in the U.S. several weeks ago.,ABBV,0.144708,0.119283,Neutral
Biologics CDMO market size to increase by USD 13.26 billion from 2022 to 2027: Strong research and development pipeline of biologics therapeutics to boost market growth - Technavio,https://www.prnewswire.com/news-releases/biologics-cdmo-market-size-to-increase-by-usd-13-26-billion-from-2022-to-2027-strong-research-and-development-pipeline-of-biologics-therapeutics-to-boost-market-growth---technavio-301759648.html,2023-03-02 22:05:00,Biologics CDMO market size to increase by USD 13.26 billion from ... PR ...,ABBV,0.040622,0.038595,Neutral
Viatris warns it will stop selling essential drugs in UK without changes to drug pricing agreement,https://www.reuters.com/business/healthcare-pharmaceuticals/viatris-warns-it-will-stop-selling-essential-drugs-uk-without-changes-drug-2023-03-02/,2023-03-02 21:43:59,Viatris warns it will stop selling essential drugs in UK without ... ...,ABBV,0.102888,-0.065219,Neutral
RHHBY vs. ABBV: Which Stock Is the Better Value Option?,https://www.zacks.com/stock/news/2061122/rhhby-vs-abbv-which-stock-is-the-better-value-option,2023-03-02 16:40:09,Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Roche Holding AG ( RHHBY Quick QuoteRHHBY - ) and AbbVie ( ABBV Quick QuoteABBV - ) . But which of these two companies is the best option for those looking for undervalued stocks?,ABBV,0.66878,0.575365,Bullish
"Intel Slashed Its Dividend, But These 3 Yields Are Likely to Continue Rising",https://www.fool.com/investing/2023/03/02/intel-slashed-its-dividend-but-these-3-yields-are/,2023-03-02 14:37:00,These are dividend stocks you won't have to worry about.,ABBV,0.275246,0.229779,Somewhat-Bullish
These 2 Dividend Stocks Could Be a Great Addition to Your Income Portfolio,https://www.fool.com/investing/2023/03/02/these-2-dividend-stocks-could-be-a-great-addition/,2023-03-02 13:15:00,"They'll generate cash now, and even more cash in the future.",ABBV,0.21258,0.201215,Somewhat-Bullish
Veeva Systems  ( VEEV )  Q4 2023 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/03/02/veeva-systems-veev-q4-2023-earnings-call-transcrip/,2023-03-02 05:30:23,"VEEV earnings call for the period ending December 31, 2022.",ABBV,0.010987,0.020516,Neutral
ABBV: 2 Top Stocks That Should Be on Your Radar This Spring,https://stocknews.com/news/abbv-crm-2-top-stocks-that-should-be-on-your-radar-this/,2023-03-21 16:38:24,"The stock market has witnessed significant volatility of late on concerns over the prospect of rate hikes and macro uncertainties. However, I present quality stocks AbbVie Inc. ( ABBV ) and Salesforce, Inc. ( CRM ) , which have demonstrated resiliency during challenging times and are trading at a ...",ABBV,0.385385,0.107198,Neutral
Sandoz receives US FDA approval for biosimilar Hyrimoz®  ( adalimumab-adaz )  high-concentration formulation,https://www.globenewswire.com/news-release/2023/03/21/2631529/0/en/Sandoz-receives-US-FDA-approval-for-biosimilar-Hyrimoz-adalimumab-adaz-high-concentration-formulation.html,2023-03-21 14:48:00,"Basel, March 21, 2023 - Sandoz, a global leader in generic pharmaceuticals and biosimilars, today announced that the US Food and Drug Administration ( FDA ) approved a citrate-free high-concentration formulation ( HCF ) of its biosimilar Hyrimoz® ( adalimumab-adaz ) injection.",ABBV,0.033282,0.0,Neutral
Anima Biotech to Present at the American Chemical Society Spring Meeting 2023,https://www.benzinga.com/pressreleases/23/03/g31440107/anima-biotech-to-present-at-the-american-chemical-society-spring-meeting-2023,2023-03-21 14:17:00,"BERNARDSVILLE, N.J., March 21, 2023 ( GLOBE NEWSWIRE ) -- Anima Biotech, the leader in the discovery of small molecule mRNA drugs and their mechanisms of action by phenotypic screening with AI driven MOA elucidation, today announced the company will give a presentation during the American ...",ABBV,0.104683,0.06168,Neutral
Should You Buy The Botox Maker Over Johnson & Johnson Stock?,https://www.forbes.com/sites/greatspeculations/2023/03/21/should-you-buy-the-botox-maker-over-johnson--johnson-stock/,2023-03-21 12:00:02,"Even if we look at a longer time frame, AbbVie fares better, with its sales rising at an average annual growth rate of 21% to $58 billion in 2022, compared to $33 billion in 2019, while J&J's saw its revenue rise at an average annual rate of just 5% to $95 billion in 2022, compared to $82 ...",ABBV,0.656549,0.404271,Bullish
CD47 Inhibitors Drugs Cancer Therapy Clinical Trials Market Size Companies Insight,https://www.benzinga.com/pressreleases/23/03/g31435842/cd47-inhibitors-drugs-cancer-therapy-clinical-trials-market-size-companies-insight,2023-03-21 11:49:18,"Delhi, March 21, 2023 ( GLOBE NEWSWIRE ) -- Global CD47 Inhibitor Drug Clinical Trials Insight 2028 Report Highlights: CD47 Inhibitor Drug Market Trends & Future Prospects Insight On More Than 50 CD47 Inhibitors Drugs In Clinical Trials Orphan, Fast Track, Breakthrough Therapy Designation ...",ABBV,0.099271,0.072912,Neutral
"Sonata Therapeutics Strengthens Leadership Team with Appointment of Francesco Marincola, M.D., as Chief Scientific Officer",https://www.benzinga.com/pressreleases/23/03/g31435488/sonata-therapeutics-strengthens-leadership-team-with-appointment-of-francesco-marincola-m-d-as-chi,2023-03-21 11:30:00,"WATERTOWN, Mass., March 21, 2023 ( GLOBE NEWSWIRE ) -- Sonata Therapeutics Inc., a biotechnology company creating therapeutics that transform diseased cells into coordinators of cure, today announced the appointment of Francesco Marincola, M.D., as Chief Scientific Officer.",ABBV,0.06515,-0.018113,Neutral
Buyer Beware: 3 Risks to Watch for With Biotech Stocks in 2023,https://www.fool.com/investing/2023/03/21/buyer-beware-3-risks-to-watch-for-with-biotech-sto/,2023-03-21 11:25:00,"It's still a decent time to invest, but you'll need to be more careful than usual.",ABBV,0.055109,0.03302,Neutral
AbbVie  ( ABBV )  Outpaces Stock Market Gains: What You Should Know,https://www.zacks.com/stock/news/2068182/abbvie-abbv-outpaces-stock-market-gains-what-you-should-know,2023-03-20 21:45:20,"In the latest trading session, AbbVie (ABBV) closed at $156.12, marking a +1.23% move from the previous day.",ABBV,0.618922,0.282626,Somewhat-Bullish
JNJ: 3 Stocks to Buy Now That Are Worth Every Penny,https://stocknews.com/news/jnj-abbv-ibm-gs-3-stocks-to-buy-now-that-are-worth-every-penny/,2023-03-20 18:04:56,"The Federal Reserve's aggressive rate hikes in the past year to curb inflation have proven minimally successful. However, inflation is still far above the Fed's target of 2%. Furthermore, the recent collapse of the banking system has made it even more challenging to achieve this target.",ABBV,0.224903,0.155473,Somewhat-Bullish
JNJ: 3 Highly Rated Blue-Chip Stocks for Your Portfolio,https://stocknews.com/news/jnj-ko-abbv-sivb-3-highly-rated-blue-chip-stocks-for-your-portfolio/,2023-03-20 17:46:25,"Elevated inflation, combined with a strong labor market and solid consumer spending, positioned the Fed to hike the interest rate by 50 basis points this week until the sudden collapse of the Silicon Valley Bank and other financial institutions sparked calls for a potential pause.",ABBV,0.176341,0.18744,Somewhat-Bullish
Is Roche a Buy Now?,https://www.fool.com/investing/2023/03/20/is-roche-a-buy-now/,2023-03-20 11:35:00,Roche focuses on the long-term.,ABBV,0.041394,0.135909,Neutral
Should First Trust Morningstar Dividend Leaders ETF  ( FDL )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2067776/should-first-trust-morningstar-dividend-leaders-etf-fdl-be-on-your-investing-radar,2023-03-20 10:20:09,Style Box ETF report for ...,ABBV,0.121343,0.068087,Neutral
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF  ( PJP ) ?,https://www.zacks.com/stock/news/2067783/should-you-invest-in-the-invesco-dynamic-pharmaceuticals-etf-pjp,2023-03-20 10:20:07,Sector ETF report for ...,ABBV,0.133841,0.064137,Neutral
"Aquavit Files Additional IND for DTX-024, a New Botulinum Toxin With Microchannel Technology™ for Palmar Hyperhidrosis",https://www.prnewswire.com/news-releases/aquavit-files-additional-ind-for-dtx-024-a-new-botulinum-toxin-with-microchannel-technology-for-palmar-hyperhidrosis-301775589.html,2023-03-18 15:56:00,"Aquavit Files Additional IND for DTX-024, a New Botulinum Toxin ... PR ...",ABBV,0.071145,0.129779,Neutral
AbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI® in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor Therapy,https://investingnews.com/abbvie-announces-late-breaking-results-of-study-evaluating-52-week-efficacy-and-safety-of-skyrizi-r-in-plaque-psoriasis-patients-with-a-prior-suboptimal-response-to-il-17-inhibitor-therapy/,2023-03-18 14:26:57,"ABBVie ( NYSE: ABBV ) today announced new 52-week data from an open-label, single-arm study demonstrating improved plaque psoriasis signs and symptoms among a difficult-to-treat patient population who received SKYRIZI ® ( risankizumab ) , an IL-23 inhibitor.",ABBV,0.28402,0.08839,Neutral
AbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI®  ( risankizumab )  in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor Therapy,https://www.prnewswire.com/news-releases/abbvie-announces-late-breaking-results-of-study-evaluating-52-week-efficacy-and-safety-of-skyrizi-risankizumab-in-plaque-psoriasis-patients-with-a-prior-suboptimal-response-to-il-17-inhibitor-therapy-301774195.html,2023-03-18 14:03:00,AbbVie Announces Late-Breaking Results of Study Evaluating 52 ... PR ...,ABBV,0.219312,0.12227,Neutral
This Is What Whales Are Betting On AbbVie - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/03/31401240/this-is-what-whales-are-betting-on-abbvie,2023-03-17 17:00:45,"Someone with a lot of money to spend has taken a bearish stance on AbbVie ABBV. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",ABBV,0.795859,0.286543,Somewhat-Bullish
Two Biotech Stocks Hit In Medicare Negotiation Crossfire,https://www.investors.com/research/ibd-industry-themes/regn-stock-halo-stock-tumble-on-cms-negotiation-confusion/,2023-03-17 14:50:45,"REGN Stock, HALO Stock Tumble On CMS Negotiation Confusion ... Investor's Business Daily ...",ABBV,0.127795,0.0,Neutral
"Pharma Stock Roundup: M&A Boom in Drug Industry With PFE & SNY Deals, Other Updates",https://www.zacks.com/stock/news/2067324/pharma-stock-roundup-ma-boom-in-drug-industry-with-pfe-sny-deals-other-updates,2023-03-17 14:08:00,Pfizer (PFE) is set to buy Seagen (SGEN) for $43 billion while Sanofi (SNY) is acquiring Provention Bio. Novo Nordisk (NVO) and Sanofi are looking to cut insulin prices.,ABBV,0.040145,-0.121631,Neutral
 ( ABBV )  - Analyzing AbbVie's Short Interest - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/short-sellers/23/03/31384549/abbv-analyzing-abbvies-short-interest,2023-03-16 16:45:20,"AbbVie's ABBV short percent of float has risen 9.09% since its last report. The company recently reported that it has 12.70 million shares sold short, which is 0.72% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.3 days to cover their ...",ABBV,0.224903,0.158881,Somewhat-Bullish
Two Biotech Stocks Hit In Medicare Negotiation Crossfire,https://www.investors.com/news/technology/regn-stock-halo-stock-tumble-on-cms-negotiation-confusion/,2023-03-16 16:05:45,"REGN Stock, HALO Stock Tumble On CMS Negotiation Confusion Investor's Business Daily ...",ABBV,0.1331,0.0,Neutral
EVP of AbbVie Sold $8.09M In Stock - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/news/23/03/31382451/evp-of-abbvie-sold-8-09m-in-stock,2023-03-16 15:07:21,"Jeffrey R. Stewart, EVP at AbbVie ABBV, reported a large insider sell on March 15, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Stewart sold 53,125 shares of AbbVie. The total transaction amounted to ...",ABBV,0.517168,0.288422,Somewhat-Bullish
2 Growth Stocks to Buy Before the Bull Market Arrives,https://www.fool.com/investing/2023/03/16/2-growth-stocks-to-buy-before-bull-market-arrives/,2023-03-16 12:30:00,Long-term investors shouldn't hesitate to add these stocks to their portfolios.,ABBV,0.403172,0.478251,Bullish
U.S. issues initial Medicare drug price negotiation guidance,https://www.reuters.com/business/healthcare-pharmaceuticals/us-issues-initial-medicare-drug-price-negotiation-guidance-2023-03-15/,2023-03-15 21:07:00,"WASHINGTON, March 15 ( Reuters ) - The U.S. government will select the Medicare program's 10 costliest prescription medicines based on gross spending for negotiating price cuts that will go into effect in 2026, the U.S. Centers for Medicare and Medicaid Services ( CMS ) said on Wednesday",ABBV,0.083833,0.067467,Neutral
First Drugs Facing Medicare Price Penalty Named,https://www.wsj.com/articles/first-drugs-facing-medicare-price-penalty-named-by-u-s-6453e7d9,2023-03-15 16:24:00,"U.S. health officials listed 27 medications whose prices rose faster than inflation, triggering rebates under a new federal law.",ABBV,0.371523,-0.171126,Somewhat-Bearish
Drug Companies Raising Prices Greater Than Inflation? US Government Mulling Imposing Fines - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/general/biotech/23/03/31357344/drug-companies-raising-prices-greater-than-inflation-us-government-mulling-imposing-fines,2023-03-15 12:30:10,"Under Joe Biden's signature Inflation Reduction Act, drugmakers for twenty-seven drugs will be penalized for charging prices that rise faster than inflation for people with disabilities or the elderly on the government's Medicare health program.",ABBV,0.423843,-0.302104,Somewhat-Bearish
AbbVie Partners with Award-Winning Redglass Pictures on New Film Shedding Light on the Hidden Struggles of Those Living with Eczema - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/pressreleases/23/03/n31358310/abbvie-partners-with-award-winning-redglass-pictures-on-new-film-shedding-light-on-the-hidden-stru,2023-03-15 12:03:00,"""Under My Skin: Untold Stories of Life with Eczema,"" uncovers the extraordinary physical and emotional impact of those living with the chronic skin disease, showing viewers the power of having the courage to seek help",ABBV,0.302553,0.321533,Somewhat-Bullish
Royalty Pharma Raises Full Year 2023 Guidance - Royalty Pharma  ( NASDAQ:RPRX ) ,https://www.benzinga.com/pressreleases/23/03/g31358101/royalty-pharma-raises-full-year-2023-guidance,2023-03-15 12:00:00,"Royalty Pharma now expects 2023 Adjusted Cash Receipts ( 1 ) ( non-GAAP ) to be between $2,850 million and $2,950 million, excluding contributions from future transactions",ABBV,0.033006,0.075319,Neutral
"US to impose inflation fines on first set of drugs, lowering costs",https://www.reuters.com/business/healthcare-pharmaceuticals/us-impose-inflation-fines-first-set-drugs-lowering-costs-2023-03-15/,2023-03-15 09:05:00,"WASHINGTON, March 15 ( Reuters ) - The U.S. government will subject 27 drugs to inflation penalties, it announced on Wednesday, meaning people on Medicare will pay less out-of-pocket by $2 to as high as $390 per average dose starting April 1.",ABBV,0.12165,-0.138131,Neutral
Sosei Heptares Announces Change of Market Listing Segment to the Tokyo Stock Exchange Prime Market,https://www.globenewswire.com/news-release/2023/03/15/2627310/0/en/Sosei-Heptares-Announces-Change-of-Market-Listing-Segment-to-the-Tokyo-Stock-Exchange-Prime-Market.html,2023-03-15 00:05:00,"Tokyo, Japan and Cambridge, UK, 15 March 2023 - Sosei Group Corporation ( ""the Company"". TSE: 4565 ) , the world leader in G protein-coupled receptor ( GPCR ) focused structure-based drug design ( SBDD ) and development, today announces it has changed the market on which the Company's shares are ...",ABBV,0.048621,0.04245,Neutral
"The Zacks Analyst Blog Highlights AbbVie, NextEra Energy, ConocoPhillips, Canadian Pacific Railway and Intercontinental Exchange",https://www.zacks.com/stock/news/2065403/the-zacks-analyst-blog-highlights-abbvie-nextera-energy-conocophillips-canadian-pacific-railway-and-intercontinental-exchange,2023-03-14 12:46:00,"AbbVie, NextEra Energy, ConocoPhillips, Canadian Pacific Railway and Intercontinental Exchange are part of the Zacks top Analyst Blog.",ABBV,0.716023,0.0,Neutral
"Oracle, AbbVie And This Gold Fund: CNBC's 'Final Trades' - AbbVie  ( NYSE:ABBV ) , SPDR Gold Trust  ( ARCA:GLD ) ",https://www.benzinga.com/news/23/03/31334382/oracle-abbvie-and-this-gold-fund-cnbcs-final-trades,2023-03-14 12:37:36,"On CNBC's ""Halftime Report Final Trades,"" Joshua Brown of Ritholtz Wealth Management named Oracle Corporation ORCL as his pick. The computer tech giant closed higher on Monday. Bryn Talkington of Requisite Capital Management named AbbVie Inc. ABBV, adding that healthcare is her sector pick.",ABBV,0.769861,0.586108,Bullish
Biotech deals provide a split-screen moment for battered sector,https://www.axios.com/2023/03/14/biotech-deals-split-screen-moment-sector,2023-03-14 09:56:56,A pair of big biotech deals is stirring some hope for a segment that's been in a deep funk and just starting to size up the aftereffects of Silicon Valley Bank's demise.,ABBV,0.062434,0.044114,Neutral
AbbVie  ( ABBV )  Gains As Market Dips: What You Should Know,https://www.zacks.com/stock/news/2065020/abbvie-abbv-gains-as-market-dips-what-you-should-know,2023-03-13 21:45:18,"In the latest trading session, AbbVie (ABBV) closed at $151.95, marking a +1.5% move from the previous day.",ABBV,0.672055,0.223658,Somewhat-Bullish
The Pfizer-Seagen deal has a hidden $1 billion warning for workers,https://www.businessinsider.com/pfizer-seagen-deal-cost-efficiencies-reductions-jobs-warning-workers-2023-3,2023-03-13 18:41:30,Pfizer-Seagen Deal Has $1 Billion of Cost Cuts - Business Insider ...,ABBV,0.107495,0.0,Neutral
"Best-Selling Drugs by Bristol Myers, Pfizer, AbbVie Likely Candidates For US Price Negotiation - Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/23/03/31324057/best-selling-drugs-by-bristol-myers-pfizer-abbvie-likely-candidates-for-us-price-negotiation,2023-03-13 17:18:58,"Bristol Myers Squibb & Co's BMY Eliquis, Pfizer Inc's PFE Ibrance, and AbbVie Inc's ABBV Imbruvica are expected to be among the ten top-selling drugs subject to U.S. price negotiations for 2026.",ABBV,0.294093,0.0,Neutral
"Top Research Reports for AbbVie, NextEra Energy & ConocoPhillips",https://www.zacks.com/research-daily/2064755/top-research-reports-for-abbvie-nextera-energy-conocophillips,2023-03-13 17:10:00,"Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), NextEra Energy, Inc. (NEE) and ConocoPhillips (COP).",ABBV,0.360752,0.156293,Somewhat-Bullish
AbbVie Showcases Strength of Dermatology Portfolio with New Data Presented at the 2023 AAD Annual Meeting,https://investingnews.com/abbvie-showcases-strength-of-dermatology-portfolio-with-new-data-presented-at-the-2023-aad-annual-meeting/,2023-03-13 12:21:59,"- More than 20 abstracts, including one late-breaking presentation, underscore AbbVie's dedication to advancing care for dermatologic conditions",ABBV,0.250203,0.129022,Neutral
Pfizer to buy cancer drugmaker Seagen for $43 billion,https://www.axios.com/2023/03/13/pfizer-seagen-deal-cancer-drugs,2023-03-13 12:05:32,"Pfizer on Monday said it has agreed to buy cancer drugmaker Seagen for $43 billion in cash. Why it matters: This is the largest merger announcement so far in 2023, and the largest pharma deal since Abbvie bought Allergan in 2020. • It also reflects how Pfizer is using its COVID vaccine fortune to ...",ABBV,0.255641,0.257128,Somewhat-Bullish
"Bristol Myers, Pfizer, AbbVie drugs likely to face U.S. price negotiation",https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-pfizer-abbvie-drugs-likely-face-us-price-negotiation-2023-03-13/,2023-03-13 10:09:00,"[1/3] A pharmacist holds a bottle of the drug Eliquis, made by Bristol Myers Squibb and Pfizer, at a pharmacy in Provo, Utah, U.S. January 9, 2020. REUTERS/George Frey",ABBV,0.088964,-0.012491,Neutral
Glaucoma Week 2023: 90 percent of cases are undiagnosed in India | The Financial Express,https://www.financialexpress.com/healthcare/news-healthcare/glaucoma-week-2023-90-percent-of-glaucoma-cases-are-undiagnosed-in-india/3007074/,2023-03-13 06:41:00,Glaucoma Week 2023: 90 percent of cases are undiagnosed in India The Financial Express ...,ABBV,0.080458,-0.020682,Neutral
Galderma posts 2022 revenue growth ahead of planned IPO,https://www.reuters.com/markets/deals/galderma-posts-2022-revenue-growth-ahead-planned-ipo-2023-03-13/,2023-03-13 06:03:00,Galderma posts 2022 revenue growth ahead of planned ...,ABBV,0.081552,0.0,Neutral
StockNews.com Downgrades AbbVie  ( NYSE:ABBV )  to Buy,https://www.defenseworld.net/2023/03/12/stocknews-com-downgrades-abbvie-nyseabbv-to-buy.html,2023-03-12 07:40:48,"AbbVie ( NYSE:ABBV - Get Rating ) was downgraded by investment analysts at StockNews.com from a ""strong-buy"" rating to a ""buy"" rating in a research report issued to clients and investors on Friday.",ABBV,0.839418,0.236971,Somewhat-Bullish
The Top Healthcare Stocks to Buy With $100,https://www.fool.com/investing/2023/03/31/the-top-healthcare-stocks-to-buy-with-100/,2023-03-31 14:00:00,"With the right stocks, even a small investment can yield huge returns.",ABBV,0.219809,0.198114,Somewhat-Bullish
"ImmuneOnco Banks On Cutting-edge Cancer Drugs To Attract IPO Cash - AbbVie  ( NYSE:ABBV ) , Gilead Sciences  ( NASDAQ:GILD ) ",https://www.benzinga.com/markets/penny-stocks/23/03/31608710/immuneonco-banks-on-cutting-edge-cancer-drugs-to-attract-ipo-cash,2023-03-31 13:23:56,"ImmuneOnco's main product pipeline is a cancer drug targeting a promising protein pathway, the first such drug to enter clinical tests in China, with more intensive trials due in the fourth quarter Eli Lilly ranks as the company's biggest institutional investor after six rounds of financing",ABBV,0.067536,0.091222,Neutral
This Blockbuster Drug's Latest News Could Be Another Home Run for AbbVie,https://www.fool.com/investing/2023/03/31/this-blockbuster-drugs-latest-news-could-be-anothe/,2023-03-31 12:50:00,This medicine is approved for three indications in the U.S. and is well on its way to another.,ABBV,0.339356,0.2395,Somewhat-Bullish
"I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022",https://www.prnewswire.com/news-releases/i-mab-provides-business-and-corporate-updates-and-reports-financial-results-for-the-year-ended-december-31-2022-301786880.html,2023-03-31 10:30:00,I-Mab Provides Business and Corporate Updates and Reports ... PR ...,ABBV,0.032408,0.132282,Neutral
Alembic Pharma shares up 5% on USFDA approval for glaucoma drug,https://www.moneycontrol.com/news/business/stocks/alembic-pharma-shares-up-5-on-usfda-approval-for-glaucoma-drug-10336411.html,2023-03-31 03:59:08,"Alembic Pharmaceuticals' share touched a 52-week high of Rs 792.30 on April 28, 2022 and a 52-week low of Rs 463.30 on March ...",ABBV,0.207571,0.346912,Somewhat-Bullish
"Buzzing Stocks: GR Infraprojects, BEL, Alembic Pharma, JSW Steel & others in news today",https://www.moneycontrol.com/news/business/stocks/buzzing-stocks-gr-infraprojects-bel-alembic-pharma-jsw-steel-others-in-news-today-10334271.html,2023-03-31 01:45:28,Stocks to Watch: Check out the companies making headlines before the opening bell today.,ABBV,0.022059,0.092923,Neutral
2 High-Yielding Dividend Investments to Buy for the Long Haul,https://www.fool.com/investing/2023/03/30/2-high-yielding-dividend-investments-for-long-haul/,2023-03-30 11:45:00,"Both of these stocks are Dividend Kings, and their payouts are likely to continue rising in the future.",ABBV,0.628066,0.508931,Bullish
Alembic Pharma gets USFDA nod for generic ophthalmic solution,https://www.moneycontrol.com/news/business/alembic-pharma-gets-usfda-nod-for-generic-ophthalmic-solution-10336541.html,2023-03-30 09:02:31,"The company has received final approval from the US Food Drug Administration ( USFDA ) to market Brimonidine Tartrate Ophthalmic Solution, Alembic Pharmaceuticals said in a statement.",ABBV,0.285526,0.591131,Bullish
USFDA gives final nod to Alembic Pharmaceuticals' Glaucoma drug | The Financial Express,https://www.financialexpress.com/healthcare/pharma-healthcare/usfda-gives-final-nod-to-alembic-pharmaceuticals-glaucoma-drug/3027016/,2023-03-30 08:42:00,USFDA gives final nod to Alembic Pharmaceuticals' Glaucoma drug The Financial Express ...,ABBV,0.258351,0.395483,Bullish
NRG Therapeutics Announces International Scientific Advisory Board,https://www.benzinga.com/pressreleases/23/03/g31574017/nrg-therapeutics-announces-international-scientific-advisory-board,2023-03-30 08:00:00,"STEVENAGE, United Kingdom, March 30, 2023 ( GLOBE NEWSWIRE ) -- NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce the formation of its scientific advisory board ( SAB ) , to support and steer its R&D programmes to develop novel ...",ABBV,0.158781,0.056124,Neutral
AbbVie Unusual Options Activity - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/03/31562020/abbvie-unusual-options-activity,2023-03-29 20:45:57,"Someone with a lot of money to spend has taken a bearish stance on AbbVie ABBV. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",ABBV,0.701476,0.164621,Somewhat-Bullish
Better Growth Stock: Vertex Pharmaceuticals vs. AbbVie,https://www.fool.com/investing/2023/03/29/better-growth-stock-vertex-pharmaceuticals-abbvie/,2023-03-29 18:00:00,These stocks look reasonably priced considering their future prospects.,ABBV,0.617436,0.317637,Somewhat-Bullish
"Allergan Aesthetics* to showcase 360° approach to clinical practice, aesthetic products, and patients with expert-led symposia at AMWC 2023",https://investingnews.com/allergan-aesthetics-to-showcase-3600-approach-to-clinical-practice-aesthetic-products-and-patients-with-expert-led-symposia-at-amwc-2023/,2023-03-29 13:30:43,"-- 'Discover Your 360°' immersive experience to feature across Allergan Aesthetics events, supporting customers with all aspects of their Practice, Product and Patient needs --",ABBV,0.239541,0.249971,Somewhat-Bullish
Better Growth Stock: AbbVie vs. Pfizer,https://www.fool.com/investing/2023/03/29/better-growth-stock-abbvie-vs-pfizer/,2023-03-29 11:30:00,One of the pair will have trouble challenging its recent heights.,ABBV,0.491878,0.162745,Somewhat-Bullish
Why CytomX Therapeutics  ( CTMX )  Shares Are Falling Today - CytomX Therapeutics  ( NASDAQ:CTMX ) ,https://www.benzinga.com/general/biotech/23/03/31531824/abbvie-walks-away-from-cytomx-partnership-but-garnering-attention-of-big-pharma-partners,2023-03-28 15:35:14,"CytomX Therapeutics Inc CTMX will weigh its options for CX-2029, a CD71-directed antibody-drug conjugate, after AbbVie Inc ABBV decided not to advance the drug into additional studies. CytomX and AbbVie have also concluded their research activities under a 2016 Discovery License and Collaboration ...",ABBV,0.62523,0.10564,Neutral
Best Stocks To Buy Today? 3 Top Dividend Stocks To Watch,https://stockmarket.com/featured/best-stocks-to-buy-today-3-top-dividend-stocks-to-watch-2023-03-28,2023-03-28 14:43:54,Dividend stocks are shares of companies that pay regular dividends to their shareholders as a way to provide them with a return on their investment. These dividends are a portion of the company's profits that are distributed to investors.,ABBV,0.422366,0.115326,Neutral
2 Relatively Safe Dividend Stocks You Won't Regret Owning,https://www.fool.com/investing/2023/03/28/2-relatively-safe-dividend-stocks-you-wont-regret/,2023-03-28 14:07:00,They're both ready to continue paying a dividend that grows year after year.,ABBV,0.21258,0.140359,Neutral
This Is the Best Dividend ETF You Can Buy,https://www.fool.com/investing/2023/03/28/this-is-the-best-dividend-etf-you-can-buy/,2023-03-28 12:13:00,ETFs provide stability and diversification to a portfolio.,ABBV,0.682689,0.805282,Bullish
Council Post: How The Inflation Reduction Act Could Affect The Biopharma Industry,https://www.forbes.com/sites/forbesfinancecouncil/2023/03/28/how-the-inflation-reduction-act-could-affect-the-biopharma-industry/,2023-03-28 11:45:00,Companies are starting to express concerns about the impacts of the IRA on their future sales.,ABBV,0.043898,-0.048761,Neutral
Genmab Announces Appointment of Martine van Vugt to Chief Strategy Officer,https://www.globenewswire.com/news-release/2023/03/28/2635344/0/en/Genmab-Announces-Appointment-of-Martine-van-Vugt-to-Chief-Strategy-Officer.html,2023-03-28 06:00:00,"Media ReleaseCOPENHAGEN, Denmark. March ...",ABBV,0.049732,0.082714,Neutral
AbbVie  ( ABBV )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2071004/abbvie-abbv-stock-sinks-as-market-gains-what-you-should-know,2023-03-27 21:45:23,"In the latest trading session, AbbVie (ABBV) closed at $157.54, marking a -0.3% move from the previous day.",ABBV,0.571903,0.269992,Somewhat-Bullish
CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/03/27/2635245/37704/en/CytomX-Therapeutics-Reports-Full-Year-2022-Financial-Results-and-Provides-Business-Update.html,2023-03-27 20:15:00,- Internal focus on next generation therapeutic pipeline including ongoing Phase 1 for CX-904 ( EGFRxCD3 ) and anticipated IND filings for CX-2051 ( EpCAM-directed ADC ) and CX-801 ( Interferon alpha-2b ) in the second half of ...,ABBV,0.047528,0.055674,Neutral
Is Big Pharma Coming For Your Cannabis Business? - Jazz Pharmaceuticals  ( NASDAQ:JAZZ ) ,https://www.benzinga.com/markets/cannabis/23/03/31515177/is-big-pharma-coming-for-your-cannabis-business,2023-03-27 18:01:33,Cannabis stocks have struggled in the market in recent years as the industry push to gain ground on the regulatory front hasn't progressed as quickly as investors had hoped. Yet pharme companies outside the cannabis industry have been adding or exploring cannabis partnerships and products.,ABBV,0.295867,-0.114833,Neutral
"The Zacks Analyst Blog Highlights Sanofi, Regeneron, AbbVie, Roche and Eli Lilly",https://www.zacks.com/stock/news/2070648/the-zacks-analyst-blog-highlights-sanofi-regeneron-abbvie-roche-and-eli-lilly,2023-03-27 11:41:00,"Sanofi, Regeneron, AbbVie, Roche and Eli Lilly are included in this Analyst Blog.",ABBV,0.40711,0.209044,Somewhat-Bullish
Royalty Pharma Announces $1.0 Billion Share Repurchase Program - Royalty Pharma  ( NASDAQ:RPRX ) ,https://www.benzinga.com/pressreleases/23/03/g31508279/royalty-pharma-announces-1-0-billion-share-repurchase-program,2023-03-27 11:30:00,"NEW YORK, March 27, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that the company's Board of Directors has authorized the repurchase of up to $1.0 billion of the company's Class A ordinary shares.",ABBV,0.03448,0.075808,Neutral
"Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights",https://www.globenewswire.com/news-release/2023/03/27/2634604/0/en/Acumen-Pharmaceuticals-Reports-Financial-Results-for-Full-Year-Ended-December-31-2022-and-Business-Highlights.html,2023-03-27 11:00:00,"CHARLOTTESVILLE, Va. and CARMEL, Ind., March 27, 2023 ( GLOBE NEWSWIRE ) -- Acumen Pharmaceuticals, Inc. ( NASDAQ: ABOS ) , a clinical-stage biopharmaceutical company focused on developing a novel therapeutic that targets toxic soluble amyloid beta oligomers ( AβOs ) and is designed for the ...",ABBV,0.023626,0.074456,Neutral
Better Buy: AbbVie vs. Johnson & Johnson,https://www.fool.com/investing/2023/03/25/better-buy-abbvie-vs-johnson-johnson/,2023-03-25 09:30:00,These pharma giants beat the bear market last year.,ABBV,0.589946,0.189582,Somewhat-Bullish
"Eli Lilly Poised to Nab First to Market Advantage with its IL-23 Inhibitor Mirikizumab in Ulcerative Colitis, Creating an Opportunity to Build a Loyal Base Ahead of AbbVie and Janssen's Respective IL-23 Entries, According to Spherix Global Insights",https://www.prnewswire.com/news-releases/eli-lilly-poised-to-nab-first-to-market-advantage-with-its-il-23-inhibitor-mirikizumab-in-ulcerative-colitis-creating-an-opportunity-to-build-a-loyal-base-ahead-of-abbvie-and-janssens-respective-il-23-entries-according-to-spher-301781226.html,2023-03-24 23:00:00,Eli Lilly Poised to Nab First to Market Advantage with its IL-23 ... PR ...,ABBV,0.07887,0.13921,Neutral
SDNY Federal Judge Relies on NCLA's Amicus Curiae Brief in Key Ruling Limiting Antitrust Liability,https://www.benzinga.com/pressreleases/23/03/g31498535/sdny-federal-judge-relies-on-nclas-amicus-curiae-brief-in-key-ruling-limiting-antitrust-liability,2023-03-24 20:43:53,"Washington, D.C., March 24, 2023 ( GLOBE NEWSWIRE ) -- Today, Judge Lewis J. Liman of the U.S. District Court for the Southern District of New York unsealed an opinion in In re Bystolic Antitrust Litigation, dismissing a major antitrust lawsuit for failing to state a claim against eight ...",ABBV,0.048523,-0.102507,Neutral
"Dow Rises 50 Points; Oxford Industries Shares Plunge - Torrid Holdings  ( NYSE:CURV ) , Allarity Therapeutics  ( NASDAQ:ALLR ) ",https://www.benzinga.com/news/earnings/23/03/31496529/dow-rises-50-points-oxford-industries-shares-plunge,2023-03-24 18:28:21,"U.S. stocks pared some losses toward the end of trading, with the Dow Jones and S&P 500 turning higher on Friday. The Dow traded up 0.16% to 32,156.53 while the NASDAQ fell 0.16% to 11,768.17. The S&P 500, also rose, gaining, 0.21% to 3,956.84. Utilities shares rose by 2.2% on Friday.",ABBV,0.065685,0.0,Neutral
AbbVie  ( ABBV )  Provides Clinical Updates on Inflammatory Drugs,https://www.zacks.com/stock/news/2070329/abbvie-abbv-provides-clinical-updates-on-inflammatory-drugs,2023-03-24 16:56:00,AbbVie???s (ABBV) two studies evaluating Skyrizi in ulcerative colitis and Rinvoq in systemic lupus erythematosus meet their primary endpoints.,ABBV,0.5239,0.267004,Somewhat-Bullish
"Crude Oil Down 1%; US Composite PMI Jumps In March - Torrid Holdings  ( NYSE:CURV ) , Allarity Therapeutics  ( NASDAQ:ALLR ) ",https://www.benzinga.com/news/earnings/23/03/31494297/crude-oil-down-1-us-composite-pmi-jumps-in-march,2023-03-24 16:04:06,"U.S. stocks traded lower midway through trading, with the Dow Jones dropping around 80 points on Friday. The Dow traded down 0.26% to 32,021.81 while the NASDAQ fell 0.41% to 11,739.58. The S&P 500, also fell, dropping, 0.23% to 3,939.65. Utilities shares rose by 1.7% on Friday.",ABBV,0.067347,0.0,Neutral
"Dow Down 150 Points; US Durable Goods Orders Drop In February - ADMA Biologics  ( NASDAQ:ADMA ) , Torrid Holdings  ( NYSE:CURV ) ",https://www.benzinga.com/news/earnings/23/03/31491562/dow-down-150-points-us-durable-goods-orders-drop-in-february,2023-03-24 13:47:45,"U.S. stocks traded lower this morning, with the Dow Jones dropping around 150 points on Friday. Following the market opening Friday, the Dow traded down 0.50% to 31,944.01 while the NASDAQ fell 0.52% to 11,726.02. The S&P 500, also fell, dropping, 0.53% to 3,927.90.",ABBV,0.070105,0.0,Neutral
"Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL",https://www.zacks.com/stock/news/2070094/pharma-stock-roundup-snys-copd-study-meets-goal-abbv-parkinsons-drug-gets-crl,2023-03-24 13:04:00,"Sanofi's (SNY) Dupixent succeeds in a pivotal study for COPD. FDA gives CRL to AbbVie's (ABBV) Parkinson's disease therapy, ...",ABBV,0.372216,0.221569,Somewhat-Bullish
"This Delivery Giant Is A 'Comeback Story' Plus Nike, AbbVie And Oracle: CNBC's 'Final Trades' - AbbVie  ( NYSE:ABBV ) , FedEx  ( NYSE:FDX ) ",https://www.benzinga.com/trading-ideas/long-ideas/23/03/31487103/this-delivery-giant-is-a-comeback-story-plus-nike-abbvie-and-oracle-cnbcs-final-trades,2023-03-24 12:37:14,"On CNBC's ""Halftime Report Final Trades,"" Bryn Talkington of Requisite Capital Management named AbbVie Inc. ABBV as her final trade. Joshua Brown of Ritholtz Wealth Management said Oracle Corporation ORCL is pennies away from a 52-week high. ""I think it will break out,"" he added.",ABBV,0.360752,0.0,Neutral
AbbVie Unusual Options Activity - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/03/31483124/abbvie-unusual-options-activity,2023-03-23 20:31:03,"A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 16 strange trades. If we consider the specifics of each trade, it is accurate to state that 12% of the investors opened trades with bullish expectations ...",ABBV,0.733479,0.05813,Neutral
"NEI sets human rights, inequality, net zero, nature as focus themes for corporate engagement",https://www.newswire.ca/news-releases/nei-sets-human-rights-inequality-net-zero-nature-as-focus-themes-for-corporate-engagement-847177464.html,2023-03-23 20:30:00,"NEI sets human rights, inequality, net zero, nature as focus themes ... Canada ...",ABBV,0.038655,-0.011913,Neutral
"NEI sets human rights, inequality, net zero, nature as focus themes for corporate engagement",https://www.benzinga.com/pressreleases/23/03/n31483109/nei-sets-human-rights-inequality-net-zero-nature-as-focus-themes-for-corporate-engagement,2023-03-23 20:30:00,"Focus theme topics include digital rights, human capital, reducing methane emissions, and deforestation 40 companies identified for engagement include Apple, Meta, Johnson & Johnson, Lowe's, Microsoft, NextEra Energy, Taiwan Semiconductor, and Canada's banks",ABBV,0.036926,-0.011876,Neutral
"These 3 Dividend Growers Yield More Than The 10-Year Note - Kimberly-Clark  ( NYSE:KMB ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/news/23/03/31474732/these-3-dividend-growers-yield-more-than-the-10-year-note,2023-03-23 17:21:03,"Backed by the U.S. government, the closely watched 10-year Treasury note offers a high degree of safety that stocks and other investments can't match. What they no longer offer, however, is a 4% annualized interest rate. Since the Silicon Valley Bank collapse, Treasury rates have been in a ...",ABBV,0.182851,0.192395,Somewhat-Bullish
2 High-Yield Dividend Stocks You Won't Regret Buying Right Now,https://www.fool.com/investing/2023/03/23/2-high-yield-dividend-stocks-you-wont-regret-buyin/,2023-03-23 14:00:00,These two blue-chip dividend stocks offer investors a reliable income stream in a volatile market.,ABBV,0.284861,0.070739,Neutral
AbbVie  ( ABBV )  Gets FDA Rejection for Parkinson's Candidate,https://www.zacks.com/stock/news/2069633/abbvie-abbv-gets-fda-rejection-for-parkinsons-candidate,2023-03-23 13:51:00,"In the CRL, the FDA asks AbbVie (ABBV) for some extra information about the pump device used to administer the Parkinson's disease medicine, ABBV-951.",ABBV,0.713878,0.448489,Bullish
AbbVie Advances Upadacitinib to Phase 3 Clinical Trials in Systemic Lupus Erythematosus - Investing News Network,https://investingnews.com/abbvie-advances-upadacitinib-to-phase-3-clinical-trials-in-systemic-lupus-erythematosus/,2023-03-23 13:38:12,AbbVie Advances Upadacitinib to Phase 3 Clinical Trials in Systemic Lupus Erythematosus Investing News Network ...,ABBV,0.332883,0.118767,Neutral
Risankizumab Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis,https://investingnews.com/risankizumab-achieves-primary-and-all-secondary-endpoints-in-phase-3-induction-study-in-patients-with-ulcerative-colitis/,2023-03-23 13:05:51,"ABBVie ( NYSE: ABBV ) today announced positive top-line results from INSPIRE, a Phase 3 induction study, showing risankizumab ( SKYRIZI ® ,1200 mg intravenous [IV], at weeks 0, 4 and 8 ) met the primary endpoint of clinical remission ( per Adapted Mayo Score ) at week 12, as well as all ...",ABBV,0.25168,0.153284,Somewhat-Bullish
Biopharmaceuticals Market Growth: Worth $700Bn by 2028 Led by Monoclonal Antibodies Held Market Share of 48.42% in 2022 | The Insight Partners,https://www.benzinga.com/pressreleases/23/03/g31473568/biopharmaceuticals-market-growth-worth-700bn-by-2028-led-by-monoclonal-antibodies-held-market-shar,2023-03-23 12:46:11,"New York, March 23, 2023 ( GLOBE NEWSWIRE ) -- According to The Insight Partners, ""Biopharmaceuticals Market Size, Share, Trends, Growth and Report Forecasts to 2028 - COVID-19 Impact and Global Analysis By Product Type ( Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, ...",ABBV,0.108303,0.139637,Neutral
"Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million - Royalty Pharma  ( NASDAQ:RPRX ) , PureTech Health  ( NASDAQ:PRTC ) ",https://www.benzinga.com/pressreleases/23/03/g31471098/royalty-pharma-and-puretech-health-enter-into-karxt-royalty-agreement-for-up-to-500-million,2023-03-23 11:00:00,Royalty Pharma has acquired an interest in PureTech's royalty in Karuna Therapeutics' KarXT; Royalty Pharma and PureTech will share in royalties above certain annual sales thresholds PureTech retains its current equity stake in Karuna in addition to milestone payments and 20% of sublicense ...,ABBV,0.022494,0.071121,Neutral
"Use These 3 Strategies to Make $1,000 in Passive Income Per Year",https://www.fool.com/investing/2023/03/23/use-these-3-strategies-to-make-1000-in-passive-inc/,2023-03-23 10:15:00,It's worth having these approaches in your investor toolkit.,ABBV,0.091509,0.097744,Neutral
"2 Reasons to Buy AbbVie, and 1 Reason to Sell",https://www.fool.com/investing/2023/03/23/2-reasons-to-buy-abbvie-and-1-reason-to-sell/,2023-03-23 09:30:00,AbbVie shares rose in the double digits last year.,ABBV,0.760593,0.385082,Bullish
Sosei Heptares Confirms Changes to its Board and Executive Management Team at Annual Shareholders' Meeting,https://www.globenewswire.com/news-release/2023/03/23/2632841/0/en/Sosei-Heptares-Confirms-Changes-to-its-Board-and-Executive-Management-Team-at-Annual-Shareholders-Meeting.html,2023-03-23 07:00:00,"Tokyo, Japan and Cambridge, UK, 23 March 2023 - Sosei Group Corporation ( ""the Company"". TSE: 4565 ) , the world leader in G protein-coupled receptor ( GPCR ) focused structure-based drug design ( SBDD ) and development, announces the election of Ms. Eiko Tomita to the Board of Directors as an ...",ABBV,0.038969,0.041254,Neutral
Sosei Heptares Confirms Changes to its Board and Executive Management Team at Annual Shareholders' Meeting,https://www.benzinga.com/pressreleases/23/03/g31469178/sosei-heptares-confirms-changes-to-its-board-and-executive-management-team-at-annual-shareholders-,2023-03-23 07:00:00,"Eiko Tomita, Vice President, Global Regulatory Affairs at Bristol Myers Squibb, elected to the Company's Board of Directors Candelle Chong promoted to Executive Vice President and Chief of Staff, previously Senior Vice President, Corporate Strategy",ABBV,0.037622,0.038154,Neutral
"CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023 - CytomX Therapeutics  ( NASDAQ:CTMX ) ",https://www.benzinga.com/pressreleases/23/03/g31466980/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-27-2023,2023-03-22 23:23:33,"SOUTH SAN FRANCISCO, Calif., March 22, 2023 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. CTMX, a leader in the field of conditionally activated, localized biologics, today announced that it will report full year 2022 financial results on Monday, March 27, 2023, after the close of U.S. markets.",ABBV,0.172097,-0.036731,Neutral
"CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023",https://www.globenewswire.com/news-release/2023/03/22/2632792/37704/en/CytomX-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2022-Financial-Results-on-March-27-2023.html,2023-03-22 23:23:00,"SOUTH SAN FRANCISCO, Calif., March 22, 2023 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. ( Nasdaq: CTMX ) , a leader in the field of conditionally activated, localized biologics, today announced that it will report full year 2022 financial results on Monday, March 27, 2023, after the close of ...",ABBV,0.184598,-0.041876,Neutral
3 Key Ways That Artificial Intelligence Will Disrupt Biotech Stocks,https://www.fool.com/investing/2023/03/22/3-key-ways-artificial-intelligence-will-disrupt/,2023-03-22 14:23:00,Biotechs with an AI strategy are likely to be the first to flourish from the disruptions.,ABBV,0.047092,0.038909,Neutral
AbbVie Provides Regulatory Update On Parkinson's Disease Drug Candidate - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/news/23/03/31457862/abbvie-provides-regulatory-update-on-parkinsons-disease-drug-candidate,2023-03-22 14:22:14,AbbVie Inc ABBV provided a regulatory update on its New Drug Application ( NDA ) for ABBV-951 Wednesday morning. What To Know: AbbVie said it received a response from the U.S. Food and Drug Administration ( FDA ) on its NDA for the treatment of motor fluctuations in adults with advanced ...,ABBV,0.945142,0.224343,Somewhat-Bullish
Thinking of Buying Biotech Stocks? Do These 3 Things First,https://www.fool.com/investing/2023/03/22/thinking-of-biotech-stocks-do-these-3-things-first/,2023-03-22 14:15:00,It's better to plan ahead than to get caught by surprise.,ABBV,0.060694,-0.015045,Neutral
Price Over Earnings Overview: AbbVie - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/news/23/03/31456778/price-over-earnings-overview-abbvie,2023-03-22 13:32:54,"Looking into the current session, AbbVie Inc. ABBV shares are trading at $156.85, after a 0.05% increase. Moreover, over the past month, the stock went up by 4.05%, but in the past year, fell by 2.18%.",ABBV,0.342487,-0.044331,Neutral
US FDA declines to approve AbbVie's Parkinson's disease therapy,https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-abbvies-parkinsons-disease-therapy-2023-03-22/,2023-03-22 13:21:00,March 22 ( Reuters ) - AbbVie Inc ( ABBV.N ) said on Wednesday the U.S. Food and Drug Administration had declined to approve its Parkinson's disease therapy for adults.,ABBV,0.615462,-0.089228,Neutral
AbbVie Provides Regulatory Update on ABBV-951 New Drug Application,https://investingnews.com/abbvie-provides-regulatory-update-on-abbv-951-new-drug-application/,2023-03-22 13:01:48,ABBVie ( NYSE: ABBV ) today announced it received a Complete Response Letter ( CRL ) from the U.S. Food and Drug Administration ( FDA ) for the New Drug Application ( NDA ) for ABBV-951 ( foscarbidopafoslevodopa ) for the treatment of motor fluctuations in adults with advanced Parkinson's disease.,ABBV,0.882069,0.376143,Bullish
AbbVie Inc.  ( ABBV )  Is a Trending Stock: Facts to Know Before Betting on It,https://www.zacks.com/stock/news/2068961/abbvie-inc-abbv-is-a-trending-stock-facts-to-know-before-betting-on-it,2023-03-22 13:00:13,"Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",ABBV,0.488469,0.092671,Neutral
3 Things About Johnson & Johnson Smart Investors Know,https://www.fool.com/investing/2023/04/10/things-about-johnson-johnson-smart-investors-know/,2023-04-10 15:39:37,The healthcare giant's stock is looking like less of a safe bet than it was in the past.,ABBV,0.044304,0.025984,Neutral
"AbbVie  ( ABBV ) , J&J to Withdraw 2 Blood Cancer Nods for Imbruvica",https://www.zacks.com/stock/news/2076361/abbvie-abbv-jj-to-withdraw-2-blood-cancer-nods-for-imbruvica,2023-04-10 15:03:00,AbbVie (ABBV)/J&J's (JNJ) decision to withdraw the FDA's accelerated approval for Imbruvica in two blood cancer treatments is based on confirmatory studies data that do not support full approval.,ABBV,0.368773,0.213726,Somewhat-Bullish
Anima Biotech to Present at the 4th Annual RNA-Targeting Small Molecule Drugs hosted by CHI as part of the 18th Annual Drug Discovery Event,https://www.benzinga.com/pressreleases/23/04/g31727306/anima-biotech-to-present-at-the-4th-annual-rna-targeting-small-molecule-drugs-hosted-by-chi-as-par,2023-04-10 14:17:00,"BERNARDSVILLE, N.J., April 10, 2023 ( GLOBE NEWSWIRE ) -- Anima Biotech, the leader in the discovery of small molecule mRNA drugs and their mechanisms of action by phenotypic screening with AI driven MOA elucidation, today announced the company will give a presentation during the 18th Annual ...",ABBV,0.095899,0.060147,Neutral
Is Invesco Dynamic Pharmaceuticals ETF  ( PJP )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2076050/is-invesco-dynamic-pharmaceuticals-etf-pjp-a-strong-etf-right-now,2023-04-10 10:20:09,Smart Beta ETF report for ...,ABBV,0.11894,0.060738,Neutral
5 High-Yield Dividend Stocks in Warren Buffett's Secret Portfolio You Can Buy Right Now,https://www.fool.com/investing/2023/04/10/high-yield-dividend-stocks-warren-buffett-buy-now/,2023-04-10 09:52:00,The dividend yields for these Buffett stocks range from 3.7% to 10.6%.,ABBV,0.297301,0.199752,Somewhat-Bullish
AbbVie plans to pull US accelerated approvals for some blood cancer treatments,https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-plans-pull-us-accelerated-approvals-some-blood-cancer-treatments-2023-04-06/,2023-04-06 22:06:00,AbbVie plans to pull US accelerated approvals for some blood ... ...,ABBV,0.194242,-0.099091,Neutral
"AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors",https://www.globenewswire.com/news-release/2023/04/06/2642996/0/en/AnaptysBio-Announces-Appointment-of-Rita-Jain-M-D-to-Board-of-Directors.html,2023-04-06 20:15:00,"SAN DIEGO, April 06, 2023 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the appointment of Rita Jain, M.D., to the company's Board of Directors, effective immediately.",ABBV,0.040484,-0.085299,Neutral
"AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors - AnaptysBio  ( NASDAQ:ANAB ) ",https://www.benzinga.com/pressreleases/23/04/g31705743/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors,2023-04-06 20:15:00,"SAN DIEGO, April 06, 2023 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ANAB, a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the appointment of Rita Jain, M.D., to the company's Board of Directors, effective immediately.",ABBV,0.039353,-0.085043,Neutral
Build a Unique Portfolio with 3 Top Ranked ETFs,https://www.zacks.com/commentary/2075769/build-a-unique-portfolio-with-3-top-ranked-etfs,2023-04-06 19:38:00,The universe of ETFs these days is practically as diverse as the whole stock market ...,ABBV,0.099683,0.068892,Neutral
"AbbVie, Thermo Fisher Scientific And A Must-Watch Biotech ETF: CNBC's 'Final Trades' - iShares Biotechnology ETF  ( NASDAQ:IBB ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/trading-ideas/long-ideas/23/04/31690986/abbvie-thermo-fisher-scientific-and-a-must-watch-biotech-etf-cnbcs-final-trades,2023-04-06 12:49:24,"On CNBC's ""Halftime Report Final Trades,"" Bryn Talkington of Requisite Capital Management said she is sticking with AbbVie Inc. ABBV, which has a 7.3% free cash flow yield and a dividend of over 3%. They innovate in immunology and oncology, she added.",ABBV,0.781119,0.459266,Bullish
Johnson & Johnson  ( JNJ )  Soars 4.5%: Is Further Upside Left in the Stock?,https://www.zacks.com/stock/news/2075276/johnson-johnson-jnj-soars-45-is-further-upside-left-in-the-stock,2023-04-06 08:05:00,Johnson & Johnson (JNJ) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.,ABBV,0.390396,0.0,Neutral
AbbVie signals Q1 hit from R&D expenses,https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-signals-q1-hit-rd-expenses-2023-04-05/,2023-04-05 20:59:01,April 5 ( Reuters ) - AbbVie Inc ( ABBV.N ) said on Wednesday it expects first-quarter earnings to be hit by acquired in-process research and development ( IPR&D ) and milestones expenses.,ABBV,0.504646,0.0,Neutral
Better Dividend Stock: AbbVie vs. Johnson & Johnson,https://www.fool.com/investing/2023/04/05/better-dividend-stock-abbvie-vs-johnson-johnson/,2023-04-05 12:55:00,Both companies have a lot to offer income-seekers.,ABBV,0.457977,0.436571,Bullish
Want to Collect Big Dividends Each Month? Buy These 3 Stocks,https://www.fool.com/investing/2023/04/05/want-collect-big-dividends-month-buy-these-stocks/,2023-04-05 10:10:00,These stocks could provide your portfolio with a reliable foundation for growing passive income.,ABBV,0.175009,0.037388,Neutral
Oncternal  ( ONCT )  Down on Restructuring Plan to Extend Runway,https://www.zacks.com/stock/news/2074388/oncternal-onct-down-on-restructuring-plan-to-extend-runway,2023-04-04 16:02:00,Oncternal (ONCT) closes the development program for zilovertamab to extend its cash runway into 2025. Shares are down on the same.,ABBV,0.062761,0.095187,Neutral
Overactive Bladder Treatment Market Is Expected to Generate $3.5 Billion by 2031: Allied Market Research,https://www.benzinga.com/pressreleases/23/04/g31659799/overactive-bladder-treatment-market-is-expected-to-generate-3-5-billion-by-2031-allied-market-rese,2023-04-04 15:09:40,"Portland, OR, April 04, 2023 ( GLOBE NEWSWIRE ) -- According to the report published by Allied Market Research, the global Overactive Bladder Treatment Market garnered $2.4 billion in 2021, and is estimated to generate $3.5 billion by 2031, manifesting a CAGR of 3.6% from 2022 to 2031.",ABBV,0.034087,-0.042407,Neutral
3 Top Healthcare Stocks to Buy for April,https://www.fool.com/investing/2023/04/04/3-top-healthcare-stocks-to-buy-for-april/,2023-04-04 13:12:00,"These pharmaceutical companies' shares are down, but their prospects are rising.",ABBV,0.030331,0.196409,Somewhat-Bullish
Carisma Therapeutics Reports Fiscal 2022 Financial Results and Recent Business Highlights,https://www.prnewswire.com/news-releases/carisma-therapeutics-reports-fiscal-2022-financial-results-and-recent-business-highlights-301789029.html,2023-04-04 12:30:00,Carisma Therapeutics Reports Fiscal 2022 Financial Results and ... PR ...,ABBV,0.021293,0.0,Neutral
AbbVie to Host First-Quarter 2023 Earnings Conference Call - Investing News Network,https://investingnews.com/abbvie-to-host-first-quarter-2023-earnings-conference-call/,2023-04-04 12:27:13,AbbVie to Host First-Quarter 2023 Earnings Conference Call Investing News Network ...,ABBV,0.929273,0.426692,Bullish
AbbVie  ( ABBV )  Outpaces Stock Market Gains: What You Should Know,https://www.zacks.com/stock/news/2073976/abbvie-abbv-outpaces-stock-market-gains-what-you-should-know,2023-04-03 21:45:19,"AbbVie (ABBV) closed at $160.42 in the latest trading session, marking a +0.66% move from the prior day.",ABBV,0.624172,0.291231,Somewhat-Bullish
This Is What Whales Are Betting On AbbVie - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/04/31639651/this-is-what-whales-are-betting-on-abbvie,2023-04-03 17:16:01,"A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 12 strange trades. If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish expectations ...",ABBV,0.818966,0.230709,Somewhat-Bullish
AbbVie Inc.  ( ABBV )  is Attracting Investor Attention: Here is What You Should Know,https://www.zacks.com/stock/news/2073638/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know,2023-04-03 13:00:15,"AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",ABBV,0.487546,0.119859,Neutral
CoolSculpting® Elite Announces First Ever CoolMonth - Investing News Network,https://investingnews.com/coolsculpting-r-elite-announces-first-ever-coolmonth/,2023-04-03 12:40:33,CoolSculpting® Elite Announces First Ever CoolMonth Investing News Network ...,ABBV,0.100518,0.079514,Neutral
Sandoz receives approval by European Commission for Hyrimoz®  ( adalimumab )  high-concentration formulation,https://www.globenewswire.com/news-release/2023/04/03/2639458/0/en/Sandoz-receives-approval-by-European-Commission-for-Hyrimoz-adalimumab-high-concentration-formulation.html,2023-04-03 11:33:00,"Basel, April 3, 2023 - Sandoz, a global leader in off-patent ( generic and biosimilar ) medicines, today announced that the European Commission ( EC ) granted marketing authorization in the European Union ( EU ) for a citrate-free high concentration formulation ( HCF.",ABBV,0.036587,0.0,Neutral
"These 5 High-Yield Dividend Stocks Should Make Me $3,000 in Passive Income This Year",https://www.fool.com/investing/2023/04/02/high-yield-dividend-stocks-passive-income/,2023-04-02 09:50:00,The dividends should increase for several of these stocks.,ABBV,0.210579,0.138058,Neutral
Could This Drug News Lift AbbVie's Stock?,https://www.fool.com/investing/2023/04/01/could-this-drug-news-lift-abbvies-stock/,2023-04-01 13:15:00,"Alongside Skyrizi, the immunology medicine is part of AbbVie's bright post-Humira future.",ABBV,0.558244,0.168319,Somewhat-Bullish
Engine Sputtering: Tesla's Disappointing Quarter Weighs On Market As Recession Fears Grow - Tesla  ( NASDAQ:TSLA ) ,https://www.benzinga.com/markets/23/04/31921533/engine-sputtering-teslas-disappointing-quarter-weighs-on-market-as-recession-fears-grow,2023-04-20 17:53:49,"( Thursday market open ) Disappointing earnings from Tesla TSLA set the tone this morning, helping send major indexes lower overnight. Overall, the hot start to earnings season cooled over the last few days, though there have been some positive highlights.",ABBV,0.039977,-0.066672,Neutral
Roche  ( RHHBY )  Polivy Combination for DLBCL Gets Full Approval,https://www.zacks.com/stock/news/2082387/roche-rhhby-polivy-combination-for-dlbcl-gets-full-approval,2023-04-20 17:50:00,"Roche (RHHBY) gets full approval for Polivy (polatuzumab vedotin-piiq) in combination with Rituxan, cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of adult patients who have previously untreated DLBCL.",ABBV,0.071357,0.0,Neutral
Earnings Preview: AbbVie  ( ABBV )  Q1 Earnings Expected to Decline,https://www.zacks.com/stock/news/2082185/earnings-preview-abbvie-abbv-q1-earnings-expected-to-decline,2023-04-20 14:02:31,AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,ABBV,0.301315,-0.031395,Neutral
"Citigroup, Dell And 2 Other Stocks Insiders Are Selling - Citigroup  ( NYSE:C ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/news/23/04/31912024/citigroup-dell-and-2-other-stocks-insiders-are-selling,2023-04-20 12:23:32,"The S&P 500 closed almost flat on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it indicates their concern in the company's prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the ...",ABBV,0.366061,0.273586,Somewhat-Bullish
Asembia's AXS23 Summit: The Epicenter of the Expanding Pharmacy Market,https://www.prnewswire.com/news-releases/asembias-axs23-summit-the-epicenter-of-the-expanding-pharmacy-market-301802503.html,2023-04-20 12:15:00,Asembia's AXS23 Summit: The Epicenter of the Expanding ... PR ...,ABBV,0.099066,0.251673,Somewhat-Bullish
"Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset",https://www.globenewswire.com/news-release/2023/04/20/2650876/0/en/Blue-Water-Announces-Acquisition-of-ENTADFI-an-FDA-Approved-Benign-Prostatic-Hyperplasia-Asset.html,2023-04-20 11:30:00,Acquisition Transforms the Company into a Broader Pharmaceutical Company Spanning Multiple Sectors ...,ABBV,0.04045,0.040901,Neutral
"Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset - Blue Water Vaccines  ( NASDAQ:BWV ) ",https://www.benzinga.com/pressreleases/23/04/g31910548/blue-water-announces-acquisition-of-entadfi-an-fda-approved-benign-prostatic-hyperplasia-asset,2023-04-20 11:30:00,"Acquisition Transforms the Company into a Broader Pharmaceutical Company Spanning Multiple Sectors Company Announces Corporate Name Change to Underscore Broader Focus Company to Host a Conference call Today, April 20th, at 8:30am EDT to Discuss Asset Purchase and Company Transformation",ABBV,0.038253,0.040608,Neutral
Sarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality Officer - Alvotech  ( NASDAQ:ALVO ) ,https://www.benzinga.com/pressreleases/23/04/g31903863/sarah-tanksley-joins-board-of-directors-for-alvotech-hf-and-sandra-casaca-appointed-chief-quality-,2023-04-19 21:30:00,"REYKJAVIK, Iceland, April 19, 2023 ( GLOBE NEWSWIRE ) -- Alvotech ALVO, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced changes to the company's Quality unit.",ABBV,0.066414,0.085145,Neutral
Sarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality Officer,https://www.globenewswire.com/news-release/2023/04/19/2650589/0/en/Sarah-Tanksley-Joins-Board-of-Directors-for-Alvotech-hf-and-Sandra-Casaca-Appointed-Chief-Quality-Officer.html,2023-04-19 21:30:00,"Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced changes to the company's Quality unit. Sandra Casaca has been appointed Chief Quality Officer of Alvotech and Sarah Tanksley will be ...",ABBV,0.028089,0.078191,Neutral
Sarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality Officer,https://www.globenewswire.com/news-release/2023/04/19/2650588/0/en/Sarah-Tanksley-Joins-Board-of-Directors-for-Alvotech-hf-and-Sandra-Casaca-Appointed-Chief-Quality-Officer.html,2023-04-19 21:30:00,"REYKJAVIK, Iceland, April 19, 2023 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced changes to the company's Quality unit.",ABBV,0.027925,0.078123,Neutral
[Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche's Polivy in combination with R-CHP for people with certain types of previously untreated diffuse large B-cell lymphoma,https://www.globenewswire.com/news-release/2023/04/19/2650484/0/en/Ad-hoc-announcement-pursuant-to-Art-53-LR-FDA-approves-Roche-s-Polivy-in-combination-with-R-CHP-for-people-with-certain-types-of-previously-untreated-diffuse-large-B-cell-lymphoma.html,2023-04-19 19:30:00,"Basel, 19 April 2023 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today that the U.S. Food and Drug Administration ( FDA ) has approved Polivy® ( polatuzumab vedotin-piiq ) in combination with Rituxan® ( rituximab ) , cyclophosphamide, doxorubicin and prednisone ( R-CHP ) for the treatment of ...",ABBV,0.025325,0.06572,Neutral
Is Merck Stock a Screaming Buy After This $11 Billion Acquisition?,https://www.fool.com/investing/2023/04/19/is-merck-stock-a-screaming-buy-after-this-11-billi/,2023-04-19 14:45:00,Merck's move into immunology is a risky proposition.,ABBV,0.282234,0.0,Neutral
AbbVie  ( ABBV )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2080713/abbvie-abbv-stock-sinks-as-market-gains-what-you-should-know,2023-04-18 21:45:21,"In the latest trading session, AbbVie (ABBV) closed at $159.59, marking a -0.99% move from the previous day.",ABBV,0.673811,0.235198,Somewhat-Bullish
Harpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023,https://www.globenewswire.com/news-release/2023/04/18/2649471/0/en/Harpoon-Therapeutics-Presents-Preclinical-Results-for-Novel-T-Cell-Engagers-HPN217-and-HPN328-at-AACR-2023.html,2023-04-18 17:30:00,"SOUTH SAN FRANCISCO, Calif., April 18, 2023 ( GLOBE NEWSWIRE ) -- Harpoon Therapeutics, Inc. ( Nasdaq: HARP ) , a clinical-stage immuno-oncology company developing novel T cell engagers, today presented preclinical data for two of its key clinical programs, HPN328 and HPN217, in three poster ...",ABBV,0.052627,0.178648,Somewhat-Bullish
FDA Expands AbbVie's  ( ABBV )  Qulipta Label in Chronic Migraine,https://www.zacks.com/stock/news/2080652/fda-expands-abbvies-abbv-qulipta-label-in-chronic-migraine,2023-04-18 16:12:00,"Following FDA's label-expansion approval, AbbVie's (ABBV) Qulipta is the first and the only oral CGRP receptor antagonist approved to prevent episodic and chronic migraines.",ABBV,0.436009,0.202984,Somewhat-Bullish
Jim Cramer's top 10 things to watch in the stock market Tuesday,https://www.cnbc.com/2023/04/18/jim-cramers-top-10-things-to-watch-in-the-stock-market-tuesday.html,2023-04-18 13:20:51,"The Dow, the S&P 500 and the Nasdaq are set to open higher on strong J&J and BofA earnings.",ABBV,0.108712,-0.035255,Neutral
U.S. FDA Approves QULIPTA® for Adults With Chronic Migraine,https://investingnews.com/u-s-fda-approves-qulipta-r-for-adults-with-chronic-migraine/,2023-04-18 00:14:27,AbbVie ( NYSE: ABBV ) today announced that the U.S. Food and Drug Administration ( FDA ) has approved expanding the indication of QULIPTA ® ( atogepant ) for the preventive treatment of migraine in adults.,ABBV,0.120376,0.042733,Neutral
Merck's takeover of Prometheus gives it a foothold in immunology,https://www.marketwatch.com/story/mercks-10-8-billion-takeover-of-prometheus-is-a-good-strategic-move-that-gives-it-a-foothold-in-immunology-2f922a41,2023-04-17 16:19:00,Merck's acquisition of Prometheus Biosciences will help the drug company diversify and reduce the risk of overreliance on its cancer drug Keytruda.,ABBV,0.118064,0.0,Neutral
AbbVie Announces Provincial Reimbursement for VRAYLAR® for the Treatment of Schizophrenia in Québec,https://investingnews.com/abbvie-announces-provincial-reimbursement-for-vraylar-r-for-the-treatment-of-schizophrenia-in-quebec/,2023-04-17 12:45:57,"AbbVie ( NYSE: ABBV ) , today announced that VRAYLAR is now listed as an exception medication status on the list of medications of the Régie de l'assurance maladie du Québec ( RAMQ ) 1 for the treatment of schizophrenia.",ABBV,0.570165,0.249407,Somewhat-Bullish
Royalty Pharma Declares Second Quarter 2023 Dividend,https://www.globenewswire.com/news-release/2023/04/17/2647910/0/en/Royalty-Pharma-Declares-Second-Quarter-2023-Dividend.html,2023-04-17 12:15:00,"NEW YORK, April 17, 2023 ( GLOBE NEWSWIRE ) -- The board of directors of Royalty Pharma plc ( Nasdaq: RPRX ) has approved the payment of a dividend for the second quarter of 2023 of $0.20 per Class A ordinary share.",ABBV,0.165031,0.105018,Neutral
Royalty Pharma Declares Second Quarter 2023 Dividend - Royalty Pharma  ( NASDAQ:RPRX ) ,https://www.benzinga.com/pressreleases/23/04/g31828192/royalty-pharma-declares-second-quarter-2023-dividend,2023-04-17 12:15:00,"NEW YORK, April 17, 2023 ( GLOBE NEWSWIRE ) -- The board of directors of Royalty Pharma plc RPRX has approved the payment of a dividend for the second quarter of 2023 of $0.20 per Class A ordinary share. The dividend will be paid on June 15, 2023, to shareholders of record at the close of ...",ABBV,0.156461,0.101458,Neutral
3 Stocks You Can Keep Forever,https://www.fool.com/investing/2023/04/16/3-stocks-you-can-keep-forever/,2023-04-16 14:15:00,Three solid profitable companies that are growing their businesses and their dividends.,ABBV,0.279471,0.099122,Neutral
3 Reasons Why I Regret Selling AbbVie,https://www.fool.com/investing/2023/04/16/3-reasons-why-i-regret-selling-abbvie/,2023-04-16 11:45:00,Having the knowledge to stay steady in your convictions can be a game changer.,ABBV,0.40638,0.047774,Neutral
"A Beauty Treatment Promised to Zap Fat. For Some, It Brought Disfigurement.",https://www.nytimes.com/2023/04/16/style/coolsculpting-side-effect-risks.html,2023-04-16 07:00:20,CoolSculpting is among the most popular fixes for unwanted bulges. But the risk of a serious side effect appears to be higher than previously known.,ABBV,0.030563,0.04345,Neutral
"A Beauty Treatment Promised to Zap Fat. For Some, It Brought Disfigurement.",https://www.nytimes.com/2023/04/16/health/coolsculpting-side-effect-risks.html,2023-04-16 07:00:19,CoolSculpting is among the most popular fixes for unwanted bulges. But the risk of a serious side effect appears to be higher than previously known.,ABBV,0.030563,0.04345,Neutral
Does an FDA Fast Track Designation Make Regenxbio Stock a Buy Now?,https://www.fool.com/investing/2023/04/15/does-an-fda-fast-track-designation-make-regenxbio/,2023-04-15 12:20:00,The company focuses on using its technology for gene-editing therapies.,ABBV,0.146618,0.093241,Neutral
"AbbVie  ( NYSE:ABBV )  Upgraded by StockNews.com to ""Strong-Buy""",https://www.defenseworld.net/2023/04/15/abbvie-nyseabbv-upgraded-by-stocknews-com-to-strong-buy.html,2023-04-15 10:52:43,StockNews.com upgraded shares of AbbVie ( NYSE:ABBV - Get Rating ) from a buy rating to a strong-buy rating in a report issued on Friday.,ABBV,0.825621,0.364436,Bullish
3 Dividend Stocks to Buy and Hold for the Next Decade,https://www.fool.com/investing/2023/04/15/3-dividend-stocks-to-buy-and-hold-for-the-next-dec/,2023-04-15 10:14:00,Long-term investors looking for income should especially like these stocks.,ABBV,0.324673,0.093828,Neutral
Lilly's  ( LLY )  Ulcerative Colitis Candidate Gets CRL from FDA,https://www.zacks.com/stock/news/2079035/lillys-lly-ulcerative-colitis-candidate-gets-crl-from-fda,2023-04-14 15:33:00,"The FDA rejects Eli Lilly's (LLY) regulatory filing seeking approval for mirikizumab to treat ulcerative colitis indication, citing issues related to the drug's proposed manufacturing.",ABBV,0.172919,0.21675,Somewhat-Bullish
FDA Strikes Down Eli Lilly's Application Seeking Approval For Ulcerative Colitis Drug - Eli Lilly  ( NYSE:LLY ) ,https://www.benzinga.com/general/biotech/23/04/31803789/fda-strikes-down-eli-lillys-application-seeking-approval-for-ulcerative-colitis-drug,2023-04-14 13:33:50,"The FDA has issued a complete response letter for Eli Lilly And Co's LLY mirikizumab biologic license application ( BLA ) for ulcerative colitis ( UC ) . In the letter, the FDA cited issues related to the proposed manufacturing of mirikizumab, with no concerns about the clinical data ...",ABBV,0.277433,0.0,Neutral
J&J  ( JNJ )  to Initiate Q1 Earnings Season for Pharma Sector,https://www.zacks.com/stock/news/2078827/jj-jnj-to-initiate-q1-earnings-season-for-pharma-sector,2023-04-14 13:15:00,"Growth in J&J's (JNJ) Pharma unit is expected to have been driven by drugs like Darzalex and Stelara. In the MedTech segment, continued recovery in worldwide procedure volume should drive sales.",ABBV,0.247838,0.065892,Neutral
"Pharma Stock Roundup: FDA Rejects LLY's Mirikizumab, NVO Ups 2023 Sales & Profit View",https://www.zacks.com/stock/news/2078816/pharma-stock-roundup-fda-rejects-llys-mirikizumab-nvo-ups-2023-sales-profit-view,2023-04-14 13:05:00,FDA issues CRL to Eli Lilly's (LLY) BLA seeking approval of mirikizumab for ulcerative colitis (UC). Novo Nordisk (NVO) ups sales and profit outlook for 2023.,ABBV,0.18046,0.068674,Neutral
Here is What to Know Beyond Why AbbVie Inc.  ( ABBV )  is a Trending Stock,https://www.zacks.com/stock/news/2078797/here-is-what-to-know-beyond-why-abbvie-inc-abbv-is-a-trending-stock,2023-04-14 13:00:11,"AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",ABBV,0.483888,0.137176,Neutral
AbbVie Stock Shows Improved Relative Price Strength,https://www.investors.com/news/abbvie-stock-shows-improved-relative-price-strength/,2023-04-13 19:41:00,"AbbVie ( ABBV ) stock had its Relative Strength ( RS ) Rating upgraded from 69 to 76 Thursday -- a welcome improvement, but still shy of the 80 or higher score you prefer to see. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",ABBV,0.81619,0.368219,Bullish
"Royalty Pharma to Announce First Quarter 2023 Financial Results on May 9, 2023 - Royalty Pharma  ( NASDAQ:RPRX ) ",https://www.benzinga.com/pressreleases/23/04/g31787313/royalty-pharma-to-announce-first-quarter-2023-financial-results-on-may-9-2023,2023-04-13 13:01:34,"NEW YORK, April 13, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it will report its first quarter 2023 financial results on Tuesday, May 9, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.",ABBV,0.133841,0.092806,Neutral
"Royalty Pharma to Announce First Quarter 2023 Financial Results on May 9, 2023",https://www.globenewswire.com/news-release/2023/04/13/2646290/0/en/Royalty-Pharma-to-Announce-First-Quarter-2023-Financial-Results-on-May-9-2023.html,2023-04-13 13:01:00,"NEW YORK, April 13, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will report its first quarter 2023 financial results on Tuesday, May 9, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 ...",ABBV,0.140076,0.095066,Neutral
"The Zacks Analyst Blog Highlights JPMorgan Chase, AbbVie, NextEra Energy, The Boeing and Canadian Natural Resources",https://www.zacks.com/stock/news/2078121/the-zacks-analyst-blog-highlights-jpmorgan-chase-abbvie-nextera-energy-the-boeing-and-canadian-natural-resources,2023-04-13 12:16:00,"JPMorgan Chase, AbbVie, NextEra Energy, The Boeing and Canadian Natural Resources are part of the Zacks top Analyst Blog.",ABBV,0.380012,0.20726,Somewhat-Bullish
1 Sector Received $6.1 Billion in AI Investments Last Year: 3 Top Stocks to Buy,https://www.fool.com/investing/2023/04/13/ai-investments-top-stocks-to-buy/,2023-04-13 09:50:00,These companies are leading the way in using AI in healthcare.,ABBV,0.051003,0.0,Neutral
Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer,https://www.globenewswire.com/news-release/2023/04/12/2645756/0/en/Gain-Therapeutics-Appoints-C-Evan-Ballantyne-as-Chief-Financial-Officer.html,2023-04-12 20:30:00,"BETHESDA, Md., April 12, 2023 ( GLOBE NEWSWIRE ) -- Gain Therapeutics, Inc. ( Nasdaq: GANX ) ( ""Gain"", or the ""Company"" ) , a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced the appointment of C.",ABBV,0.027571,0.0,Neutral
"Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer - Agenus  ( NASDAQ:AGEN ) , Gain Therapeutics  ( NASDAQ:GANX ) ",https://www.benzinga.com/pressreleases/23/04/g31777838/gain-therapeutics-appoints-c-evan-ballantyne-as-chief-financial-officer,2023-04-12 20:30:00,"BETHESDA, Md., April 12, 2023 ( GLOBE NEWSWIRE ) -- Gain Therapeutics, Inc. GANX ( ""Gain"", or the ""Company"" ) , a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced the appointment of C.",ABBV,0.027288,-0.000916,Neutral
Check Out What Whales Are Doing With ABBV - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/04/31775602/check-out-what-whales-are-doing-with-abbv,2023-04-12 18:46:09,"Someone with a lot of money to spend has taken a bullish stance on AbbVie ABBV. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",ABBV,0.812724,0.439708,Bullish
"Top Research Reports for JPMorgan Chase, AbbVie & NextEra Energy",https://www.zacks.com/research-daily/2077479/top-research-reports-for-jpmorgan-chase-abbvie-nextera-energy,2023-04-12 17:21:00,"Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), AbbVie Inc. (ABBV) and NextEra Energy, Inc. (NEE).",ABBV,0.323785,0.188846,Somewhat-Bullish
Why AbbVie  ( ABBV )  Could Beat Earnings Estimates Again,https://www.zacks.com/stock/news/2077704/why-abbvie-abbv-could-beat-earnings-estimates-again,2023-04-12 16:10:13,AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,ABBV,0.418689,0.454384,Bullish
AbbVie Invites College Students Living with Cystic Fibrosis to Apply for the AbbVie CF Scholarship for the 2023-2024 Academic School Year,https://investingnews.com/abbvie-invites-college-students-living-with-cystic-fibrosis-to-apply-for-the-abbvie-cf-scholarship-for-the-2023-2024-academic-school-year/,2023-04-12 15:44:29,"AbbVie today announced that the AbbVie Cystic Fibrosis ( CF ) Scholarship, a program that is making a difference in the lives of young adults with CF and their families, is now accepting applications for the 2023-2024 academic school year.",ABBV,0.81111,0.49633,Bullish
Why 2023 Could Be a Tough Year for AbbVie Stock,https://www.fool.com/investing/2023/04/12/why-2023-could-be-a-tough-year-for-abbvie-stock/,2023-04-12 09:15:00,Should you buy the stock despite its headwinds?,ABBV,0.605937,0.014343,Neutral
AbbVie  ( ABBV )  Stock Moves 0.06%: What You Should Know,https://www.zacks.com/stock/news/2077168/abbvie-abbv-stock-moves-006-what-you-should-know,2023-04-11 21:45:20,"AbbVie (ABBV) closed the most recent trading day at $161.38, moving +0.06% from the previous trading session.",ABBV,0.670305,0.322235,Somewhat-Bullish
"Global Cosmetic Surgery Market Size Poised To Reflect USD 72.33 Billion Mark by 2030, At a CAGR Of 4.5% | Beauty & Cosmetics Industry Analysis",https://www.benzinga.com/pressreleases/23/04/g31752613/global-cosmetic-surgery-market-size-poised-to-reflect-usd-72-33-billion-mark-by-2030-at-a-cagr-of-,2023-04-11 17:59:46,"Washington, DC, April 11, 2023 ( GLOBE NEWSWIRE ) -- Zion Market Research has published a new research report titled ""Cosmetic Surgery Market By Procedures ( Invasive Procedures And Non-Invasive Procedures ) , By End-User ( Ambulatory Surgical Units, Hospitals & Clinics, And Cosmetic Surgical ...",ABBV,0.030254,-0.006568,Neutral
2 Forever Stocks to Buy No Matter What the Market Is Doing,https://www.fool.com/investing/2023/04/11/2-forever-stocks-to-buy-no-matter-what-the-market/,2023-04-11 09:30:00,These two top stocks are trading at very reasonable prices right now.,ABBV,0.062597,0.122904,Neutral
AbbVie's Blockbuster Is Falling Fast. Time to Sell?,https://moneymorning.com/investing/abbvies-blockbuster-is-falling-fast-time-to-sell/,2023-04-30 09:41:00,"Last week wasn't a great one for a lot of pharmaceutical stock investors. Shares of AbbVie ( NYSE: ABBV ) dropped by about 8% on Thursday, April 27. The market was responding to an earnings report that was the company's first since its lead product, Humira, lost patent-protected exclusivity in ...",ABBV,0.470894,-0.077539,Neutral
AbbVie's Blockbuster Is Falling Fast. Time to Sell?,https://www.fool.com/investing/2023/04/30/abbvies-blockbuster-is-falling-fast-time-to-sell/,2023-04-30 09:41:00,Rapidly declining Humira sales weren't the only disappointment AbbVie shared in its first-quarter earnings report.,ABBV,0.461699,-0.037082,Neutral
3 Unstoppable Stocks to Buy Right Now,https://moneymorning.com/investing/3-unstoppable-stocks-to-buy-right-now/,2023-04-29 10:14:00,"The laws of physics apply in some ways to investing. For example, some stocks have inertia -- they just can't break out of their rut. Others, though, either have momentum or the likelihood of gaining it in the future. Those are the kinds of stocks that are hard to keep down.",ABBV,0.45283,-0.116639,Neutral
3 Unstoppable Stocks to Buy Right Now,https://www.fool.com/investing/2023/04/29/3-unstoppable-stocks-to-buy-right-now/,2023-04-29 10:14:00,Don't let the temporary headwinds for two of these stocks fool you.,ABBV,0.252114,-0.075298,Neutral
AbbVie  ( ABBV )  Q1 2023 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/04/28/abbvie-abbv-q1-2023-earnings-call-transcript/,2023-04-28 19:35:18,"ABBV earnings call for the period ending March 31, 2023.",ABBV,0.047166,0.077735,Neutral
AbbVie  ( ABBV )  Q1 2023 Earnings Call Transcript,https://moneymorning.com/investing/abbvie-abbv-q1-2023-earnings-call-transcript/,2023-04-28 19:35:18,"Good morning, and thank you for standing by. Welcome to the AbbVie first quarter 2023 earnings conference call. All participants will be able to listen-only until the question-and-answer portion of this call. [Operator instructions] I would now like to introduce Ms. Good morning, and thanks for ...",ABBV,0.324139,0.158134,Somewhat-Bullish
"Pharma Stock Roundup: MRK & Others Post Q1 Results, LLY Drug Shines in Obesity Study",https://www.zacks.com/stock/news/2087081/pharma-stock-roundup-mrk-others-post-q1-results-lly-drug-shines-in-obesity-study,2023-04-28 16:47:00,"Merck (MRK), Eli Lilly (LLY), AstraZeneca (AZN) and others report first-quarter results. J&J (JNJ) provides an update on the IPO of its Consumer Health segment, Kenvue.",ABBV,0.105449,0.033014,Neutral
Market Rally Volatile And Tight Amid Big Earnings Moves,https://www.investors.com/news/market-rally-wobbles-amid-big-earnings-moves-from-microsoft-meta-crocs-cloudflare/,2023-04-28 16:36:00,Market Rally Wobbles Amid Big Earnings Moves From Microsoft ... Investor's Business Daily ...,ABBV,0.072987,-0.111796,Neutral
"Amgen  ( AMGN )  Q1 Earnings Beat Estimates, 2023 View Raised",https://www.zacks.com/stock/news/2087027/amgen-amgn-q1-earnings-beat-estimates-2023-view-raised,2023-04-28 15:52:00,Amgen (AMGN) beats estimates for earnings but misses the same for sales. It raises its earnings and sales guidance for 2023.,ABBV,0.050148,0.050873,Neutral
"How AI Is Revolutionizing Tech, and Why You Should Invest in These Leading Companies",https://moneymorning.com/investing/how-ai-is-revolutionizing-tech-and-why-you-should-invest-in-these-leading-companies/,2023-04-28 14:11:20,"Artificial intelligence ( AI ) permeated industries for years, but the release of ChatGPT thrust it into the limelight. It's the talk of the investment community and around the water coolers across the country. But what exactly is it?",ABBV,0.366061,0.092908,Neutral
"How AI Is Revolutionizing Tech, and Why You Should Invest in These Leading Companies",https://www.fool.com/investing/2023/04/28/how-ai-is-revolutionizing-tech-and-why-you-should/,2023-04-28 14:11:20,Check out these compelling opportunities.,ABBV,0.19871,0.057562,Neutral
Government Drug Price Curbs Could Sound A Death Knell For Industry,https://www.investors.com/news/technology/biotech-stocks-brace-for-the-worst-as-government-drug-price-negotiations-loom/,2023-04-28 12:00:00,Biotech Stocks Brace For The Worst As Government Drug Price ... Investor's Business Daily ...,ABBV,0.027118,-0.055277,Neutral
This Week in Health News: 10 Stories You Need to See,https://www.prnewswire.com/news-releases/this-week-in-health-news-10-stories-you-need-to-see-301810265.html,2023-04-28 11:32:00,"A roundup of the week's most newsworthy health industry press releases from PR Newswire, including parents' dissatisfaction with pediatric mental health benefits. NEW YORK, April 28, 2023 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with ...",ABBV,0.03319,0.098422,Neutral
Wall Street rallies as earnings season boost offsets economy worries,https://www.moneycontrol.com/news/business/markets/wall-street-rallies-as-earnings-season-boost-offsets-economy-worries-10490951.html,2023-04-28 01:06:41,"Shares in Meta closed up 13.9% after touching their highest level in more than a year after the company forecast quarterly revenue above estimates, and CEO Mark Zuckerberg said AI was increasing traffic to its services and boosting ad sales.",ABBV,0.05339,-0.192761,Somewhat-Bearish
AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS,https://investingnews.com/amgen-reports-first-quarter-financial-results/,2023-04-27 20:43:13,Amgen ( NASDAQ:AMGN ) today announced financial results for the first quarter of 2023.,ABBV,0.015675,0.0,Neutral
AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS,https://investingnews.com/amgen-reports-first-quarter-financial-results-2659922399/,2023-04-27 20:43:13,Amgen ( NASDAQ:AMGN ) today announced financial results for the first quarter of 2023.,ABBV,0.015675,0.0,Neutral
AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS,https://www.prnewswire.com/news-releases/amgen-reports-first-quarter-financial-results-301810090.html,2023-04-27 20:01:00,"THOUSAND OAKS, Calif., April 27, 2023 /PRNewswire/ -- Amgen ( NASDAQ:AMGN ) today announced financial results for the first quarter of 2023.",ABBV,0.006681,0.0,Neutral
AbbVie on track for biggest decline in about three years as newer drug sales lag estimates,https://www.marketwatch.com/story/abbvie-stock-falls-toward-a-6-week-low-after-adjusted-profit-fell-short-of-expectations-but-the-full-year-outlook-was-raised-103d942e,2023-04-27 18:38:00,"Investors were expecting the 25% decline in sales of blockbuster Humira which has lost its patent exclusivity, but newer drugs fell short of estimates.",ABBV,0.570165,-0.058689,Neutral
Why AbbVie Stock Is Crashing Today,https://www.fool.com/investing/2023/04/27/why-abbvie-stock-is-crashing-today/,2023-04-27 18:25:48,AbbVie's 2023 Q1 report isn't sitting well with shareholders today.,ABBV,0.669433,-0.298857,Somewhat-Bearish
Why AbbVie Stock Is Crashing Today,https://moneymorning.com/investing/why-abbvie-stock-is-crashing-today/,2023-04-27 18:25:48,"Shares of the pharmaceutical giant AbbVie ( NYSE: ABBV ) fell by as much as 9% in early morning trading Thursday. The drugmaker's shares have recovered since hitting this intra-day low, but they were still down by a hefty 7.8% as of 1:14 p.m. ET Thursday afternoon. What sparked this sell-off?",ABBV,0.618426,-0.101862,Neutral
"Stocks making the biggest moves midday: Honeywell, Caterpillar, Meta, First Republic & more",https://www.cnbc.com/2023/04/27/stocks-making-the-biggest-moves-midday-hon-cat-meta-and-more.html,2023-04-27 17:02:09,These are the stocks posting the largest moves in midday trading.,ABBV,0.049526,0.081866,Neutral
Wall St rallies as Meta earnings offset economy worries | The Financial Express,https://www.financialexpress.com/market/wall-st-rallies-as-meta-earnings-offset-economy-worries/3066191/,2023-04-27 16:55:37,Wall St rallies as Meta earnings offset economy worries The Financial Express ...,ABBV,0.069495,-0.189054,Somewhat-Bearish
"AbbVie  ( ABBV )  Q1 Earnings Beat, Skyrizi Sales Underperform",https://www.zacks.com/stock/news/2086355/abbvie-abbv-q1-earnings-beat-skyrizi-sales-underperform,2023-04-27 16:33:00,"AbbVie's (ABBV) first-quarter 2023 earnings and sales beat estimates. However, share price dives as some key drugs miss sales estimates.",ABBV,0.290361,0.181809,Somewhat-Bullish
$100 Invested In This Stock 10 Years Ago Would Be Worth $300 Today - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/news/earnings/23/04/32051550/100-invested-in-this-stock-10-years-ago-would-be-worth-300-today,2023-04-27 16:00:24,"AbbVie ABBV has outperformed the market over the past 10 years by 2.57% on an annualized basis producing an average annual return of 12.51%. Currently, AbbVie has a market capitalization of $261.30 billion.",ABBV,0.983605,0.387251,Bullish
AbbVie Stock Falls as Humira Sales Drop,https://www.barrons.com/articles/abbvie-stock-earnings-humira-sales-drop-10b6875e,2023-04-27 15:20:00,AbbVie shares took a tumble Thursday after the biopharmaceutical company said first-quarter sales of its anti-inflammatory drug Humira declined from a year ago.,ABBV,0.985002,-0.559142,Bearish
Why AbbVie  ( ABBV )  Shares Are Trading Lower Today - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/general/biotech/23/04/32045928/why-abbvie-shares-are-trading-lower-today,2023-04-27 13:58:47,"AbbVie Inc ABBV has reported Q1 adjusted EPS of $2.46, down 22.2% Y/Y, in line with the consensus. Overall sales decreased 9.7% Y/Y ( down 8.3% on an operational basis ) to $12.23 billion, beating the consensus of $12.17 billion.",ABBV,0.716023,0.475236,Bullish
WRAPUP Drugmakers post healthy results as growth drivers shine,https://www.reuters.com/business/healthcare-pharmaceuticals/wrapup-drugmakers-post-healthy-results-growth-drivers-shine-2023-04-27/,2023-04-27 13:33:00,"April 27 ( Reuters ) - Drugmakers including Merck & Co ( MRK.N ) , Eli Lilly ( LLY.N ) and AstraZeneca Plc ( AZN.L ) reported strong first-quarter earnings and several raised their expectations for 2023, as post-pandemic demand for cancer and other treatments jumped.",ABBV,0.169676,-0.008877,Neutral
Merck Makes a Bold Move That Could Transform Its Business,https://www.fool.com/investing/2023/04/27/merck-makes-a-bold-move-that-could-transform-its/,2023-04-27 13:15:00,"It's a risky deal for Merck, but it could pay off significantly.",ABBV,0.061949,-0.07516,Neutral
Merck Makes a Bold Move That Could Transform Its Business,https://moneymorning.com/investing/merck-makes-a-bold-move-that-could-transform-its-business/,2023-04-27 13:15:00,"There's nothing quite like a big acquisition to turn a business around. Consider how CVS Health acquired health insurer Aetna to broaden its operations. AbbVie acquired Botox-maker Allergan, which also helped diversify its business. and most recently, Pfizer announced plans to buy cancer company ...",ABBV,0.05339,-0.074985,Neutral
AbbVie's weak newer drug sales fan worries as Humira faces rivals,https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-raises-annual-profit-forecast-humira-demand-holds-steady-2023-04-27/,2023-04-27 12:58:00,"April 27 ( Reuters ) - AbbVie Inc ( ABBV.N ) on Thursday missed quarterly revenue estimates for its newer treatments, fueling concerns over the drugmaker's attempts to cushion the blow to sales from blockbuster Humira losing patent exclusivity.",ABBV,0.514619,0.140816,Neutral
AbbVie Plunges As Humira Biosimilars Take A 25% Cut,https://www.investors.com/news/technology/abbvie-stock-abbvie-earnings-q1-2023/,2023-04-27 12:46:00,AbbVie Stock Crumbles As Humira Biosimilars Take A 25% Cut ... Investor's Business Daily ...,ABBV,0.892763,0.420863,Bullish
AbbVie  ( ABBV )  Q1 Earnings and Revenues Top Estimates,https://www.zacks.com/stock/news/2085765/abbvie-abbv-q1-earnings-and-revenues-top-estimates,2023-04-27 12:45:11,"AbbVie (ABBV) delivered earnings and revenue surprises of 0.82% and 1.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?",ABBV,0.404563,0.175247,Somewhat-Bullish
1 Dividend Stock to Buy Hand Over Fist in May and 1 to Avoid,https://moneymorning.com/investing/1-dividend-stock-to-buy-hand-over-fist-in-may-and-1-to-avoid/,2023-04-27 12:30:00,"Some dividend stocks will pay a tidy and ever-increasing sum into your account for years. Others will run out of steam and slash your quarterly paycheck. Ideally, you'd buy shares of the first kind and avoid the second kind. So here's one example of each.",ABBV,0.385286,0.294787,Somewhat-Bullish
1 Dividend Stock to Buy Hand Over Fist in May and 1 to Avoid,https://www.fool.com/investing/2023/04/27/1-dividend-stock-to-buy-hand-over-fist-in-may-and/,2023-04-27 12:30:00,There's more to picking worthy dividend stocks than the forward yield.,ABBV,0.262805,0.223495,Somewhat-Bullish
AbbVie Reports First-Quarter 2023 Financial Results - Investing News Network,https://investingnews.com/abbvie-reports-first-quarter-2023-financial-results-2659919373/,2023-04-27 12:16:49,AbbVie Reports First-Quarter 2023 Financial Results Investing News Network ...,ABBV,0.495805,0.183003,Somewhat-Bullish
AbbVie Reports First-Quarter 2023 Financial Results - Investing News Network,https://investingnews.com/abbvie-reports-first-quarter-2023-financial-results/,2023-04-27 12:16:48,AbbVie Reports First-Quarter 2023 Financial Results Investing News Network ...,ABBV,0.495805,0.183003,Somewhat-Bullish
"Why US Stocks Are Poised To Open Higher Thursday - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",https://www.benzinga.com/news/earnings/23/04/32041361/us-stocks-eye-higher-open-as-meta-q1-uplifts-tech-sector-analyst-says-no-earnings-recession-in-card,2023-04-27 11:04:48,"Tech earnings could come to the market's rescue on Thursday, with all major index futures currently trading higher. Traders could also weigh in on the first-quarter GDP report to take stock of how the economy fared amid a housing market downturn, banking crisis, and rising rate environment.",ABBV,0.092927,0.0,Neutral
Morning Bid: Fresh spur from Meta and Europe's banks,https://www.reuters.com/markets/europe/global-markets-view-usa-2023-04-27/,2023-04-27 10:05:38,"A look at the day ahead in U.S. and global markets from Mike Dolan The Big Tech earnings season is going some way to justifying the striking outperformance of its mega cap shares this year, with Meta Platforms the latest to impress overnight and Amazon ( AMZN.O ) advancing ahead of its readout on ...",ABBV,0.048919,0.035546,Neutral
Futures: Meta Spikes Late; First Republic Still Hitting Market,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-meta-soars-megacaps-cant-hide-market-woes-as-first-republic-crashes/,2023-04-26 21:23:00,"Dow Jones Futures: Meta Soars, But Megacaps Can't Hide Market ... Investor's Business Daily ...",ABBV,0.096769,0.001067,Neutral
CHMP recommends EU approval of Roche's fixed-duration Columvi  ( glofitamab )  for people with relapsed or refractory diffuse large B-cell lymphoma,https://www.globenewswire.com/news-release/2023/04/26/2655504/0/en/CHMP-recommends-EU-approval-of-Roche-s-fixed-duration-Columvi-glofitamab-for-people-with-relapsed-or-refractory-diffuse-large-B-cell-lymphoma.html,2023-04-26 16:50:00,"Basel, 26 April 2023 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use ( CHMP ) has recommended the approval of Columvi® ( glofitamab ) , for the treatment of adult patients with relapsed or refractory ( R/R ...",ABBV,0.022079,0.052568,Neutral
"Microsoft's Strong Quarter Lifts Tech, But Banking Worries Keep Market Mainly On Defensive - Alphabet  ( NASDAQ:GOOGL ) , Chipotle Mexican Grill  ( NYSE:CMG ) ",https://www.benzinga.com/markets/23/04/32014643/microsofts-strong-quarter-lifts-tech-but-banking-worries-keep-market-mainly-on-defensive,2023-04-26 15:42:38,"( Wednesday market open ) When it's earnings season, the trading day seldom ends with the closing bell. If you shut down your screens at 4 p.m. ET yesterday, you might have felt gloomy after the S&P 500® index ( SPX ) posted its lowest close since March 30.",ABBV,0.03777,-0.066143,Neutral
"Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More",https://www.zacks.com/stock/news/2084870/drugbiotech-stocks-q1-earnings-due-apr-27-lly-abbv-more,2023-04-26 13:28:00,Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27.,ABBV,0.263942,0.127168,Neutral
NRG Therapeutics Appoints Dr Jonathan Savidge as Independent Chair,https://www.benzinga.com/pressreleases/23/04/g32004336/nrg-therapeutics-appoints-dr-jonathan-savidge-as-independent-chair,2023-04-26 08:00:00,"STEVENAGE, United Kingdom, April 26, 2023 ( GLOBE NEWSWIRE ) -- NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has appointed Jonathan Savidge Ph.D to its Board of Directors as an independent Non-Executive Chair.",ABBV,0.067158,0.082171,Neutral
"A Rotation Into Defensive Stocks? Market Strength Seen In Consumer Defensive And Healthcare On Tuesday - Centene  ( NYSE:CNC ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/general/health-care/23/04/31995117/a-rotation-into-defensive-stocks-market-strength-seen-in-consumer-defensive-and-healthcare-on,2023-04-25 17:23:37,"The U.S. stock market is seeing some modest selling on Tuesday morning after a series of largely uneventful sessions last week. Two hours into the trading day, the S&P 500 was down around 0.75% and the Nasdaq had pared 0.90%.",ABBV,0.141171,0.234773,Somewhat-Bullish
"Risk-Off Rerun: Banking Concerns, Nerves Ahead of Microsoft, Alphabet Earnings Bring Pressure - First Republic Bank  ( NYSE:FRC ) , General Electric  ( NYSE:GE ) ",https://www.benzinga.com/markets/23/04/31993957/risk-off-rerun-banking-concerns-nerves-ahead-of-microsoft-alphabet-earnings-bring-pressure,2023-04-25 16:25:43,( Tuesday market open ) The rubber hits the road for info tech earnings starting later today when Microsoft MSFT and Alphabet GOOGL open their quarterly books.,ABBV,0.037416,-0.066054,Neutral
This Is What Whales Are Betting On AbbVie - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/04/31993232/this-is-what-whales-are-betting-on-abbvie,2023-04-25 16:01:08,"Someone with a lot of money to spend has taken a bearish stance on AbbVie ABBV. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",ABBV,0.718485,0.166361,Somewhat-Bullish
2 Monster Stocks to Buy Without Any Hesitation,https://www.fool.com/investing/2023/04/25/2-monster-stocks-to-buy-without-any-hesitation/,2023-04-25 14:20:00,"These stocks have grown revenue, earnings and share price over the past five years.",ABBV,0.049732,0.166157,Somewhat-Bullish
This Supercharged Dividend King Stock Might Soon Run Out of Steam,https://www.fool.com/investing/2023/04/25/this-supercharged-dividend-king-stock-may-soon-run/,2023-04-25 13:45:00,"Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025.",ABBV,0.434763,0.12606,Neutral
Should SPDR Portfolio S&P 500 High Dividend ETF  ( SPYD )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2083846/should-spdr-portfolio-sp-500-high-dividend-etf-spyd-be-on-your-investing-radar,2023-04-25 10:20:07,Style Box ETF report for ...,ABBV,0.122894,0.068464,Neutral
Is Global X SuperDividend U.S. ETF  ( DIV )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2083849/is-global-x-superdividend-us-etf-div-a-strong-etf-right-now,2023-04-25 10:20:07,Smart Beta ETF report for DIV ...,ABBV,0.112797,0.051756,Neutral
3 Winning Stocks to Buy No Matter What the Market Is Doing,https://www.fool.com/investing/2023/04/25/3-winning-stocks-to-buy-no-matter-what-the-market/,2023-04-25 10:00:00,The long-term picture for these stocks remains bright.,ABBV,0.30569,0.24373,Somewhat-Bullish
"Novartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance",https://www.globenewswire.com/news-release/2023/04/25/2653492/0/en/Novartis-delivers-strong-sales-growth-robust-margin-expansion-and-major-innovation-milestones-Raises-FY-guidance.html,2023-04-25 05:00:00,Ad hoc announcement pursuant to Art. 53 LR ...,ABBV,0.015512,0.0,Neutral
"Setting the Bar: After Shares Rallied in Q1, Big-Tech Companies Ready to Share Results This Week",https://www.benzinga.com/markets/23/04/31961561/setting-the-bar-after-shares-rallied-in-q1-big-tech-companies-ready-to-share-results-this-week,2023-04-24 15:51:49,"( Monday market open ) Earnings season is nearly 20% complete, but this week is when company reports could start having a more dramatic impact on major indexes. That's because ""mega-cap"" companies like Microsoft ( MSFT ) , Alphabet ( GOOGL ) , Amazon ( AMZN ) , and Meta ( META ) are among the ...",ABBV,0.04161,-0.067029,Neutral
Can Amgen  ( AMGN )  Keep the Earnings Streak Alive in Q1?,https://www.zacks.com/stock/news/2083497/can-amgen-amgn-keep-the-earnings-streak-alive-in-q1,2023-04-24 14:51:00,"Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others is expected to have been partially offset by biosimilar/generic competition for mature drugs.",ABBV,0.095327,0.179044,Somewhat-Bullish
AbbVie  ( ABBV )  to Report Q1 Earnings: What's in the Cards?,https://www.zacks.com/stock/news/2083516/abbvie-abbv-to-report-q1-earnings-whats-in-the-cards,2023-04-24 14:29:00,AbbVie's (ABBV) Q1 performance will likely reflect declining sales of Humira following the loss of exclusivity. Sales of Rinvoq and Skyrizi are expected to partially offset this fall.,ABBV,0.337811,0.178678,Somewhat-Bullish
"Mixed Macro, Fed Debate, Earnings in Full Swing, S&P, Busy Week Ahead",https://realmoney.thestreet.com/investing/mixed-macro-fed-debate-earnings-in-full-swing-s-p-busy-week-ahead-16121922,2023-04-24 12:22:40,"Mixed Macro, Fed Debate, Earnings in Full Swing, S&P, Busy Week ... ...",ABBV,0.039128,0.051653,Neutral
GRI Bio  ( NASDAQ: GRI )  Announces Board of Director Appointments Adding Leadership and Expertise Spanning a Combined 75 Years in Both Public and Private Sectors in the Life Sciences Industry,https://www.globenewswire.com/news-release/2023/04/24/2652685/0/en/GRI-Bio-NASDAQ-GRI-Announces-Board-of-Director-Appointments-Adding-Leadership-and-Expertise-Spanning-a-Combined-75-Years-in-Both-Public-and-Private-Sectors-in-the-Life-Sciences-Ind.html,2023-04-24 12:05:00,"LA JOLLA, CA, April 24, 2023 ( GLOBE NEWSWIRE ) -- GRI Bio, Inc. ( NASDAQ: GRI ) ( ""GRI Bio"" or the ""Company"" ) , a biotechnology company advancing an innovative pipeline of Natural Killer T ( ""NKT"" ) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today ...",ABBV,0.025433,0.047183,Neutral
Why Did Pfizer Offload This Potential Mega-Blockbuster Drug?,https://www.fool.com/investing/2023/04/23/why-did-pfizer-offload-this-potential-mega-blockbu/,2023-04-23 20:45:00,"Pfizer's decision to offload a potential mega-blockbuster may seem counterintuitive, but the drugmaker appears to have solid reasons for doing so.",ABBV,0.033562,0.021161,Neutral
"The Best Stocks to Invest $20,000 in Right Now",https://www.fool.com/investing/2023/04/23/the-best-stocks-to-invest-20000-in-right-now/,2023-04-23 18:00:00,You'll want to hold on to these top stocks for the long term.,ABBV,0.308246,0.315174,Somewhat-Bullish
"Amazon, McDonald's, Microsoft earnings and debt limit battle top week ahead",https://www.foxbusiness.com/markets/amazon-mcdonalds-microsoft-earnings-debt-limit-battle-top-week-ahead,2023-04-23 15:07:02,"It will be another busy week for investors with a plethora of blue chip and big tech earnings on tap, as well as first quarter GDP and the ongoing battle over the nation's debt limit. The stock market closed higher on Friday but ended the week with modest losses.",ABBV,0.052685,-0.073657,Neutral
Our 8% Dividend 'Game Plan' For The Rest Of 2023,https://www.forbes.com/sites/michaelfoster/2023/04/22/our-8-dividend-game-plan-for-the-rest-of-2023/,2023-04-22 12:34:00,"With the first quarter behind us, now is a good time to ask ourselves if stock are getting just a little ahead of themselves.",ABBV,0.08183,0.106086,Neutral
3 Top Dividend Kings to Buy for the Long Haul,https://www.fool.com/investing/2023/04/22/3-top-dividend-kings-to-buy-for-the-long-haul/,2023-04-22 11:20:00,These healthcare stocks all have above-average dividends.,ABBV,0.2396,0.17618,Somewhat-Bullish
"Investing Action Plan: Microsoft, Amazon, Boeing, Alphabet Earnings",https://www.investors.com/research/investing-action-plan/stock-trading-action-plan-inflation-gauges-and-microsoft-amazon-boeing-alphabet-earnings/,2023-04-21 22:24:00,"Stock Trading Action Plan: Inflation Gauges And Microsoft, Amazon ... Investor's Business Daily ...",ABBV,0.037652,-0.037742,Neutral
Earnings Round One Ends With Banks A Clear Winner But Uncertain Results Overall As Market Sags,https://www.benzinga.com/news/earnings/23/04/31939743/earnings-round-one-ends-with-banks-a-clear-winner-but-uncertain-results-overall-as-market-sags,2023-04-21 16:59:11,( Friday market open ) Bulls and bears touch gloves and go to their separate corners at the end of the week before the bell rings to signal another heavy bout of earnings and economic data starting Monday.,ABBV,0.07654,0.019245,Neutral
Price Over Earnings Overview: AbbVie - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/news/23/04/31934216/price-over-earnings-overview-abbvie,2023-04-21 13:03:03,"In the current market session, AbbVie Inc. ABBV stock price is at $161.70, after a 0.02% decrease. However, over the past month, the company's stock spiked by 2.35%, and in the past year, by 3.40%.",ABBV,0.426225,-0.06786,Neutral
AbbVie's Preventive Treatment For Migraine Meets Primary Goal In Patients With Failed Medications - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/general/biotech/23/04/31930807/abbvies-preventive-treatment-for-migraine-meets-primary-goal-in-patients-with-failed-medications,2023-04-21 11:24:40,"AbbVie Inc ABBV announced data from its Phase 3 ELEVATE study, evaluating atogepant for the preventive treatment of episodic migraine in people who had previously failed two to four classes of oral preventive medications. The ELEVATE study met all primary and secondary endpoints.",ABBV,0.441059,0.085331,Neutral
These 6 Income Funds Use Options to Pump Up Their Yields,https://www.barrons.com/articles/income-funds-options-pump-up-yields-86f2c3fd,2023-04-21 07:30:00,A hot exchange-traded fund from JPMorgan Chase has reinvigorated the formerly sleepy category of options-writing equity funds. The JPMorgan Equity Premium Income ETF ( ticker: JEPI ) has mushroomed to $24 billion since its inception nearly three years ago.,ABBV,0.690822,0.43883,Bullish
AbbVie Announces Late-Breaking Results from Phase 3 Trial Evaluating Atogepant for the Preventive Treatment of Episodic Migraine Among Patients with Prior Treatment Failure at the 2023 AAN Annual Meeting,https://investingnews.com/abbvie-announces-late-breaking-results-from-phase-3-trial-evaluating-atogepant-for-the-preventive-treatment-of-episodic-migraine-among-patients-with-prior-treatment-failure-at-the-2023-aan-annual-meet/,2023-04-21 04:43:03,"- AbbVie ( NYSE: ABBV ) today announced positive data from its Phase 3 ELEVATE study, evaluating atogepant for the preventive treatment of episodic migraine in people who had previously failed two to four classes of oral preventive medications.",ABBV,0.27044,0.226626,Somewhat-Bullish
This Analyst Likes Evolus As 'Top Play In Aesthetics' - Evolus  ( NASDAQ:EOLS ) ,https://www.benzinga.com/analyst-ratings/analyst-color/23/05/32322081/this-analyst-likes-evolus-as-top-play-in-aesthetics,2023-05-10 18:27:21,"Evolus Inc EOLS will be the exclusive U.S. distributor for five dermal fillers currently in late-stage development from Symatese, a French regenerative medical solutions company.",ABBV,0.25168,0.0,Neutral
Genmab Announces Financial Results for the First Quarter of 2023,https://www.globenewswire.com/news-release/2023/05/10/2665762/0/en/Genmab-Announces-Financial-Results-for-the-First-Quarter-of-2023.html,2023-05-10 15:01:00,"May 10, 2023 Copenhagen, Denmark. Interim Report for the First Quarter Ended March ...",ABBV,0.122477,0.080958,Neutral
Breast Reconstruction Market is Expected to Reach $647 million | MarketsandMarkets.,https://www.benzinga.com/pressreleases/23/05/g32316473/breast-reconstruction-market-is-expected-to-reach-647-million-marketsandmarkets,2023-05-10 13:30:00,"Chicago, May 10, 2023 ( GLOBE NEWSWIRE ) -- The breast reconstruction industry is expected to witness significant advancements and growth in the near future. With the increasing focus on breast cancer awareness and improved patient outcomes, breast reconstruction procedures are becoming more ...",ABBV,0.036146,0.063795,Neutral
Should WisdomTree U.S. High Dividend ETF  ( DHS )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2093120/should-wisdomtree-us-high-dividend-etf-dhs-be-on-your-investing-radar,2023-05-10 10:20:07,Style Box ETF report for ...,ABBV,0.120733,0.067941,Neutral
Why Viking Therapeutics Stock Wobbled Today,https://www.fool.com/investing/2023/05/09/why-viking-therapeutics-stock-wobbled-today/,2023-05-09 19:40:21,The biotech's shares dipped along with the broader markets in early-morning trading today.,ABBV,0.319933,0.344571,Somewhat-Bullish
Why Enanta  ( ENTA )  Shares Are Plunging Today - Enanta Pharma  ( NASDAQ:ENTA ) ,https://www.benzinga.com/general/biotech/23/05/32293326/why-enanta-shares-are-plunging-today,2023-05-09 19:16:43,"Enanta Pharmaceuticals Inc's ENTA investigational COVID-19 pill, EDP-235, met its primary endpoints of safety and tolerability in its Phase 2 SPRINT trial but yielded mixed results on its effectiveness.",ABBV,0.316846,0.191246,Somewhat-Bullish
"Check Out 3 Health Care Stocks With Over 3% Dividend Yields From Wall Street's Most Accurate Analysts - AbbVie  ( NYSE:ABBV ) , Amgen  ( NASDAQ:AMGN ) ",https://www.benzinga.com/news/23/05/32289782/check-out-3-health-care-stocks-with-over-3-dividend-yields-from-wall-streets-most-accurate-analysts,2023-05-09 13:16:55,"During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.",ABBV,0.118064,0.0,Neutral
Health Canada Approves AbbVie's RINVOQ® for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis,https://investingnews.com/health-canada-approves-abbvie-s-rinvoq-r-for-the-treatment-of-adults-with-active-non-radiographic-axial-spondyloarthritis/,2023-05-09 11:51:53,"- Approval is based on results from the Phase 3 SELECT-AXIS 2 pivotal clinical trial in which RINVOQ delivered rapid and meaningful disease control, meeting the primary endpoint of ASAS40 response at week 14 versus placebo 1 - RINVOQ is the first and only Janus Kinase ( JAK ) inhibitor approved ...",ABBV,0.256538,0.238336,Somewhat-Bullish
Looking At AbbVie's Recent Unusual Options Activity - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/05/32274297/looking-at-abbvies-recent-unusual-options-activity,2023-05-08 20:31:37,"A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 11 strange trades. If we consider the specifics of each trade, it is accurate to state that 36% of the investors opened trades with bullish expectations ...",ABBV,0.901057,0.0,Neutral
3 Things About Eli Lilly That Smart Investors Know,https://www.fool.com/investing/2023/05/08/3-things-about-eli-lilly-that-smart-investors-know/,2023-05-08 09:05:00,"There are quite a few details to keep track of with this company, and they all matter.",ABBV,0.063933,0.134318,Neutral
2 Top Healthcare Stocks Defying the Bear Market,https://www.fool.com/investing/2023/05/07/2-top-healthcare-stocks-defying-the-bear-market/,2023-05-07 12:14:00,"These pharmaceutical companies are expected to see a big rise in revenue, thanks to new therapies.",ABBV,0.043264,0.160403,Somewhat-Bullish
1 Soaring Growth Stock That's Still an Unbeatable Bargain,https://www.fool.com/investing/2023/05/07/1-soaring-growth-stock-thats-still-an-unbeatable-b/,2023-05-07 09:17:00,This company's minimally invasive alternative to liposuction surgery isn't getting the attention it deserves.,ABBV,0.115232,0.067787,Neutral
This Incredible Growth Stock Has All the Hallmarks of a Prototypical Warren Buffett Stock,https://www.fool.com/investing/2023/05/06/this-incredible-growth-stock-has-all-the-hallmarks/,2023-05-06 17:00:00,"Vertex Pharmaceuticals faces limited competition in its core area of expertise, has a top-shelf CEO, and is building out a profoundly valuable pipeline of next-generation assets.",ABBV,0.089965,0.009879,Neutral
1 Relatively Safe Dividend Growth Stock to Buy Hand Over Fist Right Now,https://www.fool.com/investing/2023/05/06/1-relatively-safe-dividend-growth-stock-to-buy-han/,2023-05-06 13:44:00,"Look past the bad news, at how this company will perform in the future.",ABBV,0.427024,0.170532,Somewhat-Bullish
"Looking for Steady, Passive Income? Buy AbbVie Stock",https://www.fool.com/investing/2023/05/06/looking-for-steady-passive-income-buy-abbvie-stock/,2023-05-06 13:00:00,The drugmaker looks poised to rebound from its Humira loss of exclusivity.,ABBV,0.355588,0.32216,Somewhat-Bullish
AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®,https://investingnews.com/abbvie-releases-new-data-demonstrating-breadth-of-its-gastroenterology-portfolio-at-2023-digestive-disease-week-r/,2023-05-06 11:54:28,"- Oral presentations highlight efficacy and safety outcomes from the upadacitinib ( RINVOQ ® ) clinical trial program in adults with moderately to severely active Crohn's disease, and investigational use of linaclotide ( LINZESS ® ) in treating functional constipation in pediatric patients aged ...",ABBV,0.217923,0.153769,Somewhat-Bullish
3 Great Income Stocks That Retirees Should Love,https://www.fool.com/investing/2023/05/06/3-great-income-stocks-that-retirees-should-love/,2023-05-06 10:14:00,"If you're looking for additional retirement income, these three stocks should be right up your alley.",ABBV,0.288408,0.269959,Somewhat-Bullish
"Ironwood  ( IRWD )  Q1 Earnings Beat Estimates, Linzess Volume Up",https://www.zacks.com/stock/news/2090951/ironwood-irwd-q1-earnings-beat-estimates-linzess-volume-up,2023-05-05 13:31:00,"Ironwood (IRWD) reports better-than-expected results, wherein both earnings and revenues beat estimates. The strong momentum of Linzess continues with 10% growth in prescription demand.",ABBV,0.182047,0.083516,Neutral
3 Recession-Proof Mutual Funds to Buy in an Uncertain Market,https://www.zacks.com/stock/news/2090687/3-recession-proof-mutual-funds-to-buy-in-an-uncertain-market,2023-05-05 10:18:00,"In a challenging economic climate, it is wise to invest in recession-proof mutual funds like FRUAX, JNGLX and FDIGX.",ABBV,0.052226,0.053678,Neutral
"Psychedelic Drug Industry Analysis: Forecast Market Size, Major Players And Their Strategies, And Key Segments - By The Business Research Company",https://www.prnewswire.com/news-releases/psychedelic-drug-industry-analysis-forecast-market-size-major-players-and-their-strategies-and-key-segments--by-the-business-research-company-301814512.html,2023-05-04 09:30:00,"Psychedelic Drug Industry Analysis: Forecast Market Size, Major ... PR ...",ABBV,0.072,0.018172,Neutral
2 Things About AbbVie That Investors Are Ignoring,https://www.fool.com/investing/2023/05/03/2-things-about-abbvie-that-investors-are-ignoring/,2023-05-03 18:00:00,AbbVie shares slipped following the latest earnings report.,ABBV,0.71972,0.410839,Bullish
"Biopharmaceuticals Contract Manufacturing Market to Surge at 9% CAGR, Propelled by Rising Prevalence of Chronic Diseases and Outsourcing Trend, Reveals New Report.",https://markets.businessinsider.com/news/stocks/biopharmaceuticals-contract-manufacturing-market-to-surge-at-9-cagr-propelled-by-rising-prevalence-of-chronic-diseases-and-outsourcing-trend-reveals-new-report-1032286875,2023-05-03 14:25:15,"Biopharmaceuticals Contract Manufacturing Market By Source ( Mammalian, Non-mammalian ) , By Service ( Process Development [Downstream, Upstream], Fill & Finish Operations, Analytical & QC Studies, Packaging ) , By Product, By Therapeutic Area, By Region Forecast to 2032",ABBV,0.043108,0.123591,Neutral
Here's 1 Magnificent Reason to Buy Vertex Pharmaceuticals Stock,https://www.fool.com/investing/2023/05/03/heres-1-magnificent-reason-to-buy-vertex-pharmaceu/,2023-05-03 14:15:00,The bull case for the cystic fibrosis treatment maker is as strong as ever.,ABBV,0.2842,-0.048239,Neutral
7 Reasons to Buy Vertex Pharmaceuticals Stock Now,https://www.fool.com/investing/2023/05/03/7-reasons-to-buy-vertex-pharmaceuticals-stock-now/,2023-05-03 09:50:00,It's not too late to invest in this top biotech stock.,ABBV,0.064623,0.071278,Neutral
AbbVie,https://investingnews.com/stocks/nyse-abbv/abbvie/,2023-05-03 08:10:52,AbbVies mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow.,ABBV,0.436009,0.383201,Bullish
Harmony Biosciences  ( HRMY )  Q1 2023 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/05/02/harmony-biosciences-hrmy-q1-2023-earnings-call-tra/,2023-05-02 18:30:20,"HRMY earnings call for the period ending March 31, 2023.",ABBV,0.004358,0.1045,Neutral
Vertex Pharmaceuticals Just Lost a Potential Rival. Is the Stock a Buy?,https://www.fool.com/investing/2023/05/02/vertex-lost-potential-rival-is-stock-a-buy/,2023-05-02 18:00:00,Vertex dominates the cystic fibrosis market today.,ABBV,0.423251,-0.005794,Neutral
3 of the Best High-Yielding Dividend Stocks to Buy in May,https://www.fool.com/investing/2023/05/02/3-of-the-best-high-yielding-dividend-stocks-to-buy/,2023-05-02 13:39:48,"These dividend stocks are trading at cheap prices, and long-term investors should consider buying them right now.",ABBV,0.290607,0.131658,Neutral
Investors Heavily Search AbbVie Inc.  ( ABBV ) : Here is What You Need to Know,https://www.zacks.com/stock/news/2087986/investors-heavily-search-abbvie-inc-abbv-here-is-what-you-need-to-know,2023-05-02 13:00:11,"AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",ABBV,0.489394,0.135098,Neutral
AbbVie to Present at the Bank of America Securities Healthcare Conference,https://investingnews.com/abbvie-to-present-at-the-bank-of-america-securities-healthcare-conference-2659939637/,2023-05-02 12:38:14,"AbbVie ( NYSE: ABBV ) will participate in the Bank of America Securities Healthcare Conference on Tuesday, May 9, 2023 . Robert A. Michael vice chairman and president, Scott Reents executive vice president, chief financial officer, Jeffrey R.",ABBV,0.703273,0.050462,Neutral
AmerisourceBergen raises profit forecast on demand for pricier specialty drugs,https://www.reuters.com/business/healthcare-pharmaceuticals/amerisourcebergen-raises-profit-forecast-demand-pricier-specialty-drugs-2023-05-02/,2023-05-02 12:17:59,AmerisourceBergen raises profit forecast on demand for pricier ... ...,ABBV,0.140076,0.030611,Neutral
Vertex Pharmaceuticals Stock Is an Even Better Buy Now Thanks to AbbVie,https://www.fool.com/investing/2023/05/02/vertex-pharmaceuticals-stock-is-an-even-better-buy/,2023-05-02 09:50:00,One big drugmaker's pain translates into another big drugmaker's gain.,ABBV,0.359014,0.09794,Neutral
Check Out What Whales Are Doing With ABBV - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/05/32131582/check-out-what-whales-are-doing-with-abbv,2023-05-01 19:16:54,"Someone with a lot of money to spend has taken a bullish stance on AbbVie ABBV. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",ABBV,0.716023,0.348574,Somewhat-Bullish
"Substance Abuse And Addiction Treatment Market Size, Share, Revenue, Trends And Drivers For 2023-2032 As Per The Business Research Company's Substance Abuse and Addiction Treatment Global Market Report for 2023",https://www.benzinga.com/pressreleases/23/05/g32124310/substance-abuse-and-addiction-treatment-market-size-share-revenue-trends-and-drivers-for-2023-2032,2023-05-01 15:30:00,"LONDON, May 01, 2023 ( GLOBE NEWSWIRE ) -- The Business Research Company's research on the substance abuse and addiction treatment market forecasts the market to experience significant growth, increasing from $9.8 billion in 2022 to $10.9 billion in 2023 at a CAGR of more than 11%.",ABBV,0.05654,-0.094919,Neutral
Where Will AbbVie Be in 5 Years?,https://www.fool.com/investing/2023/05/01/where-will-abbvie-be-in-5-years/,2023-05-01 13:30:00,"AbbVie has been a strong performer since its split from Abbott Labs, and it's trying hard to keep the momentum going.",ABBV,0.576289,0.087056,Neutral
"PANCAN PURPLESTRIDE UNITES CELEBRITIES, SURVIVORS, CAREGIVERS AND SUPPORTERS NATIONWIDE AT THE ULTIMATE WALK TO END PANCREATIC CANCER",https://www.benzinga.com/pressreleases/23/05/n32116522/pancan-purplestride-unites-celebrities-survivors-caregivers-and-supporters-nationwide-at-the-ultim,2023-05-01 12:15:00,"Lisa Niemi Swayze, Eric Idle, Jean Trebek, Rosario Dawson Among the Notable Participants to Walk and Raise Awareness, Critical Funds for One of the Toughest Cancers Select celebrity photos can be found here.",ABBV,0.041755,0.102512,Neutral
Are These 3 Elite Dividend Stocks a Buy After Q1 Earnings?,https://moneymorning.com/investing/are-these-3-elite-dividend-stocks-a-buy-after-q1-earnings/,2023-05-01 11:00:00,Elite dividend stocks are highly prized assets by investors. The core reason is that companies with a rich tradition of paying an above average-yield and/or steadily raising their yield tend to outperform the broader markets over the long haul.,ABBV,0.361802,-0.028713,Neutral
Are These 3 Elite Dividend Stocks a Buy After Q1 Earnings?,https://www.fool.com/investing/2023/05/01/are-these-3-elite-dividend-stocks-a-buy-after-q1-e/,2023-05-01 11:00:00,These highly prized dividend stocks no longer come across as table-pounding buys.,ABBV,0.233108,-0.020393,Neutral
AbbVie Stock Plunged: Should You Buy the Dip?,https://www.fool.com/investing/2023/05/01/abbvie-stock-plunged-should-you-buy-the-dip/,2023-05-01 09:51:00,Last week's sell-off appears to have been overdone.,ABBV,0.660375,0.149349,Neutral
AbbVie Stock Plunged: Should You Buy the Dip?,https://moneymorning.com/investing/abbvie-stock-plunged-should-you-buy-the-dip/,2023-05-01 09:51:00,AbbVie ( NYSE: ABBV ) spent 11 weeks building solid momentum. Its stock climbed more than 14% during the period. But it took only one day to wipe out most of the gain. The drugmaker's shares plunged last Thursday after AbbVie announced its first-quarter results.,ABBV,0.565644,-0.013903,Neutral
3 Healthcare Mutual Funds to Counter a Likely Economic Downturn,https://www.zacks.com/stock/news/2087257/3-healthcare-mutual-funds-to-counter-a-likely-economic-downturn,2023-05-01 09:03:00,"In a challenging economic climate, it is wise to invest in healthcare mutual funds like FSHCX, JNGLX and PRHSX.",ABBV,0.040691,0.052208,Neutral
3 Relatively Safe Stocks to Buy if a Recession Is on the Way,https://www.fool.com/investing/2023/05/20/3-relatively-safe-stocks-to-buy-if-a-recession-is/,2023-05-20 10:14:00,"If the economy falters, these stocks should hold up better than most.",ABBV,0.337427,0.131217,Neutral
"3 No-Brainer Dividend Stocks to Buy With $1,000 Right Now",https://www.fool.com/investing/2023/05/20/3-no-brainer-dividend-stocks-to-buy-with-1000-righ/,2023-05-20 09:52:00,The decisions are easy with these dividend stocks.,ABBV,0.295155,0.166408,Somewhat-Bullish
Clinical Project Manager  ( CPM )  Beginner Training Course,https://www.prnewswire.com/news-releases/clinical-project-manager-cpm-beginner-training-course-301829578.html,2023-05-20 00:00:00,"DUBLIN, May 19, 2023 /PRNewswire/ -- The ""Clinical Project Manager ( CPM ) Beginner"" training has been added to ResearchAndMarkets.com's offering. If you are looking to enter the field of clinical research, this CPD-accredited is for you.",ABBV,0.072655,0.033182,Neutral
Global Cellulite Treatment Global Market 2023-2030: Increasing Trend of Anti-Cellulite Massage Presents Opportunities,https://www.prnewswire.com/news-releases/global-cellulite-treatment-global-market-2023-2030-increasing-trend-of-anti-cellulite-massage-presents-opportunities-301829574.html,2023-05-19 23:45:00,Global Cellulite Treatment Global Market 2023-2030: Increasing ... PR ...,ABBV,0.077593,0.085064,Neutral
"Autoimmune Drugs Market size to grow by USD 29,314.5 million between 2022 and 2027; AbbVie Inc., and AdvaCare Pharma among others, identified as key vendors - Technavio",https://www.prnewswire.com/news-releases/autoimmune-drugs-market-size-to-grow-by-usd-29-314-5-million-between-2022-and-2027-abbvie-inc-and-advacare-pharma-among-others-identified-as-key-vendors--technavio-301828870.html,2023-05-19 23:15:00,"Autoimmune Drugs Market size to grow by USD 29,314.5 million ... PR ...",ABBV,0.075161,0.137715,Neutral
"FDA Approves AbbVie/Genmab's Cancer Drug As First Bispecific Antibody For Type Of Lymphoma In Adult Patients - Genmab  ( NASDAQ:GMAB ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/general/biotech/23/05/32491016/fda-approves-abbviegenmabs-cancer-drug-as-first-bispecific-antibody-for-type-of-lymphoma-in-adult,2023-05-19 17:59:17,The FDA has approved Epkinly ( epcoritamab-bysp ) as the first and only T-cell engaging bispecific antibody for adult patients with relapsed or refractory ( R/R ) diffuse large B-cell lymphoma ( DLBCL ) after two or more lines of systemic therapy.,ABBV,0.582526,0.326295,Somewhat-Bullish
US FDA approves Genmab-AbbVie's blood cancer therapy,https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-genmab-abbvies-blood-cancer-therapy-2023-05-19/,2023-05-19 16:53:00,"May 19 ( Reuters ) - The U.S. Food and Drug Administration has approved AbbVie Inc ( ABBV.N ) and Danish drugmaker Genmab's ( GMAB.CO ) blood cancer therapy for adult patients who have received at least two prior lines of treatment, the companies said on Friday.",ABBV,0.214937,-0.063091,Neutral
EPKINLY™  ( epcoritamab-bysp )  Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma  ( DLBCL ) ,https://www.prnewswire.com/news-releases/epkinly-epcoritamab-bysp-approved-by-us-fda-as-the-first-and-only-bispecific-antibody-to-treat-adult-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-dlbcl-301829783.html,2023-05-19 16:34:00,EPKINLY™ ( epcoritamab-bysp ) Approved by U.S. FDA as the First ... PR ...,ABBV,0.207845,0.097797,Neutral
EPKINLY™  ( epcoritamab-bysp )  Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory  ( R/R )  Diffuse Large B-cell Lymphoma  ( DLBCL ) ,https://www.globenewswire.com/news-release/2023/05/19/2672708/0/en/EPKINLY-epcoritamab-bysp-Approved-by-U-S-Food-and-Drug-Administration-as-the-First-and-Only-Bispecific-Antibody-to-Treat-Adults-with-Relapsed-or-Refractory-R-R-Diffuse-Large-B-cell.html,2023-05-19 16:33:00,Company Announcement ...,ABBV,0.095463,0.074902,Neutral
RDY: Dr. Reddy's Laboratories  ( RDY )  Is the Pharmaceutical Stock to Buy,https://stocknews.com/news/rdy-abbv-nvs-bmy-dr-reddys-laboratories-rdy-is-the-pharmaceutical-stock-to-buy/,2023-05-19 16:27:32,RDY: Dr. Reddy's Laboratories ( RDY ) Is the Pharmaceutical Stock to ... ...,ABBV,0.070207,0.133694,Neutral
AbbVie's  ( ABBV )  Rinvoq Gets FDA Nod to Treat Crohn's Disease,https://www.zacks.com/stock/news/2097424/abbvies-abbv-rinvoq-gets-fda-nod-to-treat-crohns-disease,2023-05-19 14:24:00,"AbbVie (ABBV) announces the seventh FDA approval of its JAK inhibitor, Rinvoq, for the treatment of adults with moderately to severely active Crohn's disease.",ABBV,0.337811,0.002479,Neutral
"Global Pharma, Biotech and Diagnostics Co-development Partnering Deals Analysis Report 2023 with a Directory of Deals - Comprehensive Access to Actual Co-development Contracts",https://www.prnewswire.com/news-releases/global-pharma-biotech-and-diagnostics-co-development-partnering-deals-analysis-report-2023-with-a-directory-of-deals---comprehensive-access-to-actual-co-development-contracts-301829437.html,2023-05-19 14:15:00,"Global Pharma, Biotech and Diagnostics Co-development ... PR ...",ABBV,0.035138,0.0,Neutral
3 Large-Cap Dividend Mutual Funds to Buy as a Crisis Looms,https://www.zacks.com/stock/news/2097411/3-large-cap-dividend-mutual-funds-to-buy-as-a-crisis-looms,2023-05-19 14:09:00,"In a challenging economic climate, it is wise to invest in large-cap dividend mutual funds like IDHIX, BRGIX and EQTIX.",ABBV,0.051111,0.042016,Neutral
"FDA Approves First Oral Treatment For Crohn's Disease, Making Seventh Approval For AbbVie's Rinvoq - AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/general/biotech/23/05/32482878/fda-approves-first-oral-treatment-for-crohns-disease-making-seventh-approval-for-abbvies-rinvoq,2023-05-19 12:13:38,The FDA approved AbbVie Inc's ABBV Rinvoq ( upadacitinib ) for moderately to severely active Crohn's disease patients with inadequate response or intolerance to one or more TNF blockers.,ABBV,0.570165,-0.063969,Neutral
Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update,https://www.globenewswire.com/news-release/2023/05/19/2672401/0/en/Alvotech-Reports-Financial-Results-for-First-three-Months-of-2023-and-Provides-Business-Update.html,2023-05-19 09:00:00,"• Revenue for the first three months of 2023 increased to $15.9 million, compared to $0.8 million for the same period in 2022 • Confirmatory patient study for AVT05, a proposed biosimilar for Simponi® and Simponi Aria® ( golimumab ) initiated, marking the fifth internally developed portfolio ...",ABBV,0.025087,0.034814,Neutral
Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update,https://www.globenewswire.com/news-release/2023/05/19/2672402/0/en/Alvotech-Reports-Financial-Results-for-First-three-Months-of-2023-and-Provides-Business-Update.html,2023-05-19 09:00:00,"REYKJAVIK, Iceland, May 19, 2023 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the ""Company"" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first three months of ...",ABBV,0.025021,0.0348,Neutral
StockNews.com initiates coverage on AbbVie  ( NYSE:ABBV )  with a Strong-Buy Rating Charts Growth Trajectory in 2023.,https://beststocks.com/stocknews-com-initiates-coverage-on-abbvie-nysea/,2023-05-19 03:32:32,StockNews.com initiates coverage on AbbVie ( NYSE:ABBV ) with a ... Best Stocks ...,ABBV,0.540042,0.252758,Somewhat-Bullish
Glaucoma Clinical Trial Pipeline Accelerates as 45+ Pharma Companies Rigorously Developing Drugs for the Market Entry,https://www.prnewswire.com/news-releases/glaucoma-clinical-trial-pipeline-accelerates-as-45-pharma-companies-rigorously-developing-drugs-for-the-market-entry-301828174.html,2023-05-18 15:00:00,Glaucoma Clinical Trial Pipeline Accelerates as 45+ Pharma ... PR ...,ABBV,0.099066,0.040145,Neutral
"Global Cytotoxic Drug Market Expected to Garner $21,644.10 Million in Revenue and Rise at a CAGR of 5.7% during the Estimated Period 2022-2031 [290-Pages] | Explicated by Research Dive",https://www.benzinga.com/pressreleases/23/05/g32465499/global-cytotoxic-drug-market-expected-to-garner-21-644-10-million-in-revenue-and-rise-at-a-cagr-of,2023-05-18 13:04:00,"New York, USA, May 18, 2023 ( GLOBE NEWSWIRE ) -- According to a report published by Research Dive, the global cytotoxic drug market is projected to generate a revenue of $21,644.10 million and rise at a CAGR of 5.7% over the estimated timeframe from 2022 to 2031.",ABBV,0.054483,0.184856,Somewhat-Bullish
Should Schwab U.S. Dividend Equity ETF  ( SCHD )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2096644/should-schwab-us-dividend-equity-etf-schd-be-on-your-investing-radar,2023-05-18 10:20:07,Style Box ETF report for ...,ABBV,0.12013,0.067797,Neutral
AbbVie  ( NYSE:ABBV )  Earns Strong-Buy Rating from Analysts at StockNews.com,https://www.defenseworld.net/2023/05/18/abbvie-nyseabbv-earns-strong-buy-rating-from-analysts-at-stocknews-com.html,2023-05-18 06:00:47,AbbVie ( NYSE:ABBV ) Earns Strong-Buy Rating from Analysts at ... Defense World ...,ABBV,0.812494,0.379371,Bullish
What Does AbbVie's Debt Look Like? - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/news/23/05/32453663/what-does-abbvies-debt-look-like,2023-05-17 19:45:32,"Shares of AbbVie Inc. ABBV decreased by 5.93% in the past three months. Before having a look at the importance of debt, let's look at how much debt AbbVie has. According to the AbbVie's most recent balance sheet as reported on May 5, 2023, total debt is at $62.09 billion, with $59.29 billion in ...",ABBV,0.301933,-0.020993,Neutral
This Is What Whales Are Betting On AbbVie - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/05/32447550/this-is-what-whales-are-betting-on-abbvie,2023-05-17 15:02:35,"A whale with a lot of money to spend has taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 18 strange trades. If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations ...",ABBV,0.83383,0.085373,Neutral
"One More Quits US Pharma Lobby Group: AstraZeneca Follows Teva, AbbVie Footsteps - AstraZeneca  ( NASDAQ:AZN ) , AstraZeneca  ( OTC:AZNCF ) ",https://www.benzinga.com/general/biotech/23/05/32439917/one-more-quits-us-pharma-lobby-group-astrazeneca-follows-teva-abbvie-footsteps,2023-05-17 13:29:18,"AstraZeneca Plc AZN has decided to leave a U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America ( PhRMA ) , making it the third company to leave the group in the last six months.",ABBV,0.345674,0.374689,Bullish
P/E Ratio Insights for AbbVie - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/news/23/05/32444758/pe-ratio-insights-for-abbvie,2023-05-17 13:15:31,"In the current session, AbbVie Inc. ABBV is trading at $143.27, after a 0.01% decrease. Over the past month, the stock fell by 11.24%, and in the past year, by 5.72%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio.",ABBV,0.448842,-0.242654,Somewhat-Bearish
"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Chinook Therapeutics  ( KDNY )  Investors with Substantial Losses to Contact Firm's Attorneys, Firm Investigating Possible Securities Law Violations - Chinook Therapeutics  ( NASDAQ:KDNY ) ",https://www.benzinga.com/pressreleases/23/05/g32434460/hagens-berman-national-trial-attorneys-encourages-chinook-therapeutics-kdny-investors-with-substan,2023-05-16 20:56:57,"SAN FRANCISCO, May 16, 2023 ( GLOBE NEWSWIRE ) -- Hagens Berman urges Chinook Therapeutics, Inc. KDNY investors who suffered substantial losses to submit your losses now. Visit: www.hbsslaw.com/investor-fraud/KDNY Contact An Attorney Now: KDNY@hbsslaw.com 844-916-0895",ABBV,0.192694,-0.041236,Neutral
Chinook Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - Chinook Therapeutics  ( NASDAQ:KDNY ) ,https://www.benzinga.com/pressreleases/23/05/g32427281/chinook-therapeutics-investigated-by-block-leviton-for-potential-securities-law-violations-investo,2023-05-16 16:15:54,"BOSTON, May 16, 2023 ( GLOBE NEWSWIRE ) -- Block & Leviton is investigating Chinook Therapeutics, Inc. KDNY for potential securities law violations. Investors who have lost money in their Chinook Therapeutics, Inc. investment should contact the firm to learn more about how they might recover ...",ABBV,0.116348,-0.16777,Somewhat-Bearish
Peering Into AbbVie's Recent Short Interest - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/short-sellers/23/05/32424426/peering-into-abbvies-recent-short-interest,2023-05-16 14:45:34,"AbbVie's ABBV short percent of float has risen 19.44% since its last report. The company recently reported that it has 15.14 million shares sold short, which is 0.86% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.6 days to cover their ...",ABBV,0.224903,0.158881,Somewhat-Bullish
"Famed Short Seller Muddy Waters Targets Chinook Therapeutics, Points To Drug Data Questions - Chinook Therapeutics  ( NASDAQ:KDNY ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/general/biotech/23/05/32424140/famed-short-seller-muddy-waters-targets-chinook-therapeutics-points-to-drug-data-questions,2023-05-16 14:30:09,"Muddy Waters, a prominent short seller, has announced its short position on Chinook Therapeutics Inc KDNY, citing significant doubts about the company's lead product candidate, atrasentan.",ABBV,0.290033,-0.495344,Bearish
AbbVie Inc.  ( ABBV )  Is a Trending Stock: Facts to Know Before Betting on It,https://www.zacks.com/stock/news/2095706/abbvie-inc-abbv-is-a-trending-stock-facts-to-know-before-betting-on-it,2023-05-16 13:00:13,"AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",ABBV,0.485711,0.137496,Neutral
AstraZeneca to leave leading U.S. drug lobby group,https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-leave-leading-us-drug-lobby-group-2023-05-16/,2023-05-16 11:38:00,"LONDON, May 16 ( Reuters ) - AstraZeneca ( AZN.L ) has decided to leave the main U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America ( PhRMA ) , and pursue other ways of engaging in advocacy at the state and federal level, the company said.",ABBV,0.18967,0.219655,Somewhat-Bullish
Aspergillosis Treatment Market is to reach USD 3569.72 Mn by 2029 at a growth rate of 5.4 percent over the forecast period,https://www.benzinga.com/pressreleases/23/05/g32416515/aspergillosis-treatment-market-is-to-reach-usd-3569-72-mn-by-2029-at-a-growth-rate-of-5-4-percent-,2023-05-16 10:16:55,"Pune, May 16, 2023 ( GLOBE NEWSWIRE ) -- Maximize Market Research, a global Healthcare market research firm has published a competitive intelligence and market research report on the ""Aspergillosis Treatment Market"". The Aspergillosis Treatment Market size was valued at USD 2470.30 Mn in 2022.",ABBV,0.031159,0.133497,Neutral
FCM Director Nominees Will Put MindMed Drug Development Process Back on Track - Mind Medicine  ( NASDAQ:MNMD ) ,https://www.benzinga.com/pressreleases/23/05/g32391165/fcm-director-nominees-will-put-mindmed-drug-development-process-back-on-track,2023-05-15 12:24:20,"FCM Believes MindMed Focused on Pursuing Misguided Clinical Path for MM-120 MindMed Executives, Advisors - Barrow, Karlin, and Liechti - Do Not Have Experience in Bringing Drugs to Market and Are Making Fundamental Errors in Approach MindMed Cash Expected to Run Out in 2024 and Dilution Set to Soar",ABBV,0.043134,0.034584,Neutral
Report Forecasts Promising Future for Alzheimer's Disease Market with New Therapeutic Approaches | Brandessence Market Research,https://www.prnewswire.com/news-releases/report-forecasts-promising-future-for-alzheimers-disease-market-with-new-therapeutic-approaches--brandessence-market-research-301824407.html,2023-05-15 09:32:00,Report Forecasts Promising Future for Alzheimer's Disease Market ... PR ...,ABBV,0.017394,-0.017349,Neutral
"Intrauterine Contraceptive Devices  ( IUD )  Market size to grow by USD 965.49 million between 2022 and 2027; AbbVie Inc., Bayer AG, DKT International among others, identified as key vendors - Technavio",https://www.prnewswire.com/news-releases/intrauterine-contraceptive-devices-iud-market-size-to-grow-by-usd-965-49-million-between-2022-and-2027-abbvie-inc-bayer-ag-dkt-international-among-others-identified-as-key-vendors--technavio-301822563.html,2023-05-15 00:15:00,Intrauterine Contraceptive Devices ( IUD ) Market size to grow by ... PR ...,ABBV,0.05257,0.050714,Neutral
3 Growth Stocks to Buy and Hold,https://www.fool.com/investing/2023/05/13/3-growth-stocks-to-buy-and-hold/,2023-05-13 12:00:00,These three stocks defied the bear market last year.,ABBV,0.03853,0.084813,Neutral
Pfizer CEO Fires Back: US Drug Pricing Reforms - 'Negotiation with a Gun to Your Head' - Pfizer  ( NYSE:PFE ) ,https://www.benzinga.com/general/biotech/23/05/32368106/pfizer-ceo-fires-back-us-drug-pricing-reforms-negotiation-with-a-gun-to-your-head,2023-05-12 17:28:26,"Pfizer Inc's PFE CEO Albert Bourla called U.S. plans to negotiate drug prices for its Medicare health program ""negotiation with a gun to your head."" Bristol Myers Squibb & Co's BMY Eliquis, Pfizer Inc's PFE Ibrance, and AbbVie Inc's ABBV Imbruvica are expected to be among the ten top-selling ...",ABBV,0.297661,0.0,Neutral
Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2023,https://www.globenewswire.com/news-release/2023/05/12/2667534/0/en/Sosei-Heptares-Operational-Highlights-and-Consolidated-Results-for-the-First-Quarter-2023.html,2023-05-12 06:30:00,"Tokyo, Japan and Cambridge, UK, 12 May 2023 - Sosei Group Corporation ( ""the Company"". TSE: 4565 ) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2023. The full report can be found here.",ABBV,0.030446,0.039664,Neutral
This Is What Whales Are Betting On AbbVie - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/05/32352731/this-is-what-whales-are-betting-on-abbvie,2023-05-11 20:31:02,"A whale with a lot of money to spend has taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 14 strange trades. If we consider the specifics of each trade, it is accurate to state that 78% of the investors opened trades with bullish expectations ...",ABBV,0.838176,0.085533,Neutral
Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2023/05/11/2667375/0/en/Harpoon-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html,2023-05-11 20:30:00,"Enrollment for HPN217 ( BCMA ) and HPN328 ( DLL3 ) remain on track, with data updates and selection of recommended Phase 2 doses for both ongoing clinical programs planned in ...",ABBV,0.042876,0.074121,Neutral
"GOP law cut Big Pharma tax rates by 40%, Senate report says",https://www.cnbc.com/2023/05/11/gop-law-cut-big-pharma-tax-rates-by-40percent-senate-report-says.html,2023-05-11 17:07:41,Senate Finance Committee Democrats said the Republican bill resulted in billion of dollars in tax savings for pharmaceutical companies.,ABBV,0.232069,0.099088,Neutral
Is WisdomTree U.S. High Dividend ETF  ( DHS )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2093953/is-wisdomtree-us-high-dividend-etf-dhs-a-strong-etf-right-now,2023-05-11 10:20:08,Smart Beta ETF report for ...,ABBV,0.116067,0.066855,Neutral
Should You Invest in the Vanguard Health Care ETF  ( VHT ) ?,https://www.zacks.com/stock/news/2093950/should-you-invest-in-the-vanguard-health-care-etf-vht,2023-05-11 10:20:06,Sector ETF report for ...,ABBV,0.136888,0.072135,Neutral
ABBV: AbbVie  ( ABBV )  and Catalyst Pharmaceuticals  ( CPRX ) : Analyzing Investment Potential,https://stocknews.com/news/abbv-cprx-abbvie-abbv-and-catalyst-pharmaceuticals-cprx-analyzing-investment-potential/,2023-05-30 17:27:20,ABBV: AbbVie ( ABBV ) and Catalyst Pharmaceuticals ( CPRX ... ...,ABBV,0.346365,0.173523,Somewhat-Bullish
AbbVie Unusual Options Activity - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/05/32630548/abbvie-unusual-options-activity,2023-05-30 17:15:46,"A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 17 strange trades. If we consider the specifics of each trade, it is accurate to state that 41% of the investors opened trades with bullish expectations ...",ABBV,0.730535,0.05803,Neutral
Should Invesco Dynamic Large Cap Value ETF  ( PWV )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2101185/should-invesco-dynamic-large-cap-value-etf-pwv-be-on-your-investing-radar,2023-05-30 10:20:05,Style Box ETF report for ...,ABBV,0.123526,0.068619,Neutral
AbbVie Inc.  ( ABBV )  is Attracting Investor Attention: Here is What You Should Know,https://www.zacks.com/stock/news/2100818/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know,2023-05-29 13:00:11,"AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",ABBV,0.493128,0.083936,Neutral
"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Chinook Therapeutics, Inc. - KDNY",https://www.benzinga.com/pressreleases/23/05/g32609067/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-chinook-therape,2023-05-28 04:51:05,"NEW YORK, May 28, 2023 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ( ""Chinook"" or the ""Company"" ) KDNY. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.",ABBV,0.152499,-0.192941,Somewhat-Bearish
TLRY: Should You Add Shares of Tilray Brands  ( TLRY )  to Your Portfolio?,https://stocknews.com/news/tlry-nvs-nvo-abbv-should-you-add-shares-of-tilray-brands-tlry-to-your/,2023-05-26 17:44:49,TLRY: Should You Add Shares of Tilray Brands ( TLRY ) to Your ... ...,ABBV,0.11123,0.172016,Somewhat-Bullish
2 Biotech Stocks That Could Help Set You Up for Life,https://www.fool.com/investing/2023/05/26/2-biotech-stocks-could-help-set-you-up-for-life/,2023-05-26 13:37:00,These two promising companies have the potential to beat the market over time.,ABBV,0.049322,-0.027935,Neutral
Should You Pick AbbVie Stock Over LLY?,https://www.forbes.com/sites/greatspeculations/2023/05/26/should-you-pick-abbvie-stock-over-lly/,2023-05-26 11:00:56,"Looking at stock returns, Eli Lilly has outperformed AbbVie and the broader indices.",ABBV,0.658693,0.344858,Somewhat-Bullish
Roche to present new data in blood cancers and solid tumours from its broad portfolio at ASCO 2023,https://www.globenewswire.com/news-release/2023/05/26/2676842/0/en/Roche-to-present-new-data-in-blood-cancers-and-solid-tumours-from-its-broad-portfolio-at-ASCO-2023.html,2023-05-26 05:00:00,"Basel, 26 May 2023 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) will be presenting new data on six approved and investigational medicines across ten cancer types at the 2023 American Society of Clinical Oncology ( ASCO ) Annual Meeting, held 2 - 6 June.",ABBV,0.062271,0.04938,Neutral
Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology  ( ASCO )  Annual Meeting and European Hematology Association  ( EHA )  Congress,https://www.globenewswire.com/news-release/2023/05/25/2676782/0/en/Genmab-Announces-Multiple-Abstracts-to-be-Presented-at-the-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting-and-European-Hematology-Association-EHA-Congress.html,2023-05-25 21:10:00,"Media ReleaseCOPENHAGEN, Denmark. May ...",ABBV,0.092426,-0.061399,Neutral
2 Dividend Kings on Sale That Are Yielding More Than 4%,https://www.fool.com/investing/2023/05/25/2-dividend-kingsthat-are-yielding-more-than-4/,2023-05-25 13:37:00,"Before you rush out to buy these stocks, you should consider the risks that come with them.",ABBV,0.501398,0.252229,Somewhat-Bullish
2 Top Dividend Kings to Buy for the Long Haul,https://www.fool.com/investing/2023/05/25/2-top-dividend-kings-to-buy-for-the-long-haul/,2023-05-25 13:00:00,Dividend stocks are an easy way to earn passive income.,ABBV,0.252987,0.2221,Somewhat-Bullish
Worried About a Recession? Stash Your Cash in These 2 ETFs.,https://www.fool.com/investing/2023/05/25/worried-about-a-recession-stash-your-cash-in-these/,2023-05-25 12:45:00,"Rather than holding your cash, consider investing it in these stable ETFs.",ABBV,0.067347,0.033053,Neutral
"The Zacks Analyst Blog Highlights AbbVie, Intel, Qualcomm, Regeneron and CME Group",https://www.zacks.com/stock/news/2099438/the-zacks-analyst-blog-highlights-abbvie-intel-qualcomm-regeneron-and-cme-group,2023-05-25 10:38:00,"AbbVie, Intel, Qualcomm, Regeneron and CME Group are included in this Analyst Blog.",ABBV,0.724687,0.0,Neutral
Should First Trust Morningstar Dividend Leaders ETF  ( FDL )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2099424/should-first-trust-morningstar-dividend-leaders-etf-fdl-be-on-your-investing-radar,2023-05-25 10:20:07,Style Box ETF report for ...,ABBV,0.120733,0.067941,Neutral
Piramal Pharma Limited Announces Consolidated Results for Q4 and FY2023,https://www.prnewswire.com/news-releases/piramal-pharma-limited-announces-consolidated-results-for-q4-and-fy2023-301834018.html,2023-05-24 20:54:00,Piramal Pharma Limited Announces Consolidated Results for Q4 ... PR ...,ABBV,0.028868,-0.004748,Neutral
Piramal Pharma Limited Announces Consolidated Results for Q4 and FY2023,https://www.prnewswire.com/news-releases/piramal-pharma-limited-announces-consolidated-results-for-q4-and-fy2023-301834012.html,2023-05-24 20:49:00,Piramal Pharma Limited Announces Consolidated Results for Q4 ... PR ...,ABBV,0.028833,-0.004748,Neutral
Piramal Pharma Limited Announces Consolidated Results for Q4 and FY2023,https://www.newswire.ca/news-releases/piramal-pharma-limited-announces-consolidated-results-for-q4-and-fy2023-852216985.html,2023-05-24 20:49:00,Piramal Pharma Limited Announces Consolidated Results for Q4 ... Canada ...,ABBV,0.028089,-0.004731,Neutral
"Top Research Reports for AbbVie, Intel & Qualcomm",https://www.zacks.com/research-daily/2099100/top-research-reports-for-abbvie-intel-qualcomm,2023-05-24 20:26:00,"Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Intel Corporation (INTC) and Qualcomm Inc. (QCOM).",ABBV,0.365166,0.199458,Somewhat-Bullish
"Wall Street's Most Accurate Analysts Say Buy These 3 Health Care Stocks With Over 3% Dividend Yields - CVS Health  ( NYSE:CVS ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/trading-ideas/long-ideas/23/05/32550121/wall-streets-most-accurate-analysts-say-buy-these-3-health-care-stocks-with-over-3-divid,2023-05-24 12:35:38,"During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.",ABBV,0.09402,0.085727,Neutral
Jnana Therapeutics Announces Milestone Achieved Under First Collaboration with Roche - Roche Holding  ( OTC:RHHBY ) ,https://www.benzinga.com/pressreleases/23/05/g32547493/jnana-therapeutics-announces-milestone-achieved-under-first-collaboration-with-roche,2023-05-24 11:00:00,"BOSTON, May 24, 2023 ( GLOBE NEWSWIRE ) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, announces the achievement of a milestone from its first collaboration agreement ...",ABBV,0.075397,0.122934,Neutral
"Zacks Industry Outlook Highlights Amphastar, Dr. Reddy's and Teva Pharmaceutical",https://www.zacks.com/stock/news/2098801/zacks-industry-outlook-highlights-amphastar-dr-reddys-and-teva-pharmaceutical,2023-05-24 08:34:00,"Amphastar, Dr. Reddy's and Teva Pharmaceutical have been highlighted in this Industry Outlook article.",ABBV,0.029113,0.060772,Neutral
AbbVie Unusual Options Activity - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/05/32539057/abbvie-unusual-options-activity,2023-05-23 19:16:02,"A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 15 strange trades. If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with bullish expectations ...",ABBV,0.838176,-0.085443,Neutral
Clinical Triumph: MEI Pharma's Voruciclib Demonstrates Encouraging Activity in AML Patients - MEI Pharma  ( NASDAQ:MEIP ) ,https://www.benzinga.com/general/biotech/23/05/32533543/clinical-triumph-mei-pharmas-voruciclib-demonstrates-encouraging-activity-in-aml-patients,2023-05-23 18:49:11,"MEI Pharma Inc MEIP announced an update to the Phase 1 study of voruciclib, an orally administered cyclin-dependent kinase 9 inhibitor, in patients with relapsed and refractory ( R/R ) acute myeloid leukemia ( AML ) or B-cell malignancies.",ABBV,0.31482,-0.108676,Neutral
"If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,200 Today - AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/news/earnings/23/05/32537535/if-you-invested-1000-in-this-stock-10-years-ago-you-would-have-3-200-today,2023-05-23 18:00:28,"AbbVie ABBV has outperformed the market over the past 10 years by 2.6% on an annualized basis producing an average annual return of 12.21%. Currently, AbbVie has a market capitalization of $253.33 billion.",ABBV,0.983605,0.387251,Bullish
"Ironwood  ( IRWD )  to Acquire VectivBio for $1B, Stock Up 3.6%",https://www.zacks.com/stock/news/2098696/ironwood-irwd-to-acquire-vectivbio-for-1b-stock-up-36,2023-05-23 16:07:00,"Ironwood (IRWD) offers to acquire VectivBio, which will help strengthen its gastrointestinal treatment portfolio.",ABBV,0.31282,0.106117,Neutral
Leading Patient Advocate Slams AbbVie's Moves to Deny Vital Drugs to Needy Patients,https://www.prnewswire.com/news-releases/leading-patient-advocate-slams-abbvies-moves-to-deny-vital-drugs-to-needy-patients-301831464.html,2023-05-23 12:03:00,Leading Patient Advocate Slams AbbVie's Moves to Deny Vital ... PR ...,ABBV,0.526707,0.027284,Neutral
3 Generic Drug Stocks to Watch Amid Macro Headwinds,https://www.zacks.com/commentary/2098340/3-generic-drug-stocks-to-watch-amid-macro-headwinds,2023-05-23 12:01:00,"The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.",ABBV,0.030292,0.051993,Neutral
Why Ironwood Pharmaceuticals Stock Bumped Higher Today,https://www.fool.com/investing/2023/05/22/why-ironwood-pharmaceuticals-stock-bumped-higher-t/,2023-05-22 21:43:00,Investors indicated approval of the company's upcoming $1 billion asset purchase.,ABBV,0.148731,0.160553,Somewhat-Bullish
AbbVie Unusual Options Activity - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/05/32516481/abbvie-unusual-options-activity,2023-05-22 19:45:54,"A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 12 strange trades. If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations ...",ABBV,0.838176,-0.085443,Neutral
AbbVie  ( ABBV )  Gets FDA Nod for Lymphoma Drug Epcoritamab,https://www.zacks.com/stock/news/2098146/abbvie-abbv-gets-fda-nod-for-lymphoma-drug-epcoritamab,2023-05-22 16:23:00,"The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug.",ABBV,0.439243,0.228327,Somewhat-Bullish
"KDNY INVESTIGATION: Hagens Berman, National Trial Attorneys, Encourages Chinook Therapeutics  ( KDNY )  Investors with Substantial Losses to Contact Firm's Attorneys, Firm Investigating Possible Securities Law Violations - Chinook Therapeutics  ( NASDAQ:KDNY ) ",https://www.benzinga.com/pressreleases/23/05/g32511518/kdny-investigation-hagens-berman-national-trial-attorneys-encourages-chinook-therapeutics-kdny-inv,2023-05-22 15:35:34,"SAN FRANCISCO, May 22, 2023 ( GLOBE NEWSWIRE ) -- Hagens Berman urges Chinook Therapeutics, Inc. KDNY investors who suffered substantial losses to submit your losses now. Visit: www.hbsslaw.com/investor-fraud/KDNY Contact An Attorney Now: KDNY@hbsslaw.com 844-916-0895",ABBV,0.192694,-0.041236,Neutral
Biotech Mash-Up: $1 Billion Deal Sends Top 2% Stock Flying,https://www.investors.com/news/technology/irwd-stock-dips-as-ironwood-agrees-to-vectivbio-takeover-vect-stock-soars/,2023-05-22 13:43:00,IRWD Stock Dips As Ironwood Agrees to $1 Billion VectivBio ... Investor's Business Daily ...,ABBV,0.199037,-0.308767,Somewhat-Bearish
2 Hot Stocks to Buy and Hold Until You Retire,https://www.fool.com/investing/2023/05/22/2-hot-stocks-to-buy-and-hold-until-you-retire/,2023-05-22 11:15:00,A perk of investing in growth stocks is that they have a lot of room to run.,ABBV,0.051441,0.097945,Neutral
Is Invesco Dynamic Large Cap Value ETF  ( PWV )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2097785/is-invesco-dynamic-large-cap-value-etf-pwv-a-strong-etf-right-now,2023-05-22 10:20:09,Smart Beta ETF report for ...,ABBV,0.115787,0.061204,Neutral
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF  ( PJP ) ?,https://www.zacks.com/stock/news/2097783/should-you-invest-in-the-invesco-dynamic-pharmaceuticals-etf-pjp,2023-05-22 10:20:07,Sector ETF report for ...,ABBV,0.129516,0.063099,Neutral
"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Chinook Therapeutics, Inc. - KDNY",https://www.benzinga.com/pressreleases/23/05/g32501396/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-chinook-therape,2023-05-21 22:21:56,"NEW YORK, May 21, 2023 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ( ""Chinook"" or the ""Company"" ) KDNY. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.",ABBV,0.148731,-0.190055,Somewhat-Bearish
CPRX: Is Catalyst Pharmaceuticals  ( CPRX )  a Buy in the Near Future?,https://stocknews.com/news/cprx-nvs-nvo-abbv-is-catalyst-pharmaceuticals-cprx-a-buy-in-the-near-future/,2023-06-09 18:46:19,"Biopharmaceutical company Catalyst Pharmaceuticals, Inc. ( CPRX ) develops and commercializes therapies for people with rare debilitating, chronic neuromuscular and neurological diseases. The company's offerings include Firdapse to treat Lambert-Eaton Myasthenic Syndrome ( LEMS ) patients.",ABBV,0.133841,0.186357,Somewhat-Bullish
This Foreboding Sign Looms Over AbbVie's Chart - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/23/06/32796983/this-foreboding-sign-looms-over-abbvies-chart,2023-06-09 14:48:24,"If history is any guide, there may be trouble ahead for shares of AbbVie ABBV. A so-called ""death cross"" has formed on its chart and, not surprisingly, this could be bearish for the stock. What To Know: Many traders use moving average crossover systems to make their decisions.",ABBV,0.570165,-0.461617,Bearish
Here is What to Know Beyond Why AbbVie Inc.  ( ABBV )  is a Trending Stock,https://www.zacks.com/stock/news/2106290/here-is-what-to-know-beyond-why-abbvie-inc-abbv-is-a-trending-stock,2023-06-09 13:00:13,"AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",ABBV,0.491255,0.095868,Neutral
Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association  ( EHA )  Annual Meeting 2023,https://www.globenewswire.com/news-release/2023/06/09/2685324/0/en/Genmab-Showcases-Data-From-Comprehensive-Epcoritamab-Development-Program-in-Patients-Across-B-Cell-Lymphomas-at-European-Hematology-Association-EHA-Annual-Meeting-2023.html,2023-06-09 07:01:00,"Media ReleaseCOPENHAGEN, Denmark. June 9, 2023, at 9:00am CEST ...",ABBV,0.084001,-0.056949,Neutral
Is AbbVie or Amgen the Better Bargain Buy Right Now?,https://www.fool.com/investing/2023/06/08/is-abbvie-or-amgen-the-better-bargain-buy-right-no/,2023-06-08 16:15:00,These elite drugmakers are both working through a number of headwinds.,ABBV,0.463792,0.040423,Neutral
5 Top Stocks to Buy in June,https://www.fool.com/investing/2023/06/08/5-top-stocks-to-buy-in-june/,2023-06-08 13:21:00,There are always buying opportunities in the stock market.,ABBV,0.02372,0.091035,Neutral
"Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields - AbbVie  ( NYSE:ABBV ) , Amgen  ( NASDAQ:AMGN ) ",https://www.benzinga.com/news/23/06/32778040/wall-streets-most-accurate-analysts-say-hold-these-3-health-care-stocks-with-over-3-dividend-yields,2023-06-08 13:07:35,"During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.",ABBV,0.110973,0.131969,Neutral
$100 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/news/earnings/23/06/32764918/100-invested-in-abbvie-10-years-ago-would-be-worth-this-much-today,2023-06-07 18:00:37,"AbbVie ABBV has outperformed the market over the past 10 years by 2.04% on an annualized basis producing an average annual return of 12.13%. Currently, AbbVie has a market capitalization of $241.60 billion.",ABBV,0.983605,0.387251,Bullish
Vertex  ( VRTX )  Stock Poised Well for Growth in 2023: Here's Why,https://www.zacks.com/stock/news/2104944/vertex-vrtx-stock-poised-well-for-growth-in-2023-heres-why,2023-06-07 12:55:00,"Vertex Pharmaceuticals (VRTX) stock is likely to be driven by several catalysts this year. Multiple clinical milestones are likely to be achieved in 2023 and 2024, both in its CF and non-CF portfolio.",ABBV,0.218325,0.057814,Neutral
Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference,https://www.globenewswire.com/news-release/2023/06/07/2683740/0/en/Royalty-Pharma-to-Present-at-the-Goldman-Sachs-44th-Annual-Global-Healthcare-Conference.html,2023-06-07 12:15:00,"NEW YORK, June 07, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it is scheduled to present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023 at 5:00 p.m. ET / 2:00 p.m. PT.",ABBV,0.154455,0.099348,Neutral
Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference - Royalty Pharma  ( NASDAQ:RPRX ) ,https://www.benzinga.com/pressreleases/23/06/g32755864/royalty-pharma-to-present-at-the-goldman-sachs-44th-annual-global-healthcare-conference,2023-06-07 12:15:00,"NEW YORK, June 07, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it is scheduled to present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023 at 5:00 p.m. ET / 2:00 p.m. PT.",ABBV,0.146916,0.096402,Neutral
"Pharmaceutical Giant Merck Challenges Inflation Reduction Act over Medicare Drug Pricing, Calls It 'Extortion' - Merck & Co  ( NYSE:MRK ) ",https://www.benzinga.com/general/biotech/23/06/32743949/pharmaceutical-giant-merck-challenges-inflation-reduction-act-over-medicare-drug-pricing-calls-it,2023-06-06 19:03:23,Merck & Co Inc MRK has reportedly filed a lawsuit against the U.S. government to halt implementing the Medicare drug price negotiation program outlined in the Inflation Reduction Act ( IRA ) .,ABBV,0.301315,0.0,Neutral
$300 a Month in These 3 Stocks Could Make You a Millionaire by Retirement,https://www.fool.com/investing/2023/06/06/300-a-month-in-these-3-stocks-could-make-you-a-mil/,2023-06-06 11:30:00,These three stocks have all produced market-beating returns for shareholders in recent years.,ABBV,0.262805,0.2323,Somewhat-Bullish
Piramal Critical Care Appoints Jeffrey Hampton as President & Chief Operating Officer,https://www.prnewswire.com/news-releases/piramal-critical-care-appoints-jeffrey-hampton-as-president--chief-operating-officer-301843488.html,2023-06-06 10:37:00,Piramal Critical Care Appoints Jeffrey Hampton as President & Chief ... PR ...,ABBV,0.058188,-0.020034,Neutral
Piramal Critical Care Appoints Jeffrey Hampton as President & Chief Operating Officer,https://www.prnewswire.com/news-releases/piramal-critical-care-appoints-jeffrey-hampton-as-president--chief-operating-officer-301843483.html,2023-06-06 10:31:00,Piramal Critical Care Appoints Jeffrey Hampton as President & Chief ... PR ...,ABBV,0.058188,-0.020034,Neutral
Piramal Critical Care Appoints Jeffrey Hampton as President & Chief Operating Officer,https://www.newswire.ca/news-releases/piramal-critical-care-appoints-jeffrey-hampton-as-president-amp-chief-operating-officer-860294381.html,2023-06-06 10:31:00,Piramal Critical Care Appoints Jeffrey Hampton as President & Chief ... Canada ...,ABBV,0.055621,-0.020012,Neutral
"Have $1,500? 2 Top Growth Stocks to Buy and Hold for the Long Haul",https://www.fool.com/investing/2023/06/06/have-1500-2-top-growth-stocks-to-buy-and-hold-for/,2023-06-06 09:30:00,Fears of a bear market shouldn't deter long-term investors from quality businesses.,ABBV,0.04076,0.280389,Somewhat-Bullish
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma - Coherus BioSciences  ( NASDAQ:CHRS ) ,https://www.benzinga.com/pressreleases/23/06/g32727642/coherus-announces-positive-final-overall-survival-results-of-jupiter-02-phase-3-trial-evaluating-t,2023-06-05 21:30:00,"- Toripalimab plus chemotherapy resulted in a 37% reduction in the risk of death, HR=0.63, versus chemotherapy alone, in nasopharyngeal carcinoma patients - - No treatments are approved for NPC in the US; if approved, toripalimab will address a critical unmet need -",ABBV,0.023441,0.0,Neutral
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma,https://www.globenewswire.com/news-release/2023/06/05/2682408/33333/en/Coherus-Announces-Positive-Final-Overall-Survival-Results-of-JUPITER-02-Phase-3-Trial-Evaluating-Toripalimab-in-Nasopharyngeal-Carcinoma.html,2023-06-05 21:30:00,"- Toripalimab plus chemotherapy resulted in a 37% reduction in the risk of death, HR=0.63, versus chemotherapy alone, in nasopharyngeal carcinoma patients ...",ABBV,0.018187,0.0,Neutral
Biotech stocks could soon get a M&A boost. Here are 3 likely takeover plays.,https://www.marketwatch.com/story/biotech-stocks-could-soon-get-a-m-a-boost-here-are-3-likely-takeover-plays-206b79c3,2023-06-05 19:05:00,Big pharma will be looking to acquire companies with promsing new medicines.,ABBV,0.129342,-0.065386,Neutral
Morgan Stanley Says S&P 500 Will Slide 9% By Year's End--But These Stocks Could Weather The Storm,https://www.forbes.com/sites/dereksaul/2023/06/05/morgan-stanley-says-sp-500-will-slide-9-by-years-end--but-these-stocks-could-weather-the-storm/,2023-06-05 15:26:39,"AI cheer won't ""be able to stop, or even cushion"" the upcoming earnings recession, Morgan Stanley warned.",ABBV,0.089129,0.152433,Somewhat-Bullish
"Teva Pharmaceuticals Just Made a Big Announcement, but Is It a Buy?",https://www.fool.com/investing/2023/06/05/teva-pharmaceuticals-just-made-a-big-announcement/,2023-06-05 14:00:00,It's unclear whether the pivot will be enough to halt its recent decline.,ABBV,0.058903,0.0,Neutral
Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results at ASCO 2023 Annual Meeting,https://www.newswire.ca/news-releases/dragonfly-therapeutics-announces-the-presentation-of-phase-1-df1001-trinket-r-dose-escalation-results-at-asco-2023-annual-meeting-859454173.html,2023-06-05 14:00:00,Dragonfly Therapeutics Announces the Presentation of Phase 1 ... Canada ...,ABBV,0.043421,0.183294,Somewhat-Bullish
"INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm",https://markets.businessinsider.com/news/stocks/investigation-alert-the-schall-law-firm-announces-it-is-investigating-claims-against-chinook-therapeutics-inc-and-encourages-investors-with-losses-to-contact-the-firm-1032368985,2023-06-04 16:30:00,"LOS ANGELES, CA / ACCESSWIRE / June 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ( ""Chinook"" or ""the Company"" ) ( NASDAQ: KDNY ) for violations of the securities laws.",ABBV,0.156461,-0.218105,Somewhat-Bearish
Autoinjectors Global Market Report 2023: Increasing Prevalence of Chronic Disease Drives Growth,https://www.prnewswire.com/news-releases/autoinjectors-global-market-report-2023-increasing-prevalence-of-chronic-disease-drives-growth-301841281.html,2023-06-03 01:00:00,Autoinjectors Global Market Report 2023: Increasing Prevalence of ... PR ...,ABBV,0.03853,0.12297,Neutral
AbbVie Unusual Options Activity - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/06/32698390/abbvie-unusual-options-activity,2023-06-02 20:01:41,"Someone with a lot of money to spend has taken a bearish stance on AbbVie ABBV. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",ABBV,0.720958,0.166609,Somewhat-Bullish
Why The Biotech Buying Bonanza Will Likely Continue,https://www.investors.com/news/technology/biotech-stocks-are-in-blistering-ma-climate-ftc-could-change-that/,2023-06-02 17:17:00,Biotech Stocks Are In A 'Blistering' M&A Climate. The FTC Could ... Investor's Business Daily ...,ABBV,0.078714,-0.025629,Neutral
Autoinjectors Market worth $1.7 billion | MarketsandMarkets,https://www.prnewswire.com/news-releases/autoinjectors-market-worth-1-7-billion--marketsandmarkets-301840949.html,2023-06-02 17:00:00,"CHICAGO, June 2, 2023 /PRNewswire/ -- The autoinjectors industry is set to experience significant growth in the near future as a result of several factors. With the rise in chronic diseases and the increasing need for self-administration of medication, autoinjectors have emerged as a convenient ...",ABBV,0.021937,0.013872,Neutral
"Pharma Stock Roundup: FDA Okays PFE RSV Jab for Elderly, AZN Ends Brazikumab Studies",https://www.zacks.com/stock/news/2103200/pharma-stock-roundup-fda-okays-pfe-rsv-jab-for-elderly-azn-ends-brazikumab-studies,2023-06-02 14:14:00,FDA approves Pfizer's (PFE) RSV vaccine for older adults and AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated metastatic castration-resistant prostate cancer ...,ABBV,0.092095,-0.041691,Neutral
Dragonfly Therapeutics to Present Phase 1 DF1001 Monotherapy Dose Escalation Results at ASCO 2023 Annual Meeting,https://www.newswire.ca/news-releases/dragonfly-therapeutics-to-present-phase-1-df1001-monotherapy-dose-escalation-results-at-asco-2023-annual-meeting-843394787.html,2023-06-02 11:00:00,Dragonfly Therapeutics to Present Phase 1 DF1001 Monotherapy ... Canada ...,ABBV,0.079392,0.189431,Somewhat-Bullish
SNDL: Is SNDL Inc.  ( SNDL )  Overbought?,https://stocknews.com/news/sndl-nvs-nvo-abbv-is-sndl-inc-sndl-overbought/,2023-06-01 18:17:52,"Headquartered in Calgary, Canada, SNDL Inc. ( SNDL ) produces, distributes, and sells cannabis products under the four broad segments of Liquor Retail; Cannabis Retail; Cannabis Operations; and Investments. The company enjoys significant investor attention, as evident from its position in the ...",ABBV,0.142989,0.192997,Somewhat-Bullish
Mark Cuban Helping Lower Cost Of Bestselling Humira With Cost Plus Drug Company: 'The Game Just Changed',https://markets.businessinsider.com/news/stocks/mark-cuban-helping-lower-cost-of-bestselling-humira-with-cost-plus-drug-company-the-game-just-changed-1032365572,2023-06-01 18:13:51,"One of the bestselling medical drugs of all time has come off patent. The result could mean lower costs for those who need the drug as a treatment option. Enter Mark Cuban and his Cost Plus Drug Company, which announced a new initiative Thursday.",ABBV,0.158868,0.122829,Neutral
AstraZeneca  ( AZN )  Discontinues Brazikumab Development,https://www.zacks.com/stock/news/2102597/astrazeneca-azn-discontinues-brazikumab-development,2023-06-01 14:40:00,AstraZeneca (AZN) announces its decision to discontinue the development of brazikumab for all indications under its inflammatory bowel disease program.,ABBV,0.430088,0.249377,Somewhat-Bullish
AstraZeneca to stop developing Crohn's disease drug,https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-stop-developing-crohns-disease-drug-2023-06-01/,2023-06-01 14:23:00,"June 1 ( Reuters ) - British drugmaker AstraZeneca ( AZN.L ) said on Thursday it would stop developing its drug brazikumab to treat inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.",ABBV,0.350564,-0.488643,Bearish
Coherus BioSciences to launch Humira biosimilar at 85% discount,https://www.reuters.com/business/healthcare-pharmaceuticals/coherus-biosciences-launch-humira-biosimilar-995-per-carton-2023-06-01/,2023-06-01 14:15:00,"June 1 ( Reuters ) - Coherus BioSciences Inc ( CHRS.O ) said on Thursday it plans to launch a biosimilar of AbbVie Inc's ( ABBV.N ) Humira in July at a list price of $995 per carton, representing a discount of about 85% from the blockbuster arthritis drug.",ABBV,0.306963,0.114419,Neutral
Is Merck Stock A Better Pick Over ABBV?,https://www.forbes.com/sites/greatspeculations/2023/06/01/is-merck-stock-a-better-pick-over-abbv/,2023-06-01 12:00:00,"There is more to the comparison, and in the sections below, we discuss why we believe ABBV stock will offer higher returns than MRK stock in the next three years.",ABBV,0.716023,0.363885,Bullish
"Jnana Therapeutics Reports Positive Topline Results from Phase 1a Clinical Study of JNT-517, a Potential First-in-Class Oral Treatment for PKU",https://www.benzinga.com/pressreleases/23/05/g32642999/jnana-therapeutics-reports-positive-topline-results-from-phase-1a-clinical-study-of-jnt-517-a-pote,2023-05-31 11:00:00,JNT-517 demonstrated proof of mechanism and was safe and well tolerated in healthy volunteers Results support advancement to Phase 1b study in individuals with PKU; study now open for enrollment,ABBV,0.045054,0.123941,Neutral
Should You Invest in the Fidelity MSCI Health Care Index ETF  ( FHLC ) ?,https://www.zacks.com/stock/news/2101734/should-you-invest-in-the-fidelity-msci-health-care-index-etf-fhlc,2023-05-31 10:20:08,Sector ETF report for ...,ABBV,0.128135,0.051111,Neutral
"Bragar Eagel & Squire, P.C. Is Investigating Integra, and Chinook and Encourages Investors to Contact the Firm - Chinook Therapeutics  ( NASDAQ:KDNY ) , Integra Lifesciences  ( NASDAQ:IART ) ",https://www.benzinga.com/pressreleases/23/05/g32639975/bragar-eagel-squire-p-c-is-investigating-integra-and-chinook-and-encourages-investors-to-contact-t,2023-05-31 01:00:00,"NEW YORK, May 30, 2023 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Integra LifeSciences Holdings Corp. IART, and Chinook Therapeutics, Inc.",ABBV,0.107495,-0.206213,Somewhat-Bearish
"Department of Health - Abu Dhabi, M42 and AbbVie enter a strategic partnership to advance personalised medicine and genomics",https://www.benzinga.com/pressreleases/23/06/n32914404/department-of-health-abu-dhabi-m42-and-abbvie-enter-a-strategic-partnership-to-advance-personalise,2023-06-19 18:26:00,"ABU DHABI, UAE, June 19, 2023 /PRNewswire/ -- The Department of Health - Abu Dhabi ( DoH ) , the regulator of the healthcare sector in the Emirate, has signed a Memorandum of Understanding ( MoU ) with AbbVie Biopharmaceutical and M42 to elevate collaborative efforts in tailoring personalised ...",ABBV,0.31482,0.402401,Bullish
Lilly's  ( LLY )  Migraine Drug Fails Vis-a-Vis Pfizer's Nurtec ODT,https://www.zacks.com/stock/news/2110200/lillys-lly-migraine-drug-fails-vis-a-vis-pfizers-nurtec-odt,2023-06-19 15:01:00,Results from a post-approval study show that treatment with Lilly's (LLY) Emgality failed to achieve statistical superiority over Pfizer's Nurtec ODT in preventing episodic migraine in adults.,ABBV,0.262994,0.096358,Neutral
"Got $5,000? Buy These 2 Stocks and Hold Them Until Retirement",https://www.fool.com/investing/2023/06/18/buy-nvidia-merck-and-hold-until-retirement/,2023-06-18 11:20:00,"Not every familiar name is a company you can comfortably tuck away in your portfolio for decades, but these two are.",ABBV,0.03792,-0.004955,Neutral
"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Chinook Therapeutics, Inc. - KDNY",https://www.benzinga.com/pressreleases/23/06/g32906259/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-chinook-therape,2023-06-18 02:43:57,"NEW YORK, June 17, 2023 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ( ""Chinook"" or the ""Company"" ) KDNY. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.",ABBV,0.146025,-0.188013,Somewhat-Bearish
"BeiGene, Ltd. Investors: Please contact the Portnoy Law Firm to recover your losses - BeiGene  ( NASDAQ:BGNE ) ",https://www.benzinga.com/pressreleases/23/06/g32903713/beigene-ltd-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses,2023-06-16 23:36:18,"Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 16, 2023 ( GLOBE NEWSWIRE ) -- The Portnoy Law Firm advises BeiGene, Ltd. ( ""BeiGene"" or ""the Company"" ) BGNE investors that the law firm has initiated an investigation on behalf of ...",ABBV,0.204936,-0.20698,Somewhat-Bearish
"Testosterone-replacement therapy doesn't raise 'major' heart risks, study says",https://www.cnn.com/2023/06/16/health/testosterone-replacement-heart-risks/index.html,2023-06-16 20:50:00,"For men who use testosterone-replacement therapy because of low levels of the hormone, the treatment does not appear to be associated with any ""major"" heart risks, according to a new study.",ABBV,0.05133,0.14943,Neutral
"This Biotech Is About to Eat AbbVie's Market Share, but Is It a Buy?",https://www.fool.com/investing/2023/06/16/this-biotech-is-about-to-eat-abbvies-market-share/,2023-06-16 12:30:00,Coherus' biosimilar to Humira could catapult the company to success.,ABBV,0.148426,0.050444,Neutral
AbbVie's  ( ABBV )  Skyrizi Meets Ulcerative Colitis Study Goals,https://www.zacks.com/stock/news/2109293/abbvies-abbv-skyrizi-meets-ulcerative-colitis-study-goals,2023-06-16 11:45:00,AbbVie's (ABBV) Skyrizi achieves statistical significance with its primary endpoint of clinical remission in a late-stage study as a maintenance treatment for ulcerative colitis.,ABBV,0.489394,0.261914,Somewhat-Bullish
"Roche's cancer therapy gets US FDA nod, heating up competition with AbbVie",https://www.reuters.com/business/healthcare-pharmaceuticals/roches-cancer-therapy-gets-us-fda-nod-heating-up-competition-with-abbvie-2023-06-16/,2023-06-16 11:27:00,"Roche's cancer therapy gets US FDA nod, heating up competition with ...",ABBV,0.271274,0.116569,Neutral
"FDA approves Roche's Columvi, the first and only bispecific antibody with a fixed-duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma",https://www.globenewswire.com/news-release/2023/06/16/2689505/0/en/FDA-approves-Roche-s-Columvi-the-first-and-only-bispecific-antibody-with-a-fixed-duration-treatment-for-people-with-relapsed-or-refractory-diffuse-large-B-cell-lymphoma.html,2023-06-16 05:00:00,"Basel, 16 June 2023 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today that the U.S. Food and Drug Administration ( FDA ) has approved Columvi® ( glofitamab-gxbm ) for the treatment of adult patients with relapsed or refractory ( R/R ) diffuse large B-cell lymphoma ( DLBCL ) not otherwise ...",ABBV,0.023214,0.052919,Neutral
"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Chinook Therapeutics, Inc. - KDNY",https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-chinook-therapeutics-inc---kdny-301852580.html,2023-06-15 23:06:00,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Chinook Therapeutics, Inc ... PR ...",ABBV,0.121037,-0.170658,Somewhat-Bearish
AbbVie Touts Promising Results For Risankizumab For Ulcerative Colitis Maintenance - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/general/biotech/23/06/32877734/abbvie-touts-promising-results-for-risankizumab-for-ulcerative-colitis-maintenance,2023-06-15 15:39:16,"AbbVie Inc ABBV announced top-line results from the COMMAND Phase 3 maintenance study, showing risankizumab ( Skyrizi ) achieved the primary endpoint of clinical remission at week 52, as well as key secondary endpoints in moderately to severely active ulcerative colitis.",ABBV,0.558244,0.325593,Somewhat-Bullish
"AbbVie vs Coherus: Dispute Emerges over Upcoming Launch of Low-Cost Biosimilar, Yusimry - AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/general/biotech/23/06/32876282/abbvie-vs-coherus-dispute-emerges-over-upcoming-launch-of-low-cost-biosimilar-yusimry,2023-06-15 15:24:24,"AbbVie Inc ABBV has challenged Coherus BioSciences Inc CHRS, alleging Coherus breached its settlement and license agreement after it announced its plans to launch Yusimry, a biosimilar of blockbuster drug Humira ( adalimumab ) , for rheumatoid arthritis.",ABBV,0.785534,0.334319,Somewhat-Bullish
AbbVie Says BeiGene's Flagship Blood Cancer Drug Infringes Imbruvica Patent - BeiGene  ( NASDAQ:BGNE ) ,https://www.benzinga.com/general/biotech/23/06/32875595/abbvie-says-beigenes-flagship-blood-cancer-drug-infringes-imbruvica-patent,2023-06-15 15:20:54,"BeiGene Ltd BGNE says it is aware that Pharmacyclics LLC has filed a complaint alleging that BeiGene's blood cancer therapy Brukinsa ( zanubrutinib ) infringes a Pharmacyclics patent issued on June 13, 2023. Pharmacyclics is an AbbVie Inc ABBV company.",ABBV,0.501398,-0.501927,Bearish
"Biotech Stock Roundup: KDNY Up on NVS Buyout, BIIB & Eisai's AD Drug Update & More",https://www.zacks.com/stock/news/2108932/biotech-stock-roundup-kdny-up-on-nvs-buyout-biib-eisais-ad-drug-update-more,2023-06-15 14:21:00,Acquisition and regulatory updates from Chinook Therapeutics (KDNY) and Biogen (BIIB) are in focus in the biotech sector.,ABBV,0.078226,0.004104,Neutral
Anti-Ageing Drugs Market to Amass Notable Gains by 2029 Says Brandessence Market Research,https://www.prnewswire.com/news-releases/anti-ageing-drugs-market-to-amass-notable-gains-by-2029-says-brandessence-market-research-301851923.html,2023-06-15 14:01:00,"LONDON, June 15, 2023 /PRNewswire/ -- The body undergoes numerous changes as people age. They eventually start showing signs of ageing and become susceptible to numerous diseases.",ABBV,0.023933,0.100746,Neutral
"Abbvie, Coherus agree to resolve dispute over Humira biosimilar",https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-coherus-agree-resolve-dispute-over-humira-biosimilar-2023-06-15/,2023-06-15 11:17:00,"Abbvie, Coherus agree to resolve dispute over ...",ABBV,0.863144,0.513375,Bullish
Drugmakers want to stop Medicare from negotiating prices. Here's what you should know | Politics,https://www.cnn.com/2023/06/15/politics/medicare-drug-price-negotiations-lawsuits/index.html,2023-06-15 11:04:00,Drugmakers want to stop Medicare from negotiating prices. Here's what you should know ...,ABBV,0.030759,0.015469,Neutral
Biomarkers Market to Grow Significantly by 2029- Brandessence Market Research,https://www.prnewswire.com/news-releases/biomarkers-market-to-grow-significantly-by-2029--brandessence-market-research-301851886.html,2023-06-15 10:40:00,"LONDON, June 15, 2023 /PRNewswire/ -- Biomarkers are referred to as a type of measurable biological indicators or characteristics found in body tissues or fluids like blood.",ABBV,0.023861,0.109009,Neutral
Anaemia Drugs Market to Grow Exponentially by 2029 Says Brandessence Market Research,https://www.prnewswire.com/news-releases/anaemia-drugs-market-to-grow-exponentially-by-2029-says-brandessence-market-research-301851868.html,2023-06-15 10:22:00,"LONDON, June 15, 2023 /PRNewswire/ -- Anaemia is a disorder occurrence by the deficiency of red blood cells or decreasing amount of haemoglobin in the blood. It often leads to extreme weakness, fatigue, pale skin and irregular heartbeat, among others.",ABBV,0.028626,0.100156,Neutral
"Bragar Eagel & Squire, P.C. Is Investigating Integra, Chinook, and DZS and Encourages Investors to Contact the Firm - Integra Lifesciences  ( NASDAQ:IART ) , DZS  ( NASDAQ:DZSI ) ",https://www.benzinga.com/pressreleases/23/06/g32867074/bragar-eagel-squire-p-c-is-investigating-integra-chinook-and-dzs-and-encourages-investors-to-conta,2023-06-15 01:00:00,"NEW YORK, June 14, 2023 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Integra LifeSciences Holdings Corp. IART, Chinook Therapeutics, Inc. KDNY, and DZS Inc.",ABBV,0.092213,-0.197144,Somewhat-Bearish
Mustang  ( MBIO )  Up 9% on Rare Blood Cancer Study's Upbeat Data,https://www.zacks.com/stock/news/2107821/mustang-mbio-up-9-on-rare-blood-cancer-studys-upbeat-data,2023-06-13 17:49:00,Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) CAR T cell therapy has achieved an overall response rate of 83% in patients with Waldenstrom macroglobulinemia.,ABBV,0.432291,0.465369,Bullish
"Ironwood  ( IRWD ) , AbbVie Get FDA Nod for Linzess Label Expansion",https://www.zacks.com/stock/news/2107661/ironwood-irwd-abbvie-get-fda-nod-for-linzess-label-expansion,2023-06-13 13:18:00,Ironwood (IRWD) lead drug Linzess gets FDA approval for pediatric functional constipation The label expansion of the drug is expected to boost the company's sales.,ABBV,0.339978,0.068487,Neutral
"AbbVie, Deere And A Major Chipmaker Set To Win In AI: CNBC's 'Final Trades' - Broadcom  ( NASDAQ:AVGO ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/trading-ideas/long-ideas/23/06/32829494/abbvie-deere-and-a-major-chipmaker-set-to-win-in-ai-cnbcs-final-trades,2023-06-13 12:48:45,"On CNBC's ""Halftime Report Final Trades,"" Bryn Talkington of Requisite Capital Management said AbbVie Inc. ABBV has a 4.5% yield and high free cash flow yield. AbbVie reported reimbursement for VRAYLAR for the treatment of schizophrenia under Non-Insured Health Benefits ( NIHB ) Program.",ABBV,0.690822,0.279462,Somewhat-Bullish
Is SPDR Portfolio S&P 500 High Dividend ETF  ( SPYD )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2107410/is-spdr-portfolio-sp-500-high-dividend-etf-spyd-a-strong-etf-right-now,2023-06-13 10:20:09,Smart Beta ETF report for ...,ABBV,0.114137,0.060868,Neutral
"SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm",https://markets.businessinsider.com/news/stocks/shareholder-action-notice-the-schall-law-firm-announces-it-is-investigating-claims-against-chinook-therapeutics-inc-and-encourages-investors-with-losses-to-contact-the-firm-1032385474,2023-06-13 10:00:00,"LOS ANGELES, CA / ACCESSWIRE / June 13, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ( ""Chinook"" or ""the Company"" ) ( NASDAQ:KDNY ) for violations of the securities laws.",ABBV,0.157483,-0.218995,Somewhat-Bearish
AbbVie  ( ABBV )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2107269/abbvie-abbv-stock-sinks-as-market-gains-what-you-should-know,2023-06-12 21:45:19,"AbbVie (ABBV) closed the most recent trading day at $137.73, moving -0.33% from the previous trading session.",ABBV,0.627711,0.365863,Bullish
SNDL: Is SNDL Inc.  ( SNDL )  a Buy or Sell this Summer?,https://stocknews.com/news/sndl-nvo-abbv-alpmy-is-sndl-inc-sndl-a-buy-or-sell-this-summer/,2023-06-12 18:23:59,"Cannabis companies have been facing severe headwinds, struggling to generate stable revenues and improve their bottom line. Canadian cannabis producer SNDL Inc. ( SNDL ) dealt with these issues through strategic acquisitions and diversifying into the retail liquor business, which helped maintain ...",ABBV,0.16171,0.194371,Somewhat-Bullish
Negotiation or Coercion? Big Pharma and US Chamber of Commerce Tackle Government on Drug Prices - Merck & Co  ( NYSE:MRK ) ,https://www.benzinga.com/general/biotech/23/06/32818125/negotiation-or-coercion-big-pharma-and-us-chamber-of-commerce-tackle-government-on-drug-prices,2023-06-12 16:06:31,"The U.S. Chamber of Commerce has filed a lawsuit against the federal government, challenging a recent law that grants Medicare the authority to negotiate drug prices with pharmaceutical companies. In the complaint, the chamber argued that the pricing program violated the due process rights of ...",ABBV,0.2872,0.0,Neutral
"With the Potential to Revolutionize Personalized Health, Range Biotechnologies Receives $5.2 Million in Seed Funding Led by TechBio-Focused ARTIS Ventures",https://www.benzinga.com/pressreleases/23/06/g32818056/with-the-potential-to-revolutionize-personalized-health-range-biotechnologies-receives-5-2-million,2023-06-12 15:00:00,"San Francisco, CA, June 12, 2023 ( GLOBE NEWSWIRE ) -- Range Biotechnologies ( ""Range Bio"" ) , a proteomics-focused biotech company that has developed an innovative translational platform to enable better diagnostics and faster drug development, has received $5.2 million in Seed funding led by ...",ABBV,0.044304,0.046903,Neutral
"XPeng's New EV Is a Hit, but This Biotech Stock Is Leaving It in the Dust",https://www.fool.com/investing/2023/06/12/xpengs-new-ev-is-a-hit-but-this-biotech-stock-is-l/,2023-06-12 14:07:43,Find out more about two big winners Monday morning.,ABBV,0.1331,0.041506,Neutral
"Down 7% in 2023, This Struggling Growth Stock Could Soon Make a Turnaround",https://www.fool.com/investing/2023/06/12/down-2023-struggle-growth-stock-turnaround/,2023-06-12 13:54:54,Ironwood's plan to purchase a smaller biotech should address some issues that have shareholders concerned.,ABBV,0.05749,0.004007,Neutral
3 Vanguard ETFs That Could Help You Retire a Millionaire,https://www.fool.com/investing/2023/06/12/3-vanguard-etf-could-help-you-retire-a-millionaire/,2023-06-12 12:30:00,"Known for its low-cost ETFs, Vanguard continues to provide investors with innovative and attainable ways to grow wealth.",ABBV,0.048327,0.156858,Somewhat-Bullish
Better Long-Term Buy: AbbVie or Novo Nordisk?,https://www.fool.com/investing/2023/06/10/better-long-term-buy-abbvie-or-novo-nordisk/,2023-06-10 12:05:00,It's important to factor in a pharmaceutical company's pipeline depth.,ABBV,0.543935,0.360598,Bullish
3 No-Brainer Stocks to Buy in June,https://www.fool.com/investing/2023/06/10/3-no-brainer-stocks-to-buy-in-june/,2023-06-10 10:14:00,These biopharma stocks could be big winners.,ABBV,0.044551,0.212788,Somewhat-Bullish
"Bragar Eagel & Squire, P.C. Is Investigating JinkoSolar, Integra, and Chinook and Encourages Investors to Contact the Firm - JinkoSolar Holding Co  ( NYSE:JKS ) , Integra Lifesciences  ( NASDAQ:IART ) ",https://www.benzinga.com/pressreleases/23/06/g32806373/bragar-eagel-squire-p-c-is-investigating-jinkosolar-integra-and-chinook-and-encourages-investors-t,2023-06-10 01:00:00,"NEW YORK, June 09, 2023 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against JinkoSolar Holding Co., Ltd. JKS, Integra LifeSciences Holdings Corp. IART, and Chinook Therapeutics, Inc.",ABBV,0.090134,-0.196102,Somewhat-Bearish
3 Dividend Kings Yielding Royal Sums,https://www.zacks.com/commentary/2114999/3-dividend-kings-yielding-royal-sums,2023-06-29 21:15:00,Dividend Kings are stocks that have raised their dividends for at least 50 consecutive years ...,ABBV,0.514619,0.236102,Somewhat-Bullish
7 Best Dividend Stocks to Buy Now in July 2023,https://www.fool.com/investing/2023/06/29/7-best-dividend-stocks-to-buy-now-in-july-2023/,2023-06-29 21:02:24,"These top dividend stocks are attractive at these levels and lower, and they add excellent diversity to a long-term investing portfolio.",ABBV,0.674691,0.534488,Bullish
This Is What Whales Are Betting On AbbVie - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/06/33066462/this-is-what-whales-are-betting-on-abbvie,2023-06-29 19:39:09,"A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 12 strange trades. If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish expectations ...",ABBV,0.727604,0.05793,Neutral
Hepatitis C cure is not reaching overwhelming majority of patients due to financial barriers,https://www.cnbc.com/2023/06/29/hepatitis-c-cure-isnt-reaching-patients-due-to-cost-cdc-says.html,2023-06-29 17:47:37,Hepatitis C is often referred to as the silent killer because the initial infection has few to no symptoms.,ABBV,0.116348,0.006929,Neutral
Why Are Immunome Shares Trading Higher Today - Immunome  ( NASDAQ:IMNM ) ,https://www.benzinga.com/general/biotech/23/06/33060517/why-are-immunome-shares-trading-higher-today,2023-06-29 14:48:27,"Immunome Inc IMNM and Morphimmune have announced a merger agreement in an all-stock transaction. Combined company to operate as Immunome and retain the same ticker symbol, headquartered in Seattle, WA Clay B. Siegall was appointed CEO, President, and Chairman of Immunome's Board.",ABBV,0.301315,0.178797,Somewhat-Bullish
5 High-Yielding Dividend Stocks That Are Bargain Buys,https://www.fool.com/investing/2023/06/29/5-high-yielding-dividend-stocks-that-are-bargain/,2023-06-29 14:00:00,This is a good time for investors to load up on healthcare companies.,ABBV,0.250816,0.105485,Neutral
Lupin gets $25 mn from AbbVie for meeting key product development milestone,https://www.business-standard.com/companies/news/lupin-gets-25-mn-from-abbvie-for-meeting-key-product-development-milestone-123062900574_1.html,2023-06-29 12:01:29,Drug firm Lupin on Thursday said it has received USD 25 million (around Rs 205 crore) from AbbVie Inc for meeting a key development milestone for a product to treat hematological cancers. The company has achieved a key milestone for its novel MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma ...,ABBV,0.758753,0.495611,Bullish
This may be your best way to make money with S&P 500 Dividend Aristocrat stocks,https://www.marketwatch.com/story/this-may-be-your-best-way-to-make-money-with-s-p-500-dividend-aristocrat-stocks-db2e5887,2023-06-28 15:48:00,"The Aristocrats are dedicated to raising dividends, and the ones that have done so most quickly have tended to be excellent long-term performers in the stock market.",ABBV,0.088964,-0.043599,Neutral
What Will AbbVie Buy Next?,https://www.fool.com/investing/2023/06/28/what-will-abbvie-buy-next/,2023-06-28 12:30:00,Two mid-cap drugmakers stand out as logical targets for AbbVie.,ABBV,0.580018,0.178322,Somewhat-Bullish
"Genmab/AbbVie's Blood Cancer Treatment Shows 82% Response Rate In Pretreated Follicular Lymphoma Patients - Genmab  ( NASDAQ:GMAB ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/general/biotech/23/06/33037640/genmababbvies-blood-cancer-treatment-shows-82-response-rate-in-pretreated-follicular-lymphoma-pat,2023-06-28 10:49:58,"Genmab A/S GMAB and AbbVie Inc ABBV have announced topline results from the follicular lymphoma ( FL ) cohort of the phase 1/2 EPCORE NHL-1 clinical trial evaluating epcoritamab ( DuoBody CD3xCD20 ) , an investigational T-cell engaging bispecific antibody administered subcutaneously.",ABBV,0.377142,0.244959,Somewhat-Bullish
Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla,https://www.globenewswire.com/news-release/2023/06/28/2695996/0/en/Kineta-Expands-Board-of-Directors-with-Biotech-Industry-Leaders-Kim-Drapkin-and-Scott-Dylla.html,2023-06-28 10:30:00,"SEATTLE, June 28, 2023 ( GLOBE NEWSWIRE ) -- Kineta, Inc. ( Nasdaq: KA ) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the appointment of Kim Drapkin and Scott Dylla, Ph.D. to its ...",ABBV,0.098524,-0.008629,Neutral
"Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla - AbbVie  ( NYSE:ABBV ) , Acumen Pharmaceuticals  ( NASDAQ:ABOS ) ",https://www.benzinga.com/pressreleases/23/06/g33038429/kineta-expands-board-of-directors-with-biotech-industry-leaders-kim-drapkin-and-scott-dylla,2023-06-28 10:30:00,"SEATTLE, June 28, 2023 ( GLOBE NEWSWIRE ) -- Kineta, Inc. KA, a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the appointment of Kim Drapkin and Scott Dylla, Ph.D. to its Board of ...",ABBV,0.097457,-0.008598,Neutral
"The Zacks Analyst Blog Highlights Novo Nordisk, Home Depot, Disney, AbbVie and Automatic Data Processing",https://www.zacks.com/stock/news/2113964/the-zacks-analyst-blog-highlights-novo-nordisk-home-depot-disney-abbvie-and-automatic-data-processing,2023-06-28 09:26:00,"Novo Nordisk, Home Depot, Disney, AbbVie and Automatic Data Processing are included in this Analyst Blog.",ABBV,0.699089,0.0,Neutral
Ophthalmology therapeutics market size to increase by USD 15.72 billion from 2022 to 2027; North America will account for 44% of market growth - Technavio,https://www.prnewswire.com/news-releases/ophthalmology-therapeutics-market-size-to-increase-by-usd-15-72-billion-from-2022-to-2027-north-america-will-account-for-44-of-market-growth---technavio-301864687.html,2023-06-28 01:15:00,Ophthalmology therapeutics market size to increase by USD 15.72 billion from 2022 to 2027. North America will ... PR ...,ABBV,0.026013,0.191762,Somewhat-Bullish
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab  ( DuoBody® CD3xCD20 )  in Patients with Relapsed/Refractory Follicular Lymphoma  ( FL ) ,https://www.globenewswire.com/news-release/2023/06/27/2695833/0/en/Genmab-and-AbbVie-Announce-Positive-Topline-Results-from-Phase-1-2-EPCORE-NHL-1-Trial-Evaluating-Epcoritamab-DuoBody-CD3xCD20-in-Patients-with-Relapsed-Refractory-Follicular-Lympho.html,2023-06-27 22:49:00,Company Announcement ...,ABBV,0.13873,0.039029,Neutral
"Top Stock Reports for Novo Nordisk, Home Depot & Walt Disney",https://www.zacks.com/research-daily/2113647/top-stock-reports-for-novo-nordisk-home-depot-walt-disney,2023-06-27 16:29:00,"Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), The Home Depot, Inc. (HD) and The Walt Disney Company (DIS).",ABBV,0.119532,0.152231,Somewhat-Bullish
Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma,https://www.globenewswire.com/news-release/2023/06/27/2695191/0/en/Harpoon-Therapeutics-Announces-Completion-of-Planned-Patient-Enrollment-in-Phase-1-Study-of-HPN217-in-Relapsed-Refractory-Multiple-Myeloma.html,2023-06-27 11:30:00,"SOUTH SAN FRANCISCO, Calif., June 27, 2023 ( GLOBE NEWSWIRE ) -- Harpoon Therapeutics, Inc. ( Nasdaq: HARP ) , a clinical-stage immuno-oncology company developing novel T cell engagers, today announced the completion of planned patient enrollment in the Phase 1 dose escalation study evaluating ...",ABBV,0.074345,0.180947,Somewhat-Bullish
Is Global X SuperDividend U.S. ETF  ( DIV )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2113409/is-global-x-superdividend-us-etf-div-a-strong-etf-right-now,2023-06-27 10:20:06,Smart Beta ETF report for DIV ...,ABBV,0.112532,0.05392,Neutral
Sosei Heptares Provides Update on Lotiglipron Development,https://www.globenewswire.com/news-release/2023/06/26/2694892/0/en/Sosei-Heptares-Provides-Update-on-Lotiglipron-Development.html,2023-06-26 22:40:00,"Tokyo, Japan and Cambridge, UK, 27 June 2023 - Sosei Group Corporation ( ""the Company"". TSE: 4565 ) notes the decision by its partner Pfizer to prioritize the development of clinical-stage GLP-1 receptor agonist candidate danuglipron for the treatment of diabetes and obesity and as a result has ...",ABBV,0.06179,0.061004,Neutral
AbbVie  ( ABBV )  Dips More Than Broader Markets: What You Should Know,https://www.zacks.com/stock/news/2113248/abbvie-abbv-dips-more-than-broader-markets-what-you-should-know,2023-06-26 21:45:23,"AbbVie (ABBV) closed the most recent trading day at $134.95, moving -0.71% from the previous trading session.",ABBV,0.615462,0.043093,Neutral
Antibody-drug Conjugates Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain,https://www.prnewswire.com/news-releases/antibody-drug-conjugates-clinical-trial-pipeline-experiences-momentum-delveinsight-estimates-a-diverse-pipeline-comprising-180-companies-working-in-the-domain-301862784.html,2023-06-26 21:01:00,Antibody-drug Conjugates Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline ... PR ...,ABBV,0.020903,0.064977,Neutral
AbbVie  ( ABBV )  Gets CHMP Positive Opinion for Atogepant Approval,https://www.zacks.com/stock/news/2113181/abbvie-abbv-gets-chmp-positive-opinion-for-atogepant-approval,2023-06-26 15:23:00,"AbbVie (ABBV) receives a positive recommendation from the European Union's medicinal products committee for the approval of its migraine treatment candidate, atogepant.",ABBV,0.490323,0.231421,Somewhat-Bullish
Why This Mutual Fund Darling And Top 1% Stock Nearly Doubled,https://www.investors.com/news/technology/biotech-stock-and-mutual-fund-darling-moonlake-nearly-doubles-here-is-why/,2023-06-26 13:39:00,Biotech Stock And Mutual Fund Darling MoonLake Nearly Doubles ... Investor's Business Daily ...,ABBV,0.325208,0.57014,Bullish
Why CollPlant Biotechnologies Stock Is Trading Higher - CollPlant Biotechnologies  ( NASDAQ:CLGN ) ,https://www.benzinga.com/news/23/06/33005213/why-collplant-biotechnologies-stock-is-trading-higher,2023-06-26 13:17:16,CollPlant Biotechnologies Ltd CLGN shares are trading higher Monday after the company announced it achieved a milestone in its product collaboration agreement with AbbVie Inc ABBV.,ABBV,0.773597,0.366064,Bullish
CollPlant Achieves Milestone and To Receive $10 Million From AbbVie in Accordance with its Regenerative Dermal Filler Product Collaboration Agreement,https://www.prnewswire.com/news-releases/collplant-achieves-milestone-and-to-receive-10-million-from-abbvie-in-accordance-with-its-regenerative-dermal-filler-product-collaboration-agreement-301862929.html,2023-06-26 11:00:00,CollPlant Achieves Milestone and To Receive $10 Million From AbbVie in Accordance with its Regenerative Dermal ... PR ...,ABBV,0.284696,0.219684,Somewhat-Bullish
Should SPDR Portfolio S&P 500 High Dividend ETF  ( SPYD )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2112828/should-spdr-portfolio-sp-500-high-dividend-etf-spyd-be-on-your-investing-radar,2023-06-26 10:20:07,Style Box ETF report for ...,ABBV,0.123844,0.068698,Neutral
"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Chinook Therapeutics, Inc. - KDNY",https://www.benzinga.com/pressreleases/23/06/g33000016/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-chinook-therape,2023-06-26 00:53:30,"NEW YORK, June 25, 2023 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ( ""Chinook"" or the ""Company"" ) KDNY. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.",ABBV,0.148731,-0.190055,Somewhat-Bearish
"ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE - BeiGene  ( NASDAQ:BGNE ) ",https://www.benzinga.com/pressreleases/23/06/g32999638/rosen-a-leading-investor-rights-law-firm-encourages-beigene-ltd-investors-to-inquire-about-securit,2023-06-25 20:00:00,"WHY: NEW YORK, June 25, 2023 ( GLOBE NEWSWIRE ) -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of BeiGene, Ltd. BGNE resulting from allegations that BeiGene may have issued materially misleading business ...",ABBV,0.147366,-0.156712,Somewhat-Bearish
1 Phenomenal High-Yield Dividend Stock You Can Buy and Hold Forever,https://www.fool.com/investing/2023/06/25/1-phenomenal-high-yield-dividend-stock-you-can-buy/,2023-06-25 09:55:00,Few high-yield dividend stocks offer all that this one does.,ABBV,0.769861,0.543238,Bullish
"Bragar Eagel & Squire, P.C. Is Investigating Bowlero, Integra, Chinook, and DLocal and Encourages Investors to Contact the Firm - DLocal  ( NASDAQ:DLO ) , Bowlero  ( NYSE:BOWL ) ",https://www.benzinga.com/pressreleases/23/06/g32998451/bragar-eagel-squire-p-c-is-investigating-bowlero-integra-chinook-and-dlocal-and-encourages-investo,2023-06-25 01:00:00,"NEW YORK, June 24, 2023 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Bowlero Corp. BOWL, Integra LifeSciences Holdings Corp. IART, Chinook Therapeutics, Inc. KDNY, and DLocal Ltd.",ABBV,0.053509,-0.186975,Somewhat-Bearish
"4 Stocks That Can Turn $100,000 Into $500,000 by the Time You Retire",https://www.fool.com/investing/2023/06/24/4-growth-stocks-for-retirement/,2023-06-24 11:20:00,Buy 'em and then just get out of the way. Time and these companies' long-term strength will take care of the rest.,ABBV,0.103479,0.181498,Somewhat-Bullish
"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Chinook Therapeutics, Inc. - KDNY",https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-chinook-therapeutics-inc---kdny-301861428.html,2023-06-24 03:50:00,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Chinook Therapeutics, Inc ... PR ...",ABBV,0.154455,-0.194457,Somewhat-Bearish
Here's How Much $1000 Invested In AbbVie 10 Years Ago Would Be Worth Today - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/news/earnings/23/06/32989732/heres-how-much-1000-invested-in-abbvie-10-years-ago-would-be-worth-today,2023-06-23 18:00:30,"AbbVie ABBV has outperformed the market over the past 10 years by 1.8% on an annualized basis producing an average annual return of 12.24%. Currently, AbbVie has a market capitalization of $241.42 billion.",ABBV,0.983605,0.387251,Bullish
UnitedHealth unit to add Boehringer's Humira biosimilar to reimbursement list,https://www.reuters.com/business/healthcare-pharmaceuticals/unitedhealth-unit-add-boehringers-humira-biosimilar-reimbursement-list-2023-06-23/,2023-06-23 16:23:00,"June 23 ( Reuters ) - Boehringer Ingelheim's biosimilar of AbbVie Inc's ( ABBV.N ) blockbuster arthritis drug Humira will be included in the reimbursement list of UnitedHealth Group Inc's ( UNH.N ) OptumRx unit, the German drugmaker said on Friday.",ABBV,0.407844,0.183739,Somewhat-Bullish
"BGNE LOSS ALERT: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE",https://www.prnewswire.com/news-releases/bgne-loss-alert-rosen-top-ranked-global-counsel-encourages-beigene-ltd-investors-to-inquire-about-securities-class-action-investigation--bgne-301861066.html,2023-06-23 14:59:00,"BGNE LOSS ALERT: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire ... PR ...",ABBV,0.166743,-0.172423,Somewhat-Bearish
"Cramer Says Datadog Will 'Put Up Some Good Numbers,' And 9 More Stock Takes From 'Mad Money' Host - ADT  ( NYSE:ADT ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/trading-ideas/long-ideas/23/06/32980350/cramer-says-datadog-will-put-up-some-good-numbers-and-9-more-stock-takes-from-mad-money-,2023-06-23 12:13:12,"On CNBC's ""Mad Money Lightning Round,"" Jim Cramer said Cummins CMI is a buy. ""Longer term, Cummins is the best there is,"" he added. Cramer said it's never too late to sell ADT ADT, ""that's how bad that is."" When asked about Simon Property Group, Inc. SPG, he said, ""Look, it is a tough situation.",ABBV,0.294093,-0.358793,Bearish
Is AstraZeneca a Top Stock to Buy Right Now?,https://www.fool.com/investing/2023/06/22/is-astrazeneca-a-top-stock-to-buy-right-now/,2023-06-22 18:00:00,The pharma specialist's top-shelf clinical pipeline and product portfolio should be tremendous growth drivers in the years ahead.,ABBV,0.068306,0.032202,Neutral
Is Pfizer Stock a Buy Now?,https://www.fool.com/investing/2023/06/22/is-pfizer-stock-a-buy-now/,2023-06-22 13:30:00,Is the pharmaceutical giant a steal or a value trap?,ABBV,0.056011,0.218981,Somewhat-Bullish
Investors Heavily Search AbbVie Inc.  ( ABBV ) : Here is What You Need to Know,https://www.zacks.com/stock/news/2111711/investors-heavily-search-abbvie-inc-abbv-here-is-what-you-need-to-know,2023-06-22 13:00:11,"AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",ABBV,0.487546,0.098472,Neutral
2 No-Brainer Healthcare Stocks to Buy Right Now,https://www.fool.com/investing/2023/06/22/2-no-brainer-healthcare-stocks-to-buy-right-now/,2023-06-22 12:00:00,Don't bet against these companies.,ABBV,0.398148,0.286844,Somewhat-Bullish
Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network®  ( NCCN® )  Clinical Practice Guidelines in Oncology  ( NCCN Guidelines® )  for 'B-Cell Lymphomas',https://www.globenewswire.com/news-release/2023/06/22/2692779/0/en/Genmab-Announces-Epcoritamab-Added-to-National-Comprehensive-Cancer-Network-NCCN-Clinical-Practice-Guidelines-in-Oncology-NCCN-Guidelines-for-B-Cell-Lymphomas.html,2023-06-22 11:00:00,"Media ReleaseCOPENHAGEN, Denmark. June 22, 2023 - Genmab A/S ( Nasdaq: GMAB ) today announced that epcoritamab, a T-cell engaging bispecific antibody, has been added to the National Comprehensive Cancer Network® ( NCCN® ) Clinical Practice Guidelines in Oncology ( NCCN Guidelines® ) for ""B-cell ...",ABBV,0.100099,-0.064835,Neutral
Alleged Industrial Espionage Makes an Interesting Story,https://www.fool.com/investing/2023/06/21/alleged-industrial-espionage-makes-an-interesting/,2023-06-22 01:09:00,We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment.,ABBV,0.009932,0.00082,Neutral
"Breast Reconstruction Market Revenue to Cross US$ 2.5 Bn, Globally by 2031 - Comprehensive Study by Transparency Market Research",https://www.benzinga.com/pressreleases/23/06/g32955063/breast-reconstruction-market-revenue-to-cross-us-2-5-bn-globally-by-2031-comprehensive-study-by-tr,2023-06-21 19:30:00,"Wilmington, Delaware, United States, June 22, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global breast reconstruction market is anticipated to reach more than US$ 2.5 Bn by 2031 and is projected to grow at a CAGR of 5.3% during the forecast period from 2022 to 2031.",ABBV,0.041682,0.058241,Neutral
"Heated Market For Dueling Blood Cancer Drugs Lands BeiGene In Court - BeiGene  ( NASDAQ:BGNE ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/23/06/32953047/heated-market-for-dueling-blood-cancer-drugs-lands-beigene-in-court,2023-06-21 17:38:42,"A unit of AbbVie has sued BeiGene for alleged patent infringement involving one of the Chinese company's core products, Brukinsa The lawsuit comes amid rapidly growing sales for Brukinsa, which is used to treat blood cancer, even as sales for AbbVie's competing product sag BeiGene Ltd.",ABBV,0.206685,-0.200776,Somewhat-Bearish
"The Zacks Analyst Blog Highlights PepsiCo, AbbVie, Honeywell, Salesforce and Goldman Sachs",https://www.zacks.com/stock/news/2110967/the-zacks-analyst-blog-highlights-pepsico-abbvie-honeywell-salesforce-and-goldman-sachs,2023-06-21 09:00:00,"PepsiCo, AbbVie, Honeywell, Salesforce and Goldman Sachs are included in this Analyst Blog.",ABBV,0.716023,0.0,Neutral
Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis,https://www.prnewswire.com/news-releases/halozyme-announces-argenx-receives-fda-approval-for-vyvgart-hytrulo-with-enhanze-for-subcutaneous-use-in-generalized-myasthenia-gravis-301855994.html,2023-06-20 22:30:00,Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use ... PR ...,ABBV,0.04406,0.083547,Neutral
AbbVie  ( ABBV )  Dips More Than Broader Markets: What You Should Know,https://www.zacks.com/stock/news/2110827/abbvie-abbv-dips-more-than-broader-markets-what-you-should-know,2023-06-20 21:45:19,"In the latest trading session, AbbVie (ABBV) closed at $137.82, marking a -0.59% move from the previous day.",ABBV,0.612033,0.114028,Neutral
Best ETFs For Income Investing: 2023,https://www.forbes.com/sites/investor-hub/article/best-etfs-for-income-investing-2023/,2023-06-20 19:52:12,"ETFs are a great way to generate income. Here's a look at some of the best ETFs for income investors, based on factors such as dividend yield, expense ratio and risk.",ABBV,0.045962,0.137343,Neutral
RegenXbio's Potential Blockbuster: Analyst is Bullish On Stock Citing Potential Gains From AAV Gene Therapies Resurgence - Regenxbio  ( NASDAQ:RGNX ) ,https://www.benzinga.com/news/23/06/32930812/regenxbios-potential-blockbuster-analyst-is-bullish-on-stock-citing-potential-gains-from-aav-gene-th,2023-06-20 18:43:36,Baird has initiated coverage on RegenXbio Inc RGNX with an Outperform rating and a price target of $42. The analyst writes that Regenx has one of the most broad approaches to AAV-based gene therapies.,ABBV,0.428632,-0.014522,Neutral
"Top Analyst Reports for PepsiCo, AbbVie & Honeywell",https://www.zacks.com/research-daily/2110565/top-analyst-reports-for-pepsico-abbvie-honeywell,2023-06-20 16:21:00,"Today's Research Daily features new research reports on 16 major stocks, including PepsiCo, Inc. (PEP), AbbVie Inc. (ABBV) and Honeywell International Inc. (HON).",ABBV,0.323927,0.296451,Somewhat-Bullish
"Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors",https://www.globenewswire.com/news-release/2023/06/20/2691253/0/en/Immix-Biopharma-Subsidiary-Nexcella-Appoints-Jeffrey-H-Cooper-former-Chief-Financial-Officer-of-BioMarin-to-Board-of-Directors.html,2023-06-20 13:45:00,"• Mr. Cooper joins the Nexcella, Inc.",ABBV,0.073773,-0.024154,Neutral
Don't Judge The Tax Cuts And Jobs Act's Anti-Profit-Shifting Measures Yet,https://www.forbes.com/sites/taxnotes/2023/06/20/dont-judge-the-tax-cuts-and-jobs-acts-anti-profit-shifting-measures-yet/,2023-06-20 13:42:11,Ryan Finley explains that casting the 2017 Tax Cuts and Jobs Act's anti-base-erosion measures as a failure is premature.,ABBV,0.031119,0.109032,Neutral
Drugmakers aim to strike down Medicare drug-price negotiations at Supreme Court,https://www.cnbc.com/2023/06/20/drug-prices-drugmakers-aim-to-fight-medicare-negotiations-at-scotus.html,2023-06-20 11:00:02,The lawsuits are the opening salvo in a historic and potentially decisive battle over Medicare's efforts to bring rising drug prices under control.,ABBV,0.023327,-0.106623,Neutral
"Bragar Eagel & Squire, P.C. Is Investigating Integra, Chinook, Phathom, and Akumin and Encourages Investors to Contact the Firm - Integra Lifesciences  ( NASDAQ:IART ) , Akumin  ( NASDAQ:AKU ) ",https://www.benzinga.com/pressreleases/23/06/g32915610/bragar-eagel-squire-p-c-is-investigating-integra-chinook-phathom-and-akumin-and-encourages-investo,2023-06-20 01:00:00,"NEW YORK, June 19, 2023 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Integra LifeSciences Holdings Corp. IART, Chinook Therapeutics, Inc. KDNY, Phathom Pharmaceuticals, Inc. PHAT, and Akumin, Inc.",ABBV,0.052801,-0.186944,Somewhat-Bearish
3 No-Brainer Stocks You Can Buy Right Now,https://www.fool.com/investing/2023/07/08/3-no-brainer-stocks-you-can-buy-right-now/,2023-07-08 10:14:00,Going with these stocks is an easy decision.,ABBV,0.34729,0.098843,Neutral
Check Out What Whales Are Doing With ABBV - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/07/33152571/check-out-what-whales-are-doing-with-abbv,2023-07-07 19:48:46,"A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 18 strange trades. If we consider the specifics of each trade, it is accurate to state that 27% of the investors opened trades with bullish expectations ...",ABBV,0.721785,0.057729,Neutral
World Advanced Wound Management  ( AWM )  Technologies Report 2023: A $15.3 Billion Market by 2028 - Technology Innovations and New Product Development Driving Growth,https://www.prnewswire.com/news-releases/world-advanced-wound-management-awm-technologies-report-2023-a-15-3-billion-market-by-2028---technology-innovations-and-new-product-development-driving-growth-301871863.html,2023-07-07 16:30:00,World Advanced Wound Management ( AWM ) Technologies Report 2023: A $15.3 Billion Market by 2028 - Technology ... PR ...,ABBV,0.072435,-0.023881,Neutral
NVO: 3 July Pharma Picks for Profit,https://stocknews.com/news/nvo-nvs-abbv-3-july-pharma-picks-for-profit/,2023-07-07 16:18:07,"The pharmaceutical industry is expected to grow steadily amid strong demand and government support. Therefore, fundamentally strong pharma stocks Novo Nordisk A/S ( NVO ) , Novartis AG ( NVS ) , and AbbVie Inc. ( ABBV ) could be wise additions to your portfolio now.",ABBV,0.21686,0.221374,Somewhat-Bullish
Global 2000 List 2023: The Top 200,https://www.forbes.com/sites/forbesstaff/2023/07/07/forbes-global-2000-list-2023-the-top-200/,2023-07-07 15:45:31,"Two years after the start of the pandemic, Covid casualties like airlines and oil producers have reclaimed top spots among the largest companies in the world.",ABBV,0.010247,0.097456,Neutral
2 Struggling Dividend Growth Stocks That Could Make You Richer,https://www.fool.com/investing/2023/07/07/2-struggling-dividend-growth-stocks-could-make/,2023-07-07 13:45:00,Let's look beyond these drugmakers' ongoing issues.,ABBV,0.471943,0.192796,Somewhat-Bullish
Buy 5 High ROE Stocks as Market Rally Skids on ADP Jobs Data,https://www.zacks.com/stock/news/2118019/buy-5-high-roe-stocks-as-market-rally-skids-on-adp-jobs-data,2023-07-07 12:09:00,"Dillard's (DDS), Suzano (SUZ), Atkore (ATKR), Nexstar (NXST) and AbbVie (ABBV) are some of the stocks with high ROE to profit from as markets decline on better-than-expected ADP jobs data.",ABBV,0.157073,0.11179,Neutral
Why Dividend Stocks Should Be a Key Part of Your Retirement Plan,https://www.fool.com/investing/2023/07/07/dividend-stocks-should-be-part-of-your-retirement/,2023-07-07 11:15:00,You can collect the dividend income while keeping your original investment intact.,ABBV,0.224383,0.053716,Neutral
Biologics CDMO Market to grow by USD 13.26 billion from 2022 to 2027 | Research and development pipeline of biologics therapeutics to boost the market - Technavio,https://www.prnewswire.com/news-releases/biologics-cdmo-market-to-grow-by-usd-13-26-billion-from-2022-to-2027--research-and-development-pipeline-of-biologics-therapeutics-to-boost-the-market---technavio-301870322.html,2023-07-06 23:45:00,Biologics CDMO Market to grow by USD 13.26 billion from 2022 to 2027 | Research and development pipeline of ... PR ...,ABBV,0.031738,0.020383,Neutral
AbbVie  ( ABBV )  Stock Moves -0.27%: What You Should Know,https://www.zacks.com/stock/news/2117756/abbvie-abbv-stock-moves--027-what-you-should-know,2023-07-06 21:45:23,"AbbVie (ABBV) closed the most recent trading day at $137.25, moving -0.27% from the previous trading session.",ABBV,0.661658,0.190582,Somewhat-Bullish
AbbVie trims full-year profit forecast due to higher R&D expenses,https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-trims-full-year-profit-forecast-due-higher-rd-expenses-2023-07-06/,2023-07-06 20:33:00,"July 6 ( Reuters ) - AbbVie Inc ( ABBV.N ) cut full-year profit forecast due to unfavorable impact from R&D and milestone expenses, the drugmaker said on Thursday. The company now expects adjusted profit between $10.57 and $10.97 per share, compared with $10.72 to $11.12 per share it ...",ABBV,0.558244,-0.265581,Somewhat-Bearish
Is AbbVie's Dividend Yield Safe?,https://www.fool.com/investing/2023/07/06/is-abbvies-dividend-yield-safe/,2023-07-06 17:32:00,"With biosimilar competition ramping up, the drugmaker's free cash flows are poised to shrink this year.",ABBV,0.541766,0.299956,Somewhat-Bullish
Sarepta  ( SRPT )  Sells Priority Review Voucher for $102M,https://www.zacks.com/stock/news/2117602/sarepta-srpt-sells-priority-review-voucher-for-102m,2023-07-06 14:29:00,Sarepta (SRPT) sells its priority review voucher that was awarded following the FDA's approval to Elevidys gene therapy for treating DMD. The company will invest these proceeds into R&D.,ABBV,0.264658,0.188775,Somewhat-Bullish
2 Best Biotech Stocks to Buy in July,https://www.fool.com/investing/2023/07/06/2-best-biotech-stocks-to-buy-in-july/,2023-07-06 14:00:00,These are two of the largest pharmaceutical companies on the planet.,ABBV,0.132004,0.222046,Somewhat-Bullish
"Got $5,000? These Are 3 of the Best Stocks to Buy in July",https://www.fool.com/investing/2023/07/06/got-5000-these-are-3-of-the-best-stocks-to-buy-in/,2023-07-06 13:45:00,"There's something here for dividend, value, and growth investors.",ABBV,0.194242,0.243991,Somewhat-Bullish
2 Growth Stocks That Might Be Too Cheap to Ignore,https://www.fool.com/investing/2023/07/06/2-growth-stocks-that-might-be-too-cheap-to-ignore/,2023-07-06 13:17:00,The sky is the limit for these healthcare companies.,ABBV,0.054359,0.075984,Neutral
AbbVie Inc.  ( ABBV )  Is a Trending Stock: Facts to Know Before Betting on It,https://www.zacks.com/stock/news/2117426/abbvie-inc-abbv-is-a-trending-stock-facts-to-know-before-betting-on-it,2023-07-06 13:00:13,"Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",ABBV,0.491255,0.180342,Somewhat-Bullish
ABBV: AbbVie  ( ABBV )  vs. Pfizer  ( PFE )  - Which Pharma Stock Comes out on Top?,https://stocknews.com/news/abbv-pfe-abbvie-abbv-vs-pfizer-pfe-which-pharma-stock-comes/,2023-07-06 12:53:53,"Pharmaceutical companies are known to maintain their profit margins even during economic downturns due to inelastic demand for their products. In this piece, I evaluated two pharma stocks, AbbVie Inc. ( ABBV ) and Pfizer Inc. ( PFE ) , to determine which comes out on top.",ABBV,0.552693,0.186249,Somewhat-Bullish
"Bragar Eagel & Squire, P.C. Is Investigating Integra, Chinook, DLocal, and Comerica and Encourages Investors to Contact the Firm - Comerica  ( NYSE:CMA ) , DLocal  ( NASDAQ:DLO ) ",https://www.benzinga.com/pressreleases/23/07/g33127055/bragar-eagel-squire-p-c-is-investigating-integra-chinook-dlocal-and-comerica-and-encourages-invest,2023-07-06 01:00:00,"NEW YORK, July 05, 2023 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Integra LifeSciences Holdings Corp. IART, Chinook Therapeutics, Inc. KDNY, DLocal Ltd.",ABBV,0.054236,-0.186994,Somewhat-Bearish
"Bragar Eagel & Squire, P.C. Is Investigating Fox and BeiGene and Encourages Investors to Contact the Firm - BeiGene  ( NASDAQ:BGNE ) , Fox  ( NASDAQ:FOX ) ",https://www.benzinga.com/pressreleases/23/07/g33127051/bragar-eagel-squire-p-c-is-investigating-fox-and-beigene-and-encourages-investors-to-contact-the-f,2023-07-06 01:00:00,"NEW YORK, July 05, 2023 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fox Corp.",ABBV,0.140485,-0.157689,Somewhat-Bearish
Mark Cuban's online pharmacy set to launch Humira biosimilar,https://www.reuters.com/business/healthcare-pharmaceuticals/mark-cubans-online-pharmacy-set-launch-humira-biosimilar-2023-07-05/,2023-07-05 19:06:33,Mark Cuban's online pharmacy set to launch ...,ABBV,0.232439,-0.020074,Neutral
Meet The Company Novartis Is Spending $3.5 Billion To Acquire,https://www.investors.com/news/technology/kdny-stock-meet-chinook-the-company-novartis-is-spending-to-acquire/,2023-07-05 15:45:00,"Chinook Therapeutics ( KDNY ) wasn't looking to sell when Novartis ( NVS ) approached. But the $3.5 billion deal might be the best bet for patients - and KDNY stockholders, says Chinook Chief Executive Eric Dobmeier. The biotech company focuses on rare kidney diseases.",ABBV,0.087824,0.0,Neutral
"Biosion, Inc. Appoints Furqan Ahmed, PharmD as Vice President and Head of Business Development",https://markets.businessinsider.com/news/stocks/biosion-inc-appoints-furqan-ahmed-pharmd-as-vice-president-and-head-of-business-development-1032427692,2023-07-05 14:05:00,"NEWARK, Del. and NANJING, China, July 5, 2023 /PRNewswire/ -- Biosion, Inc. ( ""Biosion"" ) , a global, clinical-stage biotechnology company, today announced the appointment of Furqan Ahmed, PharmD., as the Vice President and Head of Business Development.",ABBV,0.072217,0.137633,Neutral
Celltrion launches biosimilar of AbbVie's blockbuster drug Humira in US,https://www.reuters.com/business/healthcare-pharmaceuticals/celltrion-launches-biosimilar-abbvies-blockbuster-drug-humira-us-2023-07-05/,2023-07-05 11:34:00,"July 5 ( Reuters ) - South Korea's Celltrion Healthcare ( 091990.KQ ) has launched a copycat version to AbbVie Inc's ( ABBV.N ) Humira at about a 5% discount, adding to the growing competition for the blockbuster rheumatoid arthritis drug in the U.S.",ABBV,0.323078,0.149625,Neutral
"Protagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatment - Protagonist Therapeutics  ( NASDAQ:PTGX ) , Johnson & Johnson  ( NYSE:JNJ ) ",https://www.benzinga.com/general/biotech/23/07/33111866/protagonist-therapeutics-janssen-partnered-psoriasis-candidate-fall-short-of-rival-treatment,2023-07-05 11:33:37,Protagonist Therapeutics Inc PTGX announced topline results from the Phase 2b FRONTIER 1 trial of the oral interleukin-23 receptor ( IL-23R ) antagonist JNJ-2113 ( formerly PN-235 ) in adult patients with moderate-to-severe plaque psoriasis presented at World Congress of Dermatology in Singapore.,ABBV,0.31282,0.270703,Somewhat-Bullish
Biosimilar Humira likely to boost US revenues for Biocon Biologics,https://www.business-standard.com/companies/news/biosimilar-humira-likely-to-boost-us-revenues-for-biocon-biologics-123070400777_1.html,2023-07-04 15:29:15,"Biocon Biologics ( BBL ) launched Hulio, a biosimilars version of Abbvie's blockbuster drug Humira, in the US, a market that is already getting crowded with several biosimilars.",ABBV,0.08183,-0.167638,Somewhat-Bearish
AstraZeneca  ( AZN )  Down 9% on Mixed Lung Cancer Study Results,https://www.zacks.com/stock/news/2116564/astrazeneca-azn-down-9-on-mixed-lung-cancer-study-results,2023-07-04 14:41:00,"While AstraZeneca's (AZN) late-stage study evaluating an experimental lung cancer treatment showed improvement in progression free survival, it did not meet the threshold for statistical significance in overall survival.",ABBV,0.237551,0.167927,Somewhat-Bullish
3 Spectacular Dividend Stocks to Buy in July,https://www.fool.com/investing/2023/07/04/3-spectacular-dividend-stocks-to-buy-in-july/,2023-07-04 12:14:00,Heat up your portfolio this month with these dividend stocks.,ABBV,0.377855,0.149887,Neutral
Biocon shares rise after launch of inflammatory disease injection in US,https://www.moneycontrol.com/news/business/stocks/biocon-shares-rise-after-launch-of-inflammatory-disease-injection-in-us-10900181.html,2023-07-04 05:02:18,HULIO is citrate-free and is made without natural rubber latex to help reduce hypersensitivity reactions.,ABBV,0.139265,-0.037733,Neutral
Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight,https://www.prnewswire.com/news-releases/bispecific-antibody-clinical-trial-pipeline-appears-robust-with-250-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-301868673.html,2023-07-03 21:01:00,Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the ... PR ...,ABBV,0.020404,-0.005463,Neutral
India's Biocon Biologics launches biosimilar for AbbVie's Humira in US,https://www.reuters.com/business/healthcare-pharmaceuticals/indias-biocon-biologics-launches-biosimilar-abbvies-humira-us-2023-07-03/,2023-07-03 17:58:00,July 3 ( Reuters ) - India's Biocon Biologics ( BIOC.NS ) said on Monday it has launched a biosimilar version of AbbVie's ( ABBV.N ) blockbuster rheumatoid arthritis drug Humira in the United States.,ABBV,0.128135,-0.07212,Neutral
"Novartis  ( NVS )  to Divest Xiidra, SAF312 to Streamline Focus",https://www.zacks.com/stock/news/2116129/novartis-nvs-to-divest-xiidra-saf312-to-streamline-focus,2023-07-03 16:18:00,Novartis (NVS) signs a deal to divest Xiidra and SAF312 (libvatrep) to Bausch + Lomb for $2.5 billion.,ABBV,0.313218,0.178667,Somewhat-Bullish
"Merck and AbbVie Are Facing Big Patent Cliffs, But Here's Why Both Are Still Buys",https://www.fool.com/investing/2023/07/03/merck-and-abbvie-are-facing-big-patent-cliffs-but/,2023-07-03 13:15:00,"Both companies are facing significant patent cliffs, but they've been preparing for this moment.",ABBV,0.331765,0.202738,Somewhat-Bullish
"Psoriasis Treatment Market Size to reach USD 44 Bn by 2031, growing at a CAGR of 8.7% from 2022-2031: TMR Report",https://www.benzinga.com/pressreleases/23/07/g33094975/psoriasis-treatment-market-size-to-reach-usd-44-bn-by-2031-growing-at-a-cagr-of-8-7-from-2022-2031,2023-07-03 11:30:00,"Wilmington, Delaware, United States, July 03, 2023 ( GLOBE NEWSWIRE ) -- The global psoriasis treatment market is estimated to flourish at a CAGR of 8.7% from 2022 to 2031. According to Transparency Market Research, sales of Psoriasis Treatment are slated to total US$ 44 billion by the end of the ...",ABBV,0.035345,0.158918,Somewhat-Bullish
3 Magnificent Dividend Stocks to Buy Hand Over Fist in July,https://www.fool.com/investing/2023/07/03/magnificent-dividend-stocks-to-buy-in-july/,2023-07-03 09:52:00,These dividend stocks can add some fireworks to income investors' portfolios.,ABBV,0.346642,0.06639,Neutral
"Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for Schizophrenia",https://www.globenewswire.com/news-release/2023/07/03/2698249/0/en/Sosei-Heptares-Doses-First-Subject-in-Phase-I-Trial-with-HTL0048149-a-First-in-Class-GPR52-Agonist-for-Schizophrenia.html,2023-07-03 00:23:00,"Tokyo, Japan and Cambridge, UK, 3 July 2023 - Sosei Group Corporation ( ""the Company"". TSE: 4565 ) , the world leader in G protein-coupled receptor ( GPCR ) focused structure-based drug design ( SBDD ) and development, announces it has dosed the first subject in a Phase I trial evaluating ...",ABBV,0.048919,0.060323,Neutral
Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators?,https://www.fool.com/investing/2023/07/02/could-this-new-drug-be-a-blockbuster-for-these-2/,2023-07-02 13:30:00,"In May, the FDA approved epcoritamab, developed by AbbVie and Genmab, as a treatment for a type of blood cancer.",ABBV,0.371523,-0.084607,Neutral
10 Stocks You Can Buy Right Now With Dividend Yields of Over 4%,https://www.fool.com/investing/2023/07/02/10-stocks-you-can-buy-right-now-with-dividend-yiel/,2023-07-02 09:50:00,Income investors could love these high-yield stocks.,ABBV,0.105836,0.178621,Somewhat-Bullish
Here's How to Tackle the First Full Week of the Third Quarter,https://moneymorning.com/2023/07/01/heres-how-to-tackle-the-first-full-week-of-the-third-quarter/,2023-07-02 00:54:19,"Postcards from the florida republic: An independent and profitable state of mind. We started our return to the Florida Republic… Today, a 4.5-hour trip turned into seven hours thanks to the traffic and congestion around Washington, D.C.",ABBV,0.065957,-0.027299,Neutral
"Organon, Samsung Bioepis launch copycat for arthritis drug Humira at 85% discount",https://www.reuters.com/business/healthcare-pharmaceuticals/organon-samsung-bioepis-launch-copycat-arthritis-drug-humira-85-discount-2023-07-01/,2023-07-01 12:31:00,"July 1 ( Reuters ) - Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVie's ( ABBV.N ) blockbuster arthritis drug Humira, while two other drugmakers entered the market with much more modest discounts to the branded ...",ABBV,0.171485,0.035821,Neutral
"Organon, Samsung Bioepis launch copycat for arthritis drug Humira at 85% discount",https://www.reuters.com/business/healthcare-pharmaceuticals/organon-samsung-bioepis-launch-copycat-athritis-drug-humira-85-discount-2023-07-01/,2023-07-01 10:37:00,"July 1 ( Reuters ) - Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVie's ( ABBV.N ) blockbuster arthritis drug Humira, while another drugmaker entered the market with a much more modest discount to the branded ...",ABBV,0.174587,0.03628,Neutral
Sandoz launches rival version of AbbVie's arthritis drug Humira,https://www.reuters.com/business/healthcare-pharmaceuticals/sandoz-launches-rival-version-abbvies-arthritis-drug-humira-2023-07-01/,2023-07-01 04:20:00,Sandoz launches rival version of AbbVie's arthritis drug ...,ABBV,0.141726,-0.016269,Neutral
"Sandoz to launch Hyrimoz®  ( adalimumab-adaz )  high-concentration formulation, marking Sandoz entrance into US immunology space",https://www.globenewswire.com/news-release/2023/07/01/2698152/0/en/Sandoz-to-launch-Hyrimoz-adalimumab-adaz-high-concentration-formulation-marking-Sandoz-entrance-into-US-immunology-space.html,2023-07-01 04:15:00,"Basel, July 1, 2023 - Sandoz, a global leader in generic pharmaceuticals and biosimilars, today announced that the citrate-free high-concentration formulation ( HCF ) of its biosimilar Hyrimoz® ( adalimumab-adaz ) injection will be available in the United States starting July 1.",ABBV,0.023464,0.0,Neutral
"Bragar Eagel & Squire, P.C. Is Investigating Chinook, DLocal, Comerica, and Advanced Auto Parts and Encourages Investors to Contact the Firm - Advance Auto Parts  ( NYSE:AAP ) , Comerica  ( NYSE:CMA ) ",https://www.benzinga.com/pressreleases/23/06/g33087518/bragar-eagel-squire-p-c-is-investigating-chinook-dlocal-comerica-and-advanced-auto-parts-and-encou,2023-07-01 01:00:00,"NEW YORK, June 30, 2023 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Chinook Therapeutics, Inc. KDNY, DLocal Ltd. DLO, Comerica Incorporated CMA, and Advanced Auto Parts, Inc.",ABBV,0.050044,-0.186702,Somewhat-Bearish
"Bragar Eagel & Squire, P.C. Is Investigating EPAM, Castle, BeiGene and Fox and Encourages Investors to Contact the Firm - BeiGene  ( NASDAQ:BGNE ) , Castle Biosciences  ( NASDAQ:CSTL ) ",https://www.benzinga.com/pressreleases/23/06/g33087515/bragar-eagel-squire-p-c-is-investigating-epam-castle-beigene-and-fox-and-encourages-investors-to-c,2023-07-01 01:00:00,"NEW YORK, June 30, 2023 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against EPAM Systems, Inc. EPAM, Castle Biosciences, Inc. CSTL, BeiGene, Ltd. BGNE, and Fox Corp. FOX FOXA ) ) ) .",ABBV,0.108958,-0.139645,Neutral
"ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE",https://www.prnewswire.com/news-releases/rosen-globally-respected-investor-counsel-encourages-beigene-ltd-investors-to-inquire-about-securities-class-action-investigation--bgne-301868230.html,2023-06-30 20:12:00,"ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About ... PR ...",ABBV,0.166743,-0.172423,Somewhat-Bearish
"For AbbVie's blockbuster Humira, cheaper competitors pose surprisingly little threat, analysts say",https://www.marketwatch.com/story/for-abbvies-blockbuster-humira-cheaper-competitors-pose-surprisingly-little-threat-analysts-say-bf42114e,2023-06-30 17:28:00,Lower-price biosimilar competition for top-selling drug launching this weekend.,ABBV,0.25796,0.003919,Neutral
CPRX: Is Catalyst Pharmaceuticals  ( CPRX )  a Quality Investment?,https://stocknews.com/news/cprx-nvo-abbv-alpmy-is-catalyst-pharmaceuticals-cprx-a-quality-investment/,2023-06-30 17:09:44,"Catalyst Pharmaceuticals, Inc. ( CPRX ) experienced robust growth in the first quarter of 2023, primarily propelled by the growth of FIRDAPSE® and the strong revenue stream derived from its newly acquired product, FYCOMPA®.",ABBV,0.046724,0.165457,Somewhat-Bullish
Why Shares of Alvotech Are Jumping Friday,https://www.fool.com/investing/2023/06/30/why-shares-of-alvotech-are-jumping-friday/,2023-06-30 16:59:48,The biosimilar drug company's shares rebounded a day after it announced that the FDA had dealt it setback.,ABBV,0.132368,0.14552,Neutral
This Is What Whales Are Betting On AbbVie - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/06/33082016/this-is-what-whales-are-betting-on-abbvie,2023-06-30 16:46:05,"Someone with a lot of money to spend has taken a bullish stance on AbbVie ABBV. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",ABBV,0.730954,0.354854,Bullish
BioMarin  ( BMRN )  Gets FDA Nod for Hemophilia A Gene Therapy,https://www.zacks.com/stock/news/2115478/biomarin-bmrn-gets-fda-nod-for-hemophilia-a-gene-therapy,2023-06-30 14:57:00,"Following FDA's approval, BioMarin's (BMRN) Roctavian becomes the first gene therapy for treating severe hemophilia A.",ABBV,0.356865,0.256523,Somewhat-Bullish
Sigilon  ( SGTX )  Skyrockets 441% on Buyout Offer From Eli Lilly,https://www.zacks.com/stock/news/2115393/sigilon-sgtx-skyrockets-441-on-buyout-offer-from-eli-lilly,2023-06-30 13:07:00,"Eli Lilly (LLY) is set to acquire Sigilon (SGTX) for $14.92 per share, in cash, along with a contingent value right of $111.64 per share.",ABBV,0.239895,0.178092,Somewhat-Bullish
"Why Bausch + Lomb  ( BLCO )  Stock Is Trading Higher Premarket Today - Bausch & Lomb  ( NYSE:BLCO ) , Novartis  ( NYSE:NVS ) ",https://www.benzinga.com/general/biotech/23/06/33075984/bausch-lomb-poised-to-boost-presence-in-growing-market-with-potential-1-75b-drug-acquisition-deal,2023-06-30 12:40:15,"Bausch + Lomb Corporation BLCO has agreed to acquire 'front of eye' ophthalmology assets for $1.75 billion in upfront cash, plus additional milestone payments from Novartis AG NVS, marking the first significant move by CEO Brent Saunders since his return to Bausch + Lomb in March of this year.",ABBV,0.28442,0.0,Neutral
3 American Mutual Funds Worth Buying for Long-Term Investing,https://www.zacks.com/stock/news/2115217/3-american-mutual-funds-worth-buying-for-long-term-investing,2023-06-30 11:22:00,"Given the prevailing market conditions, it would be wise for investors to consider allocating their investments to renowned American mutual funds such as RMFEX, WSHFX and FIFAX.",ABBV,0.046907,0.048209,Neutral
Analysis: New Humira rivals likely to hit US market with small discounts in July,https://www.reuters.com/business/healthcare-pharmaceuticals/new-humira-rivals-likely-hit-us-market-with-small-discounts-july-2023-06-30/,2023-06-30 10:02:24,"[1/2] Test tubes are seen in front of a displayed Abbvie logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo",ABBV,0.165031,-0.095555,Neutral
AbbVie  ( ABBV )  Outpaces Stock Market Gains: What You Should Know,https://www.zacks.com/stock/news/2124072/abbvie-abbv-outpaces-stock-market-gains-what-you-should-know,2023-07-19 21:45:23,"AbbVie (ABBV) closed the most recent trading day at $137.68, moving +0.81% from the previous trading session.",ABBV,0.617188,0.250639,Somewhat-Bullish
Pharmaceutical Industry Overview: Top Regions  ( Updated 2023 ) ,https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/top-pharmaceutical-regions/,2023-07-19 21:15:00,"The pharmaceutical industry has a global presence, but the world's biggest markets are the US and Europe. Regions such as China and India have seen growth in recent years, but when it comes to the life science space - particularly the pharma industry - the US and Europe remain on top for ...",ABBV,0.08687,0.094695,Neutral
"Hypertension Market to Accelerate Positively, Estimates DelveInsight | Key Companies Active in the Market - Novartis, Bayer, Merck, Insmed, Acceleron, AbbVie, Alnylam, Apnimed, AstraZeneca, Gossamer Bio",https://www.prnewswire.com/news-releases/hypertension-market-to-accelerate-positively-estimates-delveinsight--key-companies-active-in-the-market---novartis-bayer-merck-insmed-acceleron-abbvie-alnylam--apnimed-astrazeneca-gossamer-bio-301880558.html,2023-07-19 21:01:00,"Hypertension Market to Accelerate Positively, Estimates DelveInsight | Key Companies Active in the Market - Novartis ... PR ...",ABBV,0.049577,0.059691,Neutral
"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Chinook Therapeutics, Inc. - KDNY",https://www.benzinga.com/pressreleases/23/07/g33290948/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-chinook-therape,2023-07-19 18:52:26,"NEW YORK, July 19, 2023 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ( ""Chinook"" or the ""Company"" ) KDNY. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.",ABBV,0.148731,-0.190055,Somewhat-Bearish
"Jnana Therapeutics Appoints George Vratsanos, M.D., as Chief Medical Officer and Head of R&D",https://www.benzinga.com/pressreleases/23/07/g33281406/jnana-therapeutics-appoints-george-vratsanos-m-d-as-chief-medical-officer-and-head-of-r-d,2023-07-19 11:00:00,"BOSTON, July 19, 2023 ( GLOBE NEWSWIRE ) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, today announced the appointment of George Vratsanos, M.D., F.A.C.R., to chief ...",ABBV,0.065685,0.121503,Neutral
Should Schwab U.S. Dividend Equity ETF  ( SCHD )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2123396/should-schwab-us-dividend-equity-etf-schd-be-on-your-investing-radar,2023-07-19 10:20:07,Style Box ETF report for ...,ABBV,0.118354,0.067379,Neutral
5 Beaten-Down Healthcare Stocks With Potential for a Rebound,https://www.barrons.com/articles/bargain-healthcare-stocks-rebound-f2c744a9,2023-07-19 07:31:00,"Investors have fled healthcare stocks this year, ducking out of a trade that seemed a smart defensive play last year, as market conditions have changed. Fear of a recession has eased and interest rates have climbed, making the pull of big pharma's steady dividends less potent.",ABBV,0.154951,0.09473,Neutral
"AbbVie Employees Volunteer to Make an Impact on over 1,300 Lives in Asia with 8th Annual ""Week of Possibilities"" to Support Local Communities",https://www.prnewswire.com/apac/news-releases/abbvie-employees-volunteer-to-make-an-impact-on-over-1-300-lives-in-asia-with-8th-annual-week-of-possibilities-to-support-local-communities-301879461.html,2023-07-19 02:00:00,"AbbVie Employees Volunteer to Make an Impact on over 1300 Lives in Asia with 8th Annual ""Week of Possibilities"" to ... PR ...",ABBV,0.586141,0.568918,Bullish
"Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023",https://www.globenewswire.com/news-release/2023/07/18/2706857/0/en/Royalty-Pharma-to-Announce-Second-Quarter-2023-Financial-Results-on-August-8-2023.html,2023-07-18 20:15:00,"NEW YORK, July 18, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at ...",ABBV,0.139265,0.093545,Neutral
"Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023 - Royalty Pharma  ( NASDAQ:RPRX ) ",https://www.benzinga.com/pressreleases/23/07/g33274257/royalty-pharma-to-announce-second-quarter-2023-financial-results-on-august-8-2023,2023-07-18 20:15:00,"NEW YORK, July 18, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.",ABBV,0.1331,0.091352,Neutral
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/news/earnings/23/07/33273447/heres-how-much-you-would-have-made-owning-abbvie-stock-in-the-last-10-years,2023-07-18 19:30:39,"AbbVie ABBV has outperformed the market over the past 10 years by 1.5% on an annualized basis producing an average annual return of 11.89%. Currently, AbbVie has a market capitalization of $240.46 billion.",ABBV,0.983605,0.387251,Bullish
"Softbank, Amgen-Backed Neumora Therapeutics Unveils Plans For Three Phase 3 Studies For Major Depressive Disorder - Amgen  ( NASDAQ:AMGN ) ",https://www.benzinga.com/general/biotech/23/07/33271456/softbank-amgen-backed-neumora-therapeutics-unveils-plans-for-three-phase-3-studies-for-major-depr,2023-07-18 18:23:56,Neumora Therapeutics unveiled plans for three late-stage studies for its major depressive disorder ( MDD ) candidate Navacaprant. The U.S.-based clinical-stage biopharmaceutical is backed by Softbank Group Corp SFTBY SFTBF and Amgen Inc AMGN via a $100 million equity investment.,ABBV,0.169676,0.174468,Somewhat-Bullish
Peering Into AbbVie's Recent Short Interest - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/short-sellers/23/07/33267070/peering-into-abbvies-recent-short-interest,2023-07-18 13:30:26,"AbbVie's ABBV short percent of float has fallen 7.81% since its last report. The company recently reported that it has 10.36 million shares sold short, which is 0.59% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.43 days to cover their ...",ABBV,0.224903,0.085754,Neutral
"The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer, and Merck",https://www.prnewswire.com/news-releases/the-alliance-for-genomic-discovery-announces-founding-biopharma-members-abbvie-amgen-astrazeneca-bayer-and-merck-301879225.html,2023-07-18 13:15:00,"The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer ... PR ...",ABBV,0.038717,0.062494,Neutral
"The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer, and Merck - Illumina  ( NASDAQ:ILMN ) ",https://www.benzinga.com/pressreleases/23/07/n33266647/the-alliance-for-genomic-discovery-announces-founding-biopharma-members-abbvie-amgen-astrazeneca-b,2023-07-18 13:15:00,"Alliance aims to accelerate therapeutic development and expand the diversity of genomic data through inclusion of more samples from currently underrepresented ancestries SAN DIEGO, July 18, 2023 /PRNewswire/ -- Illumina Inc.",ABBV,0.037681,0.058386,Neutral
"3 Dividend Stocks That Still Make Sense In 2023 - General Mills  ( NYSE:GIS ) , Coca-Cola  ( NYSE:KO ) , PepsiCo  ( NASDAQ:PEP ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33264308/3-dividend-stocks-that-still-make-sense-in-2023,2023-07-18 12:56:57,It was hard to find big stock market winners in 2022. But dividend stocks were among the better performers. Dividend-paying stocks give investors a reward for simply holding on to the stock. That money can be used to reinvest into the stock. This can either add to your gains or help to offset ...,ABBV,0.393462,-0.008195,Neutral
Softbank-backed Neumora's depression drug cuts symptoms in mid-stage trial,https://www.reuters.com/business/healthcare-pharmaceuticals/softbank-backed-neumoras-depression-drug-cuts-symptoms-mid-stage-trial-2023-07-18/,2023-07-18 10:34:00,"July 18 ( Reuters ) - Softbank-backed Neumora Therapeutics' experimental drug navacaprant has helped reduce symptoms of depression in patients with moderate-to-severe forms of the disorder in a mid-stage trial, the company said on Tuesday.",ABBV,0.133841,0.0,Neutral
"The Zacks Analyst Blog Highlights Walmart, AbbVie, Nike, Uber and PayPal",https://www.zacks.com/stock/news/2122562/the-zacks-analyst-blog-highlights-walmart-abbvie-nike-uber-and-paypal,2023-07-18 10:06:00,"Walmart, AbbVie, Nike, Uber and PayPal are included in this Analyst Blog.",ABBV,0.724687,0.0,Neutral
"Top Analyst Reports for Walmart, AbbVie & Nike",https://www.zacks.com/research-daily/2122177/top-analyst-reports-for-walmart-abbvie-nike,2023-07-17 20:54:00,"Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), AbbVie Inc. (ABBV) and Nike, Inc. (NKE).",ABBV,0.404098,0.291949,Somewhat-Bullish
Royalty Pharma Declares Third Quarter 2023 Dividend,https://www.globenewswire.com/news-release/2023/07/17/2705984/0/en/Royalty-Pharma-Declares-Third-Quarter-2023-Dividend.html,2023-07-17 20:15:00,"NEW YORK, July 17, 2023 ( GLOBE NEWSWIRE ) -- The board of directors of Royalty Pharma plc ( Nasdaq: RPRX ) has approved the payment of a dividend for the third quarter of 2023 of $0.20 per Class A ordinary share.",ABBV,0.163909,0.103199,Neutral
Royalty Pharma Declares Third Quarter 2023 Dividend - Royalty Pharma  ( NASDAQ:RPRX ) ,https://www.benzinga.com/pressreleases/23/07/g33255939/royalty-pharma-declares-third-quarter-2023-dividend,2023-07-17 20:15:00,"NEW YORK, July 17, 2023 ( GLOBE NEWSWIRE ) -- The board of directors of Royalty Pharma plc RPRX has approved the payment of a dividend for the third quarter of 2023 of $0.20 per Class A ordinary share. The dividend will be paid on September 15, 2023, to shareholders of record at the close of ...",ABBV,0.155451,0.099746,Neutral
BeiGene's Brukinsa Positioned as Preferred BTK Inhibitor: Analyst Says Survey Supports Bullish View - BeiGene  ( NASDAQ:BGNE ) ,https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33254144/beigenes-brukinsa-positioned-as-preferred-btk-inhibitor-analyst-says-survey-support,2023-07-17 19:32:47,Citi initiated coverage on BeiGene Ltd BGNE with a price target of $275 and a Buy stock rating.,ABBV,0.24289,-0.269808,Somewhat-Bearish
AbbVie Inc.  ( ABBV )  is Attracting Investor Attention: Here is What You Should Know,https://www.zacks.com/stock/news/2121992/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know,2023-07-17 13:00:12,"Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",ABBV,0.487546,0.083339,Neutral
MoonLake's Potential Sale: Stock Price Up Fivefold Since Public Debut In 2022 - MoonLake  ( NASDAQ:MLTX ) ,https://www.benzinga.com/general/biotech/23/07/33244249/moonlakes-potential-sale-stock-price-up-fivefold-since-public-debut-in-2022,2023-07-17 12:37:55,MoonLake Immunotherapeutics MLTX has reportedly engaged an investment bank as the Swiss company looks for a potential sale. The company focuses on developing antibody-derived treatments for inflammatory skin conditions. The is in preliminary talks with pharmaceutical companies interested in a ...,ABBV,0.28387,0.530876,Bullish
Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy,https://www.prnewswire.com/news-releases/positive-topline-data-reported-from-argenxs-adhere-study-of-vyvgart-hytrulo-with-halozymes-enhanze-drug-delivery-technology-in-patients-with-chronic-inflammatory-demyelinating-polyneuropathy-301878178.html,2023-07-17 05:15:00,Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE ... PR ...,ABBV,0.037155,0.082445,Neutral
"Bragar Eagel & Squire, P.C. Is Investigating Chinook, Comerica, Advance Auto Parts, and EPAM and Encourages Investors to Contact the Firm - Advance Auto Parts  ( NYSE:AAP ) , Comerica  ( NYSE:CMA ) ",https://www.benzinga.com/pressreleases/23/07/g33241911/bragar-eagel-squire-p-c-is-investigating-chinook-comerica-advance-auto-parts-and-epam-and-encourag,2023-07-17 00:55:35,"NEW YORK, July 16, 2023 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Chinook Therapeutics, Inc. KDNY, Comerica Incorporated CMA, Advance Auto Parts, Inc. AAP, and EPAM Systems, Inc.",ABBV,0.064276,-0.18769,Somewhat-Bearish
"Bragar Eagel & Squire, P.C. Is Investigating Castle, Coinbase, Arrival, and BeiGene and Encourages Investors to Contact the Firm - BeiGene  ( NASDAQ:BGNE ) , Arrival  ( NASDAQ:ARVL ) ",https://www.benzinga.com/pressreleases/23/07/g33241894/bragar-eagel-squire-p-c-is-investigating-castle-coinbase-arrival-and-beigene-and-encourages-invest,2023-07-17 00:39:00,"NEW YORK, July 16, 2023 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Castle Biosciences, Inc. CSTL, Coinbase Global, Inc. COIN, Arrival SA ARVL, and BeiGene Ltd.",ABBV,0.128822,-0.150492,Somewhat-Bearish
3 Dividend Growth Stocks to Buy and Hold,https://www.fool.com/investing/2023/07/16/3-dividend-growth-stocks-to-buy-and-hold/,2023-07-16 10:15:00,Where these dividends are going is even more important than where they've been.,ABBV,0.308407,0.25621,Somewhat-Bullish
7 Spectacular High-Yield Dividend Stocks to Buy in July,https://www.fool.com/investing/2023/07/16/7-spectacular-high-yield-dividend-stocks-to-buy-in/,2023-07-16 09:50:00,These dividend yields could be hotter for investors than the temperatures this month.,ABBV,0.12165,0.272383,Somewhat-Bullish
"Health News Trends: Mental Health, Migraine and Alzheimer's Awareness Months, and More",https://www.prnewswire.com/resources/news-trends/health-news-trends-may-june-2023,2023-07-14 19:41:47,"Health News Trends: Mental Health, Migraine and Alzheimer's Awareness Months, and More A look at health news from PR Newswire in May and June that you might have missed. Every month, we analyze thousands of wire releases and identify key topics that influence the ways health companies are ...",ABBV,0.029876,0.083848,Neutral
Exclusive: MoonLake Immunotherapeutics explores sale-sources,https://www.reuters.com/business/healthcare-pharmaceuticals/moonlake-immunotherapeutics-explores-sale-sources-2023-07-14/,2023-07-14 19:40:00,Exclusive: MoonLake Immunotherapeutics explores ...,ABBV,0.108466,0.108374,Neutral
AbbVie  ( ABBV )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2120906/abbvie-abbv-stock-sinks-as-market-gains-what-you-should-know,2023-07-13 21:45:22,"In the latest trading session, AbbVie (ABBV) closed at $133.59, marking a -1.03% move from the previous day.",ABBV,0.556576,0.234284,Somewhat-Bullish
"Progressive Supranuclear Palsy Market Growing at a CAGR of 27.7% During the Study Period  ( 2019-2032 ) , Assesses DelveInsight",https://www.prnewswire.com/news-releases/progressive-supranuclear-palsy-market-growing-at-a-cagr-of-27-7-during-the-study-period-20192032-assesses-delveinsight-301876550.html,2023-07-13 21:01:00,"Progressive Supranuclear Palsy Market Growing at a CAGR of 27.7% During the Study Period ( 2019-2032 ) , Assesses ... PR ...",ABBV,0.027731,0.096866,Neutral
2 Magnificient Growth Stocks to Buy in July,https://www.fool.com/investing/2023/07/13/2-magnificient-growth-stocks-to-buy-in-july/,2023-07-13 13:30:00,These two growth stocks might be incredibly undervalued right now.,ABBV,0.066784,-0.024099,Neutral
3Daughters™ Emerges as a Transformative Women's Healthcare Company and Announces Key Leadership and Scientific Advisory Board Appointments,https://www.benzinga.com/pressreleases/23/07/g33213131/3daughters-emerges-as-a-transformative-womens-healthcare-company-and-announces-key-leadership-and-,2023-07-13 12:00:33,3Daughters aims to uniquely address and fill major gaps in Women's Health Assembles experienced Women's Health team and World Class SAB to advance development of novel long-acting reversible contraception technology,ABBV,0.029327,0.112473,Neutral
3 Top Biotech Stocks Defying the Bear Market,https://www.fool.com/investing/2023/07/13/3-top-biotech-stocks-defying-the-bear-market/,2023-07-13 11:45:00,Each has the potential to dramatically outperform the market.,ABBV,0.046006,-0.076503,Neutral
Is WisdomTree U.S. High Dividend ETF  ( DHS )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2120350/is-wisdomtree-us-high-dividend-etf-dhs-a-strong-etf-right-now,2023-07-13 10:20:07,Smart Beta ETF report for ...,ABBV,0.116914,0.067048,Neutral
Chamber of Commerce asks judge to block Medicare drug price negotiations before October 1,https://www.cnbc.com/2023/07/12/chamber-of-commerce-asks-judge-to-block-medicare-drug-negotiations.html,2023-07-12 21:10:11,The U.S. Chamber of Commerce asked a judge to block the landmark ability of Medicare to negotiate drug prices.,ABBV,0.303175,-0.205928,Somewhat-Bearish
"Drugmakers' deal making will plow ahead despite antitrust scrutiny, analysts say",https://www.marketwatch.com/story/drugmakers-deal-making-will-plow-ahead-despite-antitrust-scrutiny-analysts-say-eb36f41b,2023-07-12 19:59:00,"Big pharma goes shopping as ""patent cliff"" puts more than $225 billion in revenues at risk.",ABBV,0.100729,0.108243,Neutral
AbbVie Unusual Options Activity For July 12 - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/07/33204658/abbvie-unusual-options-activity-for-july-12,2023-07-12 18:19:17,"Someone with a lot of money to spend has taken a bearish stance on AbbVie ABBV. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",ABBV,0.699089,0.164371,Somewhat-Bullish
Incyte's  ( INCY )  Opzelura Meets Goal in Phase III Pediatric Study,https://www.zacks.com/stock/news/2119999/incytes-incy-opzelura-meets-goal-in-phase-iii-pediatric-study,2023-07-12 14:52:00,Incyte's (INCY) Opzelura (ruxolitinib cream) meets the primary endpoint in a phase III study in children with atopic dermatitis.,ABBV,0.266828,0.137978,Neutral
Revision Skincare® to Host Annual Business-Building Elite Retreat for Top Aesthetic Practices Across the U.S.,https://www.prnewswire.com/news-releases/revision-skincare-to-host-annual-business-building-elite-retreat-for-top-aesthetic-practices-across-the-us-301875486.html,2023-07-12 13:00:00,Leading Professional Skincare Brand Provides Exclusive Business-Building Immersion for Key Experts in Aesthetics,ABBV,0.075397,0.21797,Somewhat-Bullish
Novo Nordisk  ( NVO )  Falls on EMA Safety Review of Obesity Drugs,https://www.zacks.com/stock/news/2119748/novo-nordisk-nvo-falls-on-ema-safety-review-of-obesity-drugs,2023-07-12 11:57:00,Novo Nordisk's (NVO) important diabetes care and obesity drugs are under review by the EMA's safety committee for the risk of suicidal behavior with its use. The stock falls 3%.,ABBV,0.177802,0.145259,Neutral
Should You Invest in the Vanguard Health Care ETF  ( VHT ) ?,https://www.zacks.com/stock/news/2119617/should-you-invest-in-the-vanguard-health-care-etf-vht,2023-07-12 10:20:07,Sector ETF report for ...,ABBV,0.138066,0.072464,Neutral
Neurocrine Biosciences Announces Appointment of Christine A. Poon to Board of Directors,https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-appointment-of-christine-a-poon-to-board-of-directors-301874728.html,2023-07-11 20:05:00,"SAN DIEGO, July 11, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. ( Nasdaq: NBIX ) today announced that it appointed Christine A. Poon, a business leader with extensive experience in the pharmaceutical industry, to its Board of Directors.",ABBV,0.07913,0.057942,Neutral
Roche  ( RHHBY )  Blood Cancer Drug Columvi Wins EC Approval,https://www.zacks.com/stock/news/2119452/roche-rhhby-blood-cancer-drug-columvi-wins-ec-approval,2023-07-11 16:24:00,Roche's (RHHBY) blood cancer portfolio gets a boost with the EC's approval of Columvi (glofitamab-gxbm) for treating patients with R/R DLBCL.,ABBV,0.286193,0.172492,Somewhat-Bullish
European Commission approves Roche's fixed-duration Columvi  ( glofitamab )  for people with relapsed or refractory diffuse large B-cell lymphoma,https://www.globenewswire.com/news-release/2023/07/11/2702272/0/en/European-Commission-approves-Roche-s-fixed-duration-Columvi-glofitamab-for-people-with-relapsed-or-refractory-diffuse-large-B-cell-lymphoma.html,2023-07-11 05:00:00,"Basel, 11 July 2023 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today that the European Commission ( EC ) has granted conditional marketing authorisation for Columvi® ( glofitamab ) for the treatment of adult patients with relapsed or refractory ( R/R ) diffuse large B-cell lymphoma ( DLBCL ...",ABBV,0.020526,0.052071,Neutral
"Bragar Eagel & Squire, P.C. Is Investigating Integra, Chinook, DLocal, and Comerica and Encourages Investors to Contact the Firm - Comerica  ( NYSE:CMA ) , DLocal  ( NASDAQ:DLO ) ",https://www.benzinga.com/pressreleases/23/07/g33176882/bragar-eagel-squire-p-c-is-investigating-integra-chinook-dlocal-and-comerica-and-encourages-invest,2023-07-11 01:00:00,"NEW YORK, July 10, 2023 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Integra LifeSciences Holdings Corp. IART, Chinook Therapeutics, Inc. KDNY, DLocal Ltd.",ABBV,0.054236,-0.186994,Somewhat-Bearish
"Bragar Eagel & Squire, P.C. Is Investigating BeiGene and Fox and Encourages Investors to Contact the Firm - BeiGene  ( NASDAQ:BGNE ) , Fox  ( NASDAQ:FOX ) ",https://www.benzinga.com/pressreleases/23/07/g33176885/bragar-eagel-squire-p-c-is-investigating-beigene-and-fox-and-encourages-investors-to-contact-the-f,2023-07-11 01:00:00,"NEW YORK, July 10, 2023 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims BeiGene, Ltd. BGNE and Fox Corp. FOX FOXA ) ) ) .",ABBV,0.140896,-0.157952,Somewhat-Bearish
PFE: Should Value Investors Watch Pfizer  ( PFE ) ?,https://stocknews.com/news/pfe-crbu-abbv-nvs-nvo-should-value-investors-watch-pfizer-pfe/,2023-07-10 17:00:01,"Major pharmaceutical corporation Pfizer Inc. ( PFE ) recently channeled $25 million into acquiring a minority interest in Caribou Biosciences, Inc. ( CRBU ) . This move aligns with previous strategies PFE has pursued over recent years, utilizing the substantial cash flow it generated from its ...",ABBV,0.039451,0.168835,Somewhat-Bullish
"Bausch Health  ( BHC )  Secures $600M Financing Facility, Stock Up",https://www.zacks.com/stock/news/2118738/bausch-health-bhc-secures-600m-financing-facility-stock-up,2023-07-10 15:31:00,Bausch (BHC) enters into a $600 million non-recourse financing facility with KKR to boost liquidity.,ABBV,0.338119,0.184897,Somewhat-Bullish
"Novartis  ( NVS )  Entresto Patent Faces Setback, Stock Down",https://www.zacks.com/stock/news/2118727/novartis-nvs-entresto-patent-faces-setback-stock-down,2023-07-10 15:14:00,Novartis (NVS) faces a setback in the patent litigation with respect to the blockbuster heart disease drug Entresto. Shares decline.,ABBV,0.267413,0.153717,Somewhat-Bullish
Replicate Bioscience Appoints Rachael Lester as Chief Business Officer,https://www.prnewswire.com/news-releases/replicate-bioscience-appoints-rachael-lester-as-chief-business-officer-301872292.html,2023-07-10 13:00:00,"Biopharma executive with more than 20 years of global corporate, business development, and commercial strategy experience to join Replicate leadership team",ABBV,0.061949,0.043039,Neutral
Barclays Reaffirms Their Hold Rating on AbbVie  ( ABBV ) ,https://markets.businessinsider.com/news/stocks/barclays-reaffirms-their-hold-rating-on-abbvie-abbv-1032434235,2023-07-10 08:15:12,Barclays Reaffirms Their Hold Rating on AbbVie (ABBV) - Markets Insider ...,ABBV,0.92456,0.339938,Somewhat-Bullish
3 Stocks Retirees Should Absolutely Love,https://www.fool.com/investing/2023/07/29/3-stocks-retirees-should-absolutely-love/,2023-07-29 10:14:00,These stocks offer solid income plus more.,ABBV,0.21803,0.215939,Somewhat-Bullish
"Pharma Stock Roundup: AZN, SNY, ABBV Q2 Results, MRK, MRNA Cancer Jab in Phase III",https://www.zacks.com/stock/news/2129541/pharma-stock-roundup-azn-sny-abbv-q2-results-mrk-mrna-cancer-jab-in-phase-iii,2023-07-28 15:32:00,"AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results.",ABBV,0.190096,0.052047,Neutral
"Cutera taps serial dealmaker Harris as CEO, stock price surges",https://www.reuters.com/business/healthcare-pharmaceuticals/cutera-taps-serial-dealmaker-harris-ceo-stock-price-surges-2023-07-27/,2023-07-27 20:49:00,"July 27 ( Reuters ) - Aesthetics device maker Cutera Inc ( CUTR.O ) said on Thursday it has appointed Taylor Harris, who previously helped lead three companies which ended up getting acquired, as its new chief executive, driving its shares up 23% on dealmaking hopes.",ABBV,0.095138,0.061263,Neutral
AbbVie  ( ABBV )  Q2 2023 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/07/27/abbvie-abbv-q2-2023-earnings-call-transcript/,2023-07-27 20:00:30,"ABBV earnings call for the period ending June 30, 2023.",ABBV,0.044892,0.048737,Neutral
"AbbVie  ( ABBV )  Beats on Q2 Earnings & Sales, Raises '23 View",https://www.zacks.com/stock/news/2128992/abbvie-abbv-beats-on-q2-earnings-sales-raises-23-view,2023-07-27 17:05:00,AbbVie's (ABBV) second-quarter 2023 earnings and sales beat estimates. The company raises its EPS guidance. Stock rises post the announcement.,ABBV,0.182782,0.156185,Somewhat-Bullish
Why AbbVie Stock Is Jumping Today,https://www.fool.com/investing/2023/07/27/why-abbvie-stock-is-jumping-today/,2023-07-27 16:13:37,Humira isn't the only story for AbbVie these days.,ABBV,0.746257,0.291816,Somewhat-Bullish
Why Shares of Evolus Are Jumping Thursday,https://www.fool.com/investing/2023/07/27/why-shares-of-evolus-are-jumping-thursday/,2023-07-27 15:42:19,The stock climbed on record second-quarter revenue and a raise in full-year guidance.,ABBV,0.148731,0.109779,Neutral
AbbVie shares jump as results beat expectations despite blockbuster Humira's declining sales,https://www.marketwatch.com/story/abbvie-shares-climb-after-quarterly-results-beat-expectations-602e0074,2023-07-27 15:15:00,Newer immunology drugs Skyrizi and Rinvoq boost sales in second quarter.,ABBV,0.754753,0.359932,Bullish
AbbVie Stock Jumps After Q2 Earnings - Here's Why - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/general/biotech/23/07/33419999/abbvie-stock-jumps-after-q2-earnings-heres-why,2023-07-27 15:11:25,"AbbVie Inc ABBV has reported Q2 adjusted EPS of $2.91, down 13.6% Y/Y, beating the consensus of $2.80. Overall sales decreased 4.9% Y/Y ( down 4.2% on an operational basis ) to $13.87 billion, beating the consensus of $13.52 billion.",ABBV,0.774534,0.238897,Somewhat-Bullish
"AbbVie raises profit forecast as Humira stays strong, new drugs impress",https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-raises-annual-profit-forecast-humira-stays-strong-new-drugs-impress-2023-07-27/,2023-07-27 13:05:00,July 27 ( Reuters ) - AbbVie ( ABBV.N ) on Thursday raised its annual profit forecast after beating analysts' estimates for second-quarter earnings on a lower-than-expected fall in sales of blockbuster arthritis drug Humira and strong sales of newer treatments.,ABBV,0.203215,0.176097,Somewhat-Bullish
AbbVie  ( ABBV )  Beats Q2 Earnings and Revenue Estimates,https://www.zacks.com/stock/news/2128680/abbvie-abbv-beats-q2-earnings-and-revenue-estimates,2023-07-27 12:55:04,"AbbVie (ABBV) delivered earnings and revenue surprises of 4.30% and 2.54%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?",ABBV,0.404563,0.146695,Neutral
"AbbVie Earnings, Revenue Fall Less Than Expected",https://www.investors.com/news/technology/abbvie-stock-abbvie-earnings-q22023/,2023-07-27 12:27:00,"AbbVie Stock: AbbVie Earnings, Revenue Fall But Top Expectations Investor's Business Daily ...",ABBV,0.949596,0.072879,Neutral
"US Stocks Buckle Up For Solid Open: What Futures Market Shows - KLA  ( NASDAQ:KLAC ) , Alphabet  ( NASDAQ:GOOG ) , Alphabet  ( NASDAQ:GOOGL ) , Meta Platforms  ( NASDAQ:META ) , Roku  ( NASDAQ:ROKU ) , Ford Motor  ( NYSE:F ) , Bristol-Myers Squibb  ( NYSE:BMY ) , McDonald's  ( NYSE:MCD ) , Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , Edwards Lifesciences  ( NYSE:EW ) , First Solar  ( NASDAQ:FSLR ) , Mastercard  ( NYSE:MA ) , Lam Research  ( NASDAQ:LRCX ) , Chipotle Mexican Grill  ( NYSE:CMG ) , SPDR S&P 500  ( ARCA:SPY ) , Western Union  ( NYSE:WU ) ",https://www.benzinga.com/news/earnings/23/07/33416950/us-stocks-buckle-up-for-solid-open-on-metas-earnings-boost-fed-relief-but-analyst-advises-some-valu,2023-07-27 11:48:22,"U.S. stocks could get off to a solid start on Thursday as a Federal Reserve relief rally appears to be in the works. Strong earnings from social media giant Meta Platforms, Inc. META will likely perk up risk appetite further.",ABBV,0.087824,0.0,Neutral
"Bragar Eagel & Squire, P.C. Is Investigating Integra, Chinook, DLocal, and Comerica and Encourages Investors to Contact the Firm - Comerica  ( NYSE:CMA ) , DLocal  ( NASDAQ:DLO ) ",https://www.benzinga.com/pressreleases/23/07/g33407990/bragar-eagel-squire-p-c-is-investigating-integra-chinook-dlocal-and-comerica-and-encourages-invest,2023-07-27 01:00:00,"NEW YORK, July 26, 2023 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Integra LifeSciences Holdings Corp. IART, Chinook Therapeutics, Inc. KDNY, DLocal Ltd.",ABBV,0.054236,-0.186994,Somewhat-Bearish
"Dementia Market to Grow Rapidly, Estimates DelveInsight | Key Companies Active in the Market - Pfizer, Eli Lilly and Company, Janssen, Merck, BioVie, Biogen, Vivoryon, Sage, Alnylam, BioXcel, EIP, Otsuka, Alector, Transposon",https://www.prnewswire.com/news-releases/dementia-market-to-grow-rapidly-estimates-delveinsight--key-companies-active-in-the-market---pfizer-eli-lilly-and-company-janssen-merck-biovie-biogen-vivoryon-sage-alnylam-bioxcel-eip-otsuka-alector-transposon-301885979.html,2023-07-26 21:01:00,"Dementia Market to Grow Rapidly, Estimates DelveInsight | Key Companies Active in the Market - Pfizer, Eli Lilly and ... PR ...",ABBV,0.047607,0.049275,Neutral
"Drama Lacking: Fed Seen Hiking Rates Later Today As Investors Digest Microsoft, Alphabet Results - Apple  ( NASDAQ:AAPL ) , Boeing  ( NYSE:BA ) ",https://www.benzinga.com/markets/23/07/33400341/drama-lacking-fed-seen-hiking-rates-later-today-as-investors-digest-microsoft-alphabet-results,2023-07-26 18:29:02,"( Wednesday market open ) The Federal Reserve wraps up its July meeting today, and the market widely expects a quarter-point rate increase-and wonders what's next. There's debate about whether this is the final hike or if the economy's summer sizzle might warrant another.",ABBV,0.038468,-0.021401,Neutral
AbbVie's Skyrizi Achieves Superiority Versus Amgen's Drug In Head-to-Head Study In Moderate Plaque Psoriasis - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/general/biotech/23/07/33397063/abbvies-skyrizi-achieves-superiority-versus-amgens-drug-in-head-to-head-study-in-moderate-plaque-,2023-07-26 16:25:49,AbbVie Inc ABBV announced that the British Journal of Dermatology published results from the head-to-head Phase 4 IMMpulse study that evaluated the efficacy and safety of Skyrizi ( risankizumab ) compared to Amgen Inc's AMGN Otezla ( apremilast ) for moderate plaque psoriasis eligible for ...,ABBV,0.642555,0.293333,Somewhat-Bullish
AbbVie may see less pain from Humira sales decline as rival lags,https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-may-see-less-pain-humira-sales-decline-rival-lags-2023-07-26/,2023-07-26 16:06:00,July 26 ( Reuters ) - AbbVie Inc ( ABBV.N ) is likely to beat Wall Street sales estimates for Humira in the second quarter as the only copycat in the U.S. market for the blockbuster arthritis drug struggled to gain traction.,ABBV,0.521465,-0.06581,Neutral
Seven Humira Biosimilars: Increased Competition In Arthritis Drug Market Sparks Need For Reform Of Drug Pricing Intermediaries - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/general/biotech/23/07/33386891/seven-humira-biosimilars-increased-competition-in-arthritis-drug-market-sparks-need-for-reform-of,2023-07-26 13:06:34,Seven pharmaceutical companies recently launched their biosimilars of AbbVie Inc's ABBV top-selling arthritis drug Humira.,ABBV,0.328819,0.265693,Somewhat-Bullish
3 Stocks to Buy While They Are on Sale,https://www.fool.com/investing/2023/07/26/3-stocks-to-buy-while-they-are-on-sale/,2023-07-26 09:51:00,These stocks might not remain as cheap as they are now for too much longer.,ABBV,0.373751,0.265904,Somewhat-Bullish
Looking to Get Richer? These 2 Dividend Stocks Have Doubled in 5 Years,https://www.fool.com/investing/2023/07/26/get-richer-2-dividend-stocks-doubled-5-years/,2023-07-26 09:20:00,A pharmaceutical company and a health insurance company outperformed the S&P 500 and paid a dividend.,ABBV,0.357293,0.238884,Somewhat-Bullish
"The Zacks Analyst Blog Highlights Toyota, Deere, Starbucks, AbbVie and DexCom",https://www.zacks.com/stock/news/2127481/the-zacks-analyst-blog-highlights-toyota-deere-starbucks-abbvie-and-dexcom,2023-07-26 09:00:00,"Toyota, Deere, Starbucks, AbbVie and DexCom are included in this Analyst Blog.",ABBV,0.149656,0.039096,Neutral
NCLA Amicus Brief Asks Second Circuit Appeals Court to Uphold Decision Limiting Antitrust Liability,https://www.benzinga.com/pressreleases/23/07/g33380635/ncla-amicus-brief-asks-second-circuit-appeals-court-to-uphold-decision-limiting-antitrust-liabilit,2023-07-25 22:14:31,"Washington, D.C., July 25, 2023 ( GLOBE NEWSWIRE ) -- In a major March victory, Judge Lewis J. Liman of the U.S. District Court for the Southern District of New York dismissed the In re Bystolic antitrust lawsuit, citing a powerful argument in NCLA's district court amicus curiae brief joined by ...",ABBV,0.067347,-0.034996,Neutral
"Growing Competition in Hematology, Aesthetics Complicates AbbVie's Post-Humira Landscape, Analyst Says - AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33372768/growing-competition-in-hematology-aesthetics-complicates-abbvies-post-humira-landsc,2023-07-25 19:35:37,"William Blair has initiated coverage on AbbVie Inc ABBV with a Market Perform rating. The analysts Tim Lugo, Lachlan Hanbury-Brown and John Boyle said that while the company was prepared for the launch of Humira biosimilars, the Humira loss of exclusivity is complicated by growing competition in ...",ABBV,0.470894,0.230195,Somewhat-Bullish
"Double Dipping: Microsoft, Alphabet Earnings Both Due After Close as Fed Meeting Begins - Alaska Air Gr  ( NYSE:ALK ) , Amazon.com  ( NASDAQ:AMZN ) ",https://www.benzinga.com/markets/23/07/33375056/double-dipping-microsoft-alphabet-earnings-both-due-after-close-as-fed-meeting-begins,2023-07-25 17:21:24,"( Tuesday market open ) This afternoon serves up a double-feature, and it's not ""Barbenheimer."" Microsoft MSFT and Alphabet GOOGL accelerate the mega-cap earnings season by reporting today after the close, followed by Meta Platforms META tomorrow.",ABBV,0.038437,-0.021399,Neutral
Will AbbVie's  ( ABBV )  New Drugs Make Up for Low Humira Sales?,https://www.zacks.com/stock/news/2127139/will-abbvies-abbv-new-drugs-make-up-for-low-humira-sales,2023-07-25 14:48:00,"In its Q2 earnings results, AbbVie's (ABBV) Skyrizi and Rinvoq sales are expected to have made up for the declining Humira sales following the loss of U.S. exclusivity.",ABBV,0.174587,0.126932,Neutral
AbbVie turns to newer immunology drugs as blockbuster Humira faces lower-cost competition,https://www.marketwatch.com/story/abbvie-turns-to-newer-immunology-drugs-as-blockbuster-humira-faces-lower-cost-competition-5bb93693,2023-07-25 14:41:00,"Investors look for signs that Skyrizi, Rinvoq can take the baton as Humira sales falter ...",ABBV,0.457566,0.159376,Somewhat-Bullish
ABBV: Is AbbVie  ( ABBV )  a Better Stock to Buy Than Pfizer  ( PFE ) ?,https://stocknews.com/news/abbv-pfe-opk-gmab-is-abbvie-abbv-a-better-stock-to-buy-than-pfizer/,2023-07-25 14:28:01,"In this article, I have evaluated leading medical stocks AbbVie Inc. ( ABBV ) and Pfizer Inc. ( PFE ) to analyze which stock is the better buy. After thoroughly evaluating these stocks, I think ABBV might be the right pick for the reasons discussed in this article.",ABBV,0.532941,0.23476,Somewhat-Bullish
Earnings Preview: Pfizer  ( PFE )  Q2 Earnings Expected to Decline,https://www.zacks.com/stock/news/2126966/earnings-preview-pfizer-pfe-q2-earnings-expected-to-decline,2023-07-25 14:01:33,Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,ABBV,0.176502,-0.002866,Neutral
Health Canada Approves AbbVie's RINVOQ®  ( upadacitinib )  for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis,https://www.newswire.ca/news-releases/health-canada-approves-abbvie-s-rinvoq-r-upadacitinib-for-the-treatment-of-adults-with-moderately-to-severely-active-ulcerative-colitis-819598268.html,2023-07-25 11:00:00,Health Canada Approves AbbVie's RINVOQ® ( upadacitinib ) for the Treatment of Adults with Moderately to Severely ... Canada ...,ABBV,0.244109,0.143525,Neutral
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF  ( PJP ) ?,https://www.zacks.com/stock/news/2126629/should-you-invest-in-the-invesco-dynamic-pharmaceuticals-etf-pjp,2023-07-25 10:20:08,Sector ETF report for ...,ABBV,0.131643,0.063605,Neutral
Launch of arthritis drug biosimilars ramps up US pressure on pricing 'middlemen',https://www.reuters.com/business/healthcare-pharmaceuticals/launch-arthritis-drug-biosimilars-ramps-up-us-pressure-pricing-middlemen-2023-07-25/,2023-07-25 10:08:00,"[1/3] Test tubes are seen in front of a displayed Abbvie logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo",ABBV,0.046907,0.0,Neutral
"Zacks Investment Ideas feature highlights: Chipotle Mexican Grill, Visa and AbbVie",https://www.zacks.com/stock/news/2126604/zacks-investment-ideas-feature-highlights-chipotle-mexican-grill-visa-and-abbvie,2023-07-25 09:00:00,"Chipotle Mexican Grill, Visa and AbbVie have been highlighted in this Investment Ideas article.",ABBV,0.330876,0.146215,Neutral
3 Non-Tech Reports to Watch This Week,https://www.zacks.com/commentary/2126428/3-non-tech-reports-to-watch-this-week,2023-07-24 21:32:00,"While many remain focused on tech, there are several other notable quarterly reports scheduled to come this week, including these three.",ABBV,0.390904,0.182744,Somewhat-Bullish
Check Out What Whales Are Doing With ABBV - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/07/33351456/check-out-what-whales-are-doing-with-abbv,2023-07-24 17:45:43,"Someone with a lot of money to spend has taken a bearish stance on AbbVie ABBV. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",ABBV,0.68732,0.163118,Somewhat-Bullish
"Brace For Action: Big Week Ahead Includes Fed Meeting, Heavy Earnings And Data Calendar - Apple  ( NASDAQ:AAPL ) , FedEx  ( NYSE:FDX ) ",https://www.benzinga.com/markets/23/07/33349594/brace-for-action-big-week-ahead-includes-fed-meeting-heavy-earnings-and-data-calendar,2023-07-24 16:07:03,"( Monday market open ) The week ahead has something for everyone, including a Federal Reserve meeting and reports from roughly 30% of all S&P 500® companies. Most of the action starts tomorrow, and trading was subdued in premarket hours Monday as investors awaited the excitement to come.",ABBV,0.042011,-0.021619,Neutral
"Medical Aesthetics Market size worth $ 27.55 Billion, Globally, by 2028 at 10.6% CAGR: Verified Market Research®",https://www.prnewswire.com/news-releases/medical-aesthetics-market-size-worth--27-55-billion-globally-by-2028-at-10-6-cagr-verified-market-research-301883877.html,2023-07-24 14:30:00,"The ""Global Medical Aesthetics Market Size By Product, By End User, By Geographic Scope And Forecast"" report has been published by Verified Market Research®. The report provides an in-depth analysis of the global Medical Aesthetics Market, including its growth prospects, market trends, and market ...",ABBV,0.03448,0.168288,Somewhat-Bullish
Is Invesco Dynamic Large Cap Value ETF  ( PWV )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2125863/is-invesco-dynamic-large-cap-value-etf-pwv-a-strong-etf-right-now,2023-07-24 10:20:07,Smart Beta ETF report for ...,ABBV,0.114409,0.060923,Neutral
What to Expect from Markets the Week of July 24,https://moneymorning.com/2023/07/22/what-to-expect-from-markets-the-week-of-july-24/,2023-07-22 18:05:25,"Postcards from the florida republic: An independent and profitable state of mind. Elsie, a pit-Basset mix we adopted, jumps on the bed when it booms. She builds a fort of pillows around her and then hides beneath a blanket. The other dog, Gracie, a Chihuahua mix, gets to the point.",ABBV,0.148731,0.057132,Neutral
"Bragar Eagel & Squire, P.C. Is Investigating Chinook, Comerica, Advance Auto Parts, and EPAM and Encourages Investors to Contact the Firm - Advance Auto Parts  ( NYSE:AAP ) , Comerica  ( NYSE:CMA ) ",https://www.benzinga.com/pressreleases/23/07/g33331707/bragar-eagel-squire-p-c-is-investigating-chinook-comerica-advance-auto-parts-and-epam-and-encourag,2023-07-22 01:00:00,"NEW YORK, July 21, 2023 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Chinook Therapeutics, Inc. KDNY, Comerica Incorporated CMA, Advance Auto Parts, Inc. AAP, and EPAM Systems, Inc.",ABBV,0.064104,-0.187665,Somewhat-Bearish
"Bragar Eagel & Squire, P.C. Is Investigating Viasat and BeiGene and Encourages Investors to Contact the Firm - BeiGene  ( NASDAQ:BGNE ) , Viasat  ( NASDAQ:VSAT ) ",https://www.benzinga.com/pressreleases/23/07/g33331710/bragar-eagel-squire-p-c-is-investigating-viasat-and-beigene-and-encourages-investors-to-contact-th,2023-07-22 01:00:00,"NEW YORK, July 21, 2023 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Viasat, Inc. VSAT and BeiGene Ltd.",ABBV,0.163909,-0.173451,Somewhat-Bearish
"Dow Jones Leads Weekly Gains As Tesla, Netflix Sell-Offs Dent Nasdaq; Big Banks Show Resilience To Volatility - Apple  ( NASDAQ:AAPL ) , Chevron  ( NYSE:CVX ) , Verizon Communications  ( NYSE:VZ ) , Pfizer  ( NYSE:PFE ) , Microsoft  ( NASDAQ:MSFT ) , Tesla  ( NASDAQ:TSLA ) , Mastercard  ( NYSE:MA ) , AT&T  ( NYSE:T ) , Union Pacific  ( NYSE:UNP ) , Visa  ( NYSE:V ) , Unilever  ( NYSE:UL ) , Shell  ( NYSE:SHEL ) , Netflix  ( NASDAQ:NFLX ) , Alphabet  ( NASDAQ:GOOG ) , Meta Platforms  ( NASDAQ:META ) , Bank of America  ( NYSE:BAC ) , Coca-Cola  ( NYSE:KO ) , General Motors  ( NYSE:GM ) , Morgan Stanley  ( NYSE:MS ) , Colgate-Palmolive  ( NYSE:CL ) , 3M  ( NYSE:MMM ) , McDonald's  ( NYSE:MCD ) , Comcast  ( NASDAQ:CMCSA ) , AstraZeneca  ( NASDAQ:AZN ) , Intel  ( NASDAQ:INTC ) , Procter & Gamble  ( NYSE:PG ) , Exxon Mobil  ( NYSE:XOM ) , Charles Schwab  ( NYSE:SCHW ) , Amazon.com  ( NASDAQ:AMZN ) , Boeing  ( NYSE:BA ) ",https://www.benzinga.com/markets/equities/23/07/33329067/dow-jones-leads-weekly-gains-as-tesla-netflix-sell-offs-dent-nasdaq-big-banks-show-resilience-to,2023-07-21 20:12:23,"The star of the week is the blue-chip Dow Jones, which marked a winning streak of 10 consecutive sessions through Friday, riding high on positive quarterly results from many high-profile defensive stocks. The industrial average is up 2.1% on a weekly basis.",ABBV,0.099271,0.0,Neutral
AbbVie  ( ABBV )  to Report Q2 Earnings: What's in the Cards?,https://www.zacks.com/stock/news/2125606/abbvie-abbv-to-report-q2-earnings-whats-in-the-cards,2023-07-21 17:05:00,AbbVie's (ABBV) Q2 performance will likely reflect Skyrizi and Rinvoq sales trying to make up for the declining Humira sales following the loss of U.S. exclusivity.,ABBV,0.430088,0.199482,Somewhat-Bullish
"Pharma Stock Roundup: JNJ, NVS Upbeat Q2 Results, FDA Nod to SNY & AZN RSV Antibody",https://www.zacks.com/stock/news/2125478/pharma-stock-roundup-jnj-nvs-upbeat-q2-results-fda-nod-to-sny-azn-rsv-antibody,2023-07-21 15:21:00,"FDA approves AstraZeneca (AZN) and Sanofi's (SNY) RSV antibody, Beyfortus. J&J (JNJ) and Novartis (NVS) announce strong second-quarter results.",ABBV,0.041975,0.0,Neutral
3 High-Yield Dividend Stocks I Plan on Holding Forever,https://www.fool.com/investing/2023/07/21/3-high-yield-dividend-stocks-i-plan-on-holding-for/,2023-07-21 09:50:00,These stocks offer great yields but have even better underlying businesses.,ABBV,0.31006,0.258098,Somewhat-Bullish
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab  ( TEPKINLY® )  for the Treatment of Adults with Relapsed/Refractory  ( R/R )  Diffuse Large B-cell Lymphoma  ( DLBCL ) ,https://www.globenewswire.com/news-release/2023/07/21/2708724/0/en/Genmab-Announces-AbbVie-Receives-Positive-CHMP-Opinion-for-Epcoritamab-TEPKINLY-for-the-Treatment-of-Adults-with-Relapsed-Refractory-R-R-Diffuse-Large-B-cell-Lymphoma-DLBCL.html,2023-07-21 08:30:00,Company Announcement ...,ABBV,0.076406,0.073929,Neutral
Check Out What Whales Are Doing With ABBV - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/07/33308224/check-out-what-whales-are-doing-with-abbv,2023-07-20 16:32:51,"Someone with a lot of money to spend has taken a bearish stance on AbbVie ABBV. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",ABBV,0.765213,0.282329,Somewhat-Bullish
"Win Streak Threatened: Tesla, Netflix Results Bring Pressure as Housing, Leading Indicators Data Awaited - American Express  ( NYSE:AXP ) , American Airlines Group  ( NASDAQ:AAL ) ",https://www.benzinga.com/news/earnings/23/07/33307492/win-streak-threatened-tesla-netflix-results-bring-pressure-as-housing-leading-indicators-data-await,2023-07-20 15:51:29,"( Thursday market open ) Pressure surfaced early Thursday as investors assessed yesterday's results from Tesla TSLA and Netflix NFLX. The Nasdaq ( COMP ) fell sharply in premarket trading, but the Dow Jones Industrial Average ( $DJI ) and its eight-session winning streak remained in the green.",ABBV,0.040899,-0.023524,Neutral
Analysts Estimate AbbVie  ( ABBV )  to Report a Decline in Earnings: What to Look Out for,https://www.zacks.com/stock/news/2124635/analysts-estimate-abbvie-abbv-to-report-a-decline-in-earnings-what-to-look-out-for,2023-07-20 14:02:22,AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,ABBV,0.301315,-0.015574,Neutral
Should WisdomTree U.S. High Dividend ETF  ( DHS )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2124245/should-wisdomtree-us-high-dividend-etf-dhs-be-on-your-investing-radar,2023-07-20 10:20:08,Style Box ETF report for ...,ABBV,0.125134,0.069019,Neutral
Sosei Heptares - Investor and Press Conference on Today's Announcement Regarding the Acquisition and License Transaction with Idorsia,https://www.globenewswire.com/news-release/2023/07/20/2707903/0/en/Sosei-Heptares-Investor-and-Press-Conference-on-Today-s-Announcement-Regarding-the-Acquisition-and-License-Transaction-with-Idorsia.html,2023-07-20 06:31:00,"Tokyo, Japan and Cambridge, UK, 20 July 2023 - Sosei Group Corporation ( ""the Company"". TSE: 4565 ) , will hold an investor and press conference on today's announcement. ""Sosei Heptares Acquires Idorsia's Pharmaceuticals Business in Japan and APAC ( ex-China ) , Accelerating its Transformation ...",ABBV,0.070517,0.0,Neutral
Sosei Heptares - Investor and Press Conference on Today's Announcement Regarding the Acquisition and License Transaction with Idorsia,https://www.benzinga.com/pressreleases/23/07/g33296902/sosei-heptares-investor-and-press-conference-on-todays-announcement-regarding-the-acquisition-and-,2023-07-20 06:31:00,"Tokyo, Japan and Cambridge, UK, 20 July 2023 - Sosei Group Corporation ( ""the Company"". TSE: 4565 ) , will hold an investor and press conference on today's announcement.",ABBV,0.066784,0.0,Neutral
Idorsia sells its Asia Pacific  ( ex-China )  operations - including select license rights to products - to Sosei Heptares for a total consideration of CHF 400 million,https://www.globenewswire.com/news-release/2023/07/20/2707902/0/en/Idorsia-sells-its-Asia-Pacific-ex-China-operations-including-select-license-rights-to-products-to-Sosei-Heptares-for-a-total-consideration-of-CHF-400-million.html,2023-07-20 06:30:00,Ad hoc announcement pursuant to Art. 53 LR ...,ABBV,0.038969,0.0,Neutral
"Sosei Heptares Acquires Idorsia's Pharmaceuticals Business in Japan and APAC  ( ex-China ) , Accelerating its Transformation into a Fully Integrated Biopharmaceutical Company",https://www.benzinga.com/pressreleases/23/07/g33296896/sosei-heptares-acquires-idorsias-pharmaceuticals-business-in-japan-and-apac-ex-china-accelerating-,2023-07-20 06:30:00,"PIVLAZ® ( clazosentan; commercially available in Japan for cerebral vasospasm; NHI sales of ~JPY7.5 billion in FY22A launch year, with ~76% year-on-year growth expected for FY23E ) , and Daridorexant ( Japan filing expected 2H 2023 for insomnia, marketed in US/Europe as QUVIVIQ® )",ABBV,0.012584,0.0,Neutral
"Sosei Heptares Acquires Idorsia's Pharmaceuticals Business in Japan and APAC  ( ex-China ) , Accelerating its Transformation into a Fully Integrated Biopharmaceutical Company",https://www.globenewswire.com/news-release/2023/07/20/2707901/0/en/Sosei-Heptares-Acquires-Idorsia-s-Pharmaceuticals-Business-in-Japan-and-APAC-ex-China-Accelerating-its-Transformation-into-a-Fully-Integrated-Biopharmaceutical-Company.html,2023-07-20 06:30:00,"Tokyo, Japan and Cambridge, UK, 20 July 2023 - Sosei Group Corporation ( ""the Company"". TSE: 4565 ) announces that it has resolved, at a meeting of the Board of Directors held on 20 July 2023, to acquire from Idorsia Ltd and Idorsia Pharmaceutical Ltd ( together ""Idorsia"" ) all shares of Idorsia ...",ABBV,0.012095,0.0,Neutral
"Ischemic Stroke Market is Likely to Increase at a Steady Growth Rate, Examines DelveInsight | Key Companies Working in Market - Roche, Acticor Biotech, Genentech, Mallinckrodt, AbbVie, Janssen, Bristol Myers Squibb, Bayer",https://www.prnewswire.com/news-releases/ischemic-stroke-market-is-likely-to-increase-at-a-steady-growth-rate-examines-delveinsight--key-companies-working-in-market---roche-acticor-biotech-genentech-mallinckrodt-abbvie-janssen-bristol-myers-squibb-bayer-301895355.html,2023-08-08 21:01:00,"Ischemic Stroke Market is Likely to Increase at a Steady Growth Rate, Examines DelveInsight | Key Companies ... PR ...",ABBV,0.049221,0.053506,Neutral
CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/08/08/2721181/37704/en/CytomX-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,2023-08-08 20:15:00,- CX-904 ( EGFRxCD3 ) initial Phase 1 dose escalation data anticipated first half of ...,ABBV,0.035902,0.043602,Neutral
HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS,https://www.prnewswire.com/news-releases/halozyme-reports-second-quarter-2023-financial-and-operating-results-301896108.html,2023-08-08 20:01:00,Revenue Increased 45% YOY to $221.0 million; GAAP Diluted EPS of $0.56 and Non-GAAP Diluted EPS of $0.741 Royalty Revenue Increased 31% YOY to Record $111.7 million Raised 2023 Non-GAAP Diluted EPS Guidance to $2.65-$2.75,ABBV,0.021937,0.077737,Neutral
Why Shares of Enanta Pharmaceuticals Are Dropping Tuesday,https://www.fool.com/investing/2023/08/08/why-shares-of-enanta-pharmaceuticals-are-dropping/,2023-08-08 18:23:06,The company saw a slight revenue decline in its fiscal 2023 third-quarter earnings report.,ABBV,0.138464,-0.147047,Neutral
Is Growth Priced Into Amgen Stock After Earnings Beat? - Amgen  ( NASDAQ:AMGN ) ,https://www.benzinga.com/news/earnings/23/08/33623812/is-growth-priced-into-amgen-stock-after-earnings-beat,2023-08-08 14:50:52,"Amgen Inc. AMGN delivered a solid earnings report after the market closed on August 3. Shareholders hope the results will be enough to reverse the fortunes of AMGN stock, down 12% in 2023. But heading into earnings, analyst sentiment suggests that all the growth may already be priced into the ...",ABBV,0.129866,-0.020694,Neutral
"Hyperpigmentation Disorder Treatment Market to reach US$ 9.5 billion in 2031, expanding at a CAGR of 8.5%: TMR Report",https://www.benzinga.com/pressreleases/23/08/g33626436/hyperpigmentation-disorder-treatment-market-to-reach-us-9-5-billion-in-2031-expanding-at-a-cagr-of,2023-08-08 12:30:00,"Wilmington, Delaware, United States, Aug. 08, 2023 ( GLOBE NEWSWIRE ) -- The global hyperpigmentation disorder treatment market is projected to flourish at a CAGR of 8.5% from 2022 to 2031. As per the report published by TMR, a valuation of US$ 9.5 billion is anticipated for the market in 2031.",ABBV,0.043738,0.0,Neutral
Is AbbVie Still a Good Dividend Stock to Buy?,https://www.fool.com/investing/2023/08/08/is-abbvie-still-a-good-dividend-stock-to-buy/,2023-08-08 09:37:00,Find out if AbbVie can overcome sinking sales of its top-selling product.,ABBV,0.64741,0.266308,Somewhat-Bullish
China drug-price negotiations offers glimpse into future for companies in US,https://www.financialexpress.com/healthcare/pharma-healthcare/china-drug-price-negotiations-offers-glimpse-into-future-for-companies-in-us/3202789/,2023-08-08 04:30:00,"As drugmakers in the US steel for price negotiations ushered in by President Joe Biden's Inflation Reduction Act, their experience in China, where such talks started almost a decade ago, could offer some insight into just how low costs may go.",ABBV,0.077719,0.022593,Neutral
Piramal Pharma Limited annonce ses résultats consolidés pour le premier trimestre de l'exercice 2024 - PR Newswire,https://www.prnewswire.com/news-releases/piramal-pharma-limited-annonce-ses-resultats-consolides-pour-le-premier-trimestre-de-lexercice-2024-301894190.html,2023-08-06 15:46:00,Piramal Pharma Limited annonce ses résultats consolidés pour le premier trimestre de l'exercice 2024 PR ...,ABBV,0.039944,-0.043887,Neutral
"WBA: Let's Talk About Walgreens Boots Alliance  ( WBA ) : Buy, Sell, or Hold?",https://stocknews.com/news/wba-cvs-elmd-abbv-abc-lets-talk-about-walgreens-boots-alliance-wba-buy-sell-or/,2023-08-04 19:06:19,"Walgreens Boots Alliance, Inc. ( WBA ) is a pharmacy-led health and beauty retail company that operates through two segments, the United States and International. The company sells prescription drugs and an assortment of retail products.",ABBV,0.051999,0.210616,Somewhat-Bullish
"Amgen  ( AMGN )  Q2 Earnings Beat Estimates, 2023 View Raised",https://www.zacks.com/stock/news/2132815/amgen-amgn-q2-earnings-beat-estimates-2023-view-raised,2023-08-04 16:12:00,Amgen (AMGN) beats Q2 estimates for earnings and sales. It slightly raises its earnings and sales guidance for 2023.,ABBV,0.045482,0.05258,Neutral
ABBV: Are Pfizer  ( PFE )  and AbbVie  ( ABBV )  Good Value Buys for August?,https://stocknews.com/news/abbv-pfe-opk-are-pfizer-pfe-and-abbvie-abbv-good-value-buys-for/,2023-08-04 15:18:59,"Demand for new and innovative drugs and widespread adoption of precision medicines is expected to boost the pharma industry. As the industry shows solid potential, quality pharma stock AbbVie Inc. ( ABBV ) might be a good value buy for August.",ABBV,0.35106,0.20507,Somewhat-Bullish
3 High Yield Dividend Stocks To Watch In August 2023,https://stockmarket.com/featured/3-high-yield-dividend-stocks-to-watch-in-august-2023-2023-08-04,2023-08-04 13:45:43,"Dividends are a portion of a company's earnings directly distributed to its shareholders, usually in the form of cash or additional shares.",ABBV,0.408949,0.162026,Somewhat-Bullish
Is AbbVie Stock a Buy for Income Investors?,https://www.fool.com/investing/2023/08/04/is-abbvie-stock-a-buy-for-income-investors/,2023-08-04 12:19:37,The pharmaceutical giant is forecasting a return to growth starting in 2024.,ABBV,0.279653,0.30001,Somewhat-Bullish
The Pulmonary Embolism Therapeutics Market size to grow at a CAGR of 9.52% from 2022 to 2027|The advancement ... - PR Newswire,https://www.prnewswire.com/news-releases/the-pulmonary-embolism-therapeutics-market-size-to-grow-at-a-cagr-of-9-52-from-2022-to-2027the-advancement-in-the-healthcare-and-medical-sector-is-a-major-trend-technavio-301892623.html,2023-08-04 09:30:00,The Pulmonary Embolism Therapeutics Market size to grow at a CAGR of 9.52% from 2022 to 2027|The advancement ... PR ...,ABBV,0.045569,0.139204,Neutral
Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half of 2023,https://www.globenewswire.com/news-release/2023/08/04/2718743/0/en/Sosei-Heptares-Operational-Highlights-and-Consolidated-Results-for-the-Second-Quarter-and-First-Half-of-2023.html,2023-08-04 06:37:00,"Tokyo, Japan and Cambridge, UK, 4 August 2023 - Sosei Group Corporation ( ""the Company"". TSE: 4565 ) provides an update on operational activities and reports its consolidated results for the second quarter and first half ended 30 June 2023. The full report can be found by clicking here.",ABBV,0.02118,0.0,Neutral
AbCellera Biologics  ( ABCL )  Q2 2023 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/08/04/abcellera-biologics-abcl-q2-2023-earnings-call-tra/,2023-08-04 05:00:28,"ABCL earnings call for the period ending June 30, 2023.",ABBV,0.006737,0.0,Neutral
"Hywin Holdings, Leonteq AG, and Arta TechFin jointly launch ""Global Mega-Trends Series"" principal-protected notes",https://www.globenewswire.com/news-release/2023/08/04/2718711/0/en/Hywin-Holdings-Leonteq-AG-and-Arta-TechFin-jointly-launch-Global-Mega-Trends-Series-principal-protected-notes.html,2023-08-04 01:00:00,"HONG KONG, Aug. 04, 2023 ( GLOBE NEWSWIRE ) -- Hywin Holdings Ltd. ( ""Hywin Wealth"" or ""Hywin"" ) ( NASDAQ: HYW ) , a leading independent wealth management service provider in China, Leonteq Securities AG ( ""Leonteq"" ) , a Swiss fintech company with a leading marketplace for structured investment ...",ABBV,0.029078,0.126195,Neutral
"Hywin Holdings, Leonteq AG, and Arta TechFin jointly launch ""Global Mega-Trends Series"" principal-protected notes - Hywin Holdings  ( NASDAQ:HYW ) ",https://www.benzinga.com/pressreleases/23/08/g33564916/hywin-holdings-leonteq-ag-and-arta-techfin-jointly-launch-global-mega-trends-series-principal-prot,2023-08-04 01:00:00,"HONG KONG, Aug. 04, 2023 ( GLOBE NEWSWIRE ) -- Hywin Holdings Ltd. ( ""Hywin Wealth"" or ""Hywin"" ) HYW, a leading independent wealth management service provider in China, Leonteq Securities AG ( ""Leonteq"" ) , a Swiss fintech company with a leading marketplace for structured investment solutions, ...",ABBV,0.028355,0.125769,Neutral
Piramal Pharma Limited Announces Consolidated Results for Q1FY24 USA - English - USA - English - PR Newswire,https://www.prnewswire.com/news-releases/piramal-pharma-limited-announces-consolidated-results-for-q1fy24-301893273.html,2023-08-03 22:40:00,Piramal Pharma Limited Announces Consolidated Results for Q1FY24 USA - English - USA - English PR ...,ABBV,0.092569,-0.019166,Neutral
Piramal Pharma Limited Announces Consolidated Results for Q1FY24 - PR Newswire,https://www.prnewswire.com/news-releases/piramal-pharma-limited-announces-consolidated-results-for-q1fy24-301893264.html,2023-08-03 22:28:00,Piramal Pharma Limited Announces Consolidated Results for Q1FY24 PR ...,ABBV,0.092569,-0.019166,Neutral
Piramal Pharma Limited Announces Consolidated Results for Q1FY24 - Canada NewsWire,https://www.newswire.ca/news-releases/piramal-pharma-limited-announces-consolidated-results-for-q1fy24-897273145.html,2023-08-03 22:28:00,Piramal Pharma Limited Announces Consolidated Results for Q1FY24 Canada ...,ABBV,0.085629,-0.018812,Neutral
"Pancreatic Endocrine Tumor Market is Expected to Expand at a Healthy Growth Rate by 2032, Assesses DelveInsight | Key Companies - Merck, Theradex, SynerGene, Mirati, Novartis, Syntrix Biosystems, Eli Lilly, Boehringer Ingelheim",https://www.prnewswire.com/news-releases/pancreatic-endocrine-tumor-market-is-expected-to-expand-at-a-healthy-growth-rate-by-2032-assesses-delveinsight--key-companies---merck-theradex-synergene-mirati-novartis-syntrix-biosystems-eli-lilly-boehringer-ingelheim-301892397.html,2023-08-03 21:01:00,"Pancreatic Endocrine Tumor Market is Expected to Expand at a Healthy Growth Rate by 2032, Assesses DelveInsight ... PR ...",ABBV,0.02074,-0.020974,Neutral
Peering Into AbbVie's Recent Short Interest - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/short-sellers/23/08/33557132/peering-into-abbvies-recent-short-interest,2023-08-03 18:45:32,"AbbVie's ABBV short percent of float has fallen 8.47% since its last report. The company recently reported that it has 9.51 million shares sold short, which is 0.54% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.78 days to cover their ...",ABBV,0.224903,0.085754,Neutral
Genmab Announces Financial Results for the First Half of 2023,https://www.globenewswire.com/news-release/2023/08/03/2718313/0/en/Genmab-Announces-Financial-Results-for-the-First-Half-of-2023.html,2023-08-03 15:01:00,"August 3, 2023 Copenhagen, Denmark. Interim Report for the First Six Months Ended June ...",ABBV,0.192081,0.158448,Somewhat-Bullish
"Got $5,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond",https://www.fool.com/investing/2023/08/03/got-5000-these-2-stocks-could-be-bargain-buys-for/,2023-08-03 13:45:00,There's lots of upside potential for these drugmakers.,ABBV,0.248343,-0.015738,Neutral
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023,https://www.globenewswire.com/news-release/2023/08/03/2717855/0/en/Morphic-Announces-Corporate-Highlights-and-Financial-Results-for-the-Second-Quarter-2023.html,2023-08-03 11:05:00,-Reported positive topline results from EMERALD-1 study of MORF-057 in ulcerative ...,ABBV,0.023124,0.077622,Neutral
3 High-Yielding Dividend Stocks to Buy and Hold for Decades,https://www.fool.com/investing/2023/08/03/3-high-yielding-dividend-stocks-to-hold-for/,2023-08-03 11:00:00,These are all solid businesses that could continue raising their dividend payments in the years ahead.,ABBV,0.256989,0.128934,Neutral
This Is Arguably the Single Best Stock to Buy Right Now,https://www.fool.com/investing/2023/08/03/single-best-stock-to-buy-right-now/,2023-08-03 09:51:00,This stock appears to be in a league of its own.,ABBV,0.05133,0.071208,Neutral
Big Pharma rakes in $215 billion a year in America - yet pays almost no taxes,https://www.businessinsider.com/big-pharma-companies-taxes-american-billion-dollar-profits-drugs-healthcare-2023-8,2023-08-03 09:28:00,Trick that helps Big Pharma companies avoid paying billons in US taxes - Business Insider ...,ABBV,0.113382,0.130869,Neutral
"Boehringer's Cyltezo illustrates intersection of price and regulation in biosimilar market, says GlobalData",https://www.financialexpress.com/healthcare/pharma-healthcare/boehringers-cyltezo-illustrates-intersection-of-price-and-regulation-in-biosimilar-market-says-globaldata/3197005/,2023-08-03 02:30:00,The loss of exclusivity of AbbVie's Humira ( adalimumab ) has become a perfect scenario to test if the Biologics Price Competition and Innovation ( BPCI ) act in the US can achieve the intention of the law.,ABBV,0.16849,-0.005663,Neutral
Karyopharm Therapeutics  ( KPTI )  Q2 2023 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/08/02/karyopharm-therapeutics-kpti-q2-2023-earnings-call/,2023-08-02 18:00:24,"KPTI earnings call for the period ending June 30, 2023.",ABBV,0.005981,0.077318,Neutral
Check Out What Whales Are Doing With ABBV - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/08/33526752/check-out-what-whales-are-doing-with-abbv,2023-08-02 16:45:51,"Someone with a lot of money to spend has taken a bearish stance on AbbVie ABBV. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",ABBV,0.716023,0.166114,Somewhat-Bullish
Teva Pharmaceutical Industries  ( TEVA )  Q2 2023 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/08/02/teva-pharmaceutical-industries-teva-q2-2023-earnin/,2023-08-02 15:00:24,"TEVA earnings call for the period ending June 30, 2023.",ABBV,0.005225,-0.03186,Neutral
Bausch + Lomb posts better than expected Q2 earnings,https://www.reuters.com/business/healthcare-pharmaceuticals/bausch-lomb-posts-better-than-expected-q2-earnings-2023-08-02/,2023-08-02 11:01:57,"Bausch & Lomb eye care and contact lens related products are seen for sale in a pharmacy in Washington, U.S., May 6, 2022. REUTERS/Leah Millis/File Photo Aug 2 ( Reuters ) - Bausch + Lomb ( BLCO.TO ) posted modestly better than expected second-quarter earnings on Wednesday after its new chief ...",ABBV,0.155451,0.0,Neutral
Better High-Yield Dividend Stock: AbbVie vs. Verizon Communications,https://www.fool.com/investing/2023/08/01/better-high-yield-dividend-stock-abbvie-vs-verizon/,2023-08-01 20:45:00,Which of these high-yield dividend stocks is the better buy right now?,ABBV,0.421485,0.383983,Bullish
JNJ: Is Johnson & Johnson  ( JNJ )  a Must-Buy Stability Stock?,https://stocknews.com/news/jnj-nvo-abbv-bmy-is-johnson-johnson-jnj-a-must-buy-stability-stock/,2023-08-01 17:30:14,"Johnson & Johnson ( JNJ ) is one of the world's largest pharmaceutical and medical device manufacturers, making it appealing because of its safety. Being a well-established pharmaceutical company, it could resist unfavorable headwinds.",ABBV,0.09402,0.097183,Neutral
3 Magnificent High-Yield Dividend Stocks to Buy Hand Over Fist in August,https://www.fool.com/investing/2023/08/01/magnificent-high-yield-dividend-stocks-buy-august/,2023-08-01 09:50:00,High yields aren't the only things these stocks offer.,ABBV,0.312423,0.211912,Somewhat-Bullish
"Bragar Eagel & Squire, P.C. Is Investigating JinkoSolar, Integra, Chinook, and Comerica and Encourages Investors to Contact the Firm - Comerica  ( NYSE:CMA ) , Integra Lifesciences  ( NASDAQ:IART ) ",https://www.benzinga.com/pressreleases/23/07/g33483044/bragar-eagel-squire-p-c-is-investigating-jinkosolar-integra-chinook-and-comerica-and-encourages-in,2023-08-01 01:00:00,"NEW YORK, July 31, 2023 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against JinkoSolar Holding Co., Ltd. JKS, Integra LifeSciences Holdings Corp. IART, Chinook Therapeutics, Inc.",ABBV,0.071357,-0.189092,Somewhat-Bearish
Amgen  ( AMGN )  to Report Q2 Earnings: Here's What to Expect,https://www.zacks.com/stock/news/2129960/amgen-amgn-to-report-q2-earnings-heres-what-to-expect,2023-07-31 15:09:00,"Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.",ABBV,0.105836,0.033037,Neutral
"Topical Corticosteroids Market size to grow by USD 1,089.66 million from 2022 to 2027|Advancements in drug delivery ... - PR Newswire",https://www.prnewswire.com/news-releases/topical-corticosteroids-market-size-to-grow-by-usd-1-089-66-million-from-2022-to-2027advancements-in-drug-delivery-systems-to-boost-market-growth---technavio-301888372.html,2023-07-31 14:15:00,"Topical Corticosteroids Market size to grow by USD 1,089.66 million from 2022 to 2027|Advancements in drug delivery ... PR ...",ABBV,0.034984,0.103998,Neutral
"AbbVie, Pioneer Natural Resources And This Manufacturer Are CNBC's 'Final Trades' - Deere  ( NYSE:DE ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/trading-ideas/long-ideas/23/07/33467012/abbvie-pioneer-natural-resources-and-this-manufacturer-are-cnbcs-final-trades,2023-07-31 12:59:28,"On CNBC's ""Halftime Report Final Trades,"" Bryn Talkington of Requisite Capital Management said AbbVie Inc. ABBV has a 4% yield and has underperformed this year at 10 times earnings. AbbVie reported second-quarter adjusted EPS of $2.91, down 13.6% Y/Y, beating the consensus of $2.80.",ABBV,0.729067,0.027326,Neutral
Is It Too Late to Buy InMode Stock?,https://www.fool.com/investing/2023/07/30/is-it-too-late-to-buy-inmode-stock/,2023-07-30 09:39:00,Shares of the aesthetics industry's favorite medical technology provider are already up 64% over the past 12 months.,ABBV,0.061631,0.140045,Neutral
"Want $500 in Super Safe Annual Dividend Income? Invest $9,900 in the Following 3 Dividend Kings",https://www.fool.com/investing/2023/07/30/want-500-safe-annual-dividend-income-invest-9900/,2023-07-30 09:21:00,"These truly rock-solid income stocks, which sport an average yield of 5.07%, can pad patient investors' wallets.",ABBV,0.288468,0.227847,Somewhat-Bullish
Neurocrine Biosciences Announces FDA Approval of INGREZZA®  ( valbenazine )  Capsules for the Treatment of Chorea Associated With Huntington's Disease,https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-fda-approval-of-ingrezza-valbenazine-capsules-for-the-treatment-of-chorea-associated-with-huntingtons-disease-301904823.html,2023-08-18 20:34:00,Neurocrine Biosciences Announces FDA Approval of INGREZZA® ( valbenazine ) Capsules for the Treatment of Chorea ... PR ...,ABBV,0.020387,0.057097,Neutral
"Acute Migraine Treatment Market Predicted to Reach USD 7 billion by 2031, Recording Over a 15% CAGR Says, Transparency Market Research",https://www.benzinga.com/pressreleases/23/08/g33911444/acute-migraine-treatment-market-predicted-to-reach-usd-7-billion-by-2031-recording-over-a-15-cagr-,2023-08-18 10:30:00,"Wilmington, Delaware, United States, Aug. 18, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global market for acute migraine treatment was estimated to be worth a market valuation of around US$ 2.1 billion in 2021.",ABBV,0.085022,0.002064,Neutral
AbbVie  ( ABBV )  Gets EU Approval for Migraine Prevention Drug,https://www.zacks.com/stock/news/2137725/abbvie-abbv-gets-eu-approval-for-migraine-prevention-drug,2023-08-17 15:43:00,"Following the approval, AbbVie's (ABBV) Aquipta is the first and the only oral CGRP receptor antagonist approved in the EU to prevent episodic and chronic migraines.",ABBV,0.33628,0.177232,Somewhat-Bullish
1 High-Yield Dividend Stock That Looks Like a Screaming Buy,https://www.fool.com/investing/2023/08/17/1-high-yield-dividend-stock-that-looks-like-a/,2023-08-17 12:45:00,Look beyond the company's near-term headwinds.,ABBV,0.501722,0.331541,Somewhat-Bullish
"Macular Degeneration Treatment Market to Expand USD 21.1 Bn by 2031, Registering at a CAGR of 8.8% | Exclusive Report by Transparency Market Research",https://www.benzinga.com/pressreleases/23/08/g33892714/macular-degeneration-treatment-market-to-expand-usd-21-1-bn-by-2031-registering-at-a-cagr-of-8-8-e,2023-08-17 11:30:00,"Wilmington, Delaware, United States, Aug. 17, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global macular degeneration treatment market is projected to exceed US$ 21.1 Bn by 2031, up from US$ 9.0 Bn in 2021.",ABBV,0.042048,-0.026846,Neutral
"I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates",https://www.prnewswire.com/news-releases/i-mab-provides-mid-year-2023-financial-results-business-and-corporate-updates-301903515.html,2023-08-17 10:00:00,"• Significant progress made year-to-date on key clinical assets: ‐ Uliledlimab ( CD73 antibody ) : Encouraging early results were presented at ASCO 2023 ‐ Givastomig ( Claudin 18.2 x 4-1BB bispecific antibody ) : Topline Phase 1 data with promising early efficacy signals, including patients ...",ABBV,0.04469,0.034195,Neutral
AbbVie  ( NYSE:ABBV )  Now Covered by Analysts at StockNews.com,https://www.defenseworld.net/2023/08/17/abbvie-nyseabbv-now-covered-by-analysts-at-stocknews-com.html,2023-08-17 05:54:45,"Investment analysts at StockNews.com assumed coverage on shares of AbbVie ( NYSE:ABBV - Get Free Report ) in a report issued on Thursday. The firm set a ""strong-buy"" rating on the stock.",ABBV,0.821225,0.450021,Bullish
3 Dividend Aristocrats Positively Surprising Investors,https://www.zacks.com/stock/news/2136690/3-dividend-aristocrats-positively-surprising-investors,2023-08-15 21:15:00,"The bulk of the Q2 season is in the rearview mirror, but the quarterly results from these 3 Dividend Aristocrats shouldn't be ignored.",ABBV,0.463192,0.552663,Bullish
Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update - Clearside Biomedical  ( NASDAQ:CLSD ) ,https://www.benzinga.com/pressreleases/23/08/g33843248/clearside-biomedical-announces-second-quarter-2023-financial-results-and-provides-corporate-update,2023-08-14 20:05:00,"- Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Progressing as Planned with Nearly 30 Sites Now Open - - Proprietary Suprachoroidal Injection Platform Featured in Peer-Reviewed Publication and at ARVO, ASRS and OIS Scientific Meetings - - Management to Host Webcast and Conference Call Today at ...",ABBV,0.023767,0.197594,Somewhat-Bullish
"Up 970-Fold Since Its IPO, Amgen Stock Could Be Overvalued",https://www.forbes.com/sites/petercohan/2023/08/14/up-970-fold-since-its-ipo-amgen-stock-could-be-overvalued/,2023-08-14 14:37:38,Amgen's established products declined while some of its best-selling drugs enjoyed growth.,ABBV,0.030026,0.015706,Neutral
"Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical",https://www.zacks.com/stock/news/2136126/zacks-industry-outlook-highlights-amphastar-pharmaceuticals-dr-reddys-laboratories-and-teva-pharmaceutical,2023-08-14 11:01:00,"Amphastar Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical are part of the Zacks Industry Outlook article.",ABBV,0.030641,0.063126,Neutral
"My Top Dividend King to Buy and Hold for the Next 10 Years, and It Isn't Even Close",https://www.fool.com/investing/2023/08/14/my-top-dividend-king-to-buy-and-hold-for-the-next/,2023-08-14 09:50:00,"This stock offers a high dividend yield, impressive dividend growth, and a lot more.",ABBV,0.686426,0.473481,Bullish
The Medical Aesthetics Market to grow at a CAGR of 8.6% from 2022 to 2027; Increasing global awareness about ... - PR Newswire,https://www.prnewswire.com/news-releases/the-medical-aesthetics-market-to-grow-at-a-cagr-of-8-6-from-2022-to-2027-increasing-global-awareness-about-medical-aesthetics-to-boost-market-growth---technavio-301898792.html,2023-08-14 09:00:00,The Medical Aesthetics Market to grow at a CAGR of 8.6% from 2022 to 2027. Increasing global awareness about ... PR ...,ABBV,0.056674,0.0,Neutral
3 Unstoppable Dividend Stocks to Buy Right Now,https://www.fool.com/investing/2023/08/12/3-unstoppable-dividend-stocks-to-buy-right-now/,2023-08-12 10:15:00,These stocks' dividends are more dependable than most.,ABBV,0.345674,0.048488,Neutral
More Than a Buzzword,https://www.theatlantic.com/sponsored/abbvie-2023/abbvie-qa-2023/3820/,2023-08-12 06:51:38,"A t some companies, ESG ( Environmental, Social, and Governance ) may seem like a nebulous concept-a secondary concern or a lofty notion out of touch with their very business. However, to AbbVie, the biopharmaceutical company, ESG is about helping patients today, and also ensuring a sustainable ...",ABBV,0.409655,0.377216,Bullish
"Bragar Eagel & Squire, P.C. Is Investigating JinkoSolar, Integra, Chinook, and Comerica and Encourages Investors to Contact the Firm - Comerica  ( NYSE:CMA ) , Integra Lifesciences  ( NASDAQ:IART ) ",https://www.benzinga.com/pressreleases/23/08/g33768198/bragar-eagel-squire-p-c-is-investigating-jinkosolar-integra-chinook-and-comerica-and-encourages-in,2023-08-12 01:00:00,"NEW YORK, Aug. 11, 2023 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against JinkoSolar Holding Co., Ltd. JKS, Integra LifeSciences Holdings Corp. IART, Chinook Therapeutics, Inc.",ABBV,0.071357,-0.189092,Somewhat-Bearish
AbbVie Unusual Options Activity For August 11 - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/08/33758410/abbvie-unusual-options-activity-for-august-11,2023-08-11 18:31:05,"Benzinga's options scanner just detected over 12 options trades for AbbVie ABBV summing a total amount of $516,278. At the same time, our algo caught 6 for a total amount of 225,571.",ABBV,0.814341,0.403568,Bullish
Up 45% This Year What's Driving The Growth For Eli Lilly Stock?,https://www.forbes.com/sites/greatspeculations/2023/08/11/up-45-this-year-whats-driving-the-growth-for-eli-lilly-stock/,2023-08-11 13:00:59,"The stock has been on a strong run for the last few years, primarily due to its pipeline potential.",ABBV,0.059636,-0.010001,Neutral
"Aesthetic Implants Market to reach US$ 8.4 billion by 2031, expanding at a CAGR of 5.6%: TMR Report",https://www.benzinga.com/pressreleases/23/08/g33741693/aesthetic-implants-market-to-reach-us-8-4-billion-by-2031-expanding-at-a-cagr-of-5-6-tmr-report,2023-08-11 09:30:00,"Wilmington, Delaware, United States, Aug. 11, 2023 ( GLOBE NEWSWIRE ) -- The global aesthetic implants market is projected to flourish at a CAGR of 5.6% from 2022 to 2031. As per the report published by TMR, a valuation of US$ 8.4 billion is anticipated for the market in 2031.",ABBV,0.046006,0.0,Neutral
Greenwave Appoints Henry Sicignano III and Jason Adelman to Board of Directors,https://www.prnewswire.com/news-releases/greenwave-appoints-henry-sicignano-iii-and-jason-adelman-to-board-of-directors-301898197.html,2023-08-10 20:01:00,"Former CEO of 22nd Century Group and current President of Charlie's Holdings, Henry Sicignano III is a seasoned public company executive with substantial expertise in competitive strategy and regulatory affairs.",ABBV,0.048425,0.033531,Neutral
These 10 medications are likely targets for Medicare price negotiations this fall,https://www.cnbc.com/2023/08/10/10-drugs-that-are-likely-targets-for-fall-medicare-price-negotiations.html,2023-08-10 17:21:52,"It's still unclear which drugs Medicare will select, but several companies have revealed in court filings that four of their medications are targets.",ABBV,0.093836,-0.078346,Neutral
3 Long-Short Funds to Navigate Turbulent Times,https://www.zacks.com/stock/news/2134933/3-long-short-funds-to-navigate-turbulent-times,2023-08-10 12:16:00,"Invest in long-short funds like SNOAX, BPRRX and NLSAX to hedge your portfolio amid market volatility.",ABBV,0.047844,0.049301,Neutral
This Is What Whales Are Betting On AbbVie - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/08/33677916/this-is-what-whales-are-betting-on-abbvie,2023-08-09 20:02:03,"Someone with a lot of money to spend has taken a bullish stance on AbbVie ABBV. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",ABBV,0.798255,0.437083,Bullish
3 Stocks That Recently Raised Their Guidance for the Year,https://www.fool.com/investing/2023/08/09/3-stocks-that-recently-raised-their-guidance-for/,2023-08-09 14:23:00,These businesses have rosier outlooks for the future -- but that doesn't mean they're all slam-dunk buys right now.,ABBV,0.324495,0.135834,Neutral
$100 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/news/earnings/23/08/33668642/100-invested-in-abbvie-10-years-ago-would-be-worth-this-much-today,2023-08-09 14:00:23,"AbbVie ABBV has outperformed the market over the past 10 years by 2.69% on an annualized basis producing an average annual return of 12.89%. Currently, AbbVie has a market capitalization of $266.70 billion.",ABBV,0.983605,0.387251,Bullish
"Ironwood's  ( IRWD )  Reports Q2 Loss, Linzess Volume Rises",https://www.zacks.com/stock/news/2134348/ironwoods-irwd-reports-q2-loss-linzess-volume-rises,2023-08-09 13:24:00,"Ironwood (IRWD) reports loss for second-quarter 2023. The top line increases year over year, driven by growth in Linzess collaboration revenues.",ABBV,0.200273,0.21873,Somewhat-Bullish
Jnana Therapeutics Announces Dosing of First Participant in Phase 1b Clinical Trial of JNT-517 in Individuals with PKU,https://www.benzinga.com/pressreleases/23/08/g33658838/jnana-therapeutics-announces-dosing-of-first-participant-in-phase-1b-clinical-trial-of-jnt-517-in-,2023-08-09 11:00:00,JNT-517 is a Potential First-in-Class Oral Treatment for PKU; Phase 1b Study Follows Positive Clinical Proof of Mechanism Data in Healthy Individuals Upcoming Oral Presentation of Phase 1a Study Results at the Society for the Study of Inborn Errors of Metabolism ( SSIEM ) Annual Symposium 2023,ABBV,0.044469,0.123821,Neutral
Fertility Supplement Global Market to Exhibit Growth at a CAGR of ~8% by 2028 | DelveInsight,https://www.prnewswire.com/news-releases/fertility-supplement-global-market-to-exhibit-growth-at-a-cagr-of-8-by-2028--delveinsight-301911682.html,2023-08-28 21:32:00,"The demand for fertility supplements is being driven primarily by key factors such as an increase in the number of cases of infertility, an increase in risk factors associated with causing infertility, growing reproductive health awareness, and an increase in product launches, all of which are ...",ABBV,0.028558,-0.002762,Neutral
Neurocrine Biosciences Presents New INGREZZA®  ( valbenazine )  Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease,https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-new-ingrezza-valbenazine-capsules-data-demonstrating-early-and-sustained-improvements-in-chorea-associated-with-huntingtons-disease-301910386.html,2023-08-28 12:30:00,Neurocrine Biosciences Presents New INGREZZA® ( valbenazine ) Capsules Data Demonstrating Early and Sustained ... PR ...,ABBV,0.016074,0.056615,Neutral
"30 dividend-paying stocks in solid sectors with upside outside the AI hype, according to a 30-year fund manager",https://www.businessinsider.com/30-dividend-paying-stocks-held-by-30-year-fund-manager-2023-8,2023-08-27 16:51:00,30 Dividend-Paying Stocks With Upside Held by 30-Year Fund Manager - Business Insider ...,ABBV,0.08183,0.0,Neutral
3 Surprisingly Underrated Stocks to Buy Right Now,https://www.fool.com/investing/2023/08/26/3-surprisingly-underrated-stocks-to-buy-right-now/,2023-08-26 10:55:00,These stocks deserve more respect than they're getting.,ABBV,0.386151,0.043606,Neutral
SoftBank-backed Neumora Therapeutics files paperwork for U.S. IPO,https://www.reuters.com/markets/deals/softbank-backed-neumora-therapeutics-files-paperwork-us-ipo-2023-08-25/,2023-08-25 21:53:37,SoftBank-backed Neumora Therapeutics files paperwork for U.S. ...,ABBV,0.15347,0.0,Neutral
"As Medicare picks 10 drugs for price negotiations, 50 million people stand to benefit - even if their drugs aren't on the list",https://www.marketwatch.com/story/as-medicare-picks-10-drugs-for-price-negotiations-50-million-people-stand-to-benefit-even-if-their-drugs-arent-on-the-list-aceec7e,2023-08-25 14:54:00,Government negotiations with drugmakers are set to launch amid a growing number of legal challenges.,ABBV,0.062843,-0.034042,Neutral
"The Zacks Analyst Blog Highlights Procter & Gamble, AbbVie, The Walt Disney, HSBC Holdings and Duke Energy",https://www.zacks.com/stock/news/2140809/the-zacks-analyst-blog-highlights-procter-gamble-abbvie-the-walt-disney-hsbc-holdings-and-duke-energy,2023-08-25 13:21:00,"Procter & Gamble, AbbVie, The Walt Disney, HSBC Holdings and Duke Energy are part of the Zacks top Analyst Blog.",ABBV,0.40348,0.222798,Somewhat-Bullish
Investors Heavily Search AbbVie Inc.  ( ABBV ) : Here is What You Need to Know,https://www.zacks.com/stock/news/2140688/investors-heavily-search-abbvie-inc-abbv-here-is-what-you-need-to-know,2023-08-25 13:00:11,"Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",ABBV,0.490323,0.132507,Neutral
"Top Analyst Reports for Procter & Gamble, AbbVie & Walt Disney",https://www.zacks.com/research-daily/2140275/top-analyst-reports-for-procter-gamble-abbvie-walt-disney,2023-08-24 16:50:00,"Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), AbbVie Inc. (ABBV) and The Walt Disney Company (DIS).",ABBV,0.291182,0.270397,Somewhat-Bullish
Can AbbVie  ( ABBV )  Protect Revenues After Humira Patent Loss?,https://www.zacks.com/stock/news/2140301/can-abbvie-abbv-protect-revenues-after-humira-patent-loss,2023-08-24 14:53:00,"AbbVie's (ABBV) newer products, Skyrizi and Rinvoq, are performing extremely well and have the potential to make up for lost Humira revenues.",ABBV,0.642977,0.354671,Bullish
"Boeing's 737 Deliveries Delay Due To Supplier Spirit Aerosystems, Petco Health and Wellness Stock Tumbles, AstraZeneca Under Legal Lens - AstraZeneca  ( NASDAQ:AZN ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/news/23/08/34025253/boeings-737-deliveries-delay-due-to-supplier-spirit-aerosystems-petco-health-and-wellness-stock-tumb,2023-08-24 14:22:27,"Medtronic Plc MDT says the FDA Circulatory System Devices Panel ( CSDP ) voted unanimously ( 13-0 ) on safety and in favor ( 7-6 ) of the effectiveness of the Symplicity blood pressure procedure, Spyral Renal Denervation ( RDN ) System.",ABBV,0.102668,0.05446,Neutral
Cheaper Version Of Blockbuster Arthritis Treatment Humira - CVS Health Teams With Sandoz - CVS Health  ( NYSE:CVS ) ,https://www.benzinga.com/general/biotech/23/08/34024368/cheaper-version-of-blockbuster-arthritis-treatment-humira-cvs-health-teams-with-sandoz,2023-08-24 14:04:25,"CVS Health Corp CVS has launched Cordavis, a wholly-owned subsidiary, to work directly with manufacturers to commercialize and/or co-produce biosimilar products in the U.S. pharmaceutical market. What are biosimilars?",ABBV,0.299478,0.108882,Neutral
PM360 Announces 2023 Trailblazer Award Finalists,https://www.prnewswire.com/news-releases/pm360-announces-2023-trailblazer-award-finalists-301907769.html,2023-08-24 13:00:00,"Top Companies, Marketers, CEOs, Products, and Initiatives to be Honored During Gala on October 3rd NEW YORK, Aug. 24, 2023 /PRNewswire/ -- PM360 has announced the finalists for its 15th annual Trailblazer Awards.",ABBV,0.013876,0.0,Neutral
2 No-Brainer Biotech Stocks to Buy Right Now,https://www.fool.com/investing/2023/08/24/2-no-brainer-biotech-stocks-to-buy-right-now/,2023-08-24 11:30:00,These two companies make a compelling case for a high price.,ABBV,0.051221,0.117067,Neutral
CollPlant Biotechnologies Announces Second Quarter Financial Results For 2023 with Revenues of $10.2 Million,https://www.prnewswire.com/news-releases/collplant-biotechnologies-announces-second-quarter-financial-results-for-2023-with-revenues-of-10-2-million-301909083.html,2023-08-24 11:00:00,"REHOVOT, Israel, Aug. 24, 2023 /PRNewswire/ -- CollPlant Biotechnologies ( NASDAQ: CLGN ) , a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced ...",ABBV,0.13681,0.137816,Neutral
Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin®  ( Nadofaragene Firadenovec-Vncg ) ,https://www.globenewswire.com/news-release/2023/08/24/2730957/0/en/Royalty-Pharma-and-Ferring-Pharmaceuticals-Enter-Into-US-500-Million-Royalty-Agreement-for-New-Intravesical-Gene-Therapy-Adstiladrin-Nadofaragene-Firadenovec-Vncg.html,2023-08-24 10:30:00,"NEW YORK and SAINT PREX, Switzerland, Aug. 24, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) and Ferring Pharmaceuticals today announced that Royalty Pharma has acquired a synthetic royalty on US net sales of Ferring's Adstiladrin® ( nadofaragene firadenovec-vncg ) for up to US ...",ABBV,0.019683,0.069806,Neutral
Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin®  ( Nadofaragene Firadenovec-Vncg )  - Royalty Pharma  ( NASDAQ:RPRX ) ,https://www.benzinga.com/pressreleases/23/08/g34020098/royalty-pharma-and-ferring-pharmaceuticals-enter-into-us-500-million-royalty-agreement-for-new-int,2023-08-24 10:30:00,Royalty Pharma to pay Ferring $300 million upfront and a potential $200 million milestone payment in exchange for royalties on the sales of Ferring's intravesical gene therapy Adstiladrin® ( nadofaragene firadenovec-vncg ),ABBV,0.019147,0.069548,Neutral
Contraceptives Global Market Exhibit Growth at a CAGR of ~5% by 2027 | DelveInsight,https://www.prnewswire.com/news-releases/contraceptives-global-market-exhibit-growth-at-a-cagr-of-5-by-2027--delveinsight-301907623.html,2023-08-23 21:01:00,"The contraceptives market is experiencing positive growth as a result of increased awareness about sexually transmitted diseases, an increase in government initiatives for population control, an increase in unintended pregnancies, and technological innovations leading to effective contraception, ...",ABBV,0.06697,0.006022,Neutral
CVS Health Launches Company To Produce Cheaper 'Biosimilar' Versions Of Expensive Biotech Drugs,https://www.forbes.com/sites/brucejapsen/2023/08/23/cvs-health-launches-company-to-produce-cheaper-versions-of-expensive-biotech-drugs/,2023-08-23 20:25:54,"CVS Health is launching a new company, Cordavis, to commercialize and produce biosimilar drugs, the cheaper versions of expensive prescriptions derived from biotechnology.",ABBV,0.220809,-0.03839,Neutral
CVS pushes further into generic drugs with Sandoz partnership for new discount Humira,https://www.cnbc.com/2023/08/23/cvs-health-sandoz-humira-biosimilar.html,2023-08-23 20:15:52,"CVS is looking to strengthen its foothold in the biosimilars market, which is expected to grow to $100 billion over the next six years.",ABBV,0.194242,0.04594,Neutral
Looking Into AbbVie's Recent Short Interest - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/short-sellers/23/08/33989055/looking-into-abbvies-recent-short-interest,2023-08-22 16:15:17,"AbbVie's ABBV short percent of float has risen 20.37% since its last report. The company recently reported that it has 11.44 million shares sold short, which is 0.65% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.75 days to cover their ...",ABBV,0.224903,0.158881,Somewhat-Bullish
These 3 Large-Cap Pharma Stocks Have Been Red-Hot,https://www.zacks.com/stock/news/2138896/these-3-large-cap-pharma-stocks-have-been-red-hot,2023-08-21 23:24:00,"Large-cap pharmaceuticals have enjoyed buying pressure over the last month, delivering outsized gains to investors. And these three stocks have helped lead the charge.",ABBV,0.434763,0.528557,Bullish
Medical Second Opinion Global Market to Register Stunning Growth at a CAGR of ~17% by 2028 | DelveInsight,https://www.prnewswire.com/news-releases/medical-second-opinion-global-market-to-register-stunning-growth-at-a-cagr-of-17-by-2028--delveinsight-301905294.html,2023-08-21 21:01:00,"The medical second opinion market is expanding rapidly due to the increasing frequency of malignancies, infectious diseases, genetic diseases, cardiovascular diseases, hematological diseases, orthopedic diseases, and other diseases around the world.",ABBV,0.048671,0.037506,Neutral
This Is What Whales Are Betting On AbbVie - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/08/33970931/this-is-what-whales-are-betting-on-abbvie,2023-08-21 19:45:46,"A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 11 strange trades. If we consider the specifics of each trade, it is accurate to state that 27% of the investors opened trades with bullish expectations ...",ABBV,0.818966,0.230709,Somewhat-Bullish
"Lung Cancer Treatment Market Revenue to Cross USD 102 billion by 2031, Expanding at a CAGR of 9.8% Says, Transparency Market Research Inc.",https://www.benzinga.com/pressreleases/23/08/g33964549/lung-cancer-treatment-market-revenue-to-cross-usd-102-billion-by-2031-expanding-at-a-cagr-of-9-8-s,2023-08-21 14:30:00,"Wilmington, Delaware, United States, Aug. 21, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global lung cancer treatment market is projected to flourish at a CAGR of 9.8% from 2022 to 2031. As per the report published by TMR, a valuation of US$ 102 billion is anticipated for ...",ABBV,0.041323,0.052319,Neutral
Regeneron's Eylea could return to growth after nod to high-dose version- analysts,https://www.reuters.com/business/healthcare-pharmaceuticals/regenerons-eylea-could-return-growth-after-nod-high-dose-version-analysts-2023-08-21/,2023-08-21 13:41:00,"The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. REUTERS/Brendan McDermid/File Photo Acquire Licensing Rights",ABBV,0.104683,-0.069617,Neutral
HIV Drugs Market size to grow by USD 10.47 biilion from 2022 to 2027 | Expanding access to HIV treatment is a major ... - PR Newswire,https://www.prnewswire.com/news-releases/hiv-drugs-market-size-to-grow-by-usd-10-47-biilion-from-2022-to-2027--expanding-access-to-hiv-treatment-is-a-major-trend--technavio-301905076.html,2023-08-21 11:30:00,HIV Drugs Market size to grow by USD 10.47 biilion from 2022 to 2027 | Expanding access to HIV treatment is a major ... PR ...,ABBV,0.064973,0.102266,Neutral
Chinook Investor Alert,https://markets.businessinsider.com/news/stocks/chinook-investor-alert-1032336195,2023-08-20 13:03:00,"Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Chinook To Contact Him Directly To Discuss Their Options",ABBV,0.22595,-0.048627,Neutral
Dermatology devices market to grow by USD 124.69 billion from 2022 to 2027 | Telemedicine and remote monitoring is ... - PR Newswire,https://www.prnewswire.com/news-releases/dermatology-devices-market-to-grow-by-usd-124-69-billion-from-2022-to-2027--telemedicine-and-remote-monitoring-is-the-primary-trend-in-the-market---technavio-301904099.html,2023-08-19 03:00:00,Dermatology devices market to grow by USD 124.69 billion from 2022 to 2027 | Telemedicine and remote monitoring is ... PR ...,ABBV,0.049221,0.0,Neutral
Why Is Ironwood  ( IRWD )  Down 9.6% Since Last Earnings Report?,https://www.zacks.com/stock/news/2146112/why-is-ironwood-irwd-down-96-since-last-earnings-report,2023-09-07 15:30:56,Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,ABBV,0.078099,0.149114,Neutral
"Triple-Negative Breast Cancer Market to Accelerate Substantially During the Forecast Period  ( 2023-2032 ) , Examines DelveInsight | Key Companies to Watch - Roche, AbbVie, AstraZeneca, BeiGene, GlaxoSmithKline, Genentech, Eli Lilly, Novartis",https://www.prnewswire.com/news-releases/triple-negative-breast-cancer-market-to-accelerate-substantially-during-the-forecast-period-20232032-examines-delveinsight--key-companies-to-watch---roche-abbvie-astrazeneca-beigene-glaxosmithkline-genentech-eli-lilly--301918858.html,2023-09-06 21:01:00,"Triple-Negative Breast Cancer Market to Accelerate Substantially During the Forecast Period ( 2023-2032 ) , Examines ... PR ...",ABBV,0.022494,0.023078,Neutral
Join BOTOX® Cosmetic  ( onabotulinumtoxinA )  and IFundWomen in Supporting Women Entrepreneurs,https://www.prnewswire.com/news-releases/join-botox-cosmetic-onabotulinumtoxina-and-ifundwomen-in-supporting-women-entrepreneurs-301918581.html,2023-09-06 12:45:00,"GET TO KNOW THE WOMEN-OWNED BUSINESSES RECEIVING GRANTS AND CONTRIBUTE TO THEIR SUCCESS, FURTHER CLOSING THE ""CONFIDENCE GAP""",ABBV,0.171892,0.252356,Somewhat-Bullish
Novartis names new board member after international boss steps down,https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-names-new-board-member-after-international-boss-steps-down-2023-09-06/,2023-09-06 05:40:39,"The company's logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann/File Photo Acquire Licensing Rights",ABBV,0.552443,0.00675,Neutral
"Novartis appoints Patrick Horber, M.D., President, International as Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, steps down from the Executive Committee of Novartis",https://www.globenewswire.com/news-release/2023/09/06/2737997/0/en/Novartis-appoints-Patrick-Horber-M-D-President-International-as-Marie-France-Tschudin-President-Innovative-Medicines-International-and-Chief-Commercial-Officer-steps-down-from-the-.html,2023-09-06 05:15:00,"Basel, September 06, 2023 - Novartis today announced that Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, has decided to leave the company and will step down from the Executive Committee of Novartis ( ECN ) , effective September 15, after nearly ...",ABBV,0.095517,0.051999,Neutral
AbbVie  ( ABBV )  Dips More Than Broader Markets: What You Should Know,https://www.zacks.com/stock/news/2145064/abbvie-abbv-dips-more-than-broader-markets-what-you-should-know,2023-09-05 21:45:20,"AbbVie (ABBV) closed at $146.10 in the latest trading session, marking a -1.42% move from the prior day.",ABBV,0.617188,0.167447,Somewhat-Bullish
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement,https://www.globenewswire.com/news-release/2023/09/05/2737903/0/en/Royalty-Pharma-and-Ascendis-Pharma-Enter-Into-150-Million-Royalty-Funding-Agreement.html,2023-09-05 20:15:00,• Proceeds to support continued development and commercialization of Endocrine Rare Disease products and general corporate purposes ...,ABBV,0.021797,0.070802,Neutral
"Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement - Royalty Pharma  ( NASDAQ:RPRX ) , Ascendis Pharma  ( NASDAQ:ASND ) ",https://www.benzinga.com/pressreleases/23/09/g34252746/royalty-pharma-and-ascendis-pharma-enter-into-150-million-royalty-funding-agreement,2023-09-05 20:15:00,• Proceeds to support continued development and commercialization of Endocrine Rare Disease products and general corporate purposes,ABBV,0.021484,0.070657,Neutral
AbbVie Inc.  ( ABBV )  Is a Trending Stock: Facts to Know Before Betting on It,https://www.zacks.com/stock/news/2144733/abbvie-inc-abbv-is-a-trending-stock-facts-to-know-before-betting-on-it,2023-09-05 13:00:09,"Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",ABBV,0.484798,0.1343,Neutral
Royalty Pharma to Present at Upcoming Investor Conferences,https://www.globenewswire.com/news-release/2023/09/05/2737342/0/en/Royalty-Pharma-to-Present-at-Upcoming-Investor-Conferences.html,2023-09-05 12:25:00,"NEW YORK, Sept. 05, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will participate in the following upcoming investor conferences during the month of September: ...",ABBV,0.143415,0.096318,Neutral
Royalty Pharma to Present at Upcoming Investor Conferences - Royalty Pharma  ( NASDAQ:RPRX ) ,https://www.benzinga.com/pressreleases/23/09/g34232943/royalty-pharma-to-present-at-upcoming-investor-conferences,2023-09-05 12:25:00,"NEW YORK, Sept. 05, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it will participate in the following upcoming investor conferences during the month of September: Citi's 18th Annual BioPharma Conference on Wednesday, September 6 at 11:20 a.m. ET",ABBV,0.136888,0.093897,Neutral
CollPlant to Present at the H.C. Wainwright Annual Growth Conference,https://www.prnewswire.com/news-releases/collplant-to-present-at-the-hc-wainwright-annual-growth-conference-301917564.html,2023-09-05 11:00:00,"REHOVOT, Israel, Sept. 5, 2023 /PRNewswire/ -- CollPlant Biotechnologies ( NASDAQ: CLGN ) , a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced ...",ABBV,0.141448,0.111746,Neutral
NVO: Top 3 Pharma Stocks to Boost Your Portfolio,https://stocknews.com/news/nvo-abbv-nvs-top-3-pharma-stocks-to-boost-your-portfolio/,2023-09-04 17:52:30,"The pharmaceutical industry is expected to continue to grow in the coming years, driven by factors such as the aging population, the increasing prevalence of chronic diseases, and the development of new technologies.",ABBV,0.2872,0.277546,Somewhat-Bullish
Is SPDR S&P Dividend ETF  ( SDY )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2144123/is-spdr-sp-dividend-etf-sdy-a-strong-etf-right-now,2023-09-04 10:20:05,Smart Beta ETF report for ...,ABBV,0.112532,0.050608,Neutral
Could CVS Make a Copy of Ozempic?,https://www.fool.com/investing/2023/09/02/could-cvs-make-a-copy-of-ozempic/,2023-09-02 11:35:00,"Given its new biosimilars unit, copying Ozempic is more likely than it sounds.",ABBV,0.04823,0.006,Neutral
3 No-Brainer Dividend Stocks to Buy in September,https://www.fool.com/investing/2023/09/02/3-no-brainer-dividend-stocks-to-buy-in-september/,2023-09-02 10:55:00,Income investors should really like these biopharma stocks with juicy dividends.,ABBV,0.363683,0.409901,Bullish
8 Pharma Stocks Affected by New Drug Price Negotiation Rules,https://www.fool.com/investing/2023/09/02/8-pharma-stocks-affected-by-new-drug-price-negotia/,2023-09-02 10:51:00,Which companies have the most to lose now that Medicare can negotiate directly with them on the prices of some of the most widely used drugs?,ABBV,0.094762,-0.093469,Neutral
Anti-rheumatic Market to Grow Exponentially by 2029- Brandessence Market Research,https://www.prnewswire.com/news-releases/anti-rheumatic-market-to-grow-exponentially-by-2029--brandessence-market-research-301915970.html,2023-09-01 14:34:00,"LONDON, Sept. 1, 2023 /PRNewswire/ -- Rheumatoid arthritis ( RA ) is a highly prevalent auto-immune ailment. This disease predominantly affects our joints, mainly that of hands and feet. It occurs when the immune system begins attacking the healthy tissues.",ABBV,0.054732,0.131821,Neutral
"Pharma Stock Roundup: J&J's New '23 View After Kenvue Separation, Regulatory Updates",https://www.zacks.com/stock/news/2143569/pharma-stock-roundup-jjs-new-23-view-after-kenvue-separation-regulatory-updates,2023-09-01 13:39:00,"J&J (JNJ) updates its financial guidance for 2023 after the final separation of Kenvue. Pfizer, BioNTech, Merck and AbbVie announce regulatory developments.",ABBV,0.148961,0.133477,Neutral
CVS Health Just Created a New Problem For Viatris. Here's What You Need to Know,https://www.fool.com/investing/2023/09/01/cvs-health-just-created-a-new-problem-for-viatris/,2023-09-01 12:30:00,CVS just fired a shot across Viatris' bow.,ABBV,0.056011,0.099893,Neutral
Jnana Therapeutics Presents Additional Data from Phase 1a Clinical Study of JNT-517 at SSIEM Annual Symposium,https://www.benzinga.com/pressreleases/23/08/g34138755/jnana-therapeutics-presents-additional-data-from-phase-1a-clinical-study-of-jnt-517-at-ssiem-annua,2023-08-31 11:00:03,"JNT-517 demonstrated sustained, dose-dependent pharmacodynamic effects and was safe and well tolerated in healthy volunteers Phase 1b study is ongoing in individuals with PKU",ABBV,0.040829,0.122925,Neutral
Medicare Will Soon Negotiate Some Drug Prices. Is This a Threat to Johnson & Johnson's Earnings?,https://www.fool.com/investing/2023/08/31/medicare-will-soon-negotiate-some-drug-prices-is-t/,2023-08-31 09:30:00,The healthcare giant's immunology drug Stelara brought in more than $9 billion in revenue last year.,ABBV,0.056011,0.0,Neutral
Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update,https://www.globenewswire.com/news-release/2023/08/30/2734798/0/en/Alvotech-Reports-Financial-Results-for-First-Six-Months-of-2023-and-Provides-Business-Update.html,2023-08-30 20:15:00,"Alvotech ( NASDAQ: ALVO, or the ""Company"" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of 2023 and provided a summary of recent corporate highlights.",ABBV,0.013868,0.0,Neutral
Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update,https://www.globenewswire.com/news-release/2023/08/30/2734797/0/en/Alvotech-Reports-Financial-Results-for-First-Six-Months-of-2023-and-Provides-Business-Update.html,2023-08-30 20:15:00,"REYKJAVIK, Iceland, Aug. 30, 2023 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the ""Company"" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of ...",ABBV,0.013819,0.0,Neutral
"Top Dividend Stocks: In Biotech Space, AbbVie Entices With 4% Yield",https://www.investors.com/research/the-income-investor/dividend-stock-in-biotech-space-abbvie-entices-with-four-percent-yield/,2023-08-30 18:26:00,"For investors looking for yield in the biotech sector, AbbVie ( ABBV ) is a strong candidate for investment and is in IBD's Dividend Leaders screen. It's a top dividend stock to buy and watch. Headquartered in Chicago, AbbVie is a large-cap pharmaceutical company formed from a 2013 spinoff from ...",ABBV,0.807885,0.113884,Neutral
Medicare drug price negotiations may have a muted impact on drugmakers in the near term,https://www.cnbc.com/2023/08/30/medicare-drug-price-negotiations-may-have-muted-impact-on-drugmakers.html,2023-08-30 17:48:18,Many of the drugs are already facing strong competition from other branded medications or patent expirations that will open the market to generic alternatives.,ABBV,0.034882,0.177392,Somewhat-Bullish
Should First Trust Morningstar Dividend Leaders ETF  ( FDL )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2142505/should-first-trust-morningstar-dividend-leaders-etf-fdl-be-on-your-investing-radar,2023-08-30 15:47:26,Style Box ETF report for ...,ABBV,0.122581,0.068387,Neutral
"Celltrion Healthcare announces the addition of a Yuflyma®  ( adalimumab )  80 mg dosing option, available as an auto-injector and pre-filled syringe",https://www.newswire.ca/news-releases/celltrion-healthcare-announces-the-addition-of-a-yuflyma-r-adalimumab-80-mg-dosing-option-available-as-an-auto-injector-and-pre-filled-syringe-855143692.html,2023-08-30 11:00:00,"Celltrion Healthcare announces the addition of a Yuflyma® ( adalimumab ) 80 mg dosing option, available as an auto ... Canada ...",ABBV,0.055621,0.0,Neutral
You Don't Have to Pick a Winner in Dividend Stocks. Here's Why.,https://www.fool.com/investing/2023/08/30/you-dont-have-to-pick-a-winner-in-dividend-stocks/,2023-08-30 09:50:00,This approach makes income investing easy.,ABBV,0.064104,-0.008016,Neutral
What Impact Will Medicare Price Negotiations Have on Big Pharma Stocks?,https://www.fool.com/investing/2023/08/29/medicare-price-negotiations-big-pharma-stocks/,2023-08-29 21:00:00,Investors appear to be yawning for the most part at the latest news on Medicare drug price negotiations.,ABBV,0.07913,0.045615,Neutral
"Eliquis, Jardiance among first 10 drugs selected for Medicare price negotiations",https://www.marketwatch.com/story/merck-amgen-abbvie-products-among-first-10-drugs-selected-for-medicare-price-negotiations-556c2484,2023-08-29 19:22:00,"Merck, Johnson & Johnson and Amgen are among the first drugmakers to have products chosen for a contentious initiative to rein in prescription-drug costs.",ABBV,0.058188,0.047971,Neutral
Nearing Retirement? These Stocks Will Pay You For Life,https://www.fool.com/investing/2023/08/29/nearing-retirement-these-stocks-will-pay-you-for/,2023-08-29 13:45:00,These companies are passive income machines.,ABBV,0.442767,0.315135,Somewhat-Bullish
"AbbVie, Merck, Lilly Highlight Biden List For Price Cuts",https://www.investors.com/news/technology/pharmaceutical-stocks-biden-administration-unveils-10-drugs-subject-to-price-cuts/,2023-08-29 13:28:00,Pharmaceutical Stocks: Biden Administration Unveils 10 Drugs ... Investor's Business Daily ...,ABBV,0.290607,0.311341,Somewhat-Bullish
AbbVie  ( ABBV )  Seeks Approval for Skyrizi for Ulcerative Colitis,https://www.zacks.com/stock/news/2141813/abbvie-abbv-seeks-approval-for-skyrizi-for-ulcerative-colitis,2023-08-29 13:21:00,AbbVie's (ABBV) regulatory applications filed to the FDA and the EMA seeking approval for Skyrizi for ulcerative colitis are based on data from two phase III studies.,ABBV,0.575603,0.286017,Somewhat-Bullish
"As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs - AbbVie  ( NYSE:ABBV ) , BioRestorative Therapies  ( NASDAQ:BRTX ) ",https://www.benzinga.com/general/biotech/23/08/34088884/as-america-grapples-with-a-deadly-opioid-epidemic-biorestorative-therapies-is-looking-to-treat-ch,2023-08-29 13:00:13,"Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. According to experts, up to 80% of the population will experience back pain at some point. Back pain can exist alone without nerve involvement and oftentimes, this is the most painful type ...",ABBV,0.117486,-0.113931,Neutral
U.S. Announces First Drugs Picked for Medicare Price Negotiations,https://www.nytimes.com/2023/08/29/us/politics/medicare-drug-pricing-negotiations.html,2023-08-29 11:39:43,"The Biden administration's announcement was an important moment for Democrats, who have campaigned on a promise to lower the cost of prescription drugs.",ABBV,0.054236,0.0,Neutral
Biden administration unveils first 10 drugs subject to Medicare price negotiations,https://www.cnbc.com/2023/08/29/10-drugs-to-face-medicare-price-negotiations-see-the-list.html,2023-08-29 11:37:25,The announcement of the 10 drugs kicks off a Medicare negotiation process that aims to make costly medications more affordable for older Americans.,ABBV,0.037681,0.178905,Somewhat-Bullish
Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous  ( SC )  with ENHANZE® in Great Britain,https://www.prnewswire.com/news-releases/halozyme-announces-approval-of-roches-tecentriq-subcutaneous-sc-with-enhanze-in-great-britain-301911904.html,2023-08-29 08:50:00,First subcutaneous anti-PD- ( L ) 1 cancer immunotherapy available to patients in Great Britain Tecentriq® subcutaneous formulation with ENHANZE® reduces treatment time to seven minutes compared to 30-60 minutes for standard intravenous infusion,ABBV,0.029618,0.080493,Neutral
"Faron Reports Half-Year Financial Results, January 1 - June 30, 2023",https://www.globenewswire.com/news-release/2023/08/29/2733033/0/en/Faron-Reports-Half-Year-Financial-Results-January-1-June-30-2023.html,2023-08-29 04:01:00,Summary Highlights ( including post-period events ...,ABBV,0.009601,0.030827,Neutral
Here's How Much $1000 Invested In AbbVie 10 Years Ago Would Be Worth Today - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/news/earnings/23/09/34622256/heres-how-much-1000-invested-in-abbvie-10-years-ago-would-be-worth-today,2023-09-15 16:30:28,"AbbVie ABBV has outperformed the market over the past 10 years by 2.52% on an annualized basis producing an average annual return of 12.45%. Currently, AbbVie has a market capitalization of $270.42 billion.",ABBV,0.983605,0.387251,Bullish
"Pharma Stock Roundup: FDA Nod to Updated PFE, MRNA COVID Jabs, & More",https://www.zacks.com/stock/news/2149445/pharma-stock-roundup-fda-nod-to-updated-pfe-mrna-covid-jabs-more,2023-09-15 13:33:00,The FDA authorizes Pfizer (PFE) and Moderna's (MRNA) updated mRNA-based COVID-19 vaccines. Novo Nordisk (NVO) conducts a two-for-one split of its shares and ADRs.,ABBV,0.107736,0.031869,Neutral
2 Dividend Kings to Buy on the Dip and Hold Forever,https://www.fool.com/investing/2023/09/15/2-dividend-kings-buy-on-the-dip-and-hold-forever/,2023-09-15 13:15:00,Don't ignore these stocks just because the rest of the market is.,ABBV,0.326746,0.27078,Somewhat-Bullish
We should all support Biden's war on Big Pharma,https://www.aljazeera.com/opinions/2023/9/15/we-should-all-support-bidens-war-on-big-pharma,2023-09-15 12:33:29,"If we want cutting-edge medicines at a price we can afford, the US president will need to stand his ground. ""This time, we beat Big Pharma"", United States President Joe Biden tweeted, after finally giving his government the power to negotiate the price of 10 prescription drugs, including ...",ABBV,0.034087,0.084327,Neutral
Should SPDR S&P Dividend ETF  ( SDY )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2149292/should-spdr-sp-dividend-etf-sdy-be-on-your-investing-radar,2023-09-15 10:20:04,Style Box ETF report for ...,ABBV,0.117486,0.057065,Neutral
"Why Is Immuno-Oncology Firm Harpoon Therapeutics Stock Trading Lower Today? - Harpoon Therapeutics  ( NASDAQ:HARP ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/general/biotech/23/09/34583269/why-is-immuno-oncology-firm-harpoon-therapeutics-stock-trading-lower-today,2023-09-14 15:31:14,Harpoon Therapeutics Inc HARP shares are trading lower after AbbVie Inc ABBV chose not to exercise its exclusive license option within the Development and Option Agreement regarding Harpoon's HPN217 program. This program specifically targets B cell maturation antigen or BCMA.,ABBV,0.439786,0.41063,Bullish
"Zacks Investment Ideas feature highlights: Novo Nordisk, Eli Lilly and AbbVie",https://www.zacks.com/stock/news/2148692/zacks-investment-ideas-feature-highlights-novo-nordisk-eli-lilly-and-abbvie,2023-09-14 09:00:00,"Novo Nordisk, Eli Lilly and AbbVie have been highlighted in this Investment Ideas article.",ABBV,0.414559,0.393752,Bullish
"Acute Lymphocytic Leukemia Market to Accelerate Substantially by 2032, Assesses DelveInsight | Key Companies in the Market - Beam, Pfizer, Genentech, AbbVie, Fate, Roche, Ascentage, Janssen, Jazz, ADC, Kymera, Syndax, ImmunoGen",https://www.prnewswire.com/news-releases/acute-lymphocytic-leukemia-market-to-accelerate-substantially-by-2032-assesses-delveinsight--key-companies-in-the-market---beam-pfizer-genentech-abbvie-fate-roche-ascentage-janssen-jazz-adc-kymera-syndax-immunogen-301925772.html,2023-09-13 21:01:00,"Acute Lymphocytic Leukemia Market to Accelerate Substantially by 2032, Assesses DelveInsight | Key Companies in ... PR ...",ABBV,0.043778,0.034443,Neutral
Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie - Harpoon Therapeutics  ( NASDAQ:HARP ) ,https://www.benzinga.com/pressreleases/23/09/g34550265/harpoon-therapeutics-provides-an-update-on-the-hpn217-development-and-option-agreement-with-abbvie,2023-09-13 20:05:00,"SOUTH SAN FRANCISCO, Calif., Sept. 13, 2023 ( GLOBE NEWSWIRE ) -- Harpoon Therapeutics, Inc.",ABBV,0.101582,0.155074,Somewhat-Bullish
"""Blockbuster Status"": 3 Bios to Buy and Hold",https://www.zacks.com/commentary/2148551/blockbuster-status-3-bios-to-buy-and-hold,2023-09-13 18:34:00,"The biotech sector is notorious for its sky-high R&D costs, regulatory hurdles, and lengthy timelines to bring a drug to market. Stock Strategist Andrew Rocco unveils 3 biotech stocks that have broken through and are set up for long term growth.",ABBV,0.33628,0.487247,Bullish
AbbVie Unusual Options Activity For September 13 - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/09/34547020/abbvie-unusual-options-activity-for-september-13,2023-09-13 18:15:55,"A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 16 strange trades. If we consider the specifics of each trade, it is accurate to state that 43% of the investors opened trades with bullish expectations ...",ABBV,0.727604,0.05793,Neutral
AbbVie's  ( ABBV )  Skyrizi Crohn's Disease Study Meets Goals,https://www.zacks.com/stock/news/2148368/abbvies-abbv-skyrizi-crohns-disease-study-meets-goals,2023-09-13 14:02:00,AbbVie's (ABBV) Skyrizi met both primary endpoints of non-inferiority for clinical remission at week 24 and superiority of endoscopic remission at week 48 versus J&J's Stelara in a head-to-head study.,ABBV,0.559547,0.328597,Somewhat-Bullish
NVO: 3 A-Rated Pharma Stocks to Buy Today,https://stocknews.com/news/nvo-abbv-nbix-3-a-rated-pharma-stocks-to-buy-today/,2023-09-13 13:32:22,"The pharmaceutical industry is poised for robust growth, fueled by a rapidly expanding medicinal drug and vaccine market. Due to the persistent necessity of its products, the industry retains stability, which makes it less vulnerable to economic fluctuations.",ABBV,0.238367,0.177456,Somewhat-Bullish
2 Undervalued Dividend Stocks to Buy Now,https://www.fool.com/investing/2023/09/13/2-undervalued-dividend-stocks-to-buy-now/,2023-09-13 13:30:00,These two pharma titans are proven income vehicles.,ABBV,0.531594,0.471234,Bullish
How We'll Tap This Spinoff For 200%+ Dividend Growth,https://www.forbes.com/sites/brettowens/2023/09/13/how-well-tap-this-spinoff-for-200-dividend-growth/,2023-09-13 12:21:00,"Let's dive into this Johnson & Johnson (JNJ) spinoff-because it shows exactly how we can tap ""splits"" like these to grab not one but TWO income streams.",ABBV,0.227716,0.193184,Somewhat-Bullish
Is AbbVie  ( ABBV )  a Buy as Wall Street Analysts Look Optimistic?,https://www.zacks.com/stock/news/2147707/is-abbvie-abbv-a-buy-as-wall-street-analysts-look-optimistic,2023-09-12 13:30:06,"The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",ABBV,0.359262,0.171432,Somewhat-Bullish
AbbVie Reports Top-line Results From Phase 3 SEQUENCE Clinical Trial Of Risankizumab,https://markets.businessinsider.com/news/stocks/abbvie-reports-top-line-results-from-phase-3-sequence-clinical-trial-of-risankizumab-1032623238,2023-09-12 12:52:01,AbbVie Reports Top-line Results From Phase 3 SEQUENCE Clinical Trial Of ...,ABBV,0.682689,-0.056246,Neutral
AbbVie  ( ABBV )  Gains But Lags Market: What You Should Know,https://www.zacks.com/stock/news/2147426/abbvie-abbv-gains-but-lags-market-what-you-should-know,2023-09-11 21:45:19,"AbbVie (ABBV) closed at $149.04 in the latest trading session, marking a +0.01% move from the prior day.",ABBV,0.549988,0.300077,Somewhat-Bullish
Anima Biotech's Webinar Series: Technologies developed to study mRNA life cycle,https://www.benzinga.com/pressreleases/23/09/g34443376/anima-biotechs-webinar-series-technologies-developed-to-study-mrna-life-cycle,2023-09-11 14:17:00,"BERNARDSVILLE, N.J., Sept. 11, 2023 ( GLOBE NEWSWIRE ) -- Anima Biotech, the Tech.bio leading developer of the mRNA Lightning platform at the intersection of mRNA biology and AI, announced its second webinar, part of an exclusive mRNA biology webinar series partnered with leading life science ...",ABBV,0.065506,0.071131,Neutral
Another Arthritis Blockbuster Drug Faces Generic Competition: Novartis' Sandoz Inks Pact With Samsung Bioepis - Novartis  ( NYSE:NVS ) ,https://www.benzinga.com/general/biotech/23/09/34440622/another-arthritis-blockbuster-drug-faces-generic-competition-novartis-sandoz-inks-pact-with-samsu,2023-09-11 13:32:00,"Sandoz, a generic and biosimilar medicines unit of Novartis AG NVS, has entered a development and commercialization agreement with Samsung Bioepis. The agreement provides Sandoz exclusive rights to commercialize the biosimilar SB17 ustekinumab in the US, Canada, EEA, Switzerland, and the U.K.",ABBV,0.252987,0.094961,Neutral
Could This Issue Sink Johnson & Johnson's Stock Price?,https://www.fool.com/investing/2023/09/11/could-this-issue-sink-johnson-johnson-stock/,2023-09-11 10:49:00,Don't be too quick to press the sell button.,ABBV,0.059341,-0.003005,Neutral
Oral Antiviral Market Report 2023: Demand for Novel Therapeutics Boosts Opportunities,https://www.prnewswire.com/news-releases/oral-antiviral-market-report-2023-demand-for-novel-therapeutics-boosts-opportunities-301921979.html,2023-09-09 01:15:00,"DUBLIN, Sept. 8, 2023 /PRNewswire/ -- The ""Oral Antiviral Market by Indication, Drug Class, Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031"" report has been added to ResearchAndMarkets.com's offering.",ABBV,0.085022,0.079948,Neutral
Alector  ( ALEC )  Up 7% on Finishing Enrolment in Alzheimer Study,https://www.zacks.com/stock/news/2146781/alector-alec-up-7-on-finishing-enrolment-in-alzheimer-study,2023-09-08 16:10:00,Alector (ALEC) completes enrolment in a mid-stage study evaluating its investigational monoclonal antibody in patients with early Alzheimer's disease. Data from the study is expected before year-end.,ABBV,0.350564,0.321404,Somewhat-Bullish
AbbVie Declares Quarterly Dividend,https://markets.businessinsider.com/news/stocks/abbvie-declares-quarterly-dividend-1032616724,2023-09-08 15:23:00,"NORTH CHICAGO, Ill., Sept. 8, 2023 /PRNewswire/ -- The board of directors of AbbVie Inc. ( NYSE: ABBV ) today declared a quarterly cash dividend of $1.48 per share. The cash dividend is payable November 15, 2023, to stockholders of record at the close of business on October 13, 2023.",ABBV,0.933751,0.500519,Bullish
 ( ABBV )  - Analyzing AbbVie's Short Interest - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/short-sellers/23/09/34363701/abbv-analyzing-abbvies-short-interest,2023-09-08 14:45:35,"AbbVie's ABBV short percent of float has risen 15.38% since its last report. The company recently reported that it has 13.26 million shares sold short, which is 0.75% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.35 days to cover their ...",ABBV,0.224903,0.158881,Somewhat-Bullish
AbbVie Unusual Options Activity - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/09/34924596/abbvie-unusual-options-activity,2023-09-26 19:45:45,"Someone with a lot of money to spend has taken a bearish stance on AbbVie ABBV. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",ABBV,0.716023,0.166114,Somewhat-Bullish
AbbVie's  ( ABBV )  Epcoritamab Gets Approval in Europe for DLBCL,https://www.zacks.com/stock/news/2155544/abbvies-abbv-epcoritamab-gets-approval-in-europe-for-dlbcl,2023-09-26 14:56:00,Tepkinly is AbbVie's (ABBV) second hematological cancer drug to be approved in the European Union. It is also the third blood cancer medicine in AbbVie's portfolio ...,ABBV,0.329551,0.187535,Somewhat-Bullish
Stocks Showing Improved Relative Strength: AbbVie,https://www.investors.com/ibd-data-stories/stocks-showing-improved-relative-strength-abbvie/,2023-09-26 07:00:00,"The Relative Strength ( RS ) Rating for AbbVie ( ABBV ) jumped into a new percentile Tuesday, as it got a lift from 65 to 72. X When looking for the best stocks to buy and watch, be sure to pay attention to relative price strength.",ABBV,0.705799,0.448665,Bullish
AbbVie  ( ABBV )  Outpaces Stock Market Gains: What You Should Know,https://www.zacks.com/stock/news/2155092/abbvie-abbv-outpaces-stock-market-gains-what-you-should-know,2023-09-25 21:45:19,"AbbVie (ABBV) closed at $154.65 in the latest trading session, marking a +1.25% move from the prior day.",ABBV,0.501398,0.247925,Somewhat-Bullish
"CAR T-cell Therapy for Multiple Myeloma Market to Observe Stunning Growth by 2032, Evaluates DelveInsight | Key Companies - Cartesian, Arcellx, Novartis, Bristol-Myers Squibb, CARsgen, Poseida, Juno, CRISPR, bluebird bio",https://www.prnewswire.com/news-releases/car-t-cell-therapy-for-multiple-myeloma-market-to-observe-stunning-growth-by-2032-evaluates-delveinsight--key-companies---cartesian-arcellx-novartis-bristol-myers-squibb-carsgen-poseida-juno-crispr-bluebird-bio-301937157.html,2023-09-25 21:01:00,"CAR T-cell Therapy for Multiple Myeloma Market to Observe Stunning Growth by 2032, Evaluates DelveInsight | Key ... PR ...",ABBV,0.037504,0.029512,Neutral
How Is The Market Feeling About AbbVie? - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/short-sellers/23/09/34870924/how-is-the-market-feeling-about-abbvie,2023-09-25 15:45:18,"AbbVie's ABBV short percent of float has fallen 5.33% since its last report. The company recently reported that it has 12.45 million shares sold short, which is 0.71% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.23 days to cover their ...",ABBV,0.224903,0.085754,Neutral
"The Zacks Analyst Blog Highlights Pfizer, Merck and AstraZeneca",https://www.zacks.com/stock/news/2154894/the-zacks-analyst-blog-highlights-pfizer-merck-and-astrazeneca,2023-09-25 12:55:00,"Pfizer, Merck and AstraZeneca are part of the Zacks top Analyst Blog.",ABBV,0.052455,-0.124581,Neutral
Genmab Announces European Commission Approval of TEPKINLY®  ( epcoritamab )  for Adults with Relapsed or Refractory  ( R/R )  Diffuse Large B-cell Lymphoma  ( DLBCL ) ,https://www.globenewswire.com/news-release/2023/09/25/2748547/0/en/Genmab-Announces-European-Commission-Approval-of-TEPKINLY-epcoritamab-for-Adults-with-Relapsed-or-Refractory-R-R-Diffuse-Large-B-cell-Lymphoma-DLBCL.html,2023-09-25 11:45:00,Company Announcement ...,ABBV,0.081506,0.049236,Neutral
"EPKINLYTM  ( epcoritamab )  Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory  ( R/R )  Large B-Cell Lymphoma  ( LBCL ) ",https://www.globenewswire.com/news-release/2023/09/25/2748437/0/en/EPKINLYTM-epcoritamab-Approved-by-Japan-Ministry-of-Health-Labour-and-Welfare-as-the-First-Bispecific-Antibody-to-Treat-Adults-Patients-with-Certain-Types-of-Relapsed-or-Refractory.html,2023-09-25 09:55:00,Media Release ...,ABBV,0.057113,0.059983,Neutral
The Thyroid Gland Disorder Treatment Market to grow by USD 868.87 million from 2022 to 2027 | Abbott Laboratories ... - PR Newswire,https://www.prnewswire.com/news-releases/the-thyroid-gland-disorder-treatment-market-to-grow-by-usd-868-87-million-from-2022-to-2027--abbott-laboratories-abbvie-inc-alvogen-iceland-ehf-and-more-among-key-companies--technavio-301936306.html,2023-09-25 02:15:00,The Thyroid Gland Disorder Treatment Market to grow by USD 868.87 million from 2022 to 2027 | Abbott Laboratories ... PR ...,ABBV,0.077845,0.027652,Neutral
3 Best Stocks to Buy in September and Hold Forever,https://www.fool.com/investing/2023/09/24/3-best-stocks-to-buy-in-september-and-hold-forever/,2023-09-24 11:41:00,Healthcare blue chip stocks with proven track records can be excellent long-term investments.,ABBV,0.055236,0.027074,Neutral
Innovative Gelatin Capsules Transforming Pharmaceutical Industry: A Look into the Future,https://www.prnewswire.com/news-releases/innovative-gelatin-capsules-transforming-pharmaceutical-industry-a-look-into-the-future-301936082.html,2023-09-22 21:45:00,"DUBLIN, Sept. 22, 2023 /PRNewswire/ -- The ""Pharmaceutical Gelatin Market Share, Size, Trends, Industry Analysis Report, By Source, By Function, By End Use, By Regions, Segment Forecast, 2023-2032"" report has been added to ResearchAndMarkets.com's offering.",ABBV,0.060236,-0.055999,Neutral
"Global Dermatology Drugs Market Set to Skyrocket, Anticipated Valuation of $50.47 Billion by 2032",https://www.prnewswire.com/news-releases/global-dermatology-drugs-market-set-to-skyrocket-anticipated-valuation-of-50-47-billion-by-2032--301936081.html,2023-09-22 21:30:00,"DUBLIN, Sept. 22, 2023 /PRNewswire/ -- The ""Dermatology Drugs Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Area, By Drug Class, By Route of Administration, By Distribution Channel, By Region, Segment Forecast, 2023-2032"" report has been added to ResearchAndMarkets.com's ...",ABBV,0.060541,-0.056,Neutral
AbbVie terminates deal with I-Mab to develop cancer drug,https://www.reuters.com/markets/deals/abbvie-terminates-deal-with-i-mab-develop-cancer-drug-2023-09-22/,2023-09-22 21:09:00,"Test tubes are seen in front of a displayed Abbvie logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing Rights",ABBV,0.746902,0.023358,Neutral
"Pharma Stock Roundup: EU Nod to PFE's Litfulo, FDA Priority Tag to MRK Applications",https://www.zacks.com/stock/news/2154134/pharma-stock-roundup-eu-nod-to-pfes-litfulo-fda-priority-tag-to-mrk-applications,2023-09-22 13:21:00,The European Commission approves Pfizer's (PFE) Litfulo for severe alopecia areata. FDA gives priority tag to Merck's (MRK) supplemental applications for Welireg and Keytruda.,ABBV,0.054607,-0.124806,Neutral
"Chronic Lower Back Pain Market to Showcase Tremendous Growth by 2032, Predicts DelveInsight | Key Companies to Look Out - Eli Lilly, Camurus, Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG",https://www.prnewswire.com/news-releases/chronic-lower-back-pain-market-to-showcase-tremendous-growth-by-2032-predicts-delveinsight--key-companies-to-look-out---eli-lilly-camurus-braeburn-inc-scilex-holding-mesoblast-limited-anges-mg-301934365.html,2023-09-21 21:01:00,"Chronic Lower Back Pain Market to Showcase Tremendous Growth by 2032, Predicts DelveInsight | Key Companies to ... PR ...",ABBV,0.02275,0.014186,Neutral
AbbVie Stock Shows Rising Relative Strength Rating,https://www.investors.com/research/abbvie-shows-stock-rising-relative-strength-rating/,2023-09-21 20:06:00,"On Thursday, AbbVie ( ABBV ) stock got an upgrade to its Relative Strength ( RS ) Rating, from 68 to 71. When you're researching the best stocks to buy and watch, be sure to pay attention to relative price strength.",ABBV,0.6338,0.25965,Somewhat-Bullish
3 Bargain Stocks to Buy in a Market That's Priced for Perfection,https://www.fool.com/investing/2023/09/21/3-bargain-stocks-to-buy-in-a-market-thats-priced-f/,2023-09-21 17:54:00,Many stocks have nosebleed valuations. But not these.,ABBV,0.40348,0.199045,Somewhat-Bullish
Only 7 Large-Cap Dividend Kings Yield Over 3%. Here's My Top Pick to Buy Now.,https://www.fool.com/investing/2023/09/21/only-7-large-cap-dividend-kings-high-yield/,2023-09-21 14:15:00,"Dividend Kings are passive income powerhouses, but they aren't always a good value.",ABBV,0.233556,0.230278,Somewhat-Bullish
Royalty Pharma Appoints Eric Schneider as Chief Technology Officer,https://www.globenewswire.com/news-release/2023/09/21/2747258/0/en/Royalty-Pharma-Appoints-Eric-Schneider-as-Chief-Technology-Officer.html,2023-09-21 12:25:00,"NEW YORK, Sept. 21, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also join Royalty Pharma's Senior Leadership Committee.",ABBV,0.039745,0.077346,Neutral
Royalty Pharma Appoints Eric Schneider as Chief Technology Officer - Royalty Pharma  ( NASDAQ:RPRX ) ,https://www.benzinga.com/pressreleases/23/09/g34790155/royalty-pharma-appoints-eric-schneider-as-chief-technology-officer,2023-09-21 12:25:00,"NEW YORK, Sept. 21, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also join Royalty Pharma's Senior Leadership Committee.",ABBV,0.039224,0.077209,Neutral
"Bluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice President, head of business development",https://www.benzinga.com/pressreleases/23/09/g34789158/bluejay-therapeutics-expands-management-team-and-hired-christopher-holterhoff-as-senior-vice-presi,2023-09-21 11:55:00,"SAN MATEO, Calif., Sept. 21, 2023 ( GLOBE NEWSWIRE ) -- Bluejay Therapeutics, Inc. a private clinical stage biopharmaceutical company focused on viral and liver diseases, today announced the appointment of Christopher Holterhoff as Senior Vice President, Head of Business Development.",ABBV,0.076971,0.032651,Neutral
"CollPlant Biotechnologies Joins the United Nations Global Compact, The World's Largest Corporate Sustainability Initiative",https://www.prnewswire.com/news-releases/collplant-biotechnologies-joins-the-united-nations-global-compact-the-worlds-largest-corporate-sustainability-initiative-301934595.html,2023-09-21 11:00:00,"CollPlant Biotechnologies Joins the United Nations Global Compact, The World's Largest Corporate Sustainability ... PR ...",ABBV,0.108958,0.098597,Neutral
Stock Upgrades: AbbVie Shows Rising Relative Strength,https://www.investors.com/ibd-data-stories/stock-upgrades-abbvie-shows-rising-relative-strength-7/,2023-09-21 07:00:00,"On Thursday, AbbVie ( ABBV ) got an upgrade to its Relative Strength ( RS ) Rating, from 68 to 71. X When you're researching the best stocks to buy and watch, be sure to pay attention to relative price strength.",ABBV,0.716023,0.319946,Somewhat-Bullish
Capsida Biotherapeutics to Present at Jefferies Cell & Genetic Medicine Summit and the 2023 Cell & Gene Meeting on the Mesa,https://markets.businessinsider.com/news/stocks/capsida-biotherapeutics-to-present-at-jefferies-cell-genetic-medicine-summit-and-the-2023-cell-gene-meeting-on-the-mesa-1032643111,2023-09-20 11:45:00,"THOUSAND OAKS, Calif., Sept. 20, 2023 /PRNewswire/ -- Capsida Biotherapeutics ( ""Capsida"" ) today announced that Peter Anastasiou, Chief Executive Officer, will present a corporate update at the following upcoming investor and industry conferences: • Jefferies Cell & Genetic Medicine Summit on ...",ABBV,0.140896,0.040772,Neutral
Should WisdomTree U.S. High Dividend ETF  ( DHS )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2152865/should-wisdomtree-us-high-dividend-etf-dhs-be-on-your-investing-radar,2023-09-20 10:20:05,Style Box ETF report for ...,ABBV,0.123209,0.068541,Neutral
Former IBD 50 Stock Implodes As Its 'Prestige' Plan Goes Up In Smoke,https://www.investors.com/news/technology/rvnc-stock-collapses-as-prestige-plan-goes-up-in-smoke/,2023-09-19 15:53:00,"Revance Therapeutics ( RVNC ) is reversing course to stay competitive with AbbVie's ( ABBV ) market-leading aesthetics drug, Botox - and RVNC stock crashed Tuesday in response. The company said earlier this year it was going after ""prestige"" accounts with its Daxxify, the newest in a class of ...",ABBV,0.221481,0.146182,Neutral
Crohn's and Colitis Canada Supports Post-Secondary Students Living with Inflammatory Bowel Disease  ( IBD ) ,https://www.newswire.ca/news-releases/crohn-s-and-colitis-canada-supports-post-secondary-students-living-with-inflammatory-bowel-disease-ibd--879292289.html,2023-09-19 10:00:00,"$5,000 scholarships to 15 students in collaboration with AbbVie Canada TORONTO, Sept. 19, 2023 /CNW/ - Crohn's and Colitis Canada has awarded 15 post-secondary students each with a $5,000 AbbVie IBD Scholarship Program grant.",ABBV,0.628066,0.525679,Bullish
AbbVie  ( ABBV )  Outpaces Stock Market Gains: What You Should Know,https://www.zacks.com/stock/news/2152119/abbvie-abbv-outpaces-stock-market-gains-what-you-should-know,2023-09-18 21:45:21,"In the latest trading session, AbbVie (ABBV) closed at $153.94, marking a +1.2% move from the previous day.",ABBV,0.679118,0.263067,Somewhat-Bullish
COMPASS Pathways appoints Daphne Karydas to its Board of Directors,https://investingnews.com/compass-pathways-appoints-daphne-karydas-to-its-board-of-directors/,2023-09-18 21:25:36,"COMPASS Pathways plc ( Nasdaq: CMPS ) ( ""COMPASS"" ) , a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Daphne Karydas to its Board of Directors, effective September 18, 2023.",ABBV,0.034381,-0.004831,Neutral
COMPASS Pathways appoints Daphne Karydas to its Board of Directors,https://www.globenewswire.com/news-release/2023/09/18/2745209/0/en/COMPASS-Pathways-appoints-Daphne-Karydas-to-its-Board-of-Directors.html,2023-09-18 20:31:00,"LONDON, Sept. 18, 2023 ( GLOBE NEWSWIRE ) -- COMPASS Pathways plc ( Nasdaq: CMPS ) ( ""COMPASS"" ) , a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Daphne Karydas to its Board of Directors, ...",ABBV,0.032513,-0.004796,Neutral
COMPASS Pathways appoints Daphne Karydas to its Board of Directors - Compass Pathways  ( NASDAQ:CMPS ) ,https://www.benzinga.com/pressreleases/23/09/g34702085/compass-pathways-appoints-daphne-karydas-to-its-board-of-directors,2023-09-18 20:31:00,"LONDON, Sept. 18, 2023 ( GLOBE NEWSWIRE ) -- COMPASS Pathways plc CMPS ( ""COMPASS"" ) , a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Daphne Karydas to its Board of Directors, effective September ...",ABBV,0.031822,-0.004783,Neutral
This Is What Whales Are Betting On AbbVie - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/09/34699186/this-is-what-whales-are-betting-on-abbvie,2023-09-18 17:31:21,"Someone with a lot of money to spend has taken a bearish stance on AbbVie ABBV. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",ABBV,0.716023,0.166114,Somewhat-Bullish
JNJ: 3 Healthcare Stocks to Buy Today,https://stocknews.com/news/jnj-abbv-amgn-3-healthcare-stocks-to-buy-today/,2023-09-18 16:18:05,"Johnson & Johnson ( JNJ ) , Amgen ( AMGN ) and AbbVie ( ABBV ) are healthcare sector leaders with their company specific transformative catalysts in the fray. All three stocks are rated a strong buy by the propriety POWR Rating, ranking above the 95th percentile.",ABBV,0.258743,0.158904,Somewhat-Bullish
"Regenerative Medicine Market Size is projected to reach USD 72.2 Billion by 2030, growing at a CAGR of 17.6%: Straits Research",https://www.benzinga.com/pressreleases/23/09/g34695923/regenerative-medicine-market-size-is-projected-to-reach-usd-72-2-billion-by-2030-growing-at-a-cagr,2023-09-18 15:20:00,"New York, United States, Sept. 18, 2023 ( GLOBE NEWSWIRE ) -- Regenerative drugs are used to repair, swap out, and regenerate tissues and organs harmed by injury, disease, or normal aging. Cell therapy treats patients with cellular elements like stem cells, autologous cells, xenogeneic cells, and ...",ABBV,0.037155,0.0,Neutral
AbbVie Inc.  ( ABBV )  is Attracting Investor Attention: Here is What You Should Know,https://www.zacks.com/stock/news/2151766/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know,2023-09-18 13:00:12,"Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",ABBV,0.489394,0.12321,Neutral
These 4 Dividend ETFs Are a Retiree's Best Friend,https://www.fool.com/investing/2023/09/18/these-4-dividend-etfs-are-a-retirees-best-friend/,2023-09-18 10:35:00,"Dividends can be powerful wealth-boosters in your portfolio, delivering regular (and often growing) income.",ABBV,0.056275,0.0,Neutral
Large Molecule Injectable Drugs Market to grow by USD 191.45 billion from 2022-2027 | North America to account for ... - PR Newswire,https://www.prnewswire.com/news-releases/large-molecule-injectable-drugs-market-to-grow-by-usd-191-45-billion-from-2022-2027--north-america-to-account-for-45-of-market-growth---technavio-301929312.html,2023-09-18 08:35:00,Large Molecule Injectable Drugs Market to grow by USD 191.45 billion from 2022-2027 | North America to account for ... PR ...,ABBV,0.052685,0.0,Neutral
Myopia and presbyopia treatment market to grow by USD 7.94 billion from 2022 to 2027 | Asia to account for 37% of ... - PR Newswire,https://www.prnewswire.com/news-releases/myopia-and-presbyopia-treatment-market-to-grow-by-usd-7-94-billion-from-2022-to-2027--asia-to-account-for-37-of-market-growth--technavio-301929564.html,2023-09-18 04:15:00,Myopia and presbyopia treatment market to grow by USD 7.94 billion from 2022 to 2027 | Asia to account for 37% of ... PR ...,ABBV,0.052801,0.184679,Somewhat-Bullish
Weight Management Devices Market to grow by USD 4.57 billion between 2022 - 2027 | Growth Driven by Growing ... - PR Newswire,https://www.prnewswire.com/news-releases/weight-management-devices-market-to-grow-by-usd-4-57-billion-between-2022---2027--growth-driven-by-growing-obese-population---technavio-301929563.html,2023-09-18 03:15:00,Weight Management Devices Market to grow by USD 4.57 billion between 2022 - 2027 | Growth Driven by Growing ... PR ...,ABBV,0.047559,0.159676,Somewhat-Bullish
Should You Load Up On This 1 Dividend Stock?,https://www.fool.com/investing/2023/10/06/should-you-load-up-on-this-dividend-stock/,2023-10-06 14:15:00,It's not that hard a call.,ABBV,0.608634,0.335297,Somewhat-Bullish
Pharma Stock Roundup: LLY Offers to Buy POINT Biopharma & Other Updates,https://www.zacks.com/stock/news/2161488/pharma-stock-roundup-lly-offers-to-buy-point-biopharma-other-updates,2023-10-06 13:30:00,Eli Lilly (LLY) offers to buy POINT Biopharma for approximately $1.4 billion. Sanofi (SNY) partners with Teva for co-developing immunology candidate.,ABBV,0.158519,0.095413,Neutral
AbbVie  ( ABBV )  Buys Parkinson's Disease Treatment Maker,https://www.zacks.com/stock/news/2161465/abbvie-abbv-buys-parkinsons-disease-treatment-maker,2023-10-06 13:24:00,"AbbVie's (ABBV) buyout of Mitokinin, which is making a novel treatment for Parkinson's Disease (PD), if successfully closed, is likely to strengthen its neuroscience pipeline.",ABBV,0.563609,0.365592,Bullish
Pharma Giants Combine Forces to Fight New M&A Rules,https://www.thedailyupside.com/industries/healthcare/pharma-giants-combine-forces-to-fight-new-ma-rules/,2023-10-04 22:34:38,Meet the anti-antitrust coalition. With a looming overhaul of US merger-and-acquisition law set to reshape the economics of the M&A-heavy...,ABBV,0.086245,-0.123019,Neutral
"Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period  ( 2019-2032 ) , Assesses DelveInsight | Leading Companies - Amgen, Novartis, AbbVie, BMS, Clovis Oncology, Cardiff Oncology, Roche, Daiichi Sankyo",https://www.prnewswire.com/news-releases/small-cell-lung-cancer-market-to-accelerate-substantially-during-the-study-period-20192032-assesses-delveinsight--leading-companies----amgen-novartis-abbvie-bms-clovis-oncology-cardiff-oncology-roche-daiichi-sankyo-301946615.html,2023-10-04 21:01:00,"Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period ( 2019-2032 ) , Assesses ... PR ...",ABBV,0.086948,-0.051258,Neutral
3 High-Yielding Dividend Growth Stocks That Have Increased Their Payouts by 50% in 5 Years,https://www.fool.com/investing/2023/10/04/3-high-yielding-dividend-growth-stocks-that-have/,2023-10-04 13:53:00,These are relatively safe income investments that you can hold on to for the long haul.,ABBV,0.377958,0.334023,Somewhat-Bullish
Alembic Pharma gets six USFDA approvals for its generic formulations in Q2FY24,https://www.financialexpress.com/healthcare/pharma-healthcare/alembic-pharma-gets-six-usfda-approvals-for-its-generic-formulations-in-q2fy24/3262451/,2023-10-04 06:11:39,Alembic Pharmaceuticals Limited on Wednesday announced that it has received US Food & Drug Administration ( USFDA ) approvals on six of its Abbreviated New Drug Application ( ANDA ) during Q2FY24.,ABBV,0.175221,-0.052013,Neutral
"IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z. Thompson, Ph.D. to Board of Directors",https://www.globenewswire.com/news-release/2023/10/03/2754164/0/en/IGM-Biosciences-Announces-Retirement-of-Chairman-Michael-Loberg-Ph-D-from-Board-of-Directors-and-Appointment-of-Elizabeth-H-Z-Thompson-Ph-D-to-Board-of-Directors.html,2023-10-03 20:05:00,"MOUNTAIN VIEW, Calif., Oct. 03, 2023 ( GLOBE NEWSWIRE ) -- IGM Biosciences, Inc. ( Nasdaq: IGMS ) , a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Michael Loberg, Ph.D. has retired from its Board of Directors, including ...",ABBV,0.057215,0.09895,Neutral
"IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z. Thompson, Ph.D. to Board of Directors - IGM Biosciences  ( NASDAQ:IGMS ) ",https://www.benzinga.com/pressreleases/23/10/g35072392/igm-biosciences-announces-retirement-of-chairman-michael-loberg-ph-d-from-board-of-directors-and-a,2023-10-03 20:05:00,"MOUNTAIN VIEW, Calif., Oct. 03, 2023 ( GLOBE NEWSWIRE ) -- IGM Biosciences, Inc. IGMS, a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Michael Loberg, Ph.D. has retired from its Board of Directors, including as Chairman, ...",ABBV,0.056011,0.098893,Neutral
Check Out What Whales Are Doing With ABBV - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/10/35069941/check-out-what-whales-are-doing-with-abbv,2023-10-03 17:46:17,"A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 10 strange trades. If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with bullish expectations ...",ABBV,0.701875,0.05702,Neutral
"Medicare drug price negotiations move forward with all drugmakers participating, White House says",https://www.marketwatch.com/story/medicare-drug-price-negotiations-move-forward-with-all-drugmakers-participating-white-house-says-45b891dc,2023-10-03 12:00:00,Novo Nordisk is latest drugmaker to challenge negotiation program in court.,ABBV,0.1789,-0.043857,Neutral
Capsida Biotherapeutics Enters Strategic Collaboration With Kate Therapeutics to Manufacture KateTx's Next-Generation Gene Therapies,https://www.benzinga.com/pressreleases/23/10/n35058465/capsida-biotherapeutics-enters-strategic-collaboration-with-kate-therapeutics-to-manufacture-katet,2023-10-03 11:45:00,Strategic partnership leverages Capsida's next-generation manufacturing capabilities to enable development of KateTx's gene therapy medicines for muscle and heart diseases,ABBV,0.055881,0.014998,Neutral
AbbVie  ( ABBV )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2158857/abbvie-abbv-stock-sinks-as-market-gains-what-you-should-know,2023-10-02 21:45:17,"AbbVie (ABBV) closed at $148.25 in the latest trading session, marking a -0.54% move from the prior day.",ABBV,0.682689,0.330416,Somewhat-Bullish
"Parkinson's Disease Psychosis Market is Likely to Increase at a Steady Growth Rate by 2032, Estimates DelveInsight | Key Companies Working to Develop Therapies - Vanda, Kyowa Kirin, Sage, Athira, Aptinyx, CogState, AgeneBio",https://www.prnewswire.com/news-releases/parkinsons-disease-psychosis-market-is-likely-to-increase-at-a-steady-growth-rate-by-2032-estimates-delveinsight--key-companies-working-to-develop-therapies---vanda-kyowa-kirin-sage-athira-aptinyx-cogstate-agenebio-301941331.html,2023-10-02 21:01:00,"Parkinson's Disease Psychosis Market is Likely to Increase at a Steady Growth Rate by 2032, Estimates DelveInsight ... PR ...",ABBV,0.027508,0.032597,Neutral
Drugmakers opt in to Medicare drug price negotiations - here's what happens next,https://www.cnbc.com/2023/10/02/drugmakers-agree-to-medicare-price-negotiations-whats-next.html,2023-10-02 19:34:02,"The lengthy negotiation process with Medicare won't end until August 2024, with reduced prices going into effect in January 2026.",ABBV,0.051221,0.183448,Somewhat-Bullish
3 Top Stocks to Buy in October and Hold Forever,https://www.fool.com/investing/2023/10/02/3-top-stocks-to-buy-in-october-and-hold-forever/,2023-10-02 13:40:13,Check out these three blue chip buys playing crucial roles in America's $6 trillion healthcare opportunity.,ABBV,0.216376,0.283548,Somewhat-Bullish
"The Zacks Analyst Blog Highlights AbbVie, Lilly, Sanofi, Merck and J&J",https://www.zacks.com/stock/news/2158561/the-zacks-analyst-blog-highlights-abbvie-lilly-sanofi-merck-and-jj,2023-10-02 10:31:00,"AbbVie, Lilly, Sanofi, Merck and J&J are included in this Analyst Blog.",ABBV,0.074926,0.0,Neutral
3 Magnificent Dividend Stocks to Buy in October,https://www.fool.com/investing/2023/09/30/3-magnificent-dividend-stocks-to-buy-in-october/,2023-09-30 10:55:00,These stocks come with great dividends and more.,ABBV,0.350564,0.204761,Somewhat-Bullish
Federal judge declines to block Medicare price negotiations,https://www.cnbc.com/2023/09/29/medicare-price-negotiations-federal-judge-denies-injunction-request.html,2023-09-29 21:39:58,Judge Michael Newman of the Southern District of Ohio issued a ruling denying a preliminary injunction sought by the Chamber of Commerce.,ABBV,0.057907,-0.117981,Neutral
AbbVie's Promising Leap Towards Long-Term Growth: Analyst - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/general/biotech/23/09/35007336/abbvies-promising-leap-towards-long-term-growth-analyst,2023-09-29 17:37:04,Raymond James initiated coverage on AbbVie Inc ABBV as the company looks beyond Humira's loss of exclusivity and has several levers to set up long-term growth. Analysts Gary Nachman and Denis Reznik have initiated with an Outperform rating and a price target of $177.,ABBV,0.745397,0.297938,Somewhat-Bullish
AbbVie's Leukemia Drug Falls Short In Late-Stage Study In Pretreated Blood Cancer Patients - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/general/biotech/23/09/35004872/abbvies-leukemia-drug-falls-short-in-late-stage-study-in-pretreated-blood-cancer-patients,2023-09-29 16:18:07,AbbVie Inc ABBV released data from its Phase 3 CANOVA study evaluating venetoclax ( Venclexta/ Venclyxto ) plus dexamethasone ( VenDex ) for patients with t ( 11;14 ) -positive relapsed or refractory ( R/R ) multiple myeloma who have received two or more prior treatments.,ABBV,0.436009,0.254331,Somewhat-Bullish
"As Merck, AstraZeneca and other drugmakers sign on, Medicare price negotiations face critical moment",https://www.marketwatch.com/story/as-merck-astrazeneca-and-other-drugmakers-sign-on-medicare-price-negotiations-face-critical-moment-9d85879f,2023-09-29 14:20:00,A deadline looms to sign drug-price negotiation agreements as industry watches for legal reprieve.,ABBV,0.100099,0.0,Neutral
Artwork Management Software Market worth $1.12 Billion by 2030 - Exclusive Report by The Insight Partners,https://www.benzinga.com/pressreleases/23/09/g35002288/artwork-management-software-market-worth-1-12-billion-by-2030-exclusive-report-by-the-insight-part,2023-09-29 13:26:58,"Pune, India., Sept. 29, 2023 ( GLOBE NEWSWIRE ) -- According to a new report on ""Artwork Management Software Market Size and Forecasts ( 2020 - 2030 ) , Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Deployment ( Cloud and On-Premise ) , Application ( Life ...",ABBV,0.031822,0.171305,Somewhat-Bullish
AbbVie Inc.  ( ABBV )  Is a Trending Stock: Facts to Know Before Betting on It,https://www.zacks.com/stock/news/2157671/abbvie-inc-abbv-is-a-trending-stock-facts-to-know-before-betting-on-it,2023-09-29 13:00:12,"Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",ABBV,0.487546,0.110722,Neutral
AbbVie's blood cancer combo therapy fails in late-stage study,https://www.reuters.com/business/healthcare-pharmaceuticals/abbvies-blood-cancer-combo-therapy-fails-late-stage-study-2023-09-29/,2023-09-29 12:49:00,"A woman holds a test tube in front of displayed Abbvie logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing Rights",ABBV,0.52759,0.063279,Neutral
"The Zacks Analyst Blog Highlights Oracle, AbbVie, Lowe's Companies, Ecolab and Motorola Solutions",https://www.zacks.com/stock/news/2157699/the-zacks-analyst-blog-highlights-oracle-abbvie-lowes-companies-ecolab-and-motorola-solutions,2023-09-29 12:17:00,"Oracle, AbbVie, Lowe's Companies, Ecolab and Motorola Solutions are part of the Zacks top Analyst Blog .",ABBV,0.432291,0.200782,Somewhat-Bullish
Is WisdomTree U.S. High Dividend ETF  ( DHS )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2157519/is-wisdomtree-us-high-dividend-etf-dhs-a-strong-etf-right-now,2023-09-29 10:20:06,Smart Beta ETF report for ...,ABBV,0.118064,0.06168,Neutral
"Want $500 in Passive Income? Invest $3,500 Into These 3 Dividend Stocks and Wait 4 Years",https://www.fool.com/investing/2023/09/29/want-passive-income-invest-top-3-dividend-stocks/,2023-09-29 10:15:00,"A basket of passive income opportunities in oil and gas, renewable energy, and healthcare.",ABBV,0.395012,0.391936,Bullish
"Top Analyst Reports for Oracle, AbbVie & Lowe's",https://www.zacks.com/research-daily/2156946/top-analyst-reports-for-oracle-abbvie-lowes,2023-09-28 18:00:00,"Today's Research Daily features new research reports on 16 major stocks, including Oracle Corporation (ORCL), AbbVie Inc. (ABBV) and Lowe's Companies, Inc. (LOW).",ABBV,0.318897,0.284475,Somewhat-Bullish
Is It Worth Investing in AbbVie  ( ABBV )  Based on Wall Street's Bullish Views?,https://www.zacks.com/stock/news/2157037/is-it-worth-investing-in-abbvie-abbv-based-on-wall-streets-bullish-views,2023-09-28 13:30:11,"The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",ABBV,0.363768,0.202978,Somewhat-Bullish
Is Novo Nordisk a Good Passive Income Stock?,https://www.fool.com/investing/2023/09/28/is-novo-nordisk-a-good-passive-income-stock/,2023-09-28 09:29:00,Producing cash isn't a problem for this pharma giant.,ABBV,0.039679,0.127544,Neutral
Allergan Aesthetics and University Lab Partners Announce the Golden Passport Pitch Competition to Accelerate Aesthetics Start-Ups,https://www.prnewswire.com/news-releases/allergan-aesthetics-and-university-lab-partners-announce-the-golden-passport-pitch-competition-to-accelerate-aesthetics-start-ups-301959799.html,2023-10-17 23:57:00,Allergan Aesthetics and University Lab Partners Announce the Golden Passport Pitch Competition to Accelerate ... PR ...,ABBV,0.436009,0.589501,Bullish
Allergan Aesthetics and University Lab Partners Announce the Golden Passport Pitch Competition to Accelerate Aesthetics Start-Ups,https://markets.businessinsider.com/news/stocks/allergan-aesthetics-and-university-lab-partners-announce-the-golden-passport-pitch-competition-to-accelerate-aesthetics-start-ups-1032714310,2023-10-17 23:57:00,Allergan Aesthetics and University Lab Partners Announce the Golden Passport Pitch Competition to Accelerate Aesthetics ...,ABBV,0.419733,0.578189,Bullish
Piramal Pharma Solutions Launches In-Vitro Biology Capabilities at Ahmedabad Discovery Services Site USA ... - PR Newswire,https://www.prnewswire.com/news-releases/piramal-pharma-solutions-launches-in-vitro-biology-capabilities-at-ahmedabad-discovery-services-site-301959497.html,2023-10-17 18:38:00,Piramal Pharma Solutions Launches In-Vitro Biology Capabilities at Ahmedabad Discovery Services Site USA ... PR ...,ABBV,0.059341,-0.005012,Neutral
Piramal Pharma Solutions Launches In-Vitro Biology Capabilities at Ahmedabad Discovery Services Site - Canada NewsWire,https://www.newswire.ca/news-releases/piramal-pharma-solutions-launches-in-vitro-biology-capabilities-at-ahmedabad-discovery-services-site-805431031.html,2023-10-17 18:34:00,Piramal Pharma Solutions Launches In-Vitro Biology Capabilities at Ahmedabad Discovery Services Site Canada ...,ABBV,0.059935,-0.005014,Neutral
Piramal Pharma Solutions Launches In-Vitro Biology Capabilities at Ahmedabad Discovery Services Site - PR Newswire,https://www.prnewswire.com/news-releases/piramal-pharma-solutions-launches-in-vitro-biology-capabilities-at-ahmedabad-discovery-services-site-301959491.html,2023-10-17 18:34:00,Piramal Pharma Solutions Launches In-Vitro Biology Capabilities at Ahmedabad Discovery Services Site PR ...,ABBV,0.059341,-0.005012,Neutral
Johnson & Johnson Was Saved By Its Focus On MedTech And Innovative Medicine - Johnson & Johnson  ( NYSE:JNJ ) ,https://www.benzinga.com/23/10/35294426/johnson-johnson-was-saved-by-its-focus-on-medtech-and-innovative-medicine,2023-10-17 17:16:16,Johnson & Johnson JNJ reported its third quarter results that topped Wall Street's expectations while also lifting its full year guidance fueled by a strong performance of its pharmaceutical and medical devices businesses.,ABBV,0.21803,0.080228,Neutral
3 Supercharged Dividend Stocks to Buy if There's a Stock Market Sell-Off,https://www.fool.com/investing/2023/10/17/supercharged-dividend-stocks-buy-market-sell-off/,2023-10-17 15:32:27,These three top-notch stocks would make great additions to any dividend portfolio.,ABBV,0.158868,0.048077,Neutral
AbbVie's RINVOQ®  ( upadacitinib )  Receives Health Canada Approval as the First and Only Oral Therapy for the Treatment of Adults with Moderately to Severely Active Crohn's Disease,https://www.newswire.ca/news-releases/abbvie-s-rinvoq-r-upadacitinib-receives-health-canada-approval-as-the-first-and-only-oral-therapy-for-the-treatment-of-adults-with-moderately-to-severely-active-crohn-s-disease-852232549.html,2023-10-17 11:05:00,AbbVie's RINVOQ® ( upadacitinib ) Receives Health Canada Approval as the First and Only Oral Therapy for the ... Canada ...,ABBV,0.279724,0.251673,Somewhat-Bullish
AbbVie's EPKINLY™  ( epcoritamab injection/epcoritamab for injection )  Receives Health Canada Authorization with Conditions as the First and Only Subcutaneous Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma  ( DLBCL ) ,https://www.newswire.ca/news-releases/abbvie-s-epkinly-tm-epcoritamab-injection-epcoritamab-for-injection-receives-health-canada-authorization-with-conditions-as-the-first-and-only-subcutaneous-bispecific-antibody-to-treat-adult-patients-with-relapsed-or-refractory-diffuse-larg-863040377.html,2023-10-17 11:00:00,AbbVie's EPKINLY™ ( epcoritamab injection/epcoritamab for injection ) Receives Health Canada Authorization with ... Canada ...,ABBV,0.294977,0.146249,Neutral
AbbVie  ( ABBV )  Stock Sinks As Market Gains: Here's Why,https://www.zacks.com/stock/news/2166732/abbvie-abbv-stock-sinks-as-market-gains-heres-why,2023-10-16 21:45:20,"AbbVie (ABBV) concluded the recent trading session at $147.23, signifying a -0.49% move from its prior day's close.",ABBV,0.580956,0.223955,Somewhat-Bullish
"Large Granular Lymphocyte Leukemia Market is Projected to Grow During the Study Period  ( 2019-2032 ) , Assesses DelveInsight | Key Companies - Bristol Myers Squibb, Innate Pharma, Kymera Therapeutics, EUSA Pharma, Abcuro, Dren Bio, Novotech",https://www.prnewswire.com/news-releases/large-granular-lymphocyte-leukemia-market-is-projected-to-grow-during-the-study-period-20192032-assesses-delveinsight--key-companies---bristol-myers-squibb-innate-pharma-kymera-therapeutics-eusa-pharma-abcuro-dren-bio-n-301957023.html,2023-10-16 21:01:00,"Large Granular Lymphocyte Leukemia Market is Projected to Grow During the Study Period ( 2019-2032 ) , Assesses ... PR ...",ABBV,0.051663,-0.028928,Neutral
Royalty Pharma Declares Fourth Quarter 2023 Dividend,https://www.globenewswire.com/news-release/2023/10/16/2761072/0/en/Royalty-Pharma-Declares-Fourth-Quarter-2023-Dividend.html,2023-10-16 20:15:00,"NEW YORK, Oct. 16, 2023 ( GLOBE NEWSWIRE ) -- The board of directors of Royalty Pharma plc ( Nasdaq: RPRX ) has approved the payment of a dividend for the fourth quarter of 2023 of $0.20 per Class A ordinary share.",ABBV,0.165031,0.105018,Neutral
Royalty Pharma Declares Fourth Quarter 2023 Dividend - Royalty Pharma  ( NASDAQ:RPRX ) ,https://www.benzinga.com/pressreleases/23/10/g35275801/royalty-pharma-declares-fourth-quarter-2023-dividend,2023-10-16 20:15:00,"NEW YORK, Oct. 16, 2023 ( GLOBE NEWSWIRE ) -- The board of directors of Royalty Pharma plc RPRX has approved the payment of a dividend for the fourth quarter of 2023 of $0.20 per Class A ordinary share. The dividend will be paid on December 15, 2023, to shareholders of record at the close of ...",ABBV,0.156461,0.101458,Neutral
Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery,https://www.prnewswire.com/news-releases/halozyme-announces-positive-clinical-data-of-its-high-volume-auto-injector-demonstrating-successful-rapid-subcutaneous-drug-delivery-301957079.html,2023-10-16 12:00:00,Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid ... PR ...,ABBV,0.03792,0.081581,Neutral
Infinium Global Research Forecasts Robust Growth in Ophthalmic Surgical Technologies Market: Anticipates USD 2487.63 Million Value by 2030 with a Notable CAGR of 5.25%,https://www.prnewswire.com/news-releases/infinium-global-research-forecasts-robust-growth-in-ophthalmic-surgical-technologies-market-anticipates-usd-2487-63-million-value-by-2030-with-a-notable-cagr-of-5-25-301957269.html,2023-10-16 10:00:00,Infinium Global Research Forecasts Robust Growth in Ophthalmic Surgical Technologies Market: Anticipates USD ... PR ...,ABBV,0.04882,0.092574,Neutral
Why You Should Invest In Healthcare Stocks,https://www.kiplinger.com/investing/healthcare-stocks/why-you-should-invest-in-healthcare-stocks,2023-10-15 14:00:59,"Healthcare stocks have had a rough few years. So why invest in them? First, I'm a contrarian. I like what's down. Second, healthcare is a booming industry, accounting for 18% of gross domestic product ( GDP ) in 2021, up from 12% in 1991. Third, the sector adds stability to any portfolio.",ABBV,0.066598,-0.162455,Somewhat-Bearish
3 Dividend Growth Stocks You Can Buy and Hold Forever,https://www.fool.com/investing/2023/10/14/3-dividend-growth-stocks-you-can-buy-and-hold-fore/,2023-10-14 10:52:00,Investors can sit back and let the dividends flow in with these great stocks.,ABBV,0.278561,0.130001,Neutral
Eli Lilly's  ( LLY )  Mirikizumab Meets Crohn's Disease Study Goals,https://www.zacks.com/stock/news/2165822/eli-lillys-lly-mirikizumab-meets-crohns-disease-study-goals,2023-10-13 16:29:00,"Based on this data, Eli Lilly (LLY) will initiate regulatory submissions worldwide next year seeking regulatory approval for mirikizumab in Crohn's disease.",ABBV,0.387875,0.276863,Somewhat-Bullish
Growing Geriatric Population Fuels Ankylosing Spondylitis Market: Management of Pain and Mobility Gains Importance in Aging Demographics,https://www.prnewswire.com/news-releases/growing-geriatric-population-fuels-ankylosing-spondylitis-market-management-of-pain-and-mobility-gains-importance-in-aging-demographics-301956060.html,2023-10-13 15:45:00,Growing Geriatric Population Fuels Ankylosing Spondylitis Market: Management of Pain and Mobility Gains Importance ... PR ...,ABBV,0.036643,0.067285,Neutral
AbbVie's  ( ABBV )  Rinvoq Meets Key Goal in Phase II Vitiligo Study,https://www.zacks.com/stock/news/2165416/abbvies-abbv-rinvoq-meets-key-goal-in-phase-ii-vitiligo-study,2023-10-13 11:02:00,AbbVie (ABBV) meets the primary goal in the phase II study evaluating Rinvoq in the treatment of adult patients with non-segmental vitiligo.,ABBV,0.368091,0.020823,Neutral
"Open-Angle Glaucoma Market Size and Share to Accelerate Substantially by 2032, Predicts DelveInsight | Key Companies in the Market - SPARC, AbbVie, Ocuphire, Santen, Glaukos, Ocular Therapeutix, VivaVision Biotech, MediPrint Ophthalmics",https://www.prnewswire.com/news-releases/open-angle-glaucoma-market-size-and-share-to-accelerate-substantially-by-2032-predicts-delveinsight--key-companies-in-the-market---sparc-abbvie-ocuphire-santen-glaukos-ocular-therapeutix-vivavision-biotech-mediprint-ophth-301954523.html,2023-10-12 21:01:00,"Open-Angle Glaucoma Market Size and Share to Accelerate Substantially by 2032, Predicts DelveInsight | Key ... PR ...",ABBV,0.051276,0.079668,Neutral
Looking Into AbbVie's Recent Short Interest - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/short-sellers/23/10/35228980/looking-into-abbvies-recent-short-interest,2023-10-12 20:00:23,"AbbVie's ABBV short percent of float has fallen 4.23% since its last report. The company recently reported that it has 11.93 million shares sold short, which is 0.68% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.46 days to cover their ...",ABBV,0.224903,0.085754,Neutral
Drugmaker AbbVie Stock Sees Improved Relative Price Strength,https://www.investors.com/research/drugmaker-abbvie-stock-sees-improved-relative-price-strength/,2023-10-12 18:34:00,"AbbVie ( ABBV ) had its Relative Strength ( RS ) Rating stock upgraded from 66 to 71 Thursday -- a welcome improvement, but still short of the 80 or better score you look for. As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.",ABBV,0.577527,0.389613,Bullish
"Urea Cycle Disorders Treatment Market Analysis 2023 -2027: Estimated Market Size, Major Drivers And Top Segments As Per The Business Research Company's Urea Cycle Disorders Treatment Global Market Report 2023",https://www.benzinga.com/pressreleases/23/10/g35223511/urea-cycle-disorders-treatment-market-analysis-2023-2027-estimated-market-size-major-drivers-and-t,2023-10-12 15:30:00,"LONDON, Oct. 12, 2023 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Urea Cycle Disorders Treatment Global Market Report 2023, the global urea cycle disorders ( UCD ) treatment market is poised for substantial growth and transformation.",ABBV,0.06179,0.108022,Neutral
Billionaire Paul Tudor Jones Predicts a Recession in Early 2024. Here's What It Could Mean for Stocks.,https://www.fool.com/investing/2023/10/12/billionaire-paul-tudor-jones-recession-2024/,2023-10-12 09:49:00,The successful hedge fund manager hasn't had a perfect record with his economic predictions in recent years.,ABBV,0.161349,-0.032818,Neutral
IBD Rating Upgrades: AbbVie Flashes Improved Price Strength,https://www.investors.com/ibd-data-stories/ibd-rating-upgrades-abbvie-flashes-improved-price-strength/,2023-10-12 07:00:00,"AbbVie ( ABBV ) had its Relative Strength ( RS ) Rating upgraded from 66 to 71 Thursday -- a welcome improvement, but still short of the 80 or better score you look for. As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.",ABBV,0.682689,0.457165,Bullish
"Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023",https://www.globenewswire.com/news-release/2023/10/11/2758814/0/en/Royalty-Pharma-To-Announce-Third-Quarter-2023-Financial-Results-On-November-8-2023.html,2023-10-11 20:15:00,"NEW YORK, Oct. 11, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will report its third quarter 2023 financial results on Wednesday, November 8, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at ...",ABBV,0.140076,0.095066,Neutral
Looking At AbbVie's Recent Unusual Options Activity - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/10/35201820/looking-at-abbvies-recent-unusual-options-activity,2023-10-11 18:46:26,"Someone with a lot of money to spend has taken a bearish stance on AbbVie ABBV. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",ABBV,0.803596,0.205577,Somewhat-Bullish
3 Absurdly Cheap Dividend Stocks to Buy and Hold for Years,https://www.fool.com/investing/2023/10/11/3-absurdly-cheap-dividend-stocks-to-buy-and-hold-f/,2023-10-11 09:50:00,"These stocks are potential bargain buys for investors right now, just waiting to get scooped up.",ABBV,0.380426,0.319939,Somewhat-Bullish
AbbVie Stock Moves Higher With Rising Relative Strength,https://www.investors.com/news/stocks-with-rising-relative-strength-abbvie-2/,2023-10-10 14:51:00,"AbbVie ( ABBV ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Tuesday, with an upgrade from 65 to 71. It is currently trying to break through moving averages, which may be seen as overhead resistance.",ABBV,0.551295,0.349482,Somewhat-Bullish
Should iShares Core High Dividend ETF  ( HDV )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2163163/should-ishares-core-high-dividend-etf-hdv-be-on-your-investing-radar,2023-10-10 10:20:05,Style Box ETF report for ...,ABBV,0.122894,0.068464,Neutral
Stocks With Rising Relative Strength: AbbVie,https://www.investors.com/ibd-data-stories/stocks-with-rising-relative-strength-abbvie-2/,2023-10-10 07:00:00,"AbbVie ( ABBV ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Tuesday, with an upgrade from 65 to 71. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",ABBV,0.716023,0.610207,Bullish
AbbVie  ( ABBV )  Rises Yet Lags Behind Market: Some Facts Worth Knowing,https://www.zacks.com/stock/news/2162947/abbvie-abbv-rises-yet-lags-behind-market-some-facts-worth-knowing,2023-10-09 21:45:20,"In the most recent trading session, AbbVie (ABBV) closed at $149.11, indicating a +0.59% shift from the previous trading day.",ABBV,0.596978,0.216363,Somewhat-Bullish
"The Evolving Market Dynamics of Factor-based Bleeding Disorders: Hemophilia A, Hemophilia B, and Von Willebrand Disease | Key Analysis by DelveInsight",https://www.prnewswire.com/news-releases/the-evolving-market-dynamics-of-factor-based-bleeding-disorders-hemophilia-a-hemophilia-b-and-von-willebrand-disease--key-analysis-by-delveinsight-301950491.html,2023-10-09 21:01:00,"The Evolving Market Dynamics of Factor-based Bleeding Disorders: Hemophilia A, Hemophilia B, and Von Willebrand ... PR ...",ABBV,0.036338,0.029364,Neutral
AbbVie Unusual Options Activity - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/10/35150026/abbvie-unusual-options-activity,2023-10-09 18:16:12,"A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 11 strange trades. If we consider the specifics of each trade, it is accurate to state that 45% of the investors opened trades with bullish expectations ...",ABBV,0.79415,0.228118,Somewhat-Bullish
2 Magnificent Dividend Stocks to Buy Hand Over Fist in October,https://www.fool.com/investing/2023/10/09/2-magnificent-dividend-stocks-to-buy-hand-over-fis/,2023-10-09 14:15:00,These two healthcare stocks are reliable passive income vehicles.,ABBV,0.324495,0.477298,Bullish
Why AbbVie Stock Fell Today,https://www.fool.com/investing/2023/10/27/why-abbvie-stock-fell-today/,2023-10-27 19:06:17,AbbVie stock fell despite beating third-quarter expectations and raising its full-year outlook. Here's what investors need to know.,ABBV,0.595343,0.536133,Bullish
AbbVie  ( ABBV )  Q3 2023 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/10/27/abbvie-abbv-q3-2023-earnings-call-transcript/,2023-10-27 18:30:24,"ABBV earnings call for the period ending September 30, 2023.",ABBV,0.04885,0.067877,Neutral
"AbbVie  ( ABBV )  Q3 Earnings Beat, Shares Down Despite Raised View",https://www.zacks.com/stock/news/2173886/abbvie-abbv-q3-earnings-beat-shares-down-despite-raised-view,2023-10-27 14:51:00,"AbbVie's (ABBV) third-quarter 2023 earnings and sales beat estimates. Though the company raised its EPS outlook for both 2023 and 2024, share price dives as some key drugs misses out on estimates.",ABBV,0.291038,0.312919,Somewhat-Bullish
"FDA Gives Nod To Eli Lilly's First Treatment For Type Of Inflammatory Bowel Disease, To Compete With JNJ, Pfizer, AbbVie - Eli Lilly  ( NYSE:LLY ) ",https://www.benzinga.com/general/biotech/23/10/35465199/fda-gives-nod-to-eli-lillys-first-treatment-for-type-of-inflammatory-bowel-disease-to-compete-wit,2023-10-27 14:28:19,"The FDA approved Eli Lilly And Co's LLY Omvoh ( mirikizumab-mrkz ) for moderately to severely active ulcerative colitis ( UC ) in adults, marking Lilly's first approved treatment for a type of inflammatory bowel disease.",ABBV,0.2872,0.447515,Bullish
AbbVie Raises Annual Profit Outlook As Newer Immunology Drugs Help Cushion Struggling Humira Sales - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/general/biotech/23/10/35463927/abbvie-raises-annual-profit-outlook-as-newer-immunology-drugs-help-cushion-struggling-humira-sale,2023-10-27 13:56:50,"AbbVie Inc ABBV has reported Q3 adjusted EPS of $2.95, down 19.4% Y/Y, beating the consensus of $2.88. Overall sales decreased 6% Y/Y ( down 5.8% on an operational basis ) to $13.93 billion, beating the consensus of $13.70 billion. The immunology portfolio generated $6.78 billion in sales, ...",ABBV,0.709186,0.268803,Somewhat-Bullish
MRK: Merck & Co.  ( MRK )  Q3 Earnings Assessment: Is the Pharma Stock a Buy or Sell?,https://stocknews.com/news/mrk-abbv-azn-nvs-dsnky-alpmy-merck-co-mrk-q3-earnings-assessment-is-the-pharma/,2023-10-27 13:36:45,MRK: Merck & Co. ( MRK ) Q3 Earnings Assessment: Is the Pharma ... ...,ABBV,0.08183,0.0,Neutral
"AbbVie's Humira Struggles Continue, But Drugmaker Raises Outlook",https://www.investors.com/news/technology/abbvie-stock-abbvie-earnings-q3-2023/,2023-10-27 13:14:00,AbbVie Stock Slips As Humira Struggles Continue Amid Biosimilar ... Investor's Business Daily ...,ABBV,0.947069,0.498862,Bullish
AbbVie  ( ABBV )  Q3 Earnings and Revenues Beat Estimates,https://www.zacks.com/stock/news/2173589/abbvie-abbv-q3-earnings-and-revenues-beat-estimates,2023-10-27 12:50:04,"AbbVie (ABBV) delivered earnings and revenue surprises of 3.15% and 1.65%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?",ABBV,0.404563,0.146695,Neutral
"AbbVie raises profit forecast after Humira, newer drugs drive results beat",https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-raises-profit-forecast-after-humira-newer-drugs-drive-results-beat-2023-10-27/,2023-10-27 11:46:00,"The logo for AbbVie is displayed on a screen at the New York Stock Exchange ( NYSE ) in New York City, New York, U.S., November 17, 2021. REUTERS/Andrew Kelly/File Photo Acquire Licensing Rights",ABBV,0.601928,0.010807,Neutral
AbbVie results beat expectations despite low-cost competition to blockbuster Humira,https://www.marketwatch.com/story/abbvie-results-beat-expectations-despite-low-cost-competition-to-blockbuster-humira-d86fb062,2023-10-27 11:42:00,"Drugmaker raises its full-year earnings outlook, boosts 2024 dividend ...",ABBV,0.576289,0.092929,Neutral
"Study in Contrasts: Robust Economic Data, Including GDP, Can't Stop Slide on Wall Street - General Motors  ( NYSE:GM ) , Amazon.com  ( NASDAQ:AMZN ) ",https://www.benzinga.com/markets/23/10/35447849/study-in-contrasts-robust-economic-data-including-gdp-cant-stop-slide-on-wall-street,2023-10-26 18:07:55,"( Thursday market open ) Economic vigor contrasts early Thursday with a retreating stock market. The first government estimate for third-quarter Gross Domestic Product ( GDP ) outpaced most estimates and orders for durable goods remained robust, but Wall Street lost more ground in premarket ...",ABBV,0.041755,0.055323,Neutral
"Scleroderma Market Outlook 2023-2027: Expected Market Size, Growth Drivers, And Key Trends As Per The Business Research Company's Scleroderma Global Market Report 2023",https://www.benzinga.com/pressreleases/23/10/g35444019/scleroderma-market-outlook-2023-2027-expected-market-size-growth-drivers-and-key-trends-as-per-the,2023-10-26 15:30:00,"LONDON, Oct. 26, 2023 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Scleroderma Global Market Report 2023, the global scleroderma market is on an upward trajectory, with expectations of reaching $2.15 billion in 2023, signifying a compound annual growth rate ( CAGR ) of 7.5%.",ABBV,0.068698,0.071658,Neutral
Why Earnings Season Could Be Great for AbbVie  ( ABBV ) ,https://www.zacks.com/stock/news/2172934/why-earnings-season-could-be-great-for-abbvie-abbv,2023-10-26 14:51:00,AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.,ABBV,0.906257,0.605993,Bullish
"Got $1,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond",https://www.fool.com/investing/2023/10/26/got-1000-these-2-stocks-could-be-bargain-buys-for/,2023-10-26 11:50:00,"The market has punished them, but don't overlook these stocks.",ABBV,0.306325,0.199777,Somewhat-Bullish
"Cloud Parting: Microsoft, Alphabet Drift Different Ways After Earnings, With Implications for Meta, Amazon Results - General Motors  ( NYSE:GM ) , Boeing  ( NYSE:BA ) ",https://www.benzinga.com/markets/23/10/35423554/cloud-parting-microsoft-alphabet-drift-different-ways-after-earnings-with-implications-for-meta-amaz,2023-10-25 18:55:29,( Wednesday market open ) Cloud computing dominates the proceedings this morning as Microsoft ( NASDAQ: MSFT ) and Alphabet ( NASDAQ: GOOGL ) drift in different directions following their earnings reports. A disappointing cloud performance from Alphabet clashed with sunnier tidings from Microsoft.,ABBV,0.039944,0.054986,Neutral
Why AbbVie  ( ABBV )  is Poised to Beat Earnings Estimates Again,https://www.zacks.com/stock/news/2171920/why-abbvie-abbv-is-poised-to-beat-earnings-estimates-again,2023-10-25 16:10:11,AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,ABBV,0.407844,0.460874,Bullish
USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day,https://www.zacks.com/stock/news/2171221/usa-compression-and-disney-have-been-highlighted-as-zacks-bull-and-bear-of-the-day,2023-10-25 08:49:00,"Chicago, IL - October 25, 2023 - Zacks Equity Research shares USA Compression Partners ( USAC Quick QuoteUSAC - ) as the Bull of the Day and Disney ( DIS Quick QuoteDIS - ) as the Bear of the Day.",ABBV,0.220558,0.315034,Somewhat-Bullish
"Tech Takes On Yields: Market's Attention Pulled Away From Treasuries As Microsoft, Alphabet To Report - Alphabet  ( NASDAQ:GOOGL ) , Amazon.com  ( NASDAQ:AMZN ) ",https://www.benzinga.com/markets/23/10/35401474/tech-takes-on-yields-markets-attention-pulled-away-from-treasuries-as-microsoft-alphabet-to-report,2023-10-24 18:29:10,( Tuesday market open ) Treasury yields suddenly find themselves sharing the spotlight. The next few days will test whether investors can pry their eyes away from yields that recently hovered at the highest levels since the second George W.,ABBV,0.041145,0.055213,Neutral
"Alopecia Areata Market Overview 2023-2027: Projected Market Size, Major Driver And Lucrative Segments As Per The Business Research Company's Alopecia Areata Global Market Report 2023",https://www.benzinga.com/pressreleases/23/10/g35397742/alopecia-areata-market-overview-2023-2027-projected-market-size-major-driver-and-lucrative-segment,2023-10-24 15:30:00,"LONDON, Oct. 24, 2023 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Alopecia Areata Global Market Report 2023, the global alopecia areata market is on a steady growth trajectory, with expectations to increase from $3.08 billion in 2022 to $3.31 billion in 2023, marking a ...",ABBV,0.056011,0.143223,Neutral
JNJ: Should You Invest in Johnson & Johnson  ( JNJ )  Following Q3 Results,https://stocknews.com/news/jnj-nvs-abbv-nvo-should-you-invest-in-johnson-johnson-jnj-following-q3/,2023-10-24 14:44:18,JNJ: Should You Invest in Johnson & Johnson ( JNJ ) Following Q3 ... ...,ABBV,0.083687,0.067449,Neutral
Earnings Preview: Pfizer  ( PFE )  Q3 Earnings Expected to Decline,https://www.zacks.com/stock/news/2170863/earnings-preview-pfizer-pfe-q3-earnings-expected-to-decline,2023-10-24 14:00:48,Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,ABBV,0.176825,-0.002872,Neutral
3 Biotech Stocks With Decent Dividend for a Steady Return,https://www.zacks.com/stock/news/2170733/3-biotech-stocks-with-decent-dividend-for-a-steady-return,2023-10-24 13:15:00,"Here we pick three medical device stocks, AbbVie (ABBV), Amgen (AMGN) and Gilead Sciences (GILD), which have a solid five-year dividend growth history.",ABBV,0.359262,0.524882,Bullish
AbbVie  ( ABBV )  Sees a More Significant Dip Than Broader Market: Some Facts to Know,https://www.zacks.com/stock/news/2170454/abbvie-abbv-sees-a-more-significant-dip-than-broader-market-some-facts-to-know,2023-10-23 21:45:17,"In the latest trading session, AbbVie (ABBV) closed at $144.73, marking a -1.03% move from the previous day.",ABBV,0.598621,0.108504,Neutral
"October Blues: Interest Rate Concerns Keep Stocks Under Pressure From Ahead of Big Tech Earnings - American Express  ( NYSE:AXP ) , Amazon.com  ( NASDAQ:AMZN ) ",https://www.benzinga.com/markets/23/10/35380514/october-blues-interest-rate-concerns-keep-stocks-under-pressure-from-ahead-of-big-tech-earnings,2023-10-23 18:06:19,Wall Street's red October is poised to get redder as concern over elevated interest rates and geopolitical tensions continue to burden the stock market. Futures based on the S&P 500® Index ( SPX ) and the Nasdaq Composite ( COMP ) were down about 0.4% near the close of overnight trading after ...,ABBV,0.041323,0.055245,Neutral
"Myriad of Problems, Dysfunctional DC, Charting Equites, Earnings, Week Ahead",https://realmoney.thestreet.com/investing/myriad-of-problems-dysfunctional-dc-charting-equites-earnings-week-ahead-16136139,2023-10-23 11:41:35,"The problems are still there. They haven't changed. Much. They seem almost to stagnate. Every once in a while something unforeseen up until that point happens and another log is thrown upon the fire. Existing problems seem to linger, unresolved, as newer problems are introduced and force a split ...",ABBV,0.027603,-0.123405,Neutral
AbbVie  ( ABBV )  to Report Q3 Earnings: What's in the Cards?,https://www.zacks.com/stock/news/2170056/abbvie-abbv-to-report-q3-earnings-whats-in-the-cards,2023-10-23 08:32:00,AbbVie's (ABBV) Q3 performance will likely reflect its newer immunotherapy drugs trying to compensate for declining Humira sales following the loss of U.S. exclusivity.,ABBV,0.412523,0.324419,Somewhat-Bullish
"After a robust third quarter, US economic growth will likely slow. That bodes well for rate cuts next year. | Business",https://www.cnn.com/2023/10/22/economy/stocks-week-ahead-q3-gdp/index.html,2023-10-22 12:04:00,"After a robust third quarter, US economic growth will likely slow. That bodes well for rate cuts next year. ...",ABBV,0.032207,-0.021883,Neutral
"Stock Market Outlook Clouded With Amazon, Microsoft, Meta, Alphabet Set To Report",https://www.investors.com/research/investing-action-plan/middle-east-house-leadership-cloud-stock-market-outlook-with-amazon-microsoft-meta-and-alphabet-to-report/,2023-10-20 22:22:00,"Stock Market Outlook Clouded With Amazon, Microsoft, Meta ... Investor's Business Daily ...",ABBV,0.045977,0.00496,Neutral
"Investor Risk Sentiment Wavers Amid War, Interest Rate Concerns; Tesla Earnings Disappoint: The Week In The Markets - Alphabet  ( NASDAQ:GOOGL ) , Chevron  ( NYSE:CVX ) , Verizon Communications  ( NYSE:VZ ) , Merck & Co  ( NYSE:MRK ) ",https://www.benzinga.com/markets/asia/23/10/35358005/investor-risk-sentiment-wavers-amid-war-interest-rate-concerns-tesla-earnings-disappoint-the-week-in,2023-10-20 20:08:03,"Volatility notably returned to the markets this week as investors navigated the escalating conflict between Israel and Hamas, remarks from Federal Reserve Chair Jerome Powell and mixed earning reports from leading U.S. corporations.",ABBV,0.097854,0.0,Neutral
"Caution Flag: As Yields Briefly Top 5%, Stocks Pull Back Amid Geopolitical Worries - American Express  ( NYSE:AXP ) , CSX  ( NASDAQ:CSX ) ",https://www.benzinga.com/markets/23/10/35354875/caution-flag-as-yields-briefly-top-5-stocks-pull-back-amid-geopolitical-worries,2023-10-20 16:59:14,"( Friday market open ) A wall of worry looms, and investors haven't shown much appetite to climb it the last two days. Another inflation warning from Federal Reserve Chairman Jerome Powell yesterday and an earnings deluge dialed up caution on Wall Street as stocks edged lower again in premarket ...",ABBV,0.041004,0.055187,Neutral
ABBV: 3 High-Performing Pharma Stocks to Boost Your Portfolio,https://stocknews.com/news/abbv-azn-taro-pfe-3-high-performing-pharma-stocks-to-boost-your-portfolio/,2023-10-20 16:39:40,"The pharmaceutical industry is set to grow in the coming years, thanks to an aging population, heightened toll of chronic diseases, and new technologies.",ABBV,0.366961,0.24808,Somewhat-Bullish
Earnings Preview: AbbVie  ( ABBV )  Q3 Earnings Expected to Decline,https://www.zacks.com/stock/news/2169676/earnings-preview-abbvie-abbv-q3-earnings-expected-to-decline,2023-10-20 14:00:36,AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,ABBV,0.262522,-0.016112,Neutral
"The Zacks Analyst Blog Highlights Visa, AbbVie, BHP Group, Caterpillar and Boston Scientific",https://www.zacks.com/stock/news/2169342/the-zacks-analyst-blog-highlights-visa-abbvie-bhp-group-caterpillar-and-boston-scientific,2023-10-20 09:20:00,"Visa, AbbVie, BHP Group, Caterpillar and Boston Scientific are included in this Analyst Blog.",ABBV,0.428632,0.197109,Somewhat-Bullish
"Top Research Reports for Visa, AbbVie & BHP",https://www.zacks.com/research-daily/2168804/top-research-reports-for-visa-abbvie-bhp,2023-10-19 18:24:00,"Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and BHP Group Limited (BHP).",ABBV,0.309539,0.237898,Somewhat-Bullish
Global Atherosclerosis Drugs Market Is Projected To Reach $54.8 Billion In 2027 With A CAGR Of 3% As Per The Business Research Company's Atherosclerosis Drugs Global Market Report 2023,https://www.benzinga.com/pressreleases/23/10/g35333824/global-atherosclerosis-drugs-market-is-projected-to-reach-54-8-billion-in-2027-with-a-cagr-of-3-as,2023-10-19 15:45:00,"LONDON, Oct. 19, 2023 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Atherosclerosis Drugs Global Market Report 2023, the global atherosclerosis drugs market is poised for significant growth in 2023, with a projected value of $48.72 billion, marking a steady Compound Annual Growth ...",ABBV,0.062271,0.072345,Neutral
"Announcing the Digital In Vivo Alliance  ( DIVA ) , a precompetitive consortium to develop, validate and promote the use of AI-enabled digital biomarkers in preclinical in vivo research.",https://www.prnewswire.com/news-releases/announcing-the-digital-in-vivo-alliance-diva-a-precompetitive-consortium-to-develop-validate-and-promote-the-use-of-ai-enabled-digital-biomarkers-in-preclinical-in-vivo-research-301961160.html,2023-10-19 15:00:00,"Announcing the Digital In Vivo Alliance ( DIVA ) , a precompetitive consortium to develop, validate and promote the use ... PR ...",ABBV,0.100308,0.079673,Neutral
AbbVie Unusual Options Activity - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/10/35331085/abbvie-unusual-options-activity,2023-10-19 14:16:49,"Someone with a lot of money to spend has taken a bullish stance on AbbVie ABBV. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",ABBV,0.758293,0.259259,Somewhat-Bullish
Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi,https://www.globenewswire.com/news-release/2023/10/19/2763108/0/en/Royalty-Pharma-Announces-Agreement-to-Purchase-Up-to-1-5-Billion-of-PTC-Therapeutics-Royalty-on-Evrysdi.html,2023-10-19 11:59:00,"NEW YORK, Oct. 19, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained ...",ABBV,0.028023,0.073477,Neutral
Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi - Royalty Pharma  ( NASDAQ:RPRX ) ,https://www.benzinga.com/pressreleases/23/10/g35326728/royalty-pharma-announces-agreement-to-purchase-up-to-1-5-billion-of-ptc-therapeutics-royalty-on-ev,2023-10-19 11:59:00,Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for $1.0 billion upfront PTC Therapeutics has option to sell rest of royalty for up to $500 million; Royalty Pharma has option to buy half of rest of royalty for up to $250 million,ABBV,0.027195,0.073145,Neutral
Is AbbVie Stock Too Pricey to Touch Right Now?,https://www.fool.com/investing/2023/10/19/is-abbvie-stock-too-pricey-to-touch-right-now/,2023-10-19 11:05:00,Other pharmaceutical companies are trading for far lower multiples.,ABBV,0.130926,0.116335,Neutral
Is Johnson & Johnson Still a Good Dividend Stock to Buy?,https://www.fool.com/investing/2023/10/19/is-johnson-johnson-still-a-good-dividend-stock-to/,2023-10-19 10:53:00,Investors wonder if the healthcare giant can keep raising its payout now that it no longer sells the consumer health brands that made it famous.,ABBV,0.063091,-0.073147,Neutral
Is Invesco Pharmaceuticals ETF  ( PJP )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2168544/is-invesco-pharmaceuticals-etf-pjp-a-strong-etf-right-now,2023-10-19 10:20:05,Smart Beta ETF report for ...,ABBV,0.115509,0.055568,Neutral
$100 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/news/23/10/35318986/100-invested-in-abbvie-10-years-ago-would-be-worth-this-much-today,2023-10-18 21:00:28,"AbbVie ABBV has outperformed the market over the past 10 years by 2.4% on an annualized basis producing an average annual return of 11.78%. Currently, AbbVie has a market capitalization of $263.49 billion.",ABBV,0.983605,0.387251,Bullish
AbbVie Inc.  ( ABBV )  is Attracting Investor Attention: Here is What You Should Know,https://www.zacks.com/stock/news/2167845/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know,2023-10-18 13:00:11,"Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",ABBV,0.487546,0.122931,Neutral
"Takeda's Crohn's Disease Fistulas Candidates Fall Short In Mid-Stage Study, Settles Tax Dispute With Irish Revenue Commissioners - Takeda Pharmaceutical  ( NYSE:TAK ) ",https://www.benzinga.com/general/biotech/23/10/35304007/takedas-crohns-disease-fistulas-candidates-fall-short-in-mid-stage-study-settles-tax-dispute-with,2023-10-18 12:25:22,"Takeda Pharmaceutical Co Ltd TAK released topline data from the Phase 3 ADMIRE-CD II study, assessing Alofisel ( darvadstrocel ) for complex Crohn's Perianal Fistulas ( CPF ) . Typical symptoms of perianal fistulas are anal pain with defecation, perianal itching, bleeding, and discharge ...",ABBV,0.443626,-0.084529,Neutral
"Is the ""New"" Johnson & Johnson Stock a Buy With Its Improved Profit Outlook?",https://www.fool.com/investing/2023/10/18/is-the-new-johnson-johnson-stock-a-buy-with-its-im/,2023-10-18 09:51:00,Some things are different about J&J. But other things remain the same as they've been for a long time.,ABBV,0.057079,-0.039002,Neutral
HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS,https://www.prnewswire.com/news-releases/halozyme-reports-third-quarter-2023-financial-and-operating-results-301979106.html,2023-11-06 21:01:00,Royalty Revenue Increased 15% YOY to Record $114.4 million Announces Acceleration into 2023 of Remaining $250M Share Repurchase through ASR GAAP Diluted EPS of $0.61 and Non-GAAP Diluted EPS of $0.751 Maintained Revenue Guidance and Raised 2023 EBITDA Guidance to $430-$445 million and Non-GAAP ...,ABBV,0.020526,0.076156,Neutral
"The doctor lowering drug prices for 1 million patients, with help from Mark Cuban, Sam Altman - and Martin Shkreli",https://www.marketwatch.com/story/the-doctor-lowering-drug-prices-for-1-million-patients-with-help-from-mark-cuban-sam-altman-and-martin-shkreli-5e72d77a,2023-11-06 20:32:00,Kristopher Koeller relies on two daily medications to keep his blood pressure under control. They're both generics that have been on the market for decades-the kind of drugs that should be cheap.,ABBV,0.041901,0.007958,Neutral
$1000 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/news/23/11/35624737/1000-invested-in-abbvie-10-years-ago-would-be-worth-this-much-today,2023-11-06 17:00:21,"AbbVie ABBV has outperformed the market over the past 10 years by 2.17% on an annualized basis producing an average annual return of 11.59%. Currently, AbbVie has a market capitalization of $250.16 billion.",ABBV,0.983605,0.387251,Bullish
Anima Biotech Partners with BioSpace to Present Its Latest Webinar in the LightON mRNA Biology Masterclass,https://www.benzinga.com/pressreleases/23/11/g35621998/anima-biotech-partners-with-biospace-to-present-its-latest-webinar-in-the-lighton-mrna-biology-mas,2023-11-06 15:17:00,"BERNARDSVILLE, N.J., Nov. 06, 2023 ( GLOBE NEWSWIRE ) -- Anima Biotech, the leading Tech.Bio in the discovery of mRNA drugs and targets, announced its third webinar, a part of their exclusive LightON mRNA | mRNA Biology Masterclass series partnered with leading life science media outlets.",ABBV,0.067158,0.065182,Neutral
"Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of Directors",https://www.globenewswire.com/news-release/2023/11/06/2774025/32452/en/Adverum-Biotechnologies-Appoints-C-David-Nicholson-Ph-D-to-its-Board-of-Directors.html,2023-11-06 13:00:00,"REDWOOD CITY, Calif., Nov. 06, 2023 ( GLOBE NEWSWIRE ) -- Adverum Biotechnologies, Inc. ( Nasdaq: ADVM ) , a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointment of C.",ABBV,0.042196,-0.05817,Neutral
Is SPDR S&P Dividend ETF  ( SDY )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2178894/is-spdr-sp-dividend-etf-sdy-a-strong-etf-right-now,2023-11-06 11:20:07,Smart Beta ETF report for ...,ABBV,0.112008,0.056033,Neutral
3 Spectacular High-Yield Dividend Stocks to Buy in November,https://www.fool.com/investing/2023/11/05/3-spectacular-high-yield-dividend-stocks-to-buy-in/,2023-11-05 15:00:00,Income investors should find plenty to like with these stocks.,ABBV,0.324673,0.22577,Somewhat-Bullish
Looking for a Lifetime of Passive Income? 2 Top Dividend Stocks to Buy and Hold Forever,https://www.fool.com/investing/2023/11/04/want-passive-income-top-dividend-stocks-to-buy/,2023-11-04 09:30:00,Dividend stocks can cushion your portfolio in times of market trouble.,ABBV,0.367606,0.354643,Bullish
REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery,https://www.prnewswire.com/news-releases/regenxbio-presents-positive-one-year-data-from-phase-ii-altitude-trial-of-abbv-rgx-314-for-treatment-of-diabetic-retinopathy-using-suprachoroidal-delivery-301977598.html,2023-11-03 22:53:00,REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of ... PR ...,ABBV,0.551805,0.071221,Neutral
Check Out What Whales Are Doing With ABBV - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/11/35598710/check-out-what-whales-are-doing-with-abbv,2023-11-03 18:15:36,"Someone with a lot of money to spend has taken a bullish stance on AbbVie ABBV. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",ABBV,0.790605,0.26799,Somewhat-Bullish
PFE: Is Pfizer  ( PFE )  a Stock to Buy Following Its Q3 Earnings?,https://stocknews.com/news/pfe-abbv-taro-nvs-is-pfizer-pfe-a-stock-to-buy-following-its-q3/,2023-11-03 16:58:30,Drug and vaccine manufacturing giant Pfizer Inc. ( PFE ) is facing losses due to the company's charges due to its difficulty concerning COVID antiviral treatment Paxlovid and COVID vaccine.,ABBV,0.051386,0.12044,Neutral
Which Corporations Pay The Most Federal Income Tax?,https://www.forbes.com/sites/taxnotes/2023/11/03/which-corporations-pay-the-most-federal-income-tax/,2023-11-03 14:31:05,"Corporations report their total cash payments of income tax - federal, state, and foreign combined - but they don't identify, nor does the IRS reveal, how much federal income tax they pay. We believe, however, that we can make reasonable estimates from information reported by publicly traded ...",ABBV,0.0367,0.036094,Neutral
Eli Lilly Just Added Another Potential Billion-Dollar Product: Is It a Buy?,https://www.fool.com/investing/2023/11/03/eli-lilly-just-added-another-potential-billion/,2023-11-03 13:45:00,The answer is relatively clear.,ABBV,0.072,0.111724,Neutral
Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023,https://www.globenewswire.com/news-release/2023/11/03/2773070/0/en/Morphic-Announces-Corporate-Highlights-and-Financial-Results-for-the-Third-Quarter-2023.html,2023-11-03 11:00:00,-Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative colitis at UEG Week ...,ABBV,0.023372,0.076797,Neutral
Is AbbVie Stock a Buy Now?,https://www.fool.com/investing/2023/11/03/is-abbvie-stock-a-buy-now/,2023-11-03 09:32:00,"It just had a brutal quarter, and it might have a couple more on the way.",ABBV,0.390396,0.033209,Neutral
"EXCLUSIVE: Roundhill Launches Dividend Kings ETF With 'The Gold Standard Of Dividend Growers,' Companies With 'Incredible Resilience' - Target  ( NYSE:TGT ) , Kimberly-Clark  ( NYSE:KMB ) , Coca-Cola  ( NYSE:KO ) , Listed Funds Trust Roundhill Cannabis ETF  ( BATS:WEED ) ",https://www.benzinga.com/trading-ideas/dividends/23/11/35572980/exclusive-roundhill-launches-dividend-kings-etf-with-the-gold-standard-of-dividend-grower,2023-11-02 18:25:38,"The company behind pure-play ETFs that cover sectors such as cannabis stocks, the metaverse, sports betting and meme stocks is back with a new fund that covers a popular investment strategy. What Happened: Roundhill Investments launched the Roundhill S&P Dividend Monarchs ETF KNGS on Thursday.",ABBV,0.12645,0.0,Neutral
NVO: 3 Top-Rated Pharma Stocks Worth Including in Your November Portfolio,https://stocknews.com/news/nvo-abbv-rdy-3-top-rated-pharma-stocks-worth-including-in-your-november-portfolio/,2023-11-02 14:34:02,NVO: 3 Top-Rated Pharma Stocks Worth Including in Your ... ...,ABBV,0.265378,0.2655,Somewhat-Bullish
Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology  ( ASH ) ,https://www.globenewswire.com/news-release/2023/11/02/2772431/0/en/Genmab-Announces-Multiple-Abstracts-to-be-Presented-at-the-65th-Annual-Meeting-and-Exposition-of-the-American-Society-of-Hematology-ASH.html,2023-11-02 13:05:00,Media Release ...,ABBV,0.050183,0.016918,Neutral
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar,https://www.zacks.com/stock/news/2177085/these-2-medical-stocks-could-beat-earnings-why-they-should-be-on-your-radar,2023-11-02 12:50:05,Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.,ABBV,0.266101,0.268975,Somewhat-Bullish
3 Dividend Stocks That Can Power Your Portfolio for Decades,https://www.fool.com/investing/2023/11/02/3-dividend-stocks-that-can-power-your-portfolio/,2023-11-02 12:30:00,"From healthcare to home repair to tech, these stocks can help diversify your holdings.",ABBV,0.396574,0.400562,Bullish
5 Most Active Penny Stocks Today & Why They're Moving Now,https://pennystocks.com/featured/2023/11/01/5-most-active-penny-stocks-today-why-theyre-moving-now/,2023-11-01 18:11:42,"Penny stocks are the wild west of the stock market. Fast-paced, unpredictable, and laden with potential treasures. And in this vast landscape, one metric stands out: volume. It's like the heartbeat of a stock, echoing its vitality and momentum.",ABBV,0.053449,0.08271,Neutral
LLY: Eli Lilly & Co.  ( LLY )  Earnings Forecast,https://stocknews.com/news/lly-abbv-taro-rdy-eli-lilly-co-lly-earnings-forecast/,2023-11-01 17:07:04,"Pharmaceutical major Eli Lilly and Company ( LLY ) is scheduled to release its third-quarter results on November 2. While its earnings are expected to decline year-over-year, its revenue will likely improve. In this piece, I have discussed why waiting for an opportune entry point in the stock ...",ABBV,0.080458,0.023811,Neutral
"Neurotoxin Market to Hit US$ 13.3 billion by 2031, Growing at a CAGR of 6.8 % | Says Transparency Market Research Inc.",https://www.benzinga.com/pressreleases/23/11/g35542048/neurotoxin-market-to-hit-us-13-3-billion-by-2031-growing-at-a-cagr-of-6-8-says-transparency-market,2023-11-01 16:00:02,"Wilmington, Delaware, United States, Nov. 01, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global neurotoxin market stood at US$ 7.78 billion in 2023 and is projected to reach US$ 13.3 billion in 2031. The global neurotoxin market is anticipated to expand at a CAGR of 6.8% ...",ABBV,0.041828,0.031615,Neutral
What's Going On With Aldeyra Therapeutics Stock? - Aldeyra Therapeutics  ( NASDAQ:ALDX ) ,https://www.benzinga.com/news/23/11/35541326/whats-going-on-with-aldeyra-therapeutics-stock,2023-11-01 15:52:11,"Aldeyra Therapeutics, Inc. ALDX shares are trading higher Wednesday after the company announced that it entered into an exclusive options agreement with AbbVie.",ABBV,0.608634,0.349542,Somewhat-Bullish
"The Zacks Analyst Blog Highlights AbbVie, Exxon Mobil, Kontoor Brands, Select Water Solutions and Macatawa Bank",https://www.zacks.com/stock/news/2176193/the-zacks-analyst-blog-highlights-abbvie-exxon-mobil-kontoor-brands-select-water-solutions-and-macatawa-bank,2023-11-01 12:05:00,"AbbVie, Exxon Mobil, Kontoor Brands, Select Water Solutions and Macatawa Bank are part of the Zacks top Analyst Blog.",ABBV,0.241684,0.101154,Neutral
Pfizer Posted a Steep Loss. Is It Time to Sell?,https://www.fool.com/investing/2023/11/01/pfizer-posted-a-steep-loss-is-it-time-to-sell/,2023-11-01 10:19:00,"A $5.6 billion inventory write-down isn't what investors wanted to see, but this company is made of many moving pieces.",ABBV,0.120733,0.092994,Neutral
CVS: CVS Health  ( CVS )  Earnings Insights -- Is the Drug Store Stock a Buying Opportunity?,https://stocknews.com/news/cvs-abbv-nvs-taro-cvs-health-cvs-earnings-insights-is-the-drug-store/,2023-10-31 18:50:23,CVS: CVS Health ( CVS ) Earnings Insights -- Is the Drug Store Stock ... ...,ABBV,0.050148,0.193271,Somewhat-Bullish
Amgen's stock hit by expectations its obesity pipeline is facing a longer wait,https://www.marketwatch.com/story/amgens-stock-jumps-premarket-after-earnings-beat-and-company-again-raises-guidance-d4015936,2023-10-31 15:59:00,Amgen Inc.'s stock fell 3.3% Tuesday despite an earnings beat and raised guidance. Obesity drugs were to blame.,ABBV,0.146469,-0.199329,Somewhat-Bearish
"Amgen  ( AMGN )  Beats on Q3 Earnings Beat, Lags Sales, Ups View",https://www.zacks.com/stock/news/2175771/amgen-amgn-beats-on-q3-earnings-beat-lags-sales-ups-view,2023-10-31 15:30:00,"Amgen (AMGN) beats Q3 estimates for earnings but misses on sales. Following the acquisition of Horizon Therapeutics, it raises earnings and sales guidance for 2023.",ABBV,0.053035,0.062929,Neutral
Pfizer's Coming for AbbVie's Market Share. Here's What It Means for Investors,https://www.fool.com/investing/2023/10/31/pfizers-coming-for-abbvies-market-share-heres-what/,2023-10-31 14:07:00,"AbbVie has a head start, but that might not be enough to save its top line.",ABBV,0.392362,0.240092,Somewhat-Bullish
Why Amgen  ( AMGN )  Shares Are Trading Lower Today - Amgen  ( NASDAQ:AMGN ) ,https://www.benzinga.com/general/biotech/23/10/35514314/amgen-lifts-annual-outlook-after-q3-performance-but-stock-still-falls-heres-why,2023-10-31 13:55:36,"Amgen Inc AMGN reported Q3 FY23 sales of $6.90 billion, slightly missing the consensus of $6.94 billion. Total revenues increased 4% Y/Y, resulting from a 5% increase in product sales.",ABBV,0.301315,0.0,Neutral
Here is What to Know Beyond Why AbbVie Inc.  ( ABBV )  is a Trending Stock,https://www.zacks.com/stock/news/2175275/here-is-what-to-know-beyond-why-abbvie-inc-abbv-is-a-trending-stock,2023-10-31 13:00:10,"AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",ABBV,0.487546,0.101556,Neutral
Cybin Announces Unprecedented Positive Interim Phase 2 Data for CYB003 in Major Depressive Disorder Meeting ... - Canada NewsWire,https://www.newswire.ca/news-releases/cybin-announces-unprecedented-positive-interim-phase-2-data-for-cyb003-in-major-depressive-disorder-meeting-primary-efficacy-endpoint-with-rapid-and-significant-improvements-in-depression-symptoms-after-single-dose-full-topline-data-on-trac-810755830.html,2023-10-31 13:00:00,Cybin Announces Unprecedented Positive Interim Phase 2 Data for CYB003 in Major Depressive Disorder Meeting ... Canada ...,ABBV,0.055664,0.035973,Neutral
5 Solid Stocks to Watch That Recently Hiked Dividends,https://www.zacks.com/stock/news/2175228/5-solid-stocks-to-watch-that-recently-hiked-dividends,2023-10-31 11:43:00,"AbbVie Inc. (ABBV), Exxon Mobil Corporation (XOM), Kontoor Brands, Inc. (KTB), Select Water Solutions, Inc. (WTTR) and Macatawa Bank Corporation (MCBC) recently hiked dividends.",ABBV,0.217639,0.117528,Neutral
"Zacks Industry Outlook Highlights Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies",https://www.zacks.com/stock/news/2175135/zacks-industry-outlook-highlights-dr-reddys-laboratories-amphastar-pharmaceuticals-and-sol-gel-technologies,2023-10-31 10:43:00,"Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies are part of the Zacks Industry Outlook article.",ABBV,0.031322,0.063263,Neutral
Is AbbVie Still a Good Dividend Stock to Buy?,https://www.fool.com/investing/2023/10/31/is-abbvie-still-a-good-dividend-stock-to-buy/,2023-10-31 09:23:00,"The decline in sales of Humira, AbbVie's top seller, is enough to make anyone nervous.",ABBV,0.486857,-0.01276,Neutral
Why AbbVie Stock Was a Winner on Monday,https://www.fool.com/investing/2023/10/30/why-abbvie-stock-was-a-winner-on-monday/,2023-10-30 23:07:49,One analyst tracking the pharmaceutical major upgraded his recommendation.,ABBV,0.651499,0.330253,Somewhat-Bullish
AbbVie Analysts Increase Their Forecasts After Upbeat Earnings - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/news/earnings/23/10/35498423/abbvie-analysts-increase-their-forecasts-after-upbeat-earnings,2023-10-30 18:55:03,"AbbVie Inc ABBV reported better-than-expected earnings for its third quarter and raised its profit outlook on Friday. AbbVie reported quarterly adjusted EPS of $2.95, down 19.4% Y/Y, beating the consensus of $2.88.",ABBV,0.975103,0.17979,Somewhat-Bullish
"Drug, Biotech Stocks' Q3 Earnings Due on Oct 31: AMGN, PFE, INCY",https://www.zacks.com/stock/news/2174650/drug-biotech-stocks-q3-earnings-due-on-oct-31-amgn-pfe-incy,2023-10-30 15:37:00,"Let's take a look at three biotech/drug companies, AMGN, PFE and INCY, slated to release quarterly results on Oct 31.",ABBV,0.050679,0.0,Neutral
AbbVie Unusual Options Activity - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/10/35492451/abbvie-unusual-options-activity,2023-10-30 14:46:39,"Someone with a lot of money to spend has taken a bearish stance on AbbVie ABBV. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",ABBV,0.767792,0.01975,Neutral
"Here are 16 stocks Jim Cramer is watching, including Microsoft, Chevron, Southwest",https://www.cnbc.com/2023/10/30/here-are-16-stocks-jim-cramer-is-watching-including-microsoft-chevron-southwest.html,2023-10-30 13:38:20,"Here are some of the tickers on Jim's radar for Monday, Oct. 30, taken directly from his reporter's notebook: ...",ABBV,0.140076,0.333719,Somewhat-Bullish
2 No-Brainer Dividend Stocks to Buy This Week,https://www.fool.com/investing/2023/10/30/2-no-brainer-dividend-stocks-to-buy-this-week/,2023-10-30 13:15:00,These two top-income stocks are too cheap to ignore.,ABBV,0.437082,0.330074,Somewhat-Bullish
"AbbVie Stock To Rally Over 22%? Here Are 10 Top Analyst Forecasts For Monday - Axos Financial  ( NYSE:AX ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/news/23/10/35487512/abbvie-to-rally-over-22-here-are-10-top-analyst-forecasts-for-monday,2023-10-30 11:49:37,"Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Barclays increased AbbVie Inc. ABBV price target from $160 to $170.",ABBV,0.24289,0.076109,Neutral
Aquinnah Pharmaceuticals Advances Oral Small Molecule Program Targeting Alzheimer's and Other Tauopathy Diseases,https://www.newswire.ca/news-releases/aquinnah-pharmaceuticals-advances-oral-small-molecule-program-targeting-alzheimer-s-and-other-tauopathy-diseases-873057095.html,2023-10-30 11:00:00,Aquinnah Pharmaceuticals Advances Oral Small Molecule Program Targeting Alzheimer's and Other Tauopathy ... Canada ...,ABBV,0.051774,0.162508,Somewhat-Bullish
Should First Trust Morningstar Dividend Leaders ETF  ( FDL )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2174215/should-first-trust-morningstar-dividend-leaders-etf-fdl-be-on-your-investing-radar,2023-10-30 10:20:05,Style Box ETF report for ...,ABBV,0.12165,0.068161,Neutral
Piramal Pharma Limited gibt konsolidierte Ergebnisse für das zweite Quartal  ( Q2 )  und erste Halbjahr  ( H1 )  des Geschäftsjahres 2024  ( GJ2024 )  bekannt,https://www.prnewswire.com/news-releases/piramal-pharma-limited-gibt-konsolidierte-ergebnisse-fur-das-zweite-quartal-q2-und-erste-halbjahr-h1-des-geschaftsjahres-2024-gj2024-bekannt-301970850.html,2023-10-29 20:40:00,Piramal Pharma Limited gibt konsolidierte Ergebnisse für das zweite Quartal ( Q2 ) und erste Halbjahr ( H1 ) des ... PR ...,ABBV,0.028056,-0.021335,Neutral
Piramal Pharma Limited Announces Consolidated Results for Q2 and H1 FY2024,https://www.prnewswire.com/news-releases/piramal-pharma-limited-announces-consolidated-results-for-q2-and-h1-fy2024-301970702.html,2023-10-28 11:09:00,"MUMBAI, India, Oct. 28, 2023 /PRNewswire/ -- Piramal Pharma Limited ( PPL ) , ( NSE: PPLPHARMA ) ( BSE: 543635 ) , a leading global pharmaceuticals company, today announced its consolidated results for the Second Quarter ( Q2 ) and Half Year ( H1 ) ended 30th September 2023. • Revenue from ...",ABBV,0.042496,-0.018848,Neutral
Piramal Pharma Limited Announces Consolidated Results for Q2 and H1 FY2024,https://www.newswire.ca/news-releases/piramal-pharma-limited-announces-consolidated-results-for-q2-and-h1-fy2024-805066595.html,2023-10-28 11:09:00,"MUMBAI, India, Oct. 28, 2023 /CNW/ -- Piramal Pharma Limited ( PPL ) , ( NSE: PPLPHARMA ) ( BSE: 543635 ) , a leading global pharmaceuticals company, today announced its consolidated results for the Second Quarter ( Q2 ) and Half Year ( H1 ) ended 30th September 2023. • Revenue from Operation ...",ABBV,0.041039,-0.018797,Neutral
Is Vertex Pharmaceuticals Stock a Buy Now?,https://www.fool.com/investing/2023/11/16/is-vertex-pharmaceuticals-stock-a-buy-now/,2023-11-16 12:45:00,The company is close to another breakthrough.,ABBV,0.061631,0.086194,Neutral
Should SPDR S&P Dividend ETF  ( SDY )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2185080/should-spdr-sp-dividend-etf-sdy-be-on-your-investing-radar,2023-11-16 11:20:07,Style Box ETF report for ...,ABBV,0.118354,0.057235,Neutral
AbbVie and Pfizer Have 1 Thing in Common: Their Biggest Products Are on the Decline. Time to Sell?,https://www.fool.com/investing/2023/11/16/abbvie-and-pfizer-have-1-thing-in-common-their-big/,2023-11-16 10:00:00,Both companies' share prices have slipped recently.,ABBV,0.497869,0.105215,Neutral
"JNJ: Analyzing Pharma Stock Giants: JNJ, MRK, and ABBV",https://stocknews.com/news/jnj-mrk-abbv-kvue-analyzing-pharma-stock-giants-jnj-mrk-and-abbv/,2023-11-15 16:30:13,"JNJ: Analyzing Pharma Stock Giants: JNJ, MRK, and ...",ABBV,0.204072,0.142349,Neutral
AbbVie Unusual Options Activity - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/11/35789068/abbvie-unusual-options-activity,2023-11-14 20:31:06,"Deep-pocketed investors have adopted a bullish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",ABBV,0.691734,0.359289,Bullish
U.S. Pruritus Treatment Market to Hit USD 8.4 billion by 2031 | Says Transparency Market Research Inc.,https://www.benzinga.com/pressreleases/23/11/g35784459/u-s-pruritus-treatment-market-to-hit-usd-8-4-billion-by-2031-says-transparency-market-research-inc,2023-11-14 18:00:00,"Wilmington, Delaware, United States, Nov. 14, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global U.S. pruritus treatment market was estimated at a value of US$ 5.1 billion in 2022. It is anticipated to register a 5.6% CAGR from 2023 to 2031 and by 2031.",ABBV,0.03798,0.0,Neutral
Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis - XBiotech  ( NASDAQ:XBIT ) ,https://www.benzinga.com/pressreleases/23/11/g35776284/dr-alan-kivitz-to-chair-xbiotechs-natrunix-program-in-rheumatoid-arthritis,2023-11-14 14:00:00,"AUSTIN, Texas, Nov. 14, 2023 ( GLOBE NEWSWIRE ) -- XBiotech XBIT today announced that Alan Kivitz M.D. is now Lead Investigator & Study Chairman for its clinical research program for Natrunix in Rheumatoid Arthritis. XBiotech believes Natrunix will be a breakthrough therapy for ...",ABBV,0.039614,0.037048,Neutral
"Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, J&J and AbbVie",https://www.zacks.com/stock/news/2183791/zacks-industry-outlook-highlights-eli-lilly-novo-nordisk-jj-and-abbvie,2023-11-14 12:42:00,"Eli Lilly, Novo Nordisk, J&J and AbbVie are part of the Zacks Industry Outlook article.",ABBV,0.16375,0.136116,Neutral
"Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki  ( AVT04 ) , the First Biosimilar of Stelara®  ( ustekinumab ) ",https://www.globenewswire.com/news-release/2023/11/14/2779894/0/en/Alvotech-and-JAMP-Pharma-Announce-Receipt-of-Marketing-Authorization-for-Jamteki-AVT04-the-First-Biosimilar-of-Stelara-ustekinumab.html,2023-11-14 12:00:00,"Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and JAMP Pharma Group ( ""JAMP Pharma"" ) , a Canadian owned pharmaceutical organization headquartered in the Greater Montreal area, announced today ...",ABBV,0.020885,0.0,Neutral
"Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™  ( AVT04 ) , the First Biosimilar of Stelara®  ( ustekinumab ) ",https://www.globenewswire.com/news-release/2023/11/14/2779896/0/en/Alvotech-and-JAMP-Pharma-Announce-Receipt-of-Marketing-Authorization-for-Jamteki-AVT04-the-First-Biosimilar-of-Stelara-ustekinumab.html,2023-11-14 12:00:00,PrJamtekiTM is the second biosimilar developed under this partnership that receives marketing authorization in Canada.,ABBV,0.02074,0.0,Neutral
"Alvotech and JAMP Pharma announce receipt of marketing authorization for PrJamtekiTM (AVT04), the first biosimilar ... - Canada NewsWire",https://www.newswire.ca/news-releases/alvotech-and-jamp-pharma-announce-receipt-of-marketing-authorization-for-prjamtekitm-avt04-the-first-biosimilar-of-stelara-r-ustekinumab--858287722.html,2023-11-14 12:00:00,"Alvotech and JAMP Pharma announce receipt of marketing authorization for PrJamtekiTM ( AVT04 ) , the first biosimilar ... Canada ...",ABBV,0.020579,0.0,Neutral
2 High-Yield Dividend Stocks You Can Buy Now and Hold for a Decade,https://www.fool.com/investing/2023/11/14/2-high-yield-dividend-stocks-you-can-buy-now-and-h/,2023-11-14 10:36:00,These stocks could be great investments to bump up your passive income stream.,ABBV,0.282234,0.106675,Neutral
3 Dividend Giants to Grow Wealth no Matter What the Market Is Doing,https://www.fool.com/investing/2023/11/14/3-dividend-giants-to-grow-wealth-in-any-market/,2023-11-14 10:30:00,You'll be happy to own these top companies in any market environment.,ABBV,0.300946,0.233919,Somewhat-Bullish
4 Large Drug Stocks Likely to Sail Through Industry Woes,https://www.zacks.com/commentary/2183148/4-large-drug-stocks-likely-to-sail-through-industry-woes,2023-11-13 15:03:00,"Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), J&J (JNJ) and AbbVie (ABBV) are worth retaining in your portfolio.",ABBV,0.122269,0.108175,Neutral
Investors Heavily Search AbbVie Inc.  ( ABBV ) : Here is What You Need to Know,https://www.zacks.com/stock/news/2183201/investors-heavily-search-abbvie-inc-abbv-here-is-what-you-need-to-know,2023-11-13 14:00:12,"Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",ABBV,0.49219,0.102162,Neutral
Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program,https://www.globenewswire.com/news-release/2023/11/13/2779041/0/en/Royalty-Pharma-and-Teva-Collaborate-to-Further-Accelerate-Olanzapine-Lai-Program.html,2023-11-13 13:10:00,"NEW YORK and TEL AVIV, Israel, Nov. 13, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) and Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) announced today a collaboration to further accelerate the clinical ...",ABBV,0.022643,0.071188,Neutral
Neurocrine Biosciences Announces Settlement of INGREZZA Abbreviated New Drug Application  ( ANDA )  Litigation,https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-settlement-of-ingrezza-abbreviated-new-drug-application-anda-litigation-301985856.html,2023-11-13 12:00:00,"SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. ( Nasdaq: NBIX ) , a leading neuroscience-focused biopharmaceutical company, today announced that is has resolved all patent litigation related to lawsuits resulting from Abbreviated New Drug Applications ( ANDAs ) brought by ...",ABBV,0.082963,0.064663,Neutral
"The Zacks Analyst Blog Highlights NVIDIA, Chevron, AbbVie, Alibaba Group Holding and Morgan Stanley",https://www.zacks.com/stock/news/2183047/the-zacks-analyst-blog-highlights-nvidia-chevron-abbvie-alibaba-group-holding-and-morgan-stanley,2023-11-13 10:53:00,"NVIDIA, Chevron, AbbVie, Alibaba Group Holding and Morgan Stanley are part of the Zacks top Analyst Blog.",ABBV,0.479258,0.139445,Neutral
3 Growth Stocks to Buy Right Now Without Any Hesitation,https://www.fool.com/investing/2023/11/11/3-growth-stocks-you-can-buy-right-now-without-any/,2023-11-11 11:50:00,Investors shouldn't have to deliberate for too long about these great stocks.,ABBV,0.274981,0.193113,Somewhat-Bullish
"Top Research Reports for NVIDIA, Chevron & AbbVie",https://www.zacks.com/research-daily/2182239/top-research-reports-for-nvidia-chevron-abbvie,2023-11-10 17:21:00,"Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Chevron Corporation (CVX) and AbbVie Inc. (ABBV).",ABBV,0.384397,0.150421,Somewhat-Bullish
"Ironwood's  ( IRWD )  Q3 Earnings Miss Mark, Linzess Volume Rises",https://www.zacks.com/stock/news/2182441/ironwoods-irwd-q3-earnings-miss-mark-linzess-volume-rises,2023-11-10 16:09:00,"Ironwood's (IRWD) third-quarter 2023 earnings miss estimates, while revenues beat the same. Linzess collaboration revenues drive the top line.",ABBV,0.211191,0.227581,Somewhat-Bullish
Oncology Drugs Market worth $520 billion by 2033 - Exclusive Report by We Market Research,https://www.prnewswire.com/news-releases/oncology-drugs-market-worth-520-billion-by-2033---exclusive-report-by-we-market-research-301984776.html,2023-11-10 15:01:00,"CHICAGO, Nov. 10, 2023 /PRNewswire/ -- According to the latest findings from We Market Research, the oncology drug market is on track to achieve a value of USD 205 billion by the year 2023.",ABBV,0.081138,0.083483,Neutral
AbbVie's $21 Billion Drug Humira Is on the Decline. Should You Still Buy This Dividend Stock?,https://www.fool.com/investing/2023/11/10/abbvie-after-humira-should-you-buy/,2023-11-10 10:00:00,"AbbVie is committed to rewarding shareholders, even during tough times.",ABBV,0.603465,0.527384,Bullish
AbbVie Unusual Options Activity - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/11/35705854/abbvie-unusual-options-activity,2023-11-09 17:02:54,"Investors with a lot of money to spend have taken a bearish stance on AbbVie ABBV. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",ABBV,0.659949,0.182578,Somewhat-Bullish
"Check Out 3 Health Care Stocks With Over 4% Dividend Yields From Wall Street's Most Accurate Analysts - Organon  ( NYSE:OGN ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/news/23/11/35697280/check-out-3-health-care-stocks-with-over-4-dividend-yields-from-wall-streets-most-accurate-analysts,2023-11-09 12:36:09,"During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.",ABBV,0.119235,0.393776,Bullish
REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results,https://www.prnewswire.com/news-releases/regenxbio-announces-updated-strategic-plans-and-third-quarter-2023-financial-results-301982219.html,2023-11-08 21:05:00,"ROCKVILLE, Md., Nov. 8, 2023 /PRNewswire/ -- REGENXBIO Inc. ( Nasdaq: RGNX ) today announced financial results for the third quarter ended September 30, 2023, and recent operational highlights, including a strategic pipeline prioritization and corporate restructuring intended to significantly ...",ABBV,0.184775,0.136365,Neutral
ABBV: Can Pfizer  ( PFE )  and AbbVie  ( ABBV )  Cure Your Portfolio's Ailments?,https://stocknews.com/news/abbv-pfe-can-pfizer-pfe-and-abbvie-abbv-cure-your-portfolios-ailments/,2023-11-08 15:54:19,ABBV: Can Pfizer ( PFE ) and AbbVie ( ABBV ) Cure Your Portfolio's ... ...,ABBV,0.379291,0.286326,Somewhat-Bullish
Grab these 2 funds with rich 11%-12% yields while you can,https://www.marketwatch.com/story/grab-these-2-funds-with-rich-11-12-yields-while-you-can-f2856fb2,2023-11-08 12:18:00,"If you invest for income, consider taking advantage of these unusual opportunities.",ABBV,0.13459,0.166414,Somewhat-Bullish
Royalty Pharma Reports Third Quarter 2023 Results,https://www.globenewswire.com/news-release/2023/11/08/2776040/0/en/Royalty-Pharma-Reports-Third-Quarter-2023-Results.html,2023-11-08 12:00:00,"NEW YORK, Nov. 08, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today reported financial results for the third quarter of 2023 and raised full-year 2023 guidance for Adjusted Cash Receipts ( 1 ) ( a non-GAAP financial measure ) .",ABBV,0.009506,0.063649,Neutral
Biotech Stock Surges As Activist Reportedly Builds $1 Billion Stake,https://www.investors.com/news/technology/bmrn-stock-rockets-as-activist-investor-reportedly-builds-stake/,2023-11-07 19:16:00,BMRN Stock Rockets As Activist Investor Reportedly Builds $1 ... Investor's Business Daily ...,ABBV,0.134968,0.137726,Neutral
Invest In Penny Stocks? Is It Worth It & 4 To Watch Now,https://pennystocks.com/featured/2023/11/07/invest-in-penny-stocks-is-it-worth-it-4-to-watch-now/,2023-11-07 19:12:53,"If you're looking for penny stocks to invest in right now, you've got your work cut out for you. That's because the initial strategy when approaching cheap stocks is to trade them in the short term instead of holding them forever. There is a lot more risk involved when looking at these volatile ...",ABBV,0.067632,0.071158,Neutral
Inside the Dividend Monarchs ETF  ( KNGS ) ,https://www.zacks.com/stock/news/2180335/inside-the-dividend-monarchs-etf-kngs,2023-11-07 19:00:00,The newly-launched KNGS ETF holds 30+ stocks. These stocks have been in a position to consistently raise their dividends over the last 50 years.,ABBV,0.073321,-0.005071,Neutral
US FTC disputes listing for more than 100 patents in FDA Orange Book,https://www.reuters.com/business/healthcare-pharmaceuticals/us-ftc-disputes-listing-more-than-100-patents-fda-orange-book-2023-11-07/,2023-11-07 17:36:00,"Signage is seen outside of the Food and Drug Administration ( FDA ) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo Acquire Licensing Rights WASHINGTON, Nov 7 ( Reuters ) - The U.S.",ABBV,0.151539,-0.066195,Neutral
Looking Into AbbVie's Recent Short Interest - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/short-sellers/23/11/35650624/looking-into-abbvies-recent-short-interest,2023-11-07 16:30:23,"AbbVie's ABBV short percent of float has fallen 7.14% since its last report. The company recently reported that it has 11.47 million shares sold short, which is 0.65% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.92 days to cover their ...",ABBV,0.224903,0.085754,Neutral
Genmab Announces Financial Results for the First Nine Months of 2023,https://www.globenewswire.com/news-release/2023/11/07/2775338/0/en/Genmab-Announces-Financial-Results-for-the-First-Nine-Months-of-2023.html,2023-11-07 16:01:00,"November 7, 2023 Copenhagen, Denmark. Interim Report for the First Nine Months Ended September ...",ABBV,0.143629,0.083262,Neutral
"OutSystems Announces 2023 Innovation Awards, Showcasing the Best in High-Performance Low-Code Application Development",https://www.prnewswire.com/apac/news-releases/outsystems-announces-2023-innovation-awards-showcasing-the-best-in-high-performance-low-code-application-development-301979330.html,2023-11-07 03:00:00,"OutSystems Announces 2023 Innovation Awards, Showcasing the Best in High-Performance Low-Code Application ... PR ...",ABBV,0.076358,0.16617,Somewhat-Bullish
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later,https://www.fool.com/investing/2023/11/26/3-fantastic-dividend-stocks-to-buy-sooner-rather-t/,2023-11-26 11:55:00,There's no time like the present to buy these stocks.,ABBV,0.393634,0.213478,Somewhat-Bullish
CTLT: Catalent  ( CTLT )  Loses 6.1% Over the Past Month: Can the Stock Reverse Its Fortune?,https://stocknews.com/news/ctlt-snphy-taro-abbv-catalent-ctlt-loses-6-1-over-the-past-month-can-the/,2023-11-24 16:11:08,CTLT: Catalent ( CTLT ) Loses 6.1% Over the Past Month: Can the ... ...,ABBV,0.084722,0.059367,Neutral
AbbVie Inc.  ( ABBV )  Is a Trending Stock: Facts to Know Before Betting on It,https://www.zacks.com/stock/news/2188956/abbvie-inc-abbv-is-a-trending-stock-facts-to-know-before-betting-on-it,2023-11-24 14:00:11,"Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",ABBV,0.486627,0.191213,Somewhat-Bullish
How Is The Market Feeling About AbbVie? - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/short-sellers/23/11/35939204/how-is-the-market-feeling-about-abbvie,2023-11-24 13:45:18,"AbbVie's ABBV short percent of float has risen 15.38% since its last report. The company recently reported that it has 13.23 million shares sold short, which is 0.75% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.21 days to cover their ...",ABBV,0.224903,0.158881,Somewhat-Bullish
Could AbbVie Stock Help You Become a Millionaire?,https://www.fool.com/investing/2023/11/24/could-abbvie-stock-help-you-become-a-millionaire/,2023-11-24 13:45:00,Buying the stock at a cheap price today could help you achieve some great long-term returns.,ABBV,0.562778,0.455368,Bullish
"Spasticity Market Likely to Exhibit Substantial Growth by 2032, Predicts DelveInsight | Key Pharma Companies - Saol, Jazz, Supernus, Solstice Neurosciences, Ipsen, Merz, Motric Bio, SwanBio",https://www.prnewswire.com/news-releases/spasticity-market-likely-to-exhibit-substantial-growth-by-2032-predicts-delveinsight--key-pharma-companies----saol-jazz-supernus-solstice-neurosciences-ipsen-merz-motric-bio-swanbio-301996647.html,2023-11-23 22:01:00,"Spasticity Market Likely to Exhibit Substantial Growth by 2032, Predicts DelveInsight | Key Pharma Companies - Saol ... PR ...",ABBV,0.027476,0.038084,Neutral
Should WisdomTree U.S. High Dividend ETF  ( DHS )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2188229/should-wisdomtree-us-high-dividend-etf-dhs-be-on-your-investing-radar,2023-11-23 11:20:06,Style Box ETF report for ...,ABBV,0.123209,0.068541,Neutral
"The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma | DelveInsight",https://www.prnewswire.com/news-releases/the-evolving-market-dynamics-of-b-cell-lymphomas-diffuse-large-b-cell-lymphoma-follicular-lymphoma-chronic-lymphocytic-leukemia-mantle-cell-lymphoma-marginal-zone-lymphoma-waldenstrom-macroglobulinemia-and-burkitt-lymphoma--301995626.html,2023-11-22 22:01:00,"The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic ... PR ...",ABBV,0.039505,0.102193,Neutral
J&J  ( JNJ )  Seeks Expanded Use of Lung Cancer Drug Rybrevant,https://www.zacks.com/stock/news/2187470/jj-jnj-seeks-expanded-use-of-lung-cancer-drug-rybrevant,2023-11-21 17:41:00,J&J's (JNJ) sBLA seeks label expansion for Rybrevant plus chemotherapy to treat patients with EGFR-mutated NSCLC whose disease progressed on or after treatment with AstraZeneca's Tagrisso (osimertinib).,ABBV,0.356609,0.177221,Somewhat-Bullish
ABBV vs. LLY: Which Stock Should Value Investors Buy Now?,https://www.zacks.com/stock/news/2187390/abbv-vs-lly-which-stock-should-value-investors-buy-now,2023-11-21 16:40:06,ABBV vs. LLY: Which Stock Is the Better Value Option?,ABBV,0.802099,0.607342,Bullish
Should You Invest in AbbVie  ( ABBV )  Based on Bullish Wall Street Views?,https://www.zacks.com/stock/news/2187229/should-you-invest-in-abbvie-abbv-based-on-bullish-wall-street-views,2023-11-21 14:30:05,"The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",ABBV,0.364529,0.205293,Somewhat-Bullish
Jnana Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference,https://www.benzinga.com/pressreleases/23/11/g35892337/jnana-therapeutics-to-present-at-the-piper-sandler-35th-annual-healthcare-conference,2023-11-21 13:00:12,"BOSTON, Nov. 21, 2023 ( GLOBE NEWSWIRE ) -- Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, today announced that Joanne Kotz, Ph.D., Co-founder and Chief Executive Officer, will present a ...",ABBV,0.157483,0.206879,Somewhat-Bullish
"3 ""Boring"" Stocks That Could Make You Rich",https://www.fool.com/investing/2023/11/21/3-boring-stocks-that-could-make-you-rich/,2023-11-21 10:50:00,Boring could be beautiful with these stocks.,ABBV,0.283542,0.314904,Somewhat-Bullish
Ignore Eli Lilly. These 2 Stocks Are Better Buys Right Now,https://www.fool.com/investing/2023/11/21/ignore-eli-lilly-these-2-stocks-are-better-buys/,2023-11-21 10:30:00,Investors have favored an exciting billion-dollar opportunity at Eli Lilly.,ABBV,0.47574,0.237818,Somewhat-Bullish
"Sandoz launches Hyrimoz®  ( adalimumab )  high-concentration formulation in Europe, aiming to improve patient care",https://www.globenewswire.com/news-release/2023/11/21/2783692/0/en/Sandoz-launches-Hyrimoz-adalimumab-high-concentration-formulation-in-Europe-aiming-to-improve-patient-care.html,2023-11-21 06:00:00,"Basel, November 21, 2023 - Sandoz, the global leader in generic and biosimilar medicines, today announces the launch of Hyrimoz® ( adalimumab ) citrate-free high concentration formulation ( HCF. 100 mg/mL ) in Europe. The medicine will become available to patients progressively across European ...",ABBV,0.055621,0.0,Neutral
"Sandoz launches Hyrimoz®  ( adalimumab )  high-concentration formulation in Europe, aiming to improve patient care - Sandoz Group  ( OTC:SDZNY ) ",https://www.benzinga.com/pressreleases/23/11/g35887264/sandoz-launches-hyrimoz-adalimumab-high-concentration-formulation-in-europe-aiming-to-improve-pati,2023-11-21 06:00:00,Biosimilar Hyrimoz® ( adalimumab ) citrate-free high-concentration formulation ( HCF ) indicated for all conditions of reference medicine Humira®* Hyrimoz® HCF to launch progressively across Europe Hyrimoz® HCF strengthens well-established Sandoz biosimilar immunology portfolio in Europe,ABBV,0.052918,0.0,Neutral
$100 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/news/23/11/35874289/100-invested-in-abbvie-10-years-ago-would-be-worth-this-much-today,2023-11-20 15:00:18,"AbbVie ABBV has outperformed the market over the past 10 years by 1.44% on an annualized basis producing an average annual return of 11.04%. Currently, AbbVie has a market capitalization of $244.47 billion.",ABBV,0.983605,0.387251,Bullish
Curis shares rise as analysts see 'the next Pharmacyclics',https://www.marketwatch.com/story/curiss-stock-rises-as-analysts-see-the-next-pharmacyclics-21a176e1,2023-11-17 14:04:00,Shares of Curis rose premarket Friday as analysts see biotech company as potential take-out target ...,ABBV,0.331765,-0.233227,Somewhat-Bearish
Senator's Bearish Tesla Bet Under Scrutiny As He Buys Put Options Ahead Of Elon Musk-Led Company's Q3 Results That Set Stock Slide In Motion - Tesla  ( NASDAQ:TSLA ) ,https://www.benzinga.com/markets/equities/23/11/35843401/senators-bearish-tesla-bet-under-scrutiny-as-he-buys-put-options-ahead-of-elon-musk-led-companys,2023-11-17 07:02:36,"Tesla, Inc. TSLA shares have been going through a lean phase and the modest recovery seen has been in fits-and-starts. Against this backdrop, a Congressman has disclosed on Thursday bearish bets on the electric vehicle giant. What Happened: Sen.",ABBV,0.135347,0.134306,Neutral
Why Cerevel Therapeutics Holdings Is Moving After-Hours - Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) ,https://www.benzinga.com/general/biotech/23/12/36123803/why-cerevel-therapeutics-holdings-is-moving-after-hours,2023-12-06 22:14:01,Cerevel Therapeutics Holdings Inc CERE shares are trading higher in Wednesday's after-hours session after AbbVie Inc. ABBV announced it will acquire the company for a total equity value of approximately $8.7 billion.,ABBV,0.882468,0.639224,Bullish
AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion,https://www.cnbc.com/2023/12/06/abbvie-to-acquire-cerevel-therapeutics-for-8point7-billion-.html,2023-12-06 22:06:48,"The deal is AbbVie's latest attempt to expand its drug pipeline as its top-selling treatments, such as Humira, face generic competition.",ABBV,0.912523,0.428378,Bullish
AbbVie to buy Cerevel Therapeutics in $8.7 billion all-cash deal,https://www.marketwatch.com/story/abbvie-to-buy-cerevel-therapeutics-in-8-7-billion-all-cash-deal-c1f4d96d,2023-12-06 21:59:00,"AbbVie Inc. said late Wednesday it has agreed to buy Cerevel Therapeutics Holdings Inc. for $8.7 billion, saying that Cerevel's ""robust"" neuroscience pipeline adds medications that may transform standards of care in psychiatric and neurological illnesses.",ABBV,0.882924,0.532047,Bullish
ImmunoGen  ( IMGN )  Gets FDA Priority Review for Elahere sBLA,https://www.zacks.com/stock/news/2194306/immunogen-imgn-gets-fda-priority-review-for-elahere-sbla,2023-12-06 16:33:00,"The FDA grants priority review to ImmunoGen's (IMGN) sBLA to convert the accelerated approval for Elahere to full approval for treating platinum-resistant ovarian cancer. A decision is due on Apr 5, 2024.",ABBV,0.22421,0.198985,Somewhat-Bullish
Jnana Therapeutics to Present at the RBC Capital Markets Healthcare Private Company Virtual Conference,https://www.benzinga.com/pressreleases/23/12/g36110550/jnana-therapeutics-to-present-at-the-rbc-capital-markets-healthcare-private-company-virtual-confer,2023-12-06 13:00:13,"BOSTON, Dec. 06, 2023 ( GLOBE NEWSWIRE ) -- Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, today announced that Joanne Kotz, Ph.D., Co-founder and Chief Executive Officer, will participate ...",ABBV,0.154455,0.201841,Somewhat-Bullish
Down 10% This Year Is Coca-Cola Stock A Better Pick Over AbbVie?,https://www.forbes.com/sites/greatspeculations/2023/12/06/down-10-this-year-is-coca-cola-stock-a-better-pick-over-abbvie/,2023-12-06 13:00:00,"Given its better prospects, we believe Coca-Cola stock ( NYSE: KO ) is a better pick than AbbVie stock ( NYSE: ABBV ) . Although these companies are from different sectors, we compare them because they have a similar market capitalization of a little over $250 billion.",ABBV,0.707893,0.495596,Bullish
Is WisdomTree U.S. High Dividend ETF  ( DHS )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2193938/is-wisdomtree-us-high-dividend-etf-dhs-a-strong-etf-right-now,2023-12-06 11:20:05,Smart Beta ETF report for ...,ABBV,0.119532,0.067655,Neutral
"Fallopian Tube Cancer Therapeutics Market size to grow by USD 832.01 million from 2023-2028| AbbVie Inc., Amgen ... - PR Newswire",https://www.prnewswire.com/news-releases/fallopian-tube-cancer-therapeutics-market-size-to-grow-by-usd-832-01-million-from-2023-2028-abbvie-inc-amgen-inc-arrien-pharmaceuticals-llc-and-more-among-the-key-companies-in-the-market---technavio-302006567.html,2023-12-05 22:15:00,"Fallopian Tube Cancer Therapeutics Market size to grow by USD 832.01 million from 2023-2028| AbbVie Inc., Amgen ... PR ...",ABBV,0.057628,-0.003,Neutral
Decoding AbbVie's Options Activity: What's the Big Picture? - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/12/36099918/decoding-abbvies-options-activity-whats-the-big-picture,2023-12-05 19:45:40,"Investors with a lot of money to spend have taken a bearish stance on AbbVie ABBV. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",ABBV,0.682689,0.30815,Somewhat-Bullish
Dragonfly Therapeutics Initiates Phase 1/1b Study of its IL-2 Immunotherapy in Patients with Advanced Solid Tumors,https://www.newswire.ca/news-releases/dragonfly-therapeutics-initiates-phase-1-1b-study-of-its-il-2-immunotherapy-in-patients-with-advanced-solid-tumors-897149276.html,2023-12-05 15:00:00,"The company announces the first patient dosed in a Phase 1/1b clinical trial evaluating its novel IL-2 cytokine, DF6215, the seventh Dragonfly-developed drug to enter into clinical trials.",ABBV,0.075635,0.180047,Somewhat-Bullish
AbbVie Inc.  ( ABBV )  is Attracting Investor Attention: Here is What You Should Know,https://www.zacks.com/stock/news/2193498/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know,2023-12-05 14:00:11,"Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",ABBV,0.491255,0.135422,Neutral
"STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - SRC, IMGN, PATI, ROVR",https://www.benzinga.com/pressreleases/23/12/g36083729/stockholder-alert-the-m-a-class-action-firm-continues-investigating-the-merger-src-imgn-pati-rovr,2023-12-05 00:57:39,"NEW YORK, Dec. 04, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered ...",ABBV,0.070105,0.127439,Neutral
"BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hawaiian Holdings, Inc.  ( Nasdaq - HA ) , ImmunoGen, Inc.  ( Nasdaq - IMGN ) , Graphite Bio, Inc.  ( Nasdaq - GRPH ) , CapStar Financial Holdings, Inc.  ( Nasdaq - CSTR ) ",https://www.benzinga.com/pressreleases/23/12/g36080590/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-hawaiian-hold,2023-12-04 21:28:06,"BALA CYNWYD, Pa., Dec. 04, 2023 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",ABBV,0.284696,0.299761,Somewhat-Bullish
Lilly  ( LLY )  Gets Second FDA Nod for Lymphoma Drug Jaypirca,https://www.zacks.com/stock/news/2193151/lilly-lly-gets-second-fda-nod-for-lymphoma-drug-jaypirca,2023-12-04 17:19:00,"Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.",ABBV,0.380012,0.153731,Somewhat-Bullish
"ImmunoGen, AbbVie's $10B Deal Comes At 'Right Time' Analyst Says In Downgrade Note - Immunogen  ( NASDAQ:IMGN ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36070194/immunogen-abbvies-10b-deal-comes-at-right-time-analyst-says-in-downgrade-note,2023-12-04 15:44:53,"AbbVie Inc ABBV is acquiring ImmunoGen, Inc. IMGN for around $10 billion. The deal, which is expected to close in mid-2024, represents a ""great price"" for ImmunoGen, at $31.26 per share, according to Piper Sandler.",ABBV,0.670742,0.101992,Neutral
2 Dividend Stocks to Buy and Hold Forever,https://www.fool.com/investing/2023/12/02/2-dividend-stocks-to-buy-and-hold-forever/,2023-12-02 15:00:00,These stocks offer much more than reliable dividends.,ABBV,0.30569,-0.016406,Neutral
5 S&P 500 Stocks That Pay a Generous Dividend,https://www.fool.com/investing/2023/12/02/5-sp-500-stocks-that-pay-a-generous-dividend/,2023-12-02 12:30:00,Investors are pocketing dividend yields between 4% and 9% with these stocks.,ABBV,0.149038,0.269819,Somewhat-Bullish
Dow Hits 2023 High; Cybertruck Deliveries Begin: Weekly Review,https://www.investors.com/news/dow-jones-hits-2023-high-nasdaq-slips-tesla-cybertruck-salesforce-in-focus-weekly-review/,2023-12-01 15:33:00,"Dow Hits '23 High, Nasdaq Slips. Cybertruck Debuts: Weekly Review Investor's Business Daily ...",ABBV,0.043698,-0.029,Neutral
"Pharma Stock Roundup: ABBV to Buy Immunogen, NVS Ups Mid-Term Sales View & More",https://www.zacks.com/stock/news/2192051/pharma-stock-roundup-abbv-to-buy-immunogen-nvs-ups-mid-term-sales-view-more,2023-12-01 13:13:00,AbbVie (ABBV) offers to acquire cancer biotech Immunogen for $10.1 billion. Novartis (NVS) raises its mid-term sales growth outlook by 1%.,ABBV,0.259925,0.075641,Neutral
AbbVie  ( ABBV )  to Acquire ImmunoGen  ( IMGN )  for $10.1 Billion,https://www.zacks.com/stock/news/2191954/abbvie-abbv-to-acquire-immunogen-imgn-for-101-billion,2023-12-01 10:55:00,"AbbVie (ABBV) offers to buy ImmunoGen (IMGN) for approximately $10.1 billion, which will diversify its oncology pipeline across solid tumors and hematologic malignancies.",ABBV,0.398148,0.224559,Somewhat-Bullish
Jim Cramer explains why it's hard to be bullish on the healthcare sector,https://www.cnbc.com/2023/11/30/jim-cramer-explains-why-its-hard-to-be-bullish-on-healthcare.html,2023-12-01 01:32:24,CNBC's Jim Cramer on Thursday detailed what may be hurting healthcare stocks.,ABBV,0.089797,-0.054268,Neutral
Why Abbvie Stock Popped Today,https://www.fool.com/investing/2023/11/30/why-abbvie-stock-popped-today/,2023-12-01 00:19:34,The company announces a major deal worth over $10 billion.,ABBV,0.775204,0.442449,Bullish
This Combination of 3 Stocks Provides Monthly Income,https://www.zacks.com/commentary/2191812/this-combination-of-3-stocks-provides-monthly-income,2023-11-30 21:05:00,Investors who select stocks in a structured manner can create a portfolio that pays them monthly. Who doesn't love payday?,ABBV,0.3796,0.484745,Bullish
"Nasdaq Falls Over 100 Points; Cracker Barrel Shares Slide After Q1 Results - Cracker Barrel Old  ( NASDAQ:CBRL ) , Immunogen  ( NASDAQ:IMGN ) ",https://www.benzinga.com/news/earnings/23/11/36031052/nasdaq-falls-over-100-points-cracker-barrel-shares-slide-after-q1-results,2023-11-30 19:12:52,"U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining around 300 points on Thursday. The Dow traded up 0.88% to 35,742.35 while the NASDAQ fell 0.79% to 14,145.17. The S&P 500 also fell, dropping, 0.15% to 4,543.88. Health care shares rose by 0.8% on Thursday.",ABBV,0.054983,0.295995,Somewhat-Bullish
Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion,https://www.cnbc.com/2023/11/30/biotech-stocks-jump-on-abbvie-deal-to-buy-cancer-drugmaker-immunogen.html,2023-11-30 17:28:25,"Shares of other biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the news of the buyout.",ABBV,0.34729,-0.047396,Neutral
"Crude Oil Falls Sharply; Kroger Posts Upbeat Earnings - Kroger  ( NYSE:KR ) , Immunogen  ( NASDAQ:IMGN ) ",https://www.benzinga.com/news/earnings/23/11/36028629/crude-oil-falls-sharply-kroger-posts-upbeat-earnings,2023-11-30 17:16:25,"U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 100 points on Thursday. The Dow traded up 0.85% to 35,729.88 while the NASDAQ fell 0.71% to 14,156.60. The S&P 500 also fell, dropping, 0.13% to 4,544.50. Health care shares rose by 0.9% on Thursday.",ABBV,0.057628,0.296053,Somewhat-Bullish
AbbVie  ( ABBV )  Posts Encouraging Data From Lung Cancer Study,https://www.zacks.com/stock/news/2191706/abbvie-abbv-posts-encouraging-data-from-lung-cancer-study,2023-11-30 16:56:00,Data from a mid-stage study on AbbVie's (ABBV) experimental ADC drug demonstrates compelling clinical benefits across key endpoints in certain lung cancer patients.,ABBV,0.453501,0.089073,Neutral
"Why ImmunoGen  ( IMGN )  Stock Is Soaring Today - Immunogen  ( NASDAQ:IMGN ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/general/biotech/23/11/36020779/immunogens-flagship-cancer-therapy-draws-abbvies-attention-with-10-1b-deal,2023-11-30 16:30:37,"AbbVie Inc ABBV has agreed to acquire ImmunoGen Inc IMGN and its flagship cancer therapy Elahere ( mirvetuximab soravtansine-gynx ) , a first-in-class antibody-drug conjugate ( ADC ) approved for platinum-resistant ovarian cancer.",ABBV,0.699089,0.36959,Bullish
Turkey launches investigation into 19 pharma companies,https://www.reuters.com/business/healthcare-pharmaceuticals/turkey-launches-investigation-into-19-pharma-companies-2023-11-30/,2023-11-30 16:19:00,"ANKARA, Nov 30 ( Reuters ) - Turkey's competition authority said on Thursday it had launched an investigation into 19 pharmaceutical companies to determine whether they had violated competition law.",ABBV,0.211191,-0.075673,Neutral
Is it a Good Idea to Invest in Harpoon  ( HARP )  Stock Now?,https://www.zacks.com/stock/news/2191592/is-it-a-good-idea-to-invest-in-harpoon-harp-stock-now,2023-11-30 16:07:00,"Here, we discuss some reasons why investing in Harpoon Therapeutics (HARP) stock now may turn out to be a prudent move.",ABBV,0.175859,0.20408,Somewhat-Bullish
"AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash Deal",https://www.investors.com/news/technology/imgn-stock-abbv-stock-biotech-acquisition-elahere/,2023-11-30 15:32:00,"AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion ... Investor's Business Daily ...",ABBV,0.795061,0.403995,Bullish
AbbVie's $10.1 billion deal to buy ImmunoGen values the stock at a 95% premium,https://www.marketwatch.com/story/abbvie-10-1-billion-deal-to-buy-immunogen-values-the-stock-at-a-95-premium-55c8c6ea,2023-11-30 15:24:00,ImmunoGen's stock rocketed to the highest price seen in two decades after the biotechnology company announced an agreement to be acquired buy AbbVie in a cash deal valued at $10.1 billion.,ABBV,0.920636,0.38532,Bullish
"La-Z-Boy Posts Upbeat Earnings, Joins Victoria's Secret, Snowflake And Other Big Stocks Moving Higher On Thursday - Compass Pathways  ( NASDAQ:CMPS ) , Bicycle Therapeutics  ( NASDAQ:BCYC ) ",https://www.benzinga.com/news/23/11/36024931/la-z-boy-posts-upbeat-earnings-joins-victorias-secret-snowflake-and-other-big-stocks-moving-higher-o,2023-11-30 15:12:50,"U.S. stocks traded mostly higher, with the Dow Jones index gaining around 200 points on Thursday. Shares of La-Z-Boy Incorporated LZB moved higher on Thursday as the company reported upbeat earnings results for its second quarter and increased its quarterly cash dividend by 10%.",ABBV,0.096671,0.263937,Somewhat-Bullish
Health Care Company AbbVie Announces Acquisition of Immunogen - Immunogen  ( NASDAQ:IMGN ) ,https://www.benzinga.com/m-a/23/11/36024866/health-care-company-abbvie-announces-acquisition-of-immunogen,2023-11-30 15:10:05,"AbbVie ABBV has announced an acquisition of Immunogen IMGN that is expected to be completed 2024-H1. Under the terms of the agreement, AbbVie has agreed to give Immunogen $10.10 billion in cash in exchange for IMGN stock. AbbVie is a pharmaceutical firm with a strong exposure to immunology and ...",ABBV,0.573213,0.556683,Bullish
"The Zacks Analyst Blog Highlights AbbVie, J&J, Eli Lilly, Pfizer",https://www.zacks.com/stock/news/2191547/the-zacks-analyst-blog-highlights-abbvie-jj-eli-lilly-pfizer,2023-11-30 15:08:00,"AbbVie, J&J, Eli Lilly, Pfizer are included in this Analyst Blog.",ABBV,0.25168,0.248174,Somewhat-Bullish
"Dow Jumps Around 200 Points; US Core PCE Inflation Slows In October - AgriFORCE Growing Systems  ( NASDAQ:AGRI ) , Immunogen  ( NASDAQ:IMGN ) ",https://www.benzinga.com/news/earnings/23/11/36024059/dow-jumps-around-200-points-us-core-pce-inflation-slows-in-october,2023-11-30 14:42:50,"U.S. stocks traded mostly higher this morning, with the Dow Jones index gaining around 200 points on Thursday. Following the market opening Thursday, the Dow traded up 0.56% to 35,630.09 while the NASDAQ fell 0.11% to 14,242.75. The S&P 500 also rose, gaining, 0.06% to 4,553.49.",ABBV,0.063594,0.296771,Somewhat-Bullish
AbbVie signs $10 bln deal to buy cancer drugmaker ImmunoGen,https://www.reuters.com/markets/deals/abbvie-buy-immunogen-101-billion-boost-cancer-drug-portfolio-2023-11-30/,2023-11-30 13:34:00,"A sign stands outside a Abbvie facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File Photo Acquire Licensing Rights",ABBV,0.522333,0.132352,Neutral
AbbVie Should Consider a Dividend Cut -- Here's Why,https://www.fool.com/investing/2023/11/30/abbvie-should-consider-a-dividend-cut-heres-why/,2023-11-30 13:15:00,Dividend Kings with above-average yields have been badly underperforming the broader markets.,ABBV,0.515636,0.182566,Somewhat-Bullish
Stock market today: Wall Street opens mixed and is still headed for big gains in November,https://apnews.com/article/stock-market-rates-opec-inflation-51a3156bdbc0eae60140210a10e79ebe,2023-11-30 10:04:00,"Stock market today: World shares mostly higher ahead of US price update, OPEC+ meeting The Associated Press ...",ABBV,0.056943,0.0,Neutral
AbbVie's Lung Cancer Study Shows Encouraging Clinical Benefits In Subtype Of Patients - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/general/biotech/23/11/36005584/abbvies-lung-cancer-study-shows-encouraging-clinical-benefits-in-subtype-of-patients,2023-11-29 18:21:27,"AbbVie Inc ABBV announced topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin ( Teliso-V ) in patients with c-Met protein overexpression, epidermal growth factor receptor ( EGFR ) wild type, advanced/metastatic nonsquamous non-small cell lung cancer ( ...",ABBV,0.465196,-0.079932,Neutral
4 Large Drug Stocks to Watch as IBD Market Gains Traction,https://www.zacks.com/stock/news/2190845/4-large-drug-stocks-to-watch-as-ibd-market-gains-traction,2023-11-29 14:39:00,"As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players in the market are AbbVie (ABBV), J&J (JNJ), Lilly (LLY) and Pfizer (PFE).",ABBV,0.223659,0.259888,Somewhat-Bullish
CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023,https://www.prnewswire.com/news-releases/collplant-biotechnologies-announces-third-quarter-financial-results-for-2023-302000555.html,2023-11-29 12:00:00,"REHOVOT, Israel, Nov. 29, 2023 /PRNewswire/ -- CollPlant Biotechnologies ( Nasdaq: CLGN ) , a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced ...",ABBV,0.12142,0.09882,Neutral
Medtronic Stock: Bull vs. Bear,https://www.fool.com/investing/2023/11/29/medtronic-stock-bull-vs-bear/,2023-11-29 11:00:00,The medical device maker's shares have gained a little more than 1% so far this year.,ABBV,0.046816,0.223253,Somewhat-Bullish
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update,https://www.globenewswire.com/news-release/2023/11/28/2787373/0/en/Alvotech-Reports-Financial-Results-for-First-Nine-Months-of-2023-and-Provides-Business-Update.html,2023-11-28 21:15:00,"Alvotech ( NASDAQ: ALVO, or the ""Company"" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first nine months of 2023 and provided a summary of recent corporate ...",ABBV,0.013732,0.0,Neutral
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update,https://www.globenewswire.com/news-release/2023/11/28/2787372/0/en/Alvotech-Reports-Financial-Results-for-First-Nine-Months-of-2023-and-Provides-a-Business-Update.html,2023-11-28 21:15:00,"REYKJAVIK, Iceland, Nov. 28, 2023 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the ""Company"" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first nine months of ...",ABBV,0.013685,0.0,Neutral
AbbVie  ( ABBV )  Lymphoma Drug Gets FDA Breakthrough Therapy Tag,https://www.zacks.com/stock/news/2190442/abbvie-abbv-lymphoma-drug-gets-fda-breakthrough-therapy-tag,2023-11-28 16:32:00,The FDA grants breakthrough therapy designation to AbbVie's (ABBV) Epkinly in follicular lymphoma indication. The EMA validates a regulatory filing seeking label expansion for the drug.,ABBV,0.521465,0.175519,Somewhat-Bullish
Should You Invest in the Invesco Pharmaceuticals ETF  ( PJP ) ?,https://www.zacks.com/stock/news/2190100/should-you-invest-in-the-invesco-pharmaceuticals-etf-pjp,2023-11-28 11:20:06,Sector ETF report for ...,ABBV,0.129866,0.063182,Neutral
Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference,https://www.globenewswire.com/news-release/2023/11/27/2786531/0/en/Royalty-Pharma-to-Present-at-the-Evercore-ISI-6th-Annual-HealthCONx-Conference.html,2023-11-27 21:15:00,"NEW YORK, Nov. 27, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conference on November 28, 2023 at 3:00 p.m. ET.",ABBV,0.156461,0.101458,Neutral
Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference - Royalty Pharma  ( NASDAQ:RPRX ) ,https://www.benzinga.com/pressreleases/23/11/g35968350/royalty-pharma-to-present-at-the-evercore-isi-6th-annual-healthconx-conference,2023-11-27 21:15:00,"NEW YORK, Nov. 27, 2023 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conference on November 28, 2023 at 3:00 p.m. ET.",ABBV,0.148731,0.098368,Neutral
Global Advanced Drug Delivery Systems Market To Witness Significant Growth In The Forecast Period - Projected CAGR Of 6% From 2023 To 2027 As Per The Business Research Company's Advanced Drug Delivery Systems Global Market Report 2023,https://www.benzinga.com/pressreleases/23/11/g35962849/global-advanced-drug-delivery-systems-market-to-witness-significant-growth-in-the-forecast-period-,2023-11-27 16:30:00,"LONDON, Nov. 27, 2023 ( GLOBE NEWSWIRE ) -- The latest market report from The Business Research Company reveals promising prospects for the global advanced drug delivery systems market.",ABBV,0.051999,0.178561,Somewhat-Bullish
Genmab Announces Positive Regulatory Updates for Epcoritamab  ( EPKINLY®/TEPKINLY® )  for the Treatment of Relapsed/Refractory Follicular Lymphoma,https://www.globenewswire.com/news-release/2023/11/27/2786009/0/en/Genmab-Announces-Positive-Regulatory-Updates-for-Epcoritamab-EPKINLY-TEPKINLY-for-the-Treatment-of-Relapsed-Refractory-Follicular-Lymphoma.html,2023-11-27 12:00:00,"Media ReleaseCOPENHAGEN, Denmark. November ...",ABBV,0.117716,0.072462,Neutral
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally,https://www.fool.com/investing/2023/12/16/3-fantastic-stocks-that-could-enjoy-a-santa-claus/,2023-12-16 11:55:00,These stocks could bring investors more than just a lump of coal for Christmas.,ABBV,0.278109,0.196332,Somewhat-Bullish
AbbVie  ( ABBV )  Declines More Than Market: Some Information for Investors,https://www.zacks.com/stock/news/2199022/abbvie-abbv-declines-more-than-market-some-information-for-investors,2023-12-15 22:45:13,"In the latest trading session, AbbVie (ABBV) closed at $154.04, marking a -0.54% move from the previous day.",ABBV,0.605266,0.285554,Somewhat-Bullish
"Pharma Stock Roundup: PFE Issues Weak 2024 View, AZN to Buy Icosavax & More",https://www.zacks.com/stock/news/2198513/pharma-stock-roundup-pfe-issues-weak-2024-view-azn-to-buy-icosavax-more,2023-12-15 13:34:00,"Pfizer (PFE) issues a disappointing outlook for 2024. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax.",ABBV,0.079,-0.065918,Neutral
"Sprechen Sie Growth? How Duolingo Became A Hot Stock In 2023, Plus 99 More Mid-Cap Winners",https://www.forbes.com/sites/hanktucker/2023/12/15/sprechen-sie-growth-how-duolingo-became-a-hot-stock-in-2023-plus-99-more-mid-cap-winners/,2023-12-15 11:30:26,"Duolingo has tripled this year, standing out in a corner of the market that still trades at a discount collectively compared to its larger peers.",ABBV,0.032425,0.013804,Neutral
Decoding AbbVie's Options Activity: What's the Big Picture? - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/12/36241562/decoding-abbvies-options-activity-whats-the-big-picture,2023-12-14 16:46:12,"High-rolling investors have positioned themselves bullish on AbbVie ABBV, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data.",ABBV,0.762438,0.360109,Bullish
Here's How Much You'd Have If You Invested $1000 in AbbVie a Decade Ago,https://www.zacks.com/stock/news/2197856/heres-how-much-youd-have-if-you-invested-1000-in-abbvie-a-decade-ago,2023-12-14 13:30:05,"Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.",ABBV,0.691995,0.30607,Somewhat-Bullish
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CERE, HOLI, EGLE - Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) , Eagle Bulk Shipping  ( NYSE:EGLE ) ",https://www.benzinga.com/pressreleases/23/12/g36230846/shareholder-investigation-halper-sadeh-llc-investigates-cere-holi-egle,2023-12-14 06:28:29,"NEW YORK, Dec. 14, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Cerevel Therapeutics Holdings, Inc.",ABBV,0.150592,0.0991,Neutral
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMGN, HA, EAR - Eargo  ( NASDAQ:EAR ) , Hawaiian Holdings  ( NASDAQ:HA ) ",https://www.benzinga.com/pressreleases/23/12/g36230843/shareholder-investigation-halper-sadeh-llc-investigates-imgn-ha-ear,2023-12-14 06:26:39,"NEW YORK, Dec. 14, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: ImmunoGen, Inc.",ABBV,0.16171,0.103623,Neutral
"ALERT: The M&A Class Action Firm Continues Investigating the Merger - EAR, IMGN, CVLY, EVFM",https://www.benzinga.com/pressreleases/23/12/g36228860/alert-the-m-a-class-action-firm-continues-investigating-the-merger-ear-imgn-cvly-evfm,2023-12-14 01:00:00,"NEW YORK, Dec. 13, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered ...",ABBV,0.072,0.127782,Neutral
"STOCKHOLDER ALERT: Juan Monteverde Encourages the Shareholders of CERE, SRT, WAVD, GRPH to Take Action",https://www.benzinga.com/pressreleases/23/12/g36228862/stockholder-alert-juan-monteverde-encourages-the-shareholders-of-cere-srt-wavd-grph-to-take-action,2023-12-14 01:00:00,"NEW YORK, Dec. 13, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered ...",ABBV,0.071145,0.121493,Neutral
Top Dividend Stock AbbVie Runs Hot As Market Approves Of Acquisition Spree,https://www.investors.com/research/the-income-investor/dividend-stock-abbvie-run-hot-as-market-approves-acquisition-spree/,2023-12-13 20:49:00,"Shares of biotech AbbVie ( ABBV ) are hot. The stock is nearing a buy point, having risen for 11 consecutive days - the longest streak since December 2021. The Chicago-based company - best known for its rheumatoid arthritis drug Humira - has been busy.",ABBV,0.827318,0.307615,Somewhat-Bullish
Pfizer shares fall as 2024 revenue and profit forecast disappoints,https://www.cnbc.com/2023/12/13/pfizer-forecasts-2024-revenue-below-wall-street-expectations.html,2023-12-13 14:40:18,"After raking in billions from Covid products, Pfizer has struggled to navigate a world beyond the pandemic and reassure investors about its growth potential.",ABBV,0.088472,-0.123286,Neutral
$100 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/news/23/12/36216708/100-invested-in-abbvie-10-years-ago-would-be-worth-this-much-today,2023-12-13 14:31:20,"AbbVie ABBV has outperformed the market over the past 10 years by 1.0% on an annualized basis producing an average annual return of 11.05%. Currently, AbbVie has a market capitalization of $269.95 billion.",ABBV,0.983605,0.387251,Bullish
Bristol to pay SystImmune up to $8.4 billion in cancer-drug deal,https://www.financialexpress.com/healthcare/news-healthcare/bristol-to-pay-systimmune-up-to-8-4-billion-in-cancer-drug-deal/3336763/,2023-12-13 03:30:00,"Bristol Myers Squibb Co. will pay SystImmune Inc. up to $8.4 billion for rights to co-develop and sell an experimental drug for lung and breast cancers, the latest in a string of large deals for a potent new class of oncology treatments.",ABBV,0.163909,0.094593,Neutral
Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/general/biotech/23/12/36202496/botox-and-similar-injections-have-associated-risks-consumer-group-pushes-for-stronger-warnings,2023-12-12 19:04:27,"Consumer advocacy group Public Citizen has filed a petition with the FDA, urging the agency to demand stronger warnings regarding the risk of a potentially fatal muscle-paralyzing disease linked to Botox and similar injections.",ABBV,0.277433,0.0,Neutral
"Head And Neck Cancer Diagnostics Market size to grow by USD 4.93 billion from 2022-2027 | AbbVie Inc., Accuray Inc ... - PR Newswire",https://www.prnewswire.com/news-releases/head-and-neck-cancer-diagnostics-market-size-to-grow-by-usd-4-93-billion-from-2022-2027--abbvie-inc-accuray-inc-addent-inc-and-more-among-the-key-companies-in-the-market---technavio-302013059.html,2023-12-12 18:30:00,"Head And Neck Cancer Diagnostics Market size to grow by USD 4.93 billion from 2022-2027 | AbbVie Inc., Accuray Inc ... PR ...",ABBV,0.192694,-0.152213,Somewhat-Bearish
AbbVie Just Followed Pfizer's Big Move. Here's What It Means For Investors,https://www.fool.com/investing/2023/12/12/abbvie-just-followed-pfizers-big-move-heres-what/,2023-12-12 15:15:00,It's making a major acquisition to beef up a key area of its pipeline.,ABBV,0.349153,0.191583,Somewhat-Bullish
Bristol Myers Squibb Further Diversifies Oncology Portfolio With Mega $8.4B Deal - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36195740/bristol-myers-squibb-further-diversifies-oncology-portfolio-with-mega-8-4b-deal,2023-12-12 14:00:05,"SystImmune and Bristol Myers Squibb & Co BMY announced an exclusive license and collaboration agreement for SystImmune's BL-B01D1, a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate ( ADC ) .",ABBV,0.25168,0.096416,Neutral
"US Consumer group seeks stronger warnings on Botox, similar treatments",https://www.reuters.com/business/healthcare-pharmaceuticals/us-consumer-group-seeks-stronger-warnings-botox-similar-treatments-2023-12-12/,2023-12-12 05:00:47,"A vial of Botox, owned by AbbVie, is seen next to its packaging in a photo illustration in Manhattan, New York, U.S., December 8, 2021. REUTERS/Andrew Kelly Acquire Licensing Rights Dec 12 ( Reuters ) - Consumer advocacy group Public Citizen on Tuesday filed a petition with the U.S.",ABBV,0.145583,0.003801,Neutral
University Lab Partners Announces Lionheart Health as the Winner of Golden Passport Pitch Competition to Accelerate ... - PR Newswire,https://www.prnewswire.com/news-releases/university-lab-partners-announces-lionheart-health-as-the-winner-of-golden-passport-pitch-competition-to-accelerate-aesthetics-start-ups-302011849.html,2023-12-11 21:53:00,University Lab Partners Announces Lionheart Health as the Winner of Golden Passport Pitch Competition to Accelerate ... PR ...,ABBV,0.213048,0.26611,Somewhat-Bullish
"BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc.  ( Nasdaq - CNSL ) , Cerevel Therapeutics Holdings, Inc.  ( Nasdaq - CERE ) , ImmunoGen, Inc.  ( Nasdaq - IMGN ) , Graphite Bio, Inc.  ( Nasdaq - GRPH ) ",https://www.benzinga.com/pressreleases/23/12/g36182294/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-consolidated-,2023-12-11 18:28:05,"BALA CYNWYD, Penn., Dec. 11, 2023 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",ABBV,0.504646,0.430717,Bullish
Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis  ( MF )  and Anemia at the 65th American Society of Hematology  ( ASH )  Annual Meeting,https://www.globenewswire.com/news-release/2023/12/11/2794107/0/en/Disc-Presents-Initial-Positive-Data-from-Ongoing-Phase-1b-2-Trial-of-DISC-0974-in-Patients-with-Myelofibrosis-MF-and-Anemia-at-the-65th-American-Society-of-Hematology-ASH-Annual-Me.html,2023-12-11 17:00:00,"WATERTOWN, Mass., Dec. 11, 2023 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. ( NASDAQ:IRON ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced data ...",ABBV,0.027667,-0.093605,Neutral
Anima Biotech to Present at the 6th Annual RNA-Targeted Drug Discovery & Development Summit,https://www.benzinga.com/pressreleases/23/12/g36178069/anima-biotech-to-present-at-the-6th-annual-rna-targeted-drug-discovery-development-summit,2023-12-11 15:17:00,"BERNARDSVILLE, N.J., Dec. 11, 2023 ( GLOBE NEWSWIRE ) -- Anima Biotech, the leading Tech.Bio in the discovery of mRNA drugs and targets, today announced their participation in the upcoming 6th Annual RNA-Targeted Drug Discovery and Development Summit taking place in Boston, MA from December 12 - ...",ABBV,0.077845,0.065956,Neutral
The top 10 things to watch in the stock market Monday,https://www.cnbc.com/2023/12/11/the-top-10-things-to-watch-in-the-stock-market-monday.html,2023-12-11 14:21:25,"U.S. stocks are muted Monday following last week's push to a new 52-week high, while Cigna abandons its pursuit of Humana.",ABBV,0.113062,0.113938,Neutral
New data for Roche's Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma,https://www.globenewswire.com/news-release/2023/12/11/2793530/0/en/New-data-for-Roche-s-Columvi-and-Lunsumio-presented-at-ASH-2023-support-continued-benefit-for-people-with-lymphoma.html,2023-12-11 06:00:00,"Basel, 11 December 2023 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today that new data from its CD20xCD3 T-cell engaging bispecific antibody programme, including eight oral presentations, were presented at the 65th American Society of Hematology ( ASH ) Annual Meeting & Exposition, 9-12 ...",ABBV,0.018583,0.066923,Neutral
Studies Highlight Both Novel Treatments and Enduring Value of Older Approaches,https://www.prnewswire.com/news-releases/studies-highlight-both-novel-treatments-and-enduring-value-of-older-approaches-302010757.html,2023-12-10 15:45:00,"Findings suggest ""less is more"" and ""tried and true"" may benefit select patients",ABBV,0.01818,-0.051396,Neutral
4 Top Dividend Stocks Yielding More Than 4% to Buy Hand-Over-Fist This December,https://www.fool.com/investing/2023/12/10/4-top-dividend-stocks-yielding-more-than-4-to-buy/,2023-12-10 12:45:00,These companies offer above-average income streams that should continue rising.,ABBV,0.227859,0.426675,Bullish
AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now?,https://www.fool.com/investing/2023/12/10/abbvie-big-acquisitions-dividend-king-buy/,2023-12-10 10:51:00,The big drugmaker went on a holiday shopping spree.,ABBV,0.782378,0.394737,Bullish
New Pivotal Data for Bispecific Antibody Epcoritamab  ( DuoBody® CD3xCD20 )  Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma  ( FL ) ,https://www.globenewswire.com/news-release/2023/12/09/2793439/0/en/New-Pivotal-Data-for-Bispecific-Antibody-Epcoritamab-DuoBody-CD3xCD20-Demonstrates-High-Overall-and-Complete-Responses-in-Patients-with-Hard-To-Treat-Relapsed-Refractory-Follicular.html,2023-12-09 17:00:00,Media Release ...,ABBV,0.133735,0.004875,Neutral
New data reinforce the benefit of early preventative treatment with Roche's Hemlibra for babies with severe haemophilia A,https://www.globenewswire.com/news-release/2023/12/09/2793433/0/en/New-data-reinforce-the-benefit-of-early-preventative-treatment-with-Roche-s-Hemlibra-for-babies-with-severe-haemophilia-A.html,2023-12-09 16:30:00,"Basel, 09 December 2023 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra® ( emicizumab ) in previously untreated or minimally treated infants with severe haemophilia A without factor VIII ...",ABBV,0.019147,0.063422,Neutral
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HA, PFIN, IMGN, SP - Hawaiian Holdings  ( NASDAQ:HA ) , Immunogen  ( NASDAQ:IMGN ) ",https://www.benzinga.com/pressreleases/23/12/g36166154/shareholder-investigation-halper-sadeh-llc-investigates-ha-pfin-imgn-sp,2023-12-09 13:42:28,"NEW YORK, Dec. 09, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Hawaiian Holdings, Inc.",ABBV,0.144275,0.096645,Neutral
3 Dividend Stocks You Can Safely Hold for Decades,https://www.fool.com/investing/2023/12/09/3-dividend-stocks-you-can-safely-hold-for-decades/,2023-12-09 10:51:00,These companies and their dividends are built to last.,ABBV,0.473427,0.194612,Somewhat-Bullish
Better Dividend Stock: AbbVie vs. Medical Properties Trust,https://www.fool.com/investing/2023/12/09/better-dividend-stock-abbvie-vs-medical-properties/,2023-12-09 10:12:00,Which of these high-yield stocks has what it takes to keep raising their payouts?,ABBV,0.409503,0.090621,Neutral
"ALERT: The M&A Class Action Firm Continues Investigating the Merger - PATI, ROVR, SRC, IMGN",https://www.prnewswire.com/news-releases/alert-the-ma-class-action-firm-continues-investigating-the-merger--pati-rovr-src-imgn-302010546.html,2023-12-09 01:00:00,"NEW YORK, Dec. 8, 2023 /PRNewswire/ -- , founder and managing partner of the class action firm ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, ...",ABBV,0.077845,0.145201,Neutral
"ALERT: Juan Monteverde Encourages the Shareholders of CERE, PFIN, NWLI, CSTR to Take Action",https://www.prnewswire.com/news-releases/alert-juan-monteverde-encourages-the-shareholders-of-cere-pfin-nwli-cstr-to-take-action-302010543.html,2023-12-09 01:00:00,"NEW YORK, Dec. 8, 2023 /PRNewswire/ -- , founder and managing partner of the class action firm ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, ...",ABBV,0.076358,0.139649,Neutral
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CERE, ROVR, SIX, BBAI - BigBear.ai Hldgs  ( NYSE:BBAI ) , Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) ",https://www.benzinga.com/pressreleases/23/12/g36156539/shareholder-investigation-halper-sadeh-llc-investigates-cere-rovr-six-bbai,2023-12-08 17:00:30,"NEW YORK, Dec. 08, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Cerevel Therapeutics Holdings, Inc.",ABBV,0.131643,0.092035,Neutral
"Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod",https://www.zacks.com/stock/news/2195315/pharma-stock-roundup-abbv-to-buy-cere-jnjs-2024-view-lly-nvs-get-fda-nod,2023-12-08 13:12:00,AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.,ABBV,0.172097,0.071082,Neutral
3 High-Yielding Dividend Stocks That Are Near Their 52-Week Lows,https://www.fool.com/investing/2023/12/08/3-high-yielding-divdend-stocks-that-are-near-their/,2023-12-08 13:00:00,Buying these shares can provide you with some excellent recurring income while also diversifying your portfolio.,ABBV,0.393241,0.101032,Neutral
Transdermal Patches Market is Expected to Reach $8.0 Billion | MarketsandMarkets.,https://www.benzinga.com/pressreleases/23/12/g36151396/transdermal-patches-market-is-expected-to-reach-8-0-billion-marketsandmarkets,2023-12-08 12:30:00,"Chicago, Dec. 08, 2023 ( GLOBE NEWSWIRE ) -- Transdermal Patches market in terms of revenue was estimated to be worth $6.2 billion in 2023 and is poised to reach $8.0 billion by 2029, growing at a CAGR of 4.5% from 2023 to 2029 according to a latest report published by MarketsandMarkets™.",ABBV,0.031529,0.006513,Neutral
$19 Billion in a Week: AbbVie Makes Two Big Bets,https://www.wsj.com/health/pharma/19-billion-in-a-week-abbvie-makes-two-big-bets-0ae90404,2023-12-08 12:00:00,The drugmaker is doubling down on cancer and neurology as it seeks to replace falling revenue from its top sellers.,ABBV,0.742397,-0.513801,Bearish
"The Zacks Analyst Blog Highlights AbbVie, NIKE, BHP Group, CME Group and Block",https://www.zacks.com/stock/news/2195231/the-zacks-analyst-blog-highlights-abbvie-nike-bhp-group-cme-group-and-block,2023-12-08 10:54:00,"AbbVie, NIKE, BHP Group, CME Group and Block are included in this Analyst Blog.",ABBV,0.278222,0.012484,Neutral
AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next?,https://www.fool.com/investing/2023/12/08/abbvies-on-an-acquisition-binge-could-your-favorit/,2023-12-08 10:38:00,Here's what's attracting lucrative buyout offers from big pharmaceutical companies these days.,ABBV,0.253514,0.005928,Neutral
"Red Biotechnology Market to Reach $1,513.22 Billion, Globally, by 2030 at 10.7% CAGR: Coherent Market Insights",https://www.prnewswire.com/news-releases/red-biotechnology-market-to-reach-1-513-22-billion-globally-by-2030-at-10-7-cagr-coherent-market-insights-302009313.html,2023-12-08 07:14:00,"BURLINGAME, Calif., Dec. 8, 2023 /PRNewswire/ -- According to Coherent Market Insights, The global red biotechnology market was valued at US$ 742.80 Billion in 2023 and is forecast to reach a value of US$ 1,513.22 Billion by 2030 at a CAGR of 10.7% between 2023 and 2030.",ABBV,0.028833,0.001897,Neutral
"Top Stock Reports for AbbVie, NIKE & BHP",https://www.zacks.com/research-daily/2194633/top-stock-reports-for-abbvie-nike-bhp,2023-12-07 21:11:00,"Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), NIKE, Inc. (NKE) and BHP Group Ltd. (BHP).",ABBV,0.097457,-0.065935,Neutral
"AbbVie's New $9B Neuroscience Space Deal Might Attract FTC Scrutiny, Analyst Signals - AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36138732/abbvies-new-9b-neuroscience-space-deal-might-attract-ftc-scrutiny-analyst-signals,2023-12-07 20:19:19,"Wednesday, AbbVie Inc ABBV agreed to acquire Cerevel Therapeutics Holdings Inc CERE for a total equity value of approximately $8.7 billion, or $45 per share in cash, with the transaction anticipated to close in the middle of 2024.",ABBV,0.733479,0.619714,Bullish
Is AbbVie Making an $18.8 Billion Mistake?  ( Three Ways to Play It ) ,https://moneymorning.com/2023/12/07/is-abbvie-making-an-18-8-billion-mistake-three-ways-to-play-it/,2023-12-07 19:03:48,"AbbVie ( ABBV ) has been on a buying spree the past few weeks. On November 30, they announced an all-cash acquisition of the small-cap company commercializing antibody treatments for cancer, ImmunoGen ( IMGN ) , for $10.1 billion.",ABBV,0.290033,0.096527,Neutral
"AbbVie's $8.7 bln bet on Cerevel is risky but smart, analysts say",https://www.reuters.com/business/healthcare-pharmaceuticals/abbvies-87-bln-bet-cerevel-is-risky-smart-analysts-say-2023-12-07/,2023-12-07 18:34:00,"A sign stands outside a Abbvie facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File Photo Acquire Licensing Rights",ABBV,0.451494,0.17662,Somewhat-Bullish
Woodside in talks with Santos to form $52 billion Australian gas giant,https://www.business-standard.com/world-news/woodside-in-talks-with-santos-to-form-52-billion-australian-gas-giant-123120701426_1.html,2023-12-07 17:28:54,"Woodside Energy Group Ltd. is in preliminary talks with Santos on a potential merger, opening the door for the creation of an Australian gas export powerhouse amid a global wave of multi-billion dollar energy deals.",ABBV,0.272788,0.140461,Neutral
Why Cerevel Therapeutics Stock Is Higher - Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) ,https://www.benzinga.com/general/biotech/23/12/36138161/why-cerevel-therapeutics-stock-is-higher,2023-12-07 17:05:44,"Cerevel Therapeutics Holdings, Inc. CERE shares are trading higher Thursday after AbbVie, Inc. ABBV announced it will acquire the company for a total equity value of approximately $8.7 billion. AbbVie announced that it will acquire Cerevel Therapeutics after the market close on Wednesday.",ABBV,0.716023,0.384909,Bullish
The tech billionaires trying to hack longevity and live forever,https://www.businessinsider.com/richest-wealthiest-entrepreneurs-ceo-billionaires-tech-searching-hacking-longevity,2023-12-07 16:18:00,"Tech billionaires trying to hack longevity, live forever - Business Insider ...",ABBV,0.020544,0.025693,Neutral
"Verint Reports Strong Earnings, Joins Semtech, Alphabet And Other Big Stocks Moving Higher On Thursday - Altimmune  ( NASDAQ:ALT ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/news/23/12/36135689/verint-reports-strong-earnings-joins-semtech-alphabet-and-other-big-stocks-moving-higher-on-thursday,2023-12-07 15:17:42,"U.S. stocks traded mostly higher, with the Nasdaq Composite gaining more than 100 points on Thursday. Shares of Verint Systems Inc. VRNT rose sharply during Thursday's session after the company reported better-than-expected third-quarter financial results and issued guidance.",ABBV,0.177802,0.147497,Neutral
Abbvie to focus on smaller deals after Cerevel and ImmunoGen buyout,https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-focus-smaller-deals-after-cerevel-immunogen-buyout-2023-12-07/,2023-12-07 14:51:00,Dec 7 ( Reuters ) - U.S. drugmaker Abbvie ( ABBV.N ) said on Thursday it does not expect any transactions similar to its $8.7 billion buyout of Cerevel Therapeutics ( CERE.O ) in the foreseeable future and would instead focus on smaller deals to support its growth.,ABBV,0.495015,0.370832,Bullish
U.S. poised to approve first gene-editing treatment in breakthrough for sickle cell patients,https://www.cnbc.com/2023/12/07/crispr-gene-editing-treatment-us-approval.html,2023-12-07 14:10:12,The U.S. Food and Drug Administration is expected to approve exa-cel for sickle cell disease in what would become the first marketed medicine to use CRISPR.,ABBV,0.03448,0.0,Neutral
"Why Cerevel Therapeutics Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Altisource Asset Mgmt  ( AMEX:AAMC ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/news/23/12/36131560/why-cerevel-therapeutics-shares-are-trading-higher-by-around-15-here-are-20-stocks-moving-premarket,2023-12-07 12:59:24,"Shares of Cerevel Therapeutics Holdings, Inc. CERE jumped in pre-market trading after AbbVie Inc. ABBV announced it will acquire the company for a total equity value of approximately $8.7 billion.",ABBV,0.192183,0.196425,Somewhat-Bullish
"There's a new dynamic heading into payrolls report, Goldman trading expert says",https://www.marketwatch.com/story/theres-a-new-market-dynamic-heading-into-payrolls-report-goldman-trading-expert-says-1f3798f2,2023-12-07 11:41:00,"John Flood, a managing director at Goldman Sachs who works in its trading business, says there is a ""new dynamic"" in that the market will dislike extreme jobs data changes in either direction.",ABBV,0.113597,0.0,Neutral
Is AbbVie Stock a Buy Now?,https://www.fool.com/investing/2023/12/07/is-abbvie-stock-a-buy-now/,2023-12-07 11:05:00,AbbVie's business could soon become more diversified.,ABBV,0.71032,0.315787,Somewhat-Bullish
Which Stock Is More Likely to Help You Retire as a Millionaire: AbbVie or Eli Lilly?,https://www.fool.com/investing/2023/12/07/which-stock-is-more-likely-to-help-you-retire-as-a/,2023-12-07 10:50:00,There's no guarantee that either of these big pharma stocks can help you retire as a millionaire. But one has a clear edge.,ABBV,0.47574,0.513515,Bullish
AbbVie  ( ABBV )  to Acquire Cerevel Therapeutics  ( CERE )  for $8.7B,https://www.zacks.com/stock/news/2194568/abbvie-abbv-to-acquire-cerevel-therapeutics-cere-for-87b,2023-12-07 10:38:00,AbbVie (ABBV) offers to buy Cerevel Therapeutics (CERE) for $8.7 billion. The acquisition will strengthen AbbVie's neuroscience pipeline.,ABBV,0.616089,0.235896,Somewhat-Bullish
Looking for Dividend Growth in the New Year? 3 Magnificent Stocks to Buy Now.,https://www.fool.com/investing/2023/12/07/for-dividend-growth-3-stocks-to-buy/,2023-12-07 10:00:00,These particular players look cheap right now.,ABBV,0.353418,0.334422,Somewhat-Bullish
Is AbbVie Making an $18.8 Billion Mistake?  ( Three Ways to Play It ) ,https://moneymorning.com/2023/12/07/is-abbvie-making-an-18-8-billion-mistake-three-ways-to-play-it/,2023-12-07 08:00:00,"AbbVie ( ABBV ) has been on a buying spree the past few weeks. On November 30, they announced an all-cash acquisition of the small-cap company commercializing antibody treatments for cancer, ImmunoGen ( IMGN ) , for $10.1 billion.",ABBV,0.290033,0.096527,Neutral
"ALERT: The M&A Class Action Firm Continues Investigating the Merger - BVH, HOLI, CERE, WAVD",https://www.benzinga.com/pressreleases/23/12/g36392655/alert-the-m-a-class-action-firm-continues-investigating-the-merger-bvh-holi-cere-wavd,2023-12-26 23:28:01,"NEW YORK, Dec. 26, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered ...",ABBV,0.0699,0.121288,Neutral
"BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc.  ( Nasdaq - ICVX ) , Rain Oncology, Inc.  ( Nasdaq - RAIN ) , Consolidated Communications Holdings, Inc.  ( Nasdaq - CNSL ) , Cerevel Therapeutics Holdings, Inc.  ( Nasdaq - CERE ) ",https://www.benzinga.com/pressreleases/23/12/g36389726/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-icosavax-inc-,2023-12-26 19:27:44,"BALA CYNWYD, Pa., Dec. 26, 2023 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",ABBV,0.215574,0.237772,Somewhat-Bullish
Karuna  ( KRTX )  Up 48% on $14B Buyout Offer From Bristol Myers,https://www.zacks.com/stock/news/2202260/karuna-krtx-up-48-on-14b-buyout-offer-from-bristol-myers,2023-12-26 16:20:00,Bristol Myers (BMY) is set to acquire Karuna (KRTX) for $330 per share. This transaction is expected to close in the first half of 2024.,ABBV,0.284696,0.28914,Somewhat-Bullish
AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why,https://www.fool.com/investing/2023/12/26/abbvies-immunogen-acquisition-looks-brilliant/,2023-12-26 13:30:00,The acquisition fills an immediate need with some extras to boot.,ABBV,0.82082,0.413084,Bullish
"Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio",https://apnews.com/article/bristol-myers-squibb-acquires-karuna-therapeutics-bbd1c1e1b4c219fdb822c6755fc1dd79,2023-12-22 19:53:00,"NEW YORK ( AP ) - Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics, a biopharmaceutical company that has developed a new antipsychotic, in a $14 billion deal. Bristol Myers Squibb and Karuna announced their merger agreement on Friday.",ABBV,0.099066,-0.045472,Neutral
Market Whales and Their Recent Bets on ABBV Options - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/23/12/36365790/market-whales-and-their-recent-bets-on-abbv-options,2023-12-22 16:47:29,"Investors with a lot of money to spend have taken a bearish stance on AbbVie ABBV. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",ABBV,0.729947,0.371324,Bullish
Bristol Myers  ( BMY )  to Buy Karuna Therapeutics for $14B,https://www.zacks.com/stock/news/2201667/bristol-myers-bmy-to-buy-karuna-therapeutics-for-14b,2023-12-22 16:13:00,"Bristol Myers (BMY) announces a second acquisition in two months. It is set to buy Karuna Therapeutics, Inc. (KRTX) for $14 billion to strengthen its neuroscience portfolio.",ABBV,0.131643,-0.014174,Neutral
"Pharma Stock Roundup: FDA Nod to AZN's Eplontersen, CRL to MRK's Cough Candidate",https://www.zacks.com/stock/news/2201507/pharma-stock-roundup-fda-nod-to-azns-eplontersen-crl-to-mrks-cough-candidate,2023-12-22 14:21:00,"FDA approves AstraZeneca (AZN) and Ionis' (IONS) Wainua (eplontersen) for ATTRv-PN and gives CRL to Merck's chronic cough candidate, gefapixant.",ABBV,0.04303,-0.122577,Neutral
Karuna Therapeutics' stock hits record territory after Bristol Myers' $14 billion buyout deal,https://www.marketwatch.com/story/karuna-therapeutics-stock-rockets-into-record-territory-after-report-bristol-myers-14-billion-buyout-agreement-a64768b1,2023-12-22 14:20:00,"Karuna Therapeutics stock jumped 48% into record territory early Friday, after the biopharmaceutical company announced a $14 billion agreement to be bought by Bristol Myers Squibb.",ABBV,0.266828,0.0,Neutral
Bristol Myers to buy Karuna Therapeutics for $14B,https://www.foxbusiness.com/markets/bristol-myers-buy-karuna-therapeutics-14-billion,2023-12-22 13:35:00,"Under the terms, Bristol would pay $330 a share in cash for Karuna and its experimental schizophrenia drug now up for U.S. government approval. Bristol expects the deal, which includes $1.3 billion in cash that Karuna has on hand, would close in the first half of next year.",ABBV,0.064104,0.100418,Neutral
AbbVie  ( ABBV )  Gains But Lags Market: What You Should Know,https://www.zacks.com/stock/news/2201253/abbvie-abbv-gains-but-lags-market-what-you-should-know,2023-12-21 22:45:19,"The latest trading day saw AbbVie (ABBV) settling at $152.59, representing a +0.59% change from its previous close.",ABBV,0.537213,0.278346,Somewhat-Bullish
$100 Invested In This Stock 10 Years Ago Would Be Worth $300 Today - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/news/23/12/36351732/100-invested-in-this-stock-10-years-ago-would-be-worth-300-today,2023-12-21 20:30:22,"AbbVie ABBV has outperformed the market over the past 10 years by 1.26% on an annualized basis producing an average annual return of 11.12%. Currently, AbbVie has a market capitalization of $268.50 billion.",ABBV,0.983605,0.387251,Bullish
Better Growth Stock: AbbVie vs. Abbott Laboratories,https://www.fool.com/investing/2023/12/21/better-growth-stock-unitedhealth-group-vs-abbvie/,2023-12-21 15:23:00,Do Humira's declining sales give Abbott Laboratories the edge as the better growth stock?,ABBV,0.541654,0.285246,Somewhat-Bullish
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024,https://www.zacks.com/stock/news/2201005/3-cancer-focused-biotechs-that-appear-promising-bets-for-2024,2023-12-21 14:23:00,"With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024.",ABBV,0.047371,-0.008002,Neutral
Medical Aesthetics Market is Expected to Reach $25.9 Billion | MarketsandMarkets.,https://www.benzinga.com/pressreleases/23/12/g36341317/medical-aesthetics-market-is-expected-to-reach-25-9-billion-marketsandmarkets,2023-12-21 12:30:00,"Chicago, Dec. 21, 2023 ( GLOBE NEWSWIRE ) -- Medical Aesthetics market in terms of revenue was estimated to be worth $15.4 Billion in 2023 and is poised to reach $25.9 billion by 2028, growing at a CAGR of 11.0% from 2023 to 2028 according to a latest report published by MarketsandMarkets™.",ABBV,0.083687,0.042882,Neutral
Is Invesco Pharmaceuticals ETF  ( PJP )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2200881/is-invesco-pharmaceuticals-etf-pjp-a-strong-etf-right-now,2023-12-21 11:20:06,Smart Beta ETF report for ...,ABBV,0.116631,0.055779,Neutral
"How $200 Per Month Can Create $100,000 in Yearly Dividend Income",https://www.fool.com/investing/2023/12/20/how-200-per-month-can-create-100000-in-yearly-divi/,2023-12-20 15:40:00,This plan could help solve America's retirement crisis.,ABBV,0.069294,0.031085,Neutral
"Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma",https://www.cnbc.com/2023/12/20/weight-loss-drugs-covid-downturn-pharma-had-a-year-full-of-firsts.html,2023-12-20 12:00:01,"Wall Street turned its focus to a handful of newer treatments in different disease areas in 2023, including weight loss medications and a new Alzheimer's drug.",ABBV,0.027011,0.172126,Somewhat-Bullish
PIRAMAL PHARMA SOLUTIONS COMMEMORATES OPENING OF ITS ADC MANUFACTURING EXPANSION IN ... - Canada NewsWire,https://www.newswire.ca/news-releases/piramal-pharma-solutions-commemorates-opening-of-its-adc-manufacturing-expansion-in-grangemouth-scotland-810844949.html,2023-12-18 21:10:00,PIRAMAL PHARMA SOLUTIONS COMMEMORATES OPENING OF ITS ADC MANUFACTURING EXPANSION IN ... Canada ...,ABBV,0.068404,-0.016153,Neutral
Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease,https://www.globenewswire.com/news-release/2023/12/18/2798131/0/en/Sight-Sciences-Announces-the-Publication-of-Successful-Results-of-the-SAHARA-Randomized-Controlled-Clinical-Trial-Comparing-TearCare-to-Restasis-for-the-Treatment-of-Dry-Eye-Diseas.html,2023-12-18 21:05:00,Interventional eyelid procedures enabled by TearCare technology successfully delivered clinically and statistically significant improvements in every sign and symptom measured at every time point through six months Interventional eyelid procedures enabled by TearCare technology successfully ...,ABBV,0.025929,0.0,Neutral
"BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alteryx, Inc.  ( NYSE - AYX ) , Rain Oncology, Inc.  ( Nasdaq - RAIN ) , Consolidated Communications Holdings, Inc.  ( Nasdaq - CNSL ) , Cerevel Therapeutics Holdings, Inc.  ( Nasdaq - CERE ) ",https://www.benzinga.com/pressreleases/23/12/g36287831/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-alteryx-inc-n,2023-12-18 17:36:43,"BALA CYNWYD, Pa., Dec. 18, 2023 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",ABBV,0.222838,0.243786,Somewhat-Bullish
"Schizophrenia Future Outlook 2024-2028: Forecasted Market Rate, Growth Factors, And Leading Segments As Per The Business Research Company's Schizophrenia Global Market Report 2024",https://www.benzinga.com/pressreleases/23/12/g36286286/schizophrenia-future-outlook-2024-2028-forecasted-market-rate-growth-factors-and-leading-segments-,2023-12-18 16:30:00,"LONDON, Dec. 18, 2023 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Schizophrenia Global Market Report 2024, the schizophrenia market has exhibited robust growth, surging from $5.48 billion in 2023 to $5.82 billion in 2024, reflecting a notable compound annual growth rate ( CAGR ) ...",ABBV,0.059488,0.153093,Somewhat-Bullish
These Are the 3 Hottest Biopharma Trends of 2024. Should You Invest?,https://www.fool.com/investing/2023/12/18/these-are-the-3-hottest-biopharma-trends-of-2024/,2023-12-18 14:15:00,2024 is going to be a sizzler in the biopharma sector.,ABBV,0.049424,0.043511,Neutral
3 Biotech Stocks Most Wall Street Analysts Are Bullish About,https://www.zacks.com/stock/news/2199324/3-biotech-stocks-most-wall-street-analysts-are-bullish-about,2023-12-18 14:01:00,"Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.",ABBV,0.075043,0.061531,Neutral
"Muckle Wells Syndrome Market to Reach US$ 335.9 Million by 2030, Rising at a CAGR of 12.6% | Report by CoherentMI",https://www.prnewswire.com/news-releases/muckle-wells-syndrome-market-to-reach-us-335-9-million-by-2030--rising-at-a-cagr-of-12-6--report-by-coherentmi-302017763.html,2023-12-18 11:54:00,"BURLINGAME, Calif., Dec. 18, 2023 /PRNewswire/ -- CoherentMI published a report, titled, Muckle Wells Syndrome Market is estimated to value at US$ 146.4 Million in the year 2023 and is anticipated to reach US$ 335.9 Million by 2030, at a CAGR of 12.6% during forecast period 2023-2030.",ABBV,0.030331,0.083206,Neutral
Better Income Stock: AT&T or AbbVie?,https://www.fool.com/investing/2023/12/17/better-income-stock-att-or-abbvie/,2023-12-17 20:30:00,These two blue chips are highly prized for their top-shelf dividend programs.,ABBV,0.437261,0.742529,Bullish
"Pharmaceutical Contract Manufacturing Market to grow by USD 58 billion from 2022 to 2027, North America to account ... - PR Newswire",https://www.prnewswire.com/news-releases/pharmaceutical-contract-manufacturing-market-to-grow-by-usd-58-billion-from-2022-to-2027-north-america-to-account-for-41-of-market-growth---technavio-302026185.html,2024-01-05 22:35:00,"Pharmaceutical Contract Manufacturing Market to grow by USD 58 billion from 2022 to 2027, North America to account ... PR ...",ABBV,0.06697,0.0,Neutral
"Active Pharmaceutical Ingredients Market is to grow by USD 86.47 billion from 2023 to 2028, Asia to account for 52% of ... - PR Newswire",https://www.prnewswire.com/news-releases/active-pharmaceutical-ingredients-market-is-to-grow-by-usd-86-47-billion-from-2023-to-2028--asia-to-account-for-52-of-market-growth---technavio-302026179.html,2024-01-05 22:01:00,"Active Pharmaceutical Ingredients Market is to grow by USD 86.47 billion from 2023 to 2028, Asia to account for 52% of ... PR ...",ABBV,0.132004,0.055405,Neutral
Big Players' Recent Trades in ABBV Options - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/24/01/36515720/big-players-recent-trades-in-abbv-options,2024-01-05 19:15:57,"Deep-pocketed investors have adopted a bullish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",ABBV,0.702807,0.401106,Bullish
Will AbbVie  ( ABBV )  Beat Estimates Again in Its Next Earnings Report?,https://www.zacks.com/stock/news/2206449/will-abbvie-abbv-beat-estimates-again-in-its-next-earnings-report,2024-01-05 17:10:11,AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,ABBV,0.420083,0.441597,Bullish
"Pharma Stock Roundup: LLY's New Digital Pharmacy, NVO & ABBV's Fresh R&D Deals",https://www.zacks.com/stock/news/2206363/pharma-stock-roundup-llys-new-digital-pharmacy-nvo-abbvs-fresh-rd-deals,2024-01-05 15:25:00,Eli Lilly (LLY) launches a new direct-to-consumer website to provide easy access to its medicines. Novo Nordisk (NVO) announces two research collaborations to develop novel treatments for cardiometabolic diseases.,ABBV,0.295867,0.240803,Somewhat-Bullish
It's Been An Abysmal Two Years. But Biotech Is Looking Up.,https://www.investors.com/news/technology/biotech-stocks-pharma-heat-up-in-2024-as-buyouts-obesity-ai-drive-excitement/,2024-01-05 14:00:00,"Biotech Stocks, Pharma Heat Up In 2024 As Buyouts, Obesity And AI Drive Excitement Investor's Business Daily ...",ABBV,0.035679,0.017905,Neutral
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WAVD, CSTR, CERE - CapStar Finl Hldgs  ( NASDAQ:CSTR ) , Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) ",https://www.benzinga.com/pressreleases/24/01/g36508096/shareholder-investigation-halper-sadeh-llc-investigates-wavd-cstr-cere,2024-01-05 12:44:04,"NEW YORK, Jan. 05, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: WaveDancer, Inc.",ABBV,0.144275,0.096645,Neutral
"BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc.  ( Nasdaq - ICVX ) , Rain Oncology, Inc.  ( Nasdaq - RAIN ) , Consolidated Communications Holdings, Inc.  ( Nasdaq - CNSL ) , Cerevel Therapeutics Holdings, Inc.  ( Nasdaq - CERE ) ",https://www.benzinga.com/pressreleases/24/01/g36493927/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-icosavax-inc-,2024-01-04 16:22:28,"BALA CYNWYD, Pa., Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",ABBV,0.215574,0.237772,Somewhat-Bullish
PRISM MarketView Launches Emerging Women's Health Index,https://www.benzinga.com/pressreleases/24/01/g36493710/prism-marketview-launches-emerging-womens-health-index,2024-01-04 16:14:57,"Global women's health market projected to reach $67.07 billion by 2031 Private equity investment in women's health exceeded $3 billion in 2022 NEW YORK, Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- PRISM MarketView, a leading provider of unbiased market insight and company news, today announces the ...",ABBV,0.062761,0.029029,Neutral
Jnana Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference,https://www.benzinga.com/pressreleases/24/01/g36488133/jnana-therapeutics-to-present-at-42nd-annual-j-p-morgan-healthcare-conference,2024-01-04 13:00:45,"BOSTON, Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, today announced that Joanne Kotz, Ph.D., Co-founder and Chief Executive Officer, ...",ABBV,0.154455,0.200545,Somewhat-Bullish
Antibody Therapeutics Market is Expected to Reach $479.0 Billion | MarketsandMarkets.,https://www.benzinga.com/pressreleases/24/01/g36487416/antibody-therapeutics-market-is-expected-to-reach-479-0-billion-marketsandmarkets,2024-01-04 12:30:00,"Chicago, Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Antibody Therapeutics market in terms of revenue was estimated to be worth $247.3 Billion in 2023 and is poised to reach $479.0 billion by 2028, growing at a CAGR of 14.1% from 2023 to 2028 according to a latest report published by MarketsandMarkets™.",ABBV,0.158,0.04959,Neutral
"Reverse Goldilocks - why this bank is souring on stocks, for now",https://www.marketwatch.com/story/reverse-goldilocks-why-this-bank-is-souring-on-stocks-for-now-a109f4ba,2024-01-04 11:47:00,This bank is raising dry powder as they see a tough period for stocks as well as riskier corporate bonds ...,ABBV,0.09347,0.093576,Neutral
CVS Partially Dropping Top-Selling Drug Humira In Favor Of Cheaper Biosimilars,https://www.forbes.com/sites/antoniopequenoiv/2024/01/03/cvs-partially-dropping-top-selling-drug-humira-in-favor-of-cheaper-biosimilars/,2024-01-04 00:14:09,"CVS Caremark, the pharmaceutical subsidiary of CVS Health, announced Wednesday it will replace AbbVie's Humira from its list of covered drugs with cheaper alternatives for some customers-a move that's sure to take a chunk out of eye-popping Humira sales that have generated hundreds of billions ...",ABBV,0.312158,0.162953,Somewhat-Bullish
AbbVie  ( ABBV )  Rises As Market Takes a Dip: Key Facts,https://www.zacks.com/stock/news/2205271/abbvie-abbv-rises-as-market-takes-a-dip-key-facts,2024-01-03 22:45:20,"AbbVie (ABBV) closed the most recent trading day at $160.46, moving +0.4% from the previous trading session.",ABBV,0.584328,0.212656,Somewhat-Bullish
CVS Caremark accelerates biosimilars adoption through formulary changes,https://www.prnewswire.com/news-releases/cvs-caremark-accelerates-biosimilars-adoption-through-formulary-changes-302025679.html,2024-01-03 22:00:00,"WOONSOCKET, R.I., Jan. 3, 2024 /PRNewswire/ -- Today CVS Caremark®, a CVS Health® ( NYSE: CVS ) company, announced the continuation of its efforts to expand adoption of biosimilars. Effective April 1, 2024, Humira® will be removed from our major national commercial template formularies and Humira ...",ABBV,0.064276,0.149196,Neutral
Pharmaceutical Drug Delivery Market Set For Robust Growth: Market Size To Reach $2337 Billion By 2028 As Per The Business Research Company's Pharmaceutical Drug Delivery Global Market Report 2024,https://www.benzinga.com/pressreleases/24/01/g36473207/pharmaceutical-drug-delivery-market-set-for-robust-growth-market-size-to-reach-2337-billion-by-202,2024-01-03 16:30:00,"LONDON, Jan. 03, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's pharmaceutical drug delivery global market report 2024, the global pharmaceutical drug delivery market has exhibited robust growth, expanding from $1711.47 billion in 2023 to an estimated $1816.05 billion in 2024, ...",ABBV,0.04882,0.091119,Neutral
1 Concerning Trend for AbbVie Investors to Keep an Eye On,https://www.fool.com/investing/2024/01/03/1-concerning-trend-for-abbvie-investors-to-keep-an/,2024-01-03 13:30:00,Is AbbVie a good stock for dividend investors to own?,ABBV,0.678673,0.139579,Neutral
2 Biotech Stocks You Can Buy and Hold for the Next Decade,https://www.fool.com/investing/2024/01/02/2-biotech-stocks-you-can-buy-and-hold-for-the-next/,2024-01-02 13:45:00,The types of innovative drugs these companies develop are always in high demand.,ABBV,0.474763,0.424548,Bullish
"CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants USA - English - PR Newswire",https://www.prnewswire.com/news-releases/collplant-biotechnologies-begins-preclinical-trial-with-commercial-size-regenerative-breast-implants-302024360.html,2024-01-02 12:00:00,"CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants USA - English PR ...",ABBV,0.110973,0.091758,Neutral
3 Top Dividend Growth Stocks to Buy in 2024,https://www.fool.com/investing/2024/01/02/3-top-dividend-growth-stocks-to-buy-in-2024/,2024-01-02 10:50:00,Income investors should love these great stocks.,ABBV,0.520773,0.447609,Bullish
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMGN, HA, CERE, HOLI - Hawaiian Holdings  ( NASDAQ:HA ) , Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) ",https://www.benzinga.com/pressreleases/24/01/g36443672/shareholder-investigation-halper-sadeh-llc-investigates-imgn-ha-cere-holi,2024-01-01 14:19:56,"NEW YORK, Jan. 01, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: ImmunoGen, Inc.",ABBV,0.27432,0.154927,Somewhat-Bullish
Here's How Much a $1000 Investment in AbbVie Made 10 Years Ago Would Be Worth Today,https://www.zacks.com/stock/news/2204045/heres-how-much-a-1000-investment-in-abbvie-made-10-years-ago-would-be-worth-today,2024-01-01 13:30:04,"Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.",ABBV,0.693171,0.288933,Somewhat-Bullish
Should First Trust Morningstar Dividend Leaders ETF  ( FDL )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2204026/should-first-trust-morningstar-dividend-leaders-etf-fdl-be-on-your-investing-radar,2024-01-01 11:20:06,Style Box ETF report for ...,ABBV,0.122269,0.068311,Neutral
"3 Top ETFs I'm Planning to Buy Hand Over Fist in 2024, Despite All the Cheap Stocks on My Radar",https://www.fool.com/investing/2024/01/01/3-top-etfs-im-planning-to-buy-hand-over-fist-in-20/,2024-01-01 11:17:00,I'm adding some ETFs to my retirement portfolio in 2024. here are the three I'm starting with.,ABBV,0.114682,0.006707,Neutral
"Got $1,500? You Can Confidently Add These 3 Stocks to Your Portfolio",https://www.fool.com/investing/2023/12/31/got-1500-you-can-confidently-add-these-3-stocks-to/,2023-12-31 14:15:00,Getting going on investing is a terrific way to start 2024.,ABBV,0.325515,0.214105,Somewhat-Bullish
4 Incredible Dividend Stocks Yielding 4%-Plus to Buy in 2024,https://www.fool.com/investing/2023/12/31/4-incredible-dividend-stocks-yielding-4-plus-to-bu/,2023-12-31 10:28:00,These companies pay attractive dividends that should continue rising.,ABBV,0.242406,0.318619,Somewhat-Bullish
Peering Into AbbVie's Recent Short Interest - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/short-sellers/23/12/36433135/peering-into-abbvies-recent-short-interest,2023-12-29 20:00:13,"AbbVie's ABBV short percent of float has risen 23.81% since its last report. The company recently reported that it has 13.69 million shares sold short, which is 0.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.01 days to cover their ...",ABBV,0.224903,0.158881,Somewhat-Bullish
Stocks are going out with a bang: The market is on pace for a record. The Nasdaq is having its best year since '03 | Business,https://www.cnn.com/2023/12/29/investing/stock-market-record-winners-and-losers-2023/index.html,2023-12-29 14:35:00,Stocks are going out with a bang: The market is on pace for a record. The Nasdaq is having its best year since ...,ABBV,0.04823,-0.148842,Neutral
Stocks are sliding on final trading day of 2023. But the Nasdaq is still on pace for its best year since '03 | Business,https://www.cnn.com/2023/12/29/investing/stock-market-record-winners-and-losers-2023,2023-12-29 14:35:00,Stocks are going out with a bang: The market is on pace for a record. The Nasdaq is having its best year since ...,ABBV,0.045396,-0.148123,Neutral
Here is What to Know Beyond Why AbbVie Inc.  ( ABBV )  is a Trending Stock,https://www.zacks.com/stock/news/2203608/here-is-what-to-know-beyond-why-abbvie-inc-abbv-is-a-trending-stock,2023-12-29 14:00:10,"AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",ABBV,0.487546,0.146909,Neutral
"Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 - Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/23/12/36394374/upward-trajectory-for-biotechpharma-m-a-sector-trends-towards-pre-pandemic-levels-forecasts-posit,2023-12-29 12:04:52,"According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023. Deal volume fell 9% from 242 deals in Q2 2023 to 221 M&A deals in Q3 2023. PricewaterhouseCoopers wrote in its Pharmaceutical and Life Sciences: ...",ABBV,0.316846,0.316063,Somewhat-Bullish
Biden administration's Medicare drug price negotiations will face major tests in 2024,https://www.cnbc.com/2023/12/28/medicare-drug-price-negotiations-whats-ahead-in-2024.html,2023-12-28 12:00:01,"Next year could set the precedent for the Inflation Reduction Act's controversial talks, which could affect dozens of medications by the end of the decade.",ABBV,0.029399,0.173879,Somewhat-Bullish
"Here's a 'solid contrarian idea' for 2024, according to BTIG's Krinsky",https://www.marketwatch.com/story/heres-a-solid-contrarian-idea-for-2024-according-to-btigs-krinsky-32a86261,2023-12-28 11:34:00,Investors should consider this list of healthcare stocks for ...,ABBV,0.081414,0.043737,Neutral
"STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - CERE, WAVD, ICVX, EAR",https://www.prnewswire.com/news-releases/stockholder-alert-the-ma-class-action-firm-continues-investigating-the-merger--cere-wavd-icvx-ear-302023022.html,2023-12-28 01:26:00,"NEW YORK, Dec. 27, 2023 /PRNewswire/ -- , founder and managing partner of the class action firm ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, ...",ABBV,0.077593,0.127631,Neutral
AbbVie  ( ABBV )  Laps the Stock Market: Here's Why,https://www.zacks.com/stock/news/2202847/abbvie-abbv-laps-the-stock-market-heres-why,2023-12-27 22:45:21,"AbbVie (ABBV) closed at $154.88 in the latest trading session, marking a +0.17% move from the prior day.",ABBV,0.587278,0.260802,Somewhat-Bullish
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CERE, HOLI, ICVX, CVLY - Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) , Codorus Valley Bancorp  ( NASDAQ:CVLY ) ",https://www.benzinga.com/pressreleases/23/12/g36403236/shareholder-investigation-halper-sadeh-llc-investigates-cere-holi-icvx-cvly,2023-12-27 19:51:12,"NEW YORK, Dec. 27, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Cerevel Therapeutics Holdings, Inc.",ABBV,0.116914,0.087269,Neutral
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SRC, EAR, BVH, IMGN - Bluegreen Vacations  ( NYSE:BVH ) , Eargo  ( NASDAQ:EAR ) ",https://www.benzinga.com/pressreleases/23/12/g36403146/shareholder-investigation-halper-sadeh-llc-investigates-src-ear-bvh-imgn,2023-12-27 19:42:05,"NEW YORK, Dec. 27, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Spirit Realty Capital, Inc.",ABBV,0.127456,0.090608,Neutral
Severe Acute Respiratory-Syndrome Treatment Market Set for Unprecedented Growth: Forecast Predicts $6.12 Billion by 2028 As Per The Business Research Company's Severe Acute Respiratory-Syndrome Treatment Global Market Report 2024,https://www.benzinga.com/pressreleases/23/12/g36400046/severe-acute-respiratory-syndrome-treatment-market-set-for-unprecedented-growth-forecast-predicts-,2023-12-27 16:30:00,"LONDON, Dec. 27, 2023 ( GLOBE NEWSWIRE ) -- The Business Research Company's severe acute respiratory-syndrome treatment global market report 2024, the Severe Acute Respiratory-Syndrome ( SARS ) treatment market has witnessed remarkable growth in recent years, with the market size expanding from ...",ABBV,0.053749,0.145,Neutral
AstraZeneca  ( AZN )  Set to Acquire Gracell for $1.2 Billion,https://www.zacks.com/stock/news/2202697/astrazeneca-azn-set-to-acquire-gracell-for-12-billion,2023-12-27 15:40:00,"AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Gracell, for a total deal value of up to $1.2 billion.",ABBV,0.162255,0.007352,Neutral
"SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - IMGN, CVLY, EAR",https://markets.businessinsider.com/news/stocks/shareholder-alert-the-m-a-class-action-firm-continues-investigating-the-merger---imgn-cvly-ear-1032928359,2023-12-27 15:15:00,"NEW YORK, NY / ACCESSWIRE / December 27, 2023 / Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and ...",ABBV,0.082677,0.121561,Neutral
THE SKIN OF COLOR SOCIETY  ( SOCS )  REPORTS A BANNER YEAR OF PROGRESS TOWARD GREATER DIVERSITY & INCLUSION IN DERMATOLOGY AND HEALTH EQUITY FOR PATIENTS OF COLOR,https://markets.businessinsider.com/news/stocks/the-skin-of-color-society-socs-reports-a-banner-year-of-progress-toward-greater-diversity-inclusion-in-dermatology-and-health-equity-for-patients-of-color-1032928334,2023-12-27 15:10:00,THE SKIN OF COLOR SOCIETY (SOCS) REPORTS A BANNER YEAR OF PROGRESS TOWARD GREATER DIVERSITY & INCLUSION IN DERMATOLOGY AND HEALTH EQUITY FOR PATIENTS OF COLOR ...,ABBV,0.052226,0.239708,Somewhat-Bullish
"Analysts flag Fusion Pharma as takeover candidate, as stock climbs",https://www.marketwatch.com/story/fusion-pharma-climbs-as-analyst-flags-radiopharmaceutical-company-as-potential-merger-target-e50a6cfa,2023-12-27 14:28:00,Targeted-oncology specialist draws upgrade at Raymond James after big premium paid is for Rayze Bio.,ABBV,0.272788,0.042803,Neutral
1 Concerning Number That Could Threaten to Derail the S&P 500's Rally in 2024,https://www.fool.com/investing/2023/12/27/1-concerning-number-that-could-threaten-to-derail/,2023-12-27 13:00:00,"Even if interest rates fall next year, the market could still struggle.",ABBV,0.059785,0.127155,Neutral
"Three Stocks to Watch: $350 or $150 First?, Biotech's Buying Bonanza, and the $1 Billion ""I'm Sorry"" - Money Morning",https://moneymorning.com/2023/12/27/three-stocks-to-watch-350-or-150-first-biotechs-buying-bonanza-and-the-1-billion-im-sorry/,2023-12-27 12:56:21,"Three Stocks to Watch: $350 or $150 First?, Biotech's Buying Bonanza, and the $1 Billion ""I'm Sorry"" Money Morning ...",ABBV,0.092569,0.109511,Neutral
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EAR, IMGN, CVLY",https://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llc-investigates-ear-imgn-cvly-302022606.html,2023-12-27 03:55:00,"NEW YORK, Dec. 26, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:",ABBV,0.159569,0.110674,Neutral
"SHAREHOLDER ALERT: Juan Monteverde Encourages the Shareholders of ICVX, EAR, CVLY, IMGN to Take Action",https://www.benzinga.com/pressreleases/23/12/g36392800/shareholder-alert-juan-monteverde-encourages-the-shareholders-of-icvx-ear-cvly-imgn-to-take-action,2023-12-27 00:19:40,"NEW YORK, Dec. 26, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered ...",ABBV,0.069294,0.127303,Neutral
Here's the Average Amount Investors Have in Stocks by Age 40 and Which Stocks I Recommend Today,https://www.fool.com/investing/2024/01/14/heres-the-average-amount-investors-have-in-stocks/,2024-01-14 14:10:00,Curious as to how your portfolio stacks up? Take a look.,ABBV,0.29792,0.150166,Somewhat-Bullish
3 High-Yield Stocks to Buy for 2024 and Beyond,https://www.fool.com/investing/2024/01/14/3-high-yield-stocks-to-buy-for-2024-and-beyond/,2024-01-14 12:14:00,These investments will generate lots of income for their investors in the coming years.,ABBV,0.044222,0.158731,Somewhat-Bullish
AbbVie's Options Frenzy: What You Need to Know - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/markets/options/24/01/36615734/abbvies-options-frenzy-what-you-need-to-know,2024-01-12 18:45:40,"High-rolling investors have positioned themselves bearish on AbbVie ABBV, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data.",ABBV,0.769861,0.340669,Somewhat-Bullish
"Kuehn Law Encourages PXD, IMGN, HA and ICVX Investors to Contact Law Firm",https://www.prnewswire.com/news-releases/kuehn-law-encourages-pxd-imgn-ha-and-icvx-investors-to-contact-law-firm-302033722.html,2024-01-12 16:10:00,"NEW YORK, Jan. 12, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.",ABBV,0.136113,0.300223,Somewhat-Bullish
There's A Paradigm Shift In Immunology; And Big Pharma Is Paying Richly For It,https://www.investors.com/news/technology/biotech-stocks-forge-a-paradigm-shift-in-immunology-and-big-pharma-pays-handsomely-for-it/,2024-01-12 14:00:00,There's A Paradigm Shift In Immunology. And Big Pharma Is Paying Richly For It Investor's Business Daily ...,ABBV,0.023838,-0.146266,Neutral
"Pharma Stock Roundup: MRK to Buy Harpoon, JNJ to Acquire Ambrx Biopharma & More",https://www.zacks.com/stock/news/2209354/pharma-stock-roundup-mrk-to-buy-harpoon-jnj-to-acquire-ambrx-biopharma-more,2024-01-12 12:48:00,Merck (MRK) offers to acquire Harpoon for $680 million. J&J (JNJ) is set to acquire Ambrx Biopharma for approximately $2.0 billion ...,ABBV,0.220308,-0.052005,Neutral
"ConcertAI Highlights 2024 Partnerships, Strategy, Business Results, and AI Roadmap at 42nd Annual J.P. Morgan Healthcare Conference",https://www.benzinga.com/pressreleases/24/01/n36600691/concertai-highlights-2024-partnerships-strategy-business-results-and-ai-roadmap-at-42nd-annual-j-p,2024-01-11 20:00:00,"Introduced CARA™, the predictive and generative AI Platform powered by multi-modal Real-World Data, enabling precision oncology, accelerating clinical trials, increasing patient access, driving improved patient outcomes.",ABBV,0.080593,0.263908,Somewhat-Bullish
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings,https://www.zacks.com/stock/news/2208771/want-better-returns-dont-ignore-these-2-medical-stocks-set-to-beat-earnings,2024-01-11 13:50:06,Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.,ABBV,0.202366,0.282262,Somewhat-Bullish
2 Ultrareliable Dividend Stocks to Buy in 2024 and Hold for at Least a Decade,https://www.fool.com/investing/2024/01/11/2-ultra-reliable-dividend-stocks-to-buy-in-2024-an/,2024-01-11 10:39:00,Strong advantages over the competition could allow these businesses to keep raising their dividend payouts for at least another 10 years.,ABBV,0.308246,0.206293,Somewhat-Bullish
Investors Heavily Search AbbVie Inc.  ( ABBV ) : Here is What You Need to Know,https://www.zacks.com/stock/news/2207896/investors-heavily-search-abbvie-inc-abbv-here-is-what-you-need-to-know,2024-01-09 23:21:59,"AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",ABBV,0.491255,0.132664,Neutral
AbbVie  ( ABBV )  Ascends While Market Falls: Some Facts to Note,https://www.zacks.com/stock/news/2207785/abbvie-abbv-ascends-while-market-falls-some-facts-to-note,2024-01-09 22:45:18,"The latest trading day saw AbbVie (ABBV) settling at $162.31, representing a +0.55% change from its previous close.",ABBV,0.622414,0.225897,Somewhat-Bullish
"If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,300 Today - AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/news/24/01/36565408/if-you-invested-1000-in-this-stock-10-years-ago-you-would-have-3-300-today,2024-01-09 21:00:27,"AbbVie ABBV has outperformed the market over the past 10 years by 2.42% on an annualized basis producing an average annual return of 12.35%. Currently, AbbVie has a market capitalization of $286.32 billion.",ABBV,0.983605,0.387251,Bullish
Cytokinetics  ( CYTK )  Rises on Reports of Buyout by Novartis,https://www.zacks.com/stock/news/2207655/cytokinetics-cytk-rises-on-reports-of-buyout-by-novartis,2024-01-09 18:17:00,Cytokinetics (CYTK) shares gain on reports of acquisition by pharma giant Novartis.,ABBV,0.128822,-0.014005,Neutral
Biotech ETFs Stage Solid Comeback at the Start of 2024,https://www.zacks.com/stock/news/2207551/biotech-etfs-stage-solid-comeback-at-the-start-of-2024,2024-01-09 16:05:00,"The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.",ABBV,0.089129,0.058856,Neutral
3 Simple Tricks That Every Investor Should Use  ( but Most Don't ) ,https://www.fool.com/investing/2024/01/09/3-simple-tricks-that-every-investor-should-use-but/,2024-01-09 15:15:00,Having a few tricks up your sleeve can increase your returns over time.,ABBV,0.128363,0.032509,Neutral
"NEXGEL Subsidiary, CG Converting and Packaging, Begins 12,000 Square Foot Expansion of Texas Facility to Support the Expected Growth in Product Demand in 2024",https://www.globenewswire.com/news-release/2024/01/09/2806274/0/en/NEXGEL-Subsidiary-CG-Converting-and-Packaging-Begins-12-000-Square-Foot-Expansion-of-Texas-Facility-to-Support-the-Expected-Growth-in-Product-Demand-in-2024.html,2024-01-09 13:30:00,"LANGHORNE, Pa., Jan. 09, 2024 ( GLOBE NEWSWIRE ) -- NEXGEL, Inc. ( ""NEXGEL"" or the ""Company"" ) ( NASDAQ: NXGL ) , a leading provider of medical and over-the-counter ( OTC ) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced a ...",ABBV,0.07887,0.207811,Somewhat-Bullish
Merck  ( MRK )  to Strengthen Cancer Pipeline With Harpoon Buyout,https://www.zacks.com/stock/news/2207372/merck-mrk-to-strengthen-cancer-pipeline-with-harpoon-buyout,2024-01-09 12:34:00,"Merck's (MRK) Harpoon buyout is expected to strengthen its oncology pipeline by adding the latter's lead pipeline candidate, HPN328, a T cell engager being studied for SCLC and neuroendocrine tumors.",ABBV,0.059785,-0.145006,Neutral
AbbVie  ( ABBV )  Now Trades Above Golden Cross: Time to Buy?,https://www.zacks.com/stock/news/2207004/abbvie-abbv-now-trades-above-golden-cross-time-to-buy,2024-01-08 14:55:03,Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?,ABBV,0.495015,0.512846,Bullish
J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion,https://www.cnbc.com/2024/01/08/jj-to-acquire-ambrx-biopharma-a-cancer-drug-developer.html,2024-01-08 14:09:31,"The deal, which was announced on the first day of the annual JPMorgan Healthcare Conference, makes J&J the latest drugmaker to bet on ADCs.",ABBV,0.154455,0.0,Neutral
"Cramer Says This Major Healthcare Stock Is 'Ridiculously Cheap And Doing So Many Great Things' - Bitfarms  ( NASDAQ:BITF ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/trading-ideas/long-ideas/24/01/36528274/cramer-says-this-major-healthcare-stock-is-ridiculously-cheap-and-doing-so-many-great-th,2024-01-08 13:53:11,"On CNBC's ""Mad Money Lightning Round,"" Jim Cramer said he likes Realty Income O and recommends staying with it. ""It's a very steady story,"" he noted. When asked about ImmunoGen, Inc. IMGN, he said, ""That's AbbVie's ABBV property now, let's move on."" Cramer said he is not a buyer of Ramaco ...",ABBV,0.223866,0.206875,Somewhat-Bullish
"CollPlant's CEO to Present at the Octane Aesthetic Tech Forum Conference, in Newport Beach, California USA - English - PR Newswire",https://www.prnewswire.com/news-releases/collplants-ceo-to-present-at-the-octane-aesthetic-tech-forum-conference-in-newport-beach-california-302028441.html,2024-01-08 12:18:00,"CollPlant's CEO to Present at the Octane Aesthetic Tech Forum Conference, in Newport Beach, California USA - English PR ...",ABBV,0.124809,0.096674,Neutral
Is SPDR S&P Dividend ETF  ( SDY )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2206733/is-spdr-sp-dividend-etf-sdy-a-strong-etf-right-now,2024-01-08 11:20:07,Smart Beta ETF report for ...,ABBV,0.113597,0.056325,Neutral
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference - Molecular Partners  ( NASDAQ:MOLN ) ,https://www.benzinga.com/pressreleases/24/01/g36526484/molecular-partners-provides-updates-at-42nd-annual-j-p-morgan-healthcare-conference,2024-01-07 21:00:00,Tetra-specific T-cell engager MP0533 for patients with r/r AML and AML/MDS on track to deliver expanded clinical phase 1/2a data in H1 2024 Progress of Radio-DARPin Therapy ( RDT ) platform: Improved tumor to kidney uptake ratio enables expansion of RDT pipeline. first data on DLL3 as lead ...,ABBV,0.02689,0.0,Neutral
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2024/01/07/2805018/0/en/Molecular-Partners-Provides-Updates-at-42nd-Annual-J-P-Morgan-Healthcare-Conference.html,2024-01-07 21:00:00,"ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 07, 2024 ( GLOBE NEWSWIRE ) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ( SIX: MOLN. NASDAQ: MOLN ) , a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, ...",ABBV,0.025901,0.0,Neutral
3 Boneheaded Investing Mistakes I Pledge Not to Make  ( Again )  in 2024 and Beyond,https://www.fool.com/investing/2024/01/07/3-boneheaded-investing-mistakes-i-pledge-not-to/,2024-01-07 13:30:00,You should do your best to avoid making similar mistakes too.,ABBV,0.085936,0.235201,Somewhat-Bullish
Is AbbVie Stock a Buy Now?,https://www.fool.com/investing/2024/01/07/is-abbvie-stock-a-buy-now/,2024-01-07 12:33:00,The company is grappling with losing Humira's patent protection in 2023.,ABBV,0.68039,0.234714,Somewhat-Bullish
Dogs Of The Dow 2024: 10 Blue-Chip Dividend Payers,https://www.forbes.com/sites/brettowens/2024/01/07/dogs-of-the-dow-2024-10-blue-chip-dividend-payers/,2024-01-07 12:15:00,"The 2024 Dogs of the Dow are particularly homely hounds-which means we're talking big dividends. This year's Dogs yield more than three-times the broader market's paltry payout. So, should we hold our noses and buy? Let's grab some peanut butter treats and investigate.",ABBV,0.038623,0.068065,Neutral
3 Magnificent High-Yield Dividend Stocks to Buy in 2024,https://www.fool.com/investing/2024/01/06/3-high-yield-dividend-stocks-to-buy-in-2024/,2024-01-06 12:50:00,There's more than meets the eye with all three of these dividend stocks.,ABBV,0.249106,0.117644,Neutral
"Pharma Stock Roundup: JNJ Reports Q4 Earnings, SNY Inks M&A Deal With INBX",https://www.zacks.com/stock/news/2215726/pharma-stock-roundup-jnj-reports-q4-earnings-sny-inks-ma-deal-with-inbx,2024-01-25 14:26:00,"J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sanofi (SNY) is set to acquire Inhibrx's (INBX) rare disease pipeline candidate, INBRX-101.",ABBV,0.059785,0.0,Neutral
Should WisdomTree U.S. High Dividend ETF  ( DHS )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2215498/should-wisdomtree-us-high-dividend-etf-dhs-be-on-your-investing-radar,2024-01-25 11:20:06,Style Box ETF report for ...,ABBV,0.122581,0.068387,Neutral
2 No-Brainer Dividend Stocks to Buy for the New Year,https://www.fool.com/investing/2024/01/25/no-brainer-dividend-stocks-to-buy-for-the-new-year/,2024-01-25 10:20:00,These companies have fantastic track records of maintaining and raising their payouts.,ABBV,0.093289,0.076148,Neutral
AbbVie's Options Frenzy: What You Need to Know - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/insights/options/24/01/36762162/abbvies-options-frenzy-what-you-need-to-know,2024-01-24 16:16:01,"Investors with a lot of money to spend have taken a bearish stance on AbbVie ABBV. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",ABBV,0.71032,0.170348,Somewhat-Bullish
"AbbVie Stock Moves With Rising Relative Strength, Still Room To Grow",https://www.investors.com/news/stocks-with-rising-relative-strength-abbvie-3/,2024-01-24 16:01:00,"AbbVie ( ABBV ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Wednesday, with an increase from 68 to 71. When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength.",ABBV,0.582526,0.391654,Bullish
"SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates WAVD, CERE, TGAN - Transphorm  ( NASDAQ:TGAN ) , Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) ",https://www.benzinga.com/pressreleases/24/01/g36759460/shareholder-notice-halper-sadeh-llc-investigates-wavd-cere-tgan,2024-01-24 14:45:54,"NEW YORK, Jan. 24, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: WaveDancer, Inc.",ABBV,0.151539,0.099476,Neutral
Stocks With Rising Relative Strength: AbbVie,https://www.investors.com/ibd-data-stories/stocks-with-rising-relative-strength-abbvie-3/,2024-01-24 08:00:00,"AbbVie ( ABBV ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Wednesday, with an increase from 68 to 71. When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength.",ABBV,0.733479,0.48203,Bullish
"Implantable Drug Delivery Devices Global Market to Exhibit Growth at a Considerable CAGR of ~6% by 2028, Assesses DelveInsight",https://www.prnewswire.com/news-releases/implantable-drug-delivery-devices-global-market-to-exhibit-growth-at-a-considerable-cagr-of-6-by-2028-assesses-delveinsight-302041477.html,2024-01-23 22:31:00,Implantable Drug Delivery Devices Global Market to Exhibit Growth at a Considerable CAGR of ~6% by 2028 ... PR ...,ABBV,0.054175,0.079826,Neutral
$1000 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/insights/news/24/01/36745167/1000-invested-in-abbvie-5-years-ago-would-be-worth-this-much-today,2024-01-23 19:35:13,"AbbVie ABBV has outperformed the market over the past 5 years by 3.77% on an annualized basis producing an average annual return of 16.67%. Currently, AbbVie has a market capitalization of $290.47 billion.",ABBV,0.983605,0.387251,Bullish
Gilead  ( GILD )  Down as NSCLC Study Fails to Meet Primary Goal,https://www.zacks.com/stock/news/2214367/gilead-gild-down-as-nsclc-study-fails-to-meet-primary-goal,2024-01-23 16:37:00,Gilead Sciences' (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary endpoint. Shares decline on the same.,ABBV,0.123526,-0.012369,Neutral
2 Passive Income Plays to Buy and Hold Forever,https://www.fool.com/investing/2024/01/23/2-passive-income-plays-to-buy-and-hold-forever/,2024-01-23 14:55:00,These two income vehicles can safely supplement your retirement income.,ABBV,0.081552,0.147022,Neutral
"Alkeus Pharmaceuticals Appoints Seemi Khan, M.D., Chief Medical Officer",https://markets.businessinsider.com/news/stocks/alkeus-pharmaceuticals-appoints-seemi-khan-m-d-chief-medical-officer-1032987734,2024-01-23 13:30:00,"CAMBRIDGE, Mass., Jan. 23, 2024 ( GLOBE NEWSWIRE ) -- Alkeus Pharmaceuticals, Inc. today announced that Seemi Khan, M.D., M.P.H., M.B.A., has joined the Company as Chief Medical Officer.",ABBV,0.081276,0.045765,Neutral
Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies,https://www.prnewswire.com/news-releases/accent-therapeutics-announces-75-million-series-c-financing-to-advance-small-molecule-precision-cancer-therapies-302041338.html,2024-01-23 11:00:00,"Financing led by Mirae Asset Capital Life Science with participation from additional new and existing investors Funds will support advancement of lead programs through early clinical development, including Accent's first-in-class DHX9 inhibitor and newly unveiled, potentially best-in-class KIF18A ...",ABBV,0.039418,0.045323,Neutral
2 Genius Safe Stocks to Buy for 2024 and Beyond,https://www.fool.com/investing/2024/01/23/2-genius-safe-stocks-to-buy-for-2024-and-beyond/,2024-01-23 10:15:00,These companies have considerable profits and tried-and-true dividends in common.,ABBV,0.234006,0.072217,Neutral
Gilead sinks after lung cancer drug fails to improve survival,https://www.financialexpress.com/healthcare/pharma-healthcare/gilead-sinks-after-lung-cancer-drug-fails-to-improve-survival/3372692/,2024-01-23 08:31:27,"Gilead Sciences Inc.'s Trodelvy failed to significantly improve survival in a trial of patients with advanced lung cancer, a blow to the targeted treatment that's in one of the most promising classes in oncology.",ABBV,0.098255,0.072297,Neutral
AbbVie  ( ABBV )  Exceeds Market Returns: Some Facts to Consider,https://www.zacks.com/stock/news/2213772/abbvie-abbv-exceeds-market-returns-some-facts-to-consider,2024-01-22 22:45:17,"AbbVie (ABBV) closed at $165.39 in the latest trading session, marking a +0.38% move from the prior day.",ABBV,0.613743,0.261051,Somewhat-Bullish
Gilead's stock tumbles toward biggest selloff in more than nine years as lung-cancer trial disappoints,https://www.marketwatch.com/story/gileads-stock-tumbles-toward-biggest-selloff-in-more-than-9-years-after-lung-cancer-treatment-trial-disappoints-785e6886,2024-01-22 15:04:00,Shares of Gilead Sciences tumbled 9.7% early Monday after the company reported disappointing lung-cancer trial results.,ABBV,0.212115,0.182599,Somewhat-Bullish
AbbVie Inc.  ( ABBV )  Is a Trending Stock: Facts to Know Before Betting on It,https://www.zacks.com/stock/news/2213378/abbvie-inc-abbv-is-a-trending-stock-facts-to-know-before-betting-on-it,2024-01-22 14:00:10,"Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",ABBV,0.490323,0.135263,Neutral
Tissue Engineering Market is Expected to Reach $8.9 Billion | MarketsandMarkets™,https://www.benzinga.com/pressreleases/24/01/g36713761/tissue-engineering-market-is-expected-to-reach-8-9-billion-marketsandmarkets,2024-01-22 12:30:00,"Chicago, Jan. 22, 2024 ( GLOBE NEWSWIRE ) -- Tissue Engineering market in terms of revenue was estimated to be worth $4.4 Billion in 2023 and is poised to reach $8.9 Billion by 2028, growing at a CAGR of 15.3% from 2023 to 2028 according to a latest report published by MarketsandMarkets™.",ABBV,0.03792,-0.040123,Neutral
"USD 10.40 billion growth in Vascular Endothelial Market between 2022 and 2027, The strategic alliances and ... - PR Newswire",https://www.prnewswire.com/news-releases/usd-10-40-billion-growth-in-vascular-endothelial-market-between-2022-and-2027--the-strategic-alliances-and-collaborations-are-notably-driving-market-growth-17-000-technavio-research-reports-302039609.html,2024-01-22 04:35:00,"USD 10.40 billion growth in Vascular Endothelial Market between 2022 and 2027, The strategic alliances and ... PR ...",ABBV,0.049939,0.083583,Neutral
My 5 Top Dividend Stocks to Buy Hand Over Fist in 2024,https://www.fool.com/investing/2024/01/21/my-5-top-dividend-stocks-to-buy-in-2024/,2024-01-21 11:17:00,These stocks may help you win in 2024 -- no matter what the market does.,ABBV,0.231332,0.17327,Somewhat-Bullish
Liquid Biopsy in Cancer Diagnostics Global Market is Likely to Increase at a Massive Growth Rate of ~17% by 2028 | DelveInsight,https://www.prnewswire.com/news-releases/liquid-biopsy-in-cancer-diagnostics-global-market-is-likely-to-increase-at-a-massive-growth-rate-of-17-by-2028--delveinsight-302039144.html,2024-01-19 22:01:00,Liquid Biopsy in Cancer Diagnostics Global Market is Likely to Increase at a Massive Growth Rate of ~17% by 2028 ... PR ...,ABBV,0.021143,-0.132382,Neutral
"Hyaluronic Acid Serums Market Targets US$ 506.4 Million by 2033 at 5.9% CAGR, Persistence Market Research",https://www.benzinga.com/pressreleases/24/01/g36697064/hyaluronic-acid-serums-market-targets-us-506-4-million-by-2033-at-5-9-cagr-persistence-market-rese,2024-01-19 15:45:00,"New York, Jan. 19, 2024 ( GLOBE NEWSWIRE ) -- Hyaluronic Acid Serums have witnessed significant growth in recent years, driven by increasing consumer awareness of skincare and anti-aging products.",ABBV,0.022389,-0.0018,Neutral
"Pfizer, Autodesk, AbbVie And More: CNBC's 'Final Trades' - Autodesk  ( NASDAQ:ADSK ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/trading-ideas/long-ideas/24/01/36691104/pfizer-autodesk-abbvie-and-more-cnbcs-final-trades,2024-01-19 13:57:08,"On CNBC's ""Halftime Report Final Trades,"" Liz Young of BNY Mellon Investment Management named Health Care Select Sector SPDR Fund XLV as her final trade. Joshua Brown of Ritholtz Wealth Management picked Pfizer Inc. PFE, which bottomed in the middle of December.",ABBV,0.645516,0.429571,Bullish
Royalty Pharma Announces Dividend Increase,https://www.globenewswire.com/news-release/2024/01/19/2812286/0/en/Royalty-Pharma-Announces-Dividend-Increase.html,2024-01-19 13:15:00,"NEW YORK, Jan. 19, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that its board of directors has declared a dividend for the first quarter of 2024 of $0.21 per Class A share, reflecting a 5% increase in the company's quarterly dividend over the previous quarter's ...",ABBV,0.155451,0.101048,Neutral
Royalty Pharma Announces Dividend Increase - Royalty Pharma  ( NASDAQ:RPRX ) ,https://www.benzinga.com/pressreleases/24/01/g36694014/royalty-pharma-announces-dividend-increase,2024-01-19 13:15:00,"NEW YORK, Jan. 19, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that its board of directors has declared a dividend for the first quarter of 2024 of $0.21 per Class A share, reflecting a 5% increase in the company's quarterly dividend over the previous quarter's dividend.",ABBV,0.147818,0.098011,Neutral
"AbbVie, Arch Capital, Gilead Sciences And A Telecom Giant On CNBC's 'Final Trades' - Arch Capital Group  ( NASDAQ:ACGL ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/trading-ideas/long-ideas/24/01/36673096/abbvie-arch-capital-gilead-sciences-and-a-telecom-giant-on-cnbcs-final-trades,2024-01-18 14:36:18,"On CNBC's ""Halftime Report Final Trades,"" Rob Sechan of NewEdge Wealth said Gilead Sciences, Inc. GILD is an inexpensive way to give biotech exposure. Gilead Sciences, last month, said that it has purchased 15 million shares of HOOKIPA Pharma Inc HOOK for approximately $21.25 million, at $1.4167 ...",ABBV,0.522333,0.571704,Bullish
2 Beaten-Down Stocks to Buy Hand Over Fist This Year,https://www.fool.com/investing/2024/01/18/2-beaten-down-stocks-to-buy-hand-over-fist-this/,2024-01-18 13:45:00,Don't give up on these stocks too soon.,ABBV,0.485711,0.226444,Somewhat-Bullish
2024 Will Be a Good Year for the Pharma Industry: The Kiplinger Letter,https://www.kiplinger.com/business/a-good-year-for-the-pharma-industry-the-kiplinger-letter,2024-01-18 13:30:15,2024: The Pharma Industry's Good Year Kiplinger's Personal Finance ...,ABBV,0.19661,-0.0803,Neutral
Why Is Regenxbio Stock Trading Lower Today? - Regenxbio  ( NASDAQ:RGNX ) ,https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36667270/ocular-gene-therapy-regenxbio-data-shows-consistent-preservation-of-visual-acuity-r,2024-01-17 20:28:42,"Regenxbio Inc RGNX released Tuesday, Jan. 16, interim data from the Phase 2 AAVIATE trial of ABBV-RGX-314 for wet age-related macular degeneration ( wet AMD ) using suprachoroidal delivery. Investigational ABBV-RGX-314 using suprachoroidal delivery is designed as a one-time, in-office treatment.",ABBV,0.655824,-0.29614,Somewhat-Bearish
"Biologics Contract Manufacturing Market on a Tear $14.4 Billion in 2022, Poised to Double by 2033, Persistence Market Research",https://www.benzinga.com/pressreleases/24/01/g36663729/biologics-contract-manufacturing-market-on-a-tear-14-4-billion-in-2022-poised-to-double-by-2033-pe,2024-01-17 16:50:00,"New York, Jan. 17, 2024 ( GLOBE NEWSWIRE ) -- The dynamic and rapidly expanding field of biologics contract manufacturing, also referred to as the biopharmaceutical CMO market, is witnessing substantial investments in research and development by numerous players.",ABBV,0.042011,0.0,Neutral
"Protein Therapeutics Market Size to be Worth USD 549.4 billion by 2031, at a CAGR of 6.3%| Transparency Market Research, Inc.",https://www.benzinga.com/pressreleases/24/01/g36658710/protein-therapeutics-market-size-to-be-worth-usd-549-4-billion-by-2031-at-a-cagr-of-6-3-transparen,2024-01-17 13:30:00,"Wilmington, Delaware, United States, Jan. 17, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The protein therapeutics market was valued at US$ 318.4 billion in 2022. A CAGR of 6.3% is predicted from 2023 to 2031, reaching more than US$ 549.4 billion by 2031.",ABBV,0.101725,0.010908,Neutral
"Alzheimer's Disease Diagnostics & Treatment Market Revenues to Reach US$11.9 Billion by 2030 - Market Size, Share, Forecasts, & Trends Analysis Report by Persistence Market Research",https://www.benzinga.com/pressreleases/24/01/g36655498/alzheimers-disease-diagnostics-treatment-market-revenues-to-reach-us-11-9-billion-by-2030-market-s,2024-01-17 10:00:00,"New York, Jan. 17, 2024 ( GLOBE NEWSWIRE ) -- Market Size & Overview: The global market for Alzheimer's disease diagnostics and treatment is projected to experience a compound annual growth rate ( CAGR ) of 8.9%, reaching a value of US$11.9 billion by the end of 2030, up from US$6.5 billion ...",ABBV,0.028056,0.0,Neutral
"The Zacks Analyst Blog Highlights Apple, AbbVie, Toyota Motor, Monster Beverage and General Motors",https://www.zacks.com/stock/news/2211180/the-zacks-analyst-blog-highlights-apple-abbvie-toyota-motor-monster-beverage-and-general-motors,2024-01-17 09:59:00,"Apple, AbbVie, Toyota Motor, Monster Beverage and General Motors are included in this Analyst Blog.",ABBV,0.398148,0.194204,Somewhat-Bullish
AbbVie  ( ABBV )  Registers a Bigger Fall Than the Market: Important Facts to Note,https://www.zacks.com/stock/news/2211061/abbvie-abbv-registers-a-bigger-fall-than-the-market-important-facts-to-note,2024-01-16 22:45:21,"In the closing of the recent trading day, AbbVie (ABBV) stood at $161.48, denoting a -0.57% change from the preceding trading day.",ABBV,0.610329,0.07138,Neutral
REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery,https://www.prnewswire.com/news-releases/regenxbio-announces-positive-interim-data-from-phase-ii-aaviate-trial-of-abbv-rgx-314-for-the-treatment-of-wet-amd-using-suprachoroidal-delivery-302036184.html,2024-01-16 19:47:00,REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of ... PR ...,ABBV,0.629492,0.068912,Neutral
"Q4 Earnings Season Scorecard and Analyst Reports for Apple, AbbVie & Toyota",https://www.zacks.com/research-daily/2210770/q4-earnings-season-scorecard-and-analyst-reports-for-apple-abbvie-toyota,2024-01-16 18:48:00,"Today's Research Daily features a real-time update on the Q4 earnings season and new research reports on Apple (AAPL), AbbVie (ABBV), Toyota Motor (TM) and others.",ABBV,0.18967,0.1623,Somewhat-Bullish
Charts turn bullish on health-care stocks as sector takes early lead in 2024,https://www.marketwatch.com/story/charts-turn-bullish-on-health-care-stocks-as-sector-takes-early-lead-in-2024-12272495,2024-01-16 16:29:00,"Health-care stocks are off to a strong start in 2024, and Wall Street analysts are taking notice.",ABBV,0.15697,0.0,Neutral
"Zylo Unveils Usage Connect, Setting New Standard in Enterprise SaaS Management Visibility",https://www.prnewswire.com/news-releases/zylo-unveils-usage-connect-setting-new-standard-in-enterprise-saas-management-visibility-302034144.html,2024-01-16 14:00:00,"Industry-first feature enables no-code connection into usage data for any app, unlocking thousands of applications and expanding the depth and breadth of integrations",ABBV,0.046724,0.176451,Somewhat-Bullish
"Uber, Abbott Laboratories, Vertex Pharmaceuticals And More On CNBC's 'Final Trades' - Crown Castle  ( NYSE:CCI ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/trading-ideas/long-ideas/24/01/36634562/uber-abbott-laboratories-vertex-pharmaceuticals-and-more-on-cnbcs-final-trades,2024-01-16 13:51:55,"On CNBC's ""Halftime Report Final Trades,"" Jenny Harrington of Gilman Hill Asset Management named Crown Castle Inc. CCI as her final trade. Crown Castle, last month, announced a comprehensive review of its Fiber business and the addition of two new independent directors to the company's board.",ABBV,0.573213,0.626508,Bullish
Is First Trust Value Line Dividend ETF  ( FVD )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2210512/is-first-trust-value-line-dividend-etf-fvd-a-strong-etf-right-now,2024-01-16 11:20:05,Smart Beta ETF report for ...,ABBV,0.112532,0.05392,Neutral
Better Growth Stock: Abbott vs. AbbVie,https://www.fool.com/investing/2024/01/16/better-growth-stock-abbott-vs-abbvie/,2024-01-16 10:00:00,These healthcare giants also offer investors the promise of increasing passive income.,ABBV,0.511864,0.515043,Bullish
Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD- ( L ) 1 Cancer Immunotherapy for Multiple Cancer Types,https://www.prnewswire.com/news-releases/halozyme-announces-roche-receives-european-commission-approval-of-tecentriq-sc-with-enhanze-representing-the-eus-first-subcutaneous-pd-l1-cancer-immunotherapy-for-multiple-cancer-types-302035190.html,2024-01-16 06:15:00,Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE ... PR ...,ABBV,0.034984,0.080944,Neutral
3 Fabulous Dividend Stocks to Buy in February,https://www.fool.com/investing/2024/02/04/3-fabulous-dividend-stocks-to-buy-in-february/,2024-02-04 10:50:00,These stocks offer great dividends and more.,ABBV,0.384233,0.246892,Somewhat-Bullish
AbbVie  ( ABBV )  Q4 2023 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2024/02/02/abbvie-abbv-q4-2023-earnings-call-transcript/,2024-02-02 20:45:15,"ABBV earnings call for the period ending December 31, 2023.",ABBV,0.060583,0.094248,Neutral
"AbbVie  ( ABBV )  Q4 Earnings Beat, Raises Sales View for Key Drugs",https://www.zacks.com/stock/news/2220511/abbvie-abbv-q4-earnings-beat-raises-sales-view-for-key-drugs,2024-02-02 18:04:00,AbbVie???s (ABBV) fourth-quarter earnings and sales beat estimates. Management hikes the 2027 forecast for new immunology drugs to more than $27 billion.,ABBV,0.288893,0.265849,Somewhat-Bullish
"Stocks Handle Huge Earnings, Fed, Jobs Report: Weekly Review",https://www.investors.com/news/stock-market-handles-huge-earnings-week-fed-powell-jobs-report-weekly-review/,2024-02-02 17:15:00,"Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review Investor's Business Daily ...",ABBV,0.049835,-0.136008,Neutral
"AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall - Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/general/biotech/24/02/36912453/abbvie-lifts-long-term-outlook-for-new-immunology-drugs-even-as-q4-revenue-and-profit-fall,2024-02-02 16:12:37,"Friday, AbbVie Inc ABBV reported fourth-quarter adjusted EPS of $2.79, down 22.5% Y/Y, beating the consensus of $2.77. Fourth-quarter net revenues reached $14.301 billion, down 5.4% Y/Y, beating the consensus of $14.02 billion. The immunology portfolio generated $6.95 billion in sales, down 12.3%.",ABBV,0.779232,0.419506,Bullish
Nonfarm Payrolls Increased More Than Expected,https://www.zacks.com/stock/news/2220379/nonfarm-payrolls-increased-more-than-expected,2024-02-02 15:45:00,"The big jobs numbers out this week came from this morning's U.S. Bureau of Labor Statistics' ( BLS ) Employment Situation report, which surprised to the upside in a major way: 353K new jobs created for January, nearly double the 180K or so analysts were looking for.",ABBV,0.112269,0.1648,Somewhat-Bullish
"BLS Jobs Up Big: 353K, 3.7% Unemployment",https://www.zacks.com/stock/news/2220369/bls-jobs-up-big-353k-37-unemployment,2024-02-02 15:22:00,353K new jobs created for January are nearly double the 180K or so analysts were looking for.,ABBV,0.110717,0.166188,Somewhat-Bullish
"North America Cosmetic Surgery Market is Expected to Reach USD 29.2 billion, Advancing at a CAGR of 6.8% by 2031: Transparency Market Research, Inc.",https://www.benzinga.com/pressreleases/24/02/g36909586/north-america-cosmetic-surgery-market-is-expected-to-reach-usd-29-2-billion-advancing-at-a-cagr-of,2024-02-02 14:08:11,"Wilmington, Delaware, United States, Feb. 02, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The North America cosmetic surgery market is estimated to flourish at a CAGR of 6.8% from 2023 to 2031.",ABBV,0.035502,0.366855,Bullish
AbbVie Expects Two Drugs To Top $27 Billion In Sales. And Neither Is Humira.,https://www.investors.com/news/technology/abbvie-stock-abbvie-earnings-q4-2023/,2024-02-02 13:56:00,"AbbVie Stock Rises On Long-Term Guidance, Calling For $27 Billion From Two Key Drugs Investor's Business Daily ...",ABBV,0.900719,0.431729,Bullish
4 Large Drug Stocks Trying to Survive the Industry Challenges,https://www.zacks.com/commentary/2220023/4-large-drug-stocks-trying-to-survive-the-industry-challenges,2024-02-02 13:47:00,"Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), AbbVie (ABBV) and Novartis (NVS) are worth retaining in one's portfolio.",ABBV,0.189298,0.236489,Somewhat-Bullish
AbbVie  ( ABBV )  Q4 Earnings and Revenues Top Estimates,https://www.zacks.com/stock/news/2220125/abbvie-abbv-q4-earnings-and-revenues-top-estimates,2024-02-02 13:45:02,"AbbVie (ABBV) delivered earnings and revenue surprises of 1.09% and 1.78%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?",ABBV,0.402403,0.208814,Somewhat-Bullish
AbbVie's fourth-quarter sales top estimates despite plunging Humira revenues,https://www.marketwatch.com/story/abbvies-fourth-quarter-sales-top-estimates-despite-plunging-humira-revenues-f4fdf32b,2024-02-02 12:40:00,"AbbVie on Friday reported fourth-quarter sales that topped analyst estimates, even as it faces low-cost competition for its top-seller Humira.",ABBV,0.647749,0.278672,Somewhat-Bullish
"Nasdaq Futures Climb As Meta, Amazon Gains Offset Apple Slide: Analyst Points to 2 Factors Reinforcing Bullish Outlook This Year - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",https://www.benzinga.com/news/earnings/24/02/36907360/nasdaq-futures-climb-as-meta-amazon-gains-offset-apple-slide-analyst-points-to-2-factors-reinforcin,2024-02-02 12:24:06,"Stock futures are pointing upwards on Friday as traders assess earnings reports from Meta Platforms, Inc. META, Amazon, Inc. AMZN, and Apple, Inc. AAPL. Earnings remain mixed, raising concerns about both the economy and corporate profit growth.",ABBV,0.117486,0.0,Neutral
Two Titans Signal Strong End To Huge Week Of Earnings,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-meta-amazon-fuel-techs-china-woes-hit-apple-jobs-report-looms/,2024-02-01 21:44:00,"Dow Jones Futures: Meta, Amazon Fuel Techs Late, China Woes Hit Apple. Jobs Report Looms Investor's Business Daily ...",ABBV,0.061631,0.0,Neutral
Merck  ( MRK )  Beats Q4 Earnings Estimates,https://www.zacks.com/stock/news/2219249/merck-mrk-beats-q4-earnings-estimates,2024-02-01 12:45:02,"Merck (MRK) delivered earnings and revenue surprises of 133.33% and 0.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?",ABBV,0.139669,0.0,Neutral
This Is What Whales Are Betting On AbbVie - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/insights/options/24/01/36873044/this-is-what-whales-are-betting-on-abbvie,2024-01-31 18:31:03,"Whales with a lot of money to spend have taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 10 trades. If we consider the specifics of each trade, it is accurate to state that 20% of the investors opened trades with bullish expectations and 80% ...",ABBV,0.870696,0.235456,Somewhat-Bullish
"Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024",https://www.globenewswire.com/news-release/2024/01/30/2820516/0/en/Royalty-Pharma-To-Announce-Fourth-Quarter-And-Full-Year-2023-Financial-Results-On-February-15-2024.html,2024-01-30 21:15:00,"NEW YORK, Jan. 30, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will report its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024 before the U.S. financial markets open.",ABBV,0.138464,0.094471,Neutral
Piramal Pharma Limited Announces Consolidated Results for Q3 and 9M FY2024,https://www.prnewswire.com/news-releases/piramal-pharma-limited-announces-consolidated-results-for-q3-and-9m-fy2024-302048384.html,2024-01-30 19:07:00,"MUMBAI, India, Jan. 30, 2024 /PRNewswire/ -- Piramal Pharma Limited ( NSE: PPLPHARMA | BSE: 543635 ) , a leading global pharmaceuticals company, today announced its standalone and consolidated results for the Third Quarter ( Q3 ) and Nine Months ( 9M ) ended 31st December 2023. • Revenue from ...",ABBV,0.077094,-0.017427,Neutral
Piramal Pharma Limited Announces Consolidated Results for Q3 and 9M FY2024,https://www.prnewswire.com/news-releases/piramal-pharma-limited-announces-consolidated-results-for-q3-and-9m-fy2024-302048377.html,2024-01-30 19:02:00,"MUMBAI, India, Jan. 30, 2024 /PRNewswire/ -- Piramal Pharma Limited ( NSE: PPLPHARMA | BSE: 543635 ) , a leading global pharmaceuticals company, today announced its standalone and consolidated results for the Third Quarter ( Q3 ) and Nine Months ( 9M ) ended 31st December 2023. • Revenue from ...",ABBV,0.083251,-0.017659,Neutral
Piramal Pharma Limited Announces Consolidated Results for Q3 and 9M FY2024,https://www.newswire.ca/news-releases/piramal-pharma-limited-announces-consolidated-results-for-q3-and-9m-fy2024-865425678.html,2024-01-30 19:02:00,"MUMBAI, India, Jan. 30, 2024 /CNW/ -- Piramal Pharma Limited ( NSE: PPLPHARMA | BSE: 543635 ) , a leading global pharmaceuticals company, today announced its standalone and consolidated results for the Third Quarter ( Q3 ) and Nine Months ( 9M ) ended 31st December 2023. • Revenue from ...",ABBV,0.080593,-0.017553,Neutral
Piramal Pharma Limited Announces Consolidated Results for Q3 and 9M FY2024,https://www.benzinga.com/pressreleases/24/01/n36852478/piramal-pharma-limited-announces-consolidated-results-for-q3-and-9m-fy2024,2024-01-30 19:02:00,"MUMBAI, India, Jan. 30, 2024 /PRNewswire/ -- Piramal Pharma Limited PPLPHARMA, a leading global pharmaceuticals company, today announced its standalone and consolidated results for the Third Quarter ( Q3 ) and Nine Months ( 9M ) ended 31st December 2023.",ABBV,0.068698,-0.016159,Neutral
Piramal Pharma Limited Announces Consolidated Results for Q3 and 9M FY2024,https://www.benzinga.com/pressreleases/24/01/n36852483/piramal-pharma-limited-announces-consolidated-results-for-q3-and-9m-fy2024,2024-01-30 19:02:00,"MUMBAI, India, Jan. 30, 2024 /CNW/ -- Piramal Pharma Limited PPLPHARMA, a leading global pharmaceuticals company, today announced its standalone and consolidated results for the Third Quarter ( Q3 ) and Nine Months ( 9M ) ended 31st December 2023.",ABBV,0.068698,-0.016159,Neutral
AbbVie  ( ABBV )  to Report Q4 Earnings: What's in the Cards?,https://www.zacks.com/stock/news/2218222/abbvie-abbv-to-report-q4-earnings-whats-in-the-cards,2024-01-30 18:50:00,AbbVie's (ABBV) Q4 performance will likely reflect its newer immunotherapy drugs trying to compensate for declining Humira sales following the loss of U.S. exclusivity.,ABBV,0.40638,0.269523,Somewhat-Bullish
Eli Lilly  ( LLY )  Earnings Expected to Grow: Should You Buy?,https://www.zacks.com/stock/news/2217983/eli-lilly-lly-earnings-expected-to-grow-should-you-buy,2024-01-30 15:00:56,Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,ABBV,0.174903,-0.001424,Neutral
Unveiling AbbVie  ( ABBV )  Q4 Outlook: Wall Street Estimates for Key Metrics,https://www.zacks.com/stock/news/2217823/unveiling-abbvie-abbv-q4-outlook-wall-street-estimates-for-key-metrics,2024-01-30 14:15:22,"Evaluate the expected performance of AbbVie (ABBV) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",ABBV,0.344712,0.077357,Neutral
"Goldman Sachs, AbbVie And A Major Chipmaker: CNBC's 'Final Trades' - AbbVie  ( NYSE:ABBV ) , Goldman Sachs Gr  ( NYSE:GS ) ",https://www.benzinga.com/trading-ideas/long-ideas/24/01/36838789/goldman-sachs-abbvie-and-a-major-chipmaker-cnbcs-final-trades,2024-01-30 14:00:14,"On CNBC's ""Halftime Report Final Trades,"" Steve Weiss of Short Hills Capital Partners said Taiwan Semiconductor Manufacturing Company Limited TSM goes higher. Taiwan Semiconductor Manufacturing is reportedly eyeing its second Japanese plant in the same town as its first in Kumamoto prefecture.",ABBV,0.595343,0.409764,Bullish
"Jnana Therapeutics Announces Positive Clinical Proof of Concept Achieved with JNT-517, a Potential First-in-Class Oral Treatment for PKU",https://www.benzinga.com/pressreleases/24/01/g36842900/jnana-therapeutics-announces-positive-clinical-proof-of-concept-achieved-with-jnt-517-a-potential-,2024-01-30 13:15:57,Treatment with JNT-517 demonstrated a statistically significant mean blood phenylalanine reduction of 51% versus baseline Jnana has adapted the ongoing trial to accelerate the program and aims to advance JNT-517 directly into a pivotal study in early 2025,ABBV,0.035293,0.149058,Neutral
3 Stocks Enjoying Favorable Analyst Coverage,https://www.zacks.com/stock/news/2217509/3-stocks-enjoying-favorable-analyst-coverage,2024-01-29 23:08:00,All three of these stocks have seen upgrades from analysts in recent days. Is it time to buy?,ABBV,0.493834,0.587039,Bullish
AbbVie  ( ABBV )  Stock Sinks As Market Gains: Here's Why,https://www.zacks.com/stock/news/2217445/abbvie-abbv-stock-sinks-as-market-gains-heres-why,2024-01-29 22:45:19,"The latest trading day saw AbbVie (ABBV) settling at $163.91, representing a -0.3% change from its previous close.",ABBV,0.661658,0.353841,Bullish
"AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures - Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36831249/abbvies-transformational-2023-analyst-anticipates-growth-in-2024-amid-competitive-p,2024-01-29 19:04:56,"William Blair has upgraded AbbVie Inc ABBV, noting confidence in the company's growth outlook over the near and long term as it heads into 2024.",ABBV,0.669433,0.293503,Somewhat-Bullish
"Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism? - SPDR S&P 500  ( ARCA:SPY ) ",https://www.benzinga.com/news/earnings/24/01/36820476/tech-titans-microsoft-apple-lead-magnificent-seven-earnings-wave-this-week-can-mega-caps-ignite-mar,2024-01-29 10:51:00,"The past week's earnings were bordering on the negative, impacting trader sentiment, and the focus now shifts to the unfolding week that would see the release of a slew of tech earnings reports. The Week That Was: Tesla, Inc. TSLA, Intel, Inc. INTC, and Texas Instruments, Inc.",ABBV,0.086713,0.0,Neutral
"Dementia and Movement Disorder Treatment Market to Grow by USD 8.55 billion, Market Share, Trends, and Growth ... - PR Newswire",https://www.prnewswire.com/news-releases/dementia-and-movement-disorder-treatment-market-to-grow-by-usd-8-55-billion-market-share-trends-and-growth-analysis----technavio-302045378.html,2024-01-29 10:15:00,"Dementia and Movement Disorder Treatment Market to Grow by USD 8.55 billion, Market Share, Trends, and Growth ... PR ...",ABBV,0.053509,0.125702,Neutral
2 High-Yield Healthcare Stocks to Buy With Both Hands and 1 to Avoid for Now,https://www.fool.com/investing/2024/01/28/2-high-yield-healthcare-stocks-to-buy-with-both-ha/,2024-01-28 16:42:00,"All three of these stocks offer attractive dividend yields, but one looks risky.",ABBV,0.132368,0.102219,Neutral
"Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs",https://www.cnbc.com/2024/01/28/big-pharma-merck-bristol-myers-jj-prepare-to-lose-revenue.html,2024-01-28 13:00:01,Fast-approaching patent expirations will take a bite out of revenues and put the industry's top players in the hot seat over the next few years.,ABBV,0.042838,-0.019872,Neutral
This week will make it clearer if the Fed will cut interest rates in March | Business,https://www.cnn.com/2024/01/28/business/stocks-week-ahead-economic-data-march-cut-fed/index.html,2024-01-28 12:30:00,This week will make it clearer if the Fed will cut interest rates in March ...,ABBV,0.023169,0.039643,Neutral
"CEREVEL THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cerevel Therapeutics - CERE",https://www.prnewswire.com/news-releases/cerevel-therapeutics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick--foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-cerevel-therapeutics---cere-302045996.html,2024-01-26 23:41:00,CEREVEL THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick ... PR ...,ABBV,0.455525,0.197131,Somewhat-Bullish
"Apple, Boeing, Microsoft, Alphabet And A Fed Meeting, For Starters: Investing Action Plan",https://www.investors.com/research/investing-action-plan/apple-boeing-microsoft-alphabet-and-a-fed-meeting-for-starters-investing-action-plan/,2024-01-26 22:32:00,"As the stock market pushes its rally toward the end of a third straight month, some of its biggest names line up for earnings releases in the coming week. Apple ( AAPL ) , Alphabet ( GOOGL ) , Microsoft ( MSFT ) and Meta Platforms ( META ) are part of the picture.",ABBV,0.071677,0.012189,Neutral
Earnings Preview: AbbVie  ( ABBV )  Q4 Earnings Expected to Decline,https://www.zacks.com/stock/news/2216550/earnings-preview-abbvie-abbv-q4-earnings-expected-to-decline,2024-01-26 15:00:15,AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,ABBV,0.262522,-0.022119,Neutral
AbbVie Expands Biologics Manufacturing Capacity with a $223 Million Investment in Singapore Manufacturing Site - PR Newswire,https://www.prnewswire.com/apac/news-releases/abbvie-expands-biologics-manufacturing-capacity-with-a-223-million-investment-in-singapore-manufacturing-site-302044676.html,2024-01-26 01:05:31,AbbVie Expands Biologics Manufacturing Capacity with a $223 Million Investment in Singapore Manufacturing Site PR ...,ABBV,0.596978,0.539691,Bullish
